nitrituding or or of arcitactinist	18 III.ecuon (e.g., an intecuous	disease as described below	under "Infectious Disease").	Activation of Assays for the activation of A highly preferred	transcription through the ind	9L	it in Activators of Transcription			be used or routinely modified inflammation and	to assess the ability of inflammatory disorders.	polypeptides of the invention Preferred indications include	the	 transcription factors and Related Disorders", and/or	modulate the expression of "Cardiovascular Disorders").	multiple genes. Exemplary Preferred indications include	assays for transcription autoimmune diseases (e.g.,	through the STAT6 response rheumatoid arthritis, systemic	element that may be used or lupus erythematosis, multiple	routinely modified to test sclerosis and/or as described	activity of the polypeptides of immunodeficiencies (e.g., as	the invention (including described below).	antibodies and agonists or Preferred indications include	antagonists of the invention) neoplastic diseases (e.g.,	include assays disclosed in leukemia, lymphoma,	Berger et al., Gene 66:1-10 melanoma, and/or as described	(1998): Cullen and Malm. below under	
				HSSGD52 813 Act		thr	resi	ımi	as																			

et al Disorders") Preferred			; Georas and cancers, such as, leukemia,	529-4538 Iymphoma, melanoma, and	, prostate, breast, lung, colon,):1521- pancreatic, esophageal,			et al., J indications include benign	9331- dysproliferative disorders and	ntents of pre-neoplastic conditions, such	ein as, for example, hyperplasia,	ence in its metaplasia, and/or dysplasia.		se assays anemia, pancytopenia,	(e.g., leukopenia, thrombocytopenia,	Hodgkin's disease, acute	at may be lymphocytic anemia (ALL),	se assays plasmacytomas, multiple	l line, myeloma, Burkitt's lymphoma,	culture arthritis, AIDS, granulomatous	onsive T disease, inflammatory bowel	disease, sepsis, neutropenia,	neutrophilia, psoriasis,	suppression of immune	reactions to transplanted	organs and tissues,	hemophilia, hypercoagulation,	diabetes mellitus, endocarditis,	meningitis, and Lyme Disease.
368 (1992): Henthorn et al	D. A. M. A. A. A. C. S.	Proc Ivail Acad Sci USA	85:6342-6346 (1988); Georas	et al., Blood 92(12):4529-4538	(1998); Moffatt et al.,	Transplantation 69(7):1521-	1523 (2000); Curiel et al., Eur	J Immunol 27(8):1982-1987	(1997); and Masuda et al., J	Biol Chem 275(38):29331-	29337 (2000), the contents of	each of which are herein	incorporated by reference in its	entirety. T cells that may be	used according to these assays	are publicly available (e.g.,	through the ATCC).	Exemplary T cells that may be	used according to these assays	include the SUPT cell line,	which is a suspension culture	of IL-2 and IL-4 responsive T	cells.							

				indication is infection (e.g., an infectious disease as described below under "Infectious Disease").
HSSGG82	814	Apoptosis	Caspase Apoptosis. Assays for caspase apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote caspase protease-mediated apoptosis. Induction of apoptosis in endothelial cells supporting the vasculature of tumors is associated with tumor regression due to loss of tumor blood supply. Exemplary assays for caspase apoptosis that may be used or routinely modified to test capase apoptosis activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Lee et al., FEBS Lett 485(2-3): 122-126 (2000);	A highly preferred embodiment of the invention includes a method for stimulating endothelial cell growth. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell growth. A highly preferred embodiment of the invention includes a method for stimulating endothelial cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell proliferation. A highly preferred embodiment of the invention includes a method for stimulating apoptosis of endothelial cells. An alternative highly preferred embodiment of the invention includes a method for stimulating apoptosis of endothelial cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing)
			Nor et al., J Vasc Res 37(3):	apoptosis of endothelial cells.

A highly preferred embodiment of the invention includes a method for stimulating angiogenisis. An	alternative highly preferred embodiment of the invention includes a method for inhibiting angiogenesis. A highly preferred embodiment	of the invention includes a method for reducing cardiac hypertrophy. An alternative highly preferred embodiment	of the invention includes a method for inducing cardiac hypertrophy. Highly preferred indications include		 and atherosclerotic vascular disease, diabetic nephropathy, intracardiac shunt, cardiac
and Harlan, J Atheroscler Thromb 3(2): 75-80 (1996); the contents of each of which	are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays	through commercial sources). Exemplary endothelial cells that may be used according to these assays include bovine	aortic endothelial cells (bAEC), which are an example of endothelial cells which line blood vessels and are involved	in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.	
					-

telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma.	haemangiopericytoma, lymphangiona, lymphangiosarcoma. Highly preferred indications also include cancers such as,	prostate, oreast, rung, coron, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such	as, for example, hyperplasta, metaplasia, and/or dysplasia. Highly preferred indications also include arterial disease, such as, atherosclerosis, hypertension, coronary artery disease, inflammatory	disease and Reynaud"s phenomenom, aneurysms, restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other

	_	vascular disorders such as
		peripheral vascular disease,
		 and cancer. Highly
		preferred indications also
		include trauma such as
		wounds, burns, and injured
		tissue (e.g., vascular injury
		such as, injury resulting from
		balloon angioplasty, and
		atheroschlerotic lesions),
		implant fixation, scarring,
		ischemia reperfusion injury,
	_	rheumatoid arthritis,
		cerebrovascular disease, renal
		diseases such as acute renal
		failure, and osteoporosis.
		Additional highly preferred
		indications include stroke,
		graft rejection, diabetic or
		other retinopathies, thrombotic
		and coagulative disorders,
		vascularitis, lymph
		angiogenesis, sexual disorders,
-		age-related macular
		degeneration, and treatment
-		/prevention of endometriosis
		and related conditions.
		Additional highly preferred
		indications include fibromas,
		heart disease, cardiac arrest,
	_	heart valve disease, and

				4000011
				vasculal discase.
				Preferred indications include
				blood disorders (e.g., as
				described below under
				"Immune Activity", "Blood-
				Related Disorders", and/or
				"Cardiovascular Disorders").
				Preferred indications include
				autoimmune diseases (e.g.,
				rheumatoid arthritis, systemic
				lupus erythematosis, multiple
				sclerosis and/or as described
				below) and
				immunodeficiencies (e.g., as
				described below). Additional
				preferred indications include
				inflammation and
				inflammatory disorders (such
				as acute and chronic
				inflammatory diseases, e.g.,
				inflammatory bowel disease
				and Crohn's disease), and pain
		•		management.
HSUBW09	815	Regulation of	Assays for the regulation of	A highly preferred
		transcription	transcription through the FAS	indication is diabetes mellitus.
	`	through the FAS	promoter element are well-	An additional highly preferred
		promoter element	known in the art and may be	indication is a complication
		in hepatocytes	used or routinely modified to	associated with diabetes (e.g.,
			assess the ability of	diabetic retinopathy, diabetic
		-	polypeptides of the invention	nephropathy, kidney disease
			(including antibodies and	(e.g., renal failure,

		agonists or antagonists of the	nephropathy and/or other
		invention) to activate the FAS	diseases and disorders as
		nromoter element in a reporter	described in the "Renal
		construct and to regulate	Disorders" section below),
		transcription of FAS, a key	diabetic neuropathy, nerve
		enzyme for lipogenesis. FAS	disease and nerve damage
_		promoter is regulated by many	(e.g., due to diabetic
		transcription factors including	neuropathy), blood vessel
		SREBP. Insulin increases FAS	blockage, heart disease, stroke,
		gene transcription in livers of	impotence (e.g., due to diabetic
		diabetic mice. This	neuropathy or blood vessel
		stimulation of transcription is	blockage), seizures, mental
		also somewhat glucose	confusion, drowsiness,
		dependent. Exemplary assays	nonketotic hyperglycemic-
		that may be used or routinely	hyperosmolar coma,
-		modified to test for FAS	cardiovascular disease (e.g.,
		promoter element activity (in	heart disease, atherosclerosis,
		hepatocytes) by polypeptides	microvascular disease,
		of the invention (including	hypertension, stroke, and other
		antibodies and agonists or	diseases and disorders as
		antagonists of the invention)	described in the
		include assays disclosed in	"Cardiovascular Disorders"
		Xiong, S., et al., Proc Natl	section below), dyslipidemia,
		Acad Sci U.S.A., 97(8):3948-	endocrine disorders (as
		53 (2000); Roder, K., et al.,	described in the "Endocrine
		Eur J Biochem, 260(3):743-51	Disorders" section below),
		(1999); Oskouian B, et al.,	neuropathy, vision impairment
		Biochem J, 317 (Pt 1):257-65	(e.g., diabetic retinopathy and
		(1996); Berger, et al., Gene	blindness), ulcers and impaired
		66:1-10 (1988); and, Cullen,	wound healing, and infection
-		B., et al., Methods in Enzymol. (e.g., infectious diseases and	(e.g., infectious diseases and

			216:362–368 (1992), the contents of each of which is	disorders as described in the "Infectious Diseases" section
			herein incorporated by	below, especially of the
			reference in its entirety.	urinary tract and skin), carpal
			Hepatocytes that may be used	tunnel syndrome and
			according to these assays, such	Dupuytren's contracture).
			as H4IIE cells, are publicly	An additional highly preferred
			available (e.g., through the	indication is obesity and/or
			ATCC) and/or may be	complications associated with
			routinely generated.	obesity. Additional highly
			Exemplary hepatocytes that	preferred indications include
			may be used according to these	weight loss or alternatively,
			assays include rat liver	weight gain. Aditional
			hepatoma cell line(s) inducible	highly preferred indications are
			with glucocorticoids, insulin,	complications associated with
			or cAMP derivatives.	insulin resistance.
HSUBW09	815	Inhibition of	Reporter Assay: construct	
		squalene synthetase	contains regulatory and coding	
		gene transcription.	sequence of squalene	
			synthetase, the first specific	
			enzyme in the cholesterol	
			biosynthetic pathway. See	
			Jiang, et al., J. Biol. Chem.	
			268:12818-128241(993), the	
			contents of which are herein	
			incorporated by reference in its	
			entirety. Cells were treated	
			with SID supernatants, and	
			SEAP activity was measured	
			after 72 hours. HepG2 is a	
			human hepatocellular	

				carcinoma cell line (ATCC	
				HB-8065). See Knowles et al.,	
				Science. 209:497-9 (1980), the	
				contents of which are herein	
				incorporated by reference in its	
				entirety.	
	HSUBW09	815	CD152 in Human T		
			cells		
-	HSVBU91	816	Activation of	Assays for the activation of	A highly preferred indication
			transcription	transcription through the	is obesity and/or complications
			through cAMP	cAMP response element are	associated with obesity.
			response element	well-known in the art and may	Additional highly preferred
			(CRE) in pre-	be used or routinely modified	indications include weight loss
			adipocytes.	to assess the ability of	or alternatively, weight gain.
				polypeptides of the invention	An additional highly preferred
				(including antibodies and	indication is diabetes mellitus.
				agonists or antagonists of the	An additional highly preferred
				invention) to increase cAMP,	indication is a complication
				regulate CREB transcription	associated with diabetes (e.g.,
				factors, and modulate	diabetic retinopathy, diabetic
				expression of genes involved	nephropathy, kidney disease
				in a wide variety of cell	(e.g., renal failure,
				functions. For example, a	nephropathy and/or other
				3T3-L1/CRE reporter assay	diseases and disorders as
				may be used to identify factors	described in the "Renal
				that activate the cAMP	Disorders" section below),
				signaling pathway. CREB	diabetic neuropathy, nerve
				plays a major role in	disease and nerve damage
				adipogenesis, and is involved	(e.g., due to diabetic
				in differentiation into	neuropathy), blood vessel
				adipocytes. CRE contains the	blockage, heart disease, stroke,

	+00+0# () P P D	nonromothy or blood yeared
(CRE binding protein).	(CRE binding protein).	blockage), seizures, mental
Exemplary assays for	says for	confusion, drowsiness,
transcription through the	through the	nonketotic hyperglycemic-
cAMP response	cAMP response element that	hyperosmolar coma,
may be used or routinely	or routinely	cardiovascular disease (e.g.,
modified to test cAMP-	est cAMP-	heart disease, atherosclerosis,
response eleme	response element activity of	microvascular disease,
polypeptides of	polypeptides of the invention	hypertension, stroke, and other
(including antibodies and	tibodies and	diseases and disorders as
agonists or ant	agonists or antagonists of the	described in the
invention) include assays	clude assays	"Cardiovascular Disorders"
disclosed in Be	disclosed in Berger et al., Gene	section below), dyslipidemia,
66:1-10 (1998); Cullen and	8); Cullen and	endocrine disorders (as
Malm, Methods in Enzymol	ods in Enzymol	described in the "Endocrine
216:362-368 (1	216:362-368 (1992); Henthorn	Disorders" section below),
et al., Proc Nat	et al., Proc Natl Acad Sci USA	neuropathy, vision impairment
85:6342-6346	85:6342-6346 (1988); Reusch	(e.g., diabetic retinopathy and
et al., Mol Cell Biol	all Biol	blindness), ulcers and impaired
20(3):1008-10	20(3):1008-1020 (2000); and	wound healing, and infection
Klemm et al., J Biol Chem	, J Biol Chem	(e.g., infectious diseases and
273:917-923 (1998), the	(1998), the	disorders as described in the
contents of eac	contents of each of which are	"Infectious Diseases" section
herein incorporated by	orated by	below, especially of the
reference in its	reference in its entirety. Pre-	urinary tract and skin), carpal
adipocytes that	adipocytes that may be used	tunnel syndrome and
according to th	according to these assays are	Dupuytren's contracture).
publicly available (e.g.,	lable (e.g.,	Additional highly preferred
through the ATCC) and/or	ATCC) and/or	indications are complications
may be routinely generated.	nely generated.	associated with insulin

resistance.	A highly preferred embodiment of the invention includes a method for stimulating hepatocyte cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting hepatocyte cell proliferation. A highly preferred embodiment of the invention includes a method for stimulating hepatocyte cell differentiation. An alternative highly preferred embodiment of the invention includes a method for stimulating hepatocyte cell differentiation. An alternative highly preferred embodiment of the invention includes a method for inhibiting
Exemplary mouse adipocyte cells that may be used according to these assays include 3T3-L1 cells. 3T3-L1 is an adherent mouse preadipocyte cell line that is a continuous substrain of 3T3 fibroblast cells developed through clonal isolation and undergo a pre-adipocyte to adipose-like conversion under appropriate differentiation conditions known in the art.	Kinase assay. Kinase assays, for example an Elk-1 kinase assay, for ERK signal transduction that regulate cell proliferation or differentiation are well known in the art and may be used or routinely of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and differentiation. Exemplary assays for ERK kinase activity that may be used or routinely modified to test ERK kinase-induced
	Activation of Hepatocyte ERK Signaling Pathway
	816
	HSVBU91

described below under	"Infectious Disease").	A highly preferred indication	is diabetes mellitus. An	additional highly preferred	indication is a complication	associated with diabetes (e.g.,	diabetic retinopathy, diabetic	nephropathy, kidney disease	(e.g., renal failure,	nephropathy and/or other	diseases and disorders as	described in the "Renal	Disorders" section below),	diabetic neuropathy, nerve	disease and nerve damage	(e.g., due to diabetic	neuropathy), blood vessel	blockage, heart disease, stroke,	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,	microvascular disease,	hypertension, stroke, and other	diseases and disorders as	described in the
																								sa.				****		
					·																					_				
											_					-								_						
							-				_											_				_				

"Cardiovascular Disorders"	section below), dyslipidemia,	endocrine disorders (as	described in the "Endocrine	Disorders" section below),	neuropathy, vision impairment	(e.g., diabetic retinopathy and	blindness), ulcers and impaired	wound healing, infection (e.g.,	infectious diseases and	disorders as described in the	"Infectious Diseases" section	below, especially of the	urinary tract and skin), carpal	tunnel syndrome and	Dupuytren's contracture).	An additional highly preferred	indication is obesity and/or	complications associated with	obesity. Additional highly	preferred indications include	weight loss or alternatively,	weight gain. Additional	highly preferred indications are	complications associated with	insulin resistance.	Additional highly preferred	indications are disorders of the	musculoskeletal systems	
																													_

					described herein
					Additional bimbler and formad
					Additional nigniy preferred
					indications include, hepatitis,
					jaundice, gallstones, cirrhosis
					of the liver, degenerative or
					necrotic liver disease,
					alcoholic liver diseases,
					fibrosis, liver regeneration,
_					metabolic disease,
					dyslipidemia and chlolesterol
					metabolism.
					Additional highly preferred
					indications include neoplasms
					and cancers, such as,
					hepatocarcinomas, other liver
					cancers, and colon and
					pancreatic cancer. Preferred
	_				indications also include
					prostate, breast, lung,
					esophageal, stomach, brain,
					and urinary cancer. Other
					preferred indications include
					benign dysproliferative
					disorders and pre-neoplastic
					conditions, such as, for
					example, hyperplasia,
					metaplasia, and/or dysplasia.
	HSVBU91	816	Insulin Secretion	Assays for measuring secretion	A highly preferred indication
	-			of insulin are well-known in	is diabetes mellitus. An
				the art and may be used or	additional highly preferred
				routinely modified to assess	indication is a complication

the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion from anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and disregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to component in diabetes. Exemplary assays that may be used or routinely modified to component in diabetes. Exemplary assays that may be used or routinely modified to component in diabetes. Exemplary assays that may be used or routinely modified to ells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays discosed in: Shimizu, H., et al., Endoor J, 47(3):261-9 (2000); Salapatek, A.M., et al., Mol Endocrine), 13(8):1305- (1998); Filipsson, K., et al., Disorders" section below), dyslipidemia, 17 (1999); Filipsson, K., et al., Disorders" section below),	on so	on so
the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and disregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Mol Endocrinol, 13(8):1305-17 (1999); Filipsson, K., et al., Ann N Y Acad Sci, 865:441-4 (1998); Olson, L.K., et al., J	the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and disregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Endocr J. 47(3):261-9 (2000); Salapatek, A.M., et al., Ann N Y Acad Sci, 865:441-4 (1998); Olson, L.K., et al., J	the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and disregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Endocr J, 47(3):261-9 (2000); Salapatek, A.M., et al., Mol Endocrinol, 13(8):1305-17 (1999); Filipsson, K., et al., J (1998); Olson, L.K., et al., J
	·	

(e.g., diabetic retinopathy and	blindness), ulcers and impaired	Would liealing, and infection (e.g. infections diseases and	disorders as described in the	"Infectious Diseases" section	below, especially of the	urinary tract and skin), carpal	tunnel syndrome and	Dupuytren's contracture).	An additional highly preferred	indication is obesity and/or	complications associated with	obesity. Additional highly	preferred indications include	weight loss or alternatively,	weight gain. Additional highly	preferred indications are	complications associated with	insulin resistance.											
(1996); and, Miraglia S et. al.,	Source of Biomolecular	Scienting, 4:133-204 (1999), the contents of each of which	is herein incorporated by	reference in its entirety.	Pancreatic cells that may be	used according to these assays	are publicly available (e.g.,	through the ATCC) and/or	may be routinely generated.	Exemplary pancreatic cells that	may be used according to these	assays include HITT15 Cells.	HITT15 are an adherent	epithelial cell line established	from Syrian hamster islet cells	transformed with SV40. These	cells express glucagon,	somatostatin, and	glucocorticoid receptors. The	cells secrete insulin, which is	stimulated by glucose and	glucagon and suppressed by	somatostatin or	glucocorticoids. ATTC# CRL-	1777 Refs: Lord and	Ashcroft. Biochem. J. 219:	547-551; Santerre et al. Proc.	Natl. Acad. Sci. USA 78:	4339-4343, 1981.
											_															_			

HSVBU91	816	TNFa in Human T-		
		cell 293T		
HSVBU91	816	Activation of	Assays for the activation of	A highly preferred
		transcription	transcription through the CD28	embodiment of the invention
		through CD28	response element are well-	includes a method for
		response element in	known in the art and may be	stimulating T cell proliferation.
		immune cells (such	used or routinely modified to	An alternative highly preferred
		as T-cells).	assess the ability of	embodiment of the invention
 *			polypeptides of the invention	includes a method for
 •			(including antibodies and	inhibiting T cell proliferation.
			agonists or antagonists of the	A highly preferred
			invention) to stimulate IL-2	embodiment of the invention
			expression in T cells.	includes a method for
			Exemplary assays for	activating T cells. An
			transcription through the CD28	alternative highly preferred
 -			response element that may be	embodiment of the invention
			used or routinely modified to	includes a method for
 			test CD28-response element	inhibiting the activation of
 •			activity of polypeptides of the	and/or inactivating T cells.
			invention (including antibodies	A highly preferred
			and agonists or antagonists of	embodiment of the invention
			the invention) include assays	includes a method for
			disclosed in Berger et al., Gene	stimulating (e.g., increasing)
			66:1-10 (1998); Cullen and	IL-2 production. An alternative
			Malm, Methods in Enzymol	highly preferred embodiment
 -			216:362-368 (1992); Henthorn	of the invention includes a
			et al., Proc Natl Acad Sci USA	method for inhibiting (e.g.,
 -			85:6342-6346 (1988);	reducing) IL-2 production.
			McGuire and Iacobelli, J	Additional highly preferred
			Immunol 159(3):1319-1327	indications include
			(1997); Parra et al., J Immunol	inflammation and

166(4):2437-2443 (2001); and Butscher et al., J Biol Chem	inflammatory disorders. Highly preferred indications
3(1):552-560 (1998), the	include autoimmune diseases
contents of each of which are	(e.g., rheumatoid arthritis,
herein incorporated by	systemic lupus erythematosis,
reference in its entirety. T	multiple sclerosis and/or as
cells that may be used	described below),
according to these assays are	immunodeficiencies (e.g., as
publicly available (e.g.,	described below), boosting a T
through the ATCC).	cell-mediated immune
Exemplary human T cells that	response, and suppressing a T
may be used according to these	
assays include the JURKAT	response. An additional highly
cell line, which is a suspension	preferred indication includes
culture of leukemia cells that	infection (e.g., AIDS, and/or as
produce IL-2 when stimulated.	described below under
	"Infectious Disease").
	Highly preferred indications
	include neoplastic diseases
	(e.g., melanoma, renal cell
	carcinoma, leukemia,
	lymphoma, and/or as described
	below under
	"Hyperproliferative
	Disorders"). Highly preferred
	indications include neoplasms
	and cancers, such as, for
	example, melanoma (e.g.,
	metastatic melanoma), renal
	cell carcinoma (e.g., metastatic
	renal cell carcinoma),

leukemia, lymphoma (e.g., T	cell lymphoma), and prostate,	breast, lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	A highly preferred indication	is infection (e.g., tuberculosis,	infections associated with	granulomatous disease, and	osteoporosis, and/or an	infectious disease as described	below under "Infectious	Disease"). A highly preferred	indication is AIDS.	Additional highly preferred	indications include suppression	of immune reactions to	transplanted organs and/or	tissues, uveitis, psoriasis, and	tropical spastic paraparesis.	Preferred indications include	blood disorders (e.g., as	described below under	"Immune Activity", "Blood-	Related Disorders", and/or
					-								_					•												
		_		-								-															-			

"Cardiovascular Disorders"). Preferred indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma and allergy.	tion of the highly preferred indication is obesity and/or complications associated with obesity. t and may additional highly preferred indications include weight loss or alternatively, weight gain. An additional highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic involved nephropathy, kidney disease cell nephropathy and/or other
	Assays for the activation of transcription through the cAMP response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to increase cAMP, regulate CREB transcription factors, and modulate expression of genes involved in a wide variety of cell functions. For example, a
	Activation of transcription through cAMP response element (CRE) in preadipocytes.
	817
	HSYAV50

		3T3-L1/CRF renorter assay	diseases and disorders as
		may be used to identify factors	described in the "Renal
		ind of used to identify factors	
		that activate the cAMP	Disorders" section below),
		signaling pathway. CREB	diabetic neuropathy, nerve
		plays a major role in	disease and nerve damage
		adipogenesis, and is involved	(e.g., due to diabetic
		in differentiation into	neuropathy), blood vessel
		adipocytes. CRE contains the	blockage, heart disease, stroke,
		binding sequence for the	impotence (e.g., due to diabetic
		transcription factor CREB	neuropathy or blood vessel
		(CRE binding protein).	blockage), seizures, mental
		Exemplary assays for	confusion, drowsiness,
		transcription through the	nonketotic hyperglycemic-
		cAMP response element that	hyperosmolar coma,
		may be used or routinely	cardiovascular disease (e.g.,
		modified to test cAMP-	heart disease, atherosclerosis,
-		response element activity of	microvascular disease,
		polypeptides of the invention	hypertension, stroke, and other
		(including antibodies and	diseases and disorders as
		agonists or antagonists of the	described in the
		invention) include assays	"Cardiovascular Disorders"
		disclosed in Berger et al., Gene	section below), dyslipidemia,
		66:1-10 (1998); Cullen and	endocrine disorders (as
		Malm, Methods in Enzymol	described in the "Endocrine
		216:362-368 (1992); Henthorn	Disorders" section below),
		et al., Proc Natl Acad Sci USA	neuropathy, vision impairment
		85:6342-6346 (1988); Reusch	(e.g., diabetic retinopathy and
		et al., Mol Cell Biol	blindness), ulcers and impaired
		20(3):1008-1020 (2000); and	wound healing, and infection
-	-	Klemm et al., J Biol Chem	(e.g., infectious diseases and
		273:917-923 (1998), the	disorders as described in the

			contents of each of which are herein incorporated by	"Infectious Diseases" section below, especially of the
			reference in its entirety. Pre- adipocytes that may be used	urinary tract and skin), carpal tunnel syndrome and
			according to these assays are	Dupuytren's contracture).
			publicly available (e.g.,	Additional highly preferred indications are complications
			may be routinely generated.	associated with insulin
			Exemplary mouse adipocyte	resistance.
			cells that may be used	
			according to these assays	
			include 3T3-L1 cells. 3T3-L1	
			is an adherent mouse	
			preadipocyte cell line that is a	
			continuous substrain of 3T3	
			fibroblast cells developed	
			through clonal isolation and	
			undergo a pre-adipocyte to	
			adipose-like conversion under	
			appropriate differentiation	
			conditions known in the art.	
HSYAV50	817	CXCR4 in HT1080		
HSYAV50	817	IgG in Human B		
		cells		
HSYAV50	817	IFNg in Human T-		
05VAV2H	817	Activation of	Assays for the activation of	A preferred embodiment of
22111211		1 *C. C. C. C. C. C. C. C.	rissal s for the university of	At a forest to the forest
		transcription	transcription through the	the invention includes a
		through serum	Serum Response Element	method for inhibiting (e.g.,
		response element in	(SRE) are well-known in the	reducing) TNF alpha
		immune cells (such	art and may be used or	production. An alternative

as natural killer	routinely modified to assess	highly preferred embodiment
cells).	the ability of polypeptides of	of the invention includes a
	the invention (including	method for stimulating (e.g.,
	antibodies and agonists or	increasing) TNF alpha
	antagonists of the invention) to	production. Preferred
	regulate serum response	indications include blood
	factors and modulate the	disorders (e.g., as described
	expression of genes involved	below under "Immune
	in growth and upregulate the	Activity", "Blood-Related
	function of growth-related	Disorders", and/or
	genes in many cell types.	"Cardiovascular Disorders"),
	Exemplary assays for	Highly preferred indications
	transcription through the SRE	include autoimmune diseases
	that may be used or routinely	(e.g., rheumatoid arthritis,
	modified to test SRE activity	systemic lupus erythematosis,
	of the polypeptides of the	Crohn"s disease, multiple
	invention (including antibodies	sclerosis and/or as described
	and agonists or antagonists of	below), immunodeficiencies
	the invention) include assays	(e.g., as described below),
	disclosed in Berger et al., Gene	boosting a T cell-mediated
	66:1-10 (1998); Cullen and	immune response, and
	Malm, Methods in Enzymol	suppressing a T cell-mediated
	216:362-368 (1992); Henthorn	immune response. Additional
	et al., Proc Natl Acad Sci USA	highly preferred indications
	85:6342-6346 (1988); Benson	include inflammation and
	et al., J Immunol 153(9):3862-	inflammatory disorders, and
	3873 (1994); and Black et al.,	treating joint damage in
	Virus Genes 12(2):105-117	patients with rheumatoid
	(1997), the content of each of	arthritis. An additional highly
	which are herein incorporated	preferred indication is sepsis.
	by reference in its entirety. T	Highly preferred indications

					ക്							er							4)		ia,				na,	sno		
eases homa,	elow ative	nally,	ations	p	xampl		ác	olid	breast,	S,	brain,	er. Oth	include	e/	plastic	or		splasia	includ	<u>ب</u>	ytoper	ante	(ALL),	iple	/mpho	lomato	/ bowe	
stic dis	ibed bo rolifera	dditio	d indic	sms an	s, for e	shoma,	oma (e.	ma), s	ostate,	ncreati	mach,	ry cano	ations	iferativ	re-neo	h as, f	rplasia	1/or dy	ations	openia	oquio	ase, ac	emia (s, mult	citt's ly	, granu	mator	penia,
reopla: kemia	s descr Iyperp	s"). A	referre	eopla	such a	a, lymp	na, glic	nt glion	and pro	on, pa	eal, sto	l urina	l indic	ysprol	s and p	ns, suc	, hype	sia, and	d indic	pancy	na, thr	ı's dise	ytic ar	ytomas	a, Burl	AIDS	inflam	neutro
include neoplastic diseases (e.g., leukemia, lymphoma,	and/or as described below under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia,	Hodgkin's disease, acute	lymphocytic anemia (ALL),	plasmacytomas, multiple	myeloma, Burkitt's lymphoma,	arthritis, AIDS, granulomatous	disease, inflammatory bowel	disease, neutropenia,
	<u> </u>	<u> </u>				<u>မ</u>	=	=	=		<u>မ</u>	=	<u></u>	<u>ă</u>	<u>ಶ</u>	<u>6</u>	=	<u>Ā</u>	<u></u>		王	<u>, , , , , , , , , , , , , , , , , , , </u>	<u>_</u>	=	ਲ	.	'
ays are	•	t may b	e assay	Il line,	ıral kill	and																						
e used	ole (e.g CC).	ells tha	to thes	-YT ce	an natu	tolytic	ty.																					
may bg to the	availat the AT	ry T ce	ording	he NK	a hum	with cy	activi																					
cells that may be used according to these assays are	publicly available (e.g., through the ATCC).	Exemplary T cells that may be	used according to these assays	include the NK-YT cell line,	which is a human natural killer	cell line with cytolytic and	cytotoxic activity.																					
8 8	<u>면</u> 큐	I	ä	<u>:=</u>	*	<u>ဒ</u>	<u>.</u>														-							
																									_			
																											_	
				<u></u>																								
							_																					

				neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes melitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below
HSVAV50	817	SEAD in OE-21		under "Infectious Disease").
HSYAV50	817	Activation of	Assays for the activation of	Highly preferred indications
		transcription	transcription through the	include neoplastic diseases
		through GAS	Gamma Interferon Activation	(e.g., leukemia, lymphoma,
		response element in	Site (GAS) response element	and/or as described below
		immune cells (such	are well-known in the art and	under "Hyperproliferative
		as T-cells).	may be used or routinely	Disorders"). Highly preferred
			modified to assess the ability	indications include neoplasms
			of polypeptides of the	and cancers, such as, for
			invention (including antibodies	example, leukemia, lymphoma
			and agonists or antagonists of	(e.g., T cell lymphoma,
			the invention) to regulate	Burkitt's lymphoma, non-
			STAT transcription factors and	Hodgkins lymphoma,
			modulate gene expression	Hodgkin"s disease),
			involved in a wide variety of	melanoma, and prostate,
			cell functions. Exemplary	breast, lung, colon, pancreatic,
			assays for transcription	esophageal, stomach, brain,
			through the GAS response	liver and urinary cancer. Other

	metaplasia, and/or dysplasia. Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic	lupus erythematosis, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below),	boosting a T cell-mediated immune response, and suppressing a T cell-mediated	immune response. Additional preferred indications include inflammation and inflammatory disorders.	Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or	"Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatosus disease and malignant
element that may be used or routinely modified to test GAS-response element activity of polypeptides of the invention (including antibodies	and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and	Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988);	Matikainen et al., Blood 93(6):1980-1991 (1999); and Henttinen et al., J Immunol	155(10):4582-4587 (1995), the contents of each of which are herein incorporated by reference in its entirety.	Exemplary human T cells, such as the SUPT cell line, that may be used according to these assays are publicly available (e.g., through the ATCC).	
					· · ·	· ·

				osteoporosis, and/or an
				infectious disease as described
				below under "Infectious
,				Disease"). An additional
				preferred indication is
				idiopathic pulmonary fibrosis.
				Preferred indications include
				anemia, pancytopenia,
				leukopenia, thrombocytopenia,
				acute lymphocytic anemia
				(ALL), plasmacytomas,
				multiple myeloma, arthritis,
				AIDS, granulomatous disease,
				inflammatory bowel disease,
				sepsis, neutropenia,
				neutrophilia, psoriasis,
				suppression of immune
				reactions to transplanted
				organs and tissues,
				hemophilia, hypercoagulation,
				diabetes mellitus, endocarditis,
				meningitis, Lyme Disease, and
				asthma and allergy.
HTAEE28	818	Protection from	Caspase Apoptosis Rescue.	A highly preferred
		Endothelial Cell	Assays for caspase apoptosis	embodiment of the invention
		Apoptosis.	rescue are well known in the	includes a method for
			art and may be used or	stimulating endothelial cell
			routinely modified to assess	growth. An alternative highly
			the ability of the polypeptides	preferred embodiment of the
			of the invention (including	invention includes a method
			antibodies and agonists or	for inhibiting endothelial cell

antagonists of the invention) to	growth. A highly preferred
 inhibit caspase protease-	១
mediated apoptosis.	includes a method for
Exemplary assays for caspase	stimulating endothelial cell
 apoptosis that may be used or	proliferation. An alternative
routinely modified to test	highly preferred embodiment
 caspase apoptosis rescue of	of the invention includes a
polypeptides of the invention	method for inhibiting
(including antibodies and	endothelial cell proliferation.
agonists or antagonists of the	A highly preferred
invention) include the assays	embodiment of the invention
disclosed in Romeo et al.,	includes a method for
Cardiovasc Res 45(3): 788-794	stimulating endothelial cell
(2000); Messmer et al., Br J	growth. An alternative highly
Pharmacol 127(7): 1633-1640	preferred embodiment of the
(1999); and J Atheroscler	invention includes a method
Thromb 3(2): 75-80 (1996);	for inhibiting endothelial cell
the contents of each of which	growth. A highly preferred
are herein incorporated by	embodiment of the invention
reference in its entirety.	includes a method for
 Endothelial cells that may be	stimulating apoptosis of
used according to these assays	endothelial cells. An
are publicly available (e.g.,	alternative highly preferred
through commercial sources).	embodiment of the invention
Exemplary endothelial cells	includes a method for
that may be used according to	inhibiting (e.g., decreasing)
these assays include bovine	apoptosis of endothelial cells.
aortic endothelial cells	A highly preferred
(bAEC), which are an example	embodiment of the invention
of endothelial cells which line	includes a method for
blood vessels and are involved	stimulating angiogenisis. An

		in functions that include, but	alternative highly preferred
		are not limited to.	embodiment of the invention
		angiogenesis, vascular	includes a method for
		permeability, vascular tone,	inhibiting angiogenesis. A
		and immune cell extravasation.	highly preferred embodiment
			of the invention includes a
			method for reducing cardiac
			hypertrophy. An alternative
			highly preferred embodiment
			of the invention includes a
			method for inducing cardiac
			hypertrophy. Highly
			preferred indications include
	_		neoplastic diseases (e.g., as
			described below under
			"Hyperproliferative
	al-m		Disorders"), and disorders of
			the cardiovascular system
			(e.g., heart disease, congestive
			heart failure, hypertension,
			aortic stenosis,
			cardiomyopathy, valvular
			regurgitation, left ventricular
-			dysfunction, atherosclerosis
			and atherosclerotic vascular
			disease, diabetic nephropathy,
			intracardiac shunt, cardiac
,			hypertrophy, myocardial
	-		infarction, chronic
			hemodynamic overload, and/or
			as described below under

"Cardiovascular Disorders").	Highly preferred indications	include cardiovascular,	endothelial and/or angiogenic	disorders (e.g., systemic	disorders that affect vessels	such as diabetes mellitus, as	well as diseases of the vessels	themselves, such as of the	arteries, capillaries, veins	and/or lymphatics). Highly	preferred are indications that	stimulate angiogenesis and/or	cardiovascularization. Highly	preferred are indications that	inhibit angiogenesis and/or	cardiovascularization.	Highly preferred indications	include antiangiogenic activity	to treat solid tumors,	leukemias, and Kaposi"s	sarcoma, and retinal disorders.	Highly preferred indications	include neoplasms and cancer,	such as, Kaposi"s sarcoma,	hemangioma (capillary and	cavernous), glomus tumors,	telangiectasia, bacillary	angiomatosis,	hemangioendothelioma,	angiosarcoma,
),,	H _	in	er	di di	di	ns	'M -	th	ar	ar	nd	str	ca	ıd	in	ca	H	ii –	to	le le	es	H	— in	ns	he he	Ca	te	ar	he	ar
																				-					-	<u> </u>	•			
							-																							

_			_														-													
haemangionericytoma	Ivmohangioma,	lymphangiosarcoma. Highly	preferred indications also	include cancers such as,	prostate, breast, lung, colon,	pancreatic, esophageal,	stomach, brain, liver, and	urinary cancer. Preferred	indications include benign	dysproliferative disorders and	pre-neoplastic conditions, such	as, for example, hyperplasia,	metaplasia, and/or dysplasia.	Highly preferred indications	also include arterial disease,	such as, atherosclerosis,	hypertension, coronary artery	disease, inflammatory	vasculitides, Reynaud"s	disease and Reynaud"s	phenomenom, aneurysms,	restenosis; venous and	lymphatic disorders such as	thrombophlebitis,	lymphangitis, and	lymphedema; and other	vascular disorders such as	peripheral vascular disease,	and cancer. Highly	preferred indications also
					-					_										_										
																									•					

																														:
					•							-																		
-						a								-		-														
																					_			-	_					
															_															

																					_							
include trauma such as wounds, burns, and injured	tissue (e.g., vascular injury	such as, injury resulting from balloon angioplasty, and	atheroschlerotic lesions),	implant fixation, scarring,	ischemia reperfusion injury,	rheumatoid arthritis,	cerebrovascular disease, renal	diseases such as acute renal	failure, and osteoporosis.	Additional highly preferred	indications include stroke,	graft rejection, diabetic or	other retinopathies, thrombotic	and coagulative disorders,	vascularitis, lymph	angiogenesis, sexual disorders,	age-related macular	degeneration, and treatment	/prevention of endometriosis	and related conditions.	Additional highly preferred	indications include fibromas,	heart disease, cardiac arrest,	heart valve disease, and	vascular disease. Preferred	indications include blood	disorders (e.g., as described	below under "Immune
															_							-						
																								-		•		

				Activity", "Blood-Related
				Disorders", and/or
				"Cardiovascular Disorders").
				Preferred indications include
				autoimmune diseases (e.g.,
				rheumatoid arthritis, systemic
				lupus erythematosis, multiple
				sclerosis and/or as described
				below) and
				immunodeficiencies (e.g., as
				described below). Additional
				preferred indications include
				inflammation and
				inflammatory disorders (such
				as acute and chronic
				inflammatory diseases, e.g.,
				inflammatory bowel disease
				and Crohn's disease), and pain
				management.
HTAEE28	818	Insulin Secretion	Assays for measuring secretion	A highly preferred indication
			of insulin are well-known in	is diabetes mellitus. An
			the art and may be used or	additional highly preferred
			routinely modified to assess	indication is a complication
			the ability of polypeptides of	associated with diabetes (e.g.,
			the invention (including	diabetic retinopathy, diabetic
			antibodies and agonists or	nephropathy, kidney disease
			antagonists of the invention) to	(e.g., renal failure,
			stimulate insulin secretion.	nephropathy and/or other
			For example, insulin secretion	diseases and disorders as
			is measured by FMAT using	described in the "Renal
			anti-rat insulin antibodies.	Disorders" section below),

diabetic neuropathy, nerve disease and nerve damage	(e.g., due to diabetic neuropathy), blood vessel	blockage, heart disease, stroke,	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,	microvascular disease,	hypertension, stroke, and other	diseases and disorders as	described in the	"Cardiovascular Disorders"	section below), dyslipidemia,	endocrine disorders (as	described in the "Endocrine	Disorders" section below),	neuropathy, vision impairment	(e.g., diabetic retinopathy and	blindness), ulcers and impaired	wound healing, and infection	(e.g., infectious diseases and	disorders as described in the	"Infectious Diseases" section	below, especially of the	urinary tract and skin), carpal
Insulin secretion from pancreatic beta cells is	upregulated by glucose and also by certain	proteins/peptides, and	disregulation is a key	component in diabetes.	Exemplary assays that may be	used or routinely modified to	test for stimulation of insulin	secretion (from pancreatic	cells) by polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include assays	disclosed in: Shimizu, H., et	al., Endocr J, 47(3):261-9	(2000); Salapatek, A.M., et al.,	Mol Endocrinol, 13(8):1305-	17 (1999); Filipsson, K., et al.,	Ann N Y Acad Sci, 865:441-4	(1998); Olson, L.K., et al., J	Biol Chem, 271(28):16544-52	(1996); and, Miraglia S et. al.,	Journal of Biomolecular	Screening, 4:193-204 (1999),	the contents of each of which	is herein incorporated by	reference in its entirety.	Pancreatic cells that may be	used according to these assays
								-																				

antagonists of the invention) to	nephropathy and/or other
regulate viability and	
proliferation of pancreatic beta	-
cells. For example, the Cell	Disorders" section below),
Titer-Glo luminescent cell	diabetic neuropathy, nerve
viability assay measures the	disease and nerve damage
number of viable cells in	(e.g., due to diabetic
culture based on quantitation	neuropathy), blood vessel
of the ATP present which	blockage, heart disease, stroke,
signals the presence of	impotence (e.g., due to diabetic
metabolically active cells.	neuropathy or blood vessel
Exemplary assays that may be	blockage), seizures, mental
used or routinely modified to	confusion, drowsiness,
test regulation of viability and	nonketotic hyperglycemic-
proliferation of pancreatic beta	
cells by polypeptides of the	cardiovascular disease (e.g.,
invention (including antibodies	heart disease, atherosclerosis,
and agonists or antagonists of	microvascular disease,
the invention) include assays	hypertension, stroke, and other
disclosed in: Friedrichsen BN,	diseases and disorders as
et al., Mol Endocrinol,	described in the
15(1):136-48 (2001); Huotari	"Cardiovascular Disorders"
MA, et al., Endocrinology,	section below), dyslipidemia,
139(4):1494-9 (1998); Hugl	endocrine disorders (as
SR, et al., J Biol Chem 1998	described in the "Endocrine
 Jul 10;273(28):17771-9	Disorders" section below),
(1998), the contents of each of	neuropathy, vision impairment
 which is herein incorporated	(e.g., diabetic retinopathy and
by reference in its entirety.	blindness), ulcers and impaired
Pancreatic cells that may be	wound healing, and infection
used according to these assays	\dashv

xpression is diabetic neuropathy, nerve			tified as blockage, heart disease, stroke,			1 and other blockage), seizures, mental	_	nat may be nonketotic hyperglycemic-	odified to hyperosmolar coma,	f cardiovascular disease (e.g.,	ic Enzyme heart disease, atherosclerosis,	microvascular disease,	invention hypertension, stroke, and other	s and diseases and disorders as	sts of the described in the	.ssays "Cardiovascular Disorders"	er, R.S., et section below), dyslipidemia,	endocrine disorders (as	98); described in the "Endocrine	et al., Mol Disorders" section below),		et al., J (e.g., diabetic retinopathy and	1:17997- blindness), ulcers and impaired		(e.g., infectious diseases and		66:1-10 "Infectious Diseases" section		
lipogenesisand its expression is	promoter contains two direct	repeat (DR1)- like elements	MEp and MEd identified as	putative PPAR response	elements. ME promoter may	also responds to AP1 and other	transcription factors.	Exemplary assays that may be	used or routinely modified to	test for regulation of	transcription of Malic Enzyme	(in hepatocytes) by	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in: Streeper, R.S., et	al., Mol Endocrinol,	12(11):1778-91 (1998);	Garcia-Jimenez, C., et al., Mol	Endocrinol, 8(10):1361-9	(1994); Barroso, I., et al., J	Biol Chem, 274(25):17997-	8004 (1999); Ijpenberg, A., et	al., J Biol Chem,	272(32):20108-20117 (1997);	Berger, et al., Gene 66:1-10	(1988); and, Cullen, B., et al.,	Methods in Enzymol.

tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Aditional highly preferred indications are complications associated with insulin resistance.	A highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. An additional highly preferred indication is diabetes mellitus. An additional highly preferred
216:362–368 (1992), the contents of each of which is herein incorporated by reference in its entirety. Hepatocytes that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary hepatocytes that may be used according to these assays includes the mouse assays includes the mouse assays includes the mouse assays includes the one (adherent). It is a continuous substrain of 3T3 fibroblasts developed through clonal isolation. Cells undergo a preadipocyte to adipose-like conversion under appropriate differentiation culture conditions.	Assays for the activation of transcription through the cAMP response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the
	Activation of transcription through cAMP response element (CRE) in preadipocytes.
	821
	HTEFU65

													<u>۔</u>	_								<u> </u>	-						_
indication is a complication associated with diabetes (e.g.,	diabetic retinopathy, diabetic	nephropathy, kidney disease	(e.g., renal failure,	nephropathy and/or other	diseases and disorders as	described in the "Renal	Disorders" section below),	diabetic neuropathy, nerve	disease and nerve damage	(e.g., due to diabetic	neuropathy), blood vessel	blockage, heart disease, stroke,	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,	microvascular disease,	hypertension, stroke, and other	diseases and disorders as	described in the	"Cardiovascular Disorders"	section below), dyslipidemia,	endocrine disorders (as	described in the "Endocrine	Disorders" section helow)
invention) to increase cAMP, regulate CRFB transcription	factors, and modulate	expression of genes involved	in a wide variety of cell	functions. For example, a	3T3-L1/CRE reporter assay	may be used to identify factors	that activate the cAMP	signaling pathway. CREB	plays a major role in	adipogenesis, and is involved	in differentiation into	adipocytes. CRE contains the	binding sequence for the	transcription factor CREB	(CRE binding protein).	Exemplary assays for	transcription through the	cAMP response element that	may be used or routinely	modified to test cAMP-	response element activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216.262_368 (1002). Hanthorn
				-																									
																	•									-			
								_																					

				et al., Proc Natl Acad Sci USA	neuropathy, vision impairment
				85:6342-6346 (1988); Reusch	(e.g., diabetic retinopathy and
				et al., Mol Cell Biol	blindness), ulcers and impaired
				20(3):1008-1020 (2000); and	wound healing, and infection
				Klemm et al., J Biol Chem	(e.g., infectious diseases and
				273:917-923 (1998), the	disorders as described in the
				contents of each of which are	"Infectious Diseases" section
				herein incorporated by	below, especially of the
				reference in its entirety. Pre-	urinary tract and skin), carpal
_				adipocytes that may be used	tunnel syndrome and
				according to these assays are	Dupuytren's contracture).
				publicly available (e.g.,	Additional highly preferred
				through the ATCC) and/or	indications are complications
				may be routinely generated.	associated with insulin
				Exemplary mouse adipocyte	resistance.
				cells that may be used	
				according to these assays	
				include 3T3-L1 cells. 3T3-L1	
				is an adherent mouse	
				preadipocyte cell line that is a	
				continuous substrain of 3T3	
				fibroblast cells developed	
				through clonal isolation and	
				undergo a pre-adipocyte to	
				adipose-like conversion under	
				appropriate differentiation	
				conditions known in the art.	
	HTEFU65	821	Regulation of	Assays for the regulation of	A highly preferred
			transcription of	transcription of Malic Enzyme	indication is diabetes mellitus.
			Malic Enzyme in	are well-known in the art and	An additional highly preferred
		į	hepatocytes	may be used or routinely	indication is a complication

associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as	described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel	blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemichyperosmolar coma,	cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the	section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment
modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate transcription of Malic Enzyme,	a key enzyme in lipogenesis. Malic enzyme is involved in lipogenesisand its expression is stimulted by insulin. ME promoter contains two direct repeat (DR1)- like elements	MEp and MEd identified as putative PPAR response elements. ME promoter may also responds to AP1 and other transcription factors. Exemplary assays that may be used or routinely modified to	test for regulation of transcription of Malic Enzyme (in hepatocytes) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include agonists or antagonists of the invention)	disclosed in: Streeper, R.S., et al., Mol Endocrinol, Carcia-Jimenez, C., et al., Mol Endocrinol, 8(10):1361-9

																										_				
(e.g., diabetic retinopathy and	blindness), ulcers and impaired	wound healing, and infection	(e.g., infectious diseases and	disorders as described in the	"Infectious Diseases" section	below, especially of the	urinary tract and skin), carpal	tunnel syndrome and	Dupuytren's contracture).	An additional highly preferred	indication is obesity and/or	complications associated with	obesity. Additional highly	preferred indications include	weight loss or alternatively,	weight gain. Aditional	highly preferred indications are	complications associated with	insulin resistance.											Highly preferred indications
(1994); Barroso, I., et al., J	Biol Chem, 274(25):17997-	8004 (1999); Ijpenberg, A., et	al., J Biol Chem,	272(32):20108-20117 (1997);	Berger, et al., Gene 66:1-10	(1988); and, Cullen, B., et al.,	Methods in Enzymol.	216:362–368 (1992), the	contents of each of which is	herein incorporated by	reference in its entirety.	Hepatocytes that may be used	according to these assays are	publicly available (e.g.,	through the ATCC) and/or	may be routinely generated.	Exemplary hepatocytes that	may be used according to these	assays includes the mouse	3T3-L1 cell line. 3T3-L1 is a	mouse preadipocyte cell line	(adherent). It is a continuous	substrain of 3T3 fibroblasts	developed through clonal	isolation. Cells undergo a pre-	adipocyte to adipose-like	conversion under appropriate	differentiation culture	conditions.	Assays for muscle cell
																		•												Myoblast cell
																														821
																														HTEFU65

proliferation	proliferation are well known in	include diabetes, myopathy,
1	the art and may be used or	muscle cell atrophy, cancers of
	routinely modified to assess	muscle (such as,
	the ability of polypeptides of	rhabdomyoma, and
	the invention (including	rhabdosarcoma),
	antibodies and agonists or	cardiovascular disorders (such
	antagonists of the invention) to	as congestive heart failure,
 	stimulate or inhibit myoblast	cachexia, myxomas, fibromas,
	cell proliferation. Exemplary	congenital cardiovascular
	assays for myoblast cell	abnormalities, heart disease,
	proliferation that may be used	cardiac arrest, heart valve
	or routinely modified to test	disease, vascular disease, and
	activity of polypeptides and	also as described below under
-	antibodies of the invention	"Cardiovascular Disorders"),
	(including agonists or	stimulating myoblast
	antagonists of the invention)	proliferation, and inhibiting
	include, for example, assays	myoblast proliferation.
	disclosed in: Soeta, C., et al.	
	"Possible role for the c-ski	
	gene in the proliferation of	
	myogenic cells in regenerating	
	skeletal muscles of rats" Dev	
	Growth Differ Apr;43(2):155-	
	64 (2001); Ewton DZ, et al.,	
	"IGF binding proteins-4, -5	
	and -6 may play specialized	
	roles during L6 myoblast	
	proliferation and	
	differentiation" J Endocrinol	
	Mar;144(3):539-53 (1995);	
	and, Pampusch MS, et	

al.,"Effect of transforming	growin factor beta on proliferation of L6 and	embryonic porcine myogenic	cells" J Cell Physiol	Jun;143(3):524-8 (1990); the	contents of each of which are	herein incorporated by	reference in their entirety.	Exemplary myoblast cells that	may be used according to these	assays include the rat myoblast	L6 cell line. Rat myoblast L6	cells are an adherent rat	myoblast cell line, isolated	from primary cultures of rat	thigh muscle, that fuse to form	multinucleated myotubes and	striated fibers after culture in	differentiation media.	Reporter Assay: construct	contains regulatory and coding	sequence of squalene	synthetase, the first specific	enzyme in the cholesterol	biosynthetic pathway. See	Jiang, et al., J. Biol. Chem.	268:12818-128241(993), the	contents of which are herein	incorporated by reference in its	entirety. Cells were treated
																			Inhibition of	squalene synthetase	gene transcription.								
																			821										
																			HTEFU65										

			with SID supernatants, and SEAP activity was measured after 72 hours. HepG2 is a human hepatocellular carcinoma cell line (ATCC HB-8065). See Knowles et al., Science. 209:497-9 (1980), the contents of which are herein incorporated by reference in its entirety.	
HTEFU65	821	Production of IFNgamma using a T cells	IFNgamma FMAT. IFNg plays a central role in the immune system and is considered to be a proinflammatory cytokine. IFNg promotes TH1 and inhibits TH2 differentiation; promotes IgG2a and inhibits IgE secretion; induces macrophage activation; and increases MHC expression. Assays for immunomodulatory proteins produced by T cells and NK cells that regulate a variety of inflammatory activities and inhibit TH2 helper cell functions are well known in the art and may be used or routinely modified to assess the ability of	A highly preferred embodiment of the invention includes a method for stimulating the production of IFNg. An alternative highly preferred embodiment of the invention includes a method for inhibiting the production of IFNg. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infections, tuberculosis, infections associated with chronic granulomatosus
			polypeptides of the invention (including antibodies and	disease and malignant osteoporosis, and/or as

										_															
described below under "Infectious Disease"). Highly preferred indications include	autoimmune disease (e.g.,	lupus erythematosis, multiple	scierosis and/or as described below), immunodeficiency	(e.g., as described below),	boosting a 1 cell-mediated immine response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders.	Additional preferred	indications include idiopathic	pulmonary fibrosis. Highly	preferred indications include	neoplastic diseases (e.g.,	leukemia, lymphoma,	melanoma, and/or as described	below under	"Hyperproliferative	Disorders"). Highly preferred	indications include neoplasms	and cancers, such as, for	example, leukemia, lymphoma,	melanoma, and prostate,	breast, lung, colon, pancreatic,
agonists or antagonists of the invention) to mediate immunomodulation, regulate	inflammatory activities, modulate TH2 helper cell	function, and/or mediate	immunity. Exemplary assays	that test for	immunomodulatory proteins evaluate the production of	cytokines, such as Interferon	gamma (IFNg), and the	activation of T cells. Such	assays that may be used or	routinely modified to test	immunomodulatory activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include the assays	disclosed in Miraglia et al., J	Biomolecular Screening 4:193-	204 (1999); Rowland et al.,	"Lymphocytes: a practical	approach" Chapter 6:138-160	(2000); Gonzalez et al., J Clin	Lab Anal 8(5):225-233 (1995);	Billiau et al., Ann NY Acad	Sci 856:22-32 (1998); Boehm	et al., Annu Rev Immunol
																									-

				15:749-795 (1997), and	esophageal, stomach, hrain
				Rheumatology (Oxford)	liver and urinary cancer. Other
				38(3):214-20 (1999), the	preferred indications include
				contents of each of which are	benign dysproliferative
				herein incorporated by	disorders and pre-neoplastic
				reference in its entirety.	conditions, such as, for
_				Human T cells that may be	example, hyperplasia,
				used according to these assays	metaplasia, and/or dysplasia.
	-			may be isolated using	Preferred indications include
				techniques disclosed herein or	anemia, pancytopenia,
				otherwise known in the art.	leukopenia, thrombocytopenia,
				Human T cells are primary	Hodgkin's disease, acute
				human lymphocytes that	lymphocytic anemia (ALL),
				mature in the thymus and	plasmacytomas, multiple
				express a T Cell receptor and	myeloma, Burkitt's lymphoma,
				CD3, CD4, or CD8. These	arthritis, AIDS, granulomatous
				cells mediate humoral or cell-	disease, inflammatory bowel
				mediated immunity and may	disease, sepsis, neutropenia,
				be preactivated to enhance	neutrophilia, psoriasis,
				responsiveness to	suppression of immune
				immunomodulatory factors.	reactions to transplanted
					organs and tissues,
					hemophilia, hypercoagulation,
	-				diabetes mellitus, endocarditis,
					meningitis, Lyme Disease,
					asthma and allergy.
	HIEFU65	821	Stimulation of	Assays for measuring secretion	A highly preferred
			insulin secretion	of insulin are well-known in	indication is diabetes mellitus.
			from pancreatic	the art and may be used or	An additional highly preferred
			beta cells.	routinely modified to assess	indication is a complication
				the ability of polypeptides of	associated with diabetes (e.g.,

	the invention (including	diabetic retinopathy, diabetic
	antibodies and agonists or	nephropathy, kidney disease
	antagonists of the invention) to	(e.g., renal failure,
	stimulate insulin secretion.	nephropathy and/or other
-	For example, insulin secretion	diseases and disorders as
	is measured by FMAT using	described in the "Renal
	anti-rat insulin antibodies.	Disorders" section below),
	Insulin secretion from	diabetic neuropathy, nerve
	pancreatic beta cells is	disease and nerve damage
	upregulated by glucose and	(e.g., due to diabetic
	also by certain	neuropathy), blood vessel
	proteins/peptides, and	blockage, heart disease, stroke,
	disregulation is a key	impotence (e.g., due to diabetic
	component in diabetes.	neuropathy or blood vessel
	Exemplary assays that may be	blockage), seizures, mental
	used or routinely modified to	confusion, drowsiness,
	test for stimulation of insulin	nonketotic hyperglycemic-
	secretion (from pancreatic	hyperosmolar coma,
	cells) by polypeptides of the	cardiovascular disease (e.g.,
	invention (including antibodies	heart disease, atherosclerosis,
	and agonists or antagonists of	microvascular disease,
	the invention) include assays	hypertension, stroke, and other
	disclosed in: Ahren, B., et al.,	diseases and disorders as
	Am J Physiol, 277(4 Pt	described in the
	2):R959-66 (1999); Li, M., et	"Cardiovascular Disorders"
	al., Endocrinology,	section below), dyslipidemia,
	138(9):3735-40 (1997); Kim,	endocrine disorders (as
-	K.H., et al., FEBS Lett,	described in the "Endocrine
	377(2):237-9 (1995); and,	Disorders" section below),
	Miraglia S et. al., Journal of	neuropathy, vision impairment
	Biomolecular Screening,	(e.g., diabetic retinopathy and

				4:193-204 (1999), the contents	blindness), ulcers and impaired
				of each of which is herein	wound healing, and infection
				incorporated by reference in its	(e.g., infectious diseases and
•				entirety. Pancreatic cells that	disorders as described in the
				may be used according to these	"Infectious Diseases" section
				assays are publicly available	below, especially of the
				(e.g., through the ATCC)	urinary tract and skin), carpal
				and/or may be routinely	tunnel syndrome and
				generated. Exemplary	Dupuytren's contracture).
				pancreatic cells that may be	An additional highly preferred
				used according to these assays	indication is obesity and/or
				include rat INS-1 cells. INS-1	complications associated with
				cells are a semi-adherent cell	obesity. Additional highly
				line established from cells	preferred indications include
				isolated from an X-ray induced	weight loss or alternatively,
				rat transplantable insulinoma.	weight gain. Aditional
				These cells retain	highly preferred indications are
				characteristics typical of native	complications associated with
				pancreatic beta cells including	insulin resistance.
				glucose inducible insulin	
				secretion. References: Asfari	
				et al. Endocrinology 1992	
				130:167.	
HTEGA76	1A76	822	Activation of	Kinase assay. Kinase assays,	A highly preferred
			Adipocyte ERK	for example an Elk-1 kinase	embodiment of the invention
			Signaling Pathway	assay, for ERK signal	includes a method for
				transduction that regulate cell	stimulating adipocyte
				proliferation or differentiation	proliferation. An alternative
				are well known in the art and	highly preferred embodiment
-				may be used or routinely	of the invention includes a
				modified to assess the ability	method for inhibiting

adipocyte proliferation. A highly preferred embodiment of the invention includes a	method for stimulating adipocyte differentiation. An	alternative highly preferred	embodiment of the invention	inhibiting adipocyte	differentiation. A highly	preferred embodiment of the	invention includes a method	for stimulating (e.g.,	increasing) adipocyte	activation. An alternative	highly preferred embodiment	of the invention includes a	method for inhibiting the	activation of (e.g., decreasing)	and/or inactivating adipocytes.	Highly preferred indications	include endocrine disorders	(e.g., as described below under	"Endocrine Disorders").	Highly preferred indications	also include neoplastic	diseases (e.g., lipomas,	liposarcomas, and/or as	described below under	"Hyperproliferative	Disorders"). Preferred
of polypeptides of the invention (including antibodies and agonists or antagonists of	the invention) to promote or inhibit cell proliferation.	activation, and differentiation.	Exemplary assays for ERK	used or routinely modified to	test ERK kinase-induced	activity of polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include the	assays disclosed in Forrer et	al., Biol Chem 379(8-9):1101-	1110 (1998); Le Marchand-	Brustel Y, Exp Clin	Endocrinol Diabetes	107(2):126-132 (1999);	Kyriakis JM, Biochem Soc	Symp 64:29-48 (1999); Chang	and Karin, Nature	410(6824):37-40 (2001); and	Cobb MH, Prog Biophys Mol	Biol 71(3-4):479-500 (1999);	the contents of each of which	are herein incorporated by	reference in its entirety.	Mouse adipocyte cells that	may be used according to these

indications include blood disorders (e.g., hypertension, congestive heart failure, blood vessel blockage, heart disease,	stroke, impotence and/or as described below under "Immune Activity", "Cardiovascular Disorders",	and/or "Blood-Related Disorders"), immune disorders (e.g., as described below under "Immune Activity"), neural	disorders (e.g., as described below under "Neural Activity and Neurological Diseases"),	and infection (e.g., as described below under "Infectious Disease"). A highly preferred indication	is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g.,	diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other	diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve
assays are publicly available (e.g., through the ATCC). Exemplary mouse adipocyte cells that may be used	according to these assays include 3T3-L1 cells. 3T3-L1 is an adherent mouse preadipocyte cell line that is a	continuous substrain of 3T3 fibroblast cells developed through clonal isolation and undergo a pre-adipocyte to	adipose-like conversion under appropriate differentiation conditions known in the art.				

	disease and nerve damage
_	(e.g., due to diabetic
	neuropathy), blood vessel
-	blockage, heart disease, stroke,
	impotence (e.g., due to diabetic
	neuropathy or blood vessel
	blockage), seizures, mental
	confusion, drowsiness,
	nonketotic hyperglycemic-
	hyperosmolar coma,
	cardiovascular disease (e.g.,
	heart disease, atherosclerosis,
	microvascular disease,
	hypertension, stroke, and other
	diseases and disorders as
	described in the
	"Cardiovascular Disorders"
	section below), dyslipidemia,
	endocrine disorders (as
	described in the "Endocrine
	Disorders" section below),
	neuropathy, vision impairment
_	(e.g., diabetic retinopathy and
	blindness), ulcers and impaired
	wound healing, infection (e.g.,
	infectious diseases and
	disorders as described in the
	"Infectious Diseases" section
	below (particularly of the
	urinary tract and skin). An
	additional highly preferred

		indication is obesity and/or
		committee of the control with
		complications associated with
		obesity. Additional highly
		preferred indications include
	-	weight loss or alternatively,
	-	weight gain. Additional
		highly preferred indications are
		complications associated with
		insulin resistance.
		Additional highly preferred
		indications are disorders of the
		musculoskeletal systems
		including myopathies,
		muscular dystrophy, and/or as
		described herein.
		Additional highly preferred
		indications include,
		hypertension, coronary artery
-		disease, dyslipidemia,
		gallstones, osteoarthritis,
		degenerative arthritis, eating
		disorders, fibrosis, cachexia,
		and kidney diseases or
		disorders. Preferred
		indications include neoplasms
		and cancer, such as,
		lymphoma, leukemia and
		breast, colon, and kidney
		cancer. Additional preferred
		indications include melanoma,
		prostate, lung, pancreatic,

					esophageal, stomach, brain,
					Highly preferred indications
					include lipomas and
					liposarcomas. Other preferred
					indications include benign
					dysproliferative disorders and
					pre-neoplastic conditions, such
					as, for example, hyperplasia,
					metaplasia, and/or dysplasia.
	HTEGA76	822	Endothelial Cell	Caspase Apoptosis. Assays for	A highly preferred
			Apoptosis	caspase apoptosis are well	embodiment of the invention
				known in the art and may be	includes a method for
				used or routinely modified to	stimulating endothelial cell
•				assess the ability of	growth. An alternative highly
				polypeptides of the invention	preferred embodiment of the
				(including antibodies and	invention includes a method
				agonists or antagonists of the	for inhibiting endothelial cell
				invention) to promote caspase	growth. A highly preferred
				protease-mediated apoptosis.	embodiment of the invention
				Induction of apoptosis in	includes a method for
				endothelial cells supporting the	stimulating endothelial cell
				vasculature of tumors is	proliferation. An alternative
				associated with tumor	highly preferred embodiment
				regression due to loss of tumor	of the invention includes a
				blood supply. Exemplary	method for inhibiting
				assays for caspase apoptosis	endothelial cell proliferation.
				that may be used or routinely	A highly preferred
				modified to test capase	embodiment of the invention
				apoptosis activity of	includes a method for
				polypeptides of the invention	stimulating apoptosis of

					
endothelial cells. An alternative highly preferred embodiment of the invention	includes a method for inhibiting (e.g., decreasing) apoptosis of endothelial cells. A highly preferred	embodiment of the invention includes a method for stimulating angiogenisis. An alternative highly preferred embodiment of the invention	includes a method for inhibiting angiogenesis. A highly preferred embodiment of the invention includes a method for reducing cardiac	hypertrophy. An alternative highly preferred embodiment of the invention includes a method for inducing cardiac hypertrophy. Highly preferred indications include	neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), and disorders of the cardiovascular system (e.g., heart disease, congestive heart failure, hypertension, aortic stenosis,
(including antibodies and agonists or antagonists of the invention) include the assays	disclosed in Lee et al., FEBS Lett 485(2-3): 122-126 (2000); Nor et al., J Vasc Res 37(3): 209-218 (2000): and Karsan	and Harlan, J Atheroscler Thromb 3(2): 75-80 (1996); the contents of each of which are herein incorporated by reference in its entirety.	Endothelial cells that may be used according to these assays are publicly available (e.g., through commercial sources). Exemplary endothelial cells	that may be used according to these assays include bovine aortic endothelial cells (bAEC), which are an example of endothelial cells which line blood vessels and are involved	in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.
			,		

cardiomyopathy, valvular	regurgitation, left ventricular	dysfunction, atherosclerosis	and atherosclerotic vascular	disease, diabetic nephropathy,	intracardiac shunt, cardiac	hypertrophy, myocardial	infarction, chronic	hemodynamic overload, and/or	as described below under	"Cardiovascular Disorders").	Highly preferred indications	include cardiovascular,	endothelial and/or angiogenic	disorders (e.g., systemic	disorders that affect vessels	such as diabetes mellitus, as	well as diseases of the vessels	themselves, such as of the	arteries, capillaries, veins	and/or lymphatics). Highly	preferred are indications that	stimulate angiogenesis and/or	cardiovascularization. Highly	preferred are indications that	inhibit angiogenesis and/or	cardiovascularization.	Highly preferred indications	include antiangiogenic activity	to treat solid tumors,	leukemias, and Kaposi"s
	****																										•			
	-																													
												_												-						

			sarcoma, and retinal disorders.
			Highly preferred indications
		-	include neoplasms and cancer,
			such as, Kaposi"s sarcoma,
			hemangioma (capillary and
			cavernous), glomus tumors,
		a r (13	telangiectasia, bacillary
			angiomatosis,
			hemangioendothelioma,
			angiosarcoma,
			haemangiopericytoma,
			lymphangioma,
			lymphangiosarcoma. Highly
			preferred indications also
			include cancers such as,
			prostate, breast, lung, colon,
			pancreatic, esophageal,
			stomach, brain, liver, and
			urinary cancer. Preferred
	-		indications include benign
			dysproliferative disorders and
			pre-neoplastic conditions, such
			as, for example, hyperplasia,
			metaplasia, and/or dysplasia.
			Highly preferred indications
			also include arterial disease,
			such as, atherosclerosis,
			hypertension, coronary artery
			disease, inflammatory
			vasculitides, Reynaud"s
			disease and Reynaud"s

phenomenom, aneurysms,	restenosis; venous and	lymphatic disorders such as	thrombophlebitis,	lymphangitis, and	lymphedema; and other	vascular disorders such as	peripheral vascular disease,	and cancer. Highly	preferred indications also	include trauma such as	wounds, burns, and injured	tissue (e.g., vascular injury	such as, injury resulting from	balloon angioplasty, and	atheroschlerotic lesions),	implant fixation, scarring,	ischemia reperfusion injury,	rheumatoid arthritis,	cerebrovascular disease, renal	diseases such as acute renal	failure, and osteoporosis.	Additional highly preferred	indications include stroke,	graft rejection, diabetic or	other retinopathies, thrombotic	and coagulative disorders,	vascularitis, lymph	angiogenesis, sexual disorders,	age-related macular	degeneration, and treatment
											_			 -			-													
		-														:														
					-																		-						<u> </u>	
										-				-													_			

includes a mathod for	stimulating MIP1a production.	An alternative highly preferred	embodiment of the invention	includes a method for	inhibiting (e.g., reducing)	MIP1a production. A highly	15	infection (e.g., an infectious	disease as described below	under "Infectious Disease").	Preferred indications include	blood disorders (e.g., as	described below under	"Immune Activity", "Blood-	Related Disorders", and/or	"Cardiovascular Disorders").	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	multiple sclerosis and/or as	described below) and	immunodeficiencies (e.g., as	described below). Additional	highly preferred indications	include inflammation and	inflammatory disorders.	Preferred indications also	include anemia, pancytopenia,	leukopenia, thrombocytopenia,
nrotains produced by activated	dendritic cells that upregulate	monocyte/macrophage and T	cell chemotaxis are well	known in the art and may be	used or routinely modified to	assess the ability of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) to mediate	immunomodulation, modulate	chemotaxis, and modulate T	cell differentiation. Exemplary	assays that test for	immunomodulatory proteins	evaluate the production of	chemokines, such as	macrophage inflammatory	protein 1 alpha (MIP-1a), and	the activation of	monocytes/macrophages and T	cells. Such assays that may be	used or routinely modified to	test immunomodulatory and	chemotaxis activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in Miraglia et al., J
																				-					-					
	_												_																	

		Biomolecular Screening 4:193-	Hodgkin's disease, acute
_		204(1999): Rowland et al	lymphocytic anemia (ALL),
		"Lymphocytes: a practical	plasmacytomas, multiple
		approach" Chapter 6:138-160	myeloma, Burkitt's lymphoma,
		(2000); Satthaporn and	arthritis, AIDS, granulomatous
		Eremin, J R Coll Surg Ednb	disease, inflammatory bowel
		45(1):9-19 (2001); Drakes et	disease, sepsis, neutropenia,
		al., Transp Immunol 8(1):17-	neutrophilia, psoriasis,
		29 (2000); Verhasselt et al., J	suppression of immune
		Immunol 158:2919-2925	reactions to transplanted
		(1997); and Nardelli et al., J	organs and tissues, hemophilia,
		Leukoc Biol 65:822-828	hypercoagulation, diabetes
		(1999), the contents of each of	mellitus, endocarditis,
		which are herein incorporated	meningitis, Lyme Disease,
		by reference in its entirety.	asthma, and allergy.
		Human dendritic cells that may	Preferred indications also
		be used according to these	include neoplastic diseases
		assays may be isolated using	(e.g., leukemia, lymphoma,
		techniques disclosed herein or	and/or as described below
		otherwise known in the art.	under "Hyperproliferative
		Human dendritic cells are	Disorders"). Highly preferred
		antigen presenting cells in	indications include neoplasms
		suspension culture, which,	and cancers, such as, leukemia,
		when activated by antigen	lymphoma, prostate, breast,
		and/or cytokines, initiate and	lung, colon, pancreatic,
		upregulate T cell proliferation	esophageal, stomach, brain,
		and functional activities.	liver, and urinary cancer. Other
			preferred indications include
			benign dysproliferative
			disorders and pre-neoplastic
			conditions, such as, for

				example, hyperplasia, metaplasia, and/or dysplasia.
HTELM16	823	Inhibition of	Reporter Assay: construct	
		squalene synthetase	contains regulatory and coding segmence of squalene	
		gene nanscripuon.	sequence of squarence synthetase, the first specific	
			enzyme in the cholesterol	
			biosynthetic pathway. See	
			Jiang, et al., J. Biol. Chem.	
			268:12818-128241(993), the	
			contents of which are herein	
			incorporated by reference in its	
			entirety. Cells were treated	
			with SID supernatants, and	
			SEAP activity was measured	
			after 72 hours. HepG2 is a	
			human hepatocellular	
			carcinoma cell line (ATCC	
			HB-8065). See Knowles et al.,	
			Science. 209:497-9 (1980), the	
			contents of which are herein	
			incorporated by reference in its	
			entirety.	
HTELM16	823	TNFa in Human T-		
		cell 2B9		
HTELM16	823	Activation of	Assays for the activation of	A preferred embodiment of
		transcription	transcription through the	the invention includes a
		through serum	Serum Response Element	method for inhibiting (e.g.,
		response element in	(SRE) are well-known in the	reducing) TNF alpha
		immune cells (such	art and may be used or	production. An alternative
		as T-cells).	routinely modified to assess	highly preferred embodiment

_							-								_								_							
of the invention includes a	method for stimulating (e.g.,	increasing) TNF alpha	production. Preferred	indications include blood	disorders (e.g., as described	below under "Immune	Activity", "Blood-Related	Disorders", and/or	"Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases
the ability of polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention) to	regulate serum response	factors and modulate the	expression of genes involved	in growth and upregulate the	function of growth-related	genes in many cell types.	Exemplary assays for	transcription through the SRE	that may be used or routinely	modified to test SRE activity	of the polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Benson	et al., J Immunol 153(9):3862-	3873 (1994); and Black et al.,	Virus Genes 12(2):105-117	(1997), the content of each of	which are herein incorporated	by reference in its entirety.	Human T cells that may be
																		and the second												
														_																

			used according to these assays	(e.g., leukemia, lymphoma,
-			are publicly available (e.g.,	and/or as described below
			through the ATCC).	under "Hyperproliferative
			Exemplary human T cells that	Disorders"). Additionally,
			may be used according to these	highly preferred indications
			assays include the JURKAT	include neoplasms and
			cell line, which is a suspension	cancers, such as, leukemia,
_			culture of leukemia cells that	lymphoma, melanoma, glioma
		***	produce IL-2 when stimulated.	(e.g., malignant glioma), solid
				tumors, and prostate, breast,
			-	lung, colon, pancreatic,
				esophageal, stomach, brain,
				liver and urinary cancer. Other
				preferred indications include
				benign dysproliferative
				disorders and pre-neoplastic
				conditions, such as, for
				example, hyperplasia,
				metaplasia, and/or dysplasia.
				Preferred indications include
,,,,				anemia, pancytopenia,
	-			leukopenia, thrombocytopenia,
				Hodgkin's disease, acute
				lymphocytic anemia (ALL),
				plasmacytomas, multiple
				myeloma, Burkitt's lymphoma,
				arthritis, AIDS, granulomatous
				disease, inflammatory bowel
				disease, neutropenia,
				neutrophilia, psoriasis,
				suppression of immune

reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious-Pisease.")	H	noter impotence (e.g., due to diabetic res) of neuropathy or blood vessel
		used or routinely modified to test for PEPCK promoter activity (in hepatocytes) of polynentides of the invention
	Kegulation of transcription through the PEPCK promoter in hepatocytes	

																										•				
weight gain. Additional	highly preferred indications are	complications associated with	insulin resistance.	Additional highly preferred	indications are disorders of the	musculoskeletal systems	including myopathies,	muscular dystrophy, and/or as	described herein.	Additional highly preferred	indications include glycogen	storage disease (e.g.,	glycogenoses), hepatitis,	gallstones, cirrhosis of the	liver, degenerative or necrotic	liver disease, alcoholic liver	diseases, fibrosis, liver	regeneration, metabolic	disease, dyslipidemia and	cholesterol metabolism, and	hepatocarcinomas.	Highly preferred indications	include blood disorders (e.g.,	as described below under	"Immune Activity",	"Cardiovascular Disorders",	and/or "Blood-Related	Disorders"), immune disorders	(e.g., as described below under	"Immune Activity"), infection
																		-												
	· · · · · ·									,																				
		·			-																									
			_																											
				-				-	_																					

				(e.g., an infectious disease
				and/or disorder as described
				below under "Infectious
				Disease"), endocrine disorders
				(e.g., as described below under
				"Endocrine Disorders"), and
				neural disorders (e.g., as
				described below under "Neural
				Activity and Neurological
				Diseases").
				Additional preferred
				indications include neoplastic
				diseases (e.g., as described
				below under
				"Hyperproliferative
				Disorders"). Preferred
				indications include neoplasms
				and cancers, such as, leukemia,
				lymphoma, prostate, breast,
				lung, colon, pancreatic,
				esophageal, stomach, brain,
				and urinary cancer. A highly
				preferred indication is liver
				cancer. Other preferred
				indications include benign
				dysproliferative disorders and
				pre-neoplastic conditions, such
				as, for example, hyperplasia,
				metaplasia, and/or dysplasia.
 HTELP17	824	Stimulation of	Assays for measuring calcium	A highly preferred
		Calcium Flux in	flux are well-known in the art	indication is diabetes mellitus.

	pancreatic beta	and may be used or routinely	An additional highly preferred
	cells.	modified to assess the ability	indication is a complication
		of polypeptides of the	associated with diabetes (e.g.,
		invention (including antibodies	diabetic retinopathy, diabetic
		and agonists or antagonists of	nephropathy, kidney disease
		the invention) to mobilize	(e.g., renal failure,
		calcium. For example, the	nephropathy and/or other
		FLPR assay may be used to	diseases and disorders as
		measure influx of calcium.	described in the "Renal
		Cells normally have very low	Disorders" section below),
		concentrations of cytosolic	diabetic neuropathy, nerve
		calcium compared to much	disease and nerve damage
		higher extracellular calcium.	(e.g., due to diabetic
	-	Extracellular factors can cause	neuropathy), blood vessel
		an influx of calcium, leading to	blockage, heart disease, stroke,
_		activation of calcium	impotence (e.g., due to diabetic
		responsive signaling pathways	neuropathy or blood vessel
		and alterations in cell	blockage), seizures, mental
		functions. Exemplary assays	confusion, drowsiness,
		that may be used or routinely	nonketotic hyperglycemic-
		modified to measure calcium	hyperosmolar coma,
		flux by polypeptides of the	cardiovascular disease (e.g.,
		invention (including antibodies	heart disease, atherosclerosis,
		and agonists or antagonists of	microvascular disease,
		the invention) include assays	hypertension, stroke, and other
		disclosed in: Satin LS, et al.,	diseases and disorders as
		Endocrinology, 136(10):4589-	described in the
		601 (1995);Mogami H, et al.,	"Cardiovascular Disorders"
		Endocrinology, 136(7):2960-6	section below), dyslipidemia,
		(1995); Richardson SB, et al.,	endocrine disorders (as
		Biochem J, 288 (Pt 3):847-51	described in the "Endocrine

(1992); and, Meats, JE, et al.,	Disorders" section below),
Cell Calcium 1989 Nov-	neuropathy, vision impairment
Dec;10(8):535-41 (1989), the	(e.g., diabetic retinopathy and
contents of each of which is	blindness), ulcers and impaired
herein incorporated by	wound healing, and infection
reference in its entirety.	(e.g., infectious diseases and
Pancreatic cells that may be	disorders as described in the
 used according to these assays	"Infectious Diseases" section
are publicly available (e.g.,	below, especially of the
 through the ATCC) and/or	urinary tract and skin), carpal
may be routinely generated.	tunnel syndrome and
Exemplary pancreatic cells that	Dupuytren's contracture).
may be used according to these	An additional highly preferred
assays include HITT15 Cells.	indication is obesity and/or
HITT15 are an adherent	complications associated with
epithelial cell line established	obesity. Additional highly
from Syrian hamster islet cells	preferred indications include
transformed with SV40. These	weight loss or alternatively,
cells express glucagon,	weight gain. Aditional
somatostatin, and	highly preferred indications are
 glucocorticoid receptors. The	complications associated with
cells secrete insulin, which is	insulin resistance.
stimulated by glucose and	
glucagon and suppressed by	
somatostatin or	
 glucocorticoids. ATTC# CRL-	
1777 Refs: Lord and	
 Ashcroft. Biochem. J. 219:	
547-551; Santerre et al. Proc.	
Natl. Acad. Sci. USA 78:	
4339-4343, 1981.	

	A highly preferred	indication is diabetes mellitus.	An additional highly preferred	indication is a complication	associated with diabetes (e.g.,	diabetic retinopathy, diabetic	nephropathy, kidney disease	(e.g., renal failure,	nephropathy and/or other	diseases and disorders as	described in the "Renal	Disorders" section below),	diabetic neuropathy, nerve	disease and nerve damage	(e.g., due to diabetic	neuropathy), blood vessel	blockage, heart disease, stroke,	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,	microvascular disease,	hypertension, stroke, and other	diseases and disorders as	described in the	"Cardiovascular Disorders"
	Assays for the regulation of	transcription through the	PEPCK promoter are well-	known in the art and may be	used or routinely modified to	assess the ability of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) to activate the	PEPCK promoter in a reporter	construct and regulate liver	gluconeogenesis. Exemplary	assays for regulation of	transcription through the	PEPCK promoter that may be	used or routinely modified to	test for PEPCK promoter	activity (in hepatocytes) of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988);	Lochhead et al., Diabetes
II4 in HMC	Regulation of	transcription	through the PEPCK	promoter in	hepatocytes	-																	-							
824	825																				<u> </u>									
HTEI P17	HTELS08														_															
									_																					

		49(6):896-903 (2000); and	section below), dyslipidemia,
		Yeagley et al., J Biol Chem	endocrine disorders (as
		275(23):17814-17820 (2000),	described in the "Endocrine
		the contents of each of which	Disorders" section below),
		is herein incorporated by	neuropathy, vision impairment
		reference in its entirety.	(e.g., diabetic retinopathy and
		Hepatocyte cells that may be	blindness), ulcers and impaired
·		used according to these assays	wound healing, infection (e.g.,
		are publicly available (e.g.,	an infectious diseases or
		through the ATCC) and/or	disorders as described in the
		may be routinely generated.	"Infectious Diseases" section
		Exemplary liver hepatoma	below, especially of the
		cells that may be used	urinary tract and skin), carpal
, m		according to these assays	tunnel syndrome and
	-	include H4lle cells, which	Dupuytren's contracture).
		contain a tyrosine amino	An additional highly preferred
		transferase that is inducible	indication is obesity and/or
		with glucocorticoids, insulin,	complications associated with
		or cAMP derivatives.	obesity. Additional highly
-			preferred indications include
			weight loss or alternatively,
			weight gain. Additional
			highly preferred indications are
			complications associated with
			insulin resistance.
			Additional highly preferred
			indications are disorders of the
			musculoskeletal systems
			including myopathies,
-			muscular dystrophy, and/or as
			described herein.

Additional highly preferred	indications include glycogen	storage disease (e.g.,	glycogenoses), hepatitis,	gallstones, cirrhosis of the	liver, degenerative or necrotic	liver disease, alcoholic liver	diseases, fibrosis, liver	regeneration, metabolic	disease, dyslipidemia and	cholesterol metabolism, and	hepatocarcinomas.	Highly preferred indications	include blood disorders (e.g.,	as described below under	"Immune Activity",	"Cardiovascular Disorders",	and/or "Blood-Related	Disorders"), immune disorders	(e.g., as described below under	"Immune Activity"), infection	(e.g., an infectious disease	and/or disorder as described	below under "Infectious	Disease"), endocrine disorders	(e.g., as described below under	"Endocrine Disorders"), and	neural disorders (e.g., as	described below under "Neural	Activity and Neurological	Diseases").
								-																						
	_									-				-																
	-																											-		

				Additional preferred
				indications include neoplastic
				below under
				"Hyperproliferative
				Disorders"). Preferred
				indications include neoplasms
				and cancers, such as, leukemia,
				lymphoma, prostate, breast,
				lung, colon, pancreatic,
				esophageal, stomach, brain,
				and urinary cancer. A highly
				preferred indication is liver
				cancer. Other preferred
		,		indications include benign
				dysproliferative disorders and
				pre-neoplastic conditions, such
				as, for example, hyperplasia,
				metaplasia, and/or dysplasia.
HTELS08	825	Inhibition of	Reporter Assay: construct	
		squalene synthetase	contains regulatory and coding	
		gene transcription.	sequence of squalene	
			synthetase, the first specific	
			enzyme in the cholesterol	
			biosynthetic pathway. See	
			Jiang, et al., J. Biol. Chem.	
			268:12818-128241(993), the	
			contents of which are herein	
			incorporated by reference in its	
			entirety. Cells were treated	
			with SID supernatants, and	

	adipa	adipogenesis, and is involved	(e.g., due to diabetic
	in d	in differentiation into	neuropathy), blood vessel
	adip	adipocytes. CRE contains the	blockage, heart disease, stroke,
_	bind	binding sequence for the	impotence (e.g., due to diabetic
	trans	transcription factor CREB	neuropathy or blood vessel
	(CR	(CRE binding protein).	blockage), seizures, mental
	Exe	Exemplary assays for	confusion, drowsiness,
	trans	transcription through the	nonketotic hyperglycemic-
	cAN	cAMP response element that	hyperosmolar coma,
-	may	may be used or routinely	cardiovascular disease (e.g.,
	pom	modified to test cAMP-	heart disease, atherosclerosis,
	resp	response element activity of	microvascular disease,
	poly	polypeptides of the invention	hypertension, stroke, and other
	(incl	(including antibodies and	diseases and disorders as
	agor	agonists or antagonists of the	described in the
	inve	invention) include assays	"Cardiovascular Disorders"
	disc	disclosed in Berger et al., Gene	section below), dyslipidemia,
•	66:1	66:1-10 (1998); Cullen and	endocrine disorders (as
	Malı	Malm, Methods in Enzymol	described in the "Endocrine
	216:	216:362-368 (1992); Henthorn	Disorders" section below),
	et al.	et al., Proc Natl Acad Sci USA	neuropathy, vision impairment
	85:6	85:6342-6346 (1988); Reusch	(e.g., diabetic retinopathy and
	etal.	et al., Mol Cell Biol	blindness), ulcers and impaired
	20(3	20(3):1008-1020 (2000); and	wound healing, and infection
	Klen	Klemm et al., J Biol Chem	(e.g., infectious diseases and
	273:	273:917-923 (1998), the	disorders as described in the
	conte	contents of each of which are	"Infectious Diseases" section
	herei	herein incorporated by	below, especially of the
	refer	reference in its entirety. Pre-	urinary tract and skin), carpal
	adipe	adipocytes that may be used	tunnel syndrome and
	acco	according to these assays are	Dupuytren's contracture).

				through the ATCC) and/or	indications are complications
				may be routinely generated.	associated with insulin
				Exemplary mouse adipocyte	resistance.
				cells that may be used	
	**			according to these assays	
				include 3T3-L1 cells. 3T3-L1	
				is an adherent mouse	
				preadipocyte cell line that is a	
-				continuous substrain of 3T3	
				fibroblast cells developed	
				through clonal isolation and	
				undergo a pre-adipocyte to	
	,			adipose-like conversion under	
				appropriate differentiation	
				conditions known in the art.	
1	HTEPG70	826	Activation of	Assays for the activation of	A highly preferred indication
			transcription	transcription through the	is obesity and/or complications
			through serum	Serum Response Element	associated with obesity.
			response element in	(SRE) are well-known in the	Additional highly preferred
			pre-adipocytes.	art and may be used or	indications include weight loss
				routinely modified to assess	or alternatively, weight gain.
				the ability of polypeptides of	An additional highly preferred
				the invention (including	indication is diabetes mellitus.
				antibodies and agonists or	An additional highly preferred
				antagonists of the invention) to	indication is a complication
				regulate the serum response	associated with diabetes (e.g.,
				factors and modulate the	diabetic retinopathy, diabetic
				expression of genes involved	nephropathy, kidney disease
				in growth. Exemplary assays	(e.g., renal failure,
				for transcription through the	nephropathy and/or other

diseases and disorders as described in the "Renal Disorders" section below)	diabetic neuropathy, nerve	disease and nerve damage	(e.g., due to diabetic	heuropainy), blood vessel blockage, heart disease, stroke.	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,	microvascular disease,	hypertension, stroke, and other	diseases and disorders as	described in the	"Cardiovascular Disorders"	section below), dyslipidemia,	endocrine disorders (as	described in the "Endocrine	Disorders" section below),	neuropathy, vision impairment	(e.g., diabetic retinopathy and	blindness), ulcers and impaired	wound healing, and infection	(e.g., infectious diseases and	discourt on doconitrod in the
SRE that may be used or routinely modified to test SRE activity of the polynentides of	the invention (including	antibodies and agonists or	antagonists of the invention)	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. Pre-	adipocytes that may be used	according to these assays are	publicly available (e.g.,	through the ATCC) and/or	may be routinely generated.	Exemplary mouse adipocyte	cells that may be used	according to these assays	include 3T3-L1 cells. 3T3-L1	is an adherent mouse	preadipocyte cell line that is a	continuous substrain of 3T3	Ghaphlant calle derialand
							•																				
																	-										
																				•							

				through clonal isolation and	"Infectious Diseases" section
				ulideigo a pre-adipocyte to	perow). Additional nightly
				ampose-fine conversion under	preferred indications are complications associated with
				conditions known in the art.	insulin resistance.
HTEF	HTEPG70	826	SEAP in HIB/CRE		
HTEPG70	ا 025م	826	Activation of	This reporter assay measures	Highly preferred indications
			transcription	activation of the GATA-3	include allergy, asthma, and
			through GATA-3	signaling pathway in HMC-1	rhinitis. Additional preferred
			response element in	human mast cell line.	indications include infection
			immune cells (such	Activation of GATA-3 in mast	(e.g., an infectious disease as
			as mast cells).	cells has been linked to	described below under
				cytokine and chemokine	"Infectious Disease"), and
				production. Assays for the	inflammation and
				activation of transcription	inflammatory disorders.
				through the GATA3 response	Preferred indications also
				element are well-known in the	include blood disorders (e.g.,
				art and may be used or	as described below under
				routinely modified to assess	"Immune Activity", "Blood-
				the ability of polypeptides of	Related Disorders", and/or
	-			the invention (including	"Cardiovascular Disorders").
-				antibodies and agonists or	Preferred indications include
				antagonists of the invention) to	autoimmune diseases (e.g.,
				regulate GATA3 transcription	rheumatoid arthritis, systemic
				factors and modulate	lupus erythematosis, multiple
				expression of mast cell genes	sclerosis and/or as described
				important for immune response	below) and
				development. Exemplary	immunodeficiencies (e.g., as
				assays for transcription	described below). Preferred
				through the GATA3 response	indications include neoplastic
				element that may be used or	diseases (e.g., leukemia,

		··											•		
lymphoma, melanoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and	urinary tract cancers and/or as described below under "Hyperproliferative	Disorders"). Other preferred indications include benign dysproliferative disorders and	pre-neoplastic conditions, such as, for example, hyperplasia,	metaplasia, and/or dysplasia. Preferred indications include	anemia, pancytopenia, leukopenia, thrombocytopenia,	leukemias, Hodgkin's disease,	(ALL), plasmacytomas,	multiple myeloma, Burkitt's lymphoma, arthritis, AIDS,	granulomatous disease, inflammatory bowel disease,	sepsis, neutropenia,	suppression of immune	reactions to transplanted	organs and tissues, hemophilia,	hypercoagulation, diabetes	mellitus, endocarditis,
routinely modified to test GATA3-response element activity of polypeptides of the invention (including antibodies	and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Flavell	et al., Cold Spring Harb Symp Quant Biol 64:563-571 (1999);	Rodriguez-Palmero et al., Eur J Immunol 29(12):3914-3924	(1999); Zheng and Flavell,	Henderson et al., Mol Cell Biol	14(6):4286-4294 (1994), the contents of each of which are	herein incorporated by reference in its entirety. Mast	cells that may be used	publicly available (e.g.,	through the ATCC).	Exemplary human mast cells	that may be used according to	these assays include the HMC-
				7											
															-
							-					_			

	Highly preferred indications	include allergy, asthma, and	rhinitis. Additional preferred indications include infection	(e.g., an infectious disease as	described below under	"Infectious Disease"), and	inflammation and	inflammatory disorders.	Preferred indications also	include blood disorders (e.g.,	as described below under	"Immune Activity", "Blood-	Related Disorders", and/or	"Cardiovascular Disorders").	Preferred indications include	autoimmune diseases (e.g.,	rheumatoid arthritis, systemic	lupus erythematosis, multiple	sclerosis and/or as described	below) and	immunodeficiencies (e.g., as	described below). Preferred	indications include neoplastic	diseases (e o Jemia
immature human mast cell line established from the peripheral blood of a patient with mast cell leukemia, and exhibits many characteristics of immature mast cells.	This reporter assay measures	activation of the NFAT	signaling pathway in HIMC-1 human mast cell line.	Activation of NFAT in mast	cells has been linked to	cytokine and chemokine	production. Assays for the	activation of transcription	through the Nuclear Factor of	Activated T cells (NFAT)	response element are well-	known in the art and may be	used or routinely modified to	assess the ability of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) to regulate NFAT	transcription factors and	modulate expression of genes	involved in	immunomodulatory functions.	Exemplary assays for	transcription through the
	Activation of	transcription	response element in	immune cells (such	as mast cells).																			
	826					-					<u></u>								_		_			
OF Order	HTEPG70		•																					
															•							-		

lymphoma, melanoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and	urinary tract cancers and/or as described below under	hyperpronneranve Disorders"). Other preferred indications include benign	dysproliferative disorders and pre-neoplastic conditions, such	as, for example, hyperplasia,	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia,	leukemias, Hodgkin's disease,	acute lymphocytic anemia	(ALL), plasmacytomas,	multiple myeloma, Burkitt's	lymphoma, arthritis, AIDS,	inflammatory bowel disease,	sepsis, neutropenia,	neutrophilia, psoriasis,	suppression of immune	reactions to transplanted	organs and tissues, hemophilia,	hypercoagulation, diabetes	mellitus, endocarditis,	meningitis, and Lyme Disease
NFAT response element that may be used or routinely modified to test NFAT-response element activity of	polypeptides of the invention (including antibodies and	agonists of antagonists of the invention) include assays disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and Malm, Methods in Enzymol	216:362-368 (1992); Henthorn et al. Proc Natl Acad Sci 11SA	85:6342-6346 (1988); De Boer	et al., Int J Biochem Cell Biol	31(10);1221-1236 (1999); Ali	et al., J Immunol	165(12):7215-7223 (2000);	Hutchinson and McCloskey, J	Biol Chem 270(27):16333-	10338 (1995), and 1umer et	(1998), the contents of each of	which are herein incorporated	by reference in its entirety.	Mast cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary human mast cells	that may be used according to
										_											
																			-		

	Highly preferred indication includes allergy, asthma, and rhinitis. Additional highly preferred indications include infection (e.g., an infectious disease as described below under "Infectious Disease"), and inflammation and inflammatory disorders. Preferred indications include immunological and hempatopoietic disorders (e.g., as described below under "Immune Activity", and "Blood-Related Disorders"). Preferred indications also include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as immunodeficiencies (e.g., as	described below). Preferred
these assays include the HMC-1 cell line, which is an immature human mast cell line established from the peripheral blood of a patient with mast cell leukemia, and exhibits many characteristics of immature mast cells.	This reporter assay measures activation of the NFkB signaling pathway in Ku812 human basophil cell line. Assays for the activation of transcription through the NFKB response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate NFKB transcription factors and modulate expression of immunomodulatory genes. Exemplary assays for transcription through the NFKB response element that may be used or rountinely modified to test NFKB-	response element activity of
	Activation of transcription through NFKB response element in immune cells (such as basophils).	
	826	
	HTEPG70	

			polypeptides of the invention	indications also include
 •			including antibodies and	neoplastic diseases (e.g.,
			agonists or antagonists of the	leukemia, lymphoma,
			invention) include assays	melanoma, and/or as described
 			disclosed in Berger et al., Gene	below under
	•		66:1-10 (1998); Cullen and	"Hyperproliferative
-			Malm, Methods in Enzymol	Disorders"). Preferred
			216:362-368 (1992); Henthorn	indications include neoplasms
			et al., Proc Natl Acad Sci USA	and cancer, such as, for
			85:6342-6346 (1988); Marone	example, leukemia, lymphoma,
			et al, Int Arch Allergy	melanoma, and prostate,
			Immunol 114(3):207-17	breast, lung, colon, pancreatic,
			(1997), the contents of each of	esophageal, stomach, brain,
			which are herein incorporated	liver, urinary tract cancers and
			by reference in its entirety.	as described below under
			Basophils that may be used	"Hyperproliferative
			according to these assays are	Disorders".
			publicly available (e.g.,	
			through the ATCC).	
			Exemplary human basophil	
,			cell lines that may be used	
			according to these assays	
			include Ku812, originally	
			established from a patient with	
			chronic myelogenous	
			leukemia. It is an immature	
			prebasophilic cell line that can	
			be induced to differentiate into	
			mature basophils.	
 HTEPG70	826	Activation of	Assays for the activation of	A preferred embodiment of
		transcription	transcription through the	the invention includes a

response element in (SRE) are well-known in the immune cells (such art and may be used or as natural killer toutinely modified to assess cells). the ability of polypeptides of the invention includes a method for simulating (e.g., and antagonists of the invention (including muter "Ilmmune in growth and upregulate the kexpression of genes in many cell types. Exemplary assays for the polypeptides of the provincible and agonists or antagonists of the invention including antagonists of the invention (including antagonists of the invention) to production. Preferred indications include blood factors and modulate the characteristic production. Preferred indications include blood disorders (e.g., as described genes in many cell types. Exemplary assays for transcription through the SRE activity", "Blood-Related function of growth-related function of gro
h serum se element in ne cells (such ural killer
through serum response element in immune cells (such as natural killer cells).

(1997), the content of each of	arthritis. An additional highly
which are herein incorporated	preferred indication is sepsis.
by reference in its entirety. T	Highly preferred indications
cells that may be used	include neoplastic diseases
according to these assays are	(e.g., leukemia, lymphoma,
 publicly available (e.g.,	and/or as described below
through the ATCC).	under "Hyperproliferative
Exemplary T cells that may be	Disorders"). Additionally,
used according to these assays	highly preferred indications
include the NK-YT cell line,	include neoplasms and
which is a human natural killer	cancers, such as, for example,
cell line with cytolytic and	leukemia, lymphoma,
cytotoxic activity.	melanoma, glioma (e.g.,
	malignant glioma), solid
	tumors, and prostate, breast,
	lung, colon, pancreatic,
	esophageal, stomach, brain,
	liver and urinary cancer. Other
	preferred indications include
	benign dysproliferative
	disorders and pre-neoplastic
	conditions, such as, for
	example, hyperplasia,
	metaplasia, and/or dysplasia.
	Preferred indications include
	anemia, pancytopenia,
	leukopenia, thrombocytopenia,
	Hodgkin's disease, acute
	lymphocytic anemia (ALL),
	plasmacytomas, multiple
	myeloma, Burkitt's lymphoma,

	NFKB response element that	immunodeficiencies (e.g., as
	may be used or rountinely	described below). An
	modified to test NFKB-	additional highly preferred
	response element activity of	indication is infection (e.g.,
	polypeptides of the invention	AIDS, and/or an infectious
	(including antibodies and	disease as described below
	agonists or antagonists of the	under "Infectious Disease").
	invention) include assays	Highly preferred indications
	disclosed in Berger et al., Gene	
	66:1-10 (1998); Cullen and	(e.g., melanoma, leukemia,
	Malm, Methods in Enzymol	lymphoma, and/or as described
	216:362-368 (1992); Henthorn	below under
	et al., Proc Natl Acad Sci USA	"Hyperproliferative
	85:6342-6346 (1988); Black et	Disorders"). Highly preferred
	al., Virus Gnes 15(2):105-117	indications include neoplasms
	(1997); and Fraser et al.,	and cancers, such
	29(3):838-844 (1999), the	as,melanoma, renal cell
	contents of each of which are	carcinoma, leukemia,
	herein incorporated by	lymphoma, and prostate,
	reference in its entirety. T	breast, lung, colon, pancreatic,
-	cells that may be used	esophageal, stomach, brain,
	according to these assays are	liver and urinary cancer. Other
	publicly available (e.g.,	preferred indications include
-	through the ATCC).	benign dysproliferative
	Exemplary human T cells that	disorders and pre-neoplastic
_	may be used according to these	conditions, such as, for
	assays include the SUPT cell	example, hyperplasia,
	line, which is a suspension	metaplasia, and/or dysplasia.
	culture of IL-2 and IL-4	Preferred indications also
-	responsive T cells.	include anemia, pancytopenia,
		leukopenia, thrombocytopenia,

Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, suppression of immune reactions to transplanted organs, asthma and allergy.	A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"),
	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate the serum response factors and modulate the expression of genes involved in growth. Exemplary assays for transcription through the SRE that may be used or
	Activation of transcription through serum response element in immune cells (such as T-cells).
	827
	HTGEP89

																														-
Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	
routinely modified to test SRE	activity of the polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention)	include assays disclosed in	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	dependent suspension culture	of T cells with cytotoxic	activity.			
																			•											
			•																									.=		
																		-												

		tumors, and prostate, breast,
	-	lung, colon, pancreatic,
		esophageal, stomach, brain,
		liver and urinary cancer. Other
		preferred indications include
		benign dysproliferative
		disorders and pre-neoplastic
		conditions, such as, for
		example, hyperplasia,
	-	metaplasia, and/or dysplasia.
		Preferred indications include
-		anemia, pancytopenia,
		leukopenia, thrombocytopenia,
		Hodgkin's disease, acute
		lymphocytic anemia (ALL),
		plasmacytomas, multiple
		myeloma, Burkitt's lymphoma,
		arthritis, AIDS, granulomatous
		disease, inflammatory bowel
		disease, neutropenia,
		neutrophilia, psoriasis,
		suppression of immune
		reactions to transplanted
		organs and tissues,
		hemophilia, hypercoagulation,
		diabetes mellitus, endocarditis,
		meningitis, Lyme Disease,
		cardiac reperfusion injury, and
-		asthma and allergy. An
		additional preferred indication
		is infection (e.g., an infectious

				disease as described below
				under "Infectious Disease").
HTHBG43	828	Activation of	Assays for the activation of	A preferred embodiment of
		transcription	transcription through the	the invention includes a
		through serum	Serum Response Element	method for inhibiting (e.g.,
		response element in	(SRE) are well-known in the	reducing) TNF alpha
		immune cells (such	art and may be used or	production. An alternative
		as natural killer	routinely modified to assess	highly preferred embodiment
		cells).	the ability of polypeptides of	of the invention includes a
			the invention (including	method for stimulating (e.g.,
			antibodies and agonists or	increasing) TNF alpha
			antagonists of the invention) to	production. Preferred
		-	regulate serum response	indications include blood
			factors and modulate the	disorders (e.g., as described
			expression of genes involved	below under "Immune
			in growth and upregulate the	Activity", "Blood-Related
			function of growth-related	Disorders", and/or
			genes in many cell types.	"Cardiovascular Disorders"),
			Exemplary assays for	Highly preferred indications
			transcription through the SRE	include autoimmune diseases
			that may be used or routinely	(e.g., rheumatoid arthritis,
			modified to test SRE activity	systemic lupus erythematosis,
			of the polypeptides of the	Crohn"s disease, multiple
			invention (including antibodies	sclerosis and/or as described
			and agonists or antagonists of	below), immunodeficiencies
			the invention) include assays	(e.g., as described below),
			disclosed in Berger et al., Gene	boosting a T cell-mediated
			66:1-10 (1998); Cullen and	immune response, and
			Malm, Methods in Enzymol	suppressing a T cell-mediated
			216:362-368 (1992); Henthorn	immune response. Additional
			et al., Proc Natl Acad Sci USA	highly preferred indications

																												_	_
include inflammation and	inflammatory disorders, and	reating joint damage in	patients with rneumatold	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia.
85:6342-6346 (1988); Benson	et al., J Immunol 153(9):3862-	38/3 (1994); and black et al., Viens Genes 12/2):105 117	Vitus Genes $12(z).105-111/$ (1997) the content of each of	which are herein incorporated	by reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary T cells that may be	used according to these assays	include the NK-YT cell line,	which is a human natural killer	cell line with cytolytic and	cytotoxic activity.														
				LUL																									
																													,
	_																												

					Hodgkin's disease, acute
					lymphocytic anemia (ALL),
_					plasmacytomas, multiple
					myeloma, Burkitt's lymphoma,
					arthritis, AIDS, granulomatous
					disease, inflammatory bowel
					disease, neutropenia,
					neutrophilia, psoriasis,
					suppression of immune
					reactions to transplanted
					organs and tissues, hemophilia,
					hypercoagulation, diabetes
					mellitus, endocarditis,
					meningitis, Lyme Disease,
		-			cardiac reperfusion injury, and
_					asthma and allergy. An
					additional preferred indication
					is infection (e.g., an infectious
					disease as described below
					under "Infectious Disease").
	HTHBG43	828	Activation of	Assays for the activation of	A highly preferred
			transcription	transcription through the	indication is allergy.
			through STAT6	Signal Transducers and	Another highly preferred
			response element in	Activators of Transcription	indication is asthma.
			immune cells (such	(STAT6) response element are	Additional highly preferred
			as T-cells).	well-known in the art and may	indications include
				be used or routinely modified	inflammation and
				to assess the ability of	inflammatory disorders.
		20.00		polypeptides of the invention	Preferred indications include
				(including antibodies and	blood disorders (e.g., as
				agonists or antagonists of the	described below under

		invention) to regulate STAT6	"Immine Activity", "Blood-
			Related Disorders", and/or
		modulate the everencian of	"Cardiovascular Disorders")
		iiiouuiate uie expression oi	Caldiovascular Disorders 7:
		multiple genes. Exemplary	Preferred indications include
		assays for transcription	autoimmune diseases (e.g.,
		through the STAT6 response	rheumatoid arthritis, systemic
-		element that may be used or	lupus erythematosis, multiple
		routinely modified to test	sclerosis and/or as described
		STAT6 response element	below) and
		activity of the polypeptides of	immunodeficiencies (e.g., as
		the invention (including	described below).
		antibodies and agonists or	Preferred indications include
		antagonists of the invention)	neoplastic diseases (e.g.,
		include assays disclosed in	leukemia, lymphoma,
		Berger et al., Gene 66:1-10	melanoma, and/or as described
		(1998); Cullen and Malm,	below under
		Methods in Enzymol 216:362-	"Hyperproliferative
-		368 (1992); Henthorn et al.,	Disorders"). Preferred
		Proc Natl Acad Sci USA	indications include neoplasms
		85:6342-6346 (1988); Georas	and cancers, such as, leukemia,
		et al., Blood 92(12):4529-4538	lymphoma, melanoma, and
		(1998); Moffatt et al.,	prostate, breast, lung, colon,
		Transplantation 69(7):1521-	pancreatic, esophageal,
		1523 (2000); Curiel et al., Eur	stomach, brain, liver and
	-	J Immunol 27(8):1982-1987	urinary cancer. Other preferred
		(1997); and Masuda et al., J	indications include benign
		Biol Chem 275(38):29331-	dysproliferative disorders and
		29337 (2000), the contents of	pre-neoplastic conditions, such
		each of which are herein	as, for example, hyperplasia,
		incorporated by reference in its	metaplasia, and/or dysplasia.
		entirety. T cells that may be	Preferred indications include

leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious	A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred
anemia, pancytopenia, leukopenia, thrombocytol Hodgkin's disease, acute lymphocytic anemia (AL) plasmacytomas, multiple myeloma, Burkitt's lympl arthritis, AIDS, granulom disease, inflammatory bor disease, sepsis, neutropen neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagula diabetes mellitus, endocar meningitis, and Lyme Dis An additional preferred indication is infectiou (e.g. infectious disease as descibelow under "Infectious Disease").	A preferred embodimen the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of th invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred
used according to these assays are publicly available (e.g., through the ATCC). Exemplary T cells that may be used according to these assays include the SUPT cell line, which is a suspension culture of IL-2 and IL-4 responsive T cells.	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to
	Activation of transcription through serum response element in immune cells (such as T-cells).
	829
	HTHDS25

regulate the serum response	indications include blood
factors and modulate the	disorders (e.g., as described
expression of genes involved	below under "Immune
 in growth. Exemplary assays	Activity", "Blood-Related
for transcription through the	Disorders", and/or
SRE that may be used or	"Cardiovascular Disorders"),
routinely modified to test SRE	Highly preferred indications
activity of the polypeptides of	include autoimmune diseases
the invention (including	(e.g., rheumatoid arthritis,
antibodies and agonists or	systemic lupus erythematosis,
antagonists of the invention)	Crohn"s disease, multiple
include assays disclosed in	sclerosis and/or as described
Berger et al., Gene 66:1-10	below), immunodeficiencies
(1998); Cullen and Malm,	(e.g., as described below),
Methods in Enzymol 216:362-	boosting a T cell-mediated
368 (1992); Henthorn et al.,	immune response, and
 Proc Natl Acad Sci USA.	suppressing a T cell-mediated
85:6342-6346 (1988); and	immune response. Additional
Black et al., Virus Genes	highly preferred indications
12(2):105-117 (1997), the	include inflammation and
content of each of which are	inflammatory disorders, and
herein incorporated by	treating joint damage in
reference in its entirety. T	patients with rheumatoid
cells that may be used	arthritis. An additional highly
according to these assays are	preferred indication is sepsis.
publicly available (e.g.,	Highly preferred indications
through the ATCC).	include neoplastic diseases
Exemplary mouse T cells that	(e.g., leukemia, lymphoma,
may be used according to these	and/or as described below
assays include the CTLL cell	under "Hyperproliferative
line, which is an IL-2	Disorders"). Additionally,

highly preferred indications include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia,	Hodgkin's disease, acute	lymphocytic anemia (ALL),	plasmacytomas, multiple	myeloma, Burkitt's lymphoma,	arthritis, AIDS, granulomatous	disease, inflammatory bowel	disease, neutropenia,	neutrophilia, psoriasis,	suppression of immune	reactions to transplanted	organs and tissues,	hemophilia, hypercoagulation,
dependent suspension culture of T cells with cytotoxic	activity.									1																			
																												-	
									_																				

diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").		
	Reporter Assay: construct contains regulatory and coding sequence of squalene synthetase, the first specific enzyme in the cholesterol biosynthetic pathway. See Jiang, et al., J. Biol. Chem. 268:12818-128241(993), the contents of which are herein incorporated by reference in its entirety. Cells were treated with SID supernatants, and SEAP activity was measured after 72 hours. HepG2 is a human hepatocellular carcinoma cell line (ATCC HB-8065). See Knowles et al., Science. 209:497-9 (1980), the contents of which are herein incorporated by reference in its entirety.	
	Inhibition of squalene synthetase gene transcription.	IFNg in Human T- cell 2B9
	829	829
	HTHDS25	HTHDS25

HTLEP53	830	Endothelial Cell	Caspase Apoptosis. Assays for	A highly preferred
		Apoptosis	caspase apoptosis are well	embodiment of the invention
			known in the art and may be	includes a method for
•			used or routinely modified to	stimulating endothelial cell
			assess the ability of	growth. An alternative highly
			polypeptides of the invention	preferred embodiment of the
			(including antibodies and	invention includes a method
			agonists or antagonists of the	for inhibiting endothelial cell
			invention) to promote caspase	growth. A highly preferred
			protease-mediated apoptosis.	embodiment of the invention
			Induction of apoptosis in	includes a method for
			endothelial cells supporting the	stimulating endothelial cell
			vasculature of tumors is	proliferation. An alternative
			associated with tumor	highly preferred embodiment
			regression due to loss of tumor	of the invention includes a
_		•	blood supply. Exemplary	method for inhibiting
			assays for caspase apoptosis	endothelial cell proliferation.
			that may be used or routinely	A highly preferred
			modified to test capase	embodiment of the invention
			apoptosis activity of	includes a method for
			polypeptides of the invention	stimulating apoptosis of
			(including antibodies and	endothelial cells. An
			agonists or antagonists of the	alternative highly preferred
			invention) include the assays	embodiment of the invention
			disclosed in Lee et al., FEBS	includes a method for
			Lett 485(2-3): 122-126 (2000);	inhibiting (e.g., decreasing)
			Nor et al., J Vasc Res 37(3):	apoptosis of endothelial cells.
			209-218 (2000); and Karsan	A highly preferred
			and Harlan, J Atheroscler	embodiment of the invention
			Thromb 3(2): 75-80 (1996);	includes a method for
			the contents of each of which	stimulating angiogenisis. An

are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., highly preferred embodiment of the invention includes a method for reducing cardiac hypertrophy. An alternative highly preferred embodiment of the invention includes a method for inducing cardiac hypertrophy. An alternative highly preferred embodiment of the invention includes a method for inducing cardiac of endothelial cells which line blood vessels and are involved in functions that include, but are not limited to, and immune cell extravasation. ChAEC), which are an example of endothelial cells which line of endothelial cells which line preferred indications include in functions that include, but are not limited to, and immune cell extravasation. Chapteria and discasses (e.g., as described below under and immune cell extravasation. Chapteria and discasses (e.g., as described below under and immune cell extravasation. Chapteria and discasses (e.g., as described below under and immune cell extravasation. Chapteria and discasses (e.g., as described below under and immune cell extravasation. Chapteria and discasses (e.g., as described below under and immune cell extravasation. Chapteria and disorders of the art disease, congestive heart failure, hypertension, and and atherosclerosis and atherosclerotic vascular disease, diabetic nephropathy, intracardiac shunt, cardiac hypertrophy, myocardial infarction, chronic hemodynamic overload, and/or		
are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., through commercial sources). Exemplary endothelial cells that may be used according to these assays include bovine aortic endothelial cells (bAEC), which are an example of endothelial cells which line blood vessels and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.	are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., through commercial sources). Exemplary endothelial cells that may be used according to these assays include bovine aortic endothelial cells (bAEC), which are an example of endothelial cells which line blood vessels and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.	are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., through commercial sources). Exemplary endothelial cells that may be used according to these assays include bovine aortic endothelial cells (bAEC), which are an example of endothelial cells which line blood vessels and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.

"Cardiovascular Disorders"). Highly preferred indications include cardiovascular, endothelial and/or angiogenic disorders (e.g., systemic disorders that affect vessels	such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins and/or lymphatics). Highly preferred are indications that	stimulate angiogenesis and/or cardiovascularization. Highly preferred are indications that inhibit angiogenesis and/or cardiovascularization. Highly preferred indications include antiangiogenic activity to treat solid tumors,	leukemias, and Kaposi"s sarcoma, and retinal disorders. Highly preferred indications include neoplasms and cancer, such as, Kaposi"s sarcoma, hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma,

lymphangiosarcoma. Highly preferred indications also include cancers such as, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such
preferred indications also include cancers such as, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such
prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such
pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such
stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such
urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such
indications include benign dysproliferative disorders and pre-neoplastic conditions, such
dysproliferative disorders and pre-neoplastic conditions, such
pre-neoplastic conditions, such
as, tor example, hyperplasia,
 metaplasia, and/or dysplasia.
Highly preferred indications
also include arterial disease,
such as, atherosclerosis,
hypertension, coronary artery
disease, inflammatory
vasculitides, Reynaud"s
disease and Reynaud"s
phenomenom, aneurysms,
restenosis; venous and
lymphatic disorders such as
thrombophlebitis,
lymphangitis, and
lymphedema; and other
vascular disorders such as
peripheral vascular disease,
and cancer. Highly
preferred indications also

						_																								
include trauma such as	wounds, burns, and injured	tissue (e.g., vascular injury	such as, injury resulting from	balloon angioplasty, and	atheroschlerotic lesions),	implant fixation, scarring,	ischemia reperfusion injury,	rheumatoid arthritis,	cerebrovascular disease, renal	diseases such as acute renal	failure, and osteoporosis.	Additional highly preferred	indications include stroke,	graft rejection, diabetic or	other retinopathies, thrombotic	and coagulative disorders,	vascularitis, lymph	angiogenesis, sexual disorders,	age-related macular	degeneration, and treatment	/prevention of endometriosis	and related conditions.	Additional highly preferred	indications include fibromas,	heart disease, cardiac arrest,	heart valve disease, and	vascular disease.	Preferred indications include	blood disorders (e.g., as	described below under
	<u> </u>			<u> </u>		<u></u>		_															7			<u></u>				-
_																														
		-				_																								

																							-							-
						_		_		<u> </u>				_		_			_											
_	_									_				_																

"Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional preferred indications include inflammation and inflammatory disorders (such as acute and chronic inflammatory diseases, e.g., inflammatory bowel disease and Crohn's disease), and pain management.	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to production. Preferred embodiment of the invention (including antibodies and agonists or antagonists of the invention) to production. Preferred indications include blood
	Activation of transcription through the through serum Serum Response Element response element in immune cells (such immune cells (such art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) regulate the serum response factors and modulate the
	4TLEP53 830

below under "Immune Activity", "Blood-Related	Disorders", and/or "Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neonlasms and
expression of genes involved in growth. Exemplary assays	for transcription through the SRE that may be used or	routinely modified to test SRE	activity of the polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention)	include assays disclosed in	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	dependent suspension culture	of T cells with cytotoxic
																							_					

cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia,	Hodgkin's disease, acute	lymphocytic anemia (ALL),	plasmacytomas, multiple	myeloma, Burkitt's lymphoma,	arthritis, AIDS, granulomatous	disease, inflammatory bowel	disease, neutropenia,	neutrophilia, psoriasis,	suppression of immune	reactions to transplanted	organs and tissues,	hemophilia, hypercoagulation,	diabetes mellitus, endocarditis,
activity.											•	_				***************************************	-												
													-								-								

					cardiac reperfusion injury, and
					asthma and allergy. An
					additional preferred indication
					is infection (e.g., an infectious
					disease as described below
	Carte Title				under "Infectious Disease").
	HILEP53	830	Insulin Secretion	Assays for measuring secretion	A highly preferred indication
				of insulin are well-known in	is diabetes mellitus. An
				the art and may be used or	additional highly preferred
				routinely modified to assess	indication is a complication
				the ability of polypeptides of	associated with diabetes (e.g.,
				the invention (including	diabetic retinopathy, diabetic
				antibodies and agonists or	nephropathy, kidney disease
				antagonists of the invention) to	(e.g., renal failure,
				stimulate insulin secretion.	nephropathy and/or other
				For example, insulin secretion	diseases and disorders as
				is measured by FMAT using	described in the "Renal
				anti-rat insulin antibodies.	Disorders" section below),
				Insulin secretion from	diabetic neuropathy, nerve
				pancreatic beta cells is	disease and nerve damage
				upregulated by glucose and	(e.g., due to diabetic
				also by certain	neuropathy), blood vessel
				proteins/peptides, and	blockage, heart disease, stroke,
				disregulation is a key	impotence (e.g., due to diabetic
				component in diabetes.	neuropathy or blood vessel
				Exemplary assays that may be	blockage), seizures, mental
				used or routinely modified to	confusion, drowsiness,
				test for stimulation of insulin	nonketotic hyperglycemic-
				secretion (from pancreatic	hyperosmolar coma,
, , , ,				cells) by polypeptides of the	cardiovascular disease (e.g.,
				invention (including antibodies	heart disease, atherosclerosis,

and agonists or antagonists of	microvascular disease.
the invention) include assays	hypertension, stroke, and other
disclosed in: Shimizu, H., et	diseases and disorders as
al., Endocr J, 47(3):261-9	described in the
(2000); Salapatek, A.M., et al.,	"Cardiovascular Disorders"
Mol Endocrinol, 13(8):1305-	section below), dyslipidemia,
 17 (1999); Filipsson, K., et al.,	endocrine disorders (as
Ann N Y Acad Sci, 865:441-4	described in the "Endocrine
(1998); Olson, L.K., et al., J	Disorders" section below),
Biol Chem, 271(28):16544-52	neuropathy, vision impairment
 (1996); and, Miraglia S et. al.,	(e.g., diabetic retinopathy and
Journal of Biomolecular	blindness), ulcers and impaired
 Screening, 4:193-204 (1999),	wound healing, and infection
the contents of each of which	(e.g., infectious diseases and
is herein incorporated by	disorders as described in the
 reference in its entirety.	"Infectious Diseases" section
Pancreatic cells that may be	below, especially of the
used according to these assays	urinary tract and skin), carpal
are publicly available (e.g.,	tunnel syndrome and
 through the ATCC) and/or	Dupuytren's contracture).
may be routinely generated.	An additional highly preferred
Exemplary pancreatic cells that	indication is obesity and/or
may be used according to these	complications associated with
assays include HITT15 Cells.	obesity. Additional highly
 HITT15 are an adherent	preferred indications include
epithelial cell line established	weight loss or alternatively,
from Syrian hamster islet cells	weight gain. Additional highly
transformed with SV40. These	preferred indications are
 cells express glucagon,	complications associated with
somatostatin, and	insulin resistance.
glucocorticoid receptors. The	

				cells secrete insulin, which is	
	-			stimulated by glucose and	
				glucagon and suppressed by	
	_			somatostatin or	
				glucocorticoids. ATTC# CRL-	
				1777 Refs: Lord and	
				Ashcroft. Biochem. J. 219:	
				547-551; Santerre et al. Proc.	
				Natl. Acad. Sci. USA 78:	
				4339-4343, 1981.	
	HTLEP53	830	Activation of	This reporter assay measures	Highly preferred indications
			transcription	activation of the GATA-3	include allergy, asthma, and
			through GATA-3	signaling pathway in HMC-1	rhinitis. Additional preferred
			response element in	human mast cell line.	indications include infection
			immune cells (such	Activation of GATA-3 in mast	(e.g., an infectious disease as
			as mast cells).	cells has been linked to	described below under
				cytokine and chemokine	"Infectious Disease"), and
				production. Assays for the	inflammation and
_				activation of transcription	inflammatory disorders.
				through the GATA3 response	Preferred indications also
				element are well-known in the	include blood disorders (e.g.,
				art and may be used or	as described below under
				routinely modified to assess	"Immune Activity", "Blood-
•	-			the ability of polypeptides of	Related Disorders", and/or
				the invention (including	"Cardiovascular Disorders").
•	_			antibodies and agonists or	Preferred indications include
				antagonists of the invention) to	autoimmune diseases (e.g.,
				regulate GATA3 transcription	rheumatoid arthritis, systemic
				factors and modulate	lupus erythematosis, multiple
				expression of mast cell genes	sclerosis and/or as described
				important for immune response below) and	below) and

	davalonment Evenulony	imminodefficiencies (e n e
	development. Exemplary	
	assays tor transcription	described below). Preferred
	through the GATA3 response	indications include neoplastic
-	element that may be used or	diseases (e.g., leukemia,
	routinely modified to test	lymphoma, melanoma,
	GATA3-response element	prostate, breast, lung, colon,
	activity of polypeptides of the	pancreatic, esophageal,
	invention (including antibodies	stomach, brain, liver, and
	and agonists or antagonists of	urinary tract cancers and/or as
	the invention) include assays	described below under
	disclosed in Berger et al., Gene	"Hyperproliferative
	66:1-10 (1998); Cullen and	Disorders"). Other preferred
	Malm, Methods in Enzymol	indications include benign
	216:362-368 (1992); Henthorn	dysproliferative disorders and
	et al., Proc Natl Acad Sci USA	pre-neoplastic conditions, such
	85:6342-6346 (1988); Flavell	as, for example, hyperplasia,
	et al., Cold Spring Harb Symp	metaplasia, and/or dysplasia.
	Quant Biol 64:563-571 (1999);	Preferred indications include
	Rodriguez-Palmero et al., Eur	anemia, pancytopenia,
	J Immunol 29(12):3914-3924	leukopenia, thrombocytopenia,
	(1999); Zheng and Flavell,	leukemias, Hodgkin's disease,
	Cell 89(4):587-596 (1997); and	acute lymphocytic anemia
	Henderson et al., Mol Cell Biol	(ALL), plasmacytomas,
	14(6):4286-4294 (1994), the	multiple myeloma, Burkitt's
	contents of each of which are	lymphoma, arthritis, AIDS,
	herein incorporated by	granulomatous disease,
	reference in its entirety. Mast	inflammatory bowel disease,
	cells that may be used	sepsis, neutropenia,
_	according to these assays are	neutrophilia, psoriasis,
	publicly available (e.g.,	suppression of immune
	through the ATCC).	reactions to transplanted

organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease.	Highly preferred indications include allergy, asthma, and rhinitis. Additional preferred indications include infection (e.g., an infectious disease as described below under "Infectious Disease"), and inflammation and inflammatory disorders. Preferred indications also include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and/or as described below) and
Exemplary human mast cells that may be used according to these assays include the HMC-1 cell line, which is an immature human mast cell line established from the peripheral blood of a patient with mast cell leukemia, and exhibits many characteristics of immature mast cells.	This reporter assay measures activation of the NFAT signaling pathway in HMC-1 human mast cell line. Activation of NFAT in mast cells has been linked to cytokine and chemokine production. Assays for the activation of transcription through the Nuclear Factor of Activated T cells (NFAT) response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate NFAT transcription factors and modulate expression of genes
	Activation of transcription through NFAT response element in immune cells (such as mast cells).
	830
	HTLEP53

involved in	immunodeficiencies (e.g., as
immunomodulatory functions.	described below). Preferred
Exemplary assays for	indications include neoplastic
transcription through the	diseases (e.g., leukemia,
NFAT response element that	lymphoma, melanoma,
may be used or routinely	prostate, breast, lung, colon,
modified to test NFAT-	pancreatic, esophageal,
 response element activity of	stomach, brain, liver, and
polypeptides of the invention	urinary tract cancers and/or as
 (including antibodies and	described below under
agonists or antagonists of the	"Hyperproliferative
invention) include assays	Disorders"). Other preferred
disclosed in Berger et al., Gene	indications include benign
66:1-10 (1998); Cullen and	dysproliferative disorders and
Malm, Methods in Enzymol	pre-neoplastic conditions, such
216:362-368 (1992); Henthorn	as, for example, hyperplasia,
et al., Proc Natl Acad Sci USA	metaplasia, and/or dysplasia.
85:6342-6346 (1988); De Boer	Preferred indications include
et al., Int J Biochem Cell Biol	anemia, pancytopenia,
31(10):1221-1236 (1999); Ali	leukopenia, thrombocytopenia,
et al., J Immunol	leukemias, Hodgkin's disease,
165(12):7215-7223 (2000);	acute lymphocytic anemia
 Hutchinson and McCloskey, J	(ALL), plasmacytomas,
Biol Chem 270(27):16333-	multiple myeloma, Burkitt's
16338 (1995), and Turner et	lymphoma, arthritis, AIDS,
al., J Exp Med 188:527-537	granulomatous disease,
(1998), the contents of each of	inflammatory bowel disease,
 which are herein incorporated	sepsis, neutropenia,
by reference in its entirety.	neutrophilia, psoriasis,
Mast cells that may be used	suppression of immune
according to these assays are	reactions to transplanted

			through the ATCC). Exemplary human mast cells that may be used according to these assays include the HMC-1 cell line, which is an immature human mast cell line established from the peripheral blood of a patient with mast cell leukemia, and exhibits many characteristics of immature mast cells.	hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease.
HTLEP53	830	SEAP in Jurkat/IL4 promoter (antiCD3 co-stim)		
	100	transcription through serum response element in immune cells (such as T-cells).	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate the serum response factors and modulate the expression of genes involved in growth. Exemplary assays for transcription through the	A preteriou entrocument of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or

																										_	_		
Highly preferred indications	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid
routinely modified to test SRE	activity of the polypeputes of the invention (including	antibodies and agonists or	antagonists of the invention)	include assays disclosed in	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	dependent suspension culture	of T cells with cytotoxic	activity.			
							-																						
						-									_														

tumors, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain,	liver and urinary cancer. Other preferred indications include	benign dysproliferative disorders and pre-neoplastic	conditions, such as, for example, hyperplasia,	metaplasia, and/or dysplasia. Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia, Hodokin's disease, acute	lymphocytic anemia (ALL),	plasmacytomas, multiple	myeloma, Burkitt's lymphoma,	arthritis, AIDS, granulomatous	disease, inflammatory bowel	disease, neutropenia,	neutrophilia, psoriasis,	suppression of immune	reactions to transplanted	organs and tissues,	hemophilia, hypercoagulation,	diabetes mellitus, endocarditis,	meningitis, Lyme Disease,	cardiac reperfusion injury, and	asthma and allergy. An	additional preferred indication	is infection (e.g., an infectious
																			 				
				-																			

					disease as described below
					under "Infectious Disease").
	HTLHY14	832	MIP-1a in HMC		
	HTLHY14	832	Calcium flux in	Assays for measuring calcium	Preferred embodiments of the
			immune cells (such	flux are well-known in the art	invention include using
			as monocytes)	and may be used or routinely	polypeptides of the invention
				modified to assess the ability	(or antibodies, agonists, or
				of polypeptides of the	antagonists thereof) in
				invention (including antibodies	detection, diagnosis,
-				and agonists or antagonists of	prevention, and/or treatment of
				the invention) to mobilize	Infection, Inflammation,
			-	calcium. Cells normally have	Atherosclerosis,
				very low concentrations of	Hypersensitivity, and
				cytosolic calcium compared to	Leukemias
				much higher extracellular	
				calcium. Extracellular factors	
				can cause an influx of calcium,	
				leading to activation of	
				calcium responsive signaling	
				pathways and alterations in	
				cell functions. Exemplary	
				assays that may be used or	
				routinely modified to measure	
				calcium flux in immune cells	
				(such as monocytes) include	
				assays disclosed in: Chan, CC,	
				et al., J Pharmacol Exp Ther,	
				269(3):891-896 (1994);	
				Andersson, K, et al., Cytokine,	
				12(12):1784-1787 (2000);	
				Scully, SP, et al., J Clin Invest,	

Sullivan, E, et al., Methods Mol Biol, 114:125-133 (1999), the contents of each of which is herein incorporated by reference in its entirety. Cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary cells that may be used according to these assays include the THP-1 monocyte cell line.		Assays for the activation of transcription through the nuclear Factor of Activated T cells (NFAT) response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies invention) to regulate and agonists or antagonists of modulate expression of genes involved in transcription functions.
74(2) 589-599 (1984); and, Sullivan, E, et al., Methods Mol Biol, 114:125-133 (19) the contents of each of whiis herein incorporated by reference in its entirety. Contest way be used according these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary cells that may be used according to these assimpled the THP-1 monocy cell line.	SEAP in HIB/CRE	ation of ription gh NFAT nse element in ne cells (such ural killer
		transc transc through transc through transc through transc through transc through transc through transc transc transc through transc tr
	HTLIV19	HTLIV19

"Cardiovascular Disorders"), Highly preferred indications	include autoimmune diseases	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,
genes in many cell types. Exemplary assays for	transcription through the SRE	that may be used or routhfiely modified to test SRE activity	of the polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Benson	et al., J Immunol 153(9):3862-	3873 (1994); and Black et al.,	Virus Genes 12(2):105-117	(1997), the content of each of	which are herein incorporated	by reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary T cells that may be	used according to these assays	include the NK-YT cell line,	which is a human natural killer	cell line with cytolytic and	cytotoxic activity.
																											-	
										_	_										-							
									_						-					•		_		-				-

lumovs, and prostate, breast, lumy, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include being dyspoliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaphasia, andro dysplasia, metaphasia, andro dysplasia, preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, leukopenia, leukope	malignant glioma), solid
esophageal, stor liver and urinary preferred indicarders and preferred indicarders, inflamm disease, inflamm disease, inflamm organs and tissu hypercoagulation melitius, endocor meningitis, Lym cardiac reperfus asthma and aller asthma asthma and aller asthma asthma and aller asthma asth	tume
iver and urinary preferred indicary preferred indicar pereferred indicar pereferred indicar anemic, paretred indicar anemic, pancyto leukopenia, thro Hodgkin's disea lymphecytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, indfann disease, ineutrophilia, psi suppression of i reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyn cardiac reperfus asthma and allele	lung
liver and urinary preferred indicat benign dysprolit disorders and pr conditions, such example, hypert metaplasia, and Preferred indicat anemia, pancyte teukopenia, thro Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, intlamn disease, intlamn disease, interpopinia, ps suppression of ireactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyn cardiac reperfus asthma and allen	esob
preferred indica benign dysprolit disorders and pr conditions, such example, hypert metaplasia, and Preferred indica anemia, pancytc leukopenia, thro Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, inflamn disease, inflamn organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyn cardiac reperfus	liver
benign dysprolli disorders and pr conditions, such example, hypert metaplasia, and Preferred indica anemia, pancyto leukopenia, thro Hodgkin's disea lymphocytic ane plasmacytomas, myeloma Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, inflamn organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyn cardiac reperfus	prefe
disorders and pr conditions, such example, hypery metaplasia, and Preferred indica anemia, pancytc leukopenia, thro Hodgkin's disea lymphocytic an plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, inflamn disease, inflamn disease, neutrop neutrophilia, psi suppression of i reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyn cardiac reperfus asthma and allei	beni
conditions, such example, hypert metaplasia, and Preferred indica anemia, pancytc leukopenia, thro Hodgkin's disea lymphocytic an plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, inflamn disease, inflamn organs and tissu hypercoagulatio mellitus, endoce meningtits, Lyn cardiac reperfus	disol
example, hyperg metaplasia, and Preferred indica anemia, pancytic leukopenia, thro Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamm disease, neutrop neutrophilia, ps. suppression of i reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyn cardiac reperfus asthma and allei	cond
metaplasia, and Preferred indica anemia, pancyto leukopenia, thro Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, inflamn disease, neutrophilia, pso suppression of i reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lytr cardiac reperfus asthma and allei	exan
Preferred indica anemia, pancyto leukopenia, thro Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, neutrophilia, pso suppression of i reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lytricardiac reperfus asthma and allei	meta
anemia, pancyto leukopenia, thro Hodgkin's disea lymphocytic ane plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, neutrop neutrophilia, pse suppression of ir reactions to tran organs and tissu hypercoagulatio mellitus, endocc meningitis, Lyr cardiac reperfus asthma and allei	Prefe
leukopenia, thro Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, nutrop neutrophilia, pso suppression of ir reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyr cardiac reperfus asthma and allei	anen
Hodgkin's disea lymphocytic and plasmacytomas, myeloma, Burki arthritis, AIDS, disease, indflamn disease, neutrop neutrophilia, ps. suppression of ir reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lym cardiac reperfus asthma and allei	leuk
lymphocytic ane plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, neutrop neutrophilia, pso suppression of i reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lym cardiac reperfus asthma and allei	Hod
plasmacytomas, myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, neutrop neutrophilia, pso suppression of ireactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyrr cardiac reperfus asthma and allei	lymb
myeloma, Burki arthritis, AIDS, disease, inflamn disease, inflamn disease, inflamn disease, neutrophila, pso neutrophilia, pso suppression of ir reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyrr cardiac reperfus asthma and allei	plast
arthritis, AIDS, disease, inflamn disease, inflamn disease, neutrop neutrophilia, pso suppression of ir reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyrr cardiac reperfus asthma and allei	mye
disease, inflamn disease, inflamn disease, neutrop neutrophilia, ps suppression of ii reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyrr cardiac reperfus asthma and allei	arthr
disease, neutrophila, pson neutrophilia, pson suppression of in reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyrr cardiac reperfus asthma and allei	gesip
neutrophilia, psc suppression of ir reactions to tran organs and tissu hypercoagulatio mellitus, endoce meningitis, Lyrr cardiac reperfus asthma and allei	disea
suppression of in reactions to tran organs and tissu hypercoagulatio mellitus, endoca meningitis, Lyrr cardiac reperfus asthma and allei	neut
reactions to tran organs and tissu hypercoagulatio mellitus, endoca meningitis, Lyrr cardiac reperfus asthma and allei	ddns
organs and tissu hypercoagulatio mellitus, endoca meningitis, Lyrr cardiac reperfus asthma and allei	react
hypercoagulatio mellitus, endoca meningitis, Lyrr cardiac reperfus asthma and allei	orga
mellitus, endoca meningitis, Lyrr cardiac reperfus asthma and allei	hype
meningitis, Lym cardiac reperfus asthma and aller	mell
cardiac reperfus asthma and aller	meni
asthma and aller	cardi
	asthr
additional preferred indication	addit

				is infection (e.g., an infectious disease as described below under "Infectious Disease").
HTLIV19	833	SEAP in NK16/STAT6		
HTOAK16	834	IL-13 in Human T cells		
HTOAK16	834	Production of	Endothelial cells, which are	Highly preferred indications include inflammation (acute
		endothelial cells	and are involved in functions	and chronic), restnosis,
		(such as human	that include, but are not limited	atherosclerosis, asthma and
		umbilical vein	to, angiogenesis, vascular	allergy. Highly preferred
		endothelial cells	permeability, vascular tone,	indications include
		(HUVEC))	and immune cell extravasation.	inflammation and
			Exemplary endothelial cells	inflammatory disorders,
			that may be used in ICAM	immunological disorders,
			production assays include	neoplastic disorders (e.g.
			human umbilical vein	cancer/tumorigenesis), and
			endothelial cells (HUVEC),	cardiovascular disorders (such
			and are available from	as described below under
			commercial sources. The	"Immune Activity", "Blood-
			expression of ICAM (CD54),a	Related Disorders",
			intergral membrane protein,	"Hyperproliferative Disorders"
			can be upregulated by	and/or "Cardiovascular
			cytokines or other factors, and	Disorders"). Highly preferred
			ICAM expression is important	indications include neoplasms
			in mediating immune and	and cancers such as, for
			endothelial cell interactions	example, leukemia, lymphoma,
			leading to immune and	melanoma, renal cell
			inflammatory responses.	carcinoma, and prostate,
			Assays for measuring	breast, lung, colon, pancreatic,

				expression of ICAM-1 are well-known in the art and may	esophageal, stomach, brain, liver and urinary cancer. Other
				be used or routinely modified	preferred indications include
				to assess the ability of	benign dysproliferative
				polypeptides of the invention	disorders and pre-neoplastic
				(including antibodies and	conditions, such as, for
	-			agonists or antagonists of the	example, hyperplasia,
				invention) to regulate ICAM-1	metaplasia, and/or dysplasia.
				expression. Exemplary assays	
				that may be used or routinely	
				modified to measure ICAM-1	
				expression include assays	
				disclosed in: Rolfe BE, et al.,	
				Atherosclerosis, 149(1):99-110	
				(2000); Panettieri RA Jr, et al.,	
				J Immunol, 154(5):2358-2365	
				(1995); and, Grunstein MM, et	
				al., Am J Physiol Lung Cell	
				Mol Physiol, 278(6):L1154-	
				L1163 (2000), the contents of	
			-	each of which is herein	
				incorporated by reference in its	
				entirety.	
TH	HTOAK16	834	Production of IL-8	Assays measuring production	Highly preferred indications
			by by endothelial	of IL-8 are well known in the	include immunological and
			cells (such as	art and may be used or	inflammatory disorders (e.g.,
			Human Umbilical	routinely modified to assess	such as allergy, asthma,
			Cord Endothelial	the ability of polypeptides of	leukemia, etc. and as described
			Cells).	the invention (including	below under "Immune
				antibodies and agonists or	Activity", and "Blood-Related
				antagonists of the invention) to	Disorders"). Highly preferred

indications also includie autoimmune disorders (e.g.,	lupus erythematosis, Crohn's disease, multiple sclerosis	and/or as described below),	neoplastic disorders (e.g., organ cancers such as lung,		described below under	"Hyperproliferative	Disorders"), and	cardiovascular disorders (e.g.	such as described below under	"Cardiovascular Disorders").	Preferred indications include	thrombosis, bacteremia and	sepsis syndrome and	consequent complications	(such as acute respiratory	distress syndrome and	systemic ischemia-reperfusion	resulting from septic shock),	restnosis and atherosclerosis.							
regulate production and/or secretion of IL-8. For example, FMAT may be used	or routinely modified to assess the ability of polypeptides of	the invention (including	antibodies and agonists or antagonists of the invention) to	regulate production and/or	secretion of IL-8 from	endothelial cells (such as	human umbilical vein	endothelial cells (HUVEC)).	HUVECs are endothelial cells	which line venous blood	vessels, and are involved in	functions that include, but are	not limited to, angiogenesis,	vascular permeability, vascular	tone, and immune cell	extravasation. Endothelial	cells play a pivotal role in the	initiation and perpetuation of	inflammation and secretion of	IL-8 may play an important	role in recruitment and	activation of immune cells	such as neutrophils,	macrophages, and	lymphocytes.	
																										MCP-1 in HUVEC
																										834
																										HTOAK16

	HTOAK16	834	Production of	Assays for measuring	Highly preferred indications
			VCAM in	expression of VCAM are well-	include inflammation (acute
			endothelial cells	known in the art and may be	and chronic), restnosis,
			(such as human	used or routinely modified to	atherosclerosis, asthma and
			umbilical vein	assess the ability of	allergy. Highly preferred
*			endothelial cells	polypeptides of the invention	indications include
			(HUVEC))	(including antibodies and	inflammation and
				agonists or antagonists of the	inflammatory disorders,
				invention) to regulate VCAM	immunological disorders,
				expression. For example,	neoplastic disorders (e.g.
				FMAT may be used to meaure	cancer/tumorigenesis), and
-				the upregulation of cell surface	cardiovascular disorders (such
				VCAM-1 expresssion in	as described below under
				endothelial cells. Endothelial	"Immune Activity", "Blood-
				cells are cells that line blood	Related Disorders",
				vessels, and are involved in	"Hyperproliferative Disorders"
				functions that include, but are	and/or "Cardiovascular
				not limited to, angiogenesis,	Disorders"). Highly preferred
				vascular permeability, vascular	indications include neoplasms
				tone, and immune cell	and cancers such as, for
				extravasation. Exemplary	example, leukemia, lymphoma,
				endothelial cells that may be	melanoma, renal cell
				used according to these assays	carcinoma, and prostate,
				include human umbilical vein	breast, lung, colon, pancreatic,
				endothelial cells (HUVEC),	esophageal, stomach, brain,
				which are available from	liver and urinary cancer. Other
				commercial sources. The	preferred indications include
				expression of VCAM	benign dysproliferative
				(CD106), a membrane-	disorders and pre-neoplastic
				associated protein, can be	conditions, such as, for
				upregulated by cytokines or	example, hyperplasia,

metaplasia, and/or dysplasia.	A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha	production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred indications include blood	disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), Highly preferred indications include autoimmune diseases	(e.g., rheumatoid arthritis, systemic lupus erythematosis, Crohn"s disease, multiple sclerosis and/or as described below), immunodeficiencies
other factors, and contributes to the extravasation of lymphocytes, leucocytes and other immune cells from blood vessels; thus VCAM expression plays a role in promoting immune and inflammatory responses.	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the	art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate the serum response	factors and modulate the expression of genes involved in growth. Exemplary assays for transcription through the SRE that may be used or routinely modified to test SRE activity of the polymentides of	the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10
	Activation of transcription through serum response element in	immune cells (such as T-cells).		
	835			
	HTOGR42			

	-								
(e.g., as described below), boosting a T cell-mediated immune response, and summerssing a T cell-mediated	immune response. Additional highly preferred indications include inflammation and	inflammatory disorders, and treating joint damage in patients with rheumatoid arthritis. An additional highly	preferred indication is sepsis. Highly preferred indications include neoplastic diseases		under "Hyperproliterative Disorders"). Additionally, highly preferred indications include neonlasms and	cancers, such as, for example, leukemia, lymphoma, melanoma, glioma (e.g.,	malignant glioma), solid tumors, and prostate, breast, lung, colon, pancreatic,	esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include	benign dysproliferative disorders and pre-neoplastic
(1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci 11SA	85:6342-6346 (1988); and Black et al., Virus Genes 12(2):105-117 (1997), the	content of each of which are herein incorporated by reference in its entirety. T cells that may be used	according to these assays are publicly available (e.g., through the ATCC).	Exemplary mouse T cells that may be used according to these	assays include the CILL cell line, which is an IL-2 dependent suspension culture of T cells with extotoxic	of 1 cells with cytotoxic activity.			

					conditions such as for
					Conditions, such as, for
					example, nyperplasia,
					metaplasia, and/or dysplasia.
					Preferred indications include
					anemia, pancytopenia,
					leukopenia, thrombocytopenia,
					Hodgkin's disease, acute
					lymphocytic anemia (ALL),
					plasmacytomas, multiple
					myeloma, Burkitt's lymphoma,
					arthritis, AIDS, granulomatous
			-		disease, inflammatory bowel
	-				disease, neutropenia,
					neutrophilia, psoriasis,
					suppression of immune
					reactions to transplanted
					organs and tissues,
					hemophilia, hypercoagulation,
					diabetes mellitus, endocarditis,
					meningitis, Lyme Disease,
					cardiac reperfusion injury, and
-					asthma and allergy. An
					additional preferred indication
					is infection (e.g., an infectious
					disease as described below
-				1	under "Infectious Disease").
H	HTOGR42	835	IL-10 in Human T-		
			cell 293T		
H	HTOGR42	835	IL-10 in Human T-cell 2B9		
H	HTOGR42	835	Activation of	Kinase assay. JNK kinase	A highly preferred
			¥		

Fndoth	Endothelial Cell	assavs for signal transduction	embodiment of the invention	
DIN C:		that remilete cell proliferation	includes a method for	
IC ANIC	JINN Signaning	ulat legulate cell profitciation,	includes a include 101	
Pathway.	.y.	activation, or apoptosis are	stimulating endotnelial cell	
		well known in the art and may	growth. An alternative highly	
		be used or routinely modified	preferred embodiment of the	
		to assess the ability of	invention includes a method	
		polypeptides of the invention	for inhibiting endothelial cell	
		(including antibodies and	growth. A highly preferred	
		agonists or antagonists of the	embodiment of the invention	
		invention) to promote or	includes a method for	
		inhibit cell proliferation,	stimulating endothelial cell	
		activation, and apoptosis.	proliferation. An alternative	
		Exemplary assays for JNK	highly preferred embodiment	
		kinase activity that may be	of the invention includes a	
		used or routinely modified to	method for inhibiting	
		test JNK kinase-induced	endothelial cell proliferation.	
		activity of polypeptides of the	A highly preferred	
		invention (including antibodies	embodiment of the invention	
		and agonists or antagonists of	includes a method for	
		the invention) include the	stimulating apoptosis of	
		assays disclosed in Forrer et	endothelial cells. An	
		al., Biol Chem 379(8-9):1101-	alternative highly preferred	
		1110 (1998); Gupta et al., Exp	embodiment of the invention	
		Cell Res 247(2): 495-504	includes a method for	
		(1999); Kyriakis JM, Biochem	inhibiting apoptosis of	
		Soc Symp 64:29-48 (1999);	endothelial cells. A	
	,	Chang and Karin, Nature	highly preferred embodiment	
_		410(6824):37-40 (2001); and	of the invention includes a	
		Cobb MH, Prog Biophys Mol	method for stimulating	
		Biol 71(3-4):479-500 (1999);	endothelial cell activation. An	
 		the contents of each of which	alternative highly preferred	\neg

_																														
embodiment of the invention	includes a method for	inhibiting the activation of	and/or inactivating endothelial	cells. A highly preferred	embodiment of the invention	includes a method for	stimulating angiogenisis. An	alternative highly preferred	embodiment of the invention	includes a method for	inhibiting angiogenesis. A	highly preferred embodiment	of the invention includes a	method for reducing cardiac	hypertrophy. An alternative	highly preferred embodiment	of the invention include a	method for inducing cardiac	hypertrophy. Highly	preferred indications include	neoplastic diseases (e.g., as	described below under	"Hyperproliferative	Disorders"), and disorders of	the cardiovascular system	(e.g., heart disease, congestive	heart failure, hypertension,	aortic stenosis,	cardiomyopathy, valvular	regurgitation left ventricular
are herein incorporated by	reference in its entirety.	Endothelial cells that may be	used according to these assays	are publicly available (e.g.,	through the ATCC).	Exemplary endothelial cells	that may be used according to	these assays include human	umbilical vein endothelial cells	(HUVEC), which are	endothelial cells which line	venous blood vessels, and are	involved in functions that	include, but are not limited to,	angiogenesis, vascular	permeability, vascular tone,	and immune cell extravasation.													
									•																				-	
																	-													

dysfunction, atherosclerosis	and atherosclerotic vascular	disease, diabetic nephropathy,	intracardiac shunt, cardiac	hypertrophy, myocardial	infarction, chronic	hemodynamic overload, and/or	as described below under	"Cardiovascular Disorders").	Highly preferred indications	include cardiovascular,	endothelial and/or angiogenic	disorders (e.g., systemic	disorders that affect vessels	such as diabetes mellitus, as	well as diseases of the vessels	themselves, such as of the	arteries, capillaries, veins	and/or lymphatics). Highly	preferred are indications that	stimulate angiogenesis and/or	cardiovascularization. Highly	preferred are indications that	inhibit angiogenesis and/or	cardiovascularization.	Highly preferred indications	include antiangiogenic activity	to treat solid tumors,	leukemias, and Kaposi"s	sarcoma, and retinal disorders.	Highly preferred indications
		•••																		,		•								
							. <u>-</u>						-																	
																						•								
																		•												

include neoplasms and cancer, such as, Kaposi"s sarcoma, hemangioma (capillary and cavernous), glomus tumors,	telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma,	lymphangiosarcoma. Highly preferred indications also include cancers such as,	prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benion	dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Highly preferred indications also include arterial disease,	such as, atherosclerosis, hypertension, coronary artery disease, inflammatory vasculitides, Reynaud"s disease and Reynaud"s phenomenom, aneurysms, restenosis; venous and

lymphatic disorders such as	thrombophlebitis,	lymphangitis, and	lymphedema; and other	vascular disorders such as	peripheral vascular disease,	and cancer. Highly	preferred indications also	include trauma such as	wounds, burns, and injured	tissue (e.g., vascular injury	such as, injury resulting from	balloon angioplasty, and	atheroschlerotic lesions),	implant fixation, scarring,	ischemia reperfusion injury,	rheumatoid arthritis,	cerebrovascular disease, renal	diseases such as acute renal	failure, and osteoporosis.	Additional highly preferred	indications include stroke,	graft rejection, diabetic or	other retinopathies, thrombotic	and coagulative disorders,	vascularitis, lymph	angiogenesis, sexual disorders,	age-related macular	degeneration, and treatment	/prevention of endometriosis	and related conditions.

indications include fibromas, heart disease, cardiac arrest, heart valvee disease, and vascular disease. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-"Cardiovasular Disorders", and/or "Cardiovasular Disorders", and/or and immunuted diseases (e.g., as described below) and immunuted activities as a cute and chronic inflammatory disorders (activity and Chronic Signasal). HTOGR42 835 Activation of Kinase assay. Kinase assays. Kinase assays. A highly preferred for example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example an Elst. I kinase includes an enthod for cell or example and enthod for ex						Additional highly preferred
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell pathway.						indications include fibromas,
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell pathway.						heart disease, cardiac arrest,
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell	_					heart valve disease, and
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell	-					vascular disease.
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling transduction that regulate cell pathway.						Preferred indications include
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling transduction that regulate cell pathway.						blood disorders (e.g., as
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell assay, for ERK signal transduction that regulate cell transduction that regulate cell						described below under
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell pathway				,, ,		"Immune Activity", "Blood-
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling transduction that regulate cell pathway						Related Disorders", and/or
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling transduction that regulate cell						"Cardiovascular Disorders").
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell	_					Preferred indications include
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						autoimmune diseases (e.g.,
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						rheumatoid arthritis, systemic
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						lupus erythematosis, multiple
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell		•				sclerosis and/or as described
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						below) and
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway transduction that regulate cell						immunodeficiencies (e.g., as
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						described below). Additional
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway transduction that regulate cell						preferred indications include
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway transduction that regulate cell						inflammation and
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway transduction that regulate cell						inflammatory disorders (such
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway transduction that regulate cell	-					as acute and chronic
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway						inflammatory diseases, e.g.,
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal Pathway transduction that regulate cell						inflammatory bowel disease
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						and Crohn's disease), and pain
835 Activation of Kinase assay. Kinase assays, Natural Killer Cell for example an Elk-1 kinase ERK Signaling assay, for ERK signal transduction that regulate cell						management.
ERK Signaling assay, for ERK signal transduction that regulate cell		HTOGR42	835	Activation of	Kinase assay. Kinase assays,	A highly preferred
assay, for ERK signal transduction that regulate cell				Natural Killer Cell	for example an Elk-1 kinase	embodiment of the invention
transduction that regulate cell	•			ERK Signaling	assay, for ERK signal	includes a method for
				Pathway	transduction that regulate cell	stimulating natural killer cell

proliferation. An alternative highly preferred embodiment of the invention includes a		killer cell proliteration. A highly preferred embodiment	of the invention includes a	method for stimulating natural	killer cell differentiation. An	alternative highly preferred	embodiment of the invention	includes a method for	inhibiting natural killer cell	differentiation. Highly	preferred indications include	neoplastic diseases (e.g., as	described below under	"Hyperproliferative	Disorders"), blood disorders	(e.g., as described below under	with "Immune Activity",	"Cardiovascular Disorders",	and/or "Blood-Related	Disorders"), immune disorders	(e.g., as described below under		infections (e.g., as described	below under "Infectious	Disease"). Preferred	indications include blood	hadinosal se a separation
are well known in the art and	modified to assess the ability	of polypeptides of the invention (including antibodies	and agonists or antagonists of	the invention) to promote or	inhibit cell proliferation,	activation, and differentiation.	Exemplary assays for ERK	kinase activity that may be	used or routinely modified to	test ERK kinase-induced	activity of polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include the	assays disclosed in Forrer et	al., Biol Chem 379(8-9):1101-	1110 (1998); Kyriakis JM,	Biochem Soc Symp 64:29-48	(1999); Chang and Karin,	Nature 410(6824):37-40	(2001); and Cobb MH, Prog	Biophys Mol Biol 71(3-4):479-	500 (1999); the contents of	each of which are herein	incorporated by reference in its	entirety. Natural killer cells	at at more than any of the
						-																	-		-		
				_																							_
		_		_																_						42.4	

below under "Immune Activity" "Blood-Related	Disorders", and/or	"Cardiovascular Disorders").	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	multiple sclerosis and/or as	described below) and	immunodeficiencies (e.g., as	described below). Additional	highly preferred indications	include inflammation and	inflammatory disorders.	Highly preferred indications	also include cancers such as,	kidney, melanoma, prostate,	breast, lung, colon, pancreatic,	esophageal, stomach, brain,	liver, urinary cancer,	lymphoma and leukemias.	Other preferred indications	include benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Other highly preferred	indications include,	pancytopenia, leukopenia,
these assays are publicly available (e.g., through the	ATCC). Exemplary natural	killer cells that may be used	according to these assays	include the human natural	killer cell lines (for example,	NK-YT cells which have	cytolytic and cytotoxic	activity) or primary NK cells.														•							
														=	_														

					leukemias, Hodgkin's disease, acute lymphocytic anemia (ALL), arthritis, asthma, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, psoriasis, immune reactions to transplanted organs and tissues, endocarditis, meningitis, Lyme
	HTOGR42	835	VEGF in SW480		Disease, and altergres.
	HTOHT18	836	Activation of	Assays for the activation of	A preferred embodiment of
			transcription	transcription through the	the invention includes a
			through serum	Serum Response Element	method for inhibiting (e.g.,
			response element in	(SRE) are well-known in the	reducing) TNF alpha
			immune cells (such	art and may be used or	production. An alternative
			as T-cells).	routinely modified to assess	preferred embodiment of the
				the ability of polypeptides of	invention includes a method
				the invention (including	for stimulating (e.g.,
				antibodies and agonists or	increasing) TNF alpha
				antagonists of the invention) to	production. Preferred
				regulate the serum response	indications include blood
				factors and modulate the	disorders (e.g., as described
				expression of genes involved	below under "Immune
				in growth. Exemplary assays	Activity", "Blood-Related
				for transcription through the	Disorders", and/or
				SRE that may be used or	"Cardiovascular Disorders"),
_				routinely modified to test SRE	Highly preferred indications
				activity of the polypeptides of	include autoimmune diseases
				the invention (including	(e.g., rheumatoid arthritis,
				antibodies and agonists or	systemic lupus erythematosis,

				_																		_								
Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other
antagonists of the invention)	include assays disclosed in	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	dependent suspension culture	of T cells with cytotoxic	activity.							
		-																												
	-																													
								•																						

preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease,").	TNFa FMAT. Assays for A highly preferred immunomodulatory proteins embodiment of the invention
	Production of TNF TNFa F alpha by dendritic immune
	836 Pro
	HTOHT18

				u u		(g		S	.;	_	<u> </u>	_	<u>`</u> ,	s	es		is,		ф р	S				ted	nal	···		p		
for	creasing)	ion. An	referred	inventic	for	ncreasin	ion.	ndication	rders (e.)	' under	", "Bloo	, and/or	isorders'	ndication	ne diseas	rthritis,	themator	nultiple	describe	ficiencia	below),	nediated	and	II-media	Additi	dication	ion and	rders, an	nge in	Lictor.
method	(e.g., de	product	highly I	nt of the	method	g (e.g., i	product	ferred in	osib boo	ed below	Activity'	isorders'	scular D	ferred in	toimmu	matoid a	upus ery	isease, n	nd/or as	3pounuu	scribed	T cell-r	esponse,	ıg a T ce	esponse.	ferred ir	flammat	ory diso	int dam	du d*:
includes a method for	inhibiting (e.g., decreasing)	TNF alpha production. An	alternative highly preferred	embodiment of the invention	includes a method for	stimulating (e.g., increasing)	TNF alpha production.	Highly preferred indications	include blood disorders (e.g.,	as described below under	"Immune Activity", "Blood-	Related Disorders", and/or	"Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	hiotomical drive stacitor
i	<u> </u>		rt a						٠						·=				S							ity of				
'ated	ells,	th muscl	es that ex	flammat	ects on a	e well kı	y be used	d to asse	/peptides	luding	onists or	inventic	modulati	nation ar	emplary	ır	ory prote	uction of	tumor	pha (TN	or inhib	ry or	se. Such	o pesn e	ed to test	ory activ	he inven	dies and	onists of	
by activ	ages, T c	ts, smool	r cell typ	iety of in	toxic effe	f cells ar	and may	modifie	y of poly	ition (inc	es and ag	sts of the	immunoi	inflam	ity. Exe	at test fo	modulate	the prod	s such as	factor al	nduction	lammato	c respons	iat may b	modifie	modulate	ides of t	ng antibo	or antag	L. 1
produced by activated	macrophages, T cells,	fibroblasts, smooth muscle,	and other cell types that exert a	wide variety of inflammatory	and cytotoxic effects on a	variety of cells are well known	in the art and may be used or	routinely modified to assess	the ability of polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention) to	mediate immunomodulation,	modulate inflammation and	cytotoxicity. Exemplary	assays that test for	immunomodulatory proteins	evaluate the production of	cytokines such as tumor	necrosis factor alpha (TNFa),	and the induction or inhibition	of an inflammatory or	cytotoxic response. Such	assays that may be used or	routinely modified to test	immunomodulatory activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	minister of the contraction
				<u>·</u>																										
cells												•																		
																_	_								-					
										_				_			_													

	disclosed in Miraglia et al., J	arthritis. An additional highly
	Biomolecular Screening 4:193-	preferred indication is sepsis.
	204(1999); Rowland et al.,	Highly preferred indications
	"Lymphocytes: a practical	include neoplastic diseases
	approach" Chapter 6:138-160	(e.g., leukemia, lymphoma,
	(2000); Verhasselt et al., Eur J	and/or as described below
	Immunol 28(11):3886-3890	under "Hyperproliferative
	(1198); Dahlen et al., J	Disorders"). Additionally,
	Immunol 160(7):3585-3593	highly preferred indications
	(1998); Verhasselt et al., J	include neoplasms and
	Immunol 158:2919-2925	cancers, such as, leukemia,
	(1997); and Nardelli et al., J	lymphoma, melanoma, glioma
	Leukoc Biol 65:822-828	(e.g., malignant glioma), solid
	(1999), the contents of each of	tumors, and prostate, breast,
	which are herein incorporated	lung, colon, pancreatic,
	by reference in its entirety.	esophageal, stomach, brain,
	Human dendritic cells that may	liver and urinary cancer. Other
	be used according to these	preferred indications include
	assays may be isolated using	benign dysproliferative
	techniques disclosed herein or	disorders and pre-neoplastic
	otherwise known in the art.	conditions, such as, for
	Human dendritic cells are	example, hyperplasia,
	antigen presenting cells in	metaplasia, and/or dysplasia.
	suspension culture, which,	Preferred indications include
	when activated by antigen	anemia, pancytopenia,
	and/or cytokines, initiate and	leukopenia, thrombocytopenia,
	upregulate T cell proliferation	Hodgkin's disease, acute
	and functional activities.	lymphocytic anemia (ALL),
		plasmacytomas, multiple
		myeloma, Burkitt's lymphoma,
		arthritis, AIDS, granulomatous

disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").	A highly preferred embodiment of the invention includes a method for stimulating endothelial cell growth. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell growth. A highly preferred embodiment of the invention includes a method for stimulating endothelial cell proliferation. An alternative highly preferred embodiment of the invention includes a method for stimulating endothelial cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting
	Caspase Apoptosis. Assays for caspase apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote caspase protease-mediated apoptosis. Induction of apoptosis in endothelial cells supporting the vasculature of tumors is associated with tumor regression due to loss of tumor blood supply. Exemplary
	Endothelial Cell Apoptosis
·	837
	HTOIZ02

modified to test capase apoptosis activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays
that may be used modified to test apoptosis activit polypeptides of (including antibola agonists or antagino including invention) including includ
that may be used or routinely modified to test capase apoptosis activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Lee et al. FFBS

	-		permeability, vascular tone,	Disorders"), and disorders of
_		-	and immune cell extravasation.	the cardiovascular system
				(e.g., heart disease, congestive
				heart failure, hypertension,
	_			aortic stenosis,
				cardiomyopathy, valvular
				regurgitation, left ventricular
				dysfunction, atherosclerosis
				and atherosclerotic vascular
				disease, diabetic nephropathy,
				intracardiac shunt, cardiac
				hypertrophy, myocardial
				infarction, chronic
				hemodynamic overload, and/or
				as described below under
				"Cardiovascular Disorders").
				Highly preferred indications
				include cardiovascular,
				endothelial and/or angiogenic
				disorders (e.g., systemic
				disorders that affect vessels
				such as diabetes mellitus, as
				well as diseases of the vessels
				themselves, such as of the
				arteries, capillaries, veins
				and/or lymphatics). Highly
				preferred are indications that
-				stimulate angiogenesis and/or
				cardiovascularization. Highly
				preferred are indications that
				inhibit angiogenesis and/or

cardiovascularization. Highly preferred indications	include antianglogenic activity to treat solid tumors,	leukemias, and Kaposi"s	sarcoma, and retinal disorders. Highly preferred indications	include neoplasms and cancer,	such as, Kaposi's sarcoma,	hemangioma (capillary and	cavernous), glomus tumors,	telangiectasia, bacillary	angiomatosis,	hemangioendothelioma,	angiosarcoma,	haemangiopericytoma,	lymphangioma,	lymphangiosarcoma. Highly	preferred indications also	include cancers such as,	prostate, breast, lung, colon,	pancreatic, esophageal,	stomach, brain, liver, and	urinary cancer. Preferred	indications include benign	dysproliferative disorders and	pre-neoplastic conditions, such	as, for example, hyperplasia,	metaplasia, and/or dysplasia.	Highly preferred indications	also include arterial disease,
															· · · · · ·												
											-				· · · ·												
							-				_																
																						_					
							٠																				

such as, atherosclerosis,	disease, inflammatory	vasculitides, Reynaud"s	disease and Reynaud"s	phenomenom, aneurysms,	restenosis; venous and	lymphatic disorders such as	thrombophlebitis,	lymphangitis, and	lymphedema; and other	vascular disorders such as	peripheral vascular disease,	and cancer. Highly	preferred indications also	include trauma such as	wounds, burns, and injured	tissue (e.g., vascular injury	such as, injury resulting from	balloon angioplasty, and	atheroschlerotic lesions),	implant fixation, scarring,	ischemia reperfusion injury,	rheumatoid arthritis,	cerebrovascular disease, renal	diseases such as acute renal	failure, and osteoporosis.	Additional highly preferred	indications include stroke,	graft rejection, diabetic or	other retinopathies, thrombotic
-																													
	-									**																			
			<u> </u>																		-								
									_	_								-		-									-
																	-						_						

and coagulative disorders, vascularitis, lymph	angiogenesis, sexual disorders, age-related macular	degeneration, and treatment /prevention of endometriosis	and related conditions.	Additional highly preferred	indications include fibromas,	heart disease, cardiac arrest,	heart valve disease, and	vascular disease.	Preferred indications include	blood disorders (e.g., as	described below under	"Immune Activity", "Blood-	Related Disorders", and/or	"Cardiovascular Disorders").	Preferred indications include	autoimmune diseases (e.g.,	rheumatoid arthritis, systemic	lupus erythematosis, multiple	sclerosis and/or as described	below) and	immunodeficiencies (e.g., as	described below). Additional	preferred indications include	inflammation and	inflammatory disorders (such	as acute and chronic	inflammatory diseases, e.g.,
																	()ar										
														-													

					inflammatory bowel disease
					and Crohn's disease), and pain
					management.
	HTOIZ02	837	Production of IL-6	IL-6 FMAT. IL-6 is produced	A highly preferred
				by T cells and has strong	embodiment of the invention
				effects on B cells. IL-6	includes a method for
				participates in IL-4 induced	stimulating (e.g., increasing)
				IgE production and increases	IL-6 production. An alternative
				IgA production (IgA plays a	highly preferred embodiment
				role in mucosal immunity).	of the invention includes a
				IL-6 induces cytotoxic T cells.	method for inhibiting (e.g.,
				Deregulated expression of IL-6	reducing) IL-6 production. A
				has been linked to autoimmune	highly preferrred indication is
-				disease, plasmacytomas,	the stimulation or enhancement
				myelomas, and chronic	of mucosal immunity. Highly
				hyperproliferative diseases.	preferred indications include
				Assays for immunomodulatory	blood disorders (e.g., as
				and differentiation factor	described below under
				proteins produced by a large	"Immune Activity", "Blood-
				variety of cells where the	Related Disorders", and/or
				expression level is strongly	"Cardiovascular Disorders"),
				regulated by cytokines, growth	and infection (e.g., as
				factors, and hormones are well	described below under
				known in the art and may be	"Infectious Disease"). Highly
				used or routinely modified to	preferred indications include
-				assess the ability of	autoimmune diseases (e.g.,
				polypeptides of the invention	rheumatoid arthritis, systemic
				(including antibodies and	lupus erythematosis, multiple
				agonists or antagonists of the	sclerosis and/or as described
				invention) to mediate	below) and
				immunomodulation and	immunodeficiencies (e.g., as

		_															-		<u> </u>			e,						p		
described below). Highly	preferred indications also	include boosting a B cell-	mediated immune response	and alternatively suppressing a	B cell-mediated immune	response. Highly preferred	indications include	inflammation and	inflammatory	disorders.Additional highly	preferred indications include	asthma and allergy. Highly	preferred indications include	neoplastic diseases (e.g.,	myeloma, plasmacytoma,	leukemia, lymphoma,	melanoma, and/or as described	below under	"Hyperproliferative	Disorders"). Highly preferred	indications include neoplasms	and cancers, such as, myeloma,	plasmacytoma, leukemia,	lymphoma, melanoma, and	prostate, breast, lung, colon,	pancreatic, esophageal,	stomach, brain, liver and	urinary cancer. Other preferred	indications include benign	dysproliferative disorders and
differentiation and modulate T	cell proliferation and function.	Exemplary assays that test for	immunomodulatory proteins	evaluate the production of	cytokines, such as IL-6, and	the stimulation and	upregulation of T cell	proliferation and functional	activities. Such assays that	may be used or routinely	modified to test	immunomodulatory and	diffferentiation activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in Miraglia et al., J	Biomolecular Screening 4:193-	204(1999); Rowland et al.,	"Lymphocytes: a practical	approach" Chapter 6:138-160	(2000); and Verhasselt et al., J	Immunol 158:2919-2925	(1997), the contents of each of	which are herein incorporated	by reference in its entirety.	Human dendritic cells that may	be used according to these	assays may be isolated using
												_		-	-	_										***				
			-			-																								

			techniques disclosed herein or otherwise known in the art. Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities.	pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease.
				An additonal preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").
HTOJK60	838	Activation of transcription through serum response element in immune cells (such as T-cells).	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess	A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the

																													$\overline{}$
invention includes a method for stimulating (e.g.,	increasing) TNF alpha	production. Preferred	indications include blood	disorders (e.g., as described	below under "Immune	Activity", "Blood-Related	Disorders", and/or	"Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases
the ability of polypeptides of the invention (including	antibodies and agonists or	antagonists of the invention) to	regulate the serum response	factors and modulate the	expression of genes involved	in growth. Exemplary assays	for transcription through the	SRE that may be used or	routinely modified to test SRE	activity of the polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention)	include assays disclosed in	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).
			_					-							_							-							
																									-				
							•						_																

(e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Additionally,	highly preferred indications include neoplasms and	cancers, such as, for example, leukemia, lymphoma, melanoma, glioma (e.g.,	malignant glioma), solid tumors, and prostate, breast,	lung, colon, pancreatic, esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include benign dysproliferative	disorders and pre-neoplastic	conditions, such as, tor	metaplasia, and/or dysplasia.	Preferred indications include	anemia, pancytopenia, leukopenia, thrombocytopenia,	Hodgkin's disease, acute	lymphocytic anemia (ALL),	plasmacytomas, multiple	myeloma, Burkitt's lymphoma,	arthritis, AIDS, granulomatous	disease, inflammatory bowel	disease, neutropenia,	neutrophilia, psoriasis,
	highly includ	cance leuker melan	malig	lung, esoph	liver	prerer benig	disor	condi	metar	Prefe	anem leuko	Hodg	lymp	plasm	myele	arthri	disea	disea	neutr
Exemplary mouse T cells that may be used according to these assays include the CTLL cell line, which is an IL-2	dependent suspension culture of T cells with cytotoxic	activity.													-				
							_								-				

suppressu	A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy) or blood vessel
	Assays for measuring calcium flux are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mobilize calcium. For example, the FLPR assay may be used to measure influx of calcium. Cells normally have very low concentrations of cytosolic calcium compared to much higher extracellular calcium. Extracellular factors can cause an influx of calcium, leading to activation of calcium
	Stimulation of Calcium Flux in pancreatic beta cells.
	839
	HTPCS72

and alterations in cell	blockage), seizures, mental
functions. Exemplary assays	confusion, drowsiness,
that may be used or routinely	nonketotic hyperglycemic-
modified to measure calcium	hyperosmolar coma,
flux by polypeptides of the	cardiovascular disease (e.g.,
invention (including antibodies	heart disease, atherosclerosis,
and agonists or antagonists of	microvascular disease,
the invention) include assays	hypertension, stroke, and other
disclosed in: Satin LS, et al.,	diseases and disorders as
Endocrinology, 136(10):4589-	described in the
601 (1995);Mogami H, et al.,	"Cardiovascular Disorders"
Endocrinology, 136(7):2960-6	section below), dyslipidemia,
(1995); Richardson SB, et al.,	endocrine disorders (as
Biochem J, 288 (Pt 3):847-51	described in the "Endocrine
(1992); and, Meats, JE, et al.,	Disorders" section below),
Cell Calcium 1989 Nov-	neuropathy, vision impairment
Dec;10(8):535-41 (1989), the	(e.g., diabetic retinopathy and
contents of each of which is	blindness), ulcers and impaired
herein incorporated by	wound healing, and infection
reference in its entirety.	(e.g., infectious diseases and
Pancreatic cells that may be	disorders as described in the
 used according to these assays	"Infectious Diseases" section
are publicly available (e.g.,	below, especially of the
through the ATCC) and/or	urinary tract and skin), carpal
may be routinely generated.	tunnel syndrome and
Exemplary pancreatic cells that	Dupuytren's contracture).
may be used according to these	An additional highly preferred
assays include HITT15 Cells.	indication is obesity and/or
HITT15 are an adherent	complications associated with
epithelial cell line established	obesity. Additional highly
from Syrian hamster islet cells	preferred indications include

			transformed with SV40. These cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219: 547-551; Santerre et al. Proc. Natl. Acad. Sci. USA 78: 4339-4343, 1981.	weight loss or alternatively, weight gain. Aditional highly preferred indications are complications associated with insulin resistance.
HTPCS72	839	TNFa in Human T-cell 2B9		
HTPIH83	840	Insulin Secretion	Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and	A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic

also by certain	neuropathy), blood vessel
proteins/peptides, and	blockage, heart disease, stroke,
disregulation is a key	impotence (e.g., due to diabetic
component in diabetes.	neuropathy or blood vessel
Exemplary assays that may be	blockage), seizures, mental
used or routinely modified to	confusion, drowsiness,
test for stimulation of insulin	nonketotic hyperglycemic-
secretion (from pancreatic	hyperosmolar coma,
 cells) by polypeptides of the	cardiovascular disease (e.g.,
invention (including antibodies	heart disease, atherosclerosis,
and agonists or antagonists of	microvascular disease,
the invention) include assays	hypertension, stroke, and other
disclosed in: Shimizu, H., et	diseases and disorders as
al., Endocr J, 47(3):261-9	described in the
 (2000); Salapatek, A.M., et al.,	"Cardiovascular Disorders"
Mol Endocrinol, 13(8):1305-	section below), dyslipidemia,
17 (1999); Filipsson, K., et al.,	endocrine disorders (as
Ann N Y Acad Sci, 865:441-4	described in the "Endocrine
(1998); Olson, L.K., et al., J	Disorders" section below),
Biol Chem, 271(28):16544-52	neuropathy, vision impairment
(1996); and, Miraglia S et. al.,	(e.g., diabetic retinopathy and
Journal of Biomolecular	blindness), ulcers and impaired
Screening, 4:193-204 (1999),	wound healing, and infection
the contents of each of which	(e.g., infectious diseases and
is herein incorporated by	disorders as described in the
reference in its entirety.	"Infectious Diseases" section
Pancreatic cells that may be	below, especially of the
used according to these assays	urinary tract and skin), carpal
are publicly available (e.g.,	tunnel syndrome and
through the ATCC) and/or	Dupuytren's contracture).
may be routinely generated.	An additional highly preferred

Exemplary pancreatic cells that may be used according to these may be used according to these assays include HITT15 Cells. HITT15 are an adherent epithelial cell line established weight loss or alternatively, from Syrian hamster islet cells weight gain. Additional highly preferred indications are cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219: 547-551; Santerre et al. Proc. Natl. Acad. Sci. USA 78: 4339-4343, 1981.	indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as
Exemplary pancreatic cells that may be used according to these assays include HITT15 Cells. HITT15 are an adherent epithelial cell line established from Syrian hamster islet cells transformed with SV40. These cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219: 547-551; Santerre et al. Proc. Natl. Acad. Sci. USA 78: 4339-4343, 1981.	Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion is measured by FMAT using
	Stimulation of insulin secretion from pancreatic beta cells.
	841
	HTSEW17

anti-rat insulin antibodies. Insulin secretion from	Disorders" section below), diabetic neuropathy, nerve
pancreatic beta cells is	disease and nerve damage
upregulated by glucose and	(e.g., due to diabetic
also by certain	neuropathy), blood vessel
proteins/peptides, and	blockage, heart disease, stroke,
disregulation is a key	impotence (e.g., due to diabetic
 component in diabetes.	neuropathy or blood vessel
Exemplary assays that may be	blockage), seizures, mental
used or routinely modified to	confusion, drowsiness,
test for stimulation of insulin	nonketotic hyperglycemic-
secretion (from pancreatic	hyperosmolar coma,
 cells) by polypeptides of the	cardiovascular disease (e.g.,
 invention (including antibodies	heart disease, atherosclerosis,
and agonists or antagonists of	microvascular disease,
the invention) include assays	hypertension, stroke, and other
disclosed in: Ahren, B., et al.,	diseases and disorders as
 Am J Physiol, 277(4 Pt	described in the
2):R959-66 (1999); Li, M., et	"Cardiovascular Disorders"
al., Endocrinology,	section below), dyslipidemia,
138(9):3735-40 (1997); Kim,	endocrine disorders (as
K.H., et al., FEBS Lett,	described in the "Endocrine
377(2):237-9 (1995); and,	Disorders" section below),
Miraglia S et. al., Journal of	neuropathy, vision impairment
Biomolecular Screening,	(e.g., diabetic retinopathy and
4:193-204 (1999), the contents	blindness), ulcers and impaired
of each of which is herein	wound healing, and infection
incorporated by reference in its	(e.g., infectious diseases and
entirety. Pancreatic cells that	disorders as described in the
may be used according to these	"Infectious Diseases" section
assays are publicly available	below, especially of the

				() The ATCC)	urinary tract and skin) carnal
				(c.g., unougn une rate)	uninal mac and circul, carpar
				and/or may be routinely	tunnel syndrome and
				generated. Exemplary	Dupuytren's contracture).
				pancreatic cells that may be	An additional highly preferred
				used according to these assays	indication is obesity and/or
				include rat INS-1 cells. INS-1	complications associated with
		,		cells are a semi-adherent cell	obesity. Additional highly
				line established from cells	preferred indications include
				isolated from an X-ray induced	weight loss or alternatively,
				rat transplantable insulinoma.	weight gain. Aditional
				These cells retain	highly preferred indications are
-				characteristics typical of native	complications associated with
				pancreatic beta cells including	insulin resistance.
				glucose inducible insulin	
				secretion. References: Asfari	
				et al. Endocrinology 1992	
				130:167.	
	HTSEW17	841	Activation of	Assays for the activation of	Preferred embodiments of the
			transcription	transcription through the	invention include using
			through NFKB	NFKB response element are	polypeptides of the invention
			response element in	well-known in the art and may	(or antibodies, agonists, or
			immune cells (such	be used or routinely modified	antagonists thereof) in
			as B-cells).	to assess the ability of	detection, diagnosis,
				polypeptides of the invention	prevention, and/or treatment of
				(including antibodies and	Cancer, Autoimmunity,
	•			agonists or antagonists of the	Allergy and Asthma
				invention) to regulate NFKB	
				transcription factors and	
				modulate expression of	
			-	immunomodulatory genes.	
				Exemplary assays for	

transcription through the	NFKB response element that	may be used or rountinely	modified to test NFKB-	response element activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in: Gri G, et al., Biol	Chem, 273(11):6431-6438	(1998); Pyatt DW, et al., Cell	Biol Toxicol 2000;16(1):41-51	(2000); Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Valle	Blazquez et al, Immunology	90(3):455-460 (1997);	Aramburau et al., J Exp Med	82(3):801-810 (1995); and	Fraser et al., 29(3):838-844	(1999), the contents of each of	which are herein incorporated	by reference in its entirety.	Immune cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).
												-		-					na ta da anciena											
						_								_								-								

														_												
		A highly preferred	indication is diabetes mellitus.	An additional highly preferred	indication is a complication	associated with diabetes (e.g.,	diabetic retinopathy, diabetic	nephropathy, kidney disease	(e.g., renal failure,	nephropathy and/or other	diseases and disorders as	described in the "Renal	Disorders" section below),	diabetic neuropathy, nerve	disease and nerve damage	(e.g., due to diabetic	neuropathy), blood vessel	blockage, heart disease, stroke,	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,
Exemplary immune cells that may be used according to these assays include the Reh B-cell line.		Assays for measuring secretion	of insulin are well-known in	the art and may be used or	routinely modified to assess	the ability of polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention) to	stimulate insulin secretion.	For example, insulin secretion	is measured by FMAT using	anti-rat insulin antibodies.	Insulin secretion from	pancreatic beta cells is	upregulated by glucose and	also by certain	proteins/peptides, and	disregulation is a key	component in diabetes.	Exemplary assays that may be	used or routinely modified to	test for stimulation of insulin	secretion (from pancreatic	cells) by polypeptides of the	invention (including antibodies
	CD69 in Human T cells	Stimulation of	insulin secretion	from pancreatic	beta cells.		-																			
	842	842		u.																	-					
	HTTBI76	HTTBI76																								
												_														

and agonists or antagonists of	microvascular disease.
the invention) include assays	hypertension, stroke, and other
disclosed in: Ahren, B., et al.,	diseases and disorders as
Am J Physiol, 277(4 Pt	described in the
2):R959-66 (1999); Li, M., et	"Cardiovascular Disorders"
al., Endocrinology,	section below), dyslipidemia,
138(9):3735-40 (1997); Kim,	endocrine disorders (as
K.H., et al., FEBS Lett,	described in the "Endocrine
377(2):237-9 (1995); and,	Disorders" section below),
Miraglia S et. al., Journal of	neuropathy, vision impairment
Biomolecular Screening,	(e.g., diabetic retinopathy and
4:193-204 (1999), the contents	blindness), ulcers and impaired
of each of which is herein	wound healing, and infection
incorporated by reference in its	(e.g., infectious diseases and
entirety. Pancreatic cells that	disorders as described in the
may be used according to these	"Infectious Diseases" section
assays are publicly available	below, especially of the
(e.g., through the ATCC)	urinary tract and skin), carpal
and/or may be routinely	tunnel syndrome and
 generated. Exemplary	Dupuytren's contracture).
pancreatic cells that may be	An additional highly preferred
used according to these assays	indication is obesity and/or
include rat INS-1 cells. INS-1	complications associated with
cells are a semi-adherent cell	obesity. Additional highly
line established from cells	preferred indications include
isolated from an X-ray induced	weight loss or alternatively,
rat transplantable insulinoma.	weight gain. Aditional
These cells retain	highly preferred indications are
characteristics typical of native	complications associated with
pancreatic beta cells including	insulin resistance.
glucose inducible insulin	

			secretion. References: Asfari et al. Endocrinology 1992 130:167.	
HTTBI76	842	Caspase (+camptothecin) in SW480		
HTTBS64	843	Regulation of	Assays for the regulation of	A highly preferred
		transcription of	transcription of Malic Enzyme	indication is diabetes mellitus.
		Malic Enzyme in	are well-known in the art and	An additional highly preferred
		hepatocytes	may be used or routinely	indication is a complication
			modified to assess the ability	associated with diabetes (e.g.,
			of polypeptides of the	diabetic retinopathy, diabetic
			invention (including antibodies	nephropathy, kidney disease
	3514		and agonists or antagonists of	(e.g., renal failure,
			the invention) to regulate	nephropathy and/or other
			transcription of Malic Enzyme,	diseases and disorders as
			a key enzyme in lipogenesis.	described in the "Renal
			Malic enzyme is involved in	Disorders" section below),
			lipogenesisand its expression is	diabetic neuropathy, nerve
			stimulted by insulin. ME	disease and nerve damage
			promoter contains two direct	(e.g., due to diabetic
			repeat (DR1)- like elements	neuropathy), blood vessel
			MEp and MEd identified as	blockage, heart disease, stroke,
			putative PPAR response	impotence (e.g., due to diabetic
	-		elements. ME promoter may	neuropathy or blood vessel
			also responds to AP1 and other	blockage), seizures, mental
			transcription factors.	confusion, drowsiness,
			Exemplary assays that may be	nonketotic hyperglycemic-
			used or routinely modified to	hyperosmolar coma,
			test for regulation of	cardiovascular disease (e.g.,
			transcription of Malic Enzyme	heart disease, atherosclerosis,

(in her	(in hepatocytes) by	microvascular disease.
football	polypeptides of the invention	hypertension, stroke, and other
(incluc	(including antibodies and	diseases and disorders as
agonis	agonists or antagonists of the	described in the
invent	invention) include assays	"Cardiovascular Disorders"
disclos	disclosed in: Streeper, R.S., et	section below), dyslipidemia,
al., Mc	al., Mol Endocrinol,	endocrine disorders (as
12(11)	12(11):1778-91 (1998);	described in the "Endocrine
Garcia	Garcia-Jimenez, C., et al., Mol	Disorders" section below),
Endoc	Endocrinol, 8(10):1361-9	neuropathy, vision impairment
(1994)	(1994); Barroso, I., et al., J	(e.g., diabetic retinopathy and
Biol C	Biol Chem, 274(25):17997-	blindness), ulcers and impaired
 8004 (8004 (1999); Ijpenberg, A., et	wound healing, and infection
al., J B	al., J Biol Chem,	(e.g., infectious diseases and
] 272(32	272(32):20108-20117 (1997);	disorders as described in the
 Berger	Berger, et al., Gene 66:1-10	"Infectious Diseases" section
[(1988)	(1988); and, Cullen, B., et al.,	below, especially of the
Metho	Methods in Enzymol.	urinary tract and skin), carpal
216:36	216:362–368 (1992), the	tunnel syndrome and
conten	contents of each of which is	Dupuytren's contracture).
 herein	herein incorporated by	An additional highly preferred
referer	reference in its entirety.	indication is obesity and/or
Hepate	Hepatocytes that may be used	complications associated with
accord	according to these assays are	obesity. Additional highly
public	publicly available (e.g.,	preferred indications include
throug	through the ATCC) and/or	weight loss or alternatively,
may be	may be routinely generated.	weight gain. Aditional
Exemi	Exemplary hepatocytes that	highly preferred indications are
may be	may be used according to these	complications associated with
assays	assays includes the mouse	insulin resistance.
3T3-L	3T3-L1 cell line. 3T3-L1 is a	

			mouse preadipocyte cell line (adherent). It is a continuous substrain of 3T3 fibroblasts developed through clonal isolation. Cells undergo a preadipocyte to adipose-like conversion under appropriate differentiation culture	
HTWDF76	844	Activation of transcription through AP1 response element in immune cells (such as T-cells).	Assays for the activation of transcription through the AP1 response element are known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate growth and other cell functions. Exemplary assays for transcription through the AP1 response element that may be used or routinely modified to test AP1-response element activity of polypeptides of the invention	Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple
			(including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1988); Cullen and	sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional highly preferred indications

include inflammation and inflammatory disorders. Highly preferred indications	also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described	below under "Hyperproliferative Disorders"), Hiohly preferred	indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast,	lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other	preferred indications include benign dysproliferative	disorders and pre-neoplastic conditions, such as, for example, hyperplasia,	metaplasia, and/or dysplasia. Preferred indications include arthritis, asthma, AIDS,	allergy, anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute	lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma,	granulomatous disease, inflammatory bowel disease,
include ir inflamma Highly pr	also includiseases (below under "Hyperprolis	indication and cance lymphom	lung, cold	preferred benign dy	disorders condition example.	metaplas Preferred arthritis,	allergy, a leukopen Hodgkin	lymphoc plasmacy myeloma	granulon inflamma
Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Rellahan et al., J Biol Chem 272(49):30806-30811 (1997);	Chang et al., Mol Cell Biol 18(9):4986-4993 (1998); and Fraser et al. Fur I Imminol	29(3):838-844 (1999), the contents of each of which are herein incorporated by	reference in its entirety. T cells that may be used	publicly available (e.g., through the ATCC).	Exemplary mouse T cells that may be used according to these assays include the CTLL cell	line, which is an IL-2 dependent suspension-culture cell line with cytotoxic	activity.		

				sepsis, psoriasis, suppression of immune reactions to
				transplanted organs and
				tissues, endocarditis,
				meningitis, and Lyme Disease.
HTWDF76	844	Activation of	Assays for the activation of	A highly preferred
		transcription	transcription through the CD28	embodiment of the invention
		through CD28	response element are well-	includes a method for
		response element in	known in the art and may be	stimulating T cell proliferation.
		immune cells (such	used or routinely modified to	An alternative highly preferred
		as T-cells).	assess the ability of	embodiment of the invention
		`	polypeptides of the invention	includes a method for
			(including antibodies and	inhibiting T cell proliferation.
-			agonists or antagonists of the	A highly preferred
			invention) to stimulate IL-2	embodiment of the invention
		3-2	expression in T cells.	includes a method for
			Exemplary assays for	activating T cells. An
			transcription through the CD28	alternative highly preferred
			response element that may be	embodiment of the invention
			used or routinely modified to	includes a method for
			test CD28-response element	inhibiting the activation of
			activity of polypeptides of the	and/or inactivating T cells.
			invention (including antibodies	A highly preferred
			and agonists or antagonists of	embodiment of the invention
			the invention) include assays	includes a method for
			disclosed in Berger et al., Gene	stimulating (e.g., increasing)
			66:1-10 (1998); Cullen and	IL-2 production. An alternative
			Malm, Methods in Enzymol	highly preferred embodiment
		-	216:362-368 (1992); Henthorn	of the invention includes a
			et al., Proc Natl Acad Sci USA	method for inhibiting (e.g.,
			85:6342-6346 (1988);	reducing) IL-2 production.

	McGuire and Iacobelli, J Immunol 159(3):1319-1327	Additional highly preferred indications include
	(1997); Parra et al., J Immunol	inflammation and
	166(4):2437-2443 (2001); and	inflammatory disorders.
 	Butscher et al., J Biol Chem	Highly preferred indications
 	3(1):552-560 (1998), the	include autoimmune diseases
	contents of each of which are	(e.g., rheumatoid arthritis,
-	herein incorporated by	systemic lupus erythematosis,
 	reference in its entirety. T	multiple sclerosis and/or as
 	cells that may be used	described below),
	according to these assays are	immunodeficiencies (e.g., as
	publicly available (e.g.,	described below), boosting a T
	through the ATCC).	cell-mediated immune
	Exemplary human T cells that	response, and suppressing a T
-	may be used according to these	cell-mediated immune
 	assays include the JURKAT	response. An additional highly
	cell line, which is a suspension	preferred indication includes
 	culture of leukemia cells that	infection (e.g., AIDS, and/or as
_	produce IL-2 when stimulated.	described below under
		"Infectious Disease").
 		Highly preferred indications
-		include neoplastic diseases
-		(e.g., melanoma, renal cell
		carcinoma, leukemia,
 		lymphoma, and/or as described
		below under
		"Hyperproliferative
		Disorders"). Highly preferred
 		indications include neoplasms
		and cancers, such as, for
		example, melanoma (e.g.,

			metastatic melanoma), renal
		-	cell carcinoma (e o metastatic
-		~	renal cell carcinoma).
			leukemia, lymphoma (e.g., T
			cell lymphoma), and prostate,
			breast, lung, colon, pancreatic,
			esophageal, stomach, brain,
			liver and urinary cancer. Other
			preferred indications include
	-		benign dysproliferative
	-		disorders and pre-neoplastic
			conditions, such as, for
			example, hyperplasia,
			metaplasia, and/or dysplasia.
	_		A highly preferred indication
			is infection (e.g., tuberculosis,
			infections associated with
	• •		granulomatous disease, and
			osteoporosis, and/or an
			infectious disease as described
			below under "Infectious
	-		Disease"). A highly preferred
		•	indication is AIDS.
			Additional highly preferred
			indications include suppression
	-		of immune reactions to
			transplanted organs and/or
	•		tissues, uveitis, psoriasis, and
			tropical spastic paraparesis.
			Preferred indications include
			blood disorders (e.g., as

				described below under
				"Immine Activity", "Blood-
				Related Disorders", and/or
				"Cardiovascular Disorders").
				Preferred indications also
		-		include anemia, pancytopenia,
				leukopenia, thrombocytopenia,
				Hodgkin's disease, acute
				lymphocytic anemia (ALL),
			,	plasmacytomas, multiple
				myeloma, Burkitt's lymphoma,
				arthritis, granulomatous
				disease, inflammatory bowel
				disease, sepsis, neutropenia,
				neutrophilia, hemophilia,
				hypercoagulation, diabetes
				mellitus, endocarditis,
				meningitis, Lyme Disease,
				asthma and allergy.
HTWDF76	844	Activation of	Assays for the activation of	A preferred embodiment of
		transcription	transcription through the	the invention includes a
		through serum	Serum Response Element	method for inhibiting (e.g.,
		response element in	(SRE) are well-known in the	reducing) TNF alpha
		immune cells (such	art and may be used or	production. An alternative
		as natural killer	routinely modified to assess	highly preferred embodiment
		cells).	the ability of polypeptides of	of the invention includes a
		`	the invention (including	method for stimulating (e.g.,
			antibodies and agonists or	increasing) TNF alpha
			antagonists of the invention) to	production. Preferred
			regulate serum response	indications include blood
			factors and modulate the	disorders (e.g., as described

																													\neg
below under "Immune Activity", "Blood-Related	Disorders", and/or	"Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),			suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and
expression of genes involved in growth and upregulate the	function of growth-related	genes in many cell types.	Exemplary assays for	transcription through the SRE	that may be used or routinely	modified to test SRE activity	of the polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Benson	et al., J Immunol 153(9):3862-	3873 (1994); and Black et al.,	Virus Genes 12(2):105-117	(1997), the content of each of	which are herein incorporated	by reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary T cells that may be	used according to these assays	include the NK-YT cell line,
																	-		_										

		which is a human natural killer	cancers, such as, for example,
		cell line with cytolytic and	leukemia, lymphoma,
		cytotoxic activity.	melanoma, glioma (e.g.,
			malignant glioma), solid
			tumors, and prostate, breast,
			lung, colon, pancreatic,
			esophageal, stomach, brain,
			liver and urinary cancer. Other
	-		preferred indications include
			benign dysproliferative
			disorders and pre-neoplastic
			conditions, such as, for
-			example, hyperplasia,
			metaplasia, and/or dysplasia.
			Preferred indications include
			anemia, pancytopenia,
			leukopenia, thrombocytopenia,
	-		Hodgkin's disease, acute
			lymphocytic anemia (ALL),
			plasmacytomas, multiple
			myeloma, Burkitt's lymphoma,
			arthritis, AIDS, granulomatous
			disease, inflammatory bowel
			disease, neutropenia,
			neutrophilia, psoriasis,
			suppression of immune
			reactions to transplanted
			organs and tissues, hemophilia,
			hypercoagulation, diabetes
			mellitus, endocarditis,
			meningitis, Lyme Disease,

					cardiac reperfusion injury, and
					asthma and allergy. An
					additional preferred indication
					is infection (e.g., an infectious
					disease as described below
					under "Infectious Disease").
	HTXCV12	845	Activation of	Assays for the activation of	A preferred embodiment of
			transcription	transcription through the	the invention includes a
			through serum	Serum Response Element	method for inhibiting (e.g.,
			response element in	(SRE) are well-known in the	reducing) TNF alpha
			immune cells (such	art and may be used or	production. An alternative
			as T-cells).	routinely modified to assess	preferred embodiment of the
				the ability of polypeptides of	invention includes a method
				the invention (including	for stimulating (e.g.,
				antibodies and agonists or	increasing) TNF alpha
				antagonists of the invention) to	production. Preferred
				regulate the serum response	indications include blood
				factors and modulate the	disorders (e.g., as described
				expression of genes involved	below under "Immune
				in growth. Exemplary assays	Activity", "Blood-Related
				for transcription through the	Disorders", and/or
				SRE that may be used or	"Cardiovascular Disorders"),
	-			routinely modified to test SRE	Highly preferred indications
				activity of the polypeptides of	include autoimmune diseases
				the invention (including	(e.g., rheumatoid arthritis,
				antibodies and agonists or	systemic lupus erythematosis,
				antagonists of the invention)	Crohn"s disease, multiple
_				include assays disclosed in	sclerosis and/or as described
				Berger et al., Gene 66:1-10	below), immunodeficiencies
			-	(1998); Cullen and Malm,	(e.g., as described below),
_				Methods in Enzymol 216:362-	boosting a T cell-mediated

immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,
immune	suppress	immune	highly pr	include i	inflamm	treating j	patients	arthritis.	preferred	Highly p	include r	(e.g., leu			Disorder	highly pr	include r	cancers,	leukemia	melanon	malignar	tumors,	lung, col	esophage	liver and	preferred	benign d	disorders	condition	example
368 (1992): Henthorn et al	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	dependent suspension culture	of T cells with cytotoxic	activity.												
			_	_																	_									
				_																								-		
																			,											

metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, inflammatory bowel disease, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").		for s	
		RANTES FMAT. Assays for immunomodulatory proteins	that induce chemotaxis of T cells, monocytes, and
	IFNg in Human T-cell 293T	Production of RANTES in	endothelial cells (such as human
	845	845	·
	HTXCV12	HTXCV12	
			_

the art and may be used or	routinely modified to assess	the ability of polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention) to	mediate immunomodulation,	induce chemotaxis, and/or	mediate humoral or cell-	mediated immunity.	Exemplary assays that test for	immunomodulatory proteins	evaluate the production of	cytokines, such as RANTES,	and the induction of	chemotactic responses in	immune cells. Such assays	that may be used or routinely	modified to test	immunomodulatory activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include the assays	disclosed in Miraglia et al., J	Biomolecular Screening 4:193-	204 (1999); Rowland et al.,	"Lymphocytes: a practical	approach" Chapter 6:138-160	(2000): Cocchi et al., Science	270(5243):1811-1815 (1995);
endothelial cells	(HUVEC))												-																	
											40 40																			

		Highly preferred indications include inflammatory disorders. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications
and Robinson et al., Clin Exp Immunol 101(3):398-407 (1995), the contents of each of which are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary endothelial cells that may be used according to	these assays include human umbilical vein endothelial cells (HUVEC), which are endothelial cells which line venous blood vessels, and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.	Assays for the activation of transcription through the NFKB response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate NFKB
		Activation of transcription through NFKB response element in immune cells (such as T-cells).
		845
		HTXCV12

		transcription factors and	include autoimmune diseases
		modulate expression of	(e.g., rheumatoid arthritis,
		immunomodulatory genes.	systemic lupus erythematosis,
		Exemplary assays for	multiple sclerosis and/or as
		transcription through the	described below), and
		NFKB response element that	immunodeficiencies (e.g., as
		may be used or rountinely	described below). An
		modified to test NFKB-	additional highly preferred
		response element activity of	indication is infection (e.g.,
		polypeptides of the invention	AIDS, and/or an infectious
		(including antibodies and	disease as described below
		agonists or antagonists of the	under "Infectious Disease").
		invention) include assays	Highly preferred indications
		disclosed in Berger et al., Gene	include neoplastic diseases
		66:1-10 (1998); Cullen and	(e.g., melanoma, leukemia,
		Malm, Methods in Enzymol	lymphoma, and/or as described
		216:362-368 (1992); Henthorn	below under
	-	et al., Proc Natl Acad Sci USA	"Hyperproliferative
		85:6342-6346 (1988); Black et	Disorders"). Highly preferred
		al., Virus Gnes 15(2):105-117	indications include neoplasms
		(1997); and Fraser et al.,	and cancers, such as, for
		29(3):838-844 (1999), the	example, melanoma, renal cell
		contents of each of which are	carcinoma, leukemia,
		herein incorporated by	lymphoma, and prostate,
		reference in its entirety.	breast, lung, colon, pancreatic,
		Exemplary human T cells,	esophageal, stomach, brain,
		such as the MOLT4, that may	liver and urinary cancer. Other
		be used according to these	preferred indications include
		assays are publicly available	benign dysproliferative
		(e.g., through the ATCC).	disorders and pre-neoplastic
			conditions, such as, for

				example, nyperplasia,
				metapiasia, and/or dyspiasia. Preferred indications also
		_		include anemia, pancytopenia,
				leukopenia, thrombocytopenia, Hodgkin's disease, acute
				lymphocytic anemia (ALL),
				plasmacytomas, multiple
				myeloma, Burkitt's lymphoma,
-				arthritis, AIDS, granulomatous
				disease, inflammatory bowel
				disease, sepsis, neutropenia,
				neutrophilia, psoriasis,
-				hemophilia, hypercoagulation,
				diabetes mellitus, endocarditis,
				meningitis, Lyme Disease,
				suppression of immune
				reactions to transplanted
				organs, asthma and allergy.
HTXCV12	845	Caspase		
		(+camptothecin) in SW480		
HTXFL30	846	Production of TNF	TNFa FMAT. Assays for	A highly preferred
		alpha by dendritic	immunomodulatory proteins	embodiment of the invention
		cells	produced by activated	includes a method for
			macrophages, T cells,	inhibiting (e.g., decreasing)
			fibroblasts, smooth muscle,	TNF alpha production. An
			and other cell types that exert a	alternative highly preferred
			wide variety of inflammatory	embodiment of the invention
			and cytotoxic effects on a	includes a method for
			waisty of calle are well known	etimulating (a g increasing)

TNF alpha production. Highly preferred indications include blood disorders (e.g., as described below under	"Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"),	Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis,	systemic lupus erythematosis, Crohn's disease, multiple selerosis and/or as described	below), immunodeficiencies (e.g., as described below),	boosting a T cell-mediated immune response, and	suppressing a T cell-mediated immune response. Additional	highly preferred indications include inflammation and	inflammatory disorders, and treating joint damage in	patients with rheumatoid		preferred indication is sepsis. Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below under "Hyperproliferative
in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including	antibodies and agonists or antagonists of the invention) to mediate immunomodulation,	modulate inflammation and cytotoxicity. Exemplary assays that test for	immunomodulatory proteins evaluate the production of	necrosis factor alpha (TNFa), and the induction or inhibition	of an inflammatory or cytotoxic response. Such	assays that may be used or routinely modified to test	immunomodulatory activity of polypeptides of the invention	(including antibodies and agonists or antagonists of the	invention) include assays	disclosed in Miraglia et al., J	Biomolecular Screening 4:193-204(1999); Rowland et al.,	"Lymphocytes: a practical	approach" Chapter 6:138-160	(2000); Verhasselt et al., Eur J Immunol 28(11):3886-3890
											-			

(1108). Dahlen et al I	Disorders" Additionally
(11/9), Daineil et al., 5	1. 11 6 1. 1
Immunol 160(7):3585-3593	highly preferred indications
(1998); Verhasselt et al., J	include neoplasms and
Immunol 158:2919-2925	cancers, such as, leukemia,
(1997); and Nardelli et al., J	lymphoma, melanoma, glioma
Leukoc Biol 65:822-828	(e.g., malignant glioma), solid
(1999), the contents of each of	tumors, and prostate, breast,
which are herein incorporated	lung, colon, pancreatic,
by reference in its entirety.	esophageal, stomach, brain,
Human dendritic cells that may	liver and urinary cancer. Other
be used according to these	preferred indications include
assays may be isolated using	benign dysproliferative
techniques disclosed herein or	disorders and pre-neoplastic
otherwise known in the art.	conditions, such as, for
Human dendritic cells are	example, hyperplasia,
antigen presenting cells in	metaplasia, and/or dysplasia.
suspension culture, which,	Preferred indications include
when activated by antigen	anemia, pancytopenia,
and/or cytokines, initiate and	leukopenia, thrombocytopenia,
upregulate T cell proliferation	Hodgkin's disease, acute
and functional activities.	lymphocytic anemia (ALL),
	plasmacytomas, multiple
	myeloma, Burkitt's lymphoma,
	arthritis, AIDS, granulomatous
	disease, inflammatory bowel
	disease, neutropenia,
	neutrophilia, psoriasis,
	suppression of immune
	reactions to transplanted
	organs and tissues,
	hemophilia, hypercoagulation,

				diabetes mellitus, endocarditis, meningitis, Lyme Disease,
				cardiac repertusion injury, and asthma and allergy. An
				additional preferred indication
				is infection (e.g., an infectious
				disease as described below under "Infectious Disease").
HTXFL30	846	Inhibition of	Reporter Assay: construct	
		squalene synthetase	contains regulatory and coding	
		gene transcription.	sequence of squalene	
 			synthetase, the first specific	
			enzyme in the cholesterol	
			biosynthetic pathway. See	
			Jiang, et al., J. Biol. Chem.	
			268:12818-128241(993), the	
		-	contents of which are herein	
 			incorporated by reference in its	
 -			entirety. Cells were treated	
			with SID supernatants, and	
			SEAP activity was measured	
	_		after 72 hours. HepG2 is a	
			human hepatocellular	
	- da		carcinoma cell line (ATCC	
			HB-8065). See Knowles et al.,	
			Science. 209:497-9 (1980), the	
			contents of which are herein	
			incorporated by reference in its	
			entirety.	
HTXFL30	846	Regulation of	Kinase assays, for example an	Preferred embodiments of the
		proliferation and/or	Elk-1 kinase assay for ERK	invention include using

differentiation in	signal transduction that	polypeptides of the invention
immune cells (such	regulates cell proliferation or	(or antibodies, agonists, or
 as mast cells).	differentiation, are well known	antagonists thereof) in
	in the art and may be used or	detection, diagnosis,
	routinely modified to assess	prevention, and/or treatment of
	the ability of polypeptides of	asthma, allergy,
	the invention (including	hypersensitivity and
	antibodies and agonists or	inflammation.
	antagonists of the invention) to	
	promote or inhibit cell	
	proliferation, activation, and	
	differentiation. Exemplary	
	assays for ERK kinase activity	
	that may be used or routinely	
	modified to test ERK kinase-	
	induced activity of	
	polypeptides of the invention	
	(including antibodies and	
	agonists or antagonists of the	
	invention) include the assays	
	disclosed in: Ali H, et al., J	
	Immunol, 165(12):7215-7223	
	(2000); Tam SY, et al., Blood,	
	90(5):1807-1820 (1997);	
	Forrer et al., Biol Chem 379(8-	
	9):1101-1110 (1998); Berra et	
	al., Biochem Pharmacol	
	60(8):1171-1178 (2000);	
	Gupta et al., Exp Cell Res	
	247(2):495-504 (1999); Chang	
	and Karin, Nature	

		Partition DDAR response	importence (e a due to diahetic
	464		mirpotential (c.b.) due to diacente
•		elements. ME promoter may	neuropainy or oloou vessel
		also responds to AP1 and other	blockage), seizures, mental
		transcription factors.	confusion, drowsiness,
		Exemplary assays that may be	nonketotic hyperglycemic-
		used or routinely modified to	hyperosmolar coma,
		test for regulation of	cardiovascular disease (e.g.,
		transcription of Malic Enzyme	heart disease, atherosclerosis,
		(in hepatocytes) by	microvascular disease,
		polypeptides of the invention	hypertension, stroke, and other
	•	(including antibodies and	diseases and disorders as
		agonists or antagonists of the	described in the
		invention) include assays	"Cardiovascular Disorders"
		disclosed in: Streeper, R.S., et	section below), dyslipidemia,
		al., Mol Endocrinol,	endocrine disorders (as
		12(11):1778-91 (1998);	described in the "Endocrine
		Garcia-Jimenez, C., et al., Mol	Disorders" section below),
		Endocrinol, 8(10):1361-9	neuropathy, vision impairment
		(1994); Barroso, I., et al., J	(e.g., diabetic retinopathy and
		Biol Chem, 274(25):17997-	blindness), ulcers and impaired
		8004 (1999); Ijpenberg, A., et	wound healing, and infection
		al., J Biol Chem,	(e.g., infectious diseases and
		272(32):20108-20117 (1997);	disorders as described in the
		Berger, et al., Gene 66:1-10	"Infectious Diseases" section
		(1988); and, Cullen, B., et al.,	below, especially of the
		Methods in Enzymol.	urinary tract and skin), carpal
		216:362–368 (1992), the	tunnel syndrome and
		contents of each of which is	Dupuytren's contracture).
	-	herein incorporated by	An additional highly preferred
		reference in its entirety.	indication is obesity and/or
		Hepatocytes that may be used	complications associated with

			according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary hepatocytes that may be used according to these assays includes the mouse assays includes the mouse preadipocyte cell line (adherent). It is a continuous substrain of 3T3 fibroblasts developed through clonal isolation. Cells undergo a preadipocyte to adipose-like conversion under appropriate differentiation culture	obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Aditional highly preferred indications are complications associated with insulin resistance.
HTXJM03	847	Glucose Production in H4IIE	Collections.	
HTXON32	848	Insulin Secretion	Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion is measured by FMAT using	A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below)

						7
Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and disregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention including antibodies and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Endocr 1, 47(3):261-9 (2000), Salapatek, A.M., et al., Mol Endocrino, 1, 3(2):105- 17 (1999), Filipsson, K., et al., Ann N Y Acad Sci, 865:441-4 (1998); Olson, L.K., et al., J Biol Chem, 271(28):16544-52 (1998); olm, Miragia S et al., Journal of Biomolecular Screening, 4:193-204 (1999), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells hat may be used according to these assays	diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel	blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental	contusion, arowsiness, nonketotic hyperglycemic- hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis,	microvascular disease, hypertension, stroke, and other diseases and disorders as described in the	section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment	(e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the "Infectious Diseases" section below, especially of the urinary tract and skin), carpal
	Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain	proteins/peptides, and disregulation is a key component in diabetes. Exemplary assays that may be	used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies	and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Endocr J, 47(3):261-9	(2000); Salapatek, A.M., et al., Mol Endocrinol, 13(8):1305-17 (1999); Filipsson, K., et al., Ann N Y Acad Sci, 865:441-4 (1998); Olson, L.K., et al., J Biol Chem, 271(28):16544-52	(1996); and, Miraglia S et. al., Journal of Biomolecular Screening, 4:193-204 (1999), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays
						,

			-1.			
tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.				Preferred indications include	neoplastic diseases (e.g., as	"Hyperproliferative
are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include HITT15 Cells. HITT15 are an adherent epithelial cell line established from Syrian hamster islet cells transformed with SV40. These cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219: 547-551; Santerre et al. Proc. Natl. Acad. Sci. USA 78: 4339-4343, 1981.				Kinase assay. JNK and p38	kinase assays for signal	transduction that regulate centroliferation, activation, or
	IgG in Human B cells SAC	CXCR4 in SW480	SEAP in 293/ISRE	Activation of T-	Cell p38 or JNK	Signaling Fathway.
	848	848	849	849		
	HTXON32	HTXON32	HUFBY15	HUFBY15		

	apoptosis are well known in	Disorders"), blood disorders
	the art and may be used or	(e.g., as described below under
	routinely modified to assess	"Immune Activity",
	the ability of polypeptides of	"Cardiovascular Disorders",
	the invention (including	and/or "Blood-Related
	antibodies and agonists or	Disorders"), and infection
	antagonists of the invention) to	(e.g., an infectious disease as
	promote or inhibit immune cell	described below under
	(e.g. T-cell) proliferation,	"Infectious Disease"). Highly
	activation, and apoptosis.	preferred indications include
	Exemplary assays for JNK and	autoimmune diseases (e.g.,
	p38 kinase activity that may be	rheumatoid arthritis, systemic
	used or routinely modified to	lupus erythematosis, multiple
	test JNK and p38 kinase-	sclerosis and/or as described
	induced activity of	below) and
	polypeptides of the invention	immunodeficiencies (e.g., as
	(including antibodies and	described below). Additional
	agonists or antagonists of the	highly preferred indications
	invention) include the assays	include inflammation and
	disclosed in Forrer et al., Biol	inflammatory disorders.
	Chem 379(8-9):1101-1110	Highly preferred indications
	(1998); Gupta et al., Exp Cell	also include neoplastic
	Res 247(2): 495-504 (1999);	diseases (e.g., leukemia,
	Kyriakis JM, Biochem Soc	lymphoma, and/or as described
-	Symp 64:29-48 (1999); Chang	below under
	and Karin, Nature	"Hyperproliferative
	410(6824):37-40 (2001); and	Disorders"). Highly preferred
-	Cobb MH, Prog Biophys Mol	indications include neoplasms
	Biol 71(3-4):479-500 (1999);	and cancers, such as, leukemia,
	the contents of each of which	lymphoma, prostate, breast,
	are herein incorporated by	lung, colon, pancreatic,

				reference in its entirety. T cells that may be used	esophageal, stomach, brain, liver, and urinary cancer. Other
	<u>-</u>			according to these assays are	preferred indications include
	-			publicly available (e.g.,	benign dysproliferative
				through the ATCC).	disorders and pre-neoplastic
				Exemplary mouse T cells that	conditions, such as, for
				may be used according to these	example, hyperplasia,
_				assays include the CTLL cell	metaplasia, and/or dysplasia.
	-			line, which is an IL-2	Preferred indications include
				dependent suspension-culture	arthritis, asthma, AIDS,
				cell line with cytotoxic	allergy, anemia, pancytopenia,
	_			activity.	leukopenia, thrombocytopenia,
					Hodgkin"s disease, acute
·					lymphocytic anemia (ALL),
					plasmacytomas, multiple
					myeloma, Burkitt"s lymphoma,
					granulomatous disease,
_					inflammatory bowel disease,
					sepsis, psoriasis, suppression
					of immune reactions to
					transplanted organs and
					tissues, endocarditis,
					meningitis, and Lyme Disease.
	HUFCJ30	850	IgG in Human B cells		
	HUFCJ30	850	Stimulation of	Assays for measuring secretion	A highly preferred
			insulin secretion	of insulin are well-known in	indication is diabetes mellitus.
			from pancreatic	the art and may be used or	An additional highly preferred
			beta cells.	routinely modified to assess	indication is a complication
				the ability of polypeptides of	associated with diabetes (e.g.,
				the invention (including	diabetic retinopathy, diabetic

antibodies and agonists or	nephropathy, kidney disease
antagonists of the invention) to	
stimulate insulin secretion.	
For example, insulin secretion	diseases and disorders as
is measured by FMAT using	described in the "Renal
anti-rat insulin antibodies.	Disorders" section below),
Insulin secretion from	diabetic neuropathy, nerve
pancreatic beta cells is	disease and nerve damage
upregulated by glucose and	(e.g., due to diabetic
also by certain	neuropathy), blood vessel
proteins/peptides, and	blockage, heart disease, stroke,
disregulation is a key	impotence (e.g., due to diabetic
component in diabetes.	neuropathy or blood vessel
Exemplary assays that may be	blockage), seizures, mental
used or routinely modified to	confusion, drowsiness,
test for stimulation of insulin	nonketotic hyperglycemic-
secretion (from pancreatic	hyperosmolar coma,
 cells) by polypeptides of the	cardiovascular disease (e.g.,
invention (including antibodies	heart disease, atherosclerosis,
and agonists or antagonists of	microvascular disease,
the invention) include assays	hypertension, stroke, and other
disclosed in: Ahren, B., et al.,	diseases and disorders as
Am J Physiol, 277(4 Pt	described in the
2):R959-66 (1999); Li, M., et	"Cardiovascular Disorders"
al., Endocrinology,	section below), dyslipidemia,
 138(9):3735-40 (1997); Kim,	endocrine disorders (as
K.H., et al., FEBS Lett,	described in the "Endocrine
377(2):237-9 (1995); and,	Disorders" section below),
Miraglia S et. al., Journal of	neuropathy, vision impairment
Biomolecular Screening,	
4:193-204 (1999), the contents	blindness), ulcers and impaired

	-	
wound healing, and infection (e.g., infectious diseases and disorders as described in the "Infectious Diseases" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Aditional highly preferred indications are complications associated with insulin resistance.	c	A highly preferred embodiment of the invention includes a method for stimulating endothelial cell growth. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell
of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.		Caspase Apoptosis Rescue. Assays for caspase apoptosis rescue are well known in the art and may be used or routinely modified to assess the ability of the polypeptides of the invention (including antibodies and agonists or
	SEAP in 293/ISRE	Protection from Endothelial Cell Apoptosis.
	851	851
	HUKAH51	HUKAH51

inhibit caspase protease- mediated apoptosis. Exemplary assays for caspase apoptosis that may be used or routinely modified to test caspase apoptosis rescue of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Romeo et al., Cardiovasc Res 45(3): 788-794 (2000); Messmer et al., Br J Pharmacol 127(7): 1633-1640 (1999); and J Atheroscler Thromb 3(2): 75-80 (1996); the contents of each of which are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., through commercial sources). Exemplary endothelial cells that may be used according to these assays are publicly available (e.g., through commercial sources). Exemplary endothelial cells (bAEC), which are an example

but alternative highly preferred embodiment of the invention	includes a method for		-	of the invention includes a	method for reducing cardiac	hypertrophy. An alternative	highly preferred embodiment	of the invention includes a	method for inducing cardiac	hypertrophy. Highly	preferred indications include	neoplastic diseases (e.g., as	described below under	"Hyperproliferative	Disorders"), and disorders of	the cardiovascular system	(e.g., heart disease, congestive	heart failure, hypertension,	aortic stenosis,	cardiomyopathy, valvular	regurgitation, left ventricular	dysfunction, atherosclerosis	and atherosclerotic vascular	disease, diabetic nephropathy,	intracardiac shunt, cardiac	hypertrophy, myocardial	infarction, chronic	hemodynamic overload, and/or	as described below under
in functions that include, but	angiogenesis, vascular	permeability, vascular tone,	and immune cell extravasation.																									-	

		<u></u>	"Cardiovascular Disorders")
			with the form of the dispersions
		HI	Highly preferred indications
		inc	include cardiovascular,
		enc	endothelial and/or angiogenic
		dis	disorders (e.g., systemic
		dis	disorders that affect vessels
		ons	such as diabetes mellitus, as
		we	well as diseases of the vessels
		the	themselves, such as of the
		art	arteries, capillaries, veins
		and	and/or lymphatics). Highly
		pre	preferred are indications that
		stin	stimulate angiogenesis and/or
		car	cardiovascularization. Highly
		pre	preferred are indications that
		dui	inhibit angiogenesis and/or
	-	car	cardiovascularization.
		High	Highly preferred indications
	-	inc	include antiangiogenic activity
		to	to treat solid tumors,
		leu	leukemias, and Kaposi"s
		sar	sarcoma, and retinal disorders.
		High	Highly preferred indications
		inc	include neoplasms and cancer,
		ons	such as, Kaposi"s sarcoma,
		her	hemangioma (capillary and
		cav	cavernous), glomus tumors,
		tela	telangiectasia, bacillary
_		ang	angiomatosis,
		her	hemangioendothelioma,
		\$6	

haemangiopericytoma,	lymphangioma,	lymphangiosarcoma. Highly	preferred indications also	include cancers such as,	prostate, breast, lung, colon,	pancreatic, esophageal,	stomach, brain, liver, and	urinary cancer. Preferred	indications include benign	dysproliferative disorders and	pre-neoplastic conditions, such	as, for example, hyperplasia,	metaplasia, and/or dysplasia.	Highly preferred indications	also include arterial disease,	such as, atherosclerosis,	hypertension, coronary artery	disease, inflammatory	vasculitides, Reynaud"s	disease and Reynaud's	phenomenom, aneurysms,	restenosis; venous and	lymphatic disorders such as	thrombophlebitis,	lymphangitis, and	lymphedema; and other	vascular disorders such as	peripheral vascular disease,	and cancer. Highly	preferred indications also
																											-			
												-																		
																											_			

			include trauma such as
			wounds, burns, and injured
			tissue (e.g., vascular injury
			such as, injury resulting from
			balloon angioplasty, and
			atheroschlerotic lesions),
			implant fixation, scarring,
			ischemia reperfusion injury,
			rheumatoid arthritis,
_			cerebrovascular disease, renal
			diseases such as acute renal
			failure, and osteoporosis.
			Additional highly preferred
			indications include stroke,
			graft rejection, diabetic or
			other retinopathies, thrombotic
		-	and coagulative disorders,
		-	vascularitis, lymph
		-	angiogenesis, sexual disorders,
			age-related macular
			degeneration, and treatment
			/prevention of endometriosis
			and related conditions.
			Additional highly preferred
			indications include fibromas,
			heart disease, cardiac arrest,
			heart valve disease, and
			vascular disease. Preferred
			indications include blood
			disorders (e.g., as described
			below under "Immune

ა თ	. II .	ii	er
Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis. multiple	sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional preferred indications include inflammation and inflammatory disorders (such sclerosis and control or control o	as acute and chronic inflammatory diseases, e.g., inflammatory bowel disease and Crohn's disease), and pain management.	Highly preferred indications include asthma, allergy, hypersensitivity reactions, inflammation, and inflammatory disorders. Additional highly preferred indications include immune and hematopoietic disorders (e.g., as described below under "Immune Activity", and "Blood-Related Disorders"),
			Kinase assay. JNK kinase assays for signal transduction that regulate cell proliferation, activation, or apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or
			Activation of JNK Signaling Pathway in immune cells (such as eosinophils).
			851
·			HUKAH51
·			

		activation, and apoptosis.		rheumatoid arthritis, systemic	
		Exemplary assays for JNK	<u>~</u>	lupus erythematosis, Crohn"s	
		kinase activity that may be		disease, multiple sclerosis	
_		used or routing	\$	and/or as described below),	
	-	test JNK kinase-induced		immunodeficiencies (e.g., as	
		activity of pol	of the	described below). Highly	
		invention (inc	S	preferred indications also	
		and agonists o		include boosting or inhibiting	
		the invention) include the		immune cell proliferation.	
-		assays disclos	assays disclosed in Forrer et	Preferred indications include	
		al., Biol Chem	<u>-</u>	neoplastic diseases (e.g.,	
		1110 (1998);	1110 (1998); Gupta et al., Exp	leukemia, lymphoma, and/or as	
		Cell Res 247(2): 495-504	2): 495-504	described below under	
		(1999); Kyrial	chem	"Hyperproliferative	
		Soc Symp 64:	Soc Symp 64:29-48 (1999);	Disorders"). Highly preferred	
		Chang and Karin, Nature	rin, Nature	indications include boosting an	
		410(6824):37	410(6824):37-40 (2001); and	eosinophil-mediated immune	
		Cobb MH, Pro	Cobb MH, Prog Biophys Mol	response, and suppressing an	
		Biol 71(3-4):4	Biol 71(3-4):479-500 (1999);	eosinophil-mediated immune	
		the contents o	the contents of each of which	response.	
		are herein incorporated by	orporated by		
		reference in its entirety.	s entirety.		
		Exemplary ce	Exemplary cells that may be		
		used accordin	used according to these assays		
		include eosinophils.	ophils.		
_		Eosinophils a	Eosinophils are important in		
		the late stage of allergic	of allergic		
		reactions; the	reactions; they are recruited to		
		tissues and mediate the	ediate the		
		inflammatory	inflammatory response of late		
		stage allergic reaction	reaction.		

Moreover, exemplary assays	modified to assess the ability	of polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) to modulate	signal transduction, cell	proliferation, activation, or	apoptosis in eosinophils	include assays disclosed and/or	cited in: Zhang JP, et al., "Role	of caspases in dexamethasone-	induced apoptosis and	activation of c-Jun NH2-	terminal kinase and p38	mitogen-activated protein	kinase in human eosinophils"	Clin Exp Immunol;	Oct;122(1):20-7 (2000);	Hebestreit H, et al.,	"Disruption of fas receptor	signaling by nitric oxide in	eosinophils" J Exp Med; Feb	2;187(3):415-25 (1998); J	Allergy Clin Immunol 1999	Sep;104(3 Pt 1):565-74; and,	Sousa AR, et al., "In vivo	resistance to corticosteroids in	bronchial asthma is associated	with enhanced
							•								-														
					-																								

			phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation" J Allergy Clin Immunol; Sep;104(3 Pt 1):565-74 (1999); the contents of each of which are herein incorporated by reference in its entirety.	
HUKAH51	851	SEAP in HepG2/Squale- synthetase(stimulati on)		
HUKAH51	851	IL-2 in Human T-cell 293T		
HUSXS50	8 52	Activation of T-Cell p38 or JNK Signaling Pathway.	Kinase assay. JNK and p38 kinase assays for signal transduction that regulate cell proliferation, activation, or apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit immune cell (e.g. T-cell) proliferation, activation, and apoptosis.	Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly preferred indications include autoimmune diseases (e.g.,

	n38 kinase activity that may be	rheumatoid arthritis systemic
	Too town to the south of the state of to	International manufactures of security
	nsea or routinely mounted to	iupus erymematosis, mumpie
	test JNK and p38 kinase-	sclerosis and/or as described
	induced activity of	below) and
	polypeptides of the invention	immunodeficiencies (e.g., as
	(including antibodies and	described below). Additional
	agonists or antagonists of the	highly preferred indications
	invention) include the assays	include inflammation and
	disclosed in Forrer et al., Biol	inflammatory disorders.
	Chem 379(8-9):1101-1110	Highly preferred indications
	(1998); Gupta et al., Exp Cell	also include neoplastic
	Res 247(2): 495-504 (1999);	diseases (e.g., leukemia,
	Kyriakis JM, Biochem Soc	lymphoma, and/or as described
	Symp 64:29-48 (1999); Chang	below under
	and Karin, Nature	"Hyperproliferative
	410(6824):37-40 (2001); and	Disorders"). Highly preferred
	Cobb MH, Prog Biophys Mol	indications include neoplasms
	Biol 71(3-4):479-500 (1999);	and cancers, such as, leukemia,
	the contents of each of which	lymphoma, prostate, breast,
	are herein incorporated by	lung, colon, pancreatic,
	reference in its entirety. T	esophageal, stomach, brain,
	cells that may be used	liver, and urinary cancer. Other
	according to these assays are	preferred indications include
	publicly available (e.g.,	benign dysproliferative
-	through the ATCC).	disorders and pre-neoplastic
	Exemplary mouse T cells that	conditions, such as, for
	may be used according to these	example, hyperplasia,
	assays include the CTLL cell	metaplasia, and/or dysplasia.
	line, which is an IL-2	Preferred indications include
	dependent suspension-culture	arthritis, asthma, AIDS,
	cell line with cytotoxic	allergy, anemia, pancytopenia,

-			activity.	leukopenia, thrombocytopenia,
				Hodgkin"s disease, acute
				lymphocytic anemia (ALL),
				plasmacytomas, multiple
				myeloma, Burkitt"s lymphoma,
				granulomatous disease,
				inflammatory bowel disease,
				sepsis, psoriasis, suppression
				of immune reactions to
				transplanted organs and
				tissues, endocarditis,
				meningitis, and Lyme Disease.
HUSXS50	852	Activation of	Assays for the activation of	Highly preferred indications
		transcription	transcription through the	include asthma, allergy,
		through NFKB	NFKB response element are	hypersensitivity reactions, and
		response element in	well-known in the art and may	inflammation. Preferred
		immune cells (such	be used or routinely modified	indications include infection
		as EOL1 cells).	to assess the ability of	(e.g., an infectious disease as
			polypeptides of the invention	described below under
			(including antibodies and	"Infectious Disease"),
			agonists or antagonists of the	immunological disorders,
			invention) to regulate NFKB	inflammation and
			transcription factors and	inflammatory disorders (e.g.,
			modulate expression of	as described below under
		_	immunomodulatory genes.	"Immune Activity", and
			Exemplary assays for	"Blood-Related Disorders").
			transcription through the	Preferred indications include
			NFKB response element that	autoimmune diseases (e.g.,
			may be used or rountinely	rheumatoid arthritis, systemic
			modified to test NFKB-	lupus erythematosis, multiple
			response element activity of	sclerosis and/or as described

				_											_														
below) and immunodeficiencies (e.g., as	described below).																												
polypeptides of the invention (including antibodies and	agonists or antagonists of the	invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Valle	Blazquez et al, Immunology	90(3):455-460 (1997);	Aramburau et al., J Exp Med	82(3):801-810 (1995); and	Fraser et al., 29(3):838-844	(1999), the contents of each of	which are herein incorporated	by reference in its entirety.	For example, a reporter assay	(which measures increases in	transcription inducible from a	NFkB responsive element in	EOL-1 cells) may link the	NFKB element to a repeorter	gene and binds to the NFKB	transcription factor, which is	upregulated by cytokines and	other factors. Exemplary	immune cells that may be used	according to these assays	include eosinophils such as the
						-	-																				-		
																							-						

		liments of the
		Preferred embodiments of the
human EOL-1 cell line of eosinophils. Eosinophils are a type of immune cell important in the allergic responses; they are recruited to tissues and mediate the inflammtory response of late stage allergic reaction. Eol-1 is a human eosinophil cell line.	Reporter Assay: construct contains regulatory and coding sequence of squalene synthetase, the first specific enzyme in the cholesterol biosynthetic pathway. See Jiang, et al., J. Biol. Chem. 268:12818-128241(993), the contents of which are herein incorporated by reference in its entirety. Cells were treated with SID supernatants, and SEAP activity was measured after 72 hours. HepG2 is a human hepatocellular carcinoma cell line (ATCC HB-8065). See Knowles et al., Science. 209:497-9 (1980), the contents of which are herein incorporated by reference in its entirety.	Assays for measuring calcium
	Inhibition of squalene synthetase gene transcription.	Calcium flux in
	852	852
	HUSXS50	HUSXS50

invention include using	polypeptides of the invention	(or annoones, agomsts, or				Infection, Inflammation,	Atherosclerosis,	Hypersensitivity, and	Leukemias),	
flux are well-known in the art	and may be used or routinely	modified to assess the ability	of polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) to mobilize	calcium. Cells normally have	very low concentrations of	cytosolic calcium compared to	much higher extracellular	calcium. Extracellular factors	can cause an influx of calcium,	leading to activation of	calcium responsive signaling	pathways and alterations in	cell functions. Exemplary	assays that may be used or	routinely modified to measure	calcium flux in immune cells	(such as monocytes) include	assays disclosed in: Chan, CC,	et al., J Pharmacol Exp Ther,	269(3):891-896 (1994);	Andersson, K, et al., Cytokine,	12(12):1784-1787 (2000);	Scully, SP, et al., J Clin Invest	74(2) 589-599 (1984); and,	Sullivan, E, et al., Methods	Mol Biol, 114:125-133 (1999),	the contents of each of which
immune cells (such	as monocytes)																									-				
																														-

				is herein incorporated by reference in its entirety. Cells	
				that may be used according to	
				these assays are publicly	
				available (e.g., through the	
				ATCC) and/or may be	
				routinely generated.	
				Exemplary cells that may be	
		-		used according to these assays	
-				include the THP-1 monocyte	
				cell line.	
	HUVEB53	853	SEAP in HIB/CRE		
	HUVEB53	853	Regulation of	Caspase Apoptosis. Assays	A highly preferred
			apoptosis in	for caspase apoptosis are well	indication is diabetes mellitus.
			pancreatic beta	known in the art and may be	An additional highly preferred
			cells.	used or routinely modified to	indication is a complication
				assess the ability of	associated with diabetes (e.g.,
				polypeptides of the invention	diabetic retinopathy, diabetic
				(including antibodies and	nephropathy, kidney disease
				agonists or antagonists of the	(e.g., renal failure,
				invention) to promote caspase	nephropathy and/or other
		-		protease-mediated apoptosis.	diseases and disorders as
				Apoptosis in pancreatic beta is	described in the "Renal
				associated with induction and	Disorders" section below),
				progression of diabetes.	diabetic neuropathy, nerve
				Exemplary assays for caspase	disease and nerve damage
				apoptosis that may be used or	(e.g., due to diabetic
				routinely modified to test	neuropathy), blood vessel
				capase apoptosis activity of	blockage, heart disease, stroke,
		· .		polypeptides of the invention	impotence (e.g., due to diabetic
				(including antibodies and	neuropathy or blood vessel

	agonists or antagonists of the	blockage), seizures, mental
	invention) include the assays	confusion, drowsiness,
	disclosed in: Loweth, AC, et	nonketotic hyperglycemic-
	al., FEBS Lett, 400(3):285-8	hyperosmolar coma,
	(1997); Saini, KS, et al.,	cardiovascular disease (e.g.,
	Biochem Mol Biol Int,	heart disease, atherosclerosis,
	39(6):1229-36 (1996);	microvascular disease,
	Krautheim, A., et al., Br J	hypertension, stroke, and other
	Pharmacol, 129(4):687-94	diseases and disorders as
	(2000); Chandra J, et al.,	described in the
	Diabetes, 50 Suppl 1:S44-7	"Cardiovascular Disorders"
	(2001); Suk K, et al., J	section below), dyslipidemia,
	Immunol, 166(7):4481-9	endocrine disorders (as
	(2001); Tejedo J, et al., FEBS	described in the "Endocrine
	Lett, 459(2):238-43 (1999);	Disorders" section below),
	Zhang, S., et al., FEBS Lett,	neuropathy, vision impairment
	455(3):315-20 (1999); Lee et	(e.g., diabetic retinopathy and
	al., FEBS Lett 485(2-3): 122-	blindness), ulcers and impaired
	126 (2000); Nor et al., J Vasc	wound healing, and infection
	Res 37(3): 209-218 (2000);	(e.g., infectious diseases and
	and Karsan and Harlan, J	disorders as described in the
	Atheroscler Thromb 3(2): 75-	"Infectious Diseases" section
	80 (1996); the contents of each	below, especially of the
	of which are herein	urinary tract and skin), carpal
	incorporated by reference in its	tunnel syndrome and
	entirety. Pancreatic cells that	Dupuytren's contracture).
	may be used according to these	An additional highly preferred
	assays are publicly available	indication is obesity and/or
	(e.g., through the ATCC)	complications associated with
	and/or may be routinely	obesity. Additional highly
	generated. Exemplary	preferred indications include

			pancreatic cells that may be used according to these assays include RIN-m RIN-m is a	weight loss or alternatively, weight gain. Aditional
			rat adherent pancreatic beta	complications associated with
			cell insulinoma cell line	insulin resistance.
			derived from a radiation	
			induced transplantable rat islet	
			cell tumor. The cells produce	
			and secrete islet polypeptide	
			hormones, and produce insulin,	
			somatostatin, and possibly	
			glucagon. ATTC: #CRL-2057	
			Chick et al. Proc. Natl. Acad.	
			Sci. 1977 74:628; AF et al.	
			Proc. Natl. Acad. Sci. 1980	
			77:3519.	
HWAAD63	854	Regulation of	Assays for the regulation of	A highly preferred
		transcription	transcription through the FAS	indication is diabetes mellitus.
		through the FAS	promoter element are well-	An additional highly preferred
		promoter element	known in the art and may be	indication is a complication
		in hepatocytes	used or routinely modified to	associated with diabetes (e.g.,
 			assess the ability of	diabetic retinopathy, diabetic
 			polypeptides of the invention	nephropathy, kidney disease
			(including antibodies and	(e.g., renal failure,
			agonists or antagonists of the	nephropathy and/or other
			invention) to activate the FAS	diseases and disorders as
 			promoter element in a reporter	described in the "Renal
			construct and to regulate	Disorders" section below),
			transcription of FAS, a key	diabetic neuropathy, nerve
			enzyme for lipogenesis. FAS	disease and nerve damage
	:			(e.g., due to diabetic

	inition footon incline	position (114)
	CDEDD Translin increase EAC	incuropantly, oroon vesser
	SNEDF. HISUIII HICIGASES FAS	olockage, liean disease, suoke,
	gene transcription in livers of	impotence (e.g., due to diabetic
	diabetic mice. This	neuropathy or blood vessel
	stimulation of transcription is	blockage), seizures, mental
	also somewhat glucose	confusion, drowsiness,
	dependent. Exemplary assays	nonketotic hyperglycemic-
	that may be used or routinely	hyperosmolar coma,
	modified to test for FAS	cardiovascular disease (e.g.,
	promoter element activity (in	heart disease, atherosclerosis,
	hepatocytes) by polypeptides	microvascular disease,
	of the invention (including	hypertension, stroke, and other
	antibodies and agonists or	diseases and disorders as
-	antagonists of the invention)	described in the
	include assays disclosed in	"Cardiovascular Disorders"
	Xiong, S., et al., Proc Natl	section below), dyslipidemia,
	Acad Sci U.S.A., 97(8):3948-	endocrine disorders (as
	53 (2000); Roder, K., et al.,	described in the "Endocrine
	Eur J Biochem, 260(3):743-51	Disorders" section below),
	(1999); Oskouian B, et al.,	neuropathy, vision impairment
	Biochem J, 317 (Pt 1):257-65	(e.g., diabetic retinopathy and
	(1996); Berger, et al., Gene	blindness), ulcers and impaired
	66:1-10 (1988); and, Cullen,	wound healing, and infection
	B., et al., Methods in Enzymol.	(e.g., infectious diseases and
	216:362–368 (1992), the	disorders as described in the
	contents of each of which is	"Infectious Diseases" section
	herein incorporated by	below, especially of the
	reference in its entirety.	urinary tract and skin), carpal
	Hepatocytes that may be used	tunnel syndrome and
	according to these assays, such	Dupuytren's contracture).
	as H4IIE cells, are publicly	An additional highly preferred

				available (e.g., through the	indication is obesity and/or
				ATCC) and/or may be	complications associated with
				routinely generated.	obesity. Additional highly
				Exemplary hepatocytes that	preferred indications include
-				may be used according to these	weight loss or alternatively,
				assays include rat liver	weight gain. Aditional
				hepatoma cell line(s) inducible	highly preferred indications are
				with glucocorticoids, insulin,	complications associated with
				or cAMP derivatives.	insulin resistance.
	HWABY10	855	Production of IL-6	IL-6 FMAT. IL-6 is produced	A highly preferred
		1		by T cells and has strong	embodiment of the invention
				effects on B cells. IL-6	includes a method for
				participates in IL-4 induced	stimulating (e.g., increasing)
				IgE production and increases	IL-6 production. An alternative
		•		IgA production (IgA plays a	highly preferred embodiment
				role in mucosal immunity).	of the invention includes a
				IL-6 induces cytotoxic T cells.	method for inhibiting (e.g.,
				Deregulated expression of IL-6	reducing) IL-6 production. A
				has been linked to autoimmune	highly preferrred indication is
	<u> </u>			disease, plasmacytomas,	the stimulation or enhancement
				myelomas, and chronic	of mucosal immunity. Highly
				hyperproliferative diseases.	preferred indications include
				Assays for immunomodulatory	blood disorders (e.g., as
				and differentiation factor	described below under
				proteins produced by a large	"Immune Activity", "Blood-
				variety of cells where the	Related Disorders", and/or
				expression level is strongly	"Cardiovascular Disorders"),
				regulated by cytokines, growth	and infection (e.g., as
				factors, and hormones are well	described below under
				known in the art and may be	"Infectious Disease"). Highly
				used or routinely modified to	preferred indications include

				assess the ability of	autoimmune diseases (e.g.,
				polypeptides of the invention	rheumatoid arthritis, systemic
	-			(including antibodies and	lupus erythematosis, multiple
		_		agonists or antagonists of the	sclerosis and/or as described
				invention) to mediate	below) and
-				immunomodulation and	immunodeficiencies (e.g., as
		## -		differentiation and modulate T	described below). Highly
				cell proliferation and function.	preferred indications also
		-		Exemplary assays that test for	include boosting a B cell-
			•	immunomodulatory proteins	mediated immune response
_				evaluate the production of	and alternatively suppressing a
				cytokines, such as IL-6, and	B cell-mediated immune
-				the stimulation and	response. Highly preferred
	•			upregulation of T cell	indications include
				proliferation and functional	inflammation and
				activities. Such assays that	inflammatory
				may be used or routinely	disorders.Additional highly
				modified to test	preferred indications include
		-	•	immunomodulatory and	asthma and allergy. Highly
		-		diffferentiation activity of	preferred indications include
				polypeptides of the invention	neoplastic diseases (e.g.,
		-	3	(including antibodies and	myeloma, plasmacytoma,
				agonists or antagonists of the	leukemia, lymphoma,
		-		invention) include assays	melanoma, and/or as described
				disclosed in Miraglia et al., J	below under
				Biomolecular Screening 4:193-	"Hyperproliferative
				204(1999); Rowland et al.,	Disorders"). Highly preferred
				"Lymphocytes: a practical	indications include neoplasms
				approach" Chapter 6:138-160	and cancers, such as, myeloma,
		12 3.00		(2000); and Verhasselt et al., J	plasmacytoma, leukemia,
				Immunol 158: 2919-2925	lymphoma, melanoma, and

which are herein incorporated by reference in its entirety. Human dendritic cells that may are to broad which are herein in the contents of each of prostate, breast, lung, colon, prostate, breast, lung, colon, stomach, brain, liver and uninary cancer. Other preferred	ig or	otherwise known in the art. Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen of the art. as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia,	and/or cytokines, initiate and upregulate T cell proliferation lymphocytic anemia (ALL), and functional activities. Iymphoma, arthritis, AIDS,	granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune	organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease.	An additional preserved indication is infection (e.g., an infectious disease as described below under "Infectious

it of		:		-	ent	- R	.6.				pa				s"),	suc	ases	•	osis,		pec	ies	•	þ		iated	tional	su		nd
bodimer	ndes a	ting (e.g	pha	ternative	mbodin	soludes	ating (e	ılpha	ferred	e blood	describ	nune	-Relatec	ı	Disorder	indicatic	ıne dise	arthritis	ythemat	multiple	s descril	leficienc	i below)	mediate	; and	ell-med	. Addi	indicatio	tion and	orders, a
A preferred embodiment of	tion incl	or inhibi	TNF al	n. An al	eferred e	ention in	or stimu	g) TNF a	n. Pre	ns includ	(e.g., as	der "Imı	""Blood	s", and/o	ascular l	referred	utoimm	umatoid	lupus er	disease,	and/or a	mmunoc	lescribe	a T cell.	response	ing a Τ c	response	eferred.	nflamma	atory dis
A prefe	the invention includes a	method for inhibiting (e.g.,	reducing) TNF alpha	production. An alternative	highly preferred embodiment	of the invention includes a	method for stimulating (e.g.,	increasing) TNF alpha	production. Preferred	indications include blood	disorders (e.g., as described	below under "Immune	Activity", "Blood-Related	Disorders", and/or	"Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn"s disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and
Jo								-						p											-	lou	ıthorn		nosua	3862-
tivation	ugh the	Element	nown in	sed or	ed to asse	ypeptide	luding	gonists o	e inventi	esponse	late the	nes invol	regulate	th-relate	ell types.	s for	ough the	or routi	SRE acti	les of the	ling antil	ıntagonis	clude as:	ger et al.	Cullen a	in Enzyı	92); Her	Acad Sc	988); Be	1153(9):
or the ac	tion thro	esponse	e well-k	nay be us	, modifie	y of poly	the invention (including	es and ag	sts of the	serum r	nd modu	expression of genes involved	in growth and upregulate the	function of growth-related	genes in many cell types.	Exemplary assays for	transcription through the SRE	that may be used or routinely	modified to test SRE activity	of the polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and	Malm, Methods in Enzymol	216:362-368 (1992); Henthorn	et al., Proc Natl Acad Sci USA	85:6342-6346 (1988); Benson	et al., J Immunol 153(9):3862-
Assays for the activation of	transcription through the	Serum Response Element	(SRE) are well-known in the	art and may be used or	routinely modified to assess	the ability of polypeptides of	the inver	antibodies and agonists or	antagonists of the invention) to	regulate serum response	factors and modulate the	expressi	in growt	function	genes in	Exempla	transcrip	that may	modifie	of the po	inventio	and ago	the inve	disclose	66:1-10	Malm, 1	216:362	et al., Pı	85:6342	et al., J
		c	nent in	(snch	er							•			•															
Activation of	transcription	through serum	response element in	immune cells (such	as natural killer	,																								
Activ	trans	thron	respo	immi	as na	cells)									-			<u> </u>										_		
												-																		
855	}																			_			- 1							
RV10																														
HWARY10				-																_			-							<u> </u>
										_	_							_												

																									_					
treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases	(e.g., leukemia, lymphoma,	and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia,	Hodgkin's disease, acute	lymphocytic anemia (ALL),
3873 (1994): and Black et al	Virus Genes 12(2):105-117	(1997), the content of each of	which are herein incorporated	by reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary T cells that may be	used according to these assays	include the NK-YT cell line,	which is a human natural killer	cell line with cytolytic and	cytotoxic activity.																
											_	****				-														
																		-				_								

plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted	he CD28 embodiment of the invention includes a method for asy be stimulating T cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting T cell proliferation. A highly preferred embodiment of the invention includes a method for activating T cells. An activating Hypreferred
	Assays for the activation of transcription through the CD28 response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate IL-2 expression in T cells. Exemplary assays for transcription through the CD28
	Activation of transcription through CD28 response element in immune cells (such as T-cells).
	855
	HWABY10

		response element that may be	embodiment of the invention
		used or routinely modified to	includes a method for
		test CD28-response element	inhibiting the activation of
		activity of polypeptides of the	and/or inactivating T cells.
		invention (including antibodies	A highly preferred
		and agonists or antagonists of	embodiment of the invention
		the invention) include assays	includes a method for
		disclosed in Berger et al., Gene	stimulating (e.g., increasing)
-		66:1-10 (1998); Cullen and	IL-2 production. An alternative
		Malm, Methods in Enzymol	highly preferred embodiment
		216:362-368 (1992); Henthorn	of the invention includes a
		et al., Proc Natl Acad Sci USA	method for inhibiting (e.g.,
		85:6342-6346 (1988);	reducing) IL-2 production.
		McGuire and Iacobelli, J	Additional highly preferred
		Immunol 159(3):1319-1327	indications include
		(1997); Parra et al., J Immunol	inflammation and
		166(4):2437-2443 (2001); and	inflammatory disorders.
		Butscher et al., J Biol Chem	Highly preferred indications
		3(1):552-560 (1998), the	include autoimmune diseases
		contents of each of which are	(e.g., rheumatoid arthritis,
		herein incorporated by	systemic lupus erythematosis,
		reference in its entirety. T	multiple sclerosis and/or as
		cells that may be used	described below),
		according to these assays are	immunodeficiencies (e.g., as
		publicly available (e.g.,	described below), boosting a T
		through the ATCC).	cell-mediated immune
		Exemplary human T cells that	response, and suppressing a T
		may be used according to these	cell-mediated immune
		assays include the SUPT cell	response. Highly preferred
		line, which is a suspension	indications include neoplastic
		culture of IL-2 and IL-4	diseases (e.g., melanoma, renal

cell carcinoma, leukemia,	lymphoma, and/or as described	"Hyperproliferative	Disorders"). Highly preferred	indications include neoplasms	and cancers, such as, for	example, melanoma (e.g.,	metastatic melanoma), renal	cell carcinoma (e.g., metastatic	renal cell carcinoma),	leukemia, lymphoma (e.g., T	cell lymphoma), and prostate,	breast, lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	A highly preferred indication	includes infection (e.g.,	AIDS, tuberculosis, infections	associated with granulomatous	disease, and osteoporosis,	and/or as described below	under "Infectious Disease"). A	highly preferred indication is	AIDS. Additional highly
responsive T cells.																													
													_	-	-														

					nreferred indications include
		•			
					suppression of immune
					reactions to transplanted
					organs and/or tissues, uveitis,
					psoriasis, and tropical spastic
					paraparesis. Preferred
					indications include blood
			•		disorders (e.g., as described
					below under "Immune
					Activity", "Blood-Related
					Disorders", and/or
					"Cardiovascular Disorders").
-					Preferred indications also
					include anemia, pancytopenia,
					leukopenia, thrombocytopenia,
					Hodgkin's disease, acute
					lymphocytic anemia (ALL),
					plasmacytomas, multiple
					myeloma, Burkitt's lymphoma,
					arthritis, granulomatous
					disease, inflammatory bowel
					disease, sepsis, neutropenia,
					neutrophilia, hemophilia,
					hypercoagulation, diabetes
					mellitus, endocarditis,
					meningitis, Lyme Disease,
					asthma and allergy.
	HWADJ89	856	Activation of	Assays for the activation of	A preferred embodiment of
			transcription	transcription through the	the invention includes a
			through serum	Serum Response Element	method for inhibiting (e.g.,
			response element in	(SRE) are well-known in the	reducing) TNF alpha
			TACK	7 - 2	

production. An alternative preferred embodiment of the	invention includes a method	for stimulating (e.g.,	increasing) TNF alpha	production. Preferred	indications include blood	disorders (e.g., as described	below under "Immune	Activity", "Blood-Related	Disorders", and/or	"Cardiovascular Disorders"),	Highly preferred indications	include autoimmune diseases	(e.g., rheumatoid arthritis,	systemic lupus erythematosis,	Crohn's disease, multiple	sclerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.
art and may be used or routinely modified to assess	the ability of polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention) to	regulate the serum response	factors and modulate the	expression of genes involved	in growth. Exemplary assays	for transcription through the	SRE that may be used or	routinely modified to test SRE	activity of the polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention)	include assays disclosed in	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are
immune cells (such as T-cells).																													
											_													_					

Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below		cancers, such as, for example, leukemia, lymphoma, melanoma, glioma (e.g., malignant glioma), solid	tumors, and prostate, oreast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other	preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for	example, hyperplasta, metaplasta, and/or dysplasta. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia,	Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel
publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these	assays include the CTLL cell line, which is an IL-2 dependent suspension culture of T cells with cytotoxic	activity.				

	disregulation is a key	impotence (e.g., due to diabetic
	component in diabetes.	neuropathy or blood vessel
	Exemplary assays that may be	blockage), seizures, mental
	used or routinely modified to	confusion, drowsiness,
	test for stimulation of insulin	nonketotic hyperglycemic-
	secretion (from pancreatic	hyperosmolar coma,
	cells) by polypeptides of the	cardiovascular disease (e.g.,
	invention (including antibodies	heart disease, atherosclerosis,
	and agonists or antagonists of	microvascular disease,
	the invention) include assays	hypertension, stroke, and other
	disclosed in: Ahren, B., et al.,	diseases and disorders as
	Am J Physiol, 277(4 Pt	described in the
	2):R959-66 (1999); Li, M., et	"Cardiovascular Disorders"
	al., Endocrinology,	section below), dyslipidemia,
-	138(9):3735-40 (1997); Kim,	endocrine disorders (as
	K.H., et al., FEBS Lett,	described in the "Endocrine
	377(2):237-9 (1995); and,	Disorders" section below),
	Miraglia S et. al., Journal of	neuropathy, vision impairment
	Biomolecular Screening,	(e.g., diabetic retinopathy and
	4:193-204 (1999), the contents	blindness), ulcers and impaired
	of each of which is herein	wound healing, and infection
	incorporated by reference in its	(e.g., infectious diseases and
	entirety. Pancreatic cells that	disorders as described in the
	may be used according to these	"Infectious Diseases" section
	assays are publicly available	below, especially of the
	(e.g., through the ATCC)	urinary tract and skin), carpal
	and/or may be routinely	tunnel syndrome and
	generated. Exemplary	Dupuytren's contracture).
	pancreatic cells that may be	An additional highly preferred
	used according to these assays	indication is obesity and/or
	include rat INS-1 cells. INS-1	complications associated with

			cells are a semi-adherent cell line established from cells	obesity. Additional highly preferred indications include
			isolated from an X-ray induced	weight loss or alternatively,
			rat transplantable insulinoma.	weight gain. Aditional
			These cells retain	highly preferred indications are
	-		characteristics typical of native	complications associated with
			pancreatic beta cells including	insulin resistance.
			glucose inducible insulin	
			secretion. References: Asfari	
			et al. Endocrinology 1992	
			130:167.	
HWBCB89	857	Activation of	Assays for the activation of	A preferred embodiment of
		transcription	transcription through the	the invention includes a
		through serum	Serum Response Element	method for inhibiting (e.g.,
		response element in	(SRE) are well-known in the	reducing) TNF alpha
		immune cells (such	art and may be used or	production. An alternative
		as T-cells).	routinely modified to assess	preferred embodiment of the
	-		the ability of polypeptides of	invention includes a method
			the invention (including	for stimulating (e.g.,
			antibodies and agonists or	increasing) TNF alpha
			antagonists of the invention) to	production. Preferred
			regulate the serum response	indications include blood
			factors and modulate the	disorders (e.g., as described
			expression of genes involved	below under "Immune
			in growth. Exemplary assays	Activity", "Blood-Related
			for transcription through the	Disorders", and/or
	-		SRE that may be used or	"Cardiovascular Disorders"),
		•	routinely modified to test SRE	Highly preferred indications
			activity of the polypeptides of	include autoimmune diseases
			the invention (including	(e.g., rheumatoid arthritis,
			antibodies and agonists or	systemic lupus erythematosis,

			_			_																							
Crohn"s disease, multiple selerosis and/or as described	below), immunodeficiencies	(e.g., as described below),	boosting a T cell-mediated	immune response, and	suppressing a T cell-mediated	immune response. Additional	highly preferred indications	include inflammation and	inflammatory disorders, and	treating joint damage in	patients with rheumatoid	arthritis. An additional highly	preferred indication is sepsis.	Highly preferred indications	include neoplastic diseases		and/or as described below	under "Hyperproliferative	Disorders"). Additionally,	highly preferred indications	include neoplasms and	cancers, such as, for example,	leukemia, lymphoma,	melanoma, glioma (e.g.,	malignant glioma), solid	tumors, and prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver and urinary cancer. Other
antagonists of the invention)	Berger et al., Gene 66:1-10	(1998); Cullen and Malm,	Methods in Enzymol 216:362-	368 (1992); Henthorn et al.,	Proc Natl Acad Sci USA	85:6342-6346 (1988); and	Black et al., Virus Genes	12(2):105-117 (1997), the	content of each of which are	herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	dependent suspension culture	of T cells with cytotoxic	activity.							
			-											-			-				-	-							

preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute	lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia,	suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and	asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease"). This reporter assay measures Highly preferred indications	
	,		This reporte	activation of
			Activation of	franscription
			857	100
			HWBCB89	11 w DCD67

rhinitis. Additional preferred	indications include infection	(e.g., an infectious disease as	described below under	"Infectious Disease"), and	inflammation and	inflammatory disorders.	Preferred indications also	include blood disorders (e.g.,	as described below under	with "Immune Activity", "Blood-	Related Disorders", and/or	"Cardiovascular Disorders").	Preferred indications include	autoimmune diseases (e.g.,	rheumatoid arthritis, systemic	lupus erythematosis, multiple	sclerosis and/or as described		immunodeficiencies (e.g., as	described below). Preferred	indications include neoplastic	diseases (e.g., leukemia,	lymphoma, melanoma,	prostate, breast, lung, colon,	pancreatic, esophageal,	stomach, brain, liver, and	urinary tract cancers and/or as	described below under		Disorders"). Other preferred
signaling pathway in HMC-1	human mast cell line.	Activation of GATA-3 in mast	cells has been linked to	cytokine and chemokine	production. Assays for the	activation of transcription	through the GATA3 response	element are well-known in the	art and may be used or	routinely modified to assess	the ability of polypeptides of	the invention (including	antibodies and agonists or	antagonists of the invention) to	regulate GATA3 transcription	factors and modulate	expression of mast cell genes	important for immune response	development. Exemplary	assays for transcription	through the GATA3 response	element that may be used or	routinely modified to test	GATA3-response element	activity of polypeptides of the	invention (including antibodies	and agonists or antagonists of	the invention) include assays	disclosed in Berger et al., Gene	66:1-10 (1998); Cullen and
through GATA-3	response element in	immune cells (such	as mast cells).																											
																							-		-					
																													_	

				Malm. Methods in Enzymol	indications include benign
				216:362-368 (1992): Henthorn	dysproliferative disorders and
				et al., Proc Natl Acad Sci USA	pre-neoplastic conditions, such
				85:6342-6346 (1988); Flavell	as, for example, hyperplasia,
				et al., Cold Spring Harb Symp	metaplasia, and/or dysplasia.
				Quant Biol 64:563-571 (1999);	Preferred indications include
				Rodriguez-Palmero et al., Eur	anemia, pancytopenia,
				J Immunol 29(12):3914-3924	leukopenia, thrombocytopenia,
				(1999); Zheng and Flavell,	leukemias, Hodgkin's disease,
				Cell 89(4):587-596 (1997); and	acute lymphocytic anemia
				Henderson et al., Mol Cell Biol	(ALL), plasmacytomas,
				14(6):4286-4294 (1994), the	multiple myeloma, Burkitt's
				contents of each of which are	lymphoma, arthritis, AIDS,
				herein incorporated by	granulomatous disease,
				reference in its entirety. Mast	inflammatory bowel disease,
				cells that may be used	sepsis, neutropenia,
				according to these assays are	neutrophilia, psoriasis,
_				publicly available (e.g.,	suppression of immune
				through the ATCC).	reactions to transplanted
				Exemplary human mast cells	organs and tissues, hemophilia,
				that may be used according to	hypercoagulation, diabetes
				these assays include the HMC-	mellitus, endocarditis,
				1 cell line, which is an	meningitis, and Lyme Disease.
				immature human mast cell line	
				established from the peripheral	
				blood of a patient with mast	
				cell leukemia, and exhibits	
				many characteristics of	
				immature mast cells.	
	HWBCB89	857	CD152 in Human T		

HWBCB89	857	Activation of	Assays for the activation of	Highly preferred indications
-		transcription	transcription through the	include inflammation and
		through NFKB	NFKB response element are	inflammatory disorders.
		response element in	well-known in the art and may	Highly preferred indications
		immune cells (such	be used or routinely modified	include blood disorders (e.g.,
		as T-cells).	to assess the ability of	as described below under
			polypeptides of the invention	"Immune Activity", "Blood-
			(including antibodies and	Related Disorders", and/or
			agonists or antagonists of the	"Cardiovascular Disorders").
			invention) to regulate NFKB	Highly preferred indications
			transcription factors and	include autoimmune diseases
			modulate expression of	(e.g., rheumatoid arthritis,
			immunomodulatory genes.	systemic lupus erythematosis,
			Exemplary assays for	multiple sclerosis and/or as
			transcription through the	described below), and
			NFKB response element that	immunodeficiencies (e.g., as
			may be used or rountinely	described below). An
			modified to test NFKB-	additional highly preferred
			response element activity of	indication is infection (e.g.,
			polypeptides of the invention	AIDS, and/or an infectious
			(including antibodies and	disease as described below
			agonists or antagonists of the	under "Infectious Disease").
			invention) include assays	Highly preferred indications
			disclosed in Berger et al., Gene	include neoplastic diseases
			66:1-10 (1998); Cullen and	(e.g., melanoma, leukemia,
			Malm, Methods in Enzymol	lymphoma, and/or as described
			216:362-368 (1992); Henthorn	below under
			et al., Proc Natl Acad Sci USA	"Hyperproliferative
			85:6342-6346 (1988); Black et	Disorders"). Highly preferred
			al., Virus Gnes 15(2):105-117	indications include neoplasms
			(1997); and Fraser et al.,	and cancers, such as, for

				29(3):838-844 (1999), the	example, melanoma, renal cell
				contents of each of which are	carcinoma, leukemia,
				herein incorporated by	lymphoma, and prostate,
				reference in its entirety.	breast, lung, colon, pancreatic,
				Exemplary human T cells,	esophageal, stomach, brain,
				such as the MOLT4, that may	liver and urinary cancer. Other
	_			be used according to these	preferred indications include
				assays are publicly available	benign dysproliferative
				(e.g., through the ATCC).	disorders and pre-neoplastic
		-			conditions, such as, for
					example, hyperplasia,
					metaplasia, and/or dysplasia.
					Preferred indications also
					include anemia, pancytopenia,
					leukopenia, thrombocytopenia,
					Hodgkin's disease, acute
	_				lymphocytic anemia (ALL),
			•		plasmacytomas, multiple
					myeloma, Burkitt's lymphoma,
					arthritis, AIDS, granulomatous
					disease, inflammatory bowel
					disease, sepsis, neutropenia,
					neutrophilia, psoriasis,
					hemophilia, hypercoagulation,
					diabetes mellitus, endocarditis,
-					meningitis, Lyme Disease,
					suppression of immune
		-			reactions to transplanted
•	_				organs, asthma and allergy.
HWBCB89	9 857		Production of	Assays for measuring	Preferred embodiments of the
			ICAM-1	expression of ICAM-1 are	invention include using

nd may polypeptides of the invention odified (or antibodies, agonists, or antagonists thereof) in detection, diagnosis, of the prevention, and/or treatment of Inflammation, Vascular Disease, Athereosclerosis, assays Restenosis, and Stroke tinely K, et K, et K, et Sill K, et	n of A preferred embodiment of		nt method for inhibiting (e.g., n the reducing) TNF alpha
well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate ICAM-1 expression. Exemplary assays that may be used or routinely modified to measure ICAM-1 expression include assays disclosed in: Takacs P, et al, FASEB J, 15(2):279-281 (2001); and, Miyamoto K, et al., Am J Pathol, 156(5):1733-1739 (2000), the contents of each of which is herein incorporated by reference in its entirety. Cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary cells that may be used according to these assays include microvascular endothelial cells (MVEC).	Assays for the activation of	transcription through the	Serum Response Element (SRE) are well-known in the
	Activation of	transcription	through serum response element in
	857		
	HWBCB89		

	immune cells (such	art and may be used or	production. An alternative
	as natural killer	routinely modified to assess	highly preferred embodiment
	cells).	the ability of polypeptides of	of the invention includes a
		the invention (including	method for stimulating (e.g.,
		antibodies and agonists or	increasing) TNF alpha
		antagonists of the invention) to	production. Preferred
		regulate serum response	indications include blood
		factors and modulate the	disorders (e.g., as described
	-	expression of genes involved	below under "Immune
-		in growth and upregulate the	Activity", "Blood-Related
		function of growth-related	Disorders", and/or
		genes in many cell types.	"Cardiovascular Disorders"),
		Exemplary assays for	Highly preferred indications
		transcription through the SRE	include autoimmune diseases
		that may be used or routinely	(e.g., rheumatoid arthritis,
		modified to test SRE activity	systemic lupus erythematosis,
		of the polypeptides of the	Crohn's disease, multiple
		invention (including antibodies	sclerosis and/or as described
		and agonists or antagonists of	below), immunodeficiencies
		the invention) include assays	(e.g., as described below),
		disclosed in Berger et al., Gene	boosting a T cell-mediated
		66:1-10 (1998); Cullen and	immune response, and
		Malm, Methods in Enzymol	suppressing a T cell-mediated
		216:362-368 (1992); Henthorn	immune response. Additional
		et al., Proc Natl Acad Sci USA	highly preferred indications
		85:6342-6346 (1988); Benson	include inflammation and
		et al., J Immunol 153(9):3862-	inflammatory disorders, and
		3873 (1994); and Black et al.,	treating joint damage in
		Virus Genes 12(2):105-117	patients with rheumatoid
		(1997), the content of each of	arthritis. An additional highly
		which are herein incorporated	preferred indication is sepsis.

	by reference in its entirety. T	Highly preferred indications
	cells that may be used	include neoplastic diseases
	according to these assays are	(e.g., leukemia, lymphoma,
	publicly available (e.g.,	and/or as described below
-	through the ATCC).	under "Hyperproliferative
	Exemplary T cells that may be	Disorders"). Additionally,
	used according to these assays	highly preferred indications
	include the NK-YT cell line,	include neoplasms and
	which is a human natural killer	cancers, such as, for example,
···	cell line with cytolytic and	leukemia, lymphoma,
	cytotoxic activity.	melanoma, glioma (e.g.,
		malignant glioma), solid
		tumors, and prostate, breast,
		lung, colon, pancreatic,
		esophageal, stomach, brain,
		liver and urinary cancer. Other
		preferred indications include
		benign dysproliferative
		disorders and pre-neoplastic
		conditions, such as, for
		example, hyperplasia,
		metaplasia, and/or dysplasia.
		Preferred indications include
		anemia, pancytopenia,
		leukopenia, thrombocytopenia,
		Hodgkin's disease, acute
		lymphocytic anemia (ALL),
		plasmacytomas, multiple
		myeloma, Burkitt's lymphoma,
		arthritis, AIDS, granulomatous
		disease, inflammatory bowel

				disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac renerfusion iniury, and
				asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").
HWBFX31	858	Regulation of transcription of	Assays for the regulation of transcription of Malic Enzyme	A highly preferred indication is diabetes mellitus
		Malic Enzyme in	are well-known in the art and	An additional highly preferred
		adipocytes	may be used or routinely	indication is a complication
			modified to assess the ability	associated with diabetes (e.g.,
			of polypeptides of the	diabetic retinopathy, diabetic
			invention (including antibodies	nephropathy, kidney disease
			and agonists or antagonists of	(e.g., renal failure,
			the invention) to regulate	nephropathy and/or other
			transcription of Malic Enzyme,	diseases and disorders as
			a key enzyme in lipogenesis.	described in the "Renal
		•	Malic enzyme is involved in	Disorders" section below),
			lipogenesisand its expression is	diabetic neuropathy, nerve
			stimulted by insulin. ME	disease and nerve damage
			promoter contains two direct	(e.g., due to diabetic
			repeat (DR1)- like elements	neuropathy), blood vessel
			MEp and MEd identified as	blockage, heart disease, stroke,

	putative PPAR response	impotence (e.g., due to diabetic
	elements. ME promoter may	neuropathy or blood vessel
	also responds to AP1 and other	blockage), seizures, mental
	transcription factors.	confusion, drowsiness,
	Exemplary assays that may be	nonketotic hyperglycemic-
	used or routinely modified to	hyperosmolar coma,
	test for regulation of	cardiovascular disease (e.g.,
	transcription of Malic Enzyme	heart disease, atherosclerosis,
	(in adipoocytes) by	microvascular disease,
	polypeptides of the invention	hypertension, stroke, and other
	(including antibodies and	diseases and disorders as
	agonists or antagonists of the	described in the
	invention) include assays	"Cardiovascular Disorders"
	disclosed in: Streeper, R.S., et	section below), dyslipidemia,
	al., Mol Endocrinol,	endocrine disorders (as
	12(11):1778-91 (1998);	described in the "Endocrine
	Garcia-Jimenez, C., et al., Mol	Disorders" section below),
-	Endocrinol, 8(10):1361-9	neuropathy, vision impairment
	(1994); Barroso, I., et al., J	(e.g., diabetic retinopathy and
	Biol Chem, 274(25):17997-	blindness), ulcers and impaired
	8004 (1999); Ijpenberg, A., et	wound healing, and infection
	al., J Biol Chem,	(e.g., infectious diseases and
	272(32):20108-20117 (1997);	disorders as described in the
	Berger, et al., Gene 66:1-10	"Infectious Diseases" section
	(1988); and, Cullen, B., et al.,	below, especially of the
	Methods in Enzymol.	urinary tract and skin), carpal
	216:362–368 (1992), the	tunnel syndrome and
	contents of each of which is	Dupuytren's contracture).
	herein incorporated by	An additional highly preferred
	reference in its entirety.	indication is obesity and/or
	Hepatocytes that may be used	complications associated with

			according to these assays are	obesity. Additional highly preferred indications include
			through the ATCC) and/or	weight loss or alternatively,
			may be routinely generated.	weight gain. Aditional
			Exemplary hepatocytes that	highly preferred indications are
			may be used according to these	complications associated with
			assays includes the H4IIE rat	insulin resistance.
			liver hepatoma cell line.	
HWBFX31	858	SEAP in OE-33		
HWDAH38	829	Activation of	Assays for the activation of	A preferred embodiment of
		transcription	transcription through the	the invention includes a
		through serum	Serum Response Element	method for inhibiting (e.g.,
		response element in	(SRE) are well-known in the	reducing) TNF alpha
		immune cells (such	art and may be used or	production. An alternative
		as T-cells).	routinely modified to assess	preferred embodiment of the
			the ability of polypeptides of	invention includes a method
			the invention (including	for stimulating (e.g.,
			antibodies and agonists or	increasing) TNF alpha
			antagonists of the invention) to	production. Preferred
			regulate the serum response	indications include blood
			factors and modulate the	disorders (e.g., as described
			expression of genes involved	below under "Immune
			in growth. Exemplary assays	Activity", "Blood-Related
			for transcription through the	Disorders", and/or
			SRE that may be used or	"Cardiovascular Disorders"),
			routinely modified to test SRE	Highly preferred indications
			activity of the polypeptides of	include autoimmune diseases
			the invention (including	(e.g., rheumatoid arthritis,
			antibodies and agonists or	systemic lupus erythematosis,
			antagonists of the invention)	Crohn"s disease, multiple
			include assays disclosed in	sclerosis and/or as described

below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and	suppressing a T cell-mediated immune response. Additional highly preferred indications	include inflammation and inflammatory disorders, and treating joint damage in patients with rheumatoid arthritis. An additional highly	preferred indication is sepsis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below	under "Hyperproliferative Disorders"). Additionally, highly preferred indications include neoplasms and	cancers, such as, for example, leukemia, lymphoma, melanoma, glioma (e.g., malignant glioma), solid tumors, and prostate, breast,	lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include
Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992): Henthorn et al.	906 (17)23, Including et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); and Black et al., Virus Genes	12(2):105-117 (1997), the content of each of which are herein incorporated by reference in its entirety. T cells that may be used	according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these	assays include the CTLL cell line, which is an IL-2 dependent suspension culture of T cells with cytotoxic	activity.	

disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infectiou (e.g., an infectious disease as described below under "Infectious Disease").		Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma,
		Assays for the activation of transcription through the Gamma Interferon Activation
	SEAP in OE-33	Activation of transcription through GAS
	859	098
	HWDAH38	HWHGZ51

and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms	example, leukemia, lymphoma (e.g., T cell lymphoma, Burkitt's lymphoma, non-Hodgkins lymphoma,	melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other	benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include	autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated	immune response, and suppressing a T cell-mediated immune response. Additional
Site (GAS) response element are well-known in the art and may be used or routinely modified to assess the ability of nolymentides of the	invention (including antibodies and agonists or antagonists of the invention) to regulate STAT transcription factors and modulate gene expression	involved in a wide variety of cell functions. Exemplary assays for transcription through the GAS response	routinely modified to test GAS-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays	disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Matikainen et al., Blood	93(6):1980-1991 (1999); and Henttinen et al., J Immunol 155(10):4582-4587 (1995), the
response element in immune cells (such as T-cells).		-			

preferred indications include inflammation and	inflammatory disorders. Highly preferred indications	include blood disorders (e.g.,	as described below under	"Immune Activity", "Blood-	Related Disorders", and/or	"Cardiovascular Disorders"),	and infection (e.g., viral	infections, tuberculosis,	infections associated with	chronic granulomatosus	disease and malignant	osteoporosis, and/or an	infectious disease as described	below under "Infectious	Disease"). An additional	preferred indication is	idiopathic pulmonary fibrosis.	Preferred indications include	anemia, pancytopenia,	leukopenia, thrombocytopenia,	acute lymphocytic anemia	(ALL), plasmacytomas,	multiple myeloma, arthritis,	AIDS, granulomatous disease,	inflammatory bowel disease,	sepsis, neutropenia,	neutrophilia, psoriasis,	suppression of immune
contents of each of which are herein incorporated by	reference in its entirety. Exemplary mouse T cells that	may be used according to these	assays are publicly available	(e.g., through the ATCC).	Exemplary I cells that may be	used according to these assays	include the CTLL cell line,	which is a suspension culture	of IL-2 dependent cytotoxic T	cells.			-															
										_																		
		_								_						_				_								

					reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy.	
	HWHGZ51	098	Production of MCP-1	MCP-1 FMAT. Assays for immunomodulatory proteins	A highly preferred embodiment of the invention	,
,				that are produced by a large variety of cells and act to induce chemotaxis and	includes a method for stimulating (e.g., increasing) MCP-1 production. An	
				activation of monocytes and T cells are well known in the art	alternative highly preferred embodiment of the invention	
				and may be used or rounnely modified to assess the ability of polypeptides of the	includes a method for inhibiting (e.g., reducing) MCP-1 production. A highly	
				invention (including antibodies and agonists or antagonists of the invention) to mediate	preferred indication is infection (e.g., an infectious disease as described below	
				immunomodulation, induce chemotaxis, and modulate immune cell activation.	under "Infectious Disease"). Additional highly preferred indications include	_
				Exemplary assays that test for immunomodulatory proteins evaluate the production of cell	inflammation and inflammatory disorders. Preferred indications include	
				surface markers, such as monocyte chemoattractant protein (MCP) and the	blood disorders (e.g., as described below under "Immune Activity" "Blood-	
				activation of monocytes and T cells. Such assays that may be used or routinely modified to	Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications	

	test imminomodulatory and	include autoimmune diseases
	diffficultion potinity of	(or monmotoid outbritis
	differentiation activity of	(e.g., incumatora arunus,
	polypeptides of the invention	systemic lupus erythematosis,
	(including antibodies and	multiple sclerosis and/or as
	agonists or antagonists of the	described below) and
	invention) include assays	immunodeficiencies (e.g., as
	disclosed in Miraglia et al., J	described below). Preferred
 	Biomolecular Screening 4:193-	indications also include
 	204(1999); Rowland et al.,	anemia, pancytopenia,
 	"Lymphocytes: a practical	leukopenia, thrombocytopenia,
	approach" Chapter 6:138-160	Hodgkin's disease, acute
	(2000); Satthaporn and	lymphocytic anemia (ALL),
	Eremin, J R Coll Surg Ednb	plasmacytomas, multiple
 	45(1):9-19 (2001); and	myeloma, Burkitt's lymphoma,
	Verhasselt et al., J Immunol	arthritis, AIDS, granulomatous
	158:2919-2925 (1997), the	disease, inflammatory bowel
	contents of each of which are	disease, sepsis, neutropenia,
	herein incorporated by	neutrophilia, psoriasis,
	reference in its entirety.	suppression of immune
	Human dendritic cells that may	reactions to transplanted
	be used according to these	organs and tissues,
	assays may be isolated using	hemophilia, hypercoagulation,
	techniques disclosed herein or	diabetes mellitus, endocarditis,
	otherwise known in the art.	meningitis (bacterial and
	Human dendritic cells are	viral), Lyme Disease, asthma,
	antigen presenting cells in	and allergy Preferred
	suspension culture, which,	indications also include
	when activated by antigen	neoplastic diseases (e.g.,
	and/or cytokines, initiate and	leukemia, lymphoma, and/or as
	upregulate T cell proliferation	described below under
	and functional activities.	"Hyperproliferative

Highly preferred indications include asthma, allergy, hypersensitivity reactions, and inflammation. Preferred indications include infection (e.g., an infectious disease as described below under "Infectious Disease"), imflammation and inflammation and inflammatory disorders, as described below under "Immune Activity", and "Blood-Related Disorders"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple
Assays for the activation of transcription through the NFKB response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate NFKB transcription factors and modulate expression of immunomodulatory genes. Exemplary assays for transcription through the NFKB response element that may be used or rountinely modified to test NFKB-
Activation of transcription through NFKB response element in immune cells (such as EOL I cells).
098
HWHGZ51

response element activity of selevosis and/or as described polypeptides of the invention below) and (including antibodies and immunodeficiencies (e.g., as agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Mahin, Methods in Enzymol 216:362-368 (1992); Henthom et al., Proc Natl Acad Sci USA 85:542-6446 (1998); Valle Bazquez et al., Immunology 90(3):455-460 (1997); Arambura et al., Psp Med 82(3):801-8(1092); Henthom et al., Psp Me					
response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assay disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthom et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Valle Blazquez et al., Immunology 90(3):455-460 (1997); Aramburau et al., J Exp Med 82(3):801-81 (0 (1995); and Fraser et al., 26(3):838-844 (1999), the contents of each of which are herein incorporated by reference in its entirety. For example, a reporter assay (which measures increases in transcription inducible from a NFKB responsive element in EOL-1 cells) may link the NFKB represent to a reporter gene and binds to the NFKB transcription factor, which is upregulated by cytokines and other factors. Exemplary immune cells that may be used according to these assays	sclerosis and/or as described below) and immunodeficiencies (e.g., as described below).				
,	response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays	disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Valle	Blazquez et al, Immunology 90(3):455-460 (1997); Aramburau et al., J Exp Med 82(3):801-810 (1995); and Fraser et al., 29(3):838-844 (1999), the contents of each of	which are herein incorporated by reference in its entirety. For example, a reporter assay (which measures increases in transcription inducible from a NFkB responsive element in	NFKB element to a repeorter gene and binds to the NFKB transcription factor, which is upregulated by cytokines and other factors. Exemplary immune cells that may be used according to these assays

					Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly	preferred indications include
include eosinophils such as the human EOL-1 cell line of eosinophils. Eosinophils are a type of immune cell important in the allergic responses; they are recruited to tissues and mediate the inflammtory response of late stage allergic reaction. Eol-1 is a human eosinophil cell line.					Kinase assay. JNK and p38 kinase assays for signal transduction that regulate cell proliferation, activation, or apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit immune cell (e.g. T-cell) proliferation,	activation, and apoptosis.
	CD152 in Human T cells	HLA-DR in Human T cells	SEAP in OE-33	Hexosaminidase in RBL-2H3	Activation of T-Cell p38 or JNK Signaling Pathway.	
	098	098	098	098	861	
	HWHGZ51	HWHGZ51	HWHGZ51	HWHGZ51	НWLІН65	

	0	4)											eq eq				S	ia,		-		ler								
autoimmune diseases (e.g.,	rheumatoid arthritis, systemic	lupus erythematosis, multiple	sclerosis and/or as described	below) and	immunodeficiencies (e.g., as	described below). Additional	highly preferred indications	include inflammation and	inflammatory disorders.	Highly preferred indications	also include neoplastic	diseases (e.g., leukemia,	lymphoma, and/or as described	below under	"Hyperproliferative	Disorders"). Highly preferred	indications include neoplasms	and cancers, such as, leukemia,	lymphoma, prostate, breast,	lung, colon, pancreatic,	esophageal, stomach, brain,	liver, and urinary cancer. Other	preferred indications include	benign dysproliferative	disorders and pre-neoplastic	conditions, such as, for	example, hyperplasia,	metaplasia, and/or dysplasia.	Preferred indications include	
Exemplary assays for JNK and	p38 kinase activity that may be	used or routinely modified to	test JNK and p38 kinase-	induced activity of	polypeptides of the invention	(including antibodies and	agonists or antagonists of the	invention) include the assays	disclosed in Forrer et al., Biol	Chem 379(8-9):1101-1110	(1998); Gupta et al., Exp Cell	Res 247(2): 495-504 (1999);	Kyriakis JM, Biochem Soc	Symp 64:29-48 (1999); Chang	and Karin, Nature	410(6824):37-40 (2001); and	Cobb MH, Prog Biophys Mol	Biol 71(3-4):479-500 (1999);	the contents of each of which	are herein incorporated by	reference in its entirety. T	cells that may be used	according to these assays are	publicly available (e.g.,	through the ATCC).	Exemplary mouse T cells that	may be used according to these	assays include the CTLL cell	line, which is an IL-2	

					-																									

				cell line with cytotoxic	allergy, anemia, pancytopenia,
_				activity.	leukopenia, thrombocytopenia,
				•	Hodgkin"s disease, acute
					lymphocytic anemia (ALL),
					plasmacytomas, multiple
					myeloma, Burkitt"s lymphoma,
					granulomatous disease,
					inflammatory bowel disease,
					sepsis, psoriasis, suppression
					of immune reactions to
_					transplanted organs and
					tissues, endocarditis,
					meningitis, and Lyme Disease.
	HWLIH65	861	Production of	Assays for measuring	Highly preferred indications
			VCAM in	expression of VCAM are well-	include inflammation (acute
			endothelial cells	known in the art and may be	and chronic), restnosis,
			(such as human	used or routinely modified to	atherosclerosis, asthma and
			umbilical vein	assess the ability of	allergy. Highly preferred
			endothelial cells	polypeptides of the invention	indications include
			(HUVEC))	(including antibodies and	inflammation and
				agonists or antagonists of the	inflammatory disorders,
				invention) to regulate VCAM	immunological disorders,
				expression. For example,	neoplastic disorders (e.g.
				FMAT may be used to meaure	cancer/tumorigenesis), and
				the upregulation of cell surface	cardiovascular disorders (such
				VCAM-1 expresssion in	as described below under
				endothelial cells. Endothelial	"Immune Activity", "Blood-
			-	cells are cells that line blood	Related Disorders",
				vessels, and are involved in	"Hyperproliferative Disorders"
				functions that include, but are	and/or "Cardiovascular
				not limited to, angiogenesis,	Disorders"). Highly preferred

				vascular permeability, vascular	indications include neonlasms
					and cancers such as, for
				extravasation. Exemplary	example, leukemia, lymphoma,
_				endothelial cells that may be	melanoma, renal cell
				used according to these assays	carcinoma, and prostate,
				include human umbilical vein	breast, lung, colon, pancreatic,
				endothelial cells (HUVEC),	esophageal, stomach, brain,
				which are available from	liver and urinary cancer. Other
				commercial sources. The	preferred indications include
				expression of VCAM	benign dysproliferative
				(CD106), a membrane-	disorders and pre-neoplastic
				associated protein, can be	conditions, such as, for
				upregulated by cytokines or	example, hyperplasia,
<u>.</u>				other factors, and contributes	metaplasia, and/or dysplasia.
				to the extravasation of	
				lymphocytes, leucocytes and	
				other immune cells from blood	
				vessels; thus VCAM	
				expression plays a role in	
				promoting immune and	
				inflammatory responses.	
	HTEAM34	862	TNFa in Human T- cell 2B9		
	HTEAM34	862	Activation of	Kinase assay. JNK and p38	A highly preferred
			Endothelial Cell	kinase assays for signal	embodiment of the invention
, <u>.</u>			p38 or JNK	transduction that regulate cell	includes a method for
			Signaling Pathway.	proliferation, activation, or	stimulating endothelial cell
				apoptosis are well known in	growth. An alternative highly
				the art and may be used or	preferred embodiment of the
				routinely modified to assess	invention includes a method
				the ability of polypeptides of	for inhibiting endothelial cell

	the invention (including	arough A highly preferred
	antibodies and agonists or	embodiment of the invention
	antagonists of the invention) to	includes a method for
	promote or inhibit cell	stimulating endothelial cell
	proliferation, activation, and	proliferation. An alternative
	apoptosis. Exemplary assays	highly preferred embodiment
	for JNK and p38 kinase	of the invention includes a
	activity that may be used or	method for inhibiting
	routinely modified to test JNK	endothelial cell proliferation.
	and p38 kinase-induced	A highly preferred
	activity of polypeptides of the	embodiment of the invention
	invention (including antibodies	includes a method for
	and agonists or antagonists of	stimulating apoptosis of
	the invention) include the	endothelial cells. An
-	assays disclosed in Forrer et	alternative highly preferred
	al., Biol Chem 379(8-9):1101-	embodiment of the invention
	1110 (1998); Gupta et al., Exp	includes a method for
	Cell Res 247(2): 495-504	inhibiting (e.g., decreasing)
	(1999); Kyriakis JM, Biochem	apoptosis of endothelial cells.
	Soc Symp 64:29-48 (1999);	A highly preferred
	Chang and Karin, Nature	embodiment of the invention
	410(6824):37-40 (2001); and	includes a method for
	Cobb MH, Prog Biophys Mol	stimulating (e.g., increasing)
-	Biol 71(3-4):479-500 (1999);	endothelial cell activation. An
	the contents of each of which	alternative highly preferred
	are herein incorporated by	embodiment of the invention
	reference in its entirety.	includes a method for
	Endothelial cells that may be	inhibiting (e.g., decreasing) the
	used according to these assays	activation of and/or
	are publicly available (e.g.,	inactivating endothelial cells.
	through the ATCC).	A highly preferred

									-																					
embodiment of the invention	includes a method for	stimulating angiogenisis. An	alternative highly preferred	embodiment of the invention	includes a method for	inhibiting angiogenesis. A	highly preferred embodiment	of the invention includes a	method for reducing cardiac	hypertrophy. An alternative	highly preferred embodiment	of the invention includes a	method for inducing cardiac	hypertrophy. Highly	preferred indications include	neoplastic diseases (e.g., as	described below under	"Hyperproliferative	Disorders"), and disorders of	the cardiovascular system	(e.g., heart disease, congestive	heart failure, hypertension,	aortic stenosis,	cardiomyopathy, valvular	regurgitation, left ventricular	dysfunction, atherosclerosis	and atherosclerotic vascular	disease, diabetic nephropathy,	intracardiac shunt, cardiac	hypertrophy, myocardial
Exemplary endothelial cells	that may be used according to	these assays include human	umbilical vein endothelial cells	(HUVEC), which are	endothelial cells which line	venous blood vessels, and are	involved in functions that	include, but are not limited to,	angiogenesis, vascular	permeability, vascular tone,	and immune cell extravasation.																			
			_											·-						_										

Cincing acitandari	hemodynamic overload, and/or	as described below under	"Cardiovascular Disorders").	Highly preferred indications	include cardiovascular,	endothelial and/or angiogenic	disorders (e.g., systemic	disorders that affect vessels	such as diabetes mellitus, as	well as diseases of the vessels	themselves, such as of the	arteries, capillaries, veins	and/or lymphatics). Highly	preferred are indications that	stimulate angiogenesis and/or	cardiovascularization. Highly	preferred are indications that	inhibit angiogenesis and/or	cardiovascularization.	Highly preferred indications	include antiangiogenic activity	to treat solid tumors,	leukemias, and Kaposi"s	sarcoma, and retinal disorders.	Highly preferred indications	include neoplasms and cancer,	such as, Kaposi"s sarcoma,	hemangioma (capillary and	aromit almola (allomation	cavellious), giornia tunions,
																							-							-

angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, lymphangioma, lymphangiosarcoma. Highly	preterred indications also include cancers such as, prostate, breast, lung, colon,	pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred	indications include benign dysproliferative disorders and	pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.	Highly preferred indications also include arterial disease, such as atherosclerosis.	hypertension, coronary artery disease, inflammatory vasculitides, Revnaud''s	disease and Reynaud"s phenomenom, aneurysms,	restenosis; venous and lymphatic disorders such as thrombonhlebitis	lymphangitis, and lymphedema; and other

peripheral vascular disease, and cancer. Highly preferred indications also include trauma such as	wouldes, buths, and injured tissue (e.g., vascular injury such as, injury resulting from balloon angioplasty, and atheroschlerotic lesions), implant fixation, scarring, ischemia reperfusion injury, rheumatoid arthritis,	cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis. Additional highly preferred indications include stroke, graft rejection, diabetic or other retinopathies, thrombotic and coagulative disorders, vascularitis, lymph	angiogenesis, sexual disorders, age-related macular degeneration, and treatment /prevention of endometriosis and related conditions. Additional highly preferred indications include fibromas, heart disease, cardiac arrest, heart valve disease, and vascular disease.

highly preferred embodiment of the invention includes a method for stimulating adipocyte differentiation. An alternative highly preferred embodiment of the invention	includes a method for inhibiting adipocyte differentiation. A highly preferred embodiment of the invention includes a method for stimulating (e.g.,	increasing) adipocyte activation. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of (e.g., decreasing) and/or inactivating adipocytes. Highly preferred indications	(e.g., as described below under "Endocrine Disorders"). Highly preferred indications also include neoplastic diseases (e.g., lipomas,	described below under "Hyperproliferative Disorders"). Preferred indications include blood
invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and differentiation. Exemplary assays for ERK	kinase activity that may be used or routinely modified to test ERK kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of	the invention) include the assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Le Marchand-Brustel Y, Exp Clin Endocrinol Diabetes 107(2):126-132 (1999); Kyriakis JM, Biochem Soc	Symp 64:29-48 (1999); Chang and Karin, Nature 410(6824):37-40 (2001); and Cobb MH, Prog Biophys Mol Biol 71(3-4):479-500 (1999); the contents of each of which	reference in its entirety. Mouse adipocyte cells that may be used according to these assays are publicly available

-	pocyte	cells that may be used vessel blockage, heart disease,	according to these assays stroke, impotence and/or as	include 3T3-L1 cells. 3T3-L1 described below under	is an adherent mouse "Immune Activity",	preadipocyte cell line that is a "Cardiovascular Disorders",	continuous substrain of 3T3 and/or "Blood-Related	fibroblast cells developed Disorders"), immune disorders	through clonal isolation and (e.g., as described below under	undergo a pre-adipocyte to "Immune Activity"), neural	adipose-like conversion under disorders (e.g., as described	appropriate differentiation below under "Neural Activity	ند	and infection (e.g., as	described below under	"Infectious Disease").	A highly preferred indication	is diabetes mellitus. An	additional highly preferred	indication is a complication	associated with diabetes (e.g.,	diabetic retinopathy, diabetic	nephropathy, kidney disease	(e.g., renal failure,	nephropathy and/or other	diseases and disorders as	described in the "Renal	Disorders" section below),	diabetic neuropathy, nerve	a
							-																					-		_

(e.g., due to diabetic	neuropathy), blood vessel	blockage, heart disease, stroke,	impotence (e.g., due to diabetic	neuropathy or blood vessel	blockage), seizures, mental	confusion, drowsiness,	nonketotic hyperglycemic-	hyperosmolar coma,	cardiovascular disease (e.g.,	heart disease, atherosclerosis,	microvascular disease,	hypertension, stroke, and other	diseases and disorders as	described in the	"Cardiovascular Disorders"	section below), dyslipidemia,	endocrine disorders (as	described in the "Endocrine	Disorders" section below),	neuropathy, vision impairment	(e.g., diabetic retinopathy and	blindness), ulcers and impaired	wound healing, infection (e.g.,	infectious diseases and	disorders as described in the	"Infectious Diseases" section	below (particularly of the	urinary tract and skin). An	additional highly preferred	indication is obesity and/or

complications associated with	obesity. Additional highly	preferred indications include	weight loss or alternatively,	weight gain. Additional	highly preferred indications are	complications associated with	insulin resistance.	Additional highly preferred	indications are disorders of the	musculoskeletal systems	including myopathies,	muscular dystrophy, and/or as	described herein.	Additional highly preferred	indications include,	hypertension, coronary artery	disease, dyslipidemia,	gallstones, osteoarthritis,	degenerative arthritis, eating	disorders, fibrosis, cachexia,	and kidney diseases or	disorders. Preferred	indications include neoplasms	and cancer, such as,	lymphoma, leukemia and	breast, colon, and kidney	cancer. Additional preferred	indications include melanoma,	prostate, lung, pancreatic,	esophageal, stomach, brain,
													-																	
																				-				-				-		

Highly preferred indications include lipomas and liposarcomas. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.	Reporter Assay: construct contains regulatory and coding sequence of squalene synthetase, the first specific enzyme in the cholesterol biosynthetic pathway. See Jiang, et al., J. Biol. Chem. 268:12818-128241(993), the contents of which are herein incorporated by reference in its entirety. Cells were treated with SID supernatants, and SEAP activity was measured after 72 hours. HepG2 is a human hepatocellular carcinoma cell line (ATCC HB-8065). See Knowles et al., Science. 209:497-9 (1980), the contents of which are herein incorporated by reference in its
	Inhibition of squalene synthetase gene transcription.
	863
	HTEJN13

Table 1E

Polynucleotides encoding polypeptides of the present invention can be used in assays to test for one or more biological activities. One such biological activity which may be tested includes the ability of polynucleotides and polypeptides of the invention to stimulate up-regulation or down-regulation of expression of particular genes and proteins. Hence, if polynucleotides and polypeptides of the present invention exhibit activity in altering particular gene and protein expression patterns, it is likely that these polynucleotides and polypeptides of the present invention may be involved in, or capable of effecting changes in, diseases associated with the altered gene and protein expression profiles. Hence, polynucleotides, polypeptides, or antibodies of the present invention could be used to treat said associated diseases.

TaqMan® assays may be performed to assess the ability of polynucleotides (and polypeptides they encode) to alter the expression pattern of particular "target" genes. TaqMan® reactions are performed to evaluate the ability of a test agent to induce or repress expression of specific genes in different cell types. TaqMan® gene expression quantification assays ("TaqMan® assays") are well known to, and routinely performed by, those of ordinary skill in the art. TaqMan® assays are performed in a two step reverse transcription / polymerase chain reaction (RT-PCR). In the first (RT) step, cDNA is reverse transcribed from total RNA samples using random hexamer primers. In the second (PCR) step, PCR products are synthesized from the cDNA using gene specific primers.

To quantify gene expression the Taqman® PCR reaction exploits the 5' nuclease activity of AmpliTaq Gold® DNA Polymerase to cleave a Taqman® probe (distinct from the primers) during PCR. The Taqman® probe contains a reporter dye at the 5'-end of the probe and a quencher dye at the 3' end of the probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. During PCR, if the target of interest is present, the probe specifically anneals between the forward and reverse primer sites. AmpliTaq Fold DNA Polymerase then cleaves the probe between the reporter and quencher when the probe hybridizes to the target, resulting in increased fluorescence of the reporter (see Figure 2). Accumulation of PCR products is detected directly by monitoring the increase in fluorescence of the reporter dye.

After the probe fragments are displaced from the target, polymerization of the strand continues. The 3'-end of the probe is blocked to prevent extension of the probe during PCR. This process occurs in every cycle and does not interfere with the exponential accumulation of product. The increase in fluorescence signal is detected only if the target sequence is complementary to the probe and is amplified during PCR. Because of these requirements, any nonspecific amplification is not detected.

For test sample preparation, vector controls or constructs containing the coding sequence for the gene of interest are transfected into cells, such as for example 293T cells, and supernatants collected after 48 hours. For cell treatment and RNA isolation, multiple primary human cells or human cell lines are used; such cells may include but are not limited to, Normal Human Dermal Fibroblasts, Aortic Smooth Muscle, Human Umbilical Vein Endothelial Cells, HepG2, Daudi, Jurkat, U937, Caco, and THP-1 cell lines. Cells are plated in growth media and growth is arrested by culturing without media change for 3 days, or by switching cells to low serum media and incubating overnight. Cells are treated for 1, 6, or 24 hours with either vector control supernatant or sample supernatant (or purified/partially purified protein preparations in buffer). Total RNA is isolated; for example, by using Trizol extraction or by using the Ambion RNAqueous(TM)-4PCR RNA isolation system. Expression levels of multiple genes are analyzed using TAQMAN, and expression in the test sample is compared to control vector samples to identify genes induced or repressed. Each of the above described techniques are well known to, and routinely performed by, those of ordinary skill in the art.

Table 1E indicates particular disease classes and preferred indications for which polynucleotides, polypeptides, or antibodies of the present invention may be used in detecting, diagnosing, preventing, treating and/or ameliorating said diseases and disorders based on "target" gene expression patterns which may be up- or down-regulated by polynucleotides (and the encoded polypeptides) corresponding to each indicated cDNA Clone ID (shown in Table 1E, Column 2).

Thus, in preferred embodiments, the present invention encompasses a method of detecting, diagnosing, preventing, treating, and/or ameliorating a disease or disorder listed in the "Disease Class" and/or "Preferred Indication" columns of Table 1E; comprising administering to a patient in which such detection, diagnosis, prevention, or treatment is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to detect, diagnose, prevent, treat, or ameliorate the disease or disorder. The first and second columns of Table 1D show the "Gene No." and "cDNA Clone ID No.", respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in detecting, diagnosing, preventing, treating, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in the "Disease Class" or "Preferred Indication" Columns of Table 1E.

In another embodiment, the present invention also encompasses methods of detecting, diagnosing, preventing, treating, or ameliorating a disease or disorder listed in the "Disease Class" or "Preferred Indication" Columns of Table 1E; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in the "Disease Class" or "Preferred Indication" Columns of Table 1E.

The "Disease Class" Column of Table 1E provides a categorized descriptive heading for diseases, disorders, and/or conditions (more fully described below) that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

The "Preferred Indication" Column of Table 1E describes diseases, disorders, and/or conditions that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

5

10

15

20

25

30

35

The "Cell Line" and "Exemplary Targets" Columns of Table 1E indicate particular cell lines and target genes, respectively, which may show altered gene expression patterns (i.e., up- or down-regulation of the indicated target gene) in Taqman assays, performed as described above, utilizing polynucleotides of the cDNA Clone ID shown in the corresponding row. Alteration of expression patterns of the indicated "Exemplary Target" genes is correlated with a particular "Disease Class" and/or "Preferred Indication" as shown in the corresponding row under the respective column headings.

The "Exemplary Accessions" Column indicates GenBank Accessions (available online through the National Center for Biotechnology Information (NCBI) at http://www.ncbi.nlm.nih.gov/) which correspond to the "Exemplary Targets" shown in the adjacent row.

The recitation of "Cancer" in the "Disease Class" Column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate neoplastic diseases and/or disorders (e.g., leukemias, cancers, etc., as described below under "Hyperproliferative Disorders").

The recitation of "Immune" in the "Disease Class" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity" "Cardiovascular Disorders" and/or "Blood-Related Disorders"), and infections (e.g., as described below under "Infectious Disease").

The recitation of "Angiogenesis" in the "Disease Class" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), diseases and/or disorders of the cardiovascular system (e.g., as described below under "Cardiovascular Disorders"), diseases and/or disorders involving cellular and genetic abnormalities (e.g., as described below under "Diseases at the Cellular Level"),

diseases and/or disorders involving angiogenesis (e.g., as described below under "Anti-Angiogenesis Activity"), to promote or inhibit cell or tissue regeneration (e.g., as described below under "Regeneration"), or to promote wound healing (e.g., as described below under "Wound Healing and Epithelial Cell Proliferation").

The recitation of "Diabetes" in the "Disease Class" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diabetes (including diabetes mellitus types I and II), as well as diseases and/or disorders associated with, or consequential to, diabetes (e.g. as described below under "Endocrine Disorders," "Renal Disorders," and "Gastrointestinal Disorders").

5

10

Table1E

Gene	cDNA	Disease Class	Preferred Indications	Cell Line	Exemplary	Exemplary
No.	CloneID				Targets	Accessions
7	HAGDG59	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (AOSMC cells are aortic smooth muscle cells).	AOSMC	Vegfl	gb AF024710 A F024710
2	HAGDG59	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The HEK293 cell line is a human embryonal kidney epithelial cell line available through the ATCC as cell line number CRL-1573).	HEK293	TSP-1	gb X04665 HST HROMR
7	HAGDG59	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to,	HUVEC	Vegfl	gb AF024710 A F024710

			tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (HUVEC cells are human umbilical vein endothelial cells).			
r	HAGDG59	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders, as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The SK-N-MC neuroblastoma cell line is a cell line derived from human brain tissue available through the ATCC as cell line number HTB-10).	SK-N-MC neuroblastoma	Cycloox Vegf1	gb AF024710 A F024710
40	HCHNF25	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Caco-2 cell line is a human colorectal adenocarcinoma cell line available through the ATCC as cell line number HTB-37).	Caco-2	ICAM VCAM	gb X06990 HSI CAM1 gb A30922 A30 922
40	HCHNF25	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing,	Daudi	Vegfi	gb AF024710 A F024710

		neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Daudi cell line is a human B lymphoblast cell line available through the ATCC as cell line number CCL-213).			
HCHNF25	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders, as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (HUVEC cells are human umbilical vein endothelial cells).	HUVEC	Vegf1	gb AF024710 A F024710
HCHNF25	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Jurkat cell line is a human T lymphocyte cell line available through the ATCC as cell line number TIB-152).	Jurkat	VCAM	gb A30922 A30 922
HCHNF25	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases	NHDF	PAI	gb X12701 HSE NDPAI

	Vegf1 gb AF024710 A F024710	VCAM gb A30922 A30 922	Flt1 gb AF063657 A
	THPI	U937	AOSMC
and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders, as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (NHDF cells are normal human dermal fibroblasts).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The THP-1 cell line is a human monocyte cell line available through the ATCC as cell line number TIB-202).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The U937 cell line is a human monocyte cell line available through the ATCC as cell line number CRL-1593.2).	Highly preferred indications include diagnosis,
	Angiogenesis	Angiogenesis	Angiogenesis
	HCHNF25	HCHNF25	HDPBQ71
	40	40	55

			prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (AOSMC cells are aortic smooth muscle cells).		VCAM	F063657 gb A30922 A30 922
55	н D РВQ71	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Caco-2 cell line is a human colorectal adenocarcinoma cell line available through the ATCC as cell line number HTB-37).	Caco-2	Vegf1	gb AF024710 A F024710
55	нррвQ71	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Daudi cell line is a human B lymphoblast cell line available through the ATCC as cell line number CCL-213).	Daudi	ICAM	gb X06990 HSI CAM1

Fit1 gb AF063657 A iNOS F063657 gb X85761 HSN OS2E3	Fit1 gb AF063657 A TSP-1 F063657 VCAM gb X04665 HST HROMR gb A30922 A30 922	Fit1 gb AF063657 A Vegf1 F063657 B063657 B06367 B063657 B06367 B06
HEK293	HUVEC	Jurkat
Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The HEK293 cell line is a human embryonal kidney epithelial cell line available through the ATCC as cell line number CRL-1573).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (HUVEC cells are human umbilical vein endothelial cells).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Jurkat cell line is a human T lymphocyte cell line available through the ATCC as cell
Angiogenesis	Angiogenesis	Angiogenesis
HDPBQ71	норвQ71	нррвQ71
55	55	55

			line number TIR-152)			
55	HDPBQ71	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation."	Liver	VCAM	gb A30922 A30 922
55	HDPBQ71	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (NHDF cells are normal human dermal fibroblasts).	NHDF	TSP-1 Vegfl	gb X04665 HST HROMR gb AF024710 A F024710
55	HDPBQ71	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation."	T cell	ICAM Vegfi	gb X06990 HSI CAM1 gb AF024710 A F024710
55	нррвQ71	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases	THP1	VCAM	gb A30922 A30 922

	VCAM gb A30922 A30 922	TSP-1 gb X04665 HST HROMR
	U937	1-7-
and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The THP-1 cell line is a human monocyte cell line available through the ATCC as cell line number TIB-202).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The U937 cell line is a human monocyte cell line available through the ATCC as cell line number CRL-1593.2).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The TF-1 cell line is a human erythroblast cell line available through the ATCC as cell
	Angiogenesis	Angiogenesis
	н D РВQ71	н ксс үз ү
	55	66

ICAM gb X06990 HSI CAM1	ICAM gb X06990 HSI CAM1	ICAM gb X06990 HSI PAI CAM1 CAM1 Vegf1 gb X12701 HSE NDPAI gb AF024710 A F024710
U937	U937	Adipocytes- 3/12/01
Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The U937 cell line is a human monocyte cell line available through the ATCC as cell line number CRL-1593.2).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The U937 cell line is a human monocyte cell line available through the ATCC as cell line number CRL-1593.2).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders, as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell
Angiogenesis	Angiogenesis	Angiogenesis
Н FCCQ50	HFVAB79	HJACG02
66	107	132

gb A30922 A30 922	gb X06990 HSI CAM1 gb A30922 A30 922	gb X06990 HSI CAM1 gb X04665 HST HROMR gb AF024710 A F024710
VCAM	ICAM	ICAM TSP-1 Vegf1
AOSMC	Daudi	HUVEC
Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (AOSMC cells are aortic smooth muscle cells).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Daudi cell line is a human B lymphoblast cell line available through the ATCC as cell line number CCL-213).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (HUVEC cells are human umbilical vein endothelial cells).
Angiogenesis	Angiogenesis	Angiogenesis
HJACG02	HJACG02	HJACG02
132	132	132

HKACD58	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases	AOSMC	VCAM Veofi	gb A30922 A30 922
		and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (AOSMC cells are aortic smooth muscle cells).	•		gb AF024710 A F024710
HKACD58	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The HEK293 cell line is a human embryonal kidney epithelial cell line available through the ATCC as cell line number CRL-1573).	HEK293	TSP-1 Vegf1	gb X04665 HST HROMR gb AF024710 A F024710
HKACD58	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (HUVEC cells are human umbilical vein endothelial cells).	HUVEC	ICAM	gb X06990 HSI CAM1

gb A30922 A30 922	gb AF063657 A F063657 gb X06990 HSI CAM1 gb X12701 HSE NDPAI	gb A30922 A30 922
VCAM	Flt1 ICAM PAI	VCAM
NHDF	U937	AOSMC
Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (NHDF cells are normal human dermal fibroblasts).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The U937 cell line is a human monocyte cell line available through the ATCC as cell line number CRL-1593.2).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (AOSMC cells are aortic smooth muscle cells).
Angiogenesis	Angiogenesis	Angiogenesis
HKACD58	HNHFO29	HSDSB09
142	221	275

Caco-2 ICAM gb X06990 HSI	HEK293 Cycloox gb A30922 A30 922	HUVEC ICAM gb X06990 HSI Vegf1 CAM1 gb AF024710 A F024710
Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Caco-2 cell line is a human colorectal adenocarcinoma cell line available through the ATCC as cell line number HTB-37).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The HEK293 cell line is a human embryonal kidney epithelial cell line available through the ATCC as cell line number CRL-1573).	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular
Angiogenesis	Angiogenesis	Angiogenesis
HSDSB09	HSDSB09	HSDSB09
275	275	275

			ondotholial calla)			
275	HSDSB09	Angiogenesis	iseases ealing, d to, and gs in Anti- lar II	Jurkat	Flt1	gb AF063657 A F063657
275	HSDSB09	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Molt4 cell line is a human T cell line available through the ATCC as cell line number CRL-1582).	Molt4	SONI	gb X85761 HSN OS2E3
275	HSDSB09	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell	NHDF	Vegfl	gb AF024710 A F024710

			Proliferation."(NHDF cells are normal human dermal fibrohlasts).			
275	HSDSB09	Angiogenesis	erred indications include diagnosis, treatment, and/or amelioration of diseases rs involving angiogenesis, wound healing, particularly including, but not limited to, stases), and cardiovascular diseases and s described herein under the headings iferative Disorders," "Regeneration," "Antisis Activity," "Diseases at the Cellular "Wound Healing and Epithelial Cell n." (SUPT cells are human T-cells).	SUPT	VCAM	gb A30922 A30 922
275	HSDSB09	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The THP-1 cell line is a human monocyte cell line available through the ATCC as cell line number TIB-202).	THPI	ICAM TSP-1 VCAM Vegfi	gb X06990 HSI CAM1 gb X04665 HST HROMR gb A30922 A30 922 gb AF024710 A F024710
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (AOSMC cells are aortic smooth muscle	AOSMC	TSP-1	gb X04665 HST HROMR

			cells).			
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Daudi cell line is a human B lymphoblast cell line available through the ATCC as cell line number CCL-213).	Daudi	ICAM PAI	gb X06990 HSI CAM1 gb X12701 HSE NDPAI
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The H9 cell line is a human T lymphocyte cell line available through the ATCC as cell line number HTB-176).	Н9	VCAM	gb A30922 A30 922
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders, as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell	HEK293	Flt1 iNOS	gb AF063657 A F063657 gb X85761 HSN OS2E3

			Proliferation."(The HEK293 cell line is a human embryonal kidney epithelial cell line available through			
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (HUVEC cells are human umbilical vein endothelial cells).	HUVEC	Vegfi	gb AF024710 A F024710
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation."	Liver	Flt1 ICAM PAI VCAM	gb AF063657 A F063657 gb X06990 HSI CAM1 gb X12701 HSE NDPA1 gb A30922 A30 922
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The Molt4 cell line is a human T cell line	Molt4	VCAM	gb A30922 A30 922

			available through the ATCC as cell #CR1_1582)			
334	HWHGZ51	Angiogenesis		NHDF	Veaf	abi A E02/7101A
			iseases ealing, d to, and gs " "Anti- ar ll			F024710 F024710
334	HWHGZSI	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti-Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The THP-1 cell line is a human monocyte cell line available through the ATCC as cell line number TIB-202).	THPI	Vegfl	gb AF024710 A F024710
334	HWHGZ51	Angiogenesis	Highly preferred indications include diagnosis, prevention, treatment, and/or amelioration of diseases and disorders involving angiogenesis, wound healing, neoplasia (particularly including, but not limited to, tumor metastases), and cardiovascular diseases and disorders; as described herein under the headings "Hyperproliferative Disorders," "Regeneration," "Anti- Angiogenesis Activity," "Diseases at the Cellular Level," and "Wound Healing and Epithelial Cell Proliferation." (The U937 cell line is a human monocyte	U937	ICAM Vegfi	gb X06990 HSI CAM1 gb AF024710 A F024710

cell line available through the ATCC as cell line number	CRL-1593.2).
cell line ava	

Table 2 further characterizes certain encoded polypeptides of the invention, by providing the results of comparisons to protein and protein family databases. The first column provides a unique clone identifier, "Clone ID NO:", corresponding to a cDNA clone disclosed in Table 1A and/or Table 1B. The second column provides the unique contig identifier, "Contig ID:" which allows correlation with the information in Table 1B. The third column provides the sequence identifier, "SEQ ID NO:", for the contig polynucleotide sequences. The fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined. The fifth column provides a description of the PFAM/NR hit identified by each analysis. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, score/percent identity, provides a quality score or the percent identity, of the hit disclosed in column five. Comparisons were made between polypeptides encoded by polynucleotides of the invention and a non-redundant protein database (herein referred to as "NR"), or a database of protein families (herein referred to as "PFAM"), as described below.

5

10

15

20

25

30

35

The NR database, which comprises the NBRF PIR database, the NCBI GenPept database, and the SIB SwissProt and TrEMBL databases, was made non-redundant using the computer program nrdb2 (Warren Gish, Washington University in Saint Louis). Each of the polynucleotides shown in Table 1B (e.g., SEQ ID NO:X or the 'Query' sequence) was used to search against the NR database. The computer program BLASTX was used to compare a 6-frame translation of the Query sequence to the NR database (for information about the BLASTX algorithm please see Altshul et al., J. Mol. Biol. 215:403-410 (1990), and Gish and States, Nat. Genet. 3:266-272 (1993). A description of the sequence that is most similar to the Query sequence (the highest scoring 'Subject') is shown in column five of Table 2 and the database accession number for that sequence is provided in column six. The highest scoring 'Subject' is reported in Table 2 if (a) the estimated probability that the match occurred by chance alone is less than 1.0e-07, and (b) the match was not to a known repetitive element. BLASTX returns alignments of short polypeptide segments of the Query and Subject sequences which share a high degree of similarity; these segments are known as High-Scoring Segment Pairs or HSPs. Table 2 reports the degree of similarity between the Query and the Subject for each HSP as a percent identity in Column 7. The percent identity is determined by dividing the number of exact matches between the two aligned sequences in the HSP, dividing by the number of Query amino acids in the HSP and multiplying by 100. The polynucleotides of SEQ ID NO:X which encode the polypeptide sequence that generates an HSP are delineated by columns 8 and 9 of Table 2.

The PFAM database, PFAM version 2.1, (Sonnhammer, Nucl. Acids Res., 26:320-322, 1998))consists of a series of multiple sequence alignments; one alignment for each protein family. Each multiple sequence alignment is converted into a probability model called a Hidden

Markov Model, or HMM, that represents the position-specific variation among the sequences that make up the multiple sequence alignment (see, e.g., Durbin, et al., *Biological sequence analysis: probabilistic models of proteins and nucleic acids*, Cambridge University Press, 1998 for the theory of HMMs). The program HMMER version 1.8 (Sean Eddy, Washington University in Saint Louis) was used to compare the predicted protein sequence for each Query sequence (SEQ ID NO:Y in Table 1B) to each of the HMMs derived from PFAM version 2.1. A HMM derived from PFAM version 2.1 was said to be a significant match to a polypeptide of the invention if the score returned by HMMER 1.8 was greater than 0.8 times the HMMER 1.8 score obtained with the most distantly related known member of that protein family. The description of the PFAM family which shares a significant match with a polypeptide of the invention is listed in column 5 of Table 2, and the database accession number of the PFAM hit is provided in column 6. Column 7 provides the score returned by HMMER version 1.8 for the alignment. Columns 8 and 9 delineate the polynucleotides of SEQ ID NO:X which encode the polypeptide sequence which show a significant match to a PFAM protein family.

As mentioned, columns 8 and 9 in Table 2, "NT From" and "NT To", delineate the polynucleotides of "SEQ ID NO:X" that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth column. In one embodiment, the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the polynucleotides of SEQ ID NO:X delineated in columns 8 and 9 of Table 2. Also provided are polynucleotides encoding such proteins, and the complementary strand thereto.

The nucleotide sequence SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, the nucleotide sequences of SEQ ID NO:X are useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in ATCC Deposit No:Z. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to these polypeptides, or fragments thereof, and/or to the polypeptides encoded by the cDNA clones identified in, for example, Table 1A and/or 1B.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the

generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and a predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing cDNA ATCC Deposit No:Z (e.g., as set forth in columns 2 and 3 of Table 1A and/or as set forth, for example, in Table 1B, 6, and 7). The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

Table 2

cDNA Clone	Contig ID:	SEQ ID	Analysis	PFam/NR Description	PFam/NR Accession Number	Score/ Percent	NT From	NT To
n n		NO:X	Method			Identity	Ì	
H2CBU83	884134	11	WUblastx	(Q9NYD1) G-PROTEIN-	Q9NYD1	100%	10	777
			.64	COUPLED RECEPTOR				
201100011	276376	2,40	W/T 11.12.40.	48.	OONIVI	%80	201	776
H2CBU83	/45366	348	w U blastx	(QSN YDI) G-PROLEIN-	LAINIDI	9/9/	151	207
			.o.	COUPLED RECEPTOR 48.		100%	10	297
HACBD91	637482	14	WUblastx	NADH dehydrogenase	pir JE0383 JE0383	100%	211	357
				(ubiquinone) (EC 1.6.5.3)		%56	1306	1368
				chain NDUFB4 - human				
HAGAQ26	561996	15	WUblastx	(Q9UKG4)	Q9UKG4	%66	414	1001
,			.64	NA+/SULFATE		93%	2	433
				COTRANSPORTER				
				SUT-1.				
HAGBZ81	456414	16	WUblastx	(Q9H291) JUNCTATE.	Q9H291	85%	183	329
			.64			77%	26	199
HAGDG59	534165	17	HMMER	PFAM: short chain	PF00106	182.2	232	795
			2.1.1	dehydrogenase				
			WUblastx	(Q9UKU4) RETINAL	Q9UKU4	100%	124	1023
			.64	SHORT-CHAIN				
				DEHYDROGENASE/RE				
				DUCTASE RETSDR2.				
HAJAN23	1352364	23	WUblastx .64	(Q9HCC0) NON-BIOTIN CONTAINING	бэнссо	100%	109	1797
					The second secon			

	617	1807	48	1956	2757	2756	859 1401	1416 1429 658 636
	294	120 557	229	1807	1495	1503	984 1454	1457 1458 726 857
	126.6	91%	%69	22.9	93%	93%	71%	57% 70% 56% 64%
	PF01039	бэнссо	Q9JIG5	PF00781	Q9NP48	Q9NP48	Q9NX85	
SUBUNIT OF 3- METHYLCROTONYL- COA CARBOX	PFAM: Carboxyl transferase domain	(Q9HCC0) NON-BIOTIN CONTAINING SUBUNIT OF 3- METHYLCROTONYL- COA CARBOX	(Q9JIGS) UBIQUITIN SPECIFIC PROTEASE (FRAGMENT).	PFAM: Diacylglycerol kinase catalytic domain (presumed)	(Q9NP48) PUTATIVE LIPID KINASE (CDNA FLJ10842 FIS, CLONE NT2RP4001343	(Q9NP48) PUTATIVE LIPID KINASE (CDNA FLJ10842 FIS, CLONE NT2RP4001343	(Q9NX85) CDNA FLJ20378 FIS, CLONE	KAIA0536.
	HMMER 2.1.1	WUblastx .64	WUblastx .64	HMMER 2.1.1	WUblastx .64	WUblastx .64	WUblastx .64	
	350		24	25		351	56	
	872551		638516	905695		823350	731859	
	HAJAN23		HAJBR69	HAMFE15		HAMFE15	HAMGG68	

Number September Septemb	HAMGR28	892971	27	WUblastx	(AAH07438) Similar to	AAH07438	100%	65	823
748223 352 WUblastx (AAH07438 Similar to AAH07438 100% 569 769555 28 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 251 769555 28 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 251 722386 353 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 454 722386 353 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 454 722386 354 WUblastx (Q9BZM1) Hypothetical Q8WUJ1 100% 59 722386 355 WUblastx (Q9BZM1) Hypothetical Q8WUJ1 100% 56 644272 354 WUblastx (Q9BXR6) CDNA Q96NR6 42% 617 6455514 30 WUblastx (Q9BXR6) CDNA Q96NR6 42% 617 648272 355 WUblastx (Q9BXR6) CDNA Q96NR6 42% 617 649 RREEN full-le RREEN full-le RREEN full-le RREEN full-le RREEN full-le C44 RREEN full-le C4					RIKEN cDNA				
748223 352 WUblastx (AAH07438) Similar to AH07438 100% 569 769555 28 WUblastx (QBZMI) GROUP XII Q9BZMI 99% 251 769555 28 WUblastx (QBZMI) GROUP XII Q9BZMI 100% 251 722386 353 WUblastx (QBZMI) GROUP XII Q9BZMI 100% 454 135278 29 WUblastx (QBWUI) Hypothetical Q8WUJI 100% 59 135278 29 WUblastx (QBWUI) Hypothetical Q8WUJI 100% 59 684272 354 WUblastx (QBWUI) Hypothetical Q8WUJI 100% 56 684272 354 WUblastx (QBWUI) Hypothetical Q8WUJI 100% 26 684272 354 WUblastx (QBONR6) CDNA Q96NR6 42% 617 635514 30 WUblastx (QBSNR6) CDNA Q96NR6 42% 64% 659009 33 WUblastx (QBMZN26) 13 days BABZ7250					2610511E22 gene.				,
769555 28 WUblastx (Q9BZMI) GROUP XII GPEZMI 100% 1	HAMGR28	748223	352	WUblastx	(AAH07438) Similar to	AAH07438	100%	896	992
769555 28 WUblastx Q9BZM1) GROUP XII Q9BZM1 99% 251 769555 28 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 251 722386 353 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 251 722386 353 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 251 1352278 354 WUblastx (Q8WUJ1) Hypothetical Q8WUJ1 100% 59 644 28.7 kDa protein. 64 28.7 kDa protein. 100% 54 635514 30 WUblastx (Q8WUJ1) Hypothetical Q8WUJ1 100% 56 635009 33 WUblastx (Q8WUJ1) Hypothetical Q8WUJ1 36% 617 639009 33 WUblastx (Q8WUZ1S0) 13 days BABZ7250 100% 489 64 RIKEIN full-le RIKEIN full-le RIKEIN full-le 100% 489 64 24 kDa protein 64 24 kDa protein 108WVV8 <t< td=""><td></td><td></td><td></td><td>.64</td><td>RIKEN cDNA</td><td></td><td>100%</td><td></td><td>267</td></t<>				.64	RIKEN cDNA		100%		267
769555 28 WUblastx (Q9BZM1) GROUP XII Q9BZM1 99% 251 722386 353 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 251 722386 353 WUblastx (Q9BZM1) GROUP XII Q9BZM1 100% 454 1352278 39 WUblastx (Q8WUJ1) Hypothetical (Q8WUJ1 Q8WUJ1 100% 59 644 28.7 kDa protein. Q8WUJ1 100% 54 684272 354 WUblastx (Q8WUJ1) Hypothetical (Q8WUJ1 Q8WUJ1 100% 54 635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 639009 33 WUblastx (Q8BZ7250) 13 days BABZ7250 100% 489 64 G4 RIKEN full-le 100% 22 639009 33 WUblastx (BABZ7250) 13 days BABZ7250 100% 489 1352289 35 WUblastx (Q8WVV8) Hypothetical (Q8WVV8 78% 158 709658 356 WUblastx (Q8WVV8) Hypothetical (Q8WVV8 78% 158					2610511E22 gene.				
1352286 353 WUblastx QPBZM1 QPBZM1 100% 251	HAPOM49	769555	28	WUblastx	(Q9BZM1) GROUP XII	Q9BZM1	%66	251	817
722386 353 WUblastx (Q9BZMI) GROUP XII Q9BZMI 100% 251 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 454 100% 456 100% 100% 456 100% 100% 456 100% 456 100% 456 100% 456 100% 456 100% 456 100% 456 100% 456 100% 456 100% 456				.64	SECRETED				
722386 353 WUblastx Q9BZM1) GROUP XII Q9BZM1 100% 251					PHOSPHOLIPASE A2.				
1352278 WUblastx (Q8WUJI) Hypothetical (Q8WUJI) 100% 454 1352278 29 WUblastx (Q8WUJI) Hypothetical (Q8WUJI) 100% 59 100% 54 100% 564 100% 100% 564 100% 100% 564 100% 100% 564 100% 100% 100% 100% 564 100%	HAPOM49	722386	353	WUblastx	(Q9BZM1) GROUP XII	Q9BZM1	100%	251	451
1352278 29 WUblastx (Q8WUJI) Hypothetical G8WUJI Q8WUJI 100% 59 684272 354 WUblastx (Q8WUJI) Hypothetical G8WUJI Q8WUJI 100% 54 635514 30 WUblastx (Q8WUJI) Hypothetical G8WUJI Q8WUJI 100% 54 639009 33 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 639009 33 WUblastx (Q96NR6) I3 days BAB27250 88% 160 83552 355 WUblastx (BAB27250) I3 days BAB27250 100% 489 1352289 35 WUblastx (Q8WVV8) Hypothetical G8WVV8 Q8WVV8 100% 220 64 embryo liver cDNA, G8WVV8 RIKEN full-le 1352289 35 WUblastx (Q8WVV8) Hypothetical G8WVV8 100% 220 64 embryo liver cDNA, G8WVV8 G8WVV8 158 158				.64	SECRETED		100%	454	816
1352278 29 WUblastx (Q8WUJ1) Hypothetical Q8WUJ1 100% 59 684272 354 WUblastx (Q8WUJ1) Hypothetical Q8WUJ1 100% 54 635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 639009 33 WUblastx (RABZ7250) 13 days BABZ7250 88% 160 639009 35 WUblastx (BABZ7250) 13 days BABZ7250 100% 489 1352289 35 WUblastx (BABZ7250) 13 days BABZ7250 100% 489 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 220 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158					PHOSPHOLIPASE A2.				
684272 354 WUblastx (Q8WUJ1) Hypothetical Q8WUJ1 100% 54 635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 639009 33 WUblastx (BAB27250) 13 days BAB27250 BAB27250 88% 160 835592 355 WUblastx (BAB27250) 13 days BAB27250 100% 489 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 220 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 489 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158	HAPPW30	1352278	29	WUblastx	(Q8WUJ1) Hypothetical	Q8WUJ1	100%	29	820
684272 354 WUblastx (Q8WUJI) Hypothetical Q8WUJI 100% 54 635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 639009 33 WUblastx (BABZ7250) 13 days BABZ7250 BABZ7250 160 83552 355 WUblastx (BABZ7250) 13 days BABZ7250 100% 406 1352289 35 WUblastx (BABZ7250) 13 days BABZ7250 100% 406 1352289 35 WUblastx (BABZ7250) 13 days BABZ7250 100% 406 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 220 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158	_			.64	28.7 kDa protein.		i.		
635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 750 639009 33 WUblastx (BAB27250) 13 days BAB27250 88% 160 639009 33 WUblastx (BAB27250) 13 days BAB27250 100% 489 1383592 355 WUblastx (BAB27250) 13 days BAB27250 100% 406 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 220 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 158 158 70958 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78% 158	HAPPW30	684272	354	WUblastx	(Q8WUJ1) Hypothetical	Q8WUJ1	100%	54	263
635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 639009 33 WUblastx (BAB27250) 13 days BAB27250 88% 639009 33 WUblastx (BAB27250) 13 days BAB27250 88% 83592 355 WUblastx (BAB27250) 13 days BAB27250 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 100558 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%				64	28.7 kDa protein.		36%	985	1056
635514 30 WUblastx (Q96NR6) CDNA Q96NR6 42% 64 FLJ30278 fis, clone BRACE2002755. 88% 639009 33 WUblastx (BAB27250) 13 days BAB27250 88% 708009 35 WUblastx (BAB27250) 13 days BAB27250 100% 1383592 355 WUblastx (BAB27250) 13 days BAB27250 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 1352289 35 WUblastx (Ragment). (Fragment). 78%					1		100%	566	844
639009 33 WUblastx (BAB27250) 13 days (BAB27250	HATRR65	635514	30	WUblastx	(O96NR6) CDNA	Q96NR6	45%	750	908
639009 33 WUblastx (BAB27250) 13 days BAB27250 88% embryo liver cDNA, RIKEN full-le 84 Embryo liver cDNA, BAB27250 13 days BAB27250 13 days BAB27250 100% embryo liver cDNA, RIKEN full-le RIKEN full-le 8352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% controlled 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% controlled 122.4 kDa protein (Fragment).) 1	64	FI 130278 fis. clone	,	64%	617	751
639009 33 WUblastx (BAB27250) 13 days BAB27250 88% .64 RIKEN full-le 100% 383592 355 WUblastx (BAB27250) 13 days BAB27250 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% (Fragment). (Fragment). (Fragment). 78%				5	BRACE2002755.				
383592 355 WUblastx (BAB27250) 13 days BAB27250 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 170958 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%	HAUA183	639009	33	WUblastx	(BAB27250) 13 days	BAB27250	%88	160	399
383592 355 WUblastx (BAB27250) 13 days BAB27250 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%				.64	embryo liver cDNA,		%06	25	84
383592 355 WUblastx (BAB27250) 13 days BAB27250 100% .64 RIKEN full-le Q8WVV8) Hypothetical Q8WVV8 100% .64 22.4 kDa protein (Fragment). (Fragment). 78% 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%					RIKEN full-le		100%	489	557
1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% 170958 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%	HAUAI83	383592	355	WUblastx	(BAB27250) 13 days	BAB27250	100%	406	723
RIKEN full-le				.64	embryo liver cDNA,				
1352289 35 WUblastx (Q8WVV8) Hypothetical Q8WVV8 100% .64 22.4 kDa protein (Fragment). (Fragment). 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%					RIKEN full-le				
.64 22.4 kDa protein (Fragment). 709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%	HBGBA69	1352289	35	WUblastx	(Q8WVV8) Hypothetical	8WVV8	100%	220	843
709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%				.64	22.4 kDa protein				
709658 356 WUblastx (Q8WVV8) Hypothetical Q8WVV8 78%					(Fragment).				
	HBGBA69	709658	356	WUblastx	(Q8WVV8) Hypothetical	Q8WVV8	78%	158	977

780	974 744	578	589	579	800	245	907	786	798	314
211	1009	57	71	100	99	144	77	409	64	424 345
100%	83%	81%	%08	79%	100%	30.1	%6L	250.2	100%	71%
	AAK55521	Q9D6W7	Q9D6W7	Q9D6W7	pir S14350 C1HUQA	PF01391	Q9H2L7	PF00386	pir S14350 C1HUQA	Q9NS11
22.4 kDa protein (Fragment).	(AAK55521) PRO0764.	(Q9D6W7) 2310047N01RIK PROTEIN.	(Q9D6W7) 2310047N01RIK PROTEIN.	(Q9D6W7) 2310047N01RIK PROTEIN.	complement subcomponent C1q chain A precursor [validated] -	PFAM: Collagen triple helix repeat (20 copies)	(Q9H2L7) DC33.	PFAM: C1q domain	complement subcomponent C1q chain A precursor [validated] - human	(Q9NS11) LIPOPOLYSACCHARID E SPECIFIC RESPONSE-
.64	WUblastx 64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	HMMER 2.1.1	WUblastx .64	HMMER 2.1.1	WUblastx .64	WUblastx .64
	36	37	357	358	38	359		360		40
	514418	1352386	961712	892924	1125802	899397		902207		793786
	HBIAE26	HBINS58	HBINS58	HBINS58	HBJNC59	HBJNC59		HBJNC59	3	HBOEG69

				68 DDOTEIN			-	
HCACU58	625923	14	WUblastx .64	(Q9NX85) CDNA FLJ20378 FIS, CLONE KAIA0536	Q9NX85	%69	548	820
HCE2F54	634016	42	HMMER 2.1.1	PFAM: Histone-like transcription factor (CBF/NF-Y) and archaeal histone	PF00808	19	898	1005
			WUblastx .64	(AAH07642) Unknown (protein for IMAGE:3534358) (Fra	AAH07642	82%	298	1122
HCE3G69	728432	43	WUblastx .64	(Q9H0K7) HYPOTHETICAL 12.4 KDA PROTEIN (UNKNOWN) (PROTEIN FOR	Q9H0К7	100%	1294	1647
HCE3G69	494346	361	WUblastx .64	(Q9H0K7) HYPOTHETICAL 12.4 KDA PROTEIN (UNKNOWN) (PROTEIN FOR	Q9H0К7	100%	1295	1648
HCE5F43	612796	44	WUblastx .64	(Q9H8M7) CDNA FLJ13397 FIS, CLONE PLACE1001351.	Q9H8M7	100%	95	53 928
HCEFB80	1143407	45	WUblastx .64	(Q96FR3) Unknown (protein for MGC:18083).	Q96FR3	100%	1785	1979
HCEFB80	1046853	362	WUblastx .64	(Q96FR3) Unknown (protein for MGC:18083).	Q96FR3	100%	1777	1971

HCEWE20	543370	47	WUblastx	WUblastx (09P1J1) PRO1546.	Q9P1J1	%9 <i>L</i>	501	551
			.64			462	109	717
HCGMD59	636078	49	WUblastx	catalase (EC 1.11.1.6) -	pir 140767 140767	%16	296	186
			F 0:	Callipy logacies Jejuin				
HCHNF25	1352270	50	WUblastx	(AAL76113) Androgen-	AAL76113	 %66	3069	2188
			.64	induced basic leucine		64%	3371	2811
				zipper.		24%	622	425
HCHNF25	658672	363	WUblastx	(AAH00499) Jumping	AAH00499	91%	180	620
			.64	translocation breakpoint.				
HCNDR47	1016919	51	WUblastx	(BAB84904) FLJ00149	BAB84904	93%	696	1154
			.64	protein (Fragment).		42%	180	263
HCNDR47	863677	364	WUblastx	(Q24333) ELASTIN	Q24333	27%	42	197
			.64	LIKE PROTEIN				
				(FRAGMENT).				
HCNDR47	874128	365	WUblastx	(BAB84904) FLJ00149	BAB84904	93%	148	333
			.64	protein (Fragment).				
HCNSM70	637547	53	HMMER	PFAM: Immunoglobulin	PF00047	32	224	481
			2.1.1	domain				
			WUblastx	(060487) EPITHELIAL	060487	%86	107	751
			.64	V-LIKE ANTIGEN				
				PRECURSOR				
				(EPITHELIAL V-LIKE				
				ANTIG				
HCNSM70	589445	366	WUblastx	(O60487) EPITHELIAL	060487	100%	161	409
			4 0.	V-LINE ANTIGEN		97.66	000	000
				FPITHELIAL V-LIKE				-
				ANTIG				
HCUCK44	720291	54	WUblastx 64	hypothetical protein DKFZn5641157 1 -	pir T34520 T34520	%16	21	524
				בייוכי מו סכלם דיים				

Ш
Jblastx
.64 FLJ32172 fis, clone PLACE6000555.
Jblastx
.64 HYPOTHETICAL 79.4 KDA PROTEIN.
_
WUblastx (Q9H3W5)
.64 HYPOTHETICAL 79.4 KDA PROTEIN.
Jblastx
.64 protein PA1527
[imported] - Pseudomonas
59 WUblastx (060448) NEURONAL
.64
60 WUblastx (Q9NX85) CDNA
KAIA0536.
Jblastx
.64 PEROXISOMAI
BIOGENESIS FACTOR
63 WUblastx (Q9UBJ4)
.64 TRANSPOSASE-LIKE PROTEIN.

HDPBA28	1062783	64	WUblastx	(09UKY2)	Q9UKY2	%66	259	3081
			.64	ADIPOCYTE-DERIVED	,			
				LEUCINE				_
				AMINOPEPTIDASE.		i di di		
HDPBA28	866429	369	HMMER	PFAM: Peptidase family	PF01433	613.6	228	1391
			2.1.1	M1				
			WUblastx	(Q9UKY2)	Q9UKY2	%66	69	2891
			.64	ADIPOCYTE-DERIVED				
				LEUCINE				
				AMINOPEPTIDASE.				
HDPBQ71	1160316	65	WUblastx	(Q9BRE2)	Q9BRE2	100%	06	1928
,			.64	HYPOTHETICAL 68.4				
				KDA PROTEIN				_
				(FRAGMENT).				
HDPBQ71	727200	370	WUblastx	(Q9BRE2)	Q9BRE2	%66	21	1859
			.64	HYPOTHETICAL 68.4				
				KDA PROTEIN				
				(FRAGMENT).				
HDPBQ71	290988	371	WUblastx	(Q9H2V9) CDA08.	Q9H2V9	100%	1532	1999
,			.64			929	169	797
						44%	182	322
						21%	1456	1551
						93%	186	1541
HDPCL63	1019008	99	WUblastx	(Q9Y519)	Q9Y519	%66	14	835
			.64	HYPOTHETICAL 42.3				
				KDA PROTEIN.				
HDPCL63	847045	372	WUblastx	(Q9Y519)	Q9Y519	%16	2	730
			.64	HYPOTHETICAL 42.3				
				KDA PROTEIN.				
HDPFF39	288697	89	WUblastx	(096005) CLEFT LIP	0096005	100%	3	29

			.64	AND PALATE		100%	16	762
_				TRANSMEMBRANE				
				PROTEIN 1.				
HDPGT01	771583	71	WUblastx	(Q9Y2B3) LCAT-LIKE	Q9Y2B3	100%	∞	262
			.64	PROTEIN (LLPL).		100%	264	1244
HDPJM30	879325	73	WUblastx	(094759) LONG	TRL2_HUMAN	%66	17	1633
		_	.64	TRANSIENT				
				RECEPTOR				
				POTENTIAL CHANNEL				
				2 (LTRPC				
HDPJM30	603517	374	WUblastx	(094759) LONG	TRL2 HUMAN	%68	416	1312
	-		.64	TRANSIENT	ı	%96	378	530
				RECEPTOR		%86	_	378
				POTENTIAL CHANNEL				
				2 (LTRPC				
HDPMM88	972734	74	HMMER 2 1 1	PFAM: E1-E2 ATPase	PF00122	31	475	543
			WIlhlastv	(P98198) POTENTIAL	ATID HIMAN	7089	106	7000
			.64		NUMOII TITU	32%	2917	7967
				-				1//1
				ATPASE ID (EC				
HDPMM88	906121	375	WUblastx	(Q96NQ7) CDNA	20N960	%05	356	403
			.64	FLJ30324 fis, clone		%9 <i>L</i>	3	365
				BRACE2007138, weakly				
				similar to PRO				
HDPMM88	902299	376	WUblastx	(P98199) POTENTIAL	AT1D_MOUSE	73%	2	172
			.64	PHOSPHOLIPID-				
				TRANSPORTING				-
				ATPASE ID (EC				
HDPMM88	885059	377	WUblastx	(AAH07837) Unknown	AAH07837	75%	63	16

62	Т	827 78	904	524	1791	1614	1800	949	958	1647	5194	1308	2175	4891	5045	4799
298	1023	654 37	524 315	12	28	307	40	200	161	952	5063	919	1942	4835	4983	4611
%69	%59	52% 64%	84%	%66	100%	431.1	%66	185.2	%86	99% 100%	77%	100%	%26	45%	47%	%86
	ATID_HUMAN	Q8WY51	Q9H7X1		BAB84923	PF01593	BAB84923	PF01593	BAB84923		Q9BVN4					
(protein for IMAGE:4111596) (Fra	(P98198) POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE ID (EC	(Q8WY51) HC6.	(Q9H7X1) CDNA FL 114153 FIS. CLONE	NT2RM1000092, WEAKLY SIMILAR TO MUL	(BAB84923) FLJ00168 protein (Fragment).	PFAM: Flavin containing amine oxidase	(BAB84923) FLJ00168 protein (Fragment).	PFAM: Flavin containing amine oxidase	(BAB84923) FLJ00168	protein (Fragment).	(Q9BVN4)	HYPOTHETICAL 59.4	KDA PROTEIN.			
.64	WUblastx .64	WUblastx .64	WUblastx .64		WUblastx .64	HMMER 2.1.1	WUblastx .64	HMMER 2.1.1	WUblastx	.64	WUblastx	.64				
	378	75	9/		77	381		382			78					
	874074	637585	731863		1352319	815653		743479			1037893					
	HDPMM88	HDPNC61	HDPOJ08		HDPOZ56	HDPOZ56		HDPOZ56			HDPPN86					

HDPPN86	895711	383	WUblastx	(09BVN4)	Q9BVN4	%86	606	1817
			.64	HYPOTHÉTICAL 59.4	,		-	
				KDA PROTEIN.				
HDPSB18	1043263	79	WUblastx	(Q9NX17) CDNA	Q9NX17	%99	3407	3150
			.64	FLJ20489 FIS, CLONE		46%	2573	2478
				KAT08285.				
HDPSB18	732097	386	WUblastx	(Q9NX17) CDNA	Q9NX17	41%	863	189
			.64	FLJ20489 FIS, CLONE		%99	813	226
				KAT08285.				
HDPSH53	1309174	08	WUblastx	(Q9EPY0) CASPASE	Q9EPY0	26%	262	456
			.64	RECRUITMENT		%88	1023	1184
				DOMAIN PROTEIN 9.				
HDPSH53	1040056	387	WUblastx	(Q9H257) CASPASE	Q9H257	100%	1131	1184
			.64	RECRUITMENT	•	92%	301	423
				DOMAIN PROTEIN 9.		25%	1518	1610
	_					100%	1010	1129
HDPSH53	882768	388	WUblastx	(AAH08877) Caspase	AAH08877	%86	316	480
	•		.64	recruitment domain				
				protein 9.				
HDPSP01	1352280	81	WUblastx	(Q9BR97) UNKNOWN	Q9BR97	93%	1671	1718
			.64	(PROTEIN FOR		94%	184	1674
				MGC:10763).		41%	2196	2276
HDPSP01	689129	389	WUblastx	(Q9BR97) UNKNOWN	Q9BR97	%06	227	1114
			.64	(PROTEIN FOR		%86	1078	1668
				MGC:10763).		100%	1664	1744
HDPSP54	744440	82	WUblastx	(BAB85063) CDNA	BAB85063	%66	2	307
			.64	FLJ23790 fis, clone				
				HEP21466.				
HDPTD15	692917	83	WUblastx	(Q9BU29) UNKNOWN	Q9BU29	97%	937	833
			.04	(PROTEIN FOR				

IMAGE:3954899) (FRAGMENT). PFAM: Immunoglobulin PF00047
(Q9Y286) QA79 Q9Y286 MEMBRANE PROTEIN.
ALLELIC VARIANT
(AAH25255) Similar to AAH25255
hypothetical protein
1
(AAH25255) Similar to AAH25255
hypothetical protein FLJ21347
(Q9H747) CDNA: Q9H747
FLJ21347 FIS, CLONE
COL02724.
hypothetical protein pir T43490 T43490
DKFZp434A139.1 -
human (fragments)
hypothetical protein pir T43490 T43490
DKFZp434A139.1 -
(093251) ALPHA 1 093251
FYPE I COLLAGEN.
(Q9BTV4) UNKNOWN Q9BTV4
PROTEIN FOR
MGC:3222).
(Q9BTV4) UNKNOWN Q9BTV4
PROTEIN FOR

				MGC:3222)				
HDTBV77	785879	88	WUblastx .64	(Q9BT94) UNKNOWN (PROTEIN FOR MGC:10848).	Q9BT94	%69 %66	2131	2137
ното023	1306984	68	WUblastx .64	calcium-binding protein (clone pMP41) - mouse (fragment)	pir S04970 S04970	100%	1611	1709
ното023	879009	397	WUblastx .64	calcium-binding protein (clone pMP41) - mouse (fragment)	pir S04970 S04970	100%	1623	1721
нртр023	751707	398	WUblastx .64	calcium-binding protein (clone pMP41) - mouse (fragment)	pir S04970 S04970	100%	1623	1721
HE2DE47	619852	06	WUblastx .64	(Q9NZN8) NOT2P (CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 2).	8NZN6O	%66	808	2427
HE2NV57	740750	92	WUblastx .64	(Q9UGV6) BK445C9.3 (HIGH-MOBILITY GROUP (NONHISTONE CHROMOSOMAL) PROT	9ADD6O	91%	321	866 106
нЕ2РН36	570903	93	WUblastx .64	(AAH07609) Similar to hypothetical protein PRO1722.	AAH07609	26% 88%	1359 1524 1484	1285 1492 1353
HE8DS15	847060	94	WUblastx .64	(Q9WVT0) SEVEN TRANSMEMBRANE RECEPTOR.	Q9WVT0	80% 24% 87%	1 48 269	270 146 985
HE9DG49	1299935	96	WUblastx	(Q9NYL4) FK506	Q9NYL4	100%	70	672

_	211 492	70 672	-71 -352	578 679 78 674	51 467	360 638	213 653		1715 1653 1648 1559 1881 1705	1036 1293 592 639 635 937	18 386
	91 2	100%	91	100% 5	100%	39.7	100%		52% 17 53% 16 67% 18	100% 100% 5 99%	100%
	PF00254	Q9NYL4	PF00254	Q9NYL4	AAH00573	PF00031	Q9H4G1	Q9H1M5	Q9N083	Q9ВQM3	9Нd96О
BINDING PROTEIN PRECURSOR.	trans	(Q9NYL4) FK506 BINDING PROTEIN PRECURSOR.	PFAM: FKBP-type peptidyl-prolyl cis-trans isomerases	(Q9NYL4) FK506 BINDING PROTEIN PRECURSOR.	(AAH00573) HSPC163 protein.	PFAM: Cystatin domain	(Q9H4G1) BA218C14.1 (NOVEL CYSTATIN FAMILY MEMBER).	.1	(Q9N083) UNNAMED PORTEIN PRODUCT.	(Q9BQM3) DJ842G6.1.1 (NOVEL PROTEIN) (FRAGMENT).	(Q96PH6) ESC42.
.64	HMMER 2.1.1	WUblastx .64	HMMER 2.1.1	WUblastx .64	WUblastx .64	HMMER 2.1.1	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx
	400		401		86	66		100	101	102	103
	658678		382000		701802	777843		532596	847372	603533	596830
	HE9DG49		HE9DG49		HEBEJ18	HEEAQ11		HEGAH43	НЕСНD85	неомо63	HEPAA46

	253 797	944	425	1042	1102	204	657	410	307	229
	53 237	513 9	601	365	35	4	895	249	369	23
	%88 88%	%88 %89	47%	130.8	%56	94%	100%	%26	47%	100%
	69ОХЕ9	бере бере бере бере бере бере бере бере	Q9HBN2	PF01762	Q9C0J1	Q9NYC6	075525	pir 178556 178556	AAK55521	О9Н8Р0
	(Q9QZE9) ТМ6Р1.	(Q9QZH5) PUTATIVE PHOSPHATE/PHOSPHO ENOLPYRUVATE TRANSLOCATOR.	(Q9HBN2) HYPOTHETICAL 15.8 KDA PROTEIN.	PFAM: Galactosyltransferase	(Q9C0JI) BETA-1,3-N-ACETYLGLUCOSAMIN YLTRANSFERASE BGN-T4.	(Q9NYC6) NEURONAL SPECIFIC TRANSCRIPTION FACTOR DAT1.	(075525) T-STAR.	membrane glycoprotein M6 - mouse	(AAK55521) PRO0764.	(Q9H8P0) CDNA FLJ13352 FIS, CLONE OVARC1002165, WEAKLY SIMILAR TO
.64	WUblastx .64	WUblastx .64	WUblastx .64	HMMER 2.1.1	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64
	105	106	107	109		110	112	113	114	115
	847073	566712	534142	579993		411345	560639	513669	532060	545012
	HFABG18	Н FABH95	HFAEF57	HFCCQ50		нғсев37	HFFAL36	HFGAD82	HFIUR10	HFTBM50

				3-0				
HFVAB79	1300736	117	WUblastx .64	(Q9BX93) GROUP XIII SECRETED	Q9BX93	100%	133	714
				PHOSPHOLIPASE A2.				
HFVAB79	565076	403	WUblastx	(Q9BX93) GROUP XIII	Q9BX93	100%	139	720
_			.64	SECRETED SECOND				
				PHUSPHULIPASE AZ.				
HFXJX44	701988	121	WUblastx	(Q9N083) UNNAMED	Q9N083	27%	1378	1082
			.64	PORTEIN PRODUCT.				3
HFXKJ03	505207	122	WUblastx	(O62658) LINE-1	062658	34%	492	292
			49:	ELEMENT ORF2.		36%	920	525
HFXKT05	069859	123	WUblastx	(Q9H5H7) CDNA:	7Н5Н6О	81%	5	1015
			.64	FLJ23425 FIS, CLONE		-		
				HEP22862.				
HGBHI35	570262	124	HMMER	PFAM: Enoyl-CoA	PF00378	184.6	213	722
			2.1.1	hydratase/isomerase				
				family				
	1	i	WUblastx	(AAH25104) Similar to	AAH25104	91%	225	396
-			.64	RIKEN cDNA				
				1300017C12 gene.				
HGBIB74	837220	125	WUblastx	hypothetical protein	pir T28058 T28058	20%	1387	1494
			.64	ZK858.6 - Caenorhabditis		51%	2	439
				elegans		%59	482	730
						62%	723	1403
HGBIB74	838602	405	WUblastx	(9N5V9Q)	9N5V6Q	%59	736	1257
		_	.64	BG:DS00797.1		85%	537	740
		_		PROTEIN.		81%	1251	1505
						27%	223	537
						57%	61	474
HGBIB74	899864	406	WUblastx	(9NEA6Q)	9NEV99	71%	12	950

	1230	1373	898	867	998	867	998	867	998	867	998	298	998	867	998	198	998	867	998	867	998	298	998	298	998	298	998	298	866
	10	1185	746	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744
	%26	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	Q96BH1		6Z976D	•																									
BG:DS00797.1 PROTEIN.	(Q96BH1) Ring finger	protein 25.	(O9LGZ9) GENOMIC	DNA. CHROMOSOME	3. BAC CLONE:F1D9.																								
.64	WUblastx	.64	WUblastx	64						. —						•							-						
	130		131	l)																									
	877639		821330																		-								
	ННЕРМ33		HHFBY53										-																

298	998	298	998	867	998	867	998	867	998	867	998	867	998	298	998	867	998	867	998	198	998	867	998	867	998	867	998	198	998	867
745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																													-	
										, -																				
				-																										
		_														_														

998	867	998	867	998	867	998	298	998	867	998	867	998	867	998	867	867	867	998	867	998	867	998	867	998	298	998	298	998	867	866
744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	745	745	744	745	744	745	744	745	744	745	744	745	744	745	744
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																														-
i.																														
						- -																			-					
								-										-		_										

867	998	867	998	298	998	298	998	298	998	298	998	298	998	198	998	198	998	198	998	867	998	867	998	298	998	298	998	867	998	867
745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																												- (· · · · · ·		
											-,																			
								. —																						
																_ •								_						

998	298	998	198	998	298	998	198	998	298	998	198	998	867	998	198	998	998	998	198	998	867	998	298	998	298	998	298	998	298	866
744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	744	744	745	744	745	744	745	744	745	744	745	744	745	744
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																, -													_	
												-																		
								-								-	-						-							
																									-		_			

867	998	867	998	867	998	867	998	867	998	298	998	867	998	867	998	198	998	298	998	867	998	867	998	867	998	867	998	867	998	867
745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745
100%	100%	100%	100%	- 100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
								_																						
																-	_													

998	867	998	867	998	867	998	867	998	298	998	867	998	298	998	298	998	867	998	298	998	298	998	298	998	867	998	867	998	198	866
744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
												<u>.</u>																	-	
																					-									
																														_
		<u>-</u> .												-						-										

298	998	298	998	867	998	867	998	867	998	867	998	198	998	867	998	298	998	867	998	867	998	867	998	298	998	867	998	867	998	867
745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																				·· <u>.</u> .*•										
									-,_,,																					
			- , ····							<u>-</u>	- <u></u>																			
																			_											

998	298	998	298	998	867	998	298	998	198	998	198	998	867	998	198	998	198	998	198	998	998	998	298	998	298	998	198	998	298	998
744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	744	744	745	744	745	744	745	744	745	744
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																											_			
																								. — .						
						-					-									•	-									

100% 745 100% 746 100% 747 100% 748 100	198	998	298	998	867	998	298	998	298	998	298	998	298	998	198	998	298	998	867	998	298	998	298	998	298	998	298	998	867	998	298
100% 100% 100% 100% 100% 100% 100% 100%	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745
	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																			-												
																										-					
		-	-										-																-		
·													_	<u></u>			-											_		-	
	-	_				-				-						, ,															

998	867	998	298	998	298	998	867	998	198	998	298	998	298	998	198	998	298	998	298	998	298	998	998	998	298	998	867	998	867	866
744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	744	744	745	744	745	744	745	744
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
																								-						
							***************************************			_													-							
																													-	
				·																										
				_													_												-	

298	998	867	998	867	998	867	998	198	998	867	998	198	998	198	998	198	998	298	998	867	998	867	998	867	867	198	998	867	998	867
745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	744	745	745	745	744	745	744	745
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
								•												-										
					-						<u>-</u>						·													
														_						· - <u>-</u>									- 	

998	298	998	298	998	867	998	867	998	867	298	298	998	867	998	867	998	867	298	298	998	998	998	298	.998	867	1301		807	000.	1298
744	745	744	745	744	745	744	745	744	745	745	745	744	745	744	745	744	745	745	745	744	744	744	745	744	724	132		628	6	819
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	%56	95%	%68	100%		36.3		%86
																						•				Q96AP7		PF00047		Q96AP7
																										(Q96AP7) Hypothetical	41.2 KDa protein.	PFAM: Immunoglobulin	uolilaili (00000000000000000000000000000000000	(Q96AP7) Hypothetical
																							-			WUblastx 64	.04	HMMER	+	WUblastx
																										132		407		
						-																				865581		691402		
																										HHFGR93		HHFGR93		

828	114	536		114	536			1535		1706			926	928		613		<i>L</i> 96	928		619		984	933	754	1530	1323
130	7	378		7	378			510		183			191	338		542		191	338		248		739	691	197	1435	1243
%66	%46	<u></u>		94%	%86			148.9		%66			74%	30%		122		74%	30%		77		71%	31%	74%	100%	%96
	Q96FV2			Q96FV2				PF01546		Q96KN2			Q9НВW1			PF00560		Q9НВW1			PF00560		Q9HBW1			Q9CWZ1	
41.2 kDa protein.	(Q96FV2) Unknown	(protein for IMAGE:3945715)	(Fragment).	(Q96FV2) Unknown	(protein for	IMAGE:3945715)	(Fragment).	PFAM: Peptidase family	M20/M25/M40	(Q96KN2) Glutamate	carboxypeptidase-like	protein 2.	(Q9HBW1) Brain tumor	associated protein	NAG14.	PFAM: Leucine Rich	Repeat	(Q9HBW1) Brain tumor	associated protein	NAG14.	PFAM: Leucine Rich	Repeat	(Q9HBW1) Brain tumor	associated protein	NAG14.	(Q9CWZ1)	2400006A19RIK PROTEIN.
.64	WUblastx	.64		WUblastx	.64			HMMER	2.1.1	WUblastx	.64		WUblastx	.64		HMMER	2.1.1	WUblastx	.64		HMMER	2.1.1	WUblastx	.64		WUblastx	.64
	134			408				137					138			604	·				410					140	
	662329			383547				695134					1299927			753270					696095					636025	
	HHGCM76			HHGCM76				HHPEN62					HHPGO40			HHPGO40					HHPGO40					HILCF66	

WUblastx 64
WUblastx (Q9HD89) CYSTEINE- .64 RICH SECRETED
PROTEIN (C/EBP- EPSILON REGULATED MYEL
WUblastx (Q9HD89) CYSTEINE-
EPSILON ŘEGULATED MYEL
Jblastx
MANNOSIDE B-1,4-N-
ACETYLGLUCOSAMIN YLTRANS
WUblastx (Q9D399)
.64 6330415B21RIK PROTEIN.
WUblastx hypothetical protein
WUblastx (Q9CS66)
(FRAGMENT)
Jblastx
.64 FLJ23476 FIS, CLONE

				HSI14935				
HJPCP42	852573	415	WUblastx .64	(Q9VL06) CG5604 PROTEIN.	90TA6Ò	54%	19	315
HJPCP42	824612	416	WUblastx .64	cut1 protein - fission yeast (Schizosaccharomyces pombe)	pir A35694 A35694	42%	7	201
HKABZ65	862030	150	WUblastx .64	(Q96LB9) Peptidoglycan recognition protein-I-alpha precursor.	687960	99%	137	802 541
HKABZ65	665424	417	WUblastx .64	(Q96LB9) Peptidoglycan recognition protein-I-alpha precursor.	68796О	99%	69	794 533
HKACB56	554616	151	HMMER 2.1.1	PFAM: Kazal-type serine protease inhibitor domain	PF00050	76.3	114	266
			WUblastx .64	(P01001) ACROSIN INHIBITORS IIA AND IIB (BUSI-II).	IAC2_BOVIN	82%	96	266
HKACD58	1352202	152	WUblastx .64	(Q96BH2) Hypothetical 34.4 kDa protein.	О96ВН2	86% 28% 100%	786 46 125	1199
HKACD58	552465	418	WUblastx .64	(Q96BH2) Hypothetical 34.4 kDa protein.	Q96ВН2	86% 28% 88%	795 43 122	1208 183 724
HKAEV06	1352263	154	WUblastx .64	(Q9NVA4) CDNA FLJ10846 FIS, CLONE NT2RP4001373.	Q9NVA4	%66	501	1814
HKAEV06	638238	419	WUblastx .64	(Q9NVA4) CDNA FLJ10846 FIS, CLONE NT2RP4001373.	Q9NVA4	96% 100% 96%	367 197 480	459 367 1541
HKAFT66	946512	155	WUblastx	(Q9CPS2)	Q9CPS2 -	72%	29	61

231	828	19	231	828	555	314	843		879				167		1410			305	106	129	673	1366	905			949	713	
61	274	29	61	274	298	12	178		_				78		46			132	11	82	999	293	135			704	135	
64%	84%	72%	64%	83%	%08	84%	320.5		%66				%06		36%			45%	29%	20%	37%	37%	35%			38%	32%	
		Q9CPS2			Q9CPS2		PF00919		Q9BWZ5				O9BVG6		pir T16084 T16084			pir T16084 T16084					pir T16084 T16084			pir T16084 T16084		
4933428I03RIK	PROTEIN.	(Q9CPS2)	4933428103RIK	PROTEIN.	(Q9CPS2)	4933428103RIK PROTEIN	PFAM: Uncharacterized	protein family UPF0004	(Q9BWZ5) DJ1187J4.4	(CGI-05 PROTEIN	(LOC51654) SIMILAR	TO RAT CDK5 AC	(Q9BVG6) SIMILAR TO	CGI-05 PROTEIN.	hypothetical protein	F16H11.1 -	Caenorhabditis elegans	hypothetical protein	F16H11.1 -	Caenorhabditis elegans			hypothetical protein	F16H11.1 -	Caenorhabditis elegans	hypothetical protein	F16H11.1 -	Caenorhabditis elegans
.64		WUblastx	.64		WUblastx	.64	HMMER	2.1.1	WUblastx	.64			WUblastx	.64	WUblastx	.64		WUblastx	.64				WUblastx	.64		WUblastx	.64	
		420			421		156						422		157			423					424			425		
		886588			904790		876571						654871		1352286			701893					513190			383426		
		HKAFT66			HKAFT66		HKB1E57						HKB1E57		HKFBC53			HKFBC53					HKFBC53			HKFBC53		

832	830	582	1256	966	1052	562	462	586	609	1662	757	1051	397
53	99 55	262 201	1107	532	954	332	148	∞	31	1784	867	212	332
%66	82% 49%	28%	%86	26%	44%	71%	85%	49%	49%	73%	83%	%86	45%
Q9UHG2	Q9UHG2	Q8WWW1				Q9P059		Q8VD01	Q8VD01	Q8WY51	О9Н3С0	Q9NR71	О9ЛНЕЗ
(Q9UHG2) PROSAAS PRECURSOR (GRANIN- LIKE NEUROENDOCRINE PEPTIDE PRECUR	(Q9UHG2) PROSAAS PRECURSOR (GRANIN- LIKE NEUROENDOCRINE PEPTIDE PRECUR	(Q8WWW1) Smoothelin- B3				(Q9P059) HSPC323	(FRAGMENT).	(Q8VD01) Hypothetical 61.8 kDa protein.	(Q8VD01) Hypothetical 61.8 kDa protein.	1	(Q9H3C0) РRO0898.	(Q9NR71) MITOCHONDRIAL CERAMIDASE.	(Q9JHE3) NERUTAL
WUblastx .64	WUblastx .64	WUblastx	2			WUblastx	.64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx
158	426	159				160		161	427	163	164	165	429
877489	704088	625956				514788		1037919	880047	581399	527402	836041	600362
HKGDL36	HKGDL36	HKISB57				HKMLM11		HKMLP68	HKMLP68	HKMMW74	HKMND01	HLDBE54	HLDBE54

			.64	CERAMIDASE		72%	130	306
				(NEUTRAL CERAMIDASE).		78%	375	1028
HLDBE54	800678	430	HMMER 2.1.1	PFAM: Renal dipeptidase	PF01244	466.8	352	1410
				(Q9H4A9) PUTATIVE DIPEPTIDASE.	09Н4А9	100%	133	1590
HLDBX13	815665	166	WUblastx .64	(Q9H387) PRO2550.	О9Н387	%09 %9L	1764	1681
	847397	168	WUblastx .64	(Q9BXJ8) TRANSMEMBRANE PROTEIN INDUCED BY TUMOR NECROSIS FACTOR ALPHA	Q9BXJ8	100%	28	423
HLDQR62	753742	169	WUblastx .64	(Q9NQW2) PROGRESSIVE ANKYLOSIS-LIKE PROTEIN.	Q9NQW2	100%	376	382
НГДОП79	740755	170		(075477) KE04P.	075477	100%	105	1142
HLDRM43	846330	171	WUblastx .64	(Q96NZ9) Proline-rich acidic protein.	6ZN96Ò	100%	24	476
HLDRM43	638939	431		(Q96NZ9) Proline-rich acidic protein.	6ZN96Ò	100%	164	616
HLDRP33	647430	172	WUblastx .64	(Q9H743) CDNA: FLJ21394 FIS, CLONE COL03536.	Q9H743	38%	340	278 489
HLHFP03	460467	174	WUblastx .64	(Q9WVC2) LY- 6/NEUROTOXIN HOMOLOG (ADULT	Q9WVC2	81%	224	571

	636	919		490	151	229		740	2	-172	•		922		096	123				1768	969	855	517	322
	571	ور 		173	35	2	, ,	579	<u> </u>	40			123		226	85	-	-		683	295	781	440	35
	95%	93%		32%	22.3	93%		%08	•	143.1	-		%66		94%	100%				%66	%66	40%	42%	95%
	Q96N65			AAL78047	PF01569	Q9D4F2	,	9НО96О		PF00076			9НО96О		Q9NY26					978Н6О				
MALE HIPPOCAMPUS CDNA, RIKEN	(Q96N65) CDNA	FLJ31349 fis, clone MESAN2000092,	moderately similar to	(AAL78047) Envelope protein.	PFAM: PAP2 superfamily	(Q9D4F2)	4932443D16RIK PROTEIN	(O96DH6) Hypothetical	35.2 kDa protein.	PFAM: RNA recognition	motif. (a.k.a. RRM, RBD,	or RNP domain)	(Q96DH6) Hypothetical	35.2 kDa protein.	(Q9NY26) IRT1	PROTEIN (SIMILAR TO	ZINC/IRON	REGULATED	TRANSPORTER-LIK	(Q9H8L6) CDNA	FLJ13465 FIS, CLONE	PLACE1003493,	WEAKLY SIMILAR TO	END
	WUblastx	4 0.		WUblastx .64	HMMER 2.1.1	WUblastx	.64	WUblastx	.64	HMMER	2.1.1		WUblastx	.64	WUblastx	.64				WUblastx	.64			
	176			178	179			180		433					181					182				
	791828			543017	699812			1087335		1047690					629552					588485				
	нгісо90			HLTEJ06	HLTHR66			HLTIP94		HLTIP94					HLWAA17					HLWAA88				

434
.64 FLJ13465 FIS, CLONE PLACE1003493,
WEAKLY SIMILAR TO END
183 WUblastx (Q9GZP9) F-LAN-1 .64 (HYPOTHETICAL TRANSMEMBRANE
184 HMMER PFAM: C1q domain 2.1.1
WUblastx (Q9BXI9) .64 COMPLEMENT-C1Q TUMOR NECROSIS FACTOR-RELATED PROTEIN.
Jblastx
.64 (ADKACALIN) (AAAS
PROTEIN)
(PROTEIN FOR MGC:
blastx
.64 FLJ32172 fis, clone PLACE6000555.
187 WUblastx (AAH06651) Similar to

	FLJ23153					
WUblastx	 Ξ	al protein	pir T47139 T47139	87%	394	417
.64	DKFZp76	DKFZp761P2414.1 -		100%	152	232
	human			94%	228	395
WUblastx	(AAH0772	(AAH07725) Ceroid-	AAH07725	95%	186	449
.64	lipofuscino (epile	lipofuscinosis, neuronal 8 (epile		100%	427	1041
WUblastx .64	(AAL84703 beta subunit	(AAL84703) Citrate lyase beta subunit.	AAL84703	%66	4	1023
WUblastx	(AAL8470	(AAL84703) Citrate lyase	AAL84703	100%	3	440
.64	-	it.		79%	372	920
WUblastx .64	$\overline{}$	(Q8WZ81) Chromosome	Q8WZ81	%56	36	737
WUblastx	hypothetical protein	al protein	pir T42663 T42663	95%	155	325
199	DKFZp434N0615.1	4N0615.1 -		45%	298	363
	human (fragment)	gment)		33%	248	316
				31%	345	962
			_	52%	877	984
				76%	369	764
				25%	158	298
				31%	318	818
				%29	306	956
WUblastx	(Q9Y639)	(Q9Y639) STROMAL	Q9Y639	%08	36	158
49	CELL-DERIVED RECEPTOR-1 AI	CELL-DERIVED RECEPTOR-1 ALPHA.				
Jblastx	(Q9H651) CDNA:		О9Н651	%66	34	969
.64	FLJ22604 FI HSI04630 (B	FLJ22604 FIS, CLONE HSI04630 (BBP-LIKE				
WUblastx	(Q9H743) CDNA:	cDNA:	Q9H743	%99	1189	1497

1110	1494	1107	350	39	1019	805	525		·	350		544	381	489	1225	1346	1053	845				104	721		221	405	844
931	1186	928	421	161	1075	1041	40			781		464	340	367	1341	1414	1244	69				09	107		183	229	338
999	64%	26%	%05	47%	21%	39%	%66			83%		64%	78%	462	%99	%09	%95	%68				73%	%66		100%	72%	100%
	Q9H743		pir E41925 E41925		Q14713		0MZD6O			095662		Q9H8K5			Q9H743			бар				Q9BT67			Q9BT67		
FLJ21394 FIS, CLONE COL03536.	(Q9H743) CDNA:	FLJ21394 FIS, CLONE COL03536.	hypothetical protein 3 -	human	(Q14713) POT. ORF V.		(Q9GZW0) DJ604K5.1	(15 KDA	SELENOPROTEIN).	(095662) POT. ORF VI	(FRAGMENT).	(Q9H8K5) CDNA	FLJ13501 FIS, CLONE	PLACE1004815.	(Q9H743) CDNA:	FLJ21394 FIS, CLONE	COL03536.	(Q9EQH8) NEDD4 WW	DOMAIN-BINDING	PROTEIN 5	(FRAGMENT).	(Q9BT67) UNKNOWN	(PROTEIN FOR	MGC:10924).	(Q9BT67) UNKNOWN	(PROTEIN FOR	MGC:10924).
.64	WUblastx	.64 49:	WUblastx	.64	WUblastx	.64	WUblastx	.64		WUblastx	.64	WUblastx	.64		WUblastx	.64		WUblastx	.64			WUblastx	.64		WUblastx	.64	
	438		439		200		201			203		441			204			205				442			443		
	895429		904241		560229		383470			1127691		1028961			799540			872208				723302			778820		
	HMSDL37		HMSDL37		HMSFI26		HMSGT42			HMSHS36		HMSHS36			HMSKC04			HMUAP70				HMUAP70			HMUAP70		

HMUAP70	674913	444	WUblastx	(Q9BT67) UNKNOWN	Q9BT67	 %86	209	379
			.64			94%	109	216
				MGC:10924).		82%	62	112
HMUAP70	646810	445	WUblastx	(Q9BT67) UNKNOWN	Q9BT67	73%	09	104
			.64	(PROTEIN FOR		%96	107	583
				MGC:10924).		•		
HMUAP70	381964	446	WUblastx	(Q9BT67) UNKNOWN	Q9BT67	%98	09	104
			.64	PROTEIN FOR		%66	106	720
				MGC:10924).				
HMVBS81	639203	206	WUblastx	(095070) 54TMP.	095070	100%	10	450
	-		.64					1
HMWFT65	562063	208	WUblastx	(Q96AZ2) Similar to	Q96AZ2	%19	1342	1205
		_	.64	hypothetical protein FLJ21463.				
HMWGY65	1308287	209	WUblastx	(Q8VCP9) RIKEN cDNA	Q8VCP9	%99	42	1442
-			.64	1200003C23 gene.				
HMWGY65	794987	447	WUblastx	(O8VCP9) RIKEN cDNA	Q8VCP9	28%	542	1438
			.64	1200003C23 gene.		65%	42	969
HNEEB45	1036397	211	WUblastx	hypothetical protein 3 -	pir E41925 E41925	78%	861	626
		i i	64	human		39%	523	717
						44%	548	862
HNFFC43	753337	213	WUblastx	(0969J4) Lipocalin-1	096914	%16	319	453
)			.64	interacting membrane	•	%99	428	692
				recentor (Lipocalin-		87%	651	839
				interac		%66	903	1517
HNFIY77	634551	214	WUblastx	(08WXE6) KCCR13L.	Q8WXE6	%96	998	1030
		i	.64		,	%66	105	998
HNFJF07	577013	215	WUblastx	(Q8WYX2) Hypothetical	Q8WYX2	%59	585	457
			.64					700
HNGAK47	561488	216	WUblastx	(Q96EF8) Unknown	Q96EF8	33%	12	700

			.64	(protein for MGC:21495).		31%	12	206
						20%	492	617
						34%	492	557
						25%	486	695
						39%	190	2
						29%	537	487
HNGEP09	499076	219	WUblastx	(AAK55521) PRO0764.	AAK55521	21%	965	861
			.64			53%	1021	126
						20%	867	715
HNGIJ31	519120	221	WUblastx	(Q9N083) UNNAMED	C80N6O	73%	995	610
	-		.64	PORTEIN PRODUCT.		24%	615	725
						%99	454	561
HNGJE50	561568	222	WUblastx	(Q9HBS7)	Q9HBS7	64%	1028	945
			.64	HYPOTHETICAL 14.2		62%	616	734
				KDA PROTEIN.				
HNG0112	1041375	225	WUblastx	collagen alpha 1(VIII)	pir A34246 A34246	31%	1067	2002
			.64	chain precursor - rabbit				
HNGOM56	836064	226	WUblastx	(Q96MM0) CDNA	0ММ960	38%	577	744
			.64	FLJ32172 fis, clone		28%	714	953
				PLACE6000555.			٠	
HNHEU93	634851	229	WUblastx .64	(Q9H387) PRO2550.	О9Н387	%19	741	418
HNHFM14	664507	230	WUblastx	(Q9N8S9) POSSIBLE	6S8N6O	74%	9	122
			.64	(HHV-6) U1102,	,	45%	17	223
				VARIANT A DNA,		63%	11	124
				COMPLETE VIRION		19%	6	110
				GENOM		16%	6	122
HNHF029	463568	231	WUblastx	(Q9NX85) CDNA	58XN6D	%69	522	969
			.64	FLJ20378 FIS, CLONE				
				MAIOUSO.				

1674 1553	552	921	713	894	498	625	917	792	915	791	595	552	462	839	286	1201	150	i	992	544	1206	154	973	887	378	1187	138	200	168
1543	334	949	645	844	331	353	828	721	781	558	401	283	379	486	145	1001	7		516	149	1096	11	824	285	133	1077	1	243	13
79%	76%	999	999	52%	73%	29%	20%	%0 <i>L</i>	48%	20%	35%	31%	20%	61%	%66	762	%56		%46	%16	29%	%56	%0 <i>L</i>	95%	84%	29%	%16	%86	33%
Q9P195	O60448														Q96F65				Q96F65	•			Q96F65	,				Q96AA3	
(Q9P195) PRO1722.	(060448) NEURONAL	THREAD PROTEIN	AD7C-NTP.												(096F65) Similar to	RIKEN CDNA	0610031J06 gene	(Fragment).	(096F65) Similar to	RIKEN CDNA	0610031J06 gene	(Fragment).	(Q96F65) Similar to	RIKEN cDNA	0610031J06 gene	(Fragment).		(Q96AA3) Putative	endoplasmic reticulum
WUblastx 64	WUblastx	.64				_									WUblastx	.64			WUblastx	.64			WUblastx	.64				WUblastx	.64
232	233														235				453				454					236	
895462	843488														1310821				796807				590738					545534	
HNHNB29	HNHOD46														HNTBI26				HNTB126				HNTBI26					HNTBL27	

711	261	1037		1316		218			495	3//		1021	-		1	278			781				1500		815		1499
646	13	282		111		63			370	12		1119	.,-			370	276		104	_			43		288		42
40%	%96	137.5		100%		23.2			%56	100%		100%				36%	54%		100%	_			85%		189.8		85%
		PF00001		Q9H1Y3		PF00001			Q9H1Y3			Q9H1S5				pir S23650 S23650			Q9Y2Y6				MTN3_HUMAN		PF00092		MTN3 HUMAN
miltispan transmembrane	municipal dansmir	PFAM: 7 transmembrane	receptor (rhodopsin family)	(Q9H1Y3) DJ317G22.2	(ENCEPHALOPSIN)	PFAM: 7 transmembrane	receptor (rhodopsin	family)	(Q9H1Y3) DJ317G22.2	(ENCEPHALOPSIN)	(PANOPSIN).	(Q9H1S5) BA110H4.2	(SIMILAR TO	MEMBRANE	PROTEIN).	retrovirus-related	hypothetical protein II -	human 1	(Q9Y2Y6) TADA1	PROTEIN	(DKFZP564K1964	PROTEIN).	(015232) MATRILIN-3	PRECURSOR.	PFAM: von Willebrand	factor type A domain	(015232) MATRILIN-3
		╁─	2.1.1	WUblastx	.64	HMMER	2.1.1		WUblastx	.64		WUblastx	.64			WUblastx	.64		WUblastx	.64			WUblastx	.64	HMMER	2.1.1	WUblastx
		237				455						240				242			243				244		458		
		1160395				853373						422913				834907			634994				1184465		919896		
		HNTCE26				HNTCE26						HODDN92				HODGE68			HOEDB32				HOFM033	,	HOFM033	, 	

	737	857	877		911	327	1303		1312			361	_		757			1232		1232			311		918	341	
	318	72	1584		937	914	290	-	 &3			8 3			1494		,	336		129			192		316	— ⊗	
	162.2	81%	81%		%88	%66	619		87%			%59	_					496.2		 %66			22.3		87%		
	PF00092	MTN3_HUMAN	MTN3 HUMAN		Q8WUF2		PF00026		pir A25771 KHHUD			pir A25771 KHHUD			pir A25771 KHHUD			PF00026		pir A25771 KHHUD			PF00112		BAB22302		
PRECURSOR.	PFAM: von Willebrand	(O15232) MATRILIN-3	PRECURSOR.	PRECURSOR.	(Q8WUF2) Hypothetical	23.7 kDa protein.	PFAM: Eukaryotic	aspartyl protease	cathepsin D (EC 3.4.23.5)	precursor [validated] -	human	cathepsin D (EC 3.4.23.5)	precursor [validated] -	human	cathepsin D (EC 3.4.23.5)	precursor [validated] -	human	PFAM: Eukaryotic	aspartyl protease	cathepsin D (EC 3.4.23.5)	precursor [validated] -	human	PFAM: Papain family	cysteine protease	(BAB22302) Adult male	kidney cDNA, RIKEN	full-lengt
.64	HMMER	WUblastx	.64 WI Iblacty	.64	WUblastx	.64	HMMER	2.1.1	WUblastx	.64		WUblastx	.64		WUblastx	.64		HMMER	2.1.1	WUblastx	.64		HMMER	2.1.1	WUblastx	.64	
	459		460	9	461		245					462			463			464					247				
	906694		000630	702027	702186		911180					905365			892308			892291					931871				
	НО ЕМ ОЗЗ		HOEMO22	HOFINIQSS	HOFMQ33	,	HOFMT75					HOFMT75			HOFMT75			HOFMT75					HOFOC73				

878863 467 (Cathepsin Z.) BAB55004 100% 2291 878863 467 WUblastx (BAB55004) CDNA BAB55004 100% 2291 2 FLH337 fis, clone FLH337 fis, clone 100% 35 2 FY9891 248 WUblastx (Q8WUD4) Similar to (Q8WUD4 100% 35 827481 249 WUblastx (O8WUD4) Similar to (O8S065) TEN O9S965 100% 221 REPEAT DOMAINS REPEAT DOMAINS PROTEIN PRECURSOR. 100% 324 815682 468 WUblastx (O9S965) TEN 31% 416 REPEAT DOMAINS REPEAT DOMAINS 99% 230 RS8338 469 WUblastx (CAC37794) H-I(3)mbt- CAC37794 100% 324 64 INPOPIEIN PRECURSOR. Q9BQI2 96% 40 858338 469 WUblastx (Q9BQI2) Q9BQI2 96% 41 CADA PROTEIN. CADA PROTEIN. A09C028 40% 211: 40% 21 RS4234 252 WUblastx (Q9B8Y9)	HOFOC73	620206	465	WUblastx	(CAC09370) D1543119 3	CAC09370	%9 <i>L</i>	64	414
i 878863 467 WUblastx (BABŠS004) CDNA BABSS004 100% 2291 2 579891 248 WUblastx (Q8WUD4) Similar to (Q8WUD4 100% 35 5 579891 248 WUblastx (Q85965) TEN 095965 100% 221 5 827481 249 WUblastx (O95965) TEN 095965 100% 221 5 815682 468 WUblastx (O95965) TEN O95965 100% 1623 6 815682 468 WUblastx (O95965) TEN O95965 100% 324 1352356 250 WUblastx (O95965) TEN O95965 100% 324 1352356 250 WUblastx (CA23794) H-I(3)mbr- CAC37794 100% 324 1352356 250 WUblastx (Q9BQ12) Q9BQ12 96% 40 1352356 250 WUblastx (Q9BQ12) Q9BQ12 96% 40 12.1.1 KDA PROTEIN			<u> </u>		(cathepsin Z).		84%	411	920
2 FLJ14357 fis, clone HEMBA1000005, h 35 2 579891 248 WUblastx (Q8WUD4) Similar to G8WUD4 100% 35 5 827481 249 WUblastx (O95965) TEN O95965 100% 221 5 827481 249 WUblastx (O95965) TEN O95965 100% 1623 5 815682 468 WUblastx (O95965) TEN O95965 100% 1623 5 815682 468 WUblastx (O95965) TEN O95965 100% 320 64 REPEAT DOMAINS REPEAT DOMAINS A40% 326 1352356 250 WUblastx (CAC37794) H-I(3)mbr CAC37794 100% 324 64 Ilke protein A54 HYPOTHETICAL 69.3 A90 406 858338 469 WUblastx (O98012) Q90028 98% 61 A54 BROTEIN BROTEIN A99% 21 A64 BROTEIN BROTEIN A99% 21 BROTEIN BROTEIN	73	878863	467	WUblastx	(BAB55004) CDNA	BAB55004	100%	2291	819
2 579891 248 WUblastx (MWUDA) Similar to a constraint of a constrai				.64	FLJ14357 fis, clone				
2.48 WUblastx (Q8 WUD4) Similar to 27/9891 Q8 WUD4 35 5 827481 249 WUblastx (O95965) TEN (O96028) TEN (O	67/1	10001	6	1 11 11 11	MEMBATOUOUS, II	7 di il	7000+		
5 KAKEN CLIVAA CO0094L05 gene. CO10094L05 gene. CO10094Gene.	79 <i>∧</i>	1,7,9891	248	W Ublastx	(Q8WUD4) Similar to	Q8WUD4	100%	35	130
5 827481 249 WUblastx (095965) TEÑ 095965 100% 221 5 64 REPEAT DOMAINS REPEAT DOMAINS 100% 1623 5 815682 468 WUblastx (095965) TEN 095965 1100% 1623 5 815682 468 WUblastx (095965) TEN 095965 1162 6 1352356 250 WUblastx (CAC37794) H-(3)mbt- CAC37794 100% 324 1352356 250 WUblastx (CAG37794) H-(3)mbt- CAC37794 100% 324 64 HYPOTHETICAL 69.3 Q9BQ12 56% 406 64 HYPOTHETICAL 69.3 CAC37794 100% 211.5 100 2.1.1 KDA PROTEIN. Q9BQ12 96% 416 854234 252 WUblastx (O96028) WHSC1 O96028 143 8 64 PROTEIN. Q9D8Y9 Q9D8Y9 61 8 64 PROTEIN. A99%				. 04	KINEIN CUNA 2700094L05 gene.				
Second Properties Second Properties Second Properties	155	827481	249	WUblastx	(095965) TEN	095965	100%	221	1702
5 REPEAT DOMAINS PROTEIN PRECURSOR. REPEAT DOMAINS 5 815682 468 WUblastx (095965) TEN 095965 100% 1623 1352356 250 WUblastx (CAC37794) H-I(3)mbt- CAC37794 CAC37794 100% 324 858338 469 WUblastx (CAC37794) H-I(3)mbt- CAC37794 CAC37794 406 324 858338 469 WUblastx (O9BQI2) Q9BQI2 56% 406 A70 HMMER PFAM: SET domain PF00856 211.5 100 WUblastx (Q9BQ28) WHSC1 Q96028 98% 61 WUblastx (Q9D879) Q9D879 85% 468 B64 PROTEIN. PROTEIN. 49% 2 64 PROTEIN. Q9D879 86% 468 854234 252 WUblastx (Q9D879) Q9D879 86% 143 864 PROTEIN. PROTEIN. A64 PROTEIN. A64 BROTEIN. A64 BROTEIN. A71 BROTEIN. <				.64	INTEGRIN EGF-LIKE				
5 815682 468 WUblastx (095965) TEN 095965 100% 1623 1352356 .64 INTEGRIN EGF-LIKE REPEAT DOMAINS 130% 230 230 1352356 250 WUblastx (CAC37794) H-I(3)mbt- CAC37794 CAC37794 100% 324 858338 469 WUblastx (Q9BQ12) 26% 406 KDA PROTIEIN HYPOTHETICAL 69.3 26% 41 KDA PROTIEIN PROTEIN PROTEIN 61 WUblastx (Q9BQ28) WHSC1 096028 98% 61 WUblastx (Q90828) WHSC1 096028 98% 61 WUblastx (Q90828) WHSC1 096028 98% 61 64 PROTEIN Q9D8Y9 85% 468 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 86% 143 8 64 PROTEIN PROTEIN A9% 27 8 64 PROTEIN A6 PROTEIN A6					REPEAT DOMAINS				
5 815682 468 WUblastx (095965) TEN 095965 100% 1623 1352356 .64 INTEGRIN EGF-LIKE 99% 230 1352356 250 WUblastx (CAC37794) H-I(3)mbt- CAC37794 100% 324 858338 469 WUblastx (Q9BQ12) Q9BQ12 96% 406 A70 HMMER PFAM: SET domain PF00856 211.5 100 854234 25.1.1 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 86% 143 8 64 PROTEIN. PROTEIN. PROTEIN. 49% 2 8 64 PROTEIN. PROTEIN. 468 143 8 64 PROTEIN. PROTEIN. 211 8 64 PROTEIN. PROTEIN. 468 8 64 PROTEIN. 211					PROTEIN PRECURSOR.				
1352356 250 WUblastx CAC37794 H-l(3)mbt- H-l(H55	815682	468	WUblastx	(095965) TEN	\$96560	100%	1623	1712
1352356 250 WUblastx CAC37794) H-I(3)mbt- CAC37794 100% 324 1352356 250 WUblastx (CAC37794) H-I(3)mbt- CAC37794 100% 324 858338 469 WUblastx (Q9BQ12) Q9BQ12 56% 406 2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 2 857453 470 HMMER PFAM: SET domain PF00828 98% 61 4 64 PROTEIN. Q9D879 88% 468 143 8 644 1810018L05RIK PROTEIN. PROTEIN. 697.3 -733 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733				.64	INTEGRIN EGF-LIKE		31%	416	1576
1352356 250 WUblastx CAC37794) H-I(3)mbt- CAC37794 H-I(3)mbt- CAC37794 100% 324 858338 469 WUblastx (Q9BQ12) Q9BQ12 56% 406 2 64 HYPOTHETICAL 69.3 Q9BQ12 56% 406 4 A70 HMMER PFAM: SET domain PF00856 211.5 100 854234 25.1.1 WUblastx (O96028) WHSC1 O96028 98% 61 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 864 1810018L05RIK PROTEIN. 86% 143 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733					REPEAT DOMAINS		%66	230	1621
1352356 250 WUblastx (CAC37794) H-I(3)mbt- GAC37794 CAC37794 100% 324 858338 469 WUblastx (Q9BQ12) Q9BQ12 96% 406 2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 854234 252 WUblastx (Q9028) WHSC1 Q90828 88% 468 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 86% 143 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733					PROTEIN PRECURSOR.		40%	326	1426
858338 469 WUblastx (Q9BQ12) Q9BQ12 56% 406 2 .64 HYPOTHETICAL 69.3 PF00856 211.5 100 2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 2 2.1.1 WUblastx (O96028) WHSC1 O96028 98% 61 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 64 1810018L05R1K PROTEIN. 86% 143 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733	182	1352356	250	WUblastx	(CAC37794) H-l(3)mbt-	CAC37794	100%	324	2414
858338 469 WUblastx (Q9BQ12) Q9BQ12 56% 406 1.64 HYPOTHETICAL 69.3 F00802 406 41 2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 2 2.1.1 WUblastx (O96028) WHSC1 O96028 98% 61 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 854234 252 WUblastx (Q9D8Y9) PROTEIN. 86% 143 864 1810018L0SRIK PROTEIN. 86% 143 98 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733				.64	like protein.				
2 857453 470 HMMER PFAM: SET domain PF00856 41 2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 2 2.1.1 WUblastx (O96028) WHSC1 O96028 98% 61 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 468 468 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 86% 468 86% 1810018L05RIK PROTEIN. PROTEIN. 86% 143 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733	182	828338	469	WUblastx	(Q9BQI2)	Q9BQI2	%95	406	285
2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 2 2.1.1 2.1.1 98% 61 WUblastx (O96028) WHSC1 O96028 98% 61 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 864 1810018L05RIK PROTEIN. 86% 143 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733				.64	HYPOTHETICAL 69.3		%96	41	496
2 857453 470 HMMER PFAM: SET domain PF00856 211.5 100 8 2.1.1 2.1.1 096028 WUblastx 64 PROTEIN. 64 PROTEIN. 49% 61 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 468 143 8 64 1810018L05RIK 86% 143 PROTEIN. PROTEIN. 697.3 -733					KDA PROTEIN.				
854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 64 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 86% 143 PROTEIN. PROTEIN. 86% 143 8 614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733	3182	857453	470	HMMER 2.1.1	PFAM: SET domain	PF00856	211.5	100	489
854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 854234 252 WUblastx (Q9D8Y9) Q9D8Y9 86% 143 86% 1810018L05RIK 86% 143 PROTEIN. PROTEIN. 697.3 -733				WUblastx	(096028) WHSC1	096028	%86	61	1029
854234 252 WUblastx (Q9D8Y9) Q9D8Y9 85% 468 64 1810018L05RIK 86% 143 PROTEIN. PROTEIN. 697.3 -733				.64	PROTEIN.		46%	2	166
614040 253 HMMER PFAM: ATP-sulfurylase PF01747 86% 143	125	854234	252	WUblastx	(Q9D8Y9)	6A8Q6D	%58	468	593
614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733				.64	1810018L05RIK		%98	143	544
614040 253 HMMER PFAM: ATP-sulfurylase PF01747 697.3 -733					PROTEIN.				
	,D58	614040	253	HMMER 2.1.1	PFAM: ATP-sulfurylase	PF01747	697.3	-733	-1719

7601 35	?	498	498	498 57 57 128	498 498 128 127 507 401	498 498 128 127 507 401 1138	498 498 128 127 507 507 401 1138 633	498 498 128 127 507 401 1138 633 633	498 128 128 507 507 507 617 633 24 570 1317	498 128 127 507 401 1138 633 24 570 1317	498 128 128 57 507 401 1138 633 24 570 1317 155	498 128 127 507 401 1138 633 24 570 617 633 1317 1 155 154	498 498 128 127 507 401 1138 633 24 570 617 633 1317 1 154 155 154
987 100%													
pir JW0087 JW0087		Q96NR6	Q96NR6 AAH07349	Q96NR6 AAH07349 Q9CQS3	Q96NR6 AAH07349 Q9CQS3 Q9CQS3	Q96NR6 AAH07349 Q9CQS3 Q9CQS3	Q96NR6 AAH07349 Q9CQS3 Q9CQS3 Q9NX17	Q96NR6 AAH07349 Q9CQS3 Q9CQS3 Q9NX17	Q96NR6 Q9CQS3 Q9CQS3 Q9NX17 Q9NX17	Q96NR6 AAH07349 Q9CQS3 Q9CQS3 Q9NX17 O60448	Q96NR6 AAH07349 Q9CQS3 Q9CQS3 Q9NX17	Q96NR6 Q9CQS3 Q9CQS3 Q9NX17 Q9NX17	Q96NR6 AAH07349 Q9CQS3 Q9CQS3 Q9NX17
hoadenosine-5'- sulfate synthetase		ane .				. ш	. 8 3	. E F	. 8 3		. E F		. E H
WUblastx 3'-p.	blastx	.64 FL. BR							- 	- - - - - - - - -	- - - - - - - - - - 	- - 	- - - - - - - - - -
472	255		256	256	256 257 474	256 257 474 258	256 257 474 474 258	256 257 474 474 258 259	256 257 258 258 259	256 257 258 258 259	256 257 258 258 259	256 257 258 258 259	256 257 258 258 259
383513	520202		535710	535710	535710 1310868 590741	535710 1310868 590741 1042309	535710 1310868 590741 1042309 685699	535710 1310868 590741 1042309 685699	535710 1310868 590741 1042309 685699	535710 1310868 590741 1042309 685699	535710 1310868 590741 1042309 685699	535710 1310868 590741 1042309 685699	535710 1310868 590741 1042309 685699
HOSFD58	HPEAD79		HPFCL43	HPFCL43 HPIBO15	HPFCL43 HPIBO15 HPIBO15	HPFCL43 HPIBO15 HPIBO15 HPICB53	HPFCL43 HPIBO15 HPIBO15 HPICB53 HPJBI33	HPFCL43 HPIBO15 HPICB53 HPJB133	HPFCL43 HPIBO15 HPICB53 HPICB53	HPFCL43 HPIBO15 HPIBO15 HPICB53 HPJBI33	HPFCL43 HPIBO15 HPICB53 HPJB133	HPFCL43 HPIBO15 HPICB53 HPJBI33	HPFCL43 HPIBO15 HPICB53 HPJB133

942	999	099	1312	1017	336	957	1254	284
988	163	157	62	70 490	124	157	94	ε
47%	100%	100%	%66	83% 51%	%56	336.4	%66	%86
	Q9NP77	Q9NP <i>77</i>	pir T08724 T08724	AAH08720	Q91XD7	PF00481	Q9НАҮ8	Q9НАҮ8
	(Q9NP77) CDNA FLJ10947 FIS, CLONE PLACE1000066, WEAKLY SIMILAR TO SSU	(Q9NP77) CDNA FLJ10947 FIS, CLONE PLACE1000066, WEAKLY SIMILAR TO SSU	hypothetical protein DKFZp566D213.1 - human	(AAH08720) Unknown (protein for MGC:8447).	(Q91XD7) Unknown (protein for MGC:18896).	PFAM: Protein phosphatase 2C	(Q9HAY8) SER/THR PROTEIN PHOSPHATASE TYPE 2C BETA 2 ISOFORM (PROTEIN	(Q9HAY8) SER/THR PROTEIN PHOSPHATASE TYPE 2C BETA 2 ISOFORM (PROTEIN
	WUblastx .64	WUblastx .64	WUblastx .64		WUblastx .64	HMMER 2.1.1	WUblastx .64	WUblastx .64
	261	479	263	480	481	264		482
	846357	639118	1352342	844216	484735	829136		720095
	HPMDK28	HPMDK28	HPRAL78	HPRAL78	HPRAL78	HPRBC80		HPRBC80

	5 1183	1 511			4 371			0 357	3 493	2 253				6 253			2 1472				99 1439				1 519	9 476	-	2 755
	1296		i	647	144	247		130	233	1452				1596			132			41				507		629		582
34%	55%	100%		63%	48%	93%	63%	48%	92%	%86			82%	%86		%86	%66		i	%86	%66			%96	100%	47%		32
pir E41925 E41925		AAH25678		Q9HA75			Q9HA75	•		AAH08084			AAH08084			9X5Y6Q				9X5Y6Q				Q9Y646		Q9N032		PF00047
hypothetical protein 3 -	human	(AAH25678) Similar to	putative.	(Q9HA75) CDNA	FLJ12122 FIS, CLONE	MAMMA1000129.	(Q9HA75) CDNA	FLJ12122 FIS, CLONE	MAMMA1000129.	(AAH08084)	Hypothetical 50.4 kDa	protein.	(AAH08084)	Hypothetical 50.4 kDa	protein.	(Q9Y5X6) BLOOD	PLASMA GLUTAMATE	CARBOXYPEPTIDASE	PRECURSOR (EC 3.4.17	(Q9Y5X6) BLOOD	PLASMA GLUTAMATE	CARBOXYPEPTIDASE	PRECURSOR (EC 3.4.17	(Q9Y646)	AMINOPEPTIDASE.	(Q9N032) UNNAMED	PROTEIN PRODUCT.	PFAM: Immunoglobulin
WUblastx	.64	WUblastx	.64	WUblastx	.64		WUblastx	.64		WUblastx	.64		WUblastx	.64		WUblastx	.64			WUblastx	.64			WUblastx	.64	WUblastx	.64	HMMER
266		267		268			483			269			484		_	270				485				486		271		272
585702		658717		882176			588460			871221			706332			999228				730504				470546		567004		910133
HPZAB47		HRAAB15		HRABA80			HRABA80			HRACD15			HRACD15			HRACJ35				HRACJ35				HRACJ35		HRDFD27		HRGBL78

9 1085	15 596 547 588 587 625		489 698 3 341 59 496	7 786	7 1146	10 762	7 1056	418 576 581 748	678 707 605 682	
87%	94% 100%	%96	95% 29% 98%	%88	%96	%66	%56	%99 18%	%08 %08	
Q8WXH3	Q8WXH3	09ЕРР8	О8 МХН3	Q96A82	Q96ES0	Q96ES0	Q96ES0	Q9H728	Q9UI58	
WUblastx (Q8WXH3) FREB.	(Q8WXH3) FREB.	(Q9EPP8) VIRION- ASSOCIATED NUCLEAR-SHUTTLING PROTEIN (FRAGMENT).	(Q8WXH3) FREB.	(Q96A82) CDNA FLJ30106 fis, clone BNGH41000190, weakly similar to Rat	(Q96ES0) Unknown (protein for MGC:16944).	(Q96ES0) Unknown (protein for MGC:16944).	(Q96ES0) Unknown (protein for MGC:16944).	(Q9H728) CDNA: FLJ21463 FIS, CLONE COL04765.	(Q9UIS8) PRO0483 PROTEIN.	
WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	WUblastx .64	
	487	488	489	273	274	490	491	275	276	į
	904040	904621	863802	567005	1181699	1114849	1027712	827306	531973	
	HRGBL78	HRGBL78	HRGBL78	HROAJ03	HROAJ39	HROAJ39	HROAJ39	HROBD68	HSATR82	

				PROTEIN.				
HSAWD74	460527	278	WUblastx .64	(Q9NX85) CDNA FLJ20378 FIS, CLONE KAIA0536.	Q9NX85	67%	196	674
HSAWZ41	580872	279	WUblastx .64	(Q9H387) PRO2550.	Q9H387	81%	1386	1102
HSAXA83	545051	280	WUblastx .64	(Q9NRX6) PROTEIN X 013.	Q9NRX6	100%	92	313
HSAYB43	604143	281	WUblastx .64	(Q9N083) UNNAMED PORTEIN PRODUCT.	Q9N083	60%	1662	1573
HSDEK49	1352253	282	WUblastx .64	(Q9Y279) Z39IG PROTEIN PRECURSOR.	Q9Y279	100%	09	1256
HSDEK49	625998	493	HMMER 2.1.1	PFAM: Immunoglobulin domain	PF00047	18.7	225	470
			WUblastx .64	(Q9Y279) Z39IG PROTEIN PRECURSOR.	Q9Y279	%66 %88	444 126	1040 542
HSDFJ26	834619	283	WUblastx .64	(Q9BYJ0) KSP37.	Q9BYJ0	%66	66	191
HSDFJ26	836071	494	WUblastx .64	(Q9BYJ0) KSP37.	09ВУЈ0	100%	99	281
HSDSE75	545057	586	WUblastx .64	(O60245) PCDH7 (BH- PCDH)A.	060245	100%	10	702
HSDZR <i>57</i>	651375	287	WUblastx .64	(Q9NX00) CDNA FLJ20512 FIS, CLONE KAT09739.	00XN6O	100%	6	209
HSIDJ81	589447	288	WUblastx .64	(Q9H728) CDNA: FLJ21463 FIS, CLONE COL04765.	О9H728	74%	1289	966
HSKDA27	1352409	289	WUblastx .64	(BAB85613) URB.	BAB85613	83%	786	3635

		1718 1792			0691 6	1597 1671	146 1126	436 1311		825 730		730 536	344 2161		338 2155			327 611	356 171		383 454		371 2170			
%00	%09	52%	73%	32%	%69	32%	%89	%99		62%	53%	26%	100%		100%		73%	77%	85%		97.9		%96			
BAB85613					BAB85613		Q9CZY7	Q9CZY7	,	Q9P195			Q96FI8		Q96F18		O95LL0		pir T42734 T42734		PF00560		Q96CX1			
(BAB85613) URB.					(BAB85613) URB.		(Q9CZY7) 2610307O08RIK	(09CZY7)	2610307O08RIK PROTEIN.	(Q9P195) PRO1722.			(Q96FI8) Unknown	(protein for MGC:9160).	(Q96F18) Unknown	(protein for MC.9160).	(Q95LL0) Hypothetical	11.3 kDa protein.	cytoplasmic linker protein	CLIP-115 - rat	PFAM: Leucine Rich	Repeat	(Q96CX1) Similar to	RIKEN cDNA	2610528G05 gene	(Fragment).
WUblastx					WUblastx		WUblastx .64	WUblastx		blastx			WUblastx	.64	WUblastx	÷0.	WUblastx	.64	WUblastx	.64	HMMER	2.1.1	WUblastx	.64		
496					497		290	498		292			297		501		536		300		301					
1074734					872570		676075	409905		467397			1352343		845666		413246		898965		847358					
HSKDA27					HSKDA27		HSKGN81	HSKGN81		HSNAD72			HSSGD52		HSSGD52		HSUBW09		HSVBU91		HSYAV50					

HTAEE28	(01)(00)	71700	78%	319	11911
882919 502 WUblastx .64 864120 503 WUblastx .64 206980 304 HMMER .2.1.1 WUblastx .64 8347090 309 WUblastx .64 410582 311 WUblastx .64 410582 311 WUblastx .64 504	(470444)	ZILGC			
882919 502 WUblastx .64 2 206980 304 HMMER .64 2 206980 304 HMMER .64 836072 308 WUblastx .64 847090 309 WUblastx .64 847090 309 WUblastx .64 410582 311 WUblastx .64 919911 312 WUblastx .64 .64 .64 .64 .64 .64 .64 .64	4932408F18RIK PROTEIN.				
864120 503 WUblastx .64 2 206980 304 HMMER .2.1.1 WUblastx .64 836072 308 WUblastx .64 .64 410582 311 WUblastx .64 .64 410582 311 WUblastx .64 .64 504 604 604 604 604 604 604 604 604 604 6	1.—	Q9D4I2	%8 <i>L</i>	372	617
864120 503 WUblastx .64 2 206980 304 HMMER 2.1.1 WUblastx .64 836072 308 WUblastx .64 834931 310 WUblastx .64 410582 311 WUblastx .64 919911 312 WUblastx .64 .64 564 772559 313 WUblastx .64 .64					
864120 503 WUblastx .64 2 206980 304 HMMER 2.1.1 WUblastx .64 836072 308 WUblastx .64 .64 410582 311 WUblastx .64 410582 311 WUblastx .64 .64 410582 311 WUblastx .64 .64 772559 313 WUblastx .64				,	
2 206980 304 HMMER 2.1.1 WUblastx .64 .64 .64 .64 .64 .64 .64 .64 .64 .64		Q9D4I2	%9L	142	768
2 206980 304 HMMER 2.1.1 WUblastx 64 836072 308 WUblastx .64 .64 .64 .64 .110582 311 WUblastx .64 .64 .64 .64 .64 .772559 313 WUblastx .64 .64 .64		-	-		-
2 206980 304 HMMER 2.1.1 WUblastx .64 836072 308 WUblastx .64 .64 .847090 309 WUblastx .64 .64 .64 .64 .64 .64 .64 .64 .64 .64	PROTEIN.				Š
836072 308 WUblastx 64 64 64 64 64 64 64 64 64 64 64 64 64	FR PFAM: Immunoglobulin	PF00047	48.5	200	902
836072 308 WUblastx 64 .64 .64 .64 .64 .64 .64 .64 .64 .64					
836072 308 WUblastx .64 .64 .64 .64 .64 .64 .64 .64 .64 .64		AAG49022	%66	29	952
836072 308 WUblastx .64 .64 .64 .64 .64 .64 .64 .64 .64 .64	adhesion molecule 2.				
847090 309 WUblastx .64 .64 .64 .64 .64 .64 .64 .64 .64 .64		AAH24188	100%	22	465
847090 309 WUblastx .64 834931 310 WUblastx .64 410582 311 WUblastx .64 919911 312 WUblastx .64 .64 .772559 313 WUblastx .64					
834931 310 WUblastx .64 410582 311 WUblastx .64 919911 312 WUblastx .64 .772559 313 WUblastx .64					
834931 310 WUblastx 64 410582 311 WUblastx .64 919911 312 WUblastx .64 .64 .64 .64	_	Q9JI83	34%	33	395
834931 310 WUblastx .64 410582 311 WUblastx .64 919911 312 WUblastx .64 .64 .64 .64				_	
834931 310 WUblastx .64 410582 311 WUblastx .64 .919911 312 WUblastx .64 .772559 313 WUblastx .64	SPECIFIC PROTEIN 1).				,
410582 311 WUblastx .64 919911 312 WUblastx .64 .772559 313 WUblastx .64	1stx (O75295) R27328_2.	075295	93%	23	268
919911 312 WUblastx .64 .772559 313 WUblastx .64 .64	1	Q9DAL9	44%	258	995
919911 312 WUblastx .64 .772559 313 WUblastx .64 .64		,			
919911 312 WUblastx .64 .772559 313 WUblastx .64					
772559 313 WUblastx .64		Q9NX17	. 52%	846	517
772559 313 WUblastx .64				,	
772559 313 WUblastx .64	KAT08285.				,
.04	astx (Q9P1H3) PRO1438.	Q9Р1Н3	%99	1045	911
	- 1		,000	643	400
HTLEP53 634852 314 WUblastx (Q8WTZ3) Hypo	astx (Q8WTZ3) Hypothetical	Q8WTZ3	0,00	243	499

			.64	27.2 kDa protein.		%89	908	534
I <u>``</u>	1035130	315	WUblastx .64	(Q9NY64) GLUCOSE TRANSPORTER.	Q9NY64	81%	3	149
83	838460	316	WUblastx .64	(Q96L02) Hypothetical 24.5 kDa protein.	Q96L02	99%	36 528	434
 	1046341	317	WUblastx	(Q96LS9) CDNA	6ST96Ò	20%	119	172
			.64	FLJ25101 fis, clone CBR01328.		%69	178	315
84	847904	508	WUblastx	ataxin 7 - human	pir T09193 T09193	%66	714	1196
			.64			31%	437	619
					-	47%	303	359
	_					28%	224	718
						%16	2	736
54	545067	322	WUblastx	(Q9HA67) CDNA	Q9HA67	73%	745	644
			.64	FLJ12155 FIS, CLONE		78%	870	757
				MAMMA10004/2.				
82,	854941	323	WUblastx .64	(095880) UNKNOWN.	095880	100%	2191	2577
99	566683	509	WUblastx	WUblastx (095880) UNKNOWN.	095880	100%	326	742
916	919916	324	HMMER	PFAM: PMP-	PF00822	81.5	127	099
			2.1.1					
				(P57739) CLAUDIN-2.	CLD2_HUMAN	100%	118	807
8	895024	510	HMMER	PFAM: PMP-	PF00822	55.9	120	200
			2.1.1	22/EMP/MP20/Claudin family		_ 1 = _ 1 = - 1		
			WUblastx 64	(P57739) CLAUDIN-2.	CLD2_HUMAN	%86	111	530
\dashv			.O.					

353	714	875	510	498	238	525	889	280	192	1990	89	299	94	295	1760	1498	1397	738		269	479	462
96	932	792	370	7	179	379	542	179	4	305	30	213	89	470	564	1397	1194	286		144	462	55
%96	20%	100%	92%	27%	35%	37%	79%	10%	496	%86	100%	100%	100%	100%	<u> </u> %66	28%	64%	100%		94%	100%	93%
CLD2_HUMAN	000172	Q9BTF2				-				Q96KR5				Q9BRH0		Q96NR6		6ZN96D		62N29	6ZN96D	
(P57739) CLAUDIN-2.	(O00172) LINE-1 REVERSE TRANSCRIPTASE (FRAGMENT).	(Q9BTF2) REC8P, A	MEIOTIC	RECOMBINATION	AND SISTER	CHROMATID	COHESION			(Q96KR5)	Leishmanolysin-like	peptidase, variant 2 (EC	3.4.24.36).	(Q9BRH0) SIMILAR TO	DKFZP727C091 PROTEIN.	(Q96NR6) CDNA	FLJ30278 fis, clone BRACE2002755.	(Q96NZ9) Proline-rich	acidic protein.	(Q96NZ9) Proline-rich acidic protein.	(Q96NZ9) Proline-rich	acidic protein.
	WUblastx .64	WUblastx	.64							WUblastx	.64			WUblastx	.64	WUblastx	.64	WUblastx	.64	WUblastx .64	WUblastx	.64
511	327	328								330				331		332		335		516	517	
880868	1008159	714344								620001				603918		838288		1352424		1300737	603538	
НТРІН83	HTTBS64	HTWDF76								HTXFL30				HTXJM03		HTXON32		HUKAH51		HUKAH51	HUKAH51	

HUSXS50	1352367	336	WUblastx .64	(Q9Y3II) F-BOX ONLY PROTEIN 7.	FBX7_HUMAN	100%	280	1845
HUSXS50	883176	518	WUblastx	(AAH08361) F-box only	AAH08361	%66	281	1069
			.64	protein 7.		45%	1566	1622
						100%	1067	1666
HUSXS50	655372	519	WUblastx	(AAH08361) F-box only	AAH08361	%LL	1	459
	-		.64	protein 7.		76%	43	219
						100%	317	700
HWAAD63	838626	338	HMMER	PFAM: Sodium/calcium	PF01699	62.8	346	453
			2.1.1	exchanger protein				
			WUblastx	(Q9HC58)	Q9HC58	%59	229	813
			.64	SODIUM/CALCIUM				
				EXCHANGER NCKX3.				
HWAAD63	833089	520	HMMER	PFAM: Sodium/calcium	PF01699	37.8	346	453
			2.1.1	exchanger protein				
			WUblastx	(Q9HC58)	09НС58	%8 <i>L</i>	229	453
			.64	SODIUM/CALCIUM		25%	429	969
				EXCHANGER NCKX3.		72%	533	814
HWAAD63	793875	521	HMMER	PFAM: Sodium/calcium	PF01699	113.7	336	773
			2.1.1	exchanger protein				
			WUblastx	(Q9HC58)	Q9HC58	%9 <i>L</i>	219	908
		•	.64	SODIUM/CALCIUM				
				EXCHANGER NCKX3.				
HWABY10	768334	339	WUblastx	(Q96AW1) Hypothetical	Q96AW1	100%	165	999
			.64	19.2 kDa protein.				
HWBCB89	1093347	341	WUblastx		BAB55294	100%	37	597
			.64					
				NT2RP4000259, w				
HWBCB89	886210	522	HMMER	PFAM: Glutathione	PF00255	170.2	104	433
			2.1.1	peroxidases				

FLJ14777 fis, clone NT2RP4000259, w (Q9N083) UNNAMED PORTEIN PRODUCT. (Q9NX85) CDNA FLJ20378 FIS, CLONE KAIA0536. (Q64150) NUCLEAR LOCALIZATION SIGNAL BINDING PROTEIN. (Q9UJ74) HYPOTHETICAL 36.0 KDA PROTEIN (C4.4A PROTEIN). PFAM: Integral membrane protein (AAH08596) Unknown (protein for MGC:16985). (Q96L11) Similar to RIKEN cDNA 1700034015 gene.				WUblastx	(BAB55294) CDNA	BAB55294	100%	35	595
N 12RF4000259, W					FLJ14777 fis, clone				
1028519			0, 0		(00) 1000 TB TT TE	2001600	707.5	1000	1617
1028519 343 WUblastx (Q9NX85) CDNA 64 FLJ20378 FIS, CLONE 889281 523 WUblastx (Q64150) NUCLEAR 64 LOCALIZATION SIGNAL BINDING PROTEIN. 886212 344 WUblastx (Q9UJ74) 64 HYPOTHETICAL 36.0 KDA PROTEIN (C4.4A PROTEIN). 793713 345 HMMER PFAM: Integral membrane protein WUblastx (Q9UJ1) Similar to 64 (protein for MGC:16985). 64 (RIKEN cDNA 1700034015 gene. 64 RIKEN cDNA 1700034015 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 64 (NOVEL PROTEIN).		/3942/	342	w∪blastx .64	(Q9N083) UNNAMED PORTEIN PRODUCT.	Q9N083	96%0	1003	/161
889281 523 WUblastx (Q64150) NUCLEAR 64 LOCALIZATION 64 LOCALIZATION 886212 344 WUblastx (Q9UJ74) 64 HYPOTHETICAL 36.0 KDA PROTEIN. 793713 345 HMMER PFAM: Integral membrane protein WUblastx (Q9CL11) Similar to 64 (protein for MGC:16985). 654 (Protein for MGC:16985). 654 (RKEN cDNA 1700034015 gene. 6570049 524 WUblastx (Q9CL11) Similar to 6570040 524 WUblastx (Q9CL11) Similar to	AH38	1028519	343	WUblastx	(09NX85) CDNA	09NX85	71%	943	1119
KAIA0536. 889281 523 WUblastx (Q64150) NUCLEAR			i	.64	FLJ20378 FIS, CLONE	,	%69	1113	1250
889281 523 WUblastx (Q64150) NUCLEAR					KAIA0536.		48%	1600	1340
886212 344 WUblastx (Q9UJ74) 886212 344 WUblastx (Q9UJ74) 64 KDA PROTEIN (C4.4A PROTEIN) 793713 345 HMMER PFAM: Integral membrane protein WUblastx (AAH08596) Unknown 64 (protein for MGC:16985) 898364 346 WUblastx (Q96L11) Similar to 64 (Q96L11) Similar to 64 (Q96L11) Similar to 65 WUblastx (Q96L11) Similar to 66 RIKEN cDNA 1700034015 gene. 67 WUblastx (Q96L11) Similar to 68 RIKEN cDNA 1700034015 gene. 69 RIKEN cDNA 1700034015 gene. 66 RIKEN cDNA 1700034015 gene. 66 (NOVEL PROTEIN) 67 (RAGMENT).		889281	523	WUblastx	(Q64150) NUCLEAR	Q64150	%09	795	673
886212 344 WUblastx (Q9UJ74)				.64	LOCALIZATION SIGNAL BINDING				
886212 344 WUblastx (Q9UJ74) 64 HYPOTHETICAL 36.0 KDA PROTEIN (C4.4A PROTEIN). 793713 345 HMMER PFAM: Integral 2.1.1 membrane protein WUblastx (AAH08596) Unknown .64 (protein for MGC:16985). 898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN)					PROTEIN.				
64 HYPOTHETICAL 36.0 KDA PROTEIN (C4.4A PROTEIN). 793713 345 HMMER PFAM: Integral membrane protein WUblastx (AAH08596) Unknown .64 (protein for MGC:16985). 898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 64 RIKEN cDNA 1700034015 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN)		886212	344	WUblastx	(Q9UJ74)	Q9UJ74	100%	33	1070
KDA PROTEIN (C4.4A PROTEIN). 793713 345 HMMER PFAM: Integral 2.1.1 membrane protein WUblastx (AAH08596) Unknown .64 (protein for MGC:16985). 898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA .64 REAGMENT).				.64	HYPOTHETICAL 36.0				
PROTEIN). 793713 345 HMMER PFAM: Integral 2.1.1 membrane protein WUblastx (AAH08596) Unknown .64 (protein for MGC:16985). 898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene64 RIKEN cDNA 1700034015 gene64 RIKEN cDNA 1700034015 gene64 (NOVEL PROTEIN) (FRAGMENT).					KDA PROTEIN (C4.4A				
793713 345 HMMER PFAM: Integral 2.1.1 membrane protein WUblastx (AAH08596) Unknown .64 (protein for MGC:16985). 898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034O15 gene. 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034O15 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) (FRAGMENT).					PROTEIN).				
2.1.1 membrane protein WUblastx (AAH08596) Unknown .64 (protein for MGC:16985)64 RIKEN cDNA .64 RIKEN cDNA .65 (NOVEL PROTEIN) .65 (RRAGMENT).		793713	345	HMMER	PFAM: Integral	PF01940	49.3	147	455
898364 346 WUblastx (AAH08596) Unknown 64 (protein for MGC:16985). 64 WUblastx (Q96L11) Similar to 64 1700034015 gene. 670049 524 WUblastx (Q96L11) Similar to 64 RIKEN cDNA 64 RIKEN cDNA 1700034015 gene. 64 RIKEN cDNA 1700034015 gene. 64 (NOVEL PROTEIN) 65 (RRAGMENT).				2.1.1	membrane protein				
898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA .64 (N0034015 gene64 (NOVEL PROTEIN) .64 (RRAGMENT).				WUblastx	(AAH08596) Unknown	AAH08596	%86	81	623
898364 346 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) .64 (RRAGMENT).				.64	(protein for MGC:16985).				
4 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA .64 RIKEN cDNA .1700034O15 gene64 RIKEN cDNA .1700034O15 gene64 RIKEN cDNA .64 (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) .64 (FRAGMENT).		898364	346	WUblastx	(Q96L11) Similar to	Q96L11	100%	136	501
4 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034O15 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) (FRAGMENT).				.64	RIKEN cDNA				
4 570049 524 WUblastx (Q96L11) Similar to .64 RIKEN cDNA 1700034015 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) (FRAGMENT).					1700034O15 gene.				
.64 RIKEN cDNA 1700034015 gene. 1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) (FRAGMENT).		570049	524	WUblastx	(Q96L11) Similar to	Q96L11	100%	63	428
1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) (FRAGMENT).				.64	RIKEN cDNA				
1352272 347 WUblastx (Q9BWY1) BA552M11.5 .64 (NOVEL PROTEIN) (FRAGMENT).					1700034O15 gene.				
.64		1352272	347	WUblastx	(Q9BWY1) BA552M11.5	Q9BWY1	100%	158	193
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				.64	(NOVEL PROTEIN) (FRAGMENT)		100%	351	779
HTEIN13 658744 525 WUblastx (09DAR9) 09DAR9		658744	525	WUblastx	(09DAR9)	O9DAR9	%09	525	743

			.64	1700001D09RIK		11%	163	516
HTE.IN13	381941	526	WUblastx	(O9HBK8) AD026.	O9HBK8	95%	161	229
	\ \ \ \ \)	.64			94%	214	633

RACE Protocol For Recovery of Full-Length Genes

5

10

15

20

25

30

35

Partial cDNA clones can be made full-length by utilizing the rapid amplification of cDNA ends (RACE) procedure described in Frohman, M.A., et al., Proc. Nat'l. Acad. Sci. USA, 85:8998-9002 (1988). A cDNA clone missing either the 5' or 3' end can be reconstructed to include the absent base pairs extending to the translational start or stop codon, respectively. In some cases, cDNAs are missing the start codon of translation, therefor. The following briefly describes a modification of this original 5' RACE procedure. Poly A+ or total RNA is reverse transcribed with Superscript II (Gibco/BRL) and an antisense or complementary primer specific to the cDNA sequence. The primer is removed from the reaction with a Microcon Concentrator The first-strand cDNA is then tailed with dATP and terminal deoxynucleotide transferase (Gibco/BRL). Thus, an anchor sequence is produced which is needed for PCR amplification. The second strand is synthesized from the dA-tail in PCR buffer, Taq DNA polymerase (Perkin-Elmer Cetus), an oligo-dT primer containing three adjacent restriction sites (XhoI, SalI and ClaI) at the 5' end and a primer containing just these restriction sites. This doublestranded cDNA is PCR amplified for 40 cycles with the same primers as well as a nested cDNAspecific antisense primer. The PCR products are size-separated on an ethidium bromide-agarose gel and the region of gel containing cDNA products the predicted size of missing protein-coding DNA is removed. cDNA is purified from the agarose with the Magic PCR Prep kit (Promega), restriction digested with XhoI or SalI, and ligated to a plasmid such as pBluescript SKII (Stratagene) at XhoI and EcoRV sites. This DNA is transformed into bacteria and the plasmid clones sequenced to identify the correct protein-coding inserts. Correct 5' ends are confirmed by comparing this sequence with the putatively identified homologue and overlap with the partial cDNA clone. Similar methods known in the art and/or commercial kits are used to amplify and recover 3' ends.

Several quality-controlled kits are commercially available for purchase. Similar reagents and methods to those above are supplied in kit form from Gibco/BRL for both 5' and 3' RACE for recovery of full length genes. A second kit is available from Clontech which is a modification of a related technique, SLIC (single-stranded ligation to single-stranded cDNA), developed by Dumas et al., Nucleic Acids Res., 19:5227-32 (1991). The major differences in procedure are that the RNA is alkaline hydrolyzed after reverse transcription and RNA ligase is used to join a restriction site-containing anchor primer to the first-strand cDNA. This obviates the necessity for the dA-tailing reaction which results in a polyT stretch that is difficult to sequence past.

An alternative to generating 5' or 3' cDNA from RNA is to use cDNA library doublestranded DNA. An asymmetric PCR-amplified antisense cDNA strand is synthesized with an antisense cDNA-specific primer and a plasmid-anchored primer. These primers are removed and a symmetric PCR reaction is performed with a nested cDNA-specific antisense primer and the plasmid-anchored primer.

RNA Ligase Protocol For Generating The 5' or 3' End Sequences To Obtain Full Length Genes

5

10

15

20

25

30

35

Once a gene of interest is identified, several methods are available for the identification of the 5' or 3' portions of the gene which may not be present in the original cDNA plasmid. These methods include, but are not limited to, filter probing, clone enrichment using specific probes and protocols similar and identical to 5' and 3' RACE. While the full length gene may be present in the library and can be identified by probing, a useful method for generating the 5' or 3' end is to use the existing sequence information from the original cDNA to generate the missing information. A method similar to 5' RACE is available for generating the missing 5' end of a desired full-length gene. (This method was published by Fromont-Racine et al., Nucleic Acids Res., 21(7):1683-1684 (1993)). Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcript and a primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest, is used to PCR amplify the 5' portion of the desired full length gene which may then be sequenced and used to generate the full length gene. This method starts with total RNA isolated from the desired source, poly A RNA may be used but is not a prerequisite for this procedure. The RNA preparation may then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase if used is then inactivated and the RNA is treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase. This modified RNA preparation can then be used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction can then be used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant gene.

The present invention also relates to vectors or plasmids which include such DNA sequences, as well as the use of the DNA sequences. The material deposited with the ATCC (e.g., as described in columns 2 and 3 of Table 1A, and/or as set forth in Table 1B, Table 6, or Table 7) is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as described, for example, in Table 1A and Table 7. These deposits are referred to as "the deposits" herein. The tissues from which some of the clones were derived are listed in Table 7, and the vector in which the corresponding cDNA is contained is also indicated in Table 7. The deposited material includes cDNA clones corresponding to SEQ ID NO:X described,

for example, in Table 1A and/or Table 1B (ATCC Deposit No:Z). A clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X, may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene. Furthermore, although the sequence listing may in some instances list only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to sequence the DNA included in a clone contained in the ATCC Deposits by use of a sequence (or portion thereof) described in, for example Tables 1A and/or Table 1B or Table 2, by procedures hereinafter further described, and others apparent to those skilled in the art.

Also provided in Table 1A and Table 7 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., *Nucleic Acids Res. 16:*7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., *Nucleic Acids Res. 17:*9494 (1989)) and pBK (Alting-Mees, M. A. et al., *Strategies 5:*58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into *E. coli* strain XL-1 Blue, also available from Stratagene.

Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., *Focus* 15:59- (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the deposited clone (ATCC Deposit No:Z). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X or the complement thereof, polypeptides encoded by genes corresponding to SEQ ID NO:X or the complement thereof, and/or the cDNA contained in ATCC Deposit No:Z, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the polypeptides of the present invention in methods which are well known in the art.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA sequence contained in ATCC Deposit No:Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X or a complement thereof, a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or the polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C are also encompassed by the invention. The present invention further encompasses a

polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ ID NO:X, a nucleic acid sequence encoding a polypeptide encoded by the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA contained in ATCC Deposit No:Z.

5

10

15

20

25

30

35

Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in Table 1C column 6, or any combination thereof. representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in Table 1C column 6, or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1) and have

a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

5

10

15

20

25

30

35

Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the abovedescribed polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (See Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of Table 1C column 6, or any combination thereof.

Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1C column 6, or any combination thereof. In preferred embodiments, the polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1C column 6, wherein sequentially delineated sequences in the table (i.e. corresponding to those exons located closest to each other) are directly contiguous in a 5' to 3' orientation. In further embodiments, above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1C, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1C, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1C, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

5

10

15

20

25

30

35

In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1C, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A, Table 1B, or Table 1C) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same Clone ID. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of column 6 of Table 1C, and the polynucleotide sequence

of SEQ ID NO:X (e.g., as defined in Table 1A, Table 1B, or Table 1C) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same row of column 6 of Table 1C. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X are directly contiguous Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1C are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of a fragment or variant

of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1C are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides, are also encompassed by the invention.

In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same Clone ID (see Table 1C, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one—sequence in column 6 corresponding to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same row are directly contiguous. In preferred embodiments, the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table 1C, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

Table 3

5

10

15

20

25

30

35

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. Accordingly, for each contig sequence (SEQ ID NO:X) listed in the fifth column of Table 1A and/or Table 1B, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, b is an integer of 15 to the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14. More specifically, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3. In specific embodiments, the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone). In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

Table 3

	SEQ ID				
cDNA Clone ID	» NO	Contig ID:	EST Div Range of a	EST Disclaimer Range of a Range of b	Accession #'s
H2CBU83	=	884134	1 - 2689	15 - 2703	BE613316, BE739453, AW961199, AV658769, BE785673, AW963999, BF037119, BG030580, BF036149, BF699154, BF093837, BF69524, BF695458, BF036638, BF701778, BG030507, AW377122, BF665913, BF699078, AW377125, BF665294, AV658829, BF66782, BG166746, AW851261, BF241480, AW850925, AI978869, BF665294, AV658829, BF668201, BF699860, BF001466, AI800939, BG121547, AI620357, BF700054, AW851052, AI924880, AW752845, BF7001466, AI800939, BG121547, AI620357, BF700054, AW851052, AI924880, AW752844, BF697582, BF700919, BF667321, AI139396, BE958619, AV692286, AI955392, AW752844, BF697582, BF700919, BF667321, AI139396, BE98819, AV692286, AI955392, AW752844, BF697582, AW850982, AI935579, BE089877, AW752868, AI683119, BF130660, D61864, AW630835, AI621153, BF514638, BF697211, AW192136, AI286255, AA403153, D62117, AW028833, N78154, BF154792, BF665821, AI538061, N64201, AW851056, AW938593, BE093579, AW938596, AA9228873, AV651183, BE817020, AV657915, AV657131, BF666276, AV660141, AI699025, AI016115, R66206, N45586, D61708, BE868472, AA403241, AV657914, AA313513, AV682813, AR8565, AA531589, R58698, AA857811, H42631, AA307010, R67084, BF334107, AW971385, R68027, AW021104, AW296538, BG166828, AI887214, AW468968, R64487, H88521, BF697149, R94825, R68028, R68028, AA377208, AI050980, AA318641, D62093, BF813323, N78160, T73957, D61982, D62303, D62026, AI806100, AA095925, N56560, T73925, AA507092, BF750358, BE148612, BF750357, BE867141, T73948, N88292, T73916, BE044052, H95089, H73281, AV660091, AF2571821, AF346711.
H2MAC30	12	544957	1 - 445	15 - 459	AI089027, AA308141, AW504673, AI684832, AA225036, AI806235, AA480904, AW084470, BE246140, AI769587, AA480993, AA936449, AI743330, AW025616, R84772, AI244944, N58917, AI085514, AA504299, AI273353, AI762989, AA100979, AA857531, AW276652, AW952845, AW440624, AI277859, R74507, AW269427, AI221905, AW016095, H72021, AI150547, H65671, T89998, AI937672, H86848, R74517, R52128, BE243519, AA224988, AA588111, T89414, AA976027, Z39380, BE869329, R48449, R72429, AA229997, AA308518, BF183288, AA229612, AI694870, AV755614, AV755613, T24832, AA229703, AA620967, AA59460, AA480966, AC003070, 1.
H6EDC19	13	543259	1 - 746	15 - 760	A1090153, A1767722, BG116691, A1797075, BF528376, A1698172, A1681570, BE671343, A1539236, AV704244, A1539246, BE264613, AA864681, AW204700, A1808925, BE676036, T79284, BF445461,

637482 1 - 1431 15 - 1445 AN102057, AN1023608. AN1023608. AN102369, AN102369, AN102369, AN102639, AN102639	15 - 1445	- 1445	AA400027, ABF969629, AA1123608. AA1123694, AA704675, AA704675, AV682639, A	AA400027, AI209219, AA300244, AA427390, AA302217, AA252421, AA406631, AI869251, BF969629, AI262951, AI498669, AA300243, AW072158, T79197, AA411721, AV682333, F34003, AI123608. AI123604, AA203656, AV707802, BF575227, N77966, AW956121, N71852, BF732312, AI338999, AA704675, AI742966, AA176725, AV744696, AI039168, AA329423, AA680411, F10345, T85994, AV682639, AA731436, AV735262, AV733694, AA505796, AW959998, BF793146, H79631, R00088,	
				BF978632, BG034327, AV716953, AW955313, BG032189, AV717860, AV716893, BF244606, AV733654, BG030662, AI802907, AA528524, AA973692, AA658895, AV714250, AV718258, AV716004, BF029739, F26324, AW772717, BE909294, AA370595, AI392630, BF529817, AI914394, BE748127, AA975366, BF029799, AI126532, AA977864, R38577, AI093884, AW264528, AI351443, AA916014, AA359165, AA594324, AI682171, AA404535, BG034254, T75123, AI832970, AA973611, AI833308, AI814033, BE781781, BF035996, BF036344, AA888167, BE541776, BF109665, BE551387, AI268514, AV710503, AI709250, F33691, BF216659, F33502, BE467615, AV738506, BE503802, AV763934, BG110890, AV742881, AV710956, BF965198, BG033031, T90966, R02459, F32392,	
				BF029956, BF690853, AV764373, BE738142, BF244383, AW772766, BF978393, BF030821, BE548289, N64163, BF576733, AW872492, BE218579, BE539011, BE042987, BF978138, BE217894, BF692527, AW419258, BF219313, BF244019, R02355, BF242775, AA340839, AW440167, F30529, BE748667, AA640120, BG179795, BF679132, BF382290, AI719390, R35603, BF240791, BF691038, AW009337, AA886535, BE738709, AI253328, AW268515, BF977850, H79632, AV764541, BF214426, BE184678, BE171856, BF382191, F12739, BF031722, BE564110, F21702, BF219100, F26311, F27624, F31646, F24066, F30253, F21442, BF030470, BF215493, AA365400, AV725369, BF243623, BF216495, F23622, R38445, Z20180, F23439, BF031636, AA340808, BF246303, F29361, BF212059, D19917, BF210763, AI720401, N58379, AA706899, BE737668, F37786, AC009289.8, BC000855.1, A5008804	
<u>v</u>	961996	1-1319	15 - 1333	BE111995, BF111899, AW051348, AI807015, AA349378, AA349433, H05458, T39468, T39511, F02812, T50009, T50073, Z43427, A1372659, BE843943, BE843903, AA860404, BG015163, BE938621, BE843892, A1372657, BE698483, BF092079, BE301746, BG015653, AA496848, AL045349, BE047833, BE965724, BE965430, BE964497, AW059713, AL037454, BE964512, AL119836, BE965307, A1918408, BG180506, BE964876, BF924856, AI683559, AW151136, BG107576, BE965067, AW268261, A1691088, A1798271, AV689111, BG253692, BE011885, AI868163, A1918634, AW084097, BE875022, BE8779931, A1340603, AV728806, AL036652, BF814335, A1370392, BE963838, AV725920, AW021717, AW089036, BE96404, BE964795, A1469516, A1805638, A1925404, AA291456, AL040694, A1285439, AA888196, BE966404, BE965738, BE965355, BE544111, BG180273, A1366968, AW022682, AV742698, A1560679, A1245608, BE965740, BE965740, A1245698, A1540033, A153333, A1533378, BE965708, BE9657140, A1245698, BE966404, BE540578, BE9657140, A1245698, BE966404, BE540578, BE9657140, A1245698, BE966404, BE540578, BE9667140, A1245698, BE9667140, A1245698, BE9667140, A1245698, BE9667140, A1245698, BE9667140, A1245098, BE9667140, A1245098, BE9667140, A1245698, BE9667140, A1245098, A12460978, A124	
				AW020095, BF038804, BE908276, AV742475, AI345471, BE966787, AI343091, AI345677, BE966011, BE965621, AI340519, AW162189, BF814357, AW198144, AI446809, AV717295, AV716613,	

	AV682144, Al366992, AA806719, AV682099, BE964661, AA789133, BE963918, BE904051,
	AW023338, AV /38/30, BE8/3/76, BG02/082, BF032404, BG104033, BE013/2/, BG032219, A1863357, BF965884, AL048323, BG153050, A1636719, AV756658, AW827289, AL048340,
	BE879905, BG109270, AW020693, AI686576, AW858254, BE964073, AI470293, AW827290,
	AW058233, AL038605, BG107625, AI702527, BG260037, AW834325, BE047952, BF793031,
	AA643235, AI418254, AI623905, AI538764, AI524654, AI249946, BE964006, AA848053, AV733819,
	AA635382, H42825, AI929108, BF924884, BG029053, BE974031, AI473451, AV711509, BG252714, A1048644 BF86897 A1040741 BF883591 BF968622 AW068845 AI624293 BF813196
	AW022494, BF340323, AL046463, AW020288, AI521596, AW021373, AW162194, BF915316,
	BF925370, BF886214, A1923989, BE965481, A1868204, A1242736, BE891942, BE735380, BF909758,
	AA579232, BG166687, AV715354, BE964767, AV756247, AV758825, BF814449, AL038445,
	BE965121, AW163834, BF343521, AW084056, BG032169, BE904851, BF868811, BG104782,
	AI537677, BG122101, AI628325, AI590645, BE875402, AW083804, AI561299, BE908335,
	AW059828, BF753056, AI559863, AV726125, BF750879, AW265004, F26535, AI583032, BF811808,
	A1366974, A1355765, BF822127, A1609593, A1887775, A1858865, A1500061, BG121959, AA572758,
	BF699668, Al348897, BE778024, BF814504, Al345224, Al357599, AV681949, T99953, Al589428,
	BG113851, BG110517, AL530922, AF169301.1, AC091736.1, AL442082.1, AB049853.1,
	AL389935.1, BC007364.1, S78214.1, X99717.1, AL122121.1, AK027161.1, BC006195.1,
	BC005858.1, AK000310.1,
	BC003104.1, AK025092.1, AK024524.1, AB047897.1, BC007674.1, AB044547.1, AL136789.1,
	BC004874.1, AL122045.1, AK026506.1, AL389978.1, AL049464.1, AF067420.1, BC007355.1,
	_
	•
	U42031.1, AK027142.1, U51587.1, AF17
	AL133093.1, AB063008.1, AK025431.1, AL390167.1, BC008673.1,
	AF205861.1, BC003650.1, ALI33560.1,
_	AL049382.1, AK027182.1, AK000421.1,
	AB047615.1, AL137523.1, AL353957.1,
	AK026452.1, BC008025.1, AL050170.1,
	AB060863.1, BC005160.1, AB056809.1, AB052191.1, Y14314.1, A
	AL137658.1, AL137705.1, AL137292.1, BC000778.1, BC008185.1,
	AL137283.1, AF097996.1, AL049430.1, AL390154.1, BC006164.1, AL512718.1, AL049314.1,
	117583.1, AB063046.1, AF
	BC006180.1, AK027164.1, AB047801.1, BC007534.1, BC000556.1,
	BC007021.1, AK026462.1, AL356278.8, AF162270.1,
	AB047966.1, BC006408.1, AF225424.1, AK000655.1, AB060856.1,
	BC001056.1, AB047631.1, BC005890.1, AL137273.1, BC004370.1, AF207829.1, BC002491.1,

					D85989.1, BC004943.1, AF259683.1, BC005007.1, AF111112.1, AL122049.1, BC009033.1, L19437.2, AK026086.1, AB060883.1, AK026045.1, AB056420.1, AF305835.1, AB060903.1, AK026434.1, AL133568.1, AL122118.1, AL050393.1, AL137476.1, AC023880.5, AL117435.1, AK026534.1, BC000348.1, BC0005678.1, AJ001838.1, S78453.1, AL136767.1, X76228.1, M64349.1, BC0005151.1, AB055370.1, AB060893.1, BC001963.1, AF159615.1, AK026603.1, AL17440.1, BC007897.1, AL136766.1, AL117629.1, BC006133.1, AK002460.1, AK026592.1, AL080074.1, AB048974.1, AB049900.1, AK025958.1, AK025084.1, L30117.1, AL137488.1, BC00066.1, AK026531.1, U77594.1, BC002471.1, AL33802.14, AF271350.1, BC000632.1, AK026533.1, BC00026.1, BC003683.1, AK026532.1, AK026533.1, BC002541.1, BC0026577.1, AK026552.1, AB050534.1, AL136644.1, BC006440.1, AK026885.1, AK026571.1, BC003682.1, AK025541.1, AL136843.1, AL136644.1, AF132730.1, AF1377731.1, AF1377731.1, AF137730.1, AF1377731.1, AF137730.1, AF1377731.1, AF137730.1, AF137730.1, AF1377731.1, AL136893.1, AK024944.1, AL136843.1, AL13774.1, AL136888.1, AL13774.1, AL136888.1, AL136843.1, AL136843.1, AL13774.1, AL13774.1, AL136888.1, AL136843.1, AL136843.1, AL136843.1, AL13774.1, AL13774.1, AL136843.1, AL136843.1, AL136843.1, AL136843.1, AL136843.1, AL136843.1, AL136843.1, AL136843.1, AL136843.1, AL137774.1, AL136843.1, AL136843.
HAGBZ81	91	456414	1 - 1368	15 - 1382	
HAGDG59	17	534165	1 - 1720	15 - 1734	AV694248, BE895909, BE903848, BG027942, AV651246, BG109867, BF240140, BF217526, BF669125, BE779936, AV650099, BF971092, AW875350, AW956342, BF107182, BF697022, BG166672, BF030619, BE881774, BE548671, BF247518, A1888053, BF667451, BE872808, A1768748, BG7166672, BF030619, BE881774, BE548671, BF247518, A1888053, BF667451, BE872808, A1768748, BF792803, N37046, N23484, BE872350, BF239058, AW664126, BF107464, W88681, AW338066, AW952476, AW402833, BE971415, AW853145, BF968304, A163524, N24759, BF665132, BF213364, AA830565, AV697089, AA167203, AW023148, A1815125, A1685119, H98763, BE465545, AW853521, AW405572, AA481430, AW604402, AA481434, AA223067, AA902413, AW578436, BG258700, AW169016, A1961753, H38614, AA835545, A1262411, AW192401, A1193508, AA576473, AV660930, AW262909, AA263040, BE927225, AA481670, BE782154, W88620, AA394254, BG261374, AW262909, AA263040, BE927225, AA481670, BF7821366, AW193089, BF904780, AW470979, BF904779, AW295546, AA045861, BF902314, BF674778, R23903, R80672, BF032805, R61171, N79745, BF332094, H38856, AA328661, BF902314, BF243422, R27506, BF894060, T72506, AW361405, H62468, W07107, A1468319, AA362581, R27793, AM853797, AW337877, AW075817, BF031795, BE866675, BF905580, T82403, R27885, AW339053, AA377009, BF791479, A1708354, AA485696,

					BF239244, AW051074, BE866177, Al497897, AA485827, AW273624, BF905573, BF205089, AW022407, Al678575, Z21560, BF238897, BF699925, BE926278, BF239919, AW836245, AF126780.1, BC008650.1, Z64479. 1.
HAGDS35	<u>&</u>	1352199	1 - 737	15 - 751	AI803504, AI261590, AW970422, AA430349, AI017015, AI217649, AI357214, AA425610, AW170513, N21542, AI805514, AA535732, AI922416, AI089295, AI807997, BE549761, BF434916, AI093989, AI537981, BE464016, AI128724, AA046439, AW970309, AA211360, AA974447, BE672109, BE466566, AI990335, AI655816, AI479968, AI926934, AI961572, AW970221, AW243397, AA534329, AW593487, AI283132, BF115098, AA256606, AA019380, BF061520, AA936249, AI446563, AA872374, AA011475, H25408, AI393572, AI203429, AI961183, BF735047, AW613954, AI216786, AI798452, H28374, C01415, AW016511, BE551700, AA730296, AI991488, BF476167, AA455164, AA516090, R46342, R43067, R35671, H39555, AA258077, AI950123, Z38679, AL535820, AW887425, AW958078, BE771685, AI382468, AA971129, AA090871, BF971621, AA455366.
. HAIBO71	20	490848	1 - 738	15 - 752	AI767324, AW976385, AL121194, AA972628, AI095851, AA743343, BE566411, AF118928, AW366882, D20570, AC009802, 13.
HAJAF57	22	823516	1 - 2747	15 - 2761	AI670135, AI460009, AI375542, AI338350, AA362719, AA482775, AW963333, BE160727, AI282511, BF339636, AW022897, AV757341, AV731764, AW274925, BE504746, AI254779, AW408047, AW407578, AV734583, AV731604, AV731603, AU121168, AL121904.13, AP001711.1, Z85986.1, AC009267.15, AC011485.6, AL354928.9, AP000960.2, AL132768.15, AC007358.2, AC005058.1, AL049795.20, AC005245.1, AC034193.4, AC005971.5, AL034406.1, AC002310.1, AL158040.13, AC002299.1, AL354815.10, AL121897.32, AP001705.1, AC083863.2, AL138040.13, AC008736.6, AC1010422.7, AL139009.14, AC020908.6, AF130342.1, AC006288.1, AC010494.4, AP001688.1, AF228703.1, AC005562. 1.
HAJAN23	23	1352364	1 - 2835	15 - 2849	BF337092, BF968693, AI949422, AL523556, BF798043, AV702522, AI423046, BE883392, BE786755, BG178390, BE408282, N31952, AA465612, AW195192, BE543143, AI564487, AV660395, BE543045, R88931, BE825704, AA658285, AW975104, AI740792, BE002027, BE928231, R89611, BG168885, BF331860, AW590726, AA641596, AA313322, BF358320, AW418507, AW842226, AI949987, AW615497, AW194161, BF222524, BF197303, BF755611, AI869038, AW243485, BF754745, AI367183, BE073382, AW013907, AF310971.1, AF301000.1, AB050049.1, AF261884.1, AC010279.4, AB050050.1, AK025591.1, AL079298.1, Z70695.1,
HAJBR69	24	638516	1 - 741	15 - 755	BE262907, AW503376, AW503644, BF982382, BE079288, AW504239, AA701415, BF315343, BE277664, BF921555, BF736464, BF756620, BE720223, BE815902, AA490675, BE930704, AW971745, AW804686, AW392670, BE695785, AW861944, AW604723, AW877209, AL119483, U46351, AW858526, AW858525, AL042984, AL119497, AL119324, AL119319, AL119355, AW500561, U46349, AL134538, AL119457, BE705903, BE705906, AW577135, AW372827, AW3861889, AW858455, AW363220, U46350, Z99396, AL119484, AL119363, AL119391, U46347, U46341, AL119443, BF868687, AL119444, AL119341, BF868697, AW604726, AL119439,

HAMFE15

222222222222222222222222222222222222	ALL187241, AVC19421, AVC19548, AAD101744, AIL19494, AECONOMISE2, AC0195728, ALC19548, ALC195461, AC0195728, ALC19548, ALC19548, AC00539019, ALC11610113, AP0009522, ALC195165, AC0195728, AC00539019, ALC160113, AP0009522, ALC195165, AC0063292, AC0063002, AC0063002, AC0063013, AC0063011, AC0063002, AC0063002, AC0063011, AC0063002, AC0063002, ALC195281, AC0063011, AC006301, AC006326, AC0063201, ALS946611, AC0063203, AC0063201, ALS940621, AC0063681, AC0063201, ALS946611, AC0063203, AC0063201, ALS946611, AC0063203, AC0063201, ALS946611, AC0063203, AC0063201, AC006301, AC006301, AC0063203, AC0063201, AC006301, AC
	AL080317.11, AL035705.22,

					AC016026.13, AL138759.20, AL033529.25, AC011475.6, AL034395.6, U80017.1, AF287262.1, AC008123.9, AC084356.22, AC022407.6, T50763, R53008, AA054732.
HAMGR28	27	892971	1 - 1660	15 - 1674	AL519641, AL519640, AL525613, AL526308, AL527643, AL530324, AL525663, AL525671, AL530325, AL515833, AL515832, BF313053, AL527577, BF529163, BE312001, BF984557, BF530620, BE396752, BE304484, BF983145, BE560368, BF316599, BG114646, BE269376, BF313413, BE298748, BE440179, AW953553, BF307907, AW978612, BE617303, AA845426, AI830874, A1983227, AW956917, AW410199, AW628335, BE464326, AA530876, AW452186, BE139083, A1829507, A1356849, W69111, AW084551, AA406233, A1589504, A1970964, A1420766, A1701901, A1130010, A1288363, BF571959, A1683363, BE019516, BE206283, AW272707, N23238, AA593625, A1000296, AA406505, AW593667, A1933020, A1337797, BF691989, A1139514, BF062876, W35301, A118519, AV759081, AW514035, AW004995, AW591716, F28754, AA815275, A1347528, A1624104, AA574436, A1817434, A1025110, T08849, AL527576, A1079740, AA962799, AA707405, BF445536, BE646197, A1475064, AA653748, AA312858, AW510310, AW264517, AA028008, T33149, AA723895, W69236, R40168, T23442, H88132, H78378, AW514039, D12424, W23701, F34521, AW379122, A1768799, BE877018, A1560685, AA338084, A1810799, AW861944, AW750703, F24446, AW972091, AW858525, AW972090, AW968355, AW968356, AW972093, AW968259, AH332647, A1432644, A1432653, AW861423, AW858526, A1432647, A1432653, AW888526, A1432647, A1432653, AW881103, A1432661, A1492519, BE672748, AC004150.8, AF06485411, AB026436, 1.
HAPOM49	28	769555	1 - 1991	15 - 2005	AL520731, AL520732, BE271092, BE271295, BF111901, AV650049, BF686278, BE840511, BF111645, AI809801, AW168904, AI809806, AW103024, AA933973, AI744944, AI588991, AI033486, A1096548, AA662523, AW468813, A1950317, A1279302, A1096696, BF239172, AW662564, AA417671, AI189300, AI753808, AA235373, AW960081, AI095057, W86920, AW189373, AI361321, BF061913, AI366754, AI218487, AI824959, AI348339, AI032926, AV659024, AA889791, BE243641, AA626261, AI338100, AA417558, W24077, AW974720, N72014, AA894657, N59290, R01247, AA235784, BE929365, BE929364, BE244396, AI275184, AI810247, W24089, R36924, AA356938, N91904, AA508411, AA649828, N91912, N99466, Z24931, H68902, BE782571, BF840140, AC004067.1, AF332892.1, AF306567. 1.
HAPPW30	29	1352278	1 - 1458	15 - 1472	BF568560, BF309463, BF568858, BF968457, BE729680, BG121453, BE044480, AW958703, AW957664, AW341517, AA868588, AA479992, AA758865, AA305964, AI276502, AV696016, AA846842, BF963424, AW510684, AI183515, N41325, BF674083, AW273135, AA954695, AI685296, H57026, AA969117, AI147710, N95033, AA962530, AV650263, AA758255, BF929642, BF798962, AI337591, AA150989, AI675402, AA775255, AI167695, AI798973, AW172620, AI359078, AI688288, AI151098, BE931071, AI911606, AW469667, AA383301, H83172, AW749394, AW603134, AI188832, AI078598, H58146, AA446238, AA310796, AA724109, AA864698, AI240610, BF033606, BF854704,

					AA9578573, AA421572, H41807, W15373, H48433, H46522, AI739312, AW956749, BF951265, AA977855, AA757910, H87382, AI216014, AA877407, AA098821, BE168746, BE208218, W38885, H46521, R11443, R19191, H82944, C04986, A1479980, H56935, W72627, AI216655, AA975974, R99133, AA922234, AA339733, AA375160, BF352033, AW183259, AA421590, A1459843, BE930211, BE930299, T61945, AI216656, A1902298, H70309, A1902295, A1191499, T71506, AW844824,
HATBR65	30	635514	1 - 798	15 - 812	57057, BF800855 V747079, AW96 V725414, AA826 50830, BF918715 80752269, BF755 W752269, BF755 W857010, BE182 284543, A125120 251034, A125120 251034, A125055 F952311, AV719 W975623, BF122 W975623, BF122 AF030453.1, AF0303 AC004166.12, AC004166.12, AC04166.12, AC04166.12, AC020558.4, AC161779.32, U95740.1, AL AL136984.20, AL136984.20, AL136984.20, AL136984.20,
	·				AC003323.1, AL121880.21, AC003593.6, AF000314.1, AL333713.41, AC023100.7, AL049779.6, AL355336.15, AC011479.6, AC011495.6, AL359644.10, AC020904.6, AC004706.1, Z98044.13, AL049874.3, AC007201.1, AL161757.4, AC007130.2, AL139415.10, AC022384.4, AC008738.6, Z95114.19, AC090841.1, AC005378.2, AC022001.3, AL031848.11, AC018494.6, AL445435.11, AC002128.1, AC018811.4, AC007685.2, AL121601.13,

1 - 1742 15 - 1756 A1253043, AA621792, N84222, AA094505, AL522648, AC009244.24, AK025372.1, BC008349.1, AB020635. 1.	1 - 1661 15 - 1675	1 - 896
603948	565618	639009
3.		33
HATCB92	HATEE46	HAUAI83

					BF130460, BF102497, AV745093, BE543668, AI493727, BE254068, AA934591, N24442, AI147316,
					BF680700, AV705947, BE734398, BG231583, BE256074, AV754408, AW014782, A1198642,
					BE646408, AA889969, AI709288, AW135010, AA877730, AI720901, AA496681, AA995328,
					A1032808, AW5/9254, A1186312, A1969/15, A1660672, N236/3, AA420567, AA427691, A1188938, AA471213. BG117664. BF102532, A1191317, A1332586. A1219152. AW000829. A1470155. AA843102
					AI125390, BE312355, AW182893, AI141484, H93124, AW000718, AI268069, AA815421, AA708211,
					AA129884, AI023128, AI147588, AV724436, AA159902, AI129253, AA290635, AV706639,
					AI127280, N58266, AA315771, AI673417, AI587141, AI186000, AI142324, AI128437, AA723220,
					AI335350, BF687940, AA552070, AI087415, AA995933, AW300769, AA862543, AW008043, R68241,
					BE349483, A1241459, A1355685, AW304225, AW083014, A1277068, A1038096, A1160884, AA774420,
					BE407927, AA810159, W37128, W04866, AI828898, AI093015, AA732834, AV707544, AI934627,
					AAU26633, WU16/8, H84951, AI279658, BF665006, AA419151, AA844949, A1096712, N71609,
					AV 1551174, NO2052, AA159796, AI209155, AV 125015, AA149944, NY5005, A1796245, AV 130795, AA711073 H20073 R90610 H50207 AA653001 N70406 AW104010 H40770 N33086 D65334
					AV743438, AW130386, BF977248, A1125700, BE091971, AA572869, W00449, A1744165, AA157561
					AA531221, AI275921, AA969778, H95780, N92248, AI159958, N38815, H20143, AI680770.
					AA305332, N77862, AV738026, N72206, AA037790, A1752109, AV743648, AA937128, AA962124.
					AA478395, AV741494, AV740102, H19070, R71518, H18782, R94908, BE621803, R77435, H99652,
_					AA694460, AA641831, H21165, AW511932, AI184349, W38900, AA844297, H46188, W58208,
	_				W40195, R71470, N94261, T31343, BE620993, R70469, BE909620, N25251, A1752110, AV741554,
					AA165011, AA037789, H01343, AA643896, R77524, H23656, R70556, T30654, W37143, AA326924,
					C01763, R91937, W32075, H60231, R92265, H69010, H67121, H71491, H18688, R09629, H38970,
					H27857, AA558120, R94992, R09517, H75393, R99715, H23612, AA326929, AA026672, BF436567,
					H01135, N54428, AA186949, T32463, H59520, AA339137, H39170, AI709334, R86746, N33887,
					R68534, AA305400, N58289, AI351248, AA410643, AC010422.7, AF151898.1, AF059620.1,
					BC001192.1, T52716, T61025, T61577, R26656, R79694, H03303, H03402, H18972, H22368, R87112,
UDANABIE	7,	310172	1 007	١	H60187, H60393, H81427, H84495, N71651, W31583, AA164972, AA188345, AA419096.
	ţ	660170	1 - 00/	170 - 61	WZ/053, A100U/04, AA0UY019, BF43Z9Z9, AA/06Z48, AI3/08/0, AV/48/Z4, AIZ91/3/, HY6UI3,
					AW02109/, AI033036, AI/64313, BE340233, BF960699, BF977463, ALI36479.4, ALI32833.4, AI 121755 33
HBGBA69	35	1352289	1-967	15-981	AL520900, AL520550, AL520551, AL521649, BG029889, AV704088, AW372721, BE264987,
					BE906201, AL037829, BE782595, AA779652, BF724791, AW372704, AL037830, BG104612,
					AA722880, N21569, AA478642, AA447813, BE349318, BG254734, A1168324, BE047392, AW131642,
					AI590628, AA410845, AL520901, AI829611, AA447814, AI359892, AI142945, AA252189, AA974206,
					AI142943, AI190425, BF508776, BE350039, D59872, AI446645, AI335769, AI268764, AI077663,
					AA776515, AI806892, AI085888, AW083118, AA554318, AI439022, AI373036, AA302641, W73952,
					N42730, AV683614, AA594115, AA936827, A1249488, A1917956, R66420, AW511599, AW151261,

HBIAE26	36	514418	1 - 1024	15 - 1038	AA861454, AA235619, W77995, W73457, BG164250, W73178, D59873, BE907089, AA678939, BF767379, AA447665, A1050015, H43132, A1367631, A4433148, A1693776, AA156886, BF872750, A1868651, W93317, H42365, AW960535, AA38644, AA652709, AA655796, C21518, AA479185, F21903, AA174524, A1015576, AA421010, AA766077, AA652709, AA535245, AA303411, AW326879, AA4313886, AA442399, AA4421396, AA442390, AA6742390, AA642100, AW3727119, AA952039, AA4917381, AA336082, AA433989, AA4313886, AA742390, AA603705, H84185, AA15719, A9950403, AA170721, AA827896, AA776421, A1057711, AW303838, A1636557, AL044011, AA8912040, AA667720, AA67421, A1051711, AW303838, A1636557, AL044011, AA991201, AA815406, R06679, A1076240, AA773592, BF736165, AA768150, AW170714, BE171275, T24558, A1222466, AL521648. AC008569.6, AC011479.6, AL031659.9, AC003365.2, AL353807.18, AC016464.1, AL139353.3, AC008569.6, AC011479.6, AL031659.9, AC008386.2, AL5363440, AL0373740, AL03747011, AL03747011, AL03747011, AL03747011, AL03747011, AL0374701169.6, AL139384.16, AC0063201, AL024498, 12, AC0053721, AL03747211, AL0374721, AL137224, AL1372241, AL137224, AL1372241, AL137224, AL1372241, AL137224, AL137224, AL1372241, AC0064201.3, AC006465, AC008401.5, AC006489.2, AC001261.3, AC0064901.5, AC0064901.1, AC0064901.1, AC004491.1, AC0064901.1, AC0064901.2, AC0064901.1, AC0064901.1, AC0064901.1, AC0064901.1, AC0064901.2, AC006591.2, AC001236.6, AL13771.1, AC0064901.3, AC006480.3, AC006591.1, AC006480.3, AC006591.1, AC0064901.3, AC006480.3, AC006591.1, AC006291.1, AC006391.3, AC006591.1, AC006490.2, AC006291.1, AC006291.2, AC006391.3, AC006480.3, AC006591.1, AC006291.1, AC006391.3, AC006591.3, AC006591.1, AC006291.1, AC006291.1, AC006391.3, AC006591.1, AC006291.1, A
					AL121826.11, AC005480.3, AC083871.2, AC008155.9, AP000555.1, AC009470.4, AA1136105 9, AL049776.3, AC008745 6, A
HBINS58	37	1352386	1 - 829	15 - 843	
HBJNC59	38	1125802	1 - 1047	15 - 1061	AW007501, AA902287, AI858092, AI005351, AW959933, BF342564, AW083940, BF820646, AI870864, AW960414, AI032697, AW149115, AA829811, AA709070, AW264612, AA643392,
					A1951841, AA614344, AI312642, AA533443, BF850030, AI799536, AA991955, BG222284, AI830766,

	AA594172, AI289881, AI741805, AI276207, AW088660, AW268666, AI749660, AI369678, AI264768,
	AA625243, AI816740, AI190367, AI510691, AW168615, AI817506, AI792359, AV695532, AI291890,
	AW089929, AI268176, AA617718, AI609047, AI913963, F34379, AA985480, AI282722, AI394498,
	AA864826, AW050814, AW800132, AI494152, AI868440, AW800119, AA991995, AA937062,
	AW129114, AA877343, AW594090, AI335628, AA335122, AA737786, AI708280, AA642608,
	AA318733, AI245599, AW054951, AA603928, BF877450, AI074177, AA936631, AA569858,
	AW080143, AI768186, AA995511, AA317892, AI718073, AI915027, AI963480, BF820659, BF913950,
	AA318753, AA345519, AW796949, AW800259, AV714865, BF755228, AI291076, AA335136,
	A1340221, W87494, AW083985, A1739187, A1830861, A1351218, A1266613, AA779248, T53694,
	AA335121, AI950591, AA746624, R23643, BE826140, AA804997, AA740560, AI749854, AW148663,
	BE773353, AA961830, BF810637, BF810673, BF813070, BF812010, BF813049, R35066, BF945171,
	BF813054, BF813079, AW168417, BF810677, AI299182, BF813063, AA878942, BF810666,
	BF810872, AA983420, BF813082, AA367958, BF810669, BF810657, BF811989, BF810652,
	BF813065, T53693, BF813069, BF813073, BF813052, BF812005, BF813066, BF810672, BF813053,
	BE826066, BF094201, BF813085, AA804991, BF812479, BF811996, BF812002, BG151300, AI198965,
	BF813100, A1913330, BE826068, BF849490, BF812030, BF812029, AA862333, AA632062, BE965724,
	AW084151, BE900751, BF815930, AI570169, AI281867, AI345416, AI345612, AI345415, BE891834,
	AV756343, BF911517, BF339322, AI950664, AI335426, AI348777, BG166654, AV746955, AI554821,
	AA464646, BF904192, AI690813, AW083572, AI249946, BF840692, BE967104, AL045421, AI890907,
	AW193467, AI277325, BF025791, BF812936, AW263569, H89138, AL514763, AA641818, AV709679,
	AI491916, AW005612, AV682150, AI633125, AV746964, BG104819, AW827289, AI538850,
	AL046942, AI185535, BF812963, BE906419, AW827227, AI955906, BE895585, AW162194,
	AL048644, BE295833, A1114703, A1817244, BG029829, AL134712, BF885082, AW020419,
-	AL039086, AI636619, AW168503, AA761557, AV744136, AI866469, BG032036, BF792099,
-	AL515375, AL514829, Al568060, Al540606, AA830839, Al678446, Al823719, T99953, Al567582,
	BF792961, BF872670, AL038564, BE892296, AW105601, BF911528, AF135157.1, AF260332.1,
	AL137461.1, AB052176.1, AL049452.1, AF217966.1, BC008078.1,
	BC007375.1, AK000647.1, AL122106.1, BC007198.1, AL136850.1,
	AL389935.1, AF348209.1, AL353625.5, AK027081.1, BC008280.1,
	BC006133.1, AL137548.1, AF205073.1, AL157431.1, AL050170.1,
	AF132730.1, AF061573.2, AL080074.1, AF218031.1, BC001785.1, A
	AF183393.1, AB050431.1,
	AF058921.1, AL583915.1, AL133010.1, AF026816.2, BC004222.1, AK025339.1, BC004362.1,
	AL136768.1, AF162270.1, BC004905.1, AL137476.1, BC003569.1, AL122110.1, AL133014.1,
	S78453.1, AB048888.1, AL162003.1, BC002519.1, AL389957.1, AF106697.1, BC004908.1,
	AL137539.1, BC005151.1, AF218005.1, BC002631.1, S76508.1, AB055290.1, AK026593.1,
	AL136799.1, BC003687.1, AB063088.1, AK026526.1, BC009294.1, AL137537.1, BC006164.1,

		-			AL137530.1, BC003610.1, Z82022.1, BC008485.1, BC007767.1, AL136754.1, S77771.1
	.				AF239683.1, AK024524.1, BC003052.1, AF003737.1, AK026522,
					BC008417.1, BC008751.1, AL133049.1, BC002733.1, AK026532.1,
					AF169154.1, BC003410.1, AL136928.1, BC001236.1, AF073483.1,
					, AK026947.1, BC007641.1, AL122098.1, AL133016.1, AL353940.1,
					AK024622.1,
					BC008070.1, AB062942.1, AB050410.1, AL133640.1, AL080154.1,
					, AB060916.1,
					AF022813.1, BC009033.1, X76228.1, AL.
					AB048954.1, AL137538.1,
_			-		AL136787.1, AF285167.1, A
					AB047930.1, AK025798.1, AB060903.1, AK026038.1,
					, AL137641.1, BC001470.1, AB049848.1,
					AL136845.1, AB063070.1, BC002798.1, AK027113.1, AB060873.1,
					AF114818.1, AB060929.1, AK027204.1, BC001963.1,
					AK026924.1, AJ010277.1, AF321617.1,
					AJ242859.1, 1
•					, AB060887.1,
					Ú91329.1, BC004950.1, AKÓO
					, AB060897.1, BC004370.
					AK025573.1, AL137574.1, BC005843.1, AK026649.1,
					AL137488.1, BC000348.1, BC008930.1, AL359941.1, BC000051.1
					BC004945.1, AB051158.1, BC007280.1,
					BC004530.1, AL137560.1, BC002355.1, AB060832.1, AK000636.1,
					AK026885.1, AB060863. 1.
HBNAW17	39	526797	1 - 587	15 - 601	AA713518, AA807610, AW104604, AA830415, AW975518, AL138824. 19.
HBOEG69	40	793786	1 - 1397	15 - 1411	AW576190, AA524064, BF701378, AI337569, AW058654, AW964434, BE568412, AW978965,
					AW241842, BE221243, AI346249, AW241843, AA825846, AA936562, AI184881, AI346396,
					AA570030, AW368546, AA465472, AW995507, AW361365, AV743550, W74158, AV750714,
					H80936, BF879997, BF880246, A1144077, AV743963, AV740879, A1053597, A1222773, R95913,
					BF901243, AA318779, BF088361, D62291, R27740, BF767423, AI277044, AV743740, AI053934,
					AI310256, R27741, R08998, C00592, N64904, AA827757, AK024978.1, AC006146.2, AF147723.
HCACU58	4	625923	1 - 1540	15 - 1554	AW470141, AI540555, AI150724, AU120416, AA547979, AI187148, AA287570, N32944, AA255853,
					AI802087, AW276458, BG009661, AI923052, AW976784, AA904211, BF805088, AI278972,
					AW269504, BF942976, BF939548, BF725844, BF944736, AV720367, BF920612, AA812058,
					AA410788, AA535216, AW069227, BG056362, AW965008, BE265787, AA425924, AA873573,

_	AV719902, AW819125, AI634187, BF804385, AI445582, AA487475, BF965394, AI160786,
	AA742815, AI133514, AI608699, BF767878, AW023111, AI625604, BE139139, AI491765, AI457313,
	A1733856, A1250552, A1792521, AW969743, AA228778, A1279417, AA483606, H73550, AA570740,
	AU147162, AW505253, F28204, BF857849, AI284543, AI889579, AI251034, AL527073, AI251284,
	A1251203, AA470512, AA315361, AW972919, A1679002, AV760019, AA568204, A1538236,
	BE645220, AA847508, AV695478, AI291439, AI884383, AL047467, BF968874, AI537995, AII30709,
	AA730305, N59569, AW968564, AI890324, AW674631, BF725761, AI223626, AW341978, BE138509,
	BG250286, AI679759, AI814682, AA847427, AV725627, AI889696, AI254770, AA456924, AA714110,
	AW805539, AI053688, AW575000, AW131417, AA832145, AI573198, BG230549, BE138594,
	AL041375, AC009511.16, AC005071.2, AC020913.6, AC005081.3, AC004166.12,
	ζ,
	AC005011.2, AC019206.4, AC009412.6, AC007664.12, AC018642.6, AC011461.4, AF053356.1,
_	AC005080.2, AL136123.19,
-	AC016776.6, AP001718.1, AC008569.6, AC004965.2, AC004089.25,
	AC004971.3, AC004531.1, AF001549.1, AL031276.1, AL137792.11,
	, AC011489.6, AC004859.2, AC005484.2, AL096840.25, AP001753.1,
	AP000350.1, U52111.2, AC
	•
	AC005529.7, AC022383.3, AC002300.1, AF134726.1, AL133367.4,
_	, AP001711.1, AL109623.9, AC007227.3, AJ400877.1,
	AC009509.7, AC019205.4, AC009488.5, AC009488.5, AC009509.7
	AP000045.1, AC008395.6, AL031283.26,
	AC005625.1, AC012476.8, AC020658.6,
-	, AL121586.31, AL049795.20, AE006463.1, AC003108.1
	AL049872.3, AC020904.6,
	AC002425.1, AP000116.1, AB043547.1, AC069262.24, AL354720.14,
	AC083884.6, AC006088.1, AL121972.17,
	AL390738.4,
	AC004846.2, AC004167.1, AL109758.2, AL451125.7, AL139390.15,
	, AC008481.7, AL354928.9, AL136418.4, AL139054.1,
	AC007003.4, AL050318.13, AC004638.1, AC011514.3, AC004883.2,
	AC005702.1, AC009996.7, AC010326.6, AC008521.5, A
	AC004834.2, AL022396.1, AC018711.4, AC005520.2, AL078461.38, AC074121.16,
	AL121905.23, AL022318.2, AC010494.4, AC027125.4, AC005971.5, AC005000.2, AC008551.5,

HCE5F43	44	612796	1 - 1751	15 - 1765	H56891, BF813356, BF957635, BE827070, AIS60786, R64335, T77787, AW380761, AI057520, AW380835, AI870267, AI26380, BE563729, AA52853, AA588228, AW955408, AI277032, R18259, AI566653, T33783, AW883586, D53543, BG105324, AW452975, R60940, H41337, R36021, T32921, BF895461, AI360103, AW380828, BE256741, AA057061, AI564056, AW377298, AI244916, W35216, BE562875, AL040896, BE501695, BE351024, BF658407, BE263817, T1786, AA812926, AA830861, BE562875, AL040896, BE501695, BE351024, BF658407, BE66331, AN36394, AW604793, AW273608, AA610114, AA865732, AW5039474, BF848412, BF312802, BE171868, AW604793, AW273608, AA610114, AA865732, AW365958, AA54542, AU689686, AA359625, AL520577, AI150519, W31778, AI150517, AW997867, AV704757, AV704824, AV705873, BF244940, AI050519, W31778, AI150517, AW997867, AV704757, AV704824, AV705877, BF154789, AI37490, AI800985, AW669497, AI056398, AA1522805, AU15756, AU15864, AW473477, A155531, BF248490, AI800985, AW069497, AI054499, AA1552805, BF248490, AI800985, AW069497, AI054495, AA152809, BF248416, BF248416, BF24840, AI800985, AU158677, AA3586536, BF248416, BF248494, AA256954, AA256954, AV720349, BF248595, BF24899, AA25646, BF048221, AA3560955, AU160123, AA25867, AA2566530, AW362472, AA320096, AA256646, BF094899, AA1604979, AA25899, AA1604377, AA256646, BF094899, AA1604979, AA25899, AA1604979, AA256945, AA566954, AA566959, AA73818, AA256955, BF088653, AU160284, AA256954, BF084201, AV720349, NA2280, BF084190, AA25845, AA566955, AA73818, AA256646, BF094389, AA1160739, AA25890, AA256661, AI55899, BF144811, BF536773, BF088500, BF188500, BF1888500, BF1888500, BF1888245, NG2776, BF1885600011, AB056410.1, AB056410.1, AB056410.1, AB056410.1, AA26664, AA36664, AA36664, AA166997, AA416907, AA2664, BF341481, BF536773, AA416901, AA264011, AA26664, BF341481, BF536773, AA416901, AA264010.1, AA26645, BF341481, BF536773, AA416907, AA264010.1, AA26464, AA26664, AA416900, AA36600.1, AA36696, AA416900, AA36600.1, AA36696, AA416900, AA36600.1, AA36600.1, AA36600.1, AA36600.1, AA36600.1, AA36600.1, AA36600.1, AA36600.1,
					AA228781, M86149, T08275, AA386225, AA417008, AI671567, T15689, AW128975, AA432098, AA228781, M86149, T08275, AA386225, AA417008, AI671567, T15689, AW128975, AA432098, H83023, M85314, AI277779, BG222958, BF923571, M79106, BG152559, R13095, R11764, R21361, BF921573, F05369, T28040, T10247, AA323697, AI361427, AW235399, AI352392, T10246, R37689, AW594074, R40527, H82804, N59328, BF894586, R46460, T15861, BE672078, C14288, D25217.2, AF319633.1, AL022327. 17.
HCENK38	46	658737	1 - 1495	15 - 1509	BG178033, BE896063, AV722833, BE907276, BE277857, BF952019, AA521308, AW182868, AA908959, AI628880, AW173363, AW665845, BE870003, AW631238, AI151418, BF996707, AI818267, BG180581, AI653663, AA001203, BE150445, R78710, AA130178, W03542, AA746655, A1828924, AA001202, A1961323, BE277870, A1093113, A1377976, A1951984, AI635625, AI624029, A1418242, AW088095, A1346936, W92652, AA130170, AA024605, W60401, N53543, AI207798,

HCEWE20	47	543370	1 - 871	15 - 885	AA969140, AV706224, AA206833, AA862855, AA883077, AW173095, AW467519, BF830518, AI890288, AW952261, AA676671, R76291, AA641764, W60310, A1536758, AA742467, W92685, BF830522, C01747, BF029590, AW273509, W72474, AL047568, A81863984, W46673, AA928559, H97873, W46482, AA969604, T17266, W92828, W94587, BF963436, AA024606, AA973624, R61420, BF107415, A1932612, W76228, N72501, BE147741, AA160170, A1247642, A1499771, AW582120, N92375, A1803849, C04881, AW192182, N67695, R76925, AV728500, BF906742, AA641806, AA66191, BG104607, H00789, T31087, R61378, BE706416, AL047509, R78711, R76557, AA564390, AA992073, C15162, A187994, AW779277, H39225, AA812071, W61163, H85007, AA733042, W61229, A1016971, H81599, H97053, R78466, H86612, H85634, AW952259, AW889353, AA021401, A1540906, W24617, R62435, AA714924, H86032, R78534, AW952259, AW889353, AA021401, A1540906, W24617, R62435, AA714924, H86526, H85634, AW952259, AW889353, AA021401, A1540906, W24617, R62435, AA600097, AR5526, H85633, AA021275, R21120, H85004, AA774992, A1834296, AA10089, H81598, AA918880, BE903841, T8911, BF834059, AA501886, BE90384, AA573651, BE843503, T32504, AA010588, AW380818, BE881856, A1879932, A1874934, AR573651, BE843503, T32504, AA010588, AM507504, AN10576, A10776, A10756, A10776, A107576, A107574, A1984510, AL047920, AA182081, AL133942, A194093, BE165748, A1811494, AW090210, AA346162, AW16742, A1687804, A740939, AA77672, AW889501, AA613244, A1887321, AA643785, AA633390, AU143906, AV19347, A135077, AW17724, A1887517, AA693991, AA613244, A1887321, AA643785, AA633390, AU143906, AV19347, A1362951, W58428, AU146966, AA847621, A1564233, A191109, AA633803, AV17231, AW177204, AA598717, AA5887721, AW177204, AA598717, AA5887170, AW177231, AW177204, AA598717, AA5887170, AW177231, AW177204, AA598717, AA5887170, AW177231, AW177204, AA598718, AV177231,
					AA493751, AW994225, C17730, AA724159, AU145383, AA157033, AA041332, AA166854, H96719, AA055654, H65500, AA219480, AU148220, A195333, AL523955, A1132962, AW084901, N48690, A1862874, D29455, AA598990, BE044603, AF074627, AV730577, BG235936, AA878800, R94112, AW275729, A1376984, A1951835, AA101456, AA503213, AW440351, A1735074, AW177266, BE904846, AA846188, AW177226, BE152426, AA493735, AA593081, AW615437, A1538654, AA404968, AW813744, AA669580, F03370, AA350922, AA356989, A1421079, AV728282, AW771706, N76124, A1189033, AA584498, A1961771, AA953572, AV719696, AA467957, H04879, BE159220, T69889, AV720543, H97020, AA467904, AW074001, AF2825201, AC073310, T
					AK026100.1, AL030995.1, AL445236.22, AC023160.31, AK027219.1, AC003977.1, AC008945.6, AJ271735.1, AC012172.6, AL161415.2, AL139125.18, AC002217.1, AC023892.35, AL512629.7, AC069228.26, AC011998.8, AP000075.1, AC008651.7, AL133238.3, AL359816.16, AL121694.4, AP000639.4, AC004029.1, AL121757.7, AC002349.1,

				AC004397.1, AF003627.2, AC018637.3, AL355615.12, AL133325.20, AL356113.8, AL121986.12, AC004636.1,
				AL390025.8, AC0088496.5, AC009812.11, AL136374.4, AC007388.3, AC005280.3, AL133404.8, AC012309.7, X14975.1, AL133240.3, AL158069.16, AC011310.3, AL356782.14, AL158055.12.
				AC010285.4, Z84482.1, AL359950.4, AL034428.4, AC010145.9, AL441887.9, AC003085.1,
				Z83836.2, AC025420.26, D86996.1, AC007392.3, AC007207.22, AC020717.3, AC022316.18,
				AP002532.1, AC012323.7, AC026413.5, AL590792.1, AL031387.4, AC022083.6, AL512885.4, AK021525.1, AC005614.1, AC008162.3, AL136170.12, AF248484.1, AL033524.11,
				AC007051.3, AF127577.2, AC016396.5,
				AL353580.7, AL354758.14, AJ251973.1,
				AP001669.1, AL590404.5, AC010276.6, Z73497.1, AC013355.7,
				AL049570.11, AL590387.7, AC008518.3, AC003670.1, AL160236.4, Z95114.19, AC025212.5, AC017060.7 AL031224.1 AF127936.2 AC004703.1 AC018641.3 AC000037.6 Z81007.1
				, AL031321.1, AL158841.6, AC007917.15, AL031320.6, AC005730.1
				AL121775.3, AC004692.1, A
				, AC003687.1, AL138807.12,
				AL356108.12, AC005157.1,
				AC004998.2, AC073141.4, AC003961.1, AL133211.9, A
				, AF170702.1, AC005250.1, AL159990.12, AC087083.2,
				AL034407.1, AC003666.1, AL137016.11,
				", AC008038.1, AK021760.1, AL023773.1,
				AL392166.19, AL163207.2, AC00/907.2, Z98036.1, AC087258.14,
				, AC008/23.3, AL109854 10
				AC006565.4, AL034417.14, AC010583.5, AL109742.12, AC013602.4.
				AC008561.4, AP002448.3, A
				, AC010632.6, AL160397.17
				AC000126.1, A
				AL355381.11, AL355852.23, AC007551.1, AL136315.9,
				AL161804.4, A
				AC007001.2, AL136129.23,
				AC025519.10, AL359197.20,
\dashv	\dashv	\dashv		AL391495.16, AL451146.7, AL035494.8, AL353788.33, AL163953.3, AC004189. 1.
HCFNN01 48	8 430297	7 1 - 1247	15 - 1261	BF592932, AI660093, AI917105, BE502245, AI435489, AI168436, BF131228, R69799, R67877,
				R81389, AW170015, R34017, D51015, AI283968, R69800, F08994, F08984, T16467, R81390, R67878,
				R33479, AI581033, BF981109, AL110306, AI929108, AI538885, AL046944, AI889189, AW858243,

	AL039390, BF795712, BG257535, BE963035, BG110517, BG029667, A1433157, BG252929,
	AI539771, AW162194, AI345688, AI537677, BF811804, AI500659, AI815232, AI801325, AI500523,
	BF812438, AI500714, AI433976, BE885490, AI923989, AI284517, AI500706, AI445237, AI491776,
	AW151138, AI521560, AI500662, AI284509, AI866573, AI633493, AA470491, AI434256, AI888661,
	AI284513, AI888118, AL045626, BF911521, AI671642, AL036403, AW022808, AL041150, AL513577,
	AI620284, AI582932, AI888665, BF812963, AI828574, AW022682, AW023338, AW673679,
	AI274759, AI554821, BG260144, AI648567, AW151136, BE877142, BE047852, BE897632, AL048656,
	BF338002, A1494201, A1889168, A1866465, A1355008, A1538850, A1623736, A1872423, AL046926,
	A1440252, AV729760, A1582926, AL045500, A1539800, AW172723, A1440263, A1866469, AL513991,
	BE886728, A1434242, A1805769, AL513597, BG120706, A1859991, A1436429, A1889147, A1355779,
	AI371228, AI590043, AI491710, AL047422, AI866786, AI860003, AI610557, AI242736, AI887499,
_	AI539781, BG109270, AI539707, BF965814, AI559957, AI690389, AI521571, AI363957, AW087199,
	BE620438, Al371251, BF055899, Al887775, AL513977, AL514473, BE537531, AL042377, AL514563,
	BF529870, BF725001, AW935969, BF054877, BF527014, BF092710, AV681756, BF971016,
	AL079963, BE965432, AL079960, AV682040, AW087445, AW089557, BG108350, AW150578,
	BF812961, AI491852, BE895585, BE875407, AV713079, AI345778, BG255895, BE968711, BF970768,
	A1468872, AL119863, BE612681, BE908335, BG114985, A1954422, BG249582, BF726237,
	AW827289, A1866510, BE047833, BF726207, BE910373, BF793176, A1890907, BF911517, AL120588,
	AL513757, BF812960, AL037454, BF812938, AL514763, BF970652, AL038778, A1889148, BF680133,
	AV741327, AI687166, AI273179, BF970449, BF032768, BF856052, BG151388, BE785868, BF338723,
-	A1537273, BE876033, BE874133, AW020693, BG252040, A1275175, AW827276, A1364788,
	AL038565, BG179993, AI269862, AW827206, BF038131, AI582912, BG107844, AI866461,
	BE880182, Al923046, BG058150, Al801793, BE964614, BF339322, BG110684, AL042551, BE047691,
	BF822127, AL513905, BG027628, AI499463, BE047952, AV682502, BE783752, BE018334,
	BG180295, AL514579, AW020397, AW983783, AW090393, BE878014, AW129929, AI610362,
	726183, AI254727, BG118199, BF924855, AL117435.1, BC000090.1,
	AL122050.1, AL137533.1, AF056191.1, BC005168.1, BC008282.1,
	AK024538.1, AL512733.1, AL512689.1,
	AK024992.1, AF218014.1, BC008280.1, S78214.1, AL049382.1, AF
	AB056420.1, AL096744.1, AK000391.1,
	AL136749.1, AK026592.1, AL136893.1, BC000785.1, BC004905.1,
	AL049283.1, AK026597.1, AL512684.1, BC008899.1,
	BC006412.1, AK027136.1, S61953.1, AB063093.1, AL110221.1, AL
	BC008488.1, AK027096.1, AK027146.1, AL359601.1, AK026532.1,
	AK026534.1, BC002750.1, AL162008.1, AL110196.1, BC003614.1,
	AK025435.1, AB055303.1, AB060887.1,

				AK026784.1, AK025092.1, AF159615.1, AL137574.1,	1_
				AB052200.1, AB04/631.1, AK000323.1, AL122093.1, BC00/031.1, E AL050024.1, AL133640.1, AK026164.1, AB060879.1, AL137459.1, A	BC0080/0.1, AL136622.1, AL442082.1, U80742.1,
				AL110280.1, BC008382.1, AB055315.1, AL137529.1,	~
		_		BC001967.1, AK026045.1,	AB063046.1, AK027182.1,
				, AK026927.1, AF111847.1, AF104032.1, AF078844.1,	AK026533.1, AL137283.1,
				B060826.1, BC004349.1, AK000445.1, AK000432.1, A.	99431.1, AK000212.1,
					AK027113.1, AF097996.1,
				AB050510.1, AK025339.1, AL162006.1, BC001098.1,	
				AL512719.1, AK026647.1, AL359596.1, AB047904.1,	
				AB063100.1, AL137521.1,	.122049.1, AF218031.1,
				AL133080.1, AL136786.1, 1	25209.1, AK027204.1,
				AL050116.1,	C004556.1, AL136586.1,
-				AL162004.1, AK027868.1, X82434.1, AF353396.1, A	25948.1, AL122118.1,
	_			AL136892.1, AL133072.1, AF057300.1, AF057299.1,	
				BC004529.1, AF245044.1,	BC005890.1, AB055374.1,
		-		AL122111.1, AK026741.1, AK000074.1, AK026613.1,	
				AF061795.1, AK025015.1, AF151685.1, AL122045.1,	_
				AB056768.1, AL122121.1, BC003687.1, AF061943.1,	
				AK026855.1, AL512718.1, AK024588.1, AL049466.1,	AB048964.1, AK025967.1,
				AL049452.1, AL137271.1, AB060837.1, AL353957.1	L117583.1, AK025414.1,
	-			1, AK000647.1, AK026762.1, BC008417.1, U68233.1,	
				1, AL137558.1, AL050108.1, U38847.1,	AL136845.1, AL080126.1,
_				L136787.1, AF242525.1, AL137292.1, AL137463.1,	AL136799.1, AF285167.1,
_		\dashv		AK024524.1, AL359941. 1.	
HCGMD59 49	636078	8 1 - 776	15 - 790	A1346379, AW009453, AA477432, AA152289, BE219294, T27069, A1745607, AW852105, A1807602,	7, AW852105, AI807602,
				AA234651, AA024744, BE219304, AA065244, N91858, AI242569, AI091032, BF977615, AI251849,	2, BF977615, AI251849,
				H88431, BE301616, N50522, BE762367, AW607675, F03857, H41152, BE696404, R45373, BE070278,	96404, R45373, BE070278,
				H88369, AL039156, AU133046, AL038837, AL039074, AL039564, AL039109, AL039108, AL037051,	09, AL039108, AL037051,
				AL038531, AL039659, AL039625, AL039648, AL039629, AL039678, AL039150, AL039128	9150, AL039128,
				AL037726, T79771, AL040992, AL036725, AL045337, AL042909, AL039423, H53427, AL039410,	3, H53427, AL039410,
				AL045353, AL037526, AL036973, AL044407, AL039538, AL039386, AL044530, AL036196,	4530, AL036196,
				AL039924, AL039566, AL039509, AL038025, AL039085, AL037639, AL038821, AL036767	8821, AL036767,
				AL043423, AL045341, AL037615, AV743601, H53426, AL043422, AV746102, T24119, T24112,	02, T24119, T24112,
				AW975143, AV758878, AL036238, AL043441, AL036117, AL043445, AW013814, AV718844,	13814, AV718844,
				Z99396, AV738934, AL045794, N91869, AV737584, AW973101, BF294063, BF508972, AV743654,	, BF508972, AV743654,
				AL036924, AW975229, AW979144, AI535983, AV717989, AV717980, AW451070, AV701782,	451070, AV701782,

					AV718018, AV717988, AV731085, AW973200, AV701012, AV718016, AV717953, AV717984, AW064110, AV718023, AI002696, H00069, AW607606, AV735727, AV717963, AV717962, AV720464, AL036733, AV745724, AV717966, AV745723, AV717960, AV718002, AV718000, AV702029, AV699447, AV745917, AV745080, AV717966, AV717960, AV717981, AV745350, T23947, AW975161, AL038851, AV717963, AL037054, AV701017, AV717941, AV740535, AV701043, AV77163, AV7717983, AL037054, AV701017, AV7745392, AV717978, AL036188, AL036168, AW9776163, AV7717941, AV7740535, AV701043, AV7701163, AV7742995, AV717990, AV7722801, AV7717970, AV7745392, AV717978, AL036188, AL037177, AW975203, AV717990, AV7722801, AV7717990, AV772308, AV7717978, AL036188, AW9770521, AV745089, AL036191, AV717942, AV717978, AL036189, AW975312, AW963383, AV170942, AV7179458, AV7718006, AL03698, AL036133, BF438013, AV741012, AV718010, AV717945, AV718021, AV771906, AV777911, AW979128, AV7717964, AV7724520, AL036488, AL036613, AW975312, AV7717949, AV718001, AV7718010, AV7717988, AL036163, AV7717986, AV7717949, AV7718018, AL036163, AW971000, AW063533, AV770601, AV7447001, AV717974, AL036163, AW971000, AW063533, AV701332, AV742001, AK000326.1, AL139286.13, AV718013, AW972784, AA961091, AW681208, AV701332, AV742001, AJ244005.1, AJ244005.1, AF271371.1, Z96142.1, X73004.1, AJ244003.1, AJ244003.1, AJ244005.1,
					Y11926.1, D14548.1, Y11923.1, D34614.1, L27636.1, S83538.1, M32676.1, S65373.1, S78798.1, X73003.1, Y11920.1, S85459.1, X92518.1, U50871.1, AB026436.1, D61405.1, T87293, H41179.
HCHNF25	50	1352270	1 - 3562	15 - 3576	AL528465, AL519763, AL526785, AL520938, BE792140, AL520937, AL527998, AL519764, AL528805, AL526872, BE796431, BE746920, BE383840, BE790802, BE277211, BE253824, BF314475, BE796466, BE515157, AL522365, BE792677, BE561212, BE905641, BE902997, BE744397, AL524630, AL528908, BE514253, BF310540, BF569123, BE906475, BF206368, BF528971, BE887141, BE791917, BG026441, AL522366, BG115233, BF973161, BF568333, BE250017,
					BE396510, BE903106, BF347981, BF220140, BF128023, BF310318, BE780328, BE267959, BE783597, BF972622, BE397012, BE396688, BF127846, BG105951, BF219907, BF206556, BE789125, BG113261, BF183102, BE893242, BG026796, BE271726, AV753314, BG107642, BF965674, BF185761, AI625920, BF681098, BE909654, BE561350, AW275869, AI738622, AW007183, BE9909375, BE78249, BE901071, BE785884, BE621366, AI860983, BE855860, BE252957, AI685085,
					AW250561, BE260127, AW270016, AI634191, BE300918, BE398115, BE782484, AI709014, BG036598, BE264246, BE294812, BF983181, AI670007, AW131857, AI880395, AW117176, BF104971, AI813518, BE909039, BE621619, BE795421, AV760771, BE394970, BE966882, BG257502, BF037247, AW573314, BE545785, AA203110, BE207736, AW665822, AW188410, AM5653778, AW507510, AW77850, AA147757, AI666418, A1147751

AA181845, AW241902, BE786856, AI160413, AW732763, BE880512, BE900799, AI081515, BE251158, BF677734, AI203977, BE348436, BE305074, BE296342, BE273772, BF304443, AW005522, BE561489, BF592041, AA701486, AW956672, AI567481, AI568647, AI041032, AA974916, W37397, BF313875, AW025321, AA186467, BE207298, AA404355, AA129237, AI718057, AA593316, AA478160, AA464385, AA488430, AA994961, AI149434, AI123393, AM151216, BE350585, AA147827, AI950821, AW015199, AA994961, AI149434, AI123393, AI123891, AI384079, AI384079, AI355387, AA835483, AA553902, AA761282, AA588042, AA465513, AA837073, AI334266, AI750141, AA994585, AI927130, AW328560, AA814189, AI074868, AW026369, AW027702, AA418840, AI568234, AA186580, AI560154, W22355, AI032032, AA731626, AA488156, AA411207, AA278716, AI189954, AA586725, AI858753, AA478159, AR633718, AI333776, AW955017, AI658538, AW182215, AI354691, AI369603, AA410975, AI277588, AA731628, AI333776, AW272455, H98820, BF732893, BE395014, AI369603, AA410975, AI277588, AA73380, AI807881, AB016492.1, AB016493.1, BC0004991, AB016488.1, AF115850.2, BC001363.1, BC000396.2, BC001667.1, AF131797.1, BC004239. 1.	AI621217, BF222897, AA632651, AI950250, AW139452, AW207039, AA505117, U69203, AI949187, AW953975, AI160725, BE348367, AI631345, AA707909, AA535510, BG059719, AI680791, AI700776, H17406, AA524577, AA062981, AA365529, H16756, AI699070, AW970783, BE858688, AI696027, BF766585, AV709230, BE220337, AW194354, AA365530, AA678861, BE707377, AL122003.17, AB007895. 1.	AW964468, AW975618, AV741221, AW966389, AV738928, AW949645, AV727978, AW966053, AV724520, AV701357, AV738340, AV731070, AW978633, AW964532, C14331, AW966330, AW960553, AV742090, AV723247, AV744012, AV718489, C14429, AW352117, AW752082, AV702035, AW753053, AW177440, D80045, AW949642, AV742048, AV718800, AW360811, AV741220, AW178906, AV718692, AW375405, D59927, AV742048, AV718707, AW973541, AV721784, AW753067, AV701125, AW178893, AV701216, AV701166, AV701149, AV742001, D80268, AV649986, AV720791, T03269, AW377671, C14389, AV649974, AV720211, AW179328, D80134, AA514186, AV701224, AV701154, AW966029, AW752110, AW966075, AW966065, AW966465, AW973334, AW966531, AW966029, AW752110, AW966075, AW966065, AW966560, AA305409, D58283, AW966022, AV701431, AW966059, AV723097, AW966013, D59859, AW964766, D80022, AV726390, AW966041, D80166, AW973414, AW978661, D80210, D51799, AW965163, D80391, D80164, D59275, AV720533, D80240, D80253, AW966030, AV719822, AW966054, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AV719822, AW966054, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AW966030, AV719822, AW966054, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AW966030, AV719822, AW966034, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AW966030, AV719822, AW966034, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AW966034, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AV719822, AW966034, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AW966034, AV720203, AW366296, AW964756, AW966050, AV719188, AW973307, AV719822, AW966034, AV720203, AW366296, AW966050, AV719822, AW966050, AV719820, AW966050, AW966050, AW966050, AV719820, AW966050, AW966050, AW966050, AW966050, AW966050, AW966050, AV719820, AW966050, AW966050, AW966050, AW966050, AW966050, AW966050, AW96050, AW966050, AW966050, AW966050, AW966050, AW966050, AW966050, AW966050, AW966
	15 - 1343	15 - 712
	1 - 1329	869 - 1
	6169101	526413
	51	23
	HCNDR47	HCNSB61

HCNSM70	33	637547	1 - 1075	15 - 1089	D80043, D59787, D80227, AW966062, AV719324, AV718440, AV718938, AV719783, AV720028, D59502, AW959597, AV718633, AW95628, AW965177, AW965197, AW978931, AV720878, AV718831, AV720878, AV7187831, AV720878, AV7187831, AV720878, AV720878, AV720731, AW97381, AV720878, AV720878, AV720731, AW97382, AW965947, AW9789502, AW958992, AW958993, AV722071, AW973801, AV720731, AW973801, AW9736084, AV720731, AW9736094, AW965002, AW96408, AW96408, AW96408, AW96408, AW96408, AW96408, AW9736003, AW977672, D80196, D80197, AW973406, AV720731, AW973408, AV720151, D80103, AV720151, AW97340, AV699746, AW973405, AV710132, AW7710132, AW97340, AV699866, AW973473, AW973403, AV720151, AW97340, AV699866, AW973473, AW973403, AV720151, AW97340, AV699866, AW973473, AW973473, AW97340, AV699866, AW973473, AW97340, AV699866, AW973473, AW97340, AV699866, AW973473, AW97340, AW97340, AV699866, AW973473, AW97340, AW96043, AW17032, AW710132, AW720151, AW96043, AW170320, AW720161, AW96043, AW972016, AW972019, AW7720119, AW17035, AW7300706, BF904265, BC114104, AI927755, AR67516, AL73964, AB69721, AR67301, AW972013, AW972013, AW972013, AW972013, AW972014, AW972016, AW97
					AW075084, AW073697, BG109270, BG163618, AI349937, AW983691, AV746964, AI921248, AW075084, AW073697, BG109270, BG163618, AI349937, AW983691, AV746964, AI921248, AI611738, AI334884, AI307543, AI348897, AI619502, AI677796, AI632408, AI886181, AW079572, AW071412, AI802542, AI307708, AI620089, AA449768, AI863382, AI288305, AI312325, AW118518, AI499285, AI340659, AW983829, AI886753, AI873644, AI570807, AW168485, AI933589, AW026882, AI635067, AI923370, AW130930, AI336495, AW268072, BE138658, AI783504, AI868931, AI784230, AW149925, BF812960, AI537261, BF885000, AI432040, BE047852, AI620284, BF812938, AI334930,

AI309443, AL038605, AI445992, AA908294, AI445990, AI307520, BF970652, AI284517, AI345737,
AW269098, AI434/41, AW131138, AI308032, AW268231, AI336342, AI433131, AL314877, AI345739, AI702073, AI312143, AL036802, AI345736, AI366992, BE908921, AI344785, BF812961,
BG256090, BE880923, BE536058, AI801325, BF032768, BF856052, AL036403, AW198144,
AW193134, AV716613, AI349955, BF054789, AW827276, AI364788, AW075093, AL036980,
A1499986, A1500061, BE789764, A1590120, A1312357, AL047422, BE886827, AW268768, BG150947,
AI500662, AI890907, AI633125, AI589267, AI698391, BE541445, BF885675, H89138, AI500523,
BF343172, AI915291, AW152182, AA640779, AL036265, BG029667, BG168185, AI582932,
AI554245, BG108406, BF814516, BG180996, BF339594, AI335426, AF304447.1, AF275945.1,
U58996.2, AK000486.1, AK027114.1, BC004958.1,
AL389939.1, AL512733.1, AK000083.1, AL157482.1, S78214.1, AK026741.1, AK025484.1,
 AL049382.1, AB047801.1, E
K024524.1, AK026504.1, AF
l, AL157431.1, AK027868.1, AL049300.1,
BC009033.1, AB060908.1, AL137292.1, AK025491.1, AL136799.1,
BC008488.1, AF104032.1, AF078844.1, AK027113.1, A
AK027116.1, AK026534.1, AB055315.1,
BC008899.1, AK026959.1, AF177336.1,
AL050393.1, AL122121.1, AB052191.1, BC006807.1, AL512689.1,
AL133606.1, BC008983.1, AK026464.1,
AK026086.1, BC002839.1, AB055374.1, AL136540.1, AB055368.1,
 , AK026592.1, AK000137.1, AK025414.1, AB056420.1,
AF057300.1, AF057299.1, AL136749.1, AL133067.1, A
AL162006.1, AL512746.1, AK026630.1, AL110221.1,
, AK025772.1, AL050108.1, AL122093.1, AF230496.1, AL512750.1,
BC002643.1, AL117583.1, AJ242859.1, AK026927.1
AK026629.1, U39656.1, AB060916.1, AK026462.1, AF146568.1, X
 AK000652.1, AB060912.1, AF090934.1, BC008070.1, AB060826.1,
.359618.1, AB060852.1, AI
AF090903.1, AL049464.1, AK025524.1, AL137533.1,
AB062978.1, AL136787.1, BC008387.1, AJ012755.1,
AF051325.1, AB047615.1, AK025958.1, AK026506.1,
 AK025312.1, AK026452.1,
AF106862.1, AL136805.1, X53587.1, AL136928.1, AL049466.1, AF
, AL137478.1, AK025906.1, BC001967.1, AB047904.1, AL359596.1,
AL137459.1, AK026762.1, AL117460.1, AK025798.1, AL133075.1, AL136789.1, AL117440.1,

AK000391.1, AL050277.1, AL117432.1, AL049452.1, AL049283.1, AK026353.1, AK025209.1, AL133098.1, AB055366.1, BC001045.1, AB048975.1, BC003687.1, AB05536.1, AL133113.1, AB056768.1, AL117435.1, X65873.1, AL133565.1, U91329.1, AL080124.1, AL162083.1, AK026583.1, AL390154.1, BC008417.1, AL137560.1, AL13540.1, AK025084.1, AB048954.1, AL136845.1, AK025092.1, AB062938.1, BC002733.1, AL136768.1, AF262032.1, AF190896.1, AL136845.1, AL136892.1, AL137521.1, BC008365.1, BC009341.1, AK027096.1, AL12110.1, AK027096.1, AL162003.1, AB050510.1.	AL532468, BE621866, AL521895, BE621760, BE538472, AL521894, AV734260, AV723629, BE616433, BE770935, BE790853, Al140351, BE621673, BG168718, BF793790, BE998998, BE545559, BE616433, BE395025, BE61900, BF664130, BE621673, Al140351, BE132999, BE717043, AV696286, BF726404, BE018100, BE717057, AA121648, AA762342, BF343084, AA869286, BF726404, BE018100, BE717057, AA121548, AA762342, BF343084, AR86474, AA530873, BF371804, AA722381, AR154682, AI864674, AA530873, BF371805, BF771805, BF771805, BF771805, BF771805, BF771805, BF771805, AA154664, AN6987515, BE717048, AW775317, A1544682, AI859814, BF686844, BG035461, BF977210, AW474962, AI023466, N92869, AA768339, BE395629, BE391588, AI051671, AW753719, BE965688, AI051047, AA043186, AI657303, BF717183, R83064, BE8910299, AA130599, AA582833, AI95244, BF717068, AA417302, AA13059, AA58283, AI95244, BF717068, AA417302, AA417302, AA130892, AA878833, AA100477, AA043186, AI657303, BF7171183, R83064, AW77665, AI014387, AA917486, AA100476, AW406948, A1564973, AA729835, BF594159, AA417265, AI187288, AA045597, AA306867, BE548903, AA642285, AR89903, AA642828, AR642285, AR89687, BE92994, AA588015, AW103201, AA308867, BE548903, AA642285, AR89693, AR886207, AI018462, D82429, AI87388, AI952899, HR1296, BE616655, AW13487, N801977, AA868207, AI018462, D82429, AI87382, AI952899, AR886418, BE829638, AA073892, BE829457, BE829712, BE829673, AR886418, BE829638, AA073705, BF084295, BF084295, BF084295, BF084295, BF084295, BF084295, BF084295, BF084294, BF084296, BF084297, BF084297, BF084299, BF084291, BF084297, BF084291, BF084297, BF084291, BF084297,
	15 - 1139
	1-1125
	720291
	45
	HCUCK44

					AL122042.1. AC007842.1. BC004512.1. AP000892.4. N51146. N74141. W38488. AA100050.
HCUEO60	55	499242	1 - 1208	15 - 1222	AV748967, AV762395, AV761362, AV762397, BG104686, AV760057, BF668217, BF677892,
					AL046409, AV763971, AI284640, AV761489, AI334443, AI963720, AV728425, BG249643,
					AV76349, AW303196, AW301350, AV735370, AV725423, AV762111, AW274349, BF541120,
					AV /62098, BF24196/, AV /63233, AV /392/4, AV /61/86, AIZ/0117, AV /40801, AV /63340,
					A1305766, BG167139, A1431303, AW419262, A1133164, AW268973, AW088846, AW193265,
					AV762505, AI696962, BF131362, BF684828, AW472872, AL138455, BE562953, AW963497,
					AW965008, AA490183, AI281881, AA581903, AA521323, BF827410, AI610920, AV762092,
					BF311000, AV760937, AV732891, AV763354, AL042853, AV762535, AW979060, AV759505,
					AW327868, AL119691, AV762826, AW975987, AI754658, AL038785, AI345654, AW501386,
					AV762645, AV652936, AV763558, AI613280, AV760777, AV733830, AI064864, BE049139,
					AV761941, BF680074, AV764307, BF965007, AV702857, AW662543, AV734666, AA491814,
					AV729809, AI345681, AI679782, AL046205, AW500125, AV759352, AW265393, AV757425,
					AF330238, BF/25504, AV6995/4, AV /64228, H/1429, AW9/4109, AV /64235, BG109996, BF915247,
					AW503666, AW5029/5, AV759204, AA491284, AV761106, AW518220, AW972871, AA521399,
					AV725431, AI307608, BE276880, AV759507, AA610491, AV764578, AI345675, AW975049,
					AW973397, AV762009, AV761884, BF991286, AV735495, AI570261, AL041690, AA680243,
					AV762959, AI144101, AV760486, AL045053, AA587604, AI368745, BF679304, AV710066,
					AV760466, BF793766, AV761745, AW969629, AA526787, AV763633, AF074677, AI732865,
					AI350211, AI890348, AW953071, BE150580, AW576391, AW513362, AL037683, AA469451,
					AU147104, AI708009, AW410400, F36273, BG222267, AV762067, BG036665, AW872676, BE160727,
					AV719316, AW270270, AW029038, AI732120, AA482711, AW021583, AV763847, AV742057,
					AV759172, BF691714, AV713243, AA877817, AW088202, AV729947, AV759214, AW960468,
					AA682912, AV762139, AW072923, AV759580, AV764530, A1345518, AV760106, A1355206,
					A1625244, AV760736, AV763122, AW872575, AA468022, AW769399, AV729881, AV760207,
					BF915628, AW028429, AV759322, AA533725, BF676981, AL042420, AI473943, AI133102,
					AV759518, AW438643, BE674881, BE046438, AW408717, AV733627, AI457397, AV733732,
					AW088616, AV762015, AV757607, BG059568, AW162049, AA584201, AW406755, AW975217,
					A1929531, A1821271, AV756693, AW970564, A1289067, AA629992, AV762154, AU145314,
					AW970896, AI357901, AV764241, AW956640, AI061334, AW265385, BF130605, AI567674,
					D83989.1, X55924.1, AF015148.1, AF015156.1, AL133371.3, U18391.1, U18395.1, U18394.1,
					AL358913.4, X55925.1, AL353812.13, X54180.1, U57007.1, AL391987.15, U57006.1,
					X54175.1, AF077058.1, AB020859.1, U18393.1, X55926.1, U57009.1, AL390056.7,
					AC008430.3, AL161896.16, U18392.1, X76070.1, X54181.1, U57005.1, U18387.1, Z84488.1,

нсинк65	95	651313	1 - 353	15 - 367	AC008543.7, AP001692.1, U18399.1, U18398.1, AP001342.1, AL138919.12, AL1392896, X54176.1, AF015157.1, AC005341.12, X54178.1, AL445932.12, X75335.1, AL391839, AC025865.5, AL049633.3, AP0004273, AC00311.1, U05232.1, AF020803.2, AC03357.19, AL358946.11, U57008.1, AC002462.2, AC00462.2, AC010513.6, X54179.1, Z22650.1, AC012450.3, AC004862.1, AC005297, AC005481.2, AC00581.2, AC00604.1, AL135903.12, AC012450.3, AC021001.5, AP000095.1, AC006435.7, AL050312.8, AL354936.21, AP000239.1, AC012380.1, AF020841.6, AC02221.4, AC0024145.5, AF015167.1, AL079295.1, U67231.1, AP001666.1, AF902881.1, AC002416.2, X55927.1, AL031680.20, AL354668.13, U67231.1, AP001666.1, AF902881.1, AC007403.3, AC003474.7, AL355922.4, Z49816.1, AL229041.1, U67211.1, Z94721.1, AC007403.3, AC004747.7, AL355922.4, Z49816.1, AL35406.3, AL35406.1, AC005407.1, AC004407.1, AC00637.3, AL031677.2, AC007404.3, AC002411.3, AC00241.3, AC002411.3, AC002449.1, AC006312.3, AL13698.3, AC002449.1, AC002449.1, AC006303.2, AC007384.3, AC002311.5, AC00449.19, U12580.1, U18390.1, AL10995.3, AC00748.3, AC00449.19, U12580.1, U18390.1, AL10995.3, AC00449.19, U12580.1, U18390.1, AL10995.3, AC00449.19, AC00631.2, AC006307.3, AC006307.3, AC006307.3, AC006307.3, AC006307.3, AC006307.3, AC006307.3, AC006307.3, AC006307.3, AC006491.3, AC006307.3, AC
					A1221950, Z39489, F02802, AA213383, A1205879, N92722, T08346, R42398, A1743040, R37459, C02421, F04701, N92721, A1861833, W84564, BF062378, BG032378, A1190488, AL442092.1, AC004142.1, AB060967. 1.
HCUIM65	57	550208	1 - 861	15 - 875	BE781101, BE540200, A1972511, BE300952, AA464837, BG150212, A1681901, AW172458, AA099707 AW705564 AW408650 AW705714 AA450308 AA636047 A1656447 BE437116

1, A1620473, AA369585, AW469939, BE551958, AW086133, A1917742,	2, A1334443, AW965008, AV764228, BF697673, J. AV733830, AV713243, AL046409, BE646496, T. AW301350, AL037683, AL120483, AV760466, AV73830.30, AV713243, AL046409, BE646496, T. AW301350, AL037683, AL120483, AV760466, AW008212, AV764578, BF725504, AA244357, AI567674, A. AL041690, AV762645, AV763714, AV760042, 9, AV759505, AV759204, AV760777, AW274349, AV762139, AL044940, AI963720, AV756693, AV762139, AL044940, AI963720, AV756693, AV762064, AV729809, AW518220, BE160727, AV762064, AV729809, AW518220, BE160727, AV763629, AA640772, AA526787, BE779948, O3, AI33164, BG177715, AL042853, AI754955, AV764329, AI431232, AW950797, AW021583, AV764329, AI431232, AW950797, AW19045, AI623720, AV763540, AA491814, AI538433, AU149045, AI623720, AV763540, AA491814, AI538433, AU149045, AI623244, AV763540, AA470969, AW513569, AW1934322, AI345654, AV764490, BF761328, AV762535, AV1282852, AI345654, AV764490, BF761328, AV762533, AU149041430, AC0004041, AL08718.13, AV762330, AC0044919, AR0033572, AP0016701, AC007782.20, AL0312281, AC0006133, AL359236.4, AC0046381, AC0066133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0046381, AC006133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0060133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC0046381, AC0060133, AL359236.4, AC00606381, AC006443.8, AC0060133, AL359236.4, AC004643.8, AC0066133, AL359236.4, AC0066133, AL359236.4, AC0066133, AL359236.4, AC0060133, AL359236.4, AC0066133, AL359236.4, AC0066133, AL359236.4, AC006613.3, AL359236.4, AC004643.8, AC004648.1, AL121751.12, AC0060133, AL359236.4, AC004643.1, AC006449.19, AC004493.11, AC004445.11, AC004449.19, AC004443.11, AC004449.11, AC004449.11, AC004443.11, AC004443.11, AC004443.11, AC004444.11, AC004444.11, AC004444.11, AC004444.11, AC004444.11, AC04444.11, A	ACONEO00 2 ACONOTION ACONSOLO A
BE466112, AW575656, AW962721, AW206882, AA099221, AI620473, AA369585, AW469939, AW136836, BE547752, AI638262, BF059133, AA236642, BE551958, AW086133, AI917742, AI623315, AC005391.1, AL445584. 16.	28 25 35 35 35 35 35 35 35 35 35 35 35 35 35	AT 121655 1 ADD01710 1 AT 121753 20 AC005201 1
	15 - 2777	
	1 - 2763	
	1042325	
	29	_
	HCWGU37	

					AL109965.34, AC006211.1, AL13885.21, AC021506.5,
					AC025540.7, AL136981.22, AC009412.6, AC090257.3, AC002547.1, AP001688.1, AL137141.10, AC016526,6, AP001730.1, AL356915.19, AP001716.1, AL035458.35,
					AC073138.3, AL163218.2, AP001707.1, AL033379.2, AI
		,			AL133232.15, AL096775.10, AC005486.2,
					AC009137.6, AC005019.1, AL118520.26,
					AC011816.17, AC018808.4, AL022163.1, AL139396.17, AL139113.2
					AC005154.1, AC005412.6, AC008101.15, AP003477.2, AL445984.6,
					AL445675.9, AL121868.11, AF053356.1, AC007384.3, AC004263.1,
		•			AL096700.14, AC007374.6, AC006312.8, AL021453.1,
					AC008569.6, AC002558.1, AL022316.2, AP001691.1, AC005295.1, A
_					, AC002430.1, AF003627.2, AC022013.3, AC011462.4, A
					AL122008.28, AL136969.7, AL049762.20, AL109654.22, AL137881
	_				AP001706.1, AL122021.3, AL139021.6, AC026475.6,
					AL121578.1, AL161670.4, AL034420.16, AL589723.7, A
					7, AC074391.5, AC069262.24, AP001720.1, AL355833.4
					AC083871.2, AC079906.15, AC026172.3,
					AC010650.8, AL050307.13, AP001711.1, AC004859.2,
					, AP001760.1, AC007541.9, AC007878.2, AP000215.1, AC000052.16,
					AL133373.5, AL109804.41, AC005808.1, AC008267.6, A
					AC008280.4, AC004841.2, AL157837.10, AC011247.10
-					AC004914.1, AC024563.4, AC008897.7, AF227510.1, AC008481.7,
		-			AP001533.4, AC005488.2, AP002852.3, AC025159.28,
					AC006040.3, AL031737.2, AC004987.2, AL163248.2, A
					AP001709.1, AC002375.1, AC012502.3, AC005052.2, A
		-			, AC009503.3, AF111167.2,
					AC005516.1, Z82206.1, AP000257.1, AL
		-			AL031429.11, AC005146.1, AC016830.5, AC020931.5,
					AC002369.1, AC009516.19, AC005962.1, AC005523.1,
					ч,
					AL158830.17, AL391987.15, AL033383.26, AL137128.4, AL158052.10, AL590682.9,
					AP001718.1, AL354716.9, AL096840.25, AC006006.2, AL121897.32, AC022384.4,
					AC006965.3, AL354864. 16.
HCWKC15	09	553621	969 - 1	15 - 710	AW504485, AI380617, AW805539, AV758903, AL079734, AA916430, AW819125, AV762982,
					A1625604, A1792575, AW084445, AW975210, BE138594, AW069227, AW023111, AV764259,
					A1792521, BE501593, AW021583, A1890324, BF725844, AW438542, BE138509, AV763026,
					AV763058, AA904275, AI521525, AA665330, BE077105, AA501461, AW969745, AW527591,

	AA535216, R94326, BF589824, AA574442, AW338179, AW271904, AI279417, AA651639, AI859946,
	AA524616, AW020150, AA833896, AV761862, AL042373, BE968744, AW004884, BF528591,
	AV760019, AA610509, AU131037, BF804385, AA833875, BF725761, AI053688, AI923052,
	AV761714, AI821714, AI792133, AI791913, AA013168, T74524, AI355246, AW474168, AI284543,
	BF724838, A1912401, AW068596, AV762633, A1564209, AW975626, A1620992, A1821785,
	AA483606, AV756220, AV754716, AA533176, BG236628, AI491765, H05940, BE139139, AA504906,
-	A1250552, AA019973, BE049032, AA223174, A1798449, AA570740, BF965775, AL022238.1,
	ч.
	AC007318.4, AL035659.22, AC074013.5, AC005829.1, AL035252.5, AL590762.1, AC005668.1,
	AC007216.2, U95742.1, AC005480.3, AF196969.1, AL158207.15, AC078846.2, AL121655.1,
-	
	AJ400877.1, AF317635.1, A
	, AC002553.1, AL132777.4,
	AP002815.3, AP001727.1, Z79996.2, AL035455.30, AL033529.25, A
	AC007570.23, AL137229.4, AC004084.1, AC005746.1, AF314058.1,
	, AC010463.6, AC004906.3, AC008044.4, AC022415.5, AC008848.7,
	AC007565.1, AC020904.6, AC091529.1, AC002316.1, AF283320.1,
	AL356113.8, AC005079.6, AL163210.2, AP001725.1, A
	AC008784.6, AL161937.13, AC011481.4, AL354735.14, AC008622.5, AF111167.2,
	_
	AL136300.22, AL121949.13, AL031432.1, AP001561.4, AC013355.7, AC090958.1,
	_
	AC005225.2, A
	AL512347.14,
	AP001753.1,
	AC003070.1, Z
	, AC011495.6, AL354932.26, AC024028.10, AL031846.
	AC026776.4, 1
	AC018663.3, AC009269.6, AL138720.19, A
	AL139041.17, AC004019.20, AC020550.4, AC009623.6, AC005529.7,
	4C004882.2, ∤
	-

					AC0010461.4, AC000052.16, AC025165.27, AC002310.1, AP000343.1, AF129756.1, AC007021.3, AL133245.2, AC005089.2, AC007597.3, AL022163.1, AF168787.1, AC074295.7, AP000759.1, AP000750.1, AP0000505.1, AP000750.1, AP000750.1, AP0000505.1, AP0000
_			_		AL139232.13, AP000065.1, AC016894.7, AC018636.4, AC083884.6, AL139317.5, AL021546.1,
				-	AL136179.15, Z99716.4, AL049643.12, AL022336.1, AC008372.6, AP001169.1, AC018696.4,
					AP000215.1, AC004998.2, AC002350.1,
нрнев60	62	499233	1 - 1407	15 - 1421	
					BG031399, BF219970, AW961043, AW245732, BE540977, BF125197, BE264862, BE264047,
					AA523441, BF348672, BF125434, AW250195, AW860381, AW246993, AI654715, AW168308,
			<u>.</u>		A1949310, AW068175, BE259690, A1393119, AW938768, BE279977, AW938746, BE857719,
					AW190234, AI871661, AA494392, AW900867, AA338903, BG006350, AL527587, BF091980,
					AA602247, BF804618, AW364083, AA357684, AW178944, R40832, BF374357, AW662637,
					AL524365, R42008, C20713, BF360339, BF915537, AW088134, BG035330, A1800433, A1559667,
					A1800453, A1536557, BE907440, A1689463, A1922091, AW151132, BF529043, A1285417, A1804505,
			<u>.</u>		Al952433, BF914091, AW118557, Al926593, AW151136, Al498579, Al539771, BE897632, Al432644,
					BG254284, BF304748, AI537677, AI494201, BF812963, AI500659, BG180468, BE883591, AI868831,
					A1866465, A1815232, A1866691, A1801325, BF812438, A1500523, A1538850, AW089221, BE968552,
_				•	BE885490, AI887775, AI582932, AI590043, AI284517, AI923989, AI872423, AW172981, AI500706,
					AI445237, AI491776, AI289791, AW151138, BF811804, AI521560, AI889189, AI500662, AI582912,
					AW172723, AI284509, AI539800, AI889168, AI440263, AI538885, AI927233, AI866573, AI633493,
					A1434256, A1866469, A1434242, A1805769, A1888661, A1284513, A1500714, A1888118, A1277008,
					A1285439, A1436429, A1859991, BE964045, A1355779, A1623736, A1889147, A1371228, A1581033,
					AI431307, AI440252, AI491710, AI440238, AL047422, AI866786, AI567971, AI610557, AI860003,
					A1431316, A1242736, A1539260, A1828574, A1887499, AW151979, AL038575, A1539781, A1702065,
•					A1539707, A1885949, A1285419, AW089557, A1559957, A1521571, A1469775, A1866581, AL047398,
					AW074057, AI815150, AI567953, AI446495, BE906230, AI867068, AI225248, AI698352, AI815239,
					AI371229, AI921420, AI624279, BF913616, BG252929, AI701890, AI687614, AA464646, BF038804,
_					A1919345, AW858243, AI282249, A1962040, AI829330, AW078839, BE895765, AI554821, AI561170,
					BE764656, A1636811, AL515375, A1500146, AL042365, AW059765, A1263331, A1610756, A1440260,
					AI690946, BF814072, AI890907, BF811802, AW129310, AI866458, AI431238, BF815930, AI648567,
					BF925348, AL514069, BE540578, AA830821, AI924051, AI433157, BE964497, AI273179, BE621206,
					BG108452, AI371251, AI866510, AI499986, BE968711, AW151974, AW073697, AI866461, AI923046,
					BF339011, AI049859, BF752892, AI436458, BF526393, AI379711, AI918408, AI334445, AW169643,
					AL048403, AI915201, AA878808, BF764538, AI349814, AI953880, AI702902, AI800171, BE881675,
					A1819663, A1432656, AF118240.1, AB016531.1, BC000467.1, BC004356.1, BC000632.1,
					AK025906.1, BC004937.1, AK027081.1, BC007634.1, AL133070.1, X79204.1, AK000247.1,

					BC004908.1.	AL080162.1,	AL136781.1.	AF017790.1.	Z22828.1. U	Z22828.1, U92992.1, BC002356.1	002356.1.
					BC008382.1,	BC001093.1,	AL080127.1,	AL136748.1,	BC008195.1,	BC008195.1, AB048910.1,	, BC000713.1,
					AK024550.1,	BC008818.1,	BC001470.1,	AK027116.1,		, BC008488.1,	, AB063077.1,
					AL137275.1,	AF056191.1,	AK026086.1,	BC004370.1,	AB047609.1	, BC003105.1,	AB047609.1, BC003105.1, BC006164.1,
					BC002485.1,	AL122098.1,	AF111847.1,	BC008893.1,	M92439.1, A	BC008893.1, M92439.1, AP001343.1, AL512454.6,	AL512454.6,
					BC002839.1,	AK026038.1,	_	- 1	3002491.1, A	X72889.1, BC002491.1, AK026865.1, AK026021.1,	AK026021.1,
					AK025084.1,	AK025958.1,			AL133049.1	, BC001790.1,	AL136825.1, AL133049.1, BC001790.1, BC000785.1,
					AB060905.1,	AL161953.1,	AL136765.1,	S77771.1, BC	.004926.1, A	S77771.1, BC004926.1, AL137429.1, BC006207.1,	3C006207.1,
					AL389978.1,	BC006508.1,	AF067420.1,	AK026642.1,	AK026590.1		, AF260566.1,
					AB063087.1,	BC002844.1,	AF369701.1,	BC004181.1,	AL117432.1,	BC000051.1,	
					BC007852.1,	AK026749.1,	AF151109.1,	Щ	<.	AB049629.1,	, AK025092.1,
					BC008717.1,	AK026627.1,	AL161802.15,		BC008365.1,	, D83989.1,	\supset
					AK026648.1,	BC007207.1,	BC002495.1,	BC009272.1,	AL136763.1,	•	•
					BC002777.1,	AL080154.1,	AK026532.1,	BC009284.1,	AC004690.1,	, AK026389.1,	, AF353396.1,
					AF022813.1,	BC001328.1,	BC002816.1,	AL049423.1,	AL049314.1,		AB060837.1, AL512705.1,
					BC002524.1,	AL137536.1,	AK025541.1,	AF036268.1,	AL080126.1,		AK026631.1,
					AC044797.5,	AK024622.1,	BC009212.1,	_	S61953.1, A		710080.1,
					AK025391.1,	AK000432.1,	AK026522.1,		AK026541.1,	, AK027161.1,	I, AB047941.1,
					AL157464.1,	AK026793.1,	AB060929.1,	BC008785.1,	AK025431.1	AK025431.1, AK026603.1,	, AB060839.1,
					AK027142.1,	AL137656.1,	_	A.	AJ406932.1,	AJ406932.1, AC003032.1, AC005057.2,	AC005057.2,
					AC010137.3,	⋖				AL162713.19, AL359997.8,	%.
					AC007298.17,			, BC003687.1,	AF030165.1	I, AL122100.1	AF030165.1, AL122100.1, AL133053.1,
			_		BC002476.1,	BC000066.1,	BC003122.1,	BC006133.1,	Y00093.1, A	BC006133.1, Y00093.1, AF002985.1, AB055805.1,	AB055805.1,
-					AL122049.1,	BC009395.1,	BC002519.1,		2000377.1, E	D44497.1, BC000377.1, BC001963.1, BC001191.1,	3C001191.1,
					AB060226.1,	AL137557.1,	AK000655.1,		AL162062.1,	AK027188.1,	AF218023.1, AL162062.1, AK027188.1, AF188698.1,
					BC006412.1,	AF218034.1,	BC006465.1,	S76508.1, AK	.027868.1, A	S76508.1, AK027868.1, AC021020.3, AL080158.1,	VL080158.1,
					BC000317.1,	BC005854.1,	BC008025.1,	U67211.1, Al	050138.1, >	U67211.1, AL050138.1, X99226.1, U77594.1,	7594.1,
					BC001082.1,	AL110159.1,	AF169154.1,		AL080060.1,	AF271350.1, AL080060.1, AL136884.1, AK027114.1,	AK027114.1,
					BC002647.1,	AB050418.1,	AK025209.1,		BC004119.1	AB049758.1, BC004119.1, AL157431.1,	
					BC008078.1,		AL080129.1,	AL110222.1,	AL136882.1,		_
					AL135933.11,	AL157878.1	AL157878.11, X66417.1,	AL035458.35, BC006487.1,	BC006487.1	, BC006147.1,	, BC003651.1,
					AF358829.1,	BC007280.1,	AK000445.1,	AK026571.1,	AL512746.1,	, BC002386.1,	AF358829.1, BC007280.1, AK000445.1, AK026571.1, AL512746.1, BC002386.1, BC006198.1,
					S69510.1, Al	7112208.1, AF	124728.1, AL	.162085.1, AF	321617.1, A	S69510.1, AF112208.1, AF124728.1, AL162085.1, AF321617.1, AL137662.1, AL137480.1,	L137480.1,
		1			Z94277.1, A(2006222.1, A	C010088.3, BO	C001427.1, Al	<026591.1, Е	AC006222.1, AC010088.3, BC001427.1, AK026591.1, BC004960.1, AK000450. 1	AK000450. 1.
HDLAC10	63	692299	1 - 1463	15 - 1477	BF222902, BI	3908203, AL04	9012, AV75150	15, BF589784, I	3F939631, AV	BF222902, BE908203, AL049012, AV751505, BF589784, BF939631, AV752758, AW161772,	61772,
					BF984735, BE	3156564, AI963	1569, AI627938	, AU145766, A	A430167, AV	BF984735, BE156564, A1963569, A1627938, AU145766, AA430167, AW885969, AW885971	85971,
					AU144116, A	W885970, AW	150904, AA811	288, AW14883	3, AA016001	AU144116, AW885970, AW150904, AA811288, AW148833, AA016001, AU146932, AA534493	A534493,

BE246689, AW572295, BG260240, AU155669, AI580793, AU149721, BF791136, AI473859, AU157762, AU150899, AU119418, AU150032, AA552599, BE349918, A1762820, BF572303, AA630256, AI249503, BE348915, BG257768, AI289630, BF941915, AI093700, AI683179, BE767826, AA902142, BE243543, R50658, AA994326, Z43651, AW589235, AI796343, Z39714, BE246512, AU156488, BE246684, BF184442, T36201, R50558, D60811, BE247745, BE165921, AI796404, AW023060, AI560541, AA445981, Z45738, BE242535, BF693665, AV657085, F04619, BF692774, AU121025, AW960825, BF571603, AK025407.1, AK025829.1, AF205600.1, AF205601.1, AK022942. 1.	T27258, AU140225, Al634860, Al767588, BE536545, AV689583, Al991689, Al635347, BE386012, BE767008, AW976840, Al640606, BE178142, BE177971, AW502888, AA977785, Al979247, AW503911, AA971157, AL135446, T27536, AA491080, W74279, R07065, Al687230, T27535, AW816221, AA436906, BE151455, BF510035, BF803181, BE151443, AA152394, AW505067, BG003144, AA761110, AA377229, AV648450, BE671931, Al873792, AA397568, AA399529, AA679080, Al382296, AV648107, AV648512, AV648537, Al913234, Al741350, R50230, Al920850, AI018184, AA702114, Al244588, R81654, Al126673, AA152500, BG057181, AA148355, BE817269, AF222340.1, AF183569.1, AF106037.1, AB011097.1, AC008906.5, AC009073, R	AL517702, AL535136, AL517701, BF966919, AV712906, BF310001, BE785105, BG023779, AW608043, AW959115, AW571652, BE546297, AV733133, BC164317, BF965688, AA910337, AW070547, AA630221, AA936329, A1077660, N66596, AA233825, BF769251, AW169158, BE896148, AW966447, A1092899, A1804163, BF966148, A1184325, A1400074, AW105140, A1038519, BE178803, A1243767, A1803580, AA449258, A1089365, A1969422, A1292304, AA971310, AV733091, AA2233729, A1289889, A1335939, A1275621, AV748056, BF828492, AA451735, AA971310, AV733091, AW129980, BF791539, AW472838, H65681, AA478196, AA666224, BF940460, A1002830, A134721, A1604277, H29405, BE930289, AA446666, R52737, N99048, F06358, AA233772, H11875, H65682, BF725919, R64291, R59440, AA812450, Z44951, BF825554, BE711465, F07390, AA093749, A1080343, R24935, R64256, AA878276, BF248328, AA081567, AA081513, R20695, D11945, AA249453, AW630557, AA3131924, F07956, A162272, AA383930, AA385881, R63983, AA865796, A1078076, AW964475, AA448551, BF7878091, BF091153, T97552, AA453075, BE937893, N98627, T53666, BF836787, R64175, R63901, AA319203, AA424168, BF791814, BG001790, H11513, AW810677, AW810675, AW810964, A1261898, BF216270, BF855391, AW810687, A1655026, AA884783, AL119974, AL119324, AL119324, AU19443, AW804686, AW388471, AR844783, AL119324, AL119324, AL119324, AU19443, AW804686, AW382670, AR02529, BE51587, A1935668, BF115500, BE466653, AL119443, AW804686, AW382670, AR02529, BE161864, AW149892, AL119356, AL119324, AL119324, AL119324, AL119324, AU11443, AR062961.1, AR062321.1, AF2122471, AB0629621, AB0629621, AB006533, AB006436, AW392670, AR025991.1, CD006321.1, AF2122471, AB0629621, AB0629621, AB0062321, AB0629621, AB0620204220422042042042042042
	15 - 3447	15-2312
	1 - 3433	1 - 2298
	1062783	1160316
	64	65
	HDPBA28	норвQ71

AL040501, AL040502, BF312113, BF311401, BF312099, BF969955, BG118304, BE889750,	BF528529, BE892499, BE378197, BE796737, BE312325, AL043139, BG033292, BE314857,	BE312562, AW961051, BE875599, BE395864, BF528758, BF312036, BF982580, BF511000,	BF206591, BF689722, BE278785, BE301032, BE538635, BF062495, A1074169, BF063302, BF528817,	BE550763, A1439151, BF568696, AA143267, BE044341, AA534289, A1968616, BE644848, A1374815,	AA025730, AI718363, AA984833, BE893882, AW084880, AW952114, BG012441, AA722825,	AA514696, A1809529, BF835155, BF892650, AA932271, BF739765, BF894752, BG059761,	AA134803, A1828209, AA460484, A1042088, AA134802, A1640382, R51678, A1925709, A1669079,	AW469179, AI199232, BF900427, R53751, BF349740, BE279833, BE273231, AI640403, AI074545,	BF753080, AW579547, BE731727, AI659329, AW002463, AA233548, AI003456, BG222370,	AW137214, AA230095, T55730, H43116, AW962595, BF001788, AI670726, AA626289, BF910860,	AV748998, AW276888, AA323567, AA233662, Z45129, H45702, BE245940, BE383639, R40971,	R53750, AA037073, T03319, BF813413, BE074131, BF691850, BE244555, BE146067, BF924555,	BF244566, A1141636, AA339051, H45753, BF691075, BF690883, H42344, AA291701, A1884572,	AA356368, AW080418, AW071165, AW296941, AA631213, AA317597, R39383, AA324321,	BE244793, BF221497, AI278324, BF977743, AA025729, BF055230, R10660, AA429477, AI468432,	AA291748, AI537969, H52665, U46451, AI979165, BF570791, AA378387, AI918383, BF923133,	AA455817, AW103386, BF868375, BF868370, AA922522, BF977581, R38308, Z39044, R51590,	BF737690, BF976877, R12982, F04029, A1868824, T55772, AW263568, AA233779, R14452, T31372,	AA292264, AA287135, AI560594, BF691578, AV743961, AA284706, BF894453, Z42923, AW152063,	AI916442, BE694236, AA338803, BE049333, BE904088, T32117, BF933303, BE889979, BF914434,	BF894452, BF764158, BE708005, BE892537, T92457, BF811804, BF994428, A1440263, BG167249,	A1866465, A1828574, A1623736, AL513907, AW151136, A1539771, BE897632, A1537677, A1494201,	AL513817, BF812963, AI500659, AI815232, AI801325, AI500523, AI538850, AI582932, AI923989,	1284517, A1872423, A1500706, A1445237, A1491776, AW151138, A1889189, A1521560, A1500662,	AI866786, AW172723, AI284509, AI539800, AI538885, AI889168, AI866573, AI633493, AI434256,	A1866469, A1805769, A1434242, A1888661, A1284513, A1500714, A1888118, AL096879.1,	AL117649.1, AL021977.10, AL020993.1, BC004310.1, AL049426.1, AC004213.1, AL133070.1,	AL136781.1, AL110196.1, AL136862.1, Z98744.1, AL136763.1, AL133049.1, AL110199.1,	AL137523.1, AC069387.8, AL122049.1, AL049423.1, AL133080.1, AF132495.2, AL133084.1,	AL133655.1, AL136765.1, AL050116.1, AL136825.1, AF090943.1, AF271350.1, AF002985.1,	L40386.1, AL133607.1, AL080234.1, AL133015.1, BC002695.1, BC008904.1, AL133053.1,	AK000645.1, BC008723.1, AB060917.1, AL136747.1, AB031069.1, AB063100.1, AL162062.1,	AL512733.1, BC008387.1,	AK026480.1, AB046642.1, AL022723.4, AL133608.1, AL133072.1,	AB048994.1,	
15 - 3037	-																																			
1 - 3023																																				
1019008																																				
99																																				
HDPCL63																																				

AL526869, AL523945, BE794829, AL532486, AL533032, BF969304, BG115956, AL514521, A1871493, BG028151, BF689553, AL531509, BF689896, AA005246, AW392203, A1921136, BE620088, A1921426, AL514522, A1800003, A1571833, A1097128, W68743, AA587786, A1928547, A1588884, A1366187, A1469283, BG059843, A1091266, W68721, AA731294, A1023709, BE218286, A1571471, A1628000, A1819634, BE207917, A1247849, A1085331, AW274586, A1752152, A1866693, BE32434, AW264556, A1570330, AA909256, AW602670, BF091955, A1185842, A1627586, A1871471, BF822519, BE673374, T81959, A1623337, A1970967, R86832, BE940065, AA0774519, BF924761, AW364990, AA865886, AA722301, A1539598, BF095254, A1949220, AA327238, BF345347, H82580, A1571973, AW516484, T81955, AW439461, R56100, W27475, AW470712, BE743030, AW674734, A195321, AA076557, AA731651, BF056789, AL134661, AW31498, AW772519, A886775, AA731651, BF086730, BF526571, A8W11498, AW772519, A1609719, BF852458, AW073075, AW365079, BF808730, BF526571, BF999019, BF884157, AW204188, A1032686, BE936805, BE843795, BE938378, AL533946, BF999019, BF880469, A1589571, BG120896, H16171, BE937970, AW938898, T57436, AW882041, BG1051424, BF81425, AL532487, BG163558, BF620628, A1362407, AW513032, A186691, A15007523, A1804505, A1500523, A1804505, A1804505, A1864655, A1500706, A1446536, A1817239, A1824517, A1604205, A1886661, A1500662, A1284177, A1623302, A1533980, A1284517, A1500706, A1445237, A1926539, BR1811804, A1284509, AW172723, A1889518, A18666573, AV0576981, A186649, A16376391, A1866573, A1640263, A1889168, A1888661, A1600662, A1888661, A1600662, A1888661, A1600662, A1888661, A16073391, AK0073991, AV60776981, AF0773381, AC00144896, AC00048651, AL1336551, AL1330741, AL1330731, AL133076, L	35, AW26978(1, A1924874, A AW070513, A AW070513, A AW073532 A AW083896, E AW083896, E AW075840, A AW07
15 - 1256	15 - 1057
1 - 1242	1 - 1043
588697	628254
89	69
HDPFF39	HDPFP29

	AA643261, AI432644, AI927233, BF771135, AA033725, AI699011, BE883591, AI431307, BG110517,
-	BG113493, BG029667, A1433157, A1648567, A1690946, A1554821, BG252929, AW151136, A1539771, BF897632 A1537677 A1404201 BF812963 A1500659 A1866465 A1815232 A1801325 A1500623
	A1538850, A1887775, A1582932, A1590043, A1872423, A184517, A1923989, A1500706, A1445237
	AI491776, AW151138, BF811804, AI932949, AI521560, AI889189, AI500662, AI539800, AI582912,
	AW172723, AI284509, AI538885, AI889168, AI440263, AI866573, AI633493, AI434256, AI866469,
	A1434242, A1805769, A1888661, A1500714, A1284513, A1888118, A1285439, A1859991, A1436429,
	A1355779, A1623736, A1889147, A1371228, A1581033, A1491710, A1440252, A1866786, A1610557,
	A1860003, A1242736, A1828574, A1887499, AW151979, A1539781, A1539707, A1702065, A1885949,
	AW089557, AI559957, AI285419, AI521571, AI469775, AI866581, AI815150, AI567953, AI446495,
	AW858243, BG164558, AA806719, BE885490, AI289791, BF811802, AL110306, AI929108,
	BG257535, BG027628, BF338002, AL045500, AI866820, AL042515, AI561170, BE886728, AI784028,
	A1890907, AL039390, BF795712, BE895765, BF815930, A1468872, BF802671, AW089006, BF812438,
	BG260144, Al371251, AL079960, Al866510, BE047852, Al274759, Al866461, Al923046, Al565172,
	AL047422, AI431316, AL048403, BG168086, AW827227, AA074168, AI433976, AI867068,
	BG113224, BF725463, BE537531, X79568.1, U28282.1, AK027136.1, AC007383.4, BC006408.1,
	AB060841.1, AL110280.1, AC026464.6, AL133049.1, AL137294.1, AC023880.5, BC006159.1,
	BC008078.1,
	AC006994.4, AC021325.5, U72621.3, AC
	BC008417.1, I
	BC006136.1, AL136843.1, AC011450.4, AL353625.5, AF090900.1,
	BC007998.1, AL137705.1, AB060826.1, AL080234.1, AK026894.1,
	AL136766.1, AL137292.1, AC009087.4, BC008708.1, AL137530.1, I
	AF095901.1, AL133344.28, AL353999.3,
	AB060888.1, AB060229.1, AK000432.1, AC004686.1, S77771.1, AL
	AF334404.1, BC009026.1, AL355834.4, AL353594.13, AP001873.3,
	AK025632.1, AK024546.1, AL133104.1, AC005902.7, AK000655.1,
	AK000647.1, AK025484.1, AF056191.1, AF348209.1, AK027161.1,
	AK000391.1, AC006313.1, AL122049.1, AF353396.1,
	AF179633.1, BC004215.1, BC004908.1, AB056768.1, AK025465.1, A
	AL391244.11, AK000450.1, AL512684.1, AB049900.1,
	BC002343.1, BC006494.1, AK000250.1,
	AK025383.1, AL161628.9, AK026591.1, AK000718.1, AL163282.2,
	AL137557.1, AL389978.1, AF285836.1, BC002519.1, AC006112.2, A
	BC007460.1, AB055352.1, AK000212.1, BC007571.1, AC010530.7,
	, AL137711.1, AF090886.1, AB060887.1, A
	, D55641.1, A

HDPG149	70	785887	1 - 2669	15 - 2683	AL080060.1, AK026057.1, AK027193.1, AL136781.1, AF002672.1, AL236747.18, AL133560.1, AK026408.1, AF094850.1, AL359941.1, AF003737.1, BC004945.1, AC004383.1, AL136850.1, AB047966.1, AC010972.3, AL35960.1, AB060837.1, BC006180.1, AF132730.1, AL137574.1, AL353745.7, AL162062.1, AF205861.1, AL121601.13, AL136892.1, AL050138.1, AL485236.22, S76508.1, BC004533.1, AF169154.1, AC024247.4, AC004883.2, BC009033.1, AL035407.15, AL138976.5, AE006462.1, AF151109.1, AL137756.1, BC007198.1, AL132985.4, AR056420.1, AF113222.1, AL512689.1, BC006411.1, AL137256.1, BC007198.1, AL132985.4, AK026533.1, AC006222.1, AL117463.1, AF271350.1, AK027111.1, AF078844.1, AL132985.4, AK026533.1, AC006222.1, AL117463.1, AF245044.1, AC020659.5, AK024601.1, AF069506.1, AE022165.1, AB047878. 1. BG028956, BF434796, W05746, AW965426, BF509507, BF680194, BF589350, AA287841, BE697901, AR301200, AA761846, BF27112, AA911724, AV712358, AA831097, AA040238, AA809475, AA287842, AA252943, AI610808, AA040239, AA422118, AA235003, BF477762, D80028, AA985566, AA995400, D81515, AA974489, AA507522, AA653950, BF087088, BE242538, BG005055, AA249308, BF971120, AA487000.
HDPGT01	71	771583	1 - 2673	15 - 2687	AL524311, BG251269, BF310537, AU133126, BF683381, BF038290, AW732293, BF316433, AW170099, Al056333, BF349288, AA972732, Al675184, AW177595, BE141799, AW664330, BG056730, AW751928, BE141798, AU157403, Al803604, AW516199, Al421509, Al089433, AA622275, AU154510, AA699595, AW733094, BF838983, AI148225, AA921836, AA701632, AI361562, H75815, AV701643, AA931757, AA825979, BE837455, AI247022, AA035572, AI015040, AA505697, R92850, AI204070, AA724075, H06815, AI168573, AI702086, W42567, Z43621, AW751931, AI272047, T16739, AI868745, AA860360, AI207229, AI249348, AI073394, AA035062, AA758712, AI204396, T11609, AA649046, AI168656, AA729782, AL110209.1, AL389957.1, AK001705.1, AB017494. 1.
HDPJM30	73	460679 879325	1 - 714	15 - 728 15 - 1635	AC005946.1, AC018755. 3. Al420713, BF951818, R85260, H28149, BF899899, BF594396, AW292642, H44846, BF685411, Al739196, Al867313, BF063759, Al380559, BE504664, AW166357, BE735346, BF064117, AB001535.1, AP001754.1, AP001065.1, AP001064. 1.
HDPMM88	74	972734	1 - 4879	15 - 4893	AV715713, BF446914, BG057685, BF898163, A1083524, A1290271, AA318526, BF932901, R78174, C17785, R77809, BF898707, AW795715, A1638633, BF921994, BF904690, AW016805, AC025040.7, AK025125.1, AC016045, 8.
HDPNC61	75	637585	1 - 1396	15 - 1410	AA847865, AA483400, AI016714, AI051725, N62194, BE047259, BE327006, AA483411, AI554330, AW874660, AA933624, N66755, AI825794, AW327616, AA902896, AA725234, AI769182, BF448730, AA054669, R60056, AA594900, H05474, T16298, AA977118, AI671131, AA054722, AA650410,

					BE719696, BE719698, R43427, AA716570, T82929, AW327262, BE044255, AA761969, AW974625, AA916000, T34734, BF817206, AA805766, T90105, AI249880, AA342241, AA811545, AW956711, AA484223, A1354808, 24, AC0030081, AC0070607, 15, A1,040569, 13, AC004166, 12
					AC005288.1,
		_			AL354815.10, Z
					Z83826.12, AL357515.26, AC016637.6, AP001748.1, AL445645.10, AL499628.1, AC020931.5,
					AC004826.3, AL359091.10, AC004965.2, AL353653.19, AP002852.3, AC020750.3, AC004867.5, AC00
					AC005077.5,
					. =
					, AC004820.2, U95090.1, A
				1	AC005052.2, AL049776.3, AC006117.1, AC007220.4, U95740. 1.
HDPOJ08	9/	731863	1 - 1641	15 - 1655	BF968799, BF791555, AL513581, BE879926, AI949941, BE827843, BF968555, AI765763, BE875907,
					AW959968, AW382167, BF692458, BE876162, BF106234, AV713629, AV699640, AW382174,
					AU136532, BF692025, AA449500, AW902068, AW583040, BF212019, AW382170, AI768711,
					Al918137, AW235520, AI199832, AI074542, AA243341, AA071031, AL513582, AI308913, BE150978,
					AW609396, AA604828, AA831297, AI304674, BE151243, AW391610, AA704776, BE150919,
					AU155999, AW389522, AA878385, BF979062, BE150848, BE150932, AA554171, A1086256,
					AI285140, W48831, AW379916, BF215357, AW389518, AI361484, AI290204, BE150880, AA679730,
					AA285176, AI367820, BF570762, AA287652, AI028778, AI342266, AI332795, BE501465, AW609661,
					AA564884, AA497006, BF432681, BF438907, AA496929, AI742352, BF572848, AA824372,
					AW582335, AA286805, AA809400, AA101705, BE150881, H50009, AI356809, AI863722, AA449072,
					AW394227, N64570, BE614989, H66597, BE465872, AU157281, BF792958, AW394207, BE702178,
					AI860155, BE702109, T96603, BF792810, AW802638, H47883, BE702071, AW391634, AA425753,
					BE149864, BF766698, BF766705, T96711, R59882, AW816178, AI301234, AA524763, AW582392,
		_			AW609367, AA427806, AA243537, H89251, AA297709, BE892299, AI703471, AA284029, W49812,
					A1458780, AW075621, H89250, A1867621, AW380564, BF912063, H66596, AW380556, AW814225,
					AW380562, AA730264, R59881, AI433332, AA210752, AA863154, BF513435, H47884, AA211712,
-					C00853, AU137710, AI269992, AW337692, AA489590, AA070527, AA101704, AW391666,
					AA296965, AA296966, AA497092, AI570809, BE673630, T25724, AW582435, BE150974, AW391617,
					AI954461, BF999751, AW152174, BE876251, AI587112, BF764712, AW816180, AW102931,
					AK024215.1, AK023478.1, AB014732. 1.
HDPOZ56	7.2	1352319	1 - 1891	15 - 1905	AI859620, AI830021, AI949469, AI887204, AI218392, AW194364, AW511272, AI307671, AA970014,
01.00					AW382666, AW609988, AI873619, AC011452. 6.
HDPPN86	78	1037893	1 - 6283	15 - 6297	BE250002, BE394338, AW935469, AW749660, BG250570, BF982358, AI821271, BE541597,

A1313180, BE293706, BE872198, W22478, AW976010, A1002815, AW963152, AU117456, AV762145,
AV 700 700, DF 792320, AW903008, AV 704450, AW837083, AV 700470, E002277, Tr. 200237, AV 733710, AV 739172, AA680243, AU 123691, BE908796, AL037632, BE796439, AI076616,
AW406162, AI732120, BF339640, AV700988, AA484962, AV699709, AW965642, AF074667,
BE902459, AV760599, BG164166, BE273856, AI313166, AU118745, BE387734, AW961994,
AA381195, AI364780, AU159301, AV761286, AA722372, AU158602, BE154495, AL044000,
BG250302, AL041706, AL040921, AV700545, AU145083, AI817516, AV729960, AV760258,
 AW820787, BE071876, BF965477, BE071877, AW974126, AV759362, AI565581, AI284640,
A1963600, A1608771, AL048626, AW440343, BF677892, A1204304, BE302973, AW317073,
 PR68217, A1133164, AV762395, BF736198, AW953071, AV157011, AW833862, BF241967,
AL046409, AW995093, AV711987, AA491814, N94311, AI431303, AI963720, AW276817, BF828714,
A1613280, AV762098, AA601355, BG249643, BF697673, AF330238, AV760937, AV728425,
 AW080939, AA599480, AV740801, BE156019, AI924251, AA469451, F36273, AV658688, BF055844,
A1289067, AL119691, AV763354, A1061334, AV763971, BG058664, BF680074, AV725423,
AL045053, AW970915, AW975425, AI471481, AI305766, AL138265, BE350475, AI679294,
 AA205915, AI754955, AL137737.1, BC001041.1, AK000310.1, AC010366.5, AC005280.3,
AL137852.15, AC022148.5, AC004263.1, AP001666.1, AP001630.1, AE006463.1,
AC011811.42, AC005911.6,
AL035587.5, AL162505.20, AC073138.3, AC025166.7, AL359552.16,
AC034242.5, AL139317.5, A
, AP000359.1, AC010271.6,
 AC005324.1, AC005257.1, A
AL049759.10, AP000901.5,
, AC009086.5, AC009996.7, AE000658.1, AC016898.6, AL590076.5,
AL591770.1, AC007204.1,
AL139054.1, AC006345.4, AC004821.3, AC011497.6, AC005006.1, AC004676.1, AL117531.12, 1
ALJ12430.14, AC008022.3,
AP001619.1
AL109921.21, AC005771.1, AC005234.1,
AL163279.2, AL050349.27, AC020558.4, AC005488.2,
AC005844.7, AL023575.1, AL121658.2,
AC004596.1, AC004826.3, AL160163.24,
ACU23393.3, ACU18808.4, ACU1912.4, ACU1911.11, C/3/42.1, ACU39142.1, ACU1911.11, C/3/42.1, ACU1911.11

				AL158159.14, AL118520.26, AL355094.3, AL445201.14, AC003007.1, AC002314.1, AC018828.3, AL139327.18, AC005632.2, AC007957.36, AC011472.7, AL445248.7,
				•
				AC007298.17, U82671.3, AC008893.7, AC018731.30, AC012470.8, AIZ13297.1, AC02502.1, AC087071.2, AC005696.1, AP001216.3, AC009958.2, AC005839.1, AD000092.1, AC005682.2,
				AL136126.34, AC011816.17, Z98200.8, AC005668.1,
				AC023114.5, #
				AL354808.24, AC008039.1, AC004019.20, AC008079.23, AC003330.2, AC031253.1, C78027.1, AC010740.7, AE006467.1, AC003111.1, AL359513.12, AC004975.2, AC005377.2,
				AC023669.8, AC007318.4, AC005520.2,
				AC005081.3,
				AL133367.4, AP001745.1,
				AC006468.9, AC006480.3,
				AL034380.26, AC006312.8, AC017079.5, AL157372.18, AC021752.5, AF217796.1,
				AP001688.1, AF279660.2, 1
				AL021939.1, AL035458.35, AC005052.2, AC020915.6, AL445189.7, AC024166. 3.
HDPSB18 79	1043263	1 - 3394	15 - 3408	AA631915, AA595661, AI348780, AA489390, AA640305, BG231195, AW239465, AI523205,
				AA180056, AW975434, AI819419, AV759517, AA199578, BE677227, BF740656, AW839858,
			_	A1754064, BF880881, A1270280, A1567676, AA568303, AV706458, BE062357, A1753131, AW247955,
	. .			A1610814, AA493546, A1086603, AV717475, BF875339, AL355512.22, AF207550.1, AF038458.1,
				AL109797.18, AL118520.26, AL590762.1, AC003101.1, AC004000.1, Z93023.1, AL121712.27,
				AL034549.19, AC072052.6, AL117692.5, AC020931.5, AP002852.3, AB023048.1, Z93928.1,
				AF196779.1, AL133448.4, AP000116.1, AL121886.22, AP001726.1,
				AC006013.3, AC011475.6, AP003352.2, AL121992.24,
				AC022087.8, AC011495.6, AC010271.6,
				AC008745.6, AC079316.15, AC003043.1, AC003962.1, ALU350/2.10, AC010605.4,
				AC004522.1, AC007151.2, AL159850.17, A105157.1, AC007222.13, AC007181.1, AL049569.13,
				AL138976.5, AL034372.33, L78833.1,
				AC011446.6, AC016894.7, AP001725.1, AC002300.1,
				AL137229.4, AC008891.7, AC008481.7, AC002470.17,
	-			
		_		Z93244.1, AL158040.13, AL445483.13, AC004967.3, AC006014.2,
				AC008440.8, AC011811.42, AL139809.16, AC011497.6, Z9/054.1, AL133367.4, AL022310.2,
				1100100000

AC005839.1, AP000892.4, AC009412.6, AP000744.4, AC005180.2, AL135978.4, AP000065.1, AC005098.2, AC004963.2, AC021016.4, AC024561.4, AL139396.17, AC008806.4, AC010543.8, Z93015.9, AL139415.10, AL138756.23, AC024952.4, AC010319.7, AC008806.4, AC010422.7, AL36544.11, AC008812.7, U80017.1, AL121891.22, AC000360.35, AL109743.4, AL096791.12, AL035086.12, AL132712.4, AC010463.6, AP0000048.1, AL122001.32, AC004771.1, AC004019.20, AL13527.14, AC007277.3, AC027126.4, AC022384.4, AL024498.12, AC011465.4, AC004890.2, AL132768.15, AL049538.9, AC0018751.30, AC007957.36, AC004821.3, AC010458.5, AL109825.23, AC040160.4, AC001251.1, AL109923.29, AC004526.1, AL049795.20, AB000565.1, AC006449.19, AC019205.4, AL034420.16, AC007577.2, AL020997.1, AC009060.7, AC004887.2, AC0102095.1, AC009060.7, AC004887.2, AC009375.6, AL161670.4, AC08386.14, AC0014166.12, AL161670.4, AC08386.74, AL354932.26, AC005399.19, AC005527.3, AC011248.8, AC007216.2, AC020983.7, AC004878.2, AC005399.19, AC004538.1, AC3461.11, AC02001.3, AC00438.1, AC00438.	1307612, AW077724691, AL5135661, AL5135661, AL51356724, BE0480 E964812, A1567-E964812, A1567-E964812, A1567-E964812, A1567-E967376, AL515687376, AL515687376, AL51568873731, BE048-E9779, BG2598-E81779, BG2598-E817392, AL513726297, AW1957238730, A134997723953, BG112673953, BG1126724891, BG112673953, BG112673953, BG1126724891, BG112673953, BG1126724891, BG112672
	15-10
	1 - 1649
	1309174
	08
	HDPSH53

BG121222, AV758822, BG027204, AV758592, AV682479, BE968552, AV757455, BE880190,
A1690835, BE963035, A1920968, A1818683, A1499393, BE047859, AV682267, AL120854, AV682082,
AV 738179, AV 757012, A1934036, ALS13753, A1282655, A1439087, AV 758217, AV 756477,
 AV682441, BE048026, AV681951, AV763915, AI678302, AI609592, BE048319, AV764059,
AV706777, AV710479, AW301409, BF726421, AL529946, AI699857, AV682772, AI469532,
Al207510, BE969709, AW467961, AV682792, AV717179, AV758806, Al969601, AV709517,
Al349614, AL514791, Al866608, AV755311, BF340031, AV682330, Al580190, AV681857,
AV711924, BE881155, AW166645, Al349598, Al906328, BG109125, BG114104, AV681668,
BE613622, AV708119, AW274192, AV682333, BE964486, BG031815, AW080838, AV755613,
AV660662, BE909549, AI597918, AF311287.1, AK024001.1, BC008877.1, BC008417.1,
AL136586.1, AF078844.1, AL050393.1, AL389978.1, AF090934.1, AF125949.1, AL157431.1,
AL442082.1,
AL080060.1, AB056420.1, AL133016.1, BC008365.1, AB055303.1, AF090901.1, AJ242859.1,
F090943.1, AL117460.1, AL136787.1, AL512733.1, AF090900.1, AF
 AK026608.1, AF104032.1, AB048953.1, AF218014.1, AB049758.1, AL137527.1, AL110196.1,
AL049938.1,
AK026865.1, AF1111847.1, BC003683.1,
, AB047615.1, AB056809.1, AL136892.1, AL136789.1,
AF219137.1, AB056768.1,
 AL136749.1, AB047801.1, AL122050.1, A
AB060887.1, AB019565.1, AK026045.1, AF106862.1, AL080124.1,
AK025084.1, AL049466.1, AK027868.1, AB055361.1,
AL080137.1, AL137283.1
Y16645.1, AL133557.1, AL050277.1, AK026855.1, AL
AL389982.1, AK026744.
AL133080.1, AK026533.1, BC002733.1, AL137557.1, AB060863.
AL512746.1, AL122123.1, AF097996.1, AF207829.1, U91329.1, AF
AL512754.1, AK027096.1, AB055368.1, AB060912.1, AK026784.1,
AB062938.1, AL512718.1, AL117394.1, AL050138.1, AF125948.1, A
AK000614.1, AL359941.1, AL359618.1, AK000137.1, BC004556.1,
 AL117583.1, AK000445.1, AK025092.1,
AK000652.1, AB048954.1,
 AK026480.1, AK026583.1, AK025491.1, AB055366.1, AL117585.1,
 AB052191.1, AL353940.1, AL049464.1, AK024538.1,
AB060852.1,
AL049382.1, S61953.1, AC
AB047904.1, AK026528.1, AL049300.1, AB063093.1, AC002467.1, AL133258.16, AL513015.6,

					AL050024.1, AL136845.1, BC007199.1, BC008070.1, AF348209.1,
					AC007390.3, BC002839.1,
	_		_		AK027164.1, AL122098.1, AC004690.1, BC004951.1, AB052200.1,
					AL353802.14, AK026642.1, AL157482.1,
					AF183393.1, AK026651.1, BC008280.1,
					AC000433.1, AL080127.1, AL133113.1, BC008382.1, AB060883.1, AC026787.4, AL049283.1, AF7605661 AC009364.8 AR0630841 AR0564211 AT1367861 AK075574 1
HDPSP01	8	1352280	1 - 2329	15 - 2343	
			.		BE391989, AI871101, AI458302, AW292744, BF196320, BE391322, BE390919, BF058297, BF435913
					AI560217, AI808718, AI658996, BG056475, AI199318, AI381895, AI814608, AW190726, AA047000,
					AI479404, AI660983, BE388064, AA419038, AA035467, AW517227, AI361637, AI863893, AI198435,
					AI078128, AI093316, AJ403129, AA442664, AA725194, AI831358, BE206128, AI274339, AW297826,
					AW104389, AI948638, AI261248, AI869935, AA915909, AI283200, AI871060, AI269385, AI769275,
					AI200508, AI566171, AI275083, AI857306, AA910327, AA046943, AI291474, AI291805, AI983969,
					AW070742, AA423792, AW339900, AI308118, AI869944, AA012994, AI677732, AI913920,
					AA661657, AA427407, AI197804, AI141350, AA725186, AA954707, BF111675, A1864014, A1051823,
_					AA864187, W24931, N41835, AA031475, N92812, BF734297, BF733728, AA035466, BF000025,
				_	AI026152, AA514348, R70380, AA961077, AA031617, AI673156, AA250784, AA378564, AW051192,
					AW452102, AA411122, AA886656, AW293787, AA012993, H91665, AA927216, AW149476, H91759,
					T86488, BC006411.1, AC022007.3, AC018809.4, X87479.1, Z22384.1, Z22374. 1.
HDPSP54	82	744440	1 - 3077	15 - 3091	BG256849, BG261011, BG178729, BG110345, AI923220, BE466885, BF667257, AW271504,
					AW243442, BE466659, BG171469, AV661528, AW271637, AW516811, N36059, AI804888,
			_		BE882420, AI650826, BF815232, AW964507, AI921747, BE936373, BF984751, BG259707, AI392784,
					AW076096, AI807747, AW103424, AA604757, AA633209, AW778887, AW418987, AW242326,
					BE622192, BF666519, BF978796, AW014203, AI925261, BF853590, AW131363, AW514756, N33223,
					AI819108, AI126250, AV649748, AI953896, AV714556, AI524472, BF697124, BE218100, AW629098,
		-			N21567, AI694687, AI700209, AA731730, AA577191, BE219931, N33824, BE567212, AW778908,
				_	AW087660, A1990562, BF792681, R52426, A1559108, AA743389, N35579, N25189, N30972,
					BF667662, AI339587, N24947, AI376459, AA742979, N27426, R23308, AI125720, AA954281,
,					A1801129, AW087669, A1701246, A1245517, T26975, BF572334, BE177998, BE564497, A1636147,
					AI640713, N41938, H97662, AI243263, BE967025, AI572028, BE543895, H29641, BE762905,
					BF246305, Z46022, H29640, BG223352, AI270534, AI983198, H99399, BF965116, BF692452, Z42169,
					AI521060, BF102948, R82562, AV646807, N34709, AV646406, R23233, AA373475, BE005657,
		_			AA319637, T34245, BG104469, W20047, AW962829, BF572695, AI369988, AI741908, BE830524,
		_			H29549, D78710, Z41637, H29548, AA833897, AI367191, AA659275, AW899997, F01708, BF697465,
					A1246035, A1219239, BF154447, A1221561, A1273738, A1281168, BE005723, BE170424, A1685342,

					BE882847, AB007962. 1.
HDPTD15 83	3 692917	116	1 - 1382	15 - 1396	AA428414, AL042853, AA363501, AA723017, AA513999, AI547286, BE072237, BE044986,
	-				BG008598, BE153851, AA642060, AA363207, AA828704, C15073, AU147529, AA369477,
					AW974890, AA483034, AA593060, AI285521, AA502103, AA558697, AA310158, AW851028,
					F26152, AA515435, AA828680, F36373, T66105, AA658235, AA551509, AA634227, AW844234,
					C18357, BF805334, BE958096, BG056233, BG059938, C18360, AA084863, A1133164, BG056088,
					N43757, BF769505, AA715609, AA419263, AA503947, BF869171, AA653964, AA301813,
		•			AW673241, AA450199, AW580735, AA557686, BE153330, AW589633, AI921649, AV709707,
					AA318652, A1376100, AW955577, AW276435, BF438574, AA021552, BE072020, AW664161,
					AA715362, BE221335, BF827669, AI453383, AW074059, AI356904, AI564284, BF743037,
		-			AW994731, AV759464, N66067, F25593, AI355206, BF769371, AI922654, AA747480, AW575719,
					AA829106, AA364701, AL041706, BE206021, AW274349, AW953770, AW089789, F36273, H58672,
		-			BF940837, AW169136, AI446464, AI372413, AV700545, AV699709, AV700498, AW303196,
					AW301350, T08638, AU158130, R13151, T96279, A1284640, AA654998, AV700988, AA364193,
					BE153327, AW249835, AA136829, AA309874, AC020728.4, AL137787.11, AC068533.7,
		-			AP001752.1, AP001053.1, AC004941.2, AC005166.1, AL021579.1, AC008013.8, AL133479.11,
	_				AL139022.4, AB016897.1, AL138718.17, AL096712.20, AC037423.16, AC004884.1,
					AC008733.7, AC007163.3, AL137794.5, AC007312.1, AC078929.27, AC007285.3, AC011533.6,
					AC011475.6, AC004672.1, AL137068.10, AC007318.4, AL390798.3,
					AL121893.21,
					, AP001132.4,
					AL021786.1, /
					, AC016831.1,
					AF029308.1,
-					AB017602.1, /
					AC010170.3, AC024571.4,
			•		AL121928.13, AC024341.9,
					AL138706.9,
					AC006536.2,
					AC010651.7,
					AL391478.14, AC005696.1, AC004453.1, AC024561.4, AC005703.2, AC004905.1, U22376.1,
-					AC004158.1, AC012380.1, AC002400.1, AP001628.1, AL136308.4, AC066612.7, AL139095.15,
	-				AL356601.14, AC005215.1, AL356776.21, AC006435.7, AF312032.1, D83737.1, AC009068.10,
					AC009319.19, AC010134.4, AC005792.1, AC022007.3, AP000252.1, AP001717.1, AP000553.1,
					M87918.1, AC090042.1, AC005052.2, AL512363.11, AF224669.1, AC002395.1, AC011739.7,

85 992925 1-2665 15-2679 86 879048 1-752 15-766	AC005736.1, AL121834.20, AC004478.1, AL513550.9, AC024067.4, AL449363.12, AC026120.33, BC002464.1, AL590420.5, AC011746.6, AL109984.14, AL591004.3, AC020550.4, AL590762.1, AC07325.8, AL390295.10, AC005887.3, AC021016.4, AP000313.1, AC007102.4, AL023693.25, AF108083.1, AL049613.2, AL445201.14, AK022268.1, AL162426.20, AL008629.9, AC090043.1, AL133411.8, AC016617.5, AL391114.12, AL162426.20, AL008277.4, AP000776. 4. HDPUW68 84 812737 1-1734 AW295848, AU132995, T48851, A1247571, AW469884, AV734061, T48852, BE378325, AW571432, AA344713, AW131386, AU138048, AW190967, BF896891, AA400618, AA835515, AF170485.1, AJ007395.1, AF125403.1, AF195402.1, AC008750.1, AF277806.1, AC011473.4, AF132027.1, AF310234.1, AF287892.1, AC008750.7, AJ130712.1, AJ130713.1, D86359.1, D86359.1, D86358.1, AR3828.1, I77382.1, AR532828.1, AR532828
--	--

	AV752030, BF207332, AW069193, AW850706, BE260313, AA114996, AI147007, AA287865,
	BE294206, AA779902, AW953654, BF203424, AA287665, BF102950, AW089856, BE081349,
	AW630077, AA844006, AI092051, AA035003, AW374784, W79563, AI095505, AI370765, C05140,
	A1961895, W92237, BF056098, A1431633, AA011411, A1381447, AA922567, AA688312, A1860011,
	A1200662, AA676566, H08173, AW590492, BG222429, A1741707, C02948, AA609401, AA427979,
	AV739012, H29396, AA453991, BE894938, H01836, BG165095, BF333733, W70295, BE242586,
	N41910, AA054984, R24822, AA156412, BG055899, H48740, H08272, A1241860, BE763810, T63735,
	R34728, Z42796, BE936536, W88710, AA367891, R36564, Z45070, AA412324, R78131, R56319,
	AA 103003, AA 423300, A1313030, A W 13132, A 12222281, N 14384, A 243317, A W 023300, AA 853400, AA 853401, W 52589, AA 476640, T39346, W 88711, A 1282590, T29951, AA 411419.
	AA360166, T80320, AA331893, AI754899, AA602993, AA506382, R01609, AA328290, BF808365,
	N56432, AI832140, AW890834, T31756, R45735, BE929124, AA887981, W31306, BE710919,
	BE169167, AA039914, BF748450, AW381600, BF352203, AA648132, AI564214, R36407, AW374826,
	AA383447, T53688, AW198043, AA368172, T53689, N92423, BF237454, AA304402, D79323,
	A1905754, AA319927, AW197916, AW362124, AW579061, AW579502, AW751634, AA054622,
	BF086800, D25822, BF925479, BG054837, BF904194, BE966011, BE047833, A1432570, BE966787,
	BE965067, AI244343, AI537244, AV682272, BF904176, AI702343, BE965599, BE963838, BF814761,
	BE176075, AW366372, AL513693, AI521799, BE964661, AI684164, AI370623, AW020419,
	AL042365, BE045180, BE965121, AI915201, BF968017, AW813006, AI887775, BF921291, BF990167,
	AI537677, AI500113, BF812963, BE242668, AI624245, BE967255, BE875243, AI623941, AI927233,
	N92140, AI621341, BG029399, AI819663, AI698391, AI251221, AA024941, AI570857, AW162194,
	BG164558, A1250627, BF811808, BE047798, BG104506, A1884459, BF814357, A1439903, AV758455,
	BE964617, AW078839, AI267185, AL046385, BF813196, AI610357, BG178788, AI831938, AI919547,
	AI683897, AW117926, BF337896, AI453248, AI620810, AI591228, AL038529, AW129616,
	AA665587, AW089275, AW079360, AL047854, AW051088, BE408063, AI499483, BF680133,
	AK027757.1, AK027877.1, AK027466.1,
	AF086408.1, AC090886.1, AC090004.1, AK024538.1, BC006195.1,
	AK026647.1, AC006994.4, AL136767.1, AK025391.1, BC008284.1,
	AL389935.1, AL049938.1, AF245044.1,
	BC003614.1, AL390154.1, AL359623.1,
	AL117648.1, AF114784.1, AK000432.1,
	AK026494.1, AK026534.1, AL157480.1,
-	BC003602.1, AL359615.1, AL050155.1, AL049283.1,
	AC007597.3, AK026550.1, AK026021.1,
	BC004880.1, BC007248.1, AL080234.1, I
	AK024992.1, AK02164.1, AK025209.1, AK025431.1, BC001873.1, AK027144.1, BC005843.1,

					BC008840.1, AL136842.1, BC006287.1, AL080110.1,
					BC004202.1, AK027146.1, AF126488.1, AF061795.1, AF151685.1,
					BC001778.1, BC003052.1, BC001967.1, AR027103.1, AF110640.1, AR026571.1, AR000618.1, AL137529.1, AK026927.1, AB047631.1, A1050277.1, A1137267.1, 1188966.1, M86826.1
					AB050533.1, AB048994.1, BC007460.1, AL157464.1,
					AL137550.1, AC004200.1, AB060908.1, AL389957.1,
					S76508.1, AL137294.1, BC006181.1, AF106862.1, BC
					X61970.1, AB028451.1, BC003587.1, BC002370.1,
					, BC008788.1, BC001963.1, AL136644.1, X99971.1,
					BC008708.1, AL133104.1, M64349.1, BC005805.1, YC
					AK026626.1, AK026613.1, AL512746.1, AL117585.1, AF132730.1,
				.=.	, BC003122.1, AL136787.1, AL137480.1, AL162004.1, AB063091.1, U
					AB048953.1, BC000217.1, BC008591.1, AK026590.1, AK026541.1,
					, AF094480.1, BC002413.1, BC006207.1, AK024978.1, BC001199.1, 1
					, BC000066.1, AL049426.1, AK000653.1, AY034001.1,
					, BC005073.1, BC008364.1, AK000137.1, BC004899.1, AL133640.1,
					, AB048954.1, AF218033.1, AB048974.1, AF113222.1, AK025350.
					•
					BC007499.1, BC004960.1, AK026865.1, BC008185.1, BC009221.1,
					AF069506.1, AL080154.1, BC007657.1, BC006410.1, AK026630.1,
					AB055368.1, AF262032.1, AL133062.1, AF260566.1, BC001336.1,
					AF081571.1, AL136586.1, AL080148.1, AF000145.1, AB062750.1, A
					BC009294.1, BC002733.1, BC000253.1, AK025383.1, AK026592.1,
			,	-	AB048975.1, AB060852. 1.
HDIBV//	88	785879	1 - 2167	15-2181	BF689672, BE387282, BE898209, BE386984, AA393894, BE893192, W22615, AA134750, BG006306,
					AI769121, BG006608, AA808986, AA367857, AA344170, BG013403, BF368795, AA367892,
					AW605363, BG006302, BF932070, AW948496, AK027375.1, BC004282.1, AK027831.1,
					AK027849. 1.
НДТДО23	86	1306984	1 - 2193	15 - 2207	AI872206, BF966561, AW513884, AI912340, BE856991, AI758821, AW337178, BE327923,
					AW004890, AI572080, BG109128, AW058001, BF342854, AW886887, BF967940, AW474823,
					BF337371, BF591084, AA775261, BG164538, AA831357, BE087219, AW074361, AI361820,
					BF696525, AI982775, BF793075, AI690445, AA581345, AU156793, AI917776, D20022, AA825538,
					BF382552, AI360561, AW439592, AI798286, AI140796, AI277190, AA100279, AA485257,
					AA835492, AI522238, AW517943, BG035022, AI015234, AA706811, AI469550, BF197859, AI689240,
					AW265061, AI744762, AW450726, AI884872, BE714642, BE138867, T34498, BF213985, AW769512,
					BE073192, AA122332, BE138831, BF090537, A1811224, BG167993, BE932894, BF980823, A1355770,

					AA092467, A1471817, BE904497, BE719958, A1702026, BE171537, BG166879, A1597962, BG180321, BE171499, BF914841, BF967213, BE932875, A1681670, AA089786, BE327680, BE219939, BF032916, AU136610, A1624976, AK001917.1, AF035606.1, U58773. 1.
HE2DE47	06	619852	1 - 3519	15 - 3533	AL517387, AL526769, AL526907, AL523193, AL523194, AL515001, AL515002, BG030741, BF980577, BE903149, BE729941, BG165644, BE966268, BE067770, BE613706, BE384622, BE298710, BE093149, BE729841, BG165644, BE966758, BE967770, BE613706, BE384622, BE298710, BE607771, BE2298416, BE88532, Ad126763, BF96753, A1708574, A181491, BF03635, BE607771, BE2298416, BE88532, Ad126763, BF967143, BF67187, A1708574, A181491, BF03635, AW189237, A1432659, BE22062, A864782, BF967183, BF67184, AW66708, AW958178, AM672837, A100688, A1703594, A1004470, AW880654, AN674178, BF671147, BF6748040, AA522692, AA867782, A1076495, BE166594, W73934, BF10011, BF247329, BF382964, AA711934, AA703942, A8060784, AW072956, W73954, BF10011, BF247329, BF382964, AA711934, AA703942, A8060784, AW67495, BE66594, W73954, BF10011, BF247329, BF382964, AA711934, AA703942, A8060884, AW62428, N93202, A13000584, AW673688, AW074920, AA77494, AW0790835, AR659803, AA143217, AA626686, BE614598, H96804, AW009055, AW071465, A1041197, AA9196284, AA010687, AA199756, Z30115, AW779364, AW090835, AW071465, A1041197, AA938387, AW511332, AW079882, AW079882, AW73944, AA73252, A1301049, A1582560, AA338488, A1192285, AW881224, AA761409, AW024044, AA73252, A1301049, A1582560, AA34888, A1192285, AW881220, AA738945, AA55087, AA73948, A1997751, AW881204, AA738945, A1301049, A1582560, AA33488, A1192285, AW881220, AA7659907, AA73948, A1997751, AW881204, AA7659907, AA739649, AA73948, A1997751, AW881204, AA7659907, AA739649, AA737948, A1997751, AW881204, AA7659907, AA739603, AA55087, AA473774, AA737948, A199775, AA869858, F09225, AA731115, W93220, AW381163, AA29885, R09225, AA73115, W93221, AA196142, AA73711, A8099032, AA56987, AA739948, A199756, AA3988581, AA739876, AA739678, TA77374, AA76906, A195756, AA3988581, AA739876, AA737774, AA7690728, AA396728, AA773774, AA76906, A195786, A195787, A195786, A195786, A195786, A195786, A195786, A195786, A1957874, A195786, A195786, A195786, A195786, A195786, A195786, A19578
не2ЕВ74	16	513662	1 - 1420	15 - 1434	BF431622, AL035942, AW500190, AW889139, AA136080, AW304923, AL035941, AA491000, AW002842, AA992811, AA747222, AW189910, AW026264, AA679646, AA953459, BF910533, BG179993, AW162118, BE408392, AA505898, AV682249, BF982063, AL049442.1, AL122116.1,

					AK025435.1, AL110223. 1.
HE2NV57	92	740750	1 - 853	15 - 867	C05927, R72949, AA327984, AC084730.2, AC016673.5, AC004929.2, AC016716.6,
					AC003969.1, AC024082.6, AC024082.6, AC003969.1
					AC078851.4,
					AC005227.2, /
					AL050335.32, AC007690.1
					AL008583.1, AC005868.1, AL133383.10, AC006070.1,
					AC087072.2, AC009424.2
					, AC016598.5, AP002980.2, AL158817.11,
					AC020906.6, AL391241.21, AC015983.7, AP003470.2, AP001889.4,
					, AC087430.2, AC005081.3, AC005886.2, AC018509.5, AF277315.3
					AJ011930.1, AL163300.2, AP000952.2, AL133387.8, AP000953.2, A
					AP002342.3, AL445232.5, A
					AC010206.8, AL049843.18
					, AC002487.1, AC010726.4,
					AC009498.3, AP001699.1,
НЕ2РН36	93	570903	1 - 1544	15 - 1558	AA329666, AA664883, AL133353. 6.
HE8DS15	94	847060	1-2185	15-2199	AV725650, BE161426, AW130367, BF343057, AA127680, BF575221, A1096437, BF941499, W58383,
					A1161240, N95226, AW966449, A1356752, A1093508, A1057144, AA044288, AW130361, A1423547,
					AI221152, AI094774, H47283, AI352542, AI891136, AI002491, T53270, AA044116, R48378, R24320,
					AV658066, AI829703, AI819388, BE140169, Z44849, R16574, T39273, AA095159, Z25099,
					AW273857, R16633, AA384077, AI245095, AW026140, T93764, BE927909, N73937, AW118768,
					AA121543, AA995178, AI453845, AA703455, AI452494, AW044037, H40993, R48277, AW629019,
					T64039, AA904647, AW073189, W21055, AW263913, AI096938, Z28777, W03697, AW797518,
					A1039546, A1434419, AW050649, BG003285, A1240412, AA886341, H23905, A1695284, A1767991,
					H47284, Al309041, BE927916, AA724059, Al352281, Al584012, AA618131, AA357401, Al796309,
				- 1	
HE9CP41	95	560625	1 - 1378	15 - 1392	BF032830, AL121944.14, AL138700.18, AL132988.4, AL138805.8, AC018695.6, AC005305.1,
					AC015853.8, AL049637.43, AC005536. 2.
HE9DG49	96	1299935	1 - 703	15-717	BF508798, A1829099, N25625, A1126506, A1200037, A1128843, AW024969, N34223, AW450603,
					AA743134, N36303, AW020616, AI217597, AA605122, AI160533, AA729493, AA568193, BE857354,
					AA568681, AI695490, BE855663, BG054946, N26904, N24885, W52651, AI802647, AI312534,
					AA648514, N72137, N35103, AA806507, AA729125, N34254, AI219599, H86995, N39790, R73200,
					N26781, A1032141, N25653, H86994, W00385, R73137, AW298649, AA296449, N28403, R26304,
					AW452862, AW453038, AI299683, AA988539, AI141901, W52017, AI039557, AW236299,
					AW515490, AI361669, AI674252, AA768761, AI452444, AW629545, AI984739, AW074182,

					AW583163, T25829, AI805445, N20053, BF958127, BF964329, AA543074, BE081422, T25828, AA358828, BE152130, AA653691, AI362330, AW606102, BE170656, AF238079, 1.
невел 18	86	701802	1 - 671	15 - 685	BG119433, BG248347, BG109710, BE383397, BF310661, BF035847, BG1111960, BE740887, AA872710, AW051637, BE904996, BE620053, BE294553, BG026514, BF036166, BE378983, AV716604, A1300158, AV710056, BE277692, AW778814, BE879729, BE258999, AW592818, BE261359, AA044747, AA044799, AA878925, A1921790, A1469932, AA947927, BE251176, AA05805, BF24564, AA044799, AA878925, A1921790, A1469932, AA947927, BE251176, AA05805, BF24564, AA044799, AA878925, A1921770, A1453622, AW749554, W95793, A127737, BE271728, AA903077, AW874395, A1309289, AV712772, A1085685, AW118921, W95680, A194825, AA934482, AA930077, AW5487495, AV737047, AV731330, AW749583, BF304421, T87073, A1311426, AV756120, AV681938, BE74605, AA055227, AV713230, AW749583, BF304421, T87073, A1311426, AV756120, AV681938, BE794262, AA133381, A1097662, BE258966, AA037483, AA915400, BF300782, BF909052, AA037362, A127373, BF335991, AA315305, AW374003, AA874033, AW374003, AA874034, AA874777, W24468, T81887, AA054464, AW374000, BF216378, A1016169, AW795930, BE327096, W31033, BF036705, W86895, BF792783, BF513528, T87074, A13561634, AL137294.1, AK0224591, AL136930.1, AL136930.1, AL136931, AL1369411, AK026408.1, BC004951.1, AL122098.1, BC006458.1, AK026642.1, AK026408.1, BC004951.1, AL122098.1, BC006499.1, AR0526408.1, BC004951.1, AL122098.1, BC006495.1, AR0526408.1, BC004951.1, AL136746.1, AL122098.1, BC006458.1, AR026408.1, AL13104.1, BC00725.1, AF002985.1, BC006119.1, BC008387.1, AL512746.1.
неелоп	66	777843	1 - 907	15 - 921	AW572915, BE500968, AI631708, BF056783, AI638675, AW024125, AA812885, AA911102, AI651682, AA758532, AA934362, AW104268, AA968716, BF223496, AA496078, AA608859, AA973942, AW418725, BE041425, AA931770, AA513329, BF056762, AW975618, AW949645, AW964468, AW966389, AV724520, AW966330, AW973541, C14331, AW960553, AV718692, AV718931, AW366296, AA305409, AW96534, D59619, D80210, D80166, D80240, AW973488, D81030, AW949656, AW949642, AW965185, AW965197, AV720211, AW966075, AW973488, D81030, AW949656, AW949653, AW965245, D80212, AW966053, AW9559799, D80219, D59859, D51423, AW973474, AV699550, AW966050, AV719783, AW975613, AW965029, AW97307, D51060, AV718938, AV718938, AV718938, AV718938, AV718938, AV718933, AW973605, D80219, D80

AW966477, D80188, AW966041, AW965163, D80391, D80164, AV718844, AW959582, AW966054, AW966059, AW958992, D59787, AW978648, D59502, D59467, AW949651, AW949643, AW949618, AW949655, D59275, AW960454, AW973330, AV720791, AV720203, AV719188, D80043, D80227, AW949655, D59275, AW960454, AW973330, AV720791, AV720203, AV719188, D80043, D80227, AW9606062, AW965175, AW9673482, AV700229, D57483, D59889, AW959622, AW964488, AW94966175, AW973482, AV700229, D57483, D80249, AW966043, D80260, AW966043, D80260, AW966043, D80260, AW966043, AW966032, AV738340, AV723897, AW966043, D80269, B80196, C15076, AW975405, AW966030, AV720150, AV721386, AW965158, AW966033, AW949633, AW966030, AV720150, AV721386, AW965188, AW966332, AW960532, AW720150, AW720812, D51022, C14014, AW960532, AV701149, AV701004, AW960564, AW959469, AW960504, AW72082, AW966397, AV720150, AV720533, D80248, AW966363, AW973445, AW966386, AV701125, AW972082, AW966397, AV720533, B80302, AW973465, C75259, AW960570, D80133, AW178893, AA305578, AW966369, AW966311, AW966386, AV7019913, AV720654, AW966399, D80302, D80302, D80251, AW973413, AW966317, AV719913, AV720654, AW966399, D80522, AL121894.26, AF058696.1, AF271371.1, AB028859.1, X67155.2, D34614.1, D80510, D80521, AB038216.1, U79457.1.	AA400429, AA994981, AA846419, AA453384, AI015471, AA992265, AA400538, AL3600078.16, AJ236901, AF327147. 1. AI284640, AL138265, AL046409, BF677892, AW193265, AV760937, AW969629, AI431303, AV760777, AI613280, BG249643, AW407578, AI281881, AV763354, BF130107, AI345654, AV7728425, AW965008, AI34443, AV710066, AW419262, AI350211, AI801482, AV728425, AW962075, AW965008, AI34443, AV710066, AW419262, AI350211, AI801482, AW7728425, AW728928, BE895987, AW303196, AW274349, AL119691, BF681427, AV762098, AI133164, AW438643, BF827410, AA581903, AW970848, AV762009, AI270117, AI076616, AW301350, AL045053, AW26393, AW021583, AW833862, AW276435, AL138455, AW974109, AW439558, AW327868, AV762050, AV729960, AL041690, AW276827, AI890348, AI567076, AV761362, AL044940, BG109996, AW004911, AF074677, AA720702, AV764578, AV761955, AV764398, AI421841, AL042753, AW960468, BE206443, AI624142, AA621858, AV761955, AV763971, BE389111, AV734666, AV762067, AA491814, AV763122, AW265009, AI708009, AV763971, BE389111, AV734666, AV762067, AA491814, AV763122, AW265009, AL037683, AW103758, BF940837, BE350475, AI305547, BF475381, AL121235, BF337291, AI192631, AI821771, AA469451, BF947454, AI0470, AI14164, AV710774, AV710774, AI053637, AV60458, AV60451, BF947045, AV710774, AV710774, AI053637, AV760459, AV710774, AV710774, AV702877, AV702877, BY476040, AV702877, AV40801, AV759117, AV40801, AV7080758, BF940837, BE350475, AI305547, BF475381, AL121235, BF337291, AI192631, AI297771, AV40801, BF475381, AV710774, AV702772, AV70271, AV40801, BF47000, AV70270, AV702067, AV710774, AV7027072, AV70270774, AV7027072, AV70270
AW964477, D80188, AW9 AW966059, AW958992, D AW949655, D59275, AW9 AW94966062, AW956434, A AW949641, AW962082, A D80024, AV699866, AW94 AW375405, AW964137, A AW949630, AW966030, A D80378, D80045, AW7530 AV701004, AW966030, A AW975623, AW973445, A¹ AW966369, AV699669, D8 AW966369, AV699669, D8 AW966378, AW966386, A D80522, AL121894.26, AB98547.1, AB002449.1,	AA400429, AA994981, AA846419, AA453 AJ236910.1, AJ236909.1, AF327147. 1. AI284640, AL138265, AL046409, BF67789 AV760777, A1613280, BG249643, AW4077, AV728425, AW965008, A1334 AW473163, AW238278, A1754658, BF668; AV725423, AV728928, BE895987, AW303A133164, AW438643, BF827410, AA5819 AW39558, AW327868, AV762050, AV72 AV761362, AL044940, BG109996, AW004 A1305766, AW500125, BE047069, BF9706 AV769172, AV702857, F36273, BG222267 A1708009, AV763971, BE389111, AV7346 A1344695, AV740801, AV759117, BF2419 AL037683, AW103758, BF940837, BE3502
	15 - 442
	1 - 428
	847372
	00 00 00
	HEGAH43 HELHD85

		A1679782, AL046205, AW963497, BF681576, A1457397, AW662543, BF797630, BF592311,
		A1471481, AA610491, AW088846, AV733830, BF965007, AA526787, AV759505, AV730310,
		AW302013, BG036665, BF541116, AW301809, AV764530, AL038474, AV761631, AW021207,
		AV762959, AV762395, AI289067, BG171096, AW270382, AV763633, BE042649, AW338086,
		AA491284, AA908687, AA551552, BF674620, BE160516, AW410400, BG178002, A1133102,
		AW083364, AW872676, AW088202, AI919265, AI801600, BF792870, AW979060, AV762535,
		AA630362, AL119984, AI688846, AA631507, AI537506, AV743472, AI801591, H56509, AA584145,
	_	AI312309, AI732865, AV764329, AA521323, AI937850, AW574794, AU145711, AP001423.1,
		AP001731.1, AP000021.2, AP000163.1, AC004765.2, AL391803.14, AL122001.32,
		AL139809.16, AL354932.26, AC006128.1, AC018720.5, AL160155.19, AC005696.1,
		AF207550.1, AE006462.1, AL158207.15, AL022315.1, AL513008.14, AL121904.13,
		AF129756.1, AC009412.6,
		AC073593.13,
		AC005808.1, AC007536.9, AL121903.13, AC000397.1, AL355871.5, AC073073.2, D83989.1,
		, AC009470.4, X75335.1, AP002906.2, AC018637.3, AL359457.12,
		AL354707.17, AJ400879.1, U78027.1, AL049830.3, AC018751.30,
	-	U91323.1, AL118520.26, U66059.1, AL390205.17, AC005291.1, AL035422.12, AC008543.7,
-		М.
		AC006285.11, AC007919.18, AC007620.30, AC073138.3, AC009756.9, AP001717.1,
		AF015151.1, AC090939.1, AC005839.1, AL132640.4, AC006079.1,
		•
	-	AL021808.1, AL352978.6, AL137792.11, AP001068.1, AC000360.35,
-		
		•
		AC068466.4, AC083884.6, Z82976.1, AL080243.21, AC011890.4, AL031670.6, AC008474.7,
		AC008745.6, AC002425.1, AJ009615.3, AF015156.1, AC021036.5, AC011467.7, AC002994.2,
		AC008083.23, AL353716.18, AD000092.1, AC027689.10, AC005261.1, AC011310.3,
		AC007051.3, AL121891.22, AF015147.1, AC004166.12, AC020896.5, AC004019.20,
		AL022163.1, AC018728.5, X54176.1, X55931.1, U57008.1, AP000642.5, AC011740.7,
		AL109804.41, AC004534.1, Z86061.1, AC008886.5, U57009.1, X54180.1, U18391.1,
		U18392.1, AC020906.6, U57006.1, AC005815.1, U18394.1, X55925.1, U07562.1, AF196779.1,
		AL136223.11, AC006017.2, AL049795.20, AC009087.4, AL136319.8, AP003357.2,
		AC005089.2, AL391244.11, AC016025.12, AC002549.1, AC011479.6, AC006241.1,

AP001716.1, AL138960.16, AC078961.23, AL356278.8, AC006274.1, AL353788.33, AC002430.1, AL008730.1, AP000432.4, AL139113.21, AC007404.4, AL008716.1, AF265340.1, AL138724.12, AL158850.8, AC008753.8, AL355593.21, AL031668.23, AL158040.13, AC139009.14, AL139099.2, AC007374.6, AL590043.7, X54175.1, AL157838.24, AL078639.5, AC005393.1, AC020893.5, AC009497.3, AC004990.1, AC007384.3, AC004185.1, AF217796.1, AL137778.9, AC006111.3, AC018842.5, AC055120.5, AC011461.4, AL138885.21, AC138755.13, AC016257.22, AC008812.7, AC004455.1, AP000901.5, AC009318.11, AL160411.25, AC073520.6, AL035404.20, AC034198.6, AL031650.22, X53550.1, Z83840.7.	BG026315, AW102828, AI659843, BE551400, AI640582, BE208434, BF510823, AW955647, BE669917, AA789132, AA923523, W44769, AI346827, AI092608, BE267189, AW450220, AI350733, AW090676, AA830093, N98535, N69933, BF694104, AI000893, AI379944, AW968025, AA252680, AI202595, N32022, AL522177, AI026801, BF514413, AA075433, BG014214, AW452208, BE694426, BG171349, AI335272, AI634906, BE796712, AA846518, AA954350, AL522176, AI863776, BE265224, BF359220, BF359223, AW386074, BG112515, AV662306, AA973539, AA329532, F22685, AW136310, N28654, BG014217, AA610002, BG014216, C02160, W37089, N51549, AA361150, BC005984.1, AL109657.8, AL161659.17, AK025977. 1.	AA835052, A1220434, AA335178, AA905529, AL031650. 22. AW274007, A1677890, AW510786, AW468943, AA335322, A1807924, AW172560, AC006116.1, AC011506. 3.	BF570393, BF569907, BF344166, AA758023, W63573, AA8771107, AW664584, AI924890, BE207784, AI422142, AI811174, AI891097, AI379416, AA631138, AI129321, AA233722, AA861574, AI339443, AW009533, AA635649, AA910314, BF510307, AA948287, AA421401, AA621181, H52254, AA908447, BF127938, AA330666, AA458586, AA328941, AI472877, BF337899, AA853185, R69866, AA852144, BF999691, T49327, AA677036, AW024548, R46515, R69911, BF999694, AW593365, H52351, AA976306, BF903330, T49326, AA233143, AI381786, BE827715, AA359077, AI569251, AI685425, AI826541.	BF035708, AI431513, AA832175, AI251429, AV729905, AV754716, AI538491, AU122466, AI446474, AC005006.2, AC008747.5, AC008805.7, AL160155.19, AC005081.3, AC013751.6, AC006241.1, AL157853.12, AC069285.8, AL590762.1, AC004491.1, AL035659.22, AL158040.13, AL22323.7, AL160411.25, AC005231.2, AC005952.1, AC008649.6, AC007850.29, AC024163.2, AP000501.1, Z98304.1, AL122035.6, AC008569.6, AL360227.17, AP000694.1, AC005480.3, AC009470.4, AC008392.6, AC011464.5, AC005911.6, AC008440.8, AC013734.4, AL034417.14, AL139082.18, AC005242.1, AC007686.5, Z98946.15, AC007374.6, AL137787.11, AC000159.6, AL109984.14, AC002350.1, AC009087.4, AP000351.3, AF240786.1, AC0050372.2, AC011490.7, AL022238.1, AC006101.3,
	15 - 1336	15 - 1129	15 - 1345	15 - 1347
	1 - 1322	1 - 1115 1 - 785	1 - 1331	1 - 1333
	603533	596830	847073	566712
	102	103	105	106
	неомоез	HEPAA46 HEPAB80	HFABG18	Н FАВН95

	- 1-										1					$\neg \neg$
AL356481.16, AC005971.5, AC010458.5, AC025588.1, AC005072.2, AL359091.10, AC008521.5, AC016831.1, AL117330.6, AC006312.8, AC007055.3, AC024561.4, Z83826.12, AF196969.1, AC002300.1, AL121891.22, AC005594.1, AC010319.7, AL022322.1, AL513008.14, AC008623.4, Z83838.2, AC005972.1, AC006084.1, AL117694.5, AC008119.6, AP001711.1, AC005102.1, AC004840.3, AL133174.15, AP002453.3, Z83844. 5.	AV655597, AW967329, AW963498, AV706016, AW966767, AL121984. 14.	AI340312, BE676214, AA778534, AW300884, AI609950, AI340016, AI632085, AI335706, AA768117, AW027671, AW978490, AW590880, AW589742, AI272784, AW027648, AA983621, AI421130, AA918495, AI280887, AA724472, AA830837, AI024114, R60771, AI675916, N94357, BF960835, BF953963, AW572683, AI159997, AW772189, T05324, W52231, AI394585, F35349, AI445605, AI347406, R49581, AW020397, AB051512.	AL522683, AL522684, AI628729, AA133340, AW139771, AI690104, BF195450, AA133381, AW207332, AI267992, AI961337, R41690, AB049586. 1.	AW971191, BE710287, AA493766, D56115, H06701, Z41729, AA285136, AA256963, F04210, AL118652, AW893768, AW893769, AW160783, AF258348.1, AC007552.4, AL050152. 1.	AV699250, AV662248, AV699269, AV719565.	AL537384, AI656961, AI651790, BE466895, AA481913, H54148, AW020416, AA524615, AI309941, T82299, AW971340, AI625683, AA007579, AA670123, AW088680, AA112001, AI250970, AI613405, A1376500. BF526521, AA480105, AA417299, BF054759, BF054867, AI016470, AI373731, AA416675,	BE622947, A1340568, BG180542, BE222669, A1266504, A1291507, A1672420, A1650382, BF885229, AA129526, AA081857, AV699196, AV699199, AA948596, AV699131, AV69923, AV662288,	AV699219, AV699246, AV662257, AV699269, AV699218, AV662235, AV662248, AV699182,	AV65223, AV662223, AV699144, AV699170, AV699136, AV69924, AV662272, AV699125,	AV699203, AV699200, AV699247, AV662191, AV699255, AV662185, AV662196, AV662317, AV662287, AV699236, AV726209, AV652214, AV650926, AV652066, AW956240, L48842,	AF031321.1, AF031322.1, AF035031, BF036097, AV727342, AL119977, BF920864, AW888751, N31682, AL119979, BF346635, AV726399, BF036097, AV727342, AL119979, BF32632, AV726329	AW148844, AA772781, AA326677, N23200, AW961610, BF976983, BE763872, BE763739, BE765749, BE765443, BF570590, BE765618, BF438771, BE766953, BE766490, F06586, BG057153,	R60278, F07047, AA628815, AV722183, R16237, BF364146, AA204942, AV734361, N71200, A 1000467, R54067, Z40722, BF337123, R54066, AW903171, H24278, AV726415, H16893,	AW897545, H16783, H22887, R16238, F03521, R42035, F05678, T80483, AA321847, AV731162,	AV731097, AV730504, AV730299, AV731130, BE7655330, K20855, AA386260, AW890773, N45767, R42611, N94832, R39831, F02857, F03323, T03048, R11992, F07675, AU118413, AW890773,	AA640468, N95708, F05679, BE830656, BF948144, M85660, AL119687, T08757, AV722325, AW904904, BF344999, A1003266, N76471, N47227, AW903272, BF977690, T53097, BF918689,
	15 - 642	15 - 669	15 - 1271	15 - 802	15 - 470	15 - 1020					15 - 1881					
	1 - 628	1-655	1 - 1257	1 - 788	1 - 456	1 - 1006					1 - 1867					
	534142	543486	579993	411345	520369	560639		-			513669					
	107	801	601	110	Ξ	112					113					
	HFAEF57	HFAMH77	НЕССQ50	нгсев37	HFFAD59	HFFAL36					HFGAD82					

	_				F01937, N58994, A1000789, AW898733, BE702498, BE699153, AL118827, BE708346, F07242,
					AW897547, F01938, N51309, AC003037.1, AC022486.4, AC007379.2, AC007064.27,
	-				AC006548.20, AC016752.2, AC008175.2, AC007965.3, AC007322.4, T66696, T66697.
HFIURIO 1	114 53	532060	1 - 527	15 - 541	BF195618, AA191239, AW969824, AA009856, AW019964, AA808036, BE677291, AW973259,
					AW023662, AV742957, AU146063, AI369580, BG109444, AU153717, AV709074, BG032605,
					A1357823, AW888719, AL110373, A1832009, AV708388, AV725797, BE150580, AA223512,
					AV734980, AA402529, AA595661, AW410201, AA683069, AA191418, A1144036, AW474168,
					BF681348, A1590458, A1590499, F08248, AW302048, AV760508, BE794962, AA665181, H07953,
				***	AW971071, AA654781, AV763410, AA749035, BF965290, AI609972, BF676985, AV708385,
					AW504485, AV762633, AW166808, AA282951, AI860535, AI792575, AA634889, AW302950,
					AL048060, AI254913, AW875172, AI281689, AA668587, AA084619, BF675051, AI354423,
					AA832077, AI733129, BF674550, AL041924, BE139451, H73550, AA828853, N39953, AW863393,
					AV757526, A1859946, AW976008, AW023111, AA747234, A1565084, AV710482, AW814024,
-					AV710045, AW963482, AI355246, AA814925, BE077105, AA653182, AA664521, AW440305,
					A1054397, AA651639, BF725761, AV758073, H15652, BE280771, AW438542, T74524, AW191063,
	_	<u>.</u>			BF940118, AW968205, AV762973, AA552578, BF965924, BF879045, AI251034, AI251203, AI251284,
_	_				AW805539, BG236628, BE878259, AI250552, AA632556, BF809041, BG029224, BF868994,
		<u>.</u>			AW020736, AF236698, BE139139, AW271904, BF978025, BF681424, AU118374, AV758790,
					BG110480, A1803809, AV758097, AA574442, AV733434, BE155302, AA644664, A1792521,
-		-		_	BE246472, BE901278, AA626825, AI686913, AV706237, BE155299, AW302293, AV702609,
_					AA533123, BE968477, AV738383, BF814446, AI891080, AA516190, AA533040, A1284543,
-					BE273825, AW779609, BF525663, Al380617, BF914419, AL079734, BG166965, AW069227,
_					AL043351, AI267161, AV762870, AV658819, AV709273, AL042735, AA503018, AI973173,
		•			AL046746, BE062357, AI963705, T69857, AV730245, BF810071, AW301736, Z97987.1,
					AL031281.6,
	_				AF245699.1,
					AC004990.1, AL133351.33, AC010618.7, AC006275.1, AL035405.10
-					AC006930.1,
-					AC005162.1,
					-
	-				AC005684.1,
					_
					AC006538.1,
_					AC006546.9,
					AC007381.3,
					AL109823.23, AL451107.6, AL359873.11, AC004605.1, AL035682.16, AP002453.3,

HFVAB79 HFXBL33 HFXJX44 HFXXJX44 HFXKJ03 HFXKT05	117 118 119 120 123 123	1300736 854545 778070 553685 553685 658690	1 - 1161 1 - 558 1 - 1619 1 - 1012 1 - 1370 1 - 927 1 - 1701	15 - 1175 15 - 1633 15 - 1026 15 - 1384 15 - 941 15 - 941 15 - 1715	AW905328, BE699539, AI830527, BF952755, BF210822, AA431528, AA029326, H41714, AA437157, N53641, BE699547, AW905379, BE699537, BF796741, AW89802, AI218421, AF289076.2, AC067967. 2. AG067967. 2. AG067967. 2. AG067848.4, AF349540. 1. AG069548.4, AF349540. 1. BF362920, AL160269. 14 BG141322, AV652809, AV662223, AV699247, AV699167, AV662247, AW963961, AV699098, AV662207, AV725496, AV727824, AV699218, AV719825, AV719156, AV699200, AW952432, AV69220, AV725496, AV727824, AV699218, AV719825, AV719156, AV652809, AW952432, AV699218, AV720062, AV720062, AV725496, AV727824, AV659003. AV699218, AV728496, AV727824, AV699167, AV662247, AW963961, AV662223, AV699218, AV719825, AV719156, AV652003. AV699218, AV719825, AV719156, AV720062, AV720940, BE842726, BE842730, AV699218, AV719825, AV719156, AV650903. AV699218, AV719825, AV719156, AV720062, AV720940, BE700915.2, AC070111. 1. AU124431, AW960435, BF252944, AA781090, AW514159, AW390483, AW965129, AW170237, AW52015, AI700395, AI079309, AW339256, AI140441, BE700940, BE842720, BE700861, BE700861, BE70087, AA719006, BE908235, BE772094, BE772094, BE772094, BE772094, BE772094, BE772095, BE818964, AW517983, BE772093, BE818955, BE818955, BE818962, BE772019, AB818962, BE818964, AW517983, BE772014, A7305705, BE818964, AW517983, BE772014, A7305705, BE818962, BE872015, A134444, BE772004, A8820655, BE772019, BE772019, BE872019, BE872015, A134444, BE772019, BE872019, BE872015, BE872015, BE772019, BE872019, BE872017, BE883029, BE772014, BE772004, BE772004, A8820659, BE772018, BE772014, BE772019, BE872017, BE883029, BE772014, BE772017, BE883022, A7314040, BE8772017, BE883022, A7314040, BE8772017, BE883022, A7314040, A7305702, BE883023, A7324635, A732469, BE772019, BE872019, A732019, BE872011, A732065, BE8720039, BE772019, BE872003, BE872003, A7324635, BE772019, BE872011, A7306509, BE772011, A73066, BE772019, BE872011,
ндвніз5	124	570262	1 - 1423	15 - 1437	BE818951, AW674579, BE832289, BF091071, AK001249.2, AB007936.1, AK027078.1, AL117402. 1. AL117402. 1. AW077617, AW167655, AV705616, BF112047, AV647323, AI761852, AV647362, BF475491, AW027617, AW167655, AV705616, BF112047, AV647323, AI761852, AV647362, BF475491, AU134617, AW273477, AA632135, BF589834, AW188958, BE328783, BF673582, AA974499, AA586906, AA41210, AA748561, AV647324, AA574049, BF001545, AA993212, AA974499, AA586906, AA418055, T65000, AA633212, AA417996, AA716696, AW338423, AU155540, AA405832, AA418055, T65000, AA633212, AA417996, AA716696, AW338433, A9561713, AW269824, AA705781, AW294610, N29931, AW193961, W74344, AI623473, W95062, N58311. AA434443, AI452555, AI476814, AI707848, AI591113, AW071570, AA504192, AI284330.
нбвніз5	124	570262	1 - 1423	1.	AU157402. 1. AW027617, AW167655, AV705616, BF112047, AV647323, Al761852, AV647362, BF475491, BF941241, AU134617, AW273477, AA632135, BF589834, AW188958, BE328783, BF673582, AW025350, AW469123, AI248475, AW071025, AW513405, AV707439, AA443956, AW959532, AA974499, AA586906, AA411210, AA748561, AV647324, AA574049, BF001545, AA993212, AA974499, AA586906, AA411210, AA748561, AV647324, AA574049, BF001545, AA993212, AU155540, AA405832, AA418055, T65000, AA633212, AA417996, AA716696, AW338423, AI951713, AW269824, AA705781, AW294610, N29931, AW193961, W74344, AI623473, W95062, N53311, AA434443, AI452555, AI476814, AI707848, AI591113, AW071570, AA504192, AI284330, AA993753, AA422102, AA814543, AA833607, R59175, H69589, N27730, N27744, AI050821, H91466,

					AV661353, N26927, AA384582, T53881, AA723025, AW952885, AA708478, AA412129, N80150, AA805411, AA325056, H86073, AW080735, AA719996, H48787, AW439101, AA327279, AW439110, R72184, AA317798, AA290758, A1307593, A1041429, AA932900, AV692965, H68481, AA290757
					A1301278, AA928847, AV709914, R70407, AA342345, AW971285, T71152, AA528307, R00838,
					A1915200, A1470398, AA888272, T50944, T54028, A1784177, R69430, A1298655, A1801093, A 243067, A 2035078, A 2035062, T00400, A 34450018, E37718, A 1470400, A 2419235, A 34074842
	_				AA700546, BF057503, AV656088, AI798643, AA946561, AV684912, C05231, AA342344, AA405831,
					AI682312, R72230, AV696820, AI557037, T72850, BG122003, AI478342, AA504193, AI474859,
					W91943, BG164862, AW841423, AI243763, AI364219, AA879063, AA419337, AV698254, BF847168,
			 		BG004190, AK001810. 1.
HGBIB74	125	837220	1 - 1802	15 - 1816	AU132073, AL514534, BF983632, AL526111, BF793202, BF816636, AL526167, BF207035,
					AU121857, BE312932, BF307465, AL528311, BF316637, BE878180, BF512924, BE781366,
					BE299008, BE866833, AU141579, BF307539, BE296624, BF203318, BE314690, BE247312,
					AA258714, BF203434, AA258479, AW602250, AW372226, BF358908, AA625114, AI337232,
			_		BF762063, AU134960, BF303835, AW372227, AU125523, BE840047, AI739102, BE696707,
			_	-	AA551238, AA505288, R52096, BE746044, AA853934, BG012508, AI936957, AI582908, BE245999,
					R46499, BF365473, BE296121, AW166753, AA770298, BG056533, AA481002, AW071542, H17104,
					AW007814, AI086723, AI338746, AI340064, AI094613, AI096869, AI922132, BF939399, BE855621,
		-			AI357394, AI423481, AW087313, BF475441, AI421759, AI356823, AI418892, AA287330, N94480,
		_		-	AA524286, AW005778, AI922862, AW191028, AI566341, AA470698, AI421557, AI361016,
					A1359797, A1362874, A1863909, A1880712, F09352, A1922424, AA873767, AA481480, BF447091,
					AA291405, N20109, AI263664, AW968514, AA570059, AI913894, BF057036, W94068, BF090405,
					A1381877, A1193950, A1364237, D54296, AU149162, BE828094, BF751874, AA789159, AA853935,
					AA482101, AI360188, AW952710, Z40719, AA400811, AI539565, AA629142, BE813293, AA095376,
					T58139, AU147592, AI214242, AI034063, N31573, AI040574, H43298, BF753185, AA953460,
-		•			AW131152, AV706318, A1146352, A1648405, AA921717, AW054979, A1445988, A1888216,
		-		-	BF432411, A1271977, R22588, A1360977, AW188664, AW516744, A1085523, AW057831, A1613427,
_				-	AA679957, AA524336, AW993553, AW375413, M79269, AI598125, BF819300, AW993667,
					A1083784, H65453, AW136876, BE964668, AA421021, F30056, AL515965, AI078721, AL515964,
					BG060060, AA701072, BF805411, BE815632, BF872254, BF752405, BF527514, W94067, BE762789,
		-			W23927, BF206436, BF527026, W22794, BF772933, AW265783, BE707365, AA480986, BE259841,
					BE876343, BE697298, D87444.1, AL049539. 21.
HGLAF75	126	566838	1 - 762	15 - 776	AW968403, AW268460, AV699333, BE388094, BE387809, AA805707, BF112044, AA769677,
					AI379717, AI419895, AI858342, AI708860, AA044030, AA465222, AI677780, AI189447, AI221144,
					A1073526, A1286149, A1540808, A1298414, AA847808, N29749, AW170779, AA344901, AA044352,
					R52970, BE836466, BE716265, BG057223, BE836496, H40701, R55340, AA873679, AI363753,
					BF792412, R40137, AW965142, AA725486, AA344902, T27542, BE716174, N57171.

HGLAL82	127	520261	1 - 392	15 - 406	AL117344.12.
ННЕМА59	128	823100	1 - 3088	15 - 3102	AV726528, BF574791, BF996057, BF990910, BF035428, BF695329, A1096792, AW977965, AA811457, A1742527, A1820061, A1921596, A1984225, AW961815, A1393746, A1573202, BF970504, A1245917, BE670178, A1283174, AW043715, W74699, A1174605, AA810908, A1367927, A1285046, BG117412, BF338708, A1357298, AA215462, BF810183, BE927671, A1334340, D62083, T32812, N70003, W74737, BE927668, BE568242, AA463313, A1880873, A1039073, AA862480, D61879, AA130296, H70799, AA215463, Z45087, Z40816, T60267, R76519, AL157633, A1264491, T32813, R81074, AW089194, BF088910, R80967, H70800, N62108, R76520, BF356673, BE940685, AW900254, A1885935, A1370183, BF925069, N78339, H60031, BE935677, T61647, AL136527.9, AB014529.1, AF176555. 1.
HHENV10	129	562772	1 - 1141	15 - 1155	AC004912.1.
ннерм33	130	877639	1 - 1445	15 - 1459	AL525047, BE267465, AU119027, BE728398, AU142237, BG034269, BE797542, BG110205, AL525046, BF446035, AW966408, BE695857, AA447885, BE261226, BF852227, BE858413, AU159593, AV749929, BG178599, BE856576, AA424770, A1338990, AW135009, A1423774, A1334334, AW959286, A1766429, AA417903, AA933079, AA424903, AL047160, A1685395, BF447465, AW139987, BF948688, BF745006, AW769824, AA641849, AW371401, AW371406, BF744931, BF744932, BF744930, A1250926, BF760364, AA593807, A1969741, A1263347, BF744931, BF745007, AA383851, AA482522, BF745014, A1686024, AA447724, AW613546, AW61328, A1766856, BF955849, AK023968. 1.
ННЕВУ53	131	821330	1 - 856	15 - 870	AA346699, BE897269, BG109478, BG178294, AI370129, AW238611, BF343729, AI000070, AI085870, BG179993, AI436456, BG108324, AV755207, AL514935, BE047863, AI802542, AI349772, AI500077, AL513643, AL121270, AI524684, BG165209, AL036396, AI225230, BF725126, BG260037, AL5100077, AL513643, AL121270, AI524684, BG165209, AL036396, AI225230, BF725126, BG260037, AL513907, BE048081, AL514627, AV681857, AW827203, AI064830, BG036846, AL036802, AL702406, AI475371, BF037097, BE048071, BE969709, BF727212, AV757737, BG111647, AL135661, AI513012, AI675423, AI433157, AL515041, BF971016, BF054877, BG168696, AW268253, AL121365, AV710479, AV757943, AI349645, AV711924, AW827249, AL119748, AV682224, AA187180, AV710479, AV757943, AI349645, AV711924, AW827246, BE887488, AI568870, BE613622, AV71179, AW274192, AI340582, AI681537, BG058208, AV721967, BF795712, BF968493, AV882351, AL513693, AI815383, AW071349, AW301409, AI349993, AI868831, AV682249, AI588716, BE966388, BG259801, AI349004, AI433976, AL045500, BG109125, BF795712, BF968493, BE964700, BG180996, AI969567, AI440426, BG114104, AL047763, AW074993, AI567351,

BE048179, AV755290, AI28179, AV759235, AV757158, AL513553, AW195957, AI686926, AI6817769, AA494113, AI687415, AI349937, BER695022, AV682074, AV681948, AW133397, BE877769, AA494113, AI687415, AI349937, BE782016, BF726421, A4497733, AW827211, BE965556, AV681685, AA610426, AW103371, BE048026, AI671017, AV757012, AV7734318, AW169653, AL513753, AI65241, BY72099, BE048165, AI69981, AW16071, BE018171, AV75783, AL120854, BF720364, BF72039, BF071012, BF77833, BF17364, AV757018, AV7573013, AL513803, AV757833, AI757175, AV705644, AV7583701, AV705844, AV7583701, AV705844, AV758370, BE048319, BE048198, BF70162, BE881155, AL514791, AV705644, AV758527, AW106884, AR65014, AR64719, AV682252, BF010270, BF010847, AL036774, AV75806, BF97046, BF878234, AV70684, AV77879, BE068033, AJ84036, AR65078, BF970731, AL036759, BF0108770, BF02084, AV718608, AL514701, AV681997, AV682809, BF72466, AR6608, BF726297, AV75806, BF87264, AV77809, AV77806, AL514701, BF02089, AV77777, BF0208417, AV681997, AV682809, AV75775, BF02084, AV75777, BF02084, AV77877, AV681997, AV682809, AV75772, BF02084, AV75777, BF02084, AV77877, AV681997, AV682809, AV75772, BF02084, AV75777, BF02094, AV77641, AL72691, AL726781, AL72691, AL726781, AL727821, AL7
AF125948.1, AF041428.1, AK000083.1, AK000137.1, AL133560.1, AF091084.1, AL110225.1, M22146.1, X82434.1, AK024538.1, AL5 AL050138.1, AL359941.1, AB048954.1, AL137550.1, AB060826.1, AK025092.1, AK000614.1, AK026542.1, BC001045.1, AB055368.1,

					AK026583.1, AB052191.1, BC007199.1, AK025491.1, AP001666.1, AL512689.1, AL353594.13, AL122110.1, AF225424.1, AK026927.1, AK000323.1, AB049892.1, AK000323.1, AK000320.1, AK000320.1, AK000320.1, AK000320.1, AK000320.1, AK000320.1, AK000320.1, AK000320.1, AK000
					AF177350.1, AR026304.1, AL5359013.1, AL049300.1, AB048974.1, AL049382.1, AK000432.1, AK136845.1, AK026959.1,
					AK026086.1, AK025391.1, AL050024.1, BC008485.1, AK026528.1, AB015610.1, AL353802.14, BC008070.1, AK025414.1, AL137538.1, AC026787.4, AK026642.1, AK026947.1, AK025967.1, BC002839.1, AB024285.1, AK027204.1, AF348209.1, BC008899.1,
					X72889.1, AC002467.1, AB052200.1, AL137463.1, Z82022.1, AF18 AK024524.1, AK027213.1, AL353625.5, AL133113.1, BC008382.1, AC010305.3, AL359583.1, AL137648.1, AF334404.1, AB056421.1,
HHFGR93	132	865581	1 - 1821	15 - 1835	1-1 <u>1-</u> 4
					AW300019, AW173046, AA428713, H12307, BF432551, H12782, BF115565, AI141481, A1092488, BE550395, W58612, AW172540, AI184646, BF222972, W58613, A1359381, AW361707, BE043092, A1070137, A1132555, B77354, A1674748, A1070137, A1132555, A113255, A1132555, A113255, A113255, A113255, A113255, A113255, A113255, A113255, A113
					R69232, AA514466, BF995428, AI521359, R69114, BG011026, AI347221, R76149, R73827, AA664044, R79810, H12841, AW594241, R78260, BG015155, BG002356, BF851373, H12629,
					R76098, R32862, R63063, R78261, T47327, A1189377, R73853, R62315, R68433, A1828342, R79923, H12360, AA618505, H12680, T50332, R79910, AW903922, AA733001, R35438, A1216465,
					AW903849, T98690, R73852, R81664, H00855, AA683601, AW009057, AI873711, AW513081, R33685, H02334, AI189455, AW365832, H02440, R67936, H02804, AI569353, R66838, R68432,
					H38189, R76065, R64387, R75889, R33581, R35749, AW235425, BG055882, R27675, T98640,
					R31360, AA359117, R31889, R34252, AI762218, AW002259, BF848635, W52486, H01235, AI199859,
					R62314, AA046788, AA249358, R64386, AW407088, N55686, R67441, AA446485, D45691, A1002022, AA430177, AF361746.1, AB060855.1, AF277292. 1.
нндсм76	134	662329	1 - 697	15 - 711	AW248957, BF828801, BF828604, AI675194, AW028119, BF826770, BF827069, AW452880, AI491913, AI799880, AW450970, AI377883, AI201976, AA595164, AI088096, AW612440, BE792795,
					AW006952, BF063362, AI697133, AA643065, AA580017, AI819005, AI866931, AI560641, A A A S S S A B E A A C S A A B A A A A A A A A A A A A A A A A
					AI670745, AI269568, AA326815, AI873666, AL523219, AL520944, AI478177, L31980, AW245254,
					AW194690, AW771866, A1767850, AW079488, T87766, D45523, BE242113, AA055697, A1306732, AW775417, BE280419, A1908657, R48473, AA013188, A1908646, BG250796, BE796614, T72628.

					BC002980.1, AC003665. 1.
	135	579890	1 - 876	15 - 890	AI365221, AI701000, AW954119, AW264473, BF34449, AI680921, AI492007, AW014989, AI860823, AI539819, AI473662, AW628976, AW276150, C75362, AU152947, AA167428, AI559629, AI860823, AI539819, AI473662, AW628976, AW276150, C75362, AU152947, AA167428, AI559629, AI811077, AI039475, AI686542, AI284462, AW590370, AI431949, AI656530, AW148492, N67246, AI915180, AA907555, AA047467, AA478729, AI365222, AI242862, BE018520, AA834839, AA412178, BE302119, AI823337, BF671770, T61838, AW007865, AA905198, H08613, AI382420, AA776507, AA385375, T94765, T94766, AA047401, N53320, AW890140, BF949155, N83376, BE883645, AV701945, AV704429, AW890022, AW898540, AV702726, AV703584, AV703624, C01033, AV702464, AW890015, AW956618, AV655824, AV708911, AV729091, AV704729, AW890015, AW964267, AV706912, AW890016, AV708539, AV701584, AV7056913, AV7044029, AV702601, AV655568, AV707690, AV705045, AV704029, AV702601, AV655568, AV702604, AV705604, AV705604, AV705813, AV7028464, AV705813, AV7028464, AV705813, AV7028464, AV705813, AV705813, AV705813, AV705813, AV705813, AV705813, AV705813, AV705813, AV705813, AV70580, AV705804511, AF227899. BE00606 AV705806, AV
HHPEN62	137	695134	1 - 2138	15 - 2152	AI939620, AI480056, AW300615, AW300620, AI389129, BE386438, BF920434, BE386547, AW961851, AI911546, AV726263, AI361251, AI498527, AV725146, AW901919, BE967591, H41544, AA326679, AA348503, AI422476, AA912288, AI423129, BC004271. 1.
Н	138	1299927	1 - 988		BF936014, BF926087, BF849807, BG059559, AA663575, BE464797, AL137451. 1.
HHSDX28	139	553494	1 - 1099	15 - 1113	AA548981, BF835253, BF835251, AA854044, A1784057, AL034420.16, AC006060.1, AC025470.
	140	636025	1 - 1654	1	AW86642, N50805, AW769075, BF836507, AI206345, BF840986, AA708926, AA426062, AU155280, AW866532, AW769542, AI652458, AA258053, AA532374, AW674310, AI079267, BG178864, AI918893, AI583381, AI129768, AU160789, AW151099, AI375855, AI077465, AI434984, AI084577, AA353483, AI803071, AI978803, AA625163, BF437117, AI093544, AI016100, AI951676, AI684966, AI479709, AA502596, AA075493, AI224122, AA531263, AI865571, AA424807, AI337861, AI275719, AI78447, AI393782, AA045896, AI798537, AW627862, AI362624, AW188737, AI587550, AI583574, BE242408, AI951273, AA135691, AW514022, AI262711, BF939682, AA135723, H06916, AA398860, AI583554, N93804, AI707963, BF843408, BF843416, AL522362, AA625925, BF738648, AI919121, T98717, BF059218, AL526660, T98661, AW022094, D19802, AA887448, T25800, BF950460, AL529899, AA654911, W44832, AA426475, BF773449, AL529900, AA495877, AK023371.1, BC000630.1, BC000994.2, D14663.1, AF215935.1.
HJABB94	141	456466	1 - 1541	15 - 1555	BE905356, AI026821, AA503776, BF114724, AI435527, AL036946, AW298357, BF240642, AA969442, AI767392, AI142574, AI094514, AW073866, AW241144, AA206595, AA040034, AA354909, AW972134, AA814156, AA933895, AA040828, C01416, AA457220, AL138875.8, AY027525. 1.

AA311223, BF002026, N41594, N30820, BF982046, A1829327, BE047833, A1457369, AW071417, BF968205, A1340627, R36271, AL036980, BF061283, BG168549, AW022682, BG034550, AV682418, AL047042, BF343172, BG113299, AW020693, BF751308, A1452560, A1690748, A1349645, AW946806, A1340511, BF924882, AW074869, AW196299, AL038445, BE781369, AW302992, BG110684, BE887488, AL514193, A1310575, BG164558, A1340533, A1349957, A1433384, BF680133, AV715560, A1309401, A1345005, BG163618, A1343112, AV743962, A1826225, A1811785, A1494201, AW054931, AW268302, AW301300, A1349598, BF672397, AW072719, AW075207, BF526020, AV741327, A1345735, BG036846, A1697243, BE536058, AW193134, A1889147, BF904189,	BE910373, AI500077, AA225339, BE138712, AI307210, BG033723, AI589267, AI269862, BE885353, AI313320, BG058150, BE886728, AW827106, BF527014, AI313352, BG110517, AL039086, AW079336, AI251434, AI274728, BF868928, AI524780, AI589947, AV682724, AI439717, AI312146, AI312339, AI814087, AI345745, AL036925, AI345258, AI932638, AI470651, AL036857, AW050578, AW196105, AV682227, AI306705, AW269097, AI620639, AI611348, AW090393, AL042628, AW152469, AA833760, BG256090, AI866798, AW074993, AI511738, AW169604, AW268253, AI8611404, AI567612, BE886827, BF793308, AI890806, AI349256, AL036664, AI554821, AI312152, AI955906, AI336495, BF970768, BF885000, AW075084, AL120854, BE895585, AI950664, BE897632, BE964078, BF872670, AW022699, AI349937, AL036923, AW089572, AI334884, AI307543,	AW151138, AW071412, BF885081, A1307708, A1312325, A1500659, A1868204, A1340659, BF816037, A1280655, A1612885, BF092710, AW302965, BF339322, A1334930, A1309443, AV699211, AV734185, A1307520, A1445237, AV724373, A1590423, AV756798, A1345739, A1889168, A1440263, AW117743, A1312143, AW673635, AW806761, A1343037, AV708834, A1434256, A1312428, W33163, BG109270, BE966829, A1349955, AW075093, A1371228, BE548914, AW827206, A1348897, AA427700, A1306613, A1312357, A1335426, A134777, A1308032, A1569583, A1687127, BG249582, A1783997, BG030364, BG104820, AW161579, A1627988, A1344785, BG113662, BE971716, BF970449, AL079963, AL036718, BE047852, BF970990, BF526262, BG027280, AL036274, BF061286, A1497733, AL041150, A1288285, A1890507, BG026428, AW827115, AW268964, A1343091, A1318280, A1567582,	BG165051, AI554245, BE963035, BE138658, BG260037, AI310582, BG032208, BF344691, BE885490, AF352730.1, AF205952.1, AF323081.1, AK024538.1, X53587.1, AL512765.1, AL050393.1, AK025254.1, AF090901.1, AK026542.1, AL136787.1, AK026597.1, BC006525.1, AF218031.1, AL122110.1, BC007326.1, AB055366.1, AK027213.1, AL389939.1, AK026528.1, AK026855.1, AK024524.1, AF091084.1, AL049466.1, AK025967.1, AK026480.1, BC008070.1, BC006807.1, AL136789.1, AL157482.1, AL117394.1, AK025391.1, AL137560.1, AY034001.1, AK025349.1, AF125948.1, AL359615.1, AL142859.1, AK027146.1, AB060825.1, AL130915.1, AK025484.1, AK000391.1, AL13075.1, AK025484.1, AK000391.1,
15 - 575			
1-561			
1307789			
142			
HJACG02			

AF05- AK02 AB06- AB06- AB06- AR01- AR04- AR04- AR13- A	1-1518 15-1532	15 - 1532	١.	l, AB063046.1	K026534.1, AL133067.1, AK024588.1, Al	1, AL049464.1, AL133113.1, AL133560.1, AL137521.1,	AB060912.1, AF097996.1, AK026353.1, BC008899.1, BC001967.1, AK026959.1, AL137459.1,	AL133016.	AF057300.1, AF057299.1, X72889.1, AK000618.1, BC	AK026506.1, AK026741.1,	L19437.2, AL049314.1, AB056421.1, BC004958.1, AK02	1, AL050149.1, AL389982.1, AL137463.1, AL122123.1, AF230496.1, A	, AL133080.1, AL390154.1, BC006164.1, AK000137.1, AK026762.1,	AL512689.1, AL512719.1, AL050108.1, AK026593.1, AB063100.1,	AL049452.1, BC005151.1, AK000647.1, BC001045.1, AB063079.1,	BC002342.1, AK025383.1, BC004556.1, BC009284.1, AL080086.	AF026816.2, AL136928.1, AL512750.1, BC003627.1	AL512754.1, BC006103.1, U58996.2, AB060863.1, AL136844.1,	, AL359601.1, AF262032.1, AK026600.1, AL136864.	BC008893.1, AL136892.1, BC006201.1, AL117435.1, BC008365.1,	AL136749.1, AK027868.1, AB019565.1, AF162270.1,		AL137648.1, AB060929.1,	AL122098.1, AK025573.1, AF219137.1, AF090903.1, AF125949.1,	AF111847.1, AL442072.1, AB062978.1, AJ006417.1, AL122121.1,	AF104032.1, BC008488.1, AL080060.1, AB055315.1, AL137478.1,	AF061836.1, AF183393.1, AK027204.1, AL080127.1,	AL353940.1, BC008387.1, AL137556.1,	AL162008.1,	AB048974.1, AK025798.1, AB055368.1, S78214.1, AK000486. 1.	AA311188, BF940968, AI478697, AA309875, AA481249, AL533052, AA481563, AW242463	AA760629, AV651897, AV660258, AV661286, AV709580, AV653353, AV726590, AV703632,	AV725255, AW960067, AV705453, AV726243, AV652001, AV704144, AV726194, AW956292,	AW949777, AV708520, AV727618, AW959858, AV656283, AW967329, AV727932, AV728953,	AV725582, AV708786, AV708872, AV661369, AW952013, AV705340, AV704234, AW965148,	AV726156, AV705836, AV708991, AV725618, AW952301, AW958796, AV725596, AV709248,	AW959986, AV726337, AV709407, AV728355, AV725031, AV707948, AV725441, AV729424,	AV652528, AV725577, AV707556, AV704626, AV702071, AV706223, AV705665, AV704785,
		895505 1	AF0	AK(AK(ABC	AB(ABC	ABC	AK	160	ALI	AB(AK	ALC	ALI	AF0	AFO	ALC	ALI	AFC	AFC	ALI	AL	AL(ALI	AFI	ALC	AL	AB(- 1532	AA	AV	AW	AV	AV	AW	AV

				AV729473, AV702738, AV725321, AV690930, AV728743, AV727978, AV727337, AV727562,
				AV729129, AV704712, AV701953, AV727052, AW955629, AV729532, AV704520, AV706964,
				AV704973, AV702817, AV705504, AV709356, AV704279, AV705829, AV702164, AV701880,
				AV701626, AV707401, AV704756, AW955019, AV701183, AV728289, AV708203, AV703591,
				AV697880, AV647941, AV703417, AV753624, AW963446, AV654035, AV709935, AV726628,
				AV707654, AV706290, AV655552, AV654282, AW949521, AV709880, AV709939, AV705189,
				AV704686, AV706882, AV727314, AV702954, AV727238, AV691615, AW967328, AV682997,
				AV727126, AV727347, AV728652, AV702787, AV706162, AV709596, AV686417, AV701728,
				AV701873, AV656240, AV692972, AV694871, AV705239, AV727459, AV655901, AV728715,
				AV701499, AV703972, AV703090, AV707794, AV702790, AV728546, AV705267, AV703762,
	-	-		AV703273, AV706734, AV702854, AV709025, AV706025, AV705684, AV656224, AV705299,
				AV709273, AV706165, AV727343, AV709932, AV702625, AV727468, AV707088, AV709549,
				AV645545, AV702498, AV701874, AV706671, AV705433, AV705866, AV728255, AV709256,
				AV706076, AV726559, AV651075, AV702537, AV706279, AV703436, AV727103, AV704097,
_				AV726653, AV706532, AV706133, AV701496, AV658784, AV727807, AV728459, AV729077,
-				AV707804, AV704592, AV704974, AV701858, AV703456, AV703515, AV702280, AV727032,
_				AV705416, AV704116, AV702728, AV706910, AV727047, AV706889, AV705014, AV705047,
				AV703035, AV701538, AV727029, AV702869, AV725380, AV728455, AV706741, AV707830,
_				AV707510, AV704971, AV706683, AV725956, AV707769, AV705234, AV706891, AV706527,
				AV728471, AV706758, AV690921, AV707798, AV725991, AV702725, AV724987, AV706448,
				AV725845, AV685113, AV726789, AV725387, AV726830, AV726787, AV702417, AV701844,
				AV702851, AV727189, AV706655, AV725386, AV655067, AW962136, AV706992, AV707420,
				AV706183, AV703366, AB000616.1, U94592.1, AJ244005.1, AJ244004.1, AJ244003.1,
				AJ244007.1, D78345.1, D50010.1, D13316.1, AB025273.1, AF144029.1, AJ276256.1,
				AJ276254.1, Z30183.1, AF144028.1, X82834.1, Y14219.1, U45328.1, AB005666.1, S81957. 1.
HJBCY35 144	4 719729	1 - 1545	15 - 1559	AL518865, AL526445, AL518864, BF690211, BE795952, BG261247, BG122941, BE871131,
				BF342499, BF797882, BG034854, BE874386, BF684303, AW958340, BF055513, BE265238,
				BF055496, AL042954, AL044311, AW393087, BF590235, BE251517, BF688851, AW500006,
				BF750912, BF436031, BE207255, AI523943, AI809559, AW615714, AI088845, AI199469, AI088821,
_				BE792741, AA707004, AI393362, AI859578, AA864359, AI359119, AI963339, AA259086,
				AW027379, AA186786, AA703021, AA305929, AA393356, BE729570, AI961726, AW274049,
		_		AI216448, AW503180, AW505339, AI015694, AA291342, AI049539, AW873566, AI092749,
	_			BE410341, AI817912, AI870620, H44330, AI366215, AA258242, R46300, R16949, AI744596, R54656,
				BE386449, BE410337, Al807057, AW081887, AL041401, H15972, BE710574, BE410414, BE535502,
				BE222788, AA398688, AW273864, AA404987, D59795, AA077661, BE047327, T10451, A1871075,
				D59810, Al368575, BF526818, AA962247, AA335735, AW000813, BF435172, AA188015, R75708,
				AA329264, BE713106, AI218840, AA329538, AA291343, AA826970, T35806, R10855, D59833,

D59821, BE547124, D80231, AI080034, AA299767, BF203222, AI908002, AA973311, AW087244, BF920764, AI648592, D80329, BE537114, BF511965, D59677, W93021, AI919083, AA749327, R16895, R55419, AA354448, AA136776, R54853, R46205, D59561, AI969256, W51754, AW273865, R10856, AI452772, BF765954, R10335, BF858687, AA076725, BF955782, BF206768, BF310354, BF032473, C01203, BC004286.1, AL050110.1, AB037861.1, AL137358, 1. Al928477, AA527494, AI871626, AI694451, AI613494, N21002, AI630897, AI609811, AA987612, A1373242, AA595033, AW271584, AI88763, BF1111620, AW975076, AA281453, C06206, H85386,	C05666, AL536332, T23579, R22308, AI125182, AA488619, AI914281, R45226, R37773, Z40129, AA658001, N66912, N78467, BE778573, AA211234, AL119049, AA928812, AC007622. 28. AL518937, AL518938, BE410807, BE298018, BF663486, BF664523, BE741022, A1471526, A1624274, AW006720, AW072426, AA548389, A1805053, AA649964, BE295825, AW013989, A1889549, AL525865, A1380679, AI142829, BE796333, A1968598, AW006482, A1937663, BF475729, BE645645, BE958622, BF872663, BC002598.1, BC005015.1, AK0222444. 1.	AL530365, AL524811, BG035149, AL524846, AV653215, AL525028, BF031163, BE464161, BF064198, BG057645, BE677690, AV714679, AI954819, AA708718, AA773040, AW206827, BE677490, AW590005, AL522800, AI075390, BG179367, AI933314, AA022693, AA563665, AI582700, BF591973, AI933036, AA011394, BE463890, AI304827, AW467513, AI675049, N47573, BE537595, AI075392, AI346305, AL514603, W26975, H02832, AI290715, AA535130, AW137781, AW298065, BF927479, AA917670, AA011431, AL530366, AA974770, AA535120, AI497684, AI577012, AI274193, AL514604, AW297638, AW779938, AA356778, AW067366, AL524812, AL524847, BF763877, AV652546, H03723, F09604, F09318, H83110, AA216050, AW573003, BF926201, AI572540, AL525029, BF092250, D80466, AI940747, AK027129.1, BC008984.1, AF043945.2, AL163284. 2.	AA780037, AI022797, AI023991, T86767, AL046060, T86675, AW867242, BF154952, AW966053, AW966054, AV724520, AW975618, AW949656, AW978634, D80038, AV719783, AV718800, AV719188, AV720464, AW966013, AW966534, D80195, AW975621, D51799, AW966531, D80193, AV719188, AV720464, AW966013, AW966041, AV719822, AW718692, AW966062, D58283, AV719468, AV718844, D80166, AV720211, AW966041, AV719822, AV718692, AW966062, D58283, AV719468, AW949654, D80227, AW959570, AV699927, AV723927, D81030, D59619, AW949658, AV718489, AV720203, AW973307, AW959628, AW960553, D80212, AV719557, AW949642, AV720731, AV722801, D80196, AV699550, D80269, AW966050, AV718440, AV720028, AW966043, AW949643, AW949646, AV723097, AW960551, AW949651, AW949664, AW949664, AW949664, AW949664, AW949661, AW949661, AW949661, AW949661, AW949661, AW949661, AW949661, AW949661, AW949661, AW96022, T03269, AW975605, D80378, AW959582, D59910, D80024, AV700229, D59995, AV718931, AW959799, AW96610, D80024, AV700229, D59995, AV718931, AW959799, AW96610, D80024, AV700229, D59995, AV718931, AW959799,
15 - 1021	15 - 1024	15 - 1231	15 - 1223
1 - 1007	1 - 1010	1 - 1217	1 - 1209
545492	545752	651337	1040297
145	146	147	148
HJMBI18	НЈМВМ38	HJPAD75	HJPCP42

15 - 1238 BE908972, BE871345, BE969781, AU127317, AW665494, Al650586, BF699086, BF432884, BF241722, BF087758, Al923936, AW271402, BF058229, BE349336, AA483696, BE504564, AV753084, Al553984, AA934906, AU148404, AU125401, AA521022, N53984, Al079322, AW015810, AA481668, AU120404, BE836738, AW959428, AA478921, AI341198, BF086194, Al559514, BF0955983, AW439579, R78314, BF086179, BF992221, BE930087, AA149227, AW627942, BF992221, AA831360, BE858967, AA300892, BF095985, Al909338, BE930086, AA331631, AL079584, AA971728, BF526589, T27345, AA515943, AW894981, BF086178, BG255010, AB007885.1, AC023426, 29.	15 - 1189 AA715814, AA503019, AV762033, BE155099, AV734997, BF917346, AW338860, AC011666.28, AF242518.1, AF109907.1, AC004867.5, AC020917.4, AC004166.12, AL356915.19, AC005071.2, AC004878.2, AC005081.3, AC002549.1, AL590763.1, AC020663.1, AC006064.9, AC008745.6, AC004858.2, AC022405.5, AC007666.12, AC008750.7, AL451144.5, AC010605.4, AC004067.1, AC004056.1, AL109825.23, AL355312.24, AL035086.12, AC010605.4, AC004067.1, AC004477.1, AC008736.6, AL109915.10, AC006023.2, AC009220.10, AL080243.21, AC005015.2, AC004686.1, AL032318.2, AC004971.3, AC009123.6, AC01909.4, AL355353.23, AL050318.13, AL161756.6, AC011464.5, AL132712.4, AL359513.12, AC007546.5, AP001695.1, AC008895.7, AP001713.1, Z84487.2, AL357153.4, AL163636.6, AL359382.23, AC004770.1, AP001972.4, AC0094675.1, AL355392.7, AC00906.6, AL33784.30, AC020754.4, AL162426.20, AC002288.1, AC009068.10,
1 - 1224	1-1175
565078	862030
149	150
HKABI84	HKABZ65

HKACB56	151 554616		- 482	15 - 496	AC008101.15, AC0086234, AC008891.7, 29884.11, AL136137.15, AC011247.10, AL133163.2, AP001727.1, AC005098.2, AC0045091, AC005098.2, AC0045091, AL035964.20, AL139801.7, AC005077.5, AL160271.19, AP0017241, AC00639242.1, AC0060491.1, AC005067.5, AL160271.19, AP0017241, AC006397.3, AC006491.1, AC006267.5, AL160271.19, AP0017241, AC006397.3, AC006491.1, AC006267.5, AL160271.19, AP00171.2, AC006314.4, AC006391.3, AC006491.1, AC00626.5, AL391871.5, AC010530.7, AP00335.2, AC004991.1, AC00636.1, AC001002.3, AP003357.2, AL031123.14, Z95331.2, AL139021.21, AC001345.2, AC0101002.3, AP003357.2, AL031123.14, AC011469.5, AC010508.2, AC006382.2, AC006382.3, AC006
---------	------------	--	-------	----------	--

			-		AL158198.14, AL034548.25, Z82214.23, AC012597.24, AL161781.12, AC009137.6,
		· · ·			
			-		AL358434.16, AL049776.3, U82828.1, AC005520.2, AF196779.1, A
		-			AC002352.1, 7
	_				AL034420.16,
					AC000487.6, AC010010.3, AC003812.17, AT117692 5 AC004166 12 AC0058211
					AC005071.2, AC008764.7, AC008892.5, AC009247.12
					AC005103.3, A
					AC074121.16,
		_			~
					AL109976.23,
					-
					AL136137.15, AL050349.27, AC005067.2, AC005412.6, AL139343.9, AL121895.26,
					AP000115.1, AC006101.3, AC010512.7, AC002418.1, AC018695.6, Z98941.1, AC020915.6,
		-			AC027319.5, AC004150.8, AC006345.4, AC009049.3, AC008403.6, AC005488.2, AC005207.1,
-					AL121900.26, AC020904.6, AC008066.4, AC007374.6, AP001727.1, AL136228.8, AC025166.7,
					AC083871.2, AC008752.6, AC008569.6, AC005089.2, AC013429. 12.
HKACH44	153 5	545015	1 - 672	989 - 51	BF341755, BF791960, AA877614, AU153686, BF340330, AI199494, AW004725, AA628899,
					A1042456, N74995, AV753372, A1916084, BF437469, BF446199, BF509743, BG035423, A1563977,
		-			AI276433, AI953416, AI659007, AI351215, AW769176, BF448885, BE042362, AI401836, AI440396,
					BF337499, BF970652, AA504557, BG164558, BF816037, AL515323, AI633125, AI670009, AI433157,
		_			A1702073, BF812431, A1500061, AW834302, A1637584, BF812961, BF792047, A1815232, A1471909,
		_			AL513991, BG166654, BE966278, AI687362, BF856017, AI929108, AW090071, AI915291, AI887308,
_					A1866770, A1698391, AW163834, AW198090, BF814450, AW087445, A1345587, A1889189,
			-		AL110306, A1863241, BF856052, BG107844, AL515413, A1283760, BG110577, AL039086,
					AL514025, AW148363, AW073865, AI612852, AI580435, AW190194, AI270183, AI582932,
	_				AI521560, AW131331, AI249946, BF970768, BF726421, AI826636, AA928539, AW935969,
					AL515089, BE965432, Al473471, AV682414, AL036780, AW268302, Al345415, Al890223, Al796743,
					AL513999, AI274759, AL514579, BF103225, AW827289, BF339322, AL514867, BG108288,
					AI678496, AI677796, AW130776, AL513817, AI653979, AW673679, AI288285, AI587114, AI932794,
	_				AL119836, BF724894, BE964614, BF904180, AI445992, AW301505, BF885082, AI912356, AL042745,
	_				AI340519, AI249877, AL513937, AW169671, AW192652, BF680133, AI434468, AW806761,
					AI699056, AA259207, BF813196, AV757827, BF791937, AI801325, AI564719, AW152182,
				!	BE965621, BF904194, AI242248, AA420722, AW118518, AI768496, BF868489, AI890214, BE965599,

A1349772, AL513577, AI797908, BF348329, AI864836, BF814412, AW151136, AV760409, BF814761,
 ALU3/434, ALZ30819, AW081298, BE903121, N331/3, BF344339, BE9103/3, ALZ314033, ALZ313/13, AW192687, ALZ314701, AW189196, AIZ80637, BG110241, AI800440, AI612913, AW104724,
BE778192, BF032768, BE878014, AI089782, BF822127, BF792715, AI610690, AL514087, AI870192,
A1499986, AW104827, A1445025, A1670002, A1610671, A1909641, BF812938, AV733410, A1434223,
BF343447, AI491842, AW090550, AI500523, BE877142, BE964636, BF813177, AI627988, BF812960,
A1567128, AL119457, AL513901, AW051088, A1500662, BF970731, AL514819, AW075667,
 AW 352162, AW 1464-06, ALD 14475, AI 477575, AW 353571, BOT 10517, BI 762252, AW 105363, AI 41888661, AI 469112, BE047691, AW 149069, AW 193530, AW 073270, BG 114901, AI 923370,
A1469532, A1571439, BE966550, A1866801, AV702117, AL514047, A1561231, AW087207, AV681891,
 W74529, AW026882, BG031815, A1866573, AW983703, AA572758, A1250646, BE905087, A1921464,
 AI570807, AW117746, AI620284, AI699865, BF037097, AI434432, BG179993, AI611743, AW129722,
AK001309.1, AK024588.1,
AK025092.1, BC004951.1,
 AB056421.1, AL353940.1, S61953.1, AK026744.1, AB048954.1,
 AF230496.1, AK026542.1, BC003687.1, AL137550.1, M92439.1, BC002733.1, AC002471.5,
AK026583.1, AK025484.1, X72889.1, AL122121.1,
AL117435.1, AL050277.1, AB048953.
AF177336.1, AB060863.1, 7
AL050393.1, AL137480.1, AF104032.1, AK024538.1,
AL136844.1, AL133075.1, AF146568.1, AF090896.1, S78214.1, BC
, BC000008.1, AL137283.1, AL049938.1, BC001967.1, AK000212.1,
AF125948.1, AK025339.1, AL136892.1, BC004530.1, BC002485.1
 1, AL359601.1, AB063100.1, BC001045.1, AK027868.1, X82434.1, A
, AF113222.1, BC000100.1, AF262032.1, BC003684.1, AL137658.1,
AL389935.1, AL133560.1, BC008070.1, AB060826.1, AL133080.1,
, AB056809.1, BC007680.1, AK026927.1, AF026816.2, AF091084.1,
AL110221.1, BC008417.1,
ANUZO460.1, ALI3/300.1, ALI33040.1, BC000103.1, ALI3/439.1, AD048045 1 ALI37533 1 ALI893015 1
ABU469/3.1, ABU03084.1, ALU49432.1, ALI3/333.1, AL363913.1,
 ALUSU138.1, AF1U0802.1, U3864/.1, BCUU30/8.1, ABUSSS91.1, AF131//3.1, ALU49283.1,
AF090886.1.
B060912.1, BC008387.1, A
BC007926.1, AL162006.1, AK027164.1, AL122098.1, Y14314.1, AL133016.1, AB052191.1,
AK026532.1, AK026408.1,
U92992.1, AL049300.1, AL137557.1, AL050024.1, AL049430.1, AK026642.1, BC005168.1,

AK0257173.1, AK026741.1, AF218033.1, AB060852.1, AB055303.1, AB060887.1, AL050116.1, AK025524.1, BC003122.1, AL162083.1, AK000432.1, U39656.1, AF143723.1, AL353957.1, AB060908.1, AK025435.1, AL049466.1, AF260566.1, AK000323.1, AL359615.1, BC001670.1, AL035458.35, AF271350.1, AK024524.1, AL133067.1, BC008488.1, AB050510.1, AK026659.1, BC008723.1, AL117457.1, AK025312.1, X65873.1, BC006807.1, AB049892.1, AL359941.1, BC004362.1, AK000391.1, AL136774.1, BC008823.1, AK000718.1, AL080124.1, AK026865.1, AL162002.1, BC000351.1, AL136789.1, BC003548.1, AL136765.1, AB052200.1, AL157482.1, BC004985.1, AK033593.1, AL137463.1, AK026464.1, AF097996.1, AL162008.1, AK000137.1, AK025857.1.	
	15 - 2496
	1 - 2482
	1352263
	154
	HKAEV06

				U95090.1, AL163279.2, AP000306.1, AL138759.20, AC068533.7, AC016697.8, AC002460.1, AP000349.1, AL137077.31, AC008536.6, AL031281.6, AL022322.1, AL031668.23,
				AC025165.27, AC066580.3, AP001680.1, AC034193.4, AC016831.1, AC079363.19,
				AC005695.1, AC010150.3, AC026475.6,
				AF165926.2, AC007163.3, AC025679.4, AC009086.5,
				AL096840.25, AF373586.1, AE006639.1, AC019097.5, A
				AC068660.3, AL034420.16, AC009499.4, AC022384.4, AL157938.22, AC004821.3,
				AF1967/9.1, AL139108.13, AC009007.4, AC004966. 2.
HKAFT66 155	946512	1-987	15 - 1001	AA436785, AI804932, AA310516, AW966935, AA873013, AA251417, AI798761, AA250867,
				BE720668, AW827206, BG122481, AI826225, AI811785, AI539808, BF970449, AL039086,
				AW983783, AI554821, AI784252, AW105601, AV708119, AW054931, AV727839, BF968205,
		_	•••	AL119863, AI280747, AI611738, BE047737, BF970768, AW193134, AW118518, BF904265,
				BF089711, AI610362, AL042628, BF793370, AL036980, AI312428, AA833760, AL513763, AI829327,
				A1433384, A1589267, A1269862, A1564723, BG031539, A1624548, AW302992, BG260037, A1802542,
-				AI569583, AW169653, AI800453, BE048071, BF792961, AI439717, AI567612, AI611348, AI869367,
				AW081797, BF343172, BG031815, AL038605, AI570781, AW051258, AL513901, AI802240,
				AI274728, AW071417, AI571909, BG249582, BG257535, AW152469, AI612885, AW022682,
				AW148320, A1569579, A1252023, A1608936, AW075413, A1500077, A1318280, BE781369, A1636585,
				AI251434, AI862144, BG255895, AI890806, AI625094, AI955906, AI309401, BG110517, AI431424,
				Al343112, Al612913, BG110684, BE895003, BG168549, AW268253, AW301300, Al349598,
				AI554344, AL036664, AW075207, BE886728, AI345735, AI678357, BE964078, BF872670, AI475394,
				A1633419, A1348897, BF904258, BE138712, A1500659, BE966699, A1247193, BE887488, BG0330364,
				AI648684, AI313320, AI627988, AI251221, AI630928, AI340627, AA640779, AI340603, BF904263,
				BE910373, AV743962, AI587143, AI312146, AI312339, AA572758, AI889168, AI345258, AI348854,
				AW193000, BE964614, BF817926, BE965432, AW020693, AI457369, AL040243, AI445115,
				A1620866, AL513699, AW081242, A1610645, A1801325, A1866798, A1932794, A1689248, A1340382,
				BG110241, AA2255339, AA427700, AI270707, BG179993, AV682672, AW827228, AI955467,
		-		A1681985, A1684265, BE895585, AW074993, A1349614, A1590415, A1811353, A1354283, BF868928,
	_			BE885241, AI564247, BG058398, AI302910, AI955917, AI349256, AW946806, AI312152, AI174394,
				AV682867, H89138, AW075084, AI567351, AI800433, AI950664, BE048179, AL036288, AI634224,
-				AI349937, AW089572, AI334884, AL039132, AV651436, AI670009, AI349957, AI307708, AI312325,
				BF981774, AW269097, AI609409, BG036846, AI591420, AW190042, AI572892, AL045266,
				BF971016, AV682218, AL121286, AI916419, BF925729, BF339322, AI307520, AI925156, AI445237,
_				BE047952, BG180996, AI306613, BE544111, BE885353, AI434256, AV708097, AV712838,
				BF924882, BF885000, BG113299, AV/5/028, AA012905, AI91/123, AL134999, AW073531,

	AV682521, A	1874166, AL036736, AL036901, B	AV682521, A1874166, AL036736, AL036901, BG168696, AW151138, AW268302, BG033723,
	AW023590, AI306/05, A BG250190, AW073994.	A1306/05, A1436436, A1608667, A W073994, AL390882.12, AK027	AW023590, AI306/03, AI436436, AI008060', AV682/03, W33103, AI282261, DZ/03963, VAITAGOS, BG250190, AW073994, AL390882.12, AK027164.1, AF056191.1, BC003687.1, AK000432.1,
	AL512733.1,	3.1, AL157482.	AF177336.1, AL117460.1, X72889.1, AF090934.1,
	AL359601.1,	AK026526.1, BC008488.1, AK	BC001045.1,
	AB047904.1,	AK025084.1,	`
	AL050146.1,	, AK026597.1,	AL137560.1,
	AK027868.1.	AK027096.1, AL359583.1, AL	•
	AB060916.1,	AB055368.1,	
	AL162083.1,	AK026534.1,	`
	AL137463.1,	, AB048964.1,	•
	AB060887.1,	AL359615.1, AK000618.1, AL	_ <u>`</u>
	AK026647.1.	AL133080.1, AK026629.1, AL	.1, AF111847.1
	AL133113.1.	BC007199.1,	S61953.1, AK026045.1, AB060908.1, AL133557.1, AL136789.1,
-	AB049758.1.	AL122093.1,	.1, AK026592.1,
	AK026353.1.	AB055366.1, AL050149.1,	AL133016.1, AL442082.1, AL110225.1, BC008365.1,
	AI 117394 1	AB051158.1 AL389982.1.	AL117457.1, AK026504.1, AK025092.1, AL122098.1,
	AL0501161	AK025772.1, AL080124.1,	AL136799.1, BC003683.1, AK026542.1, AK000647.1,
	AB060863.1.	AL110221.1, AL137527.1,	, AF218014.1, AL049314.1,
	AK000083.1.	AL137538.1, BC008387.1,	_
	AF091084.1,	AL136928.1, X82434.1,	AK025391.1,
	BC008899.1,	BC001967.1, ALS12754.1	1, Z82022.1, AB063046.1, /
	AB063084.1,	AB052200.1, U80742.1,	AL122123.1,
	AL137557.1,	AK000445.1, AL136786.1,	¥
	AL117585.1,	AL512689.1, AF219137.1,	AK026593.1,
	AL050108.1,	AL133565.1, AL122121.1,	AB055361.1, BC006807.1,
	AF090900.1,	AK026452.1, AL583915.1,	, AB047615.1, AL133640.1,
	AK025484.1,		l, AL122050.1,
	AL110197.1,	S78214.1, AK026784.1, AI	AL136768.1, AL
	AL136586.1,	AF090901.1, AL512718.1, A	AB052191.1, AK026086.1, A
	AL512761.1,	AK025339.1, AB063008.1,	AL359618.1, AF183393.1,
	AF207829.1,	AK026532.1, AL353940.1,	1, AK000718.1, AL390167.1,
	AK026865.1	, AF106862.1, AF104032.1,	1, AK000652.1, AL122110.1
	AK027113.1,	AB060912.1, Y16645.1, AI	AL133093.1, AL389978.1, AL
	AK026583.1,	AL049430.1, AB050510.1,	, AL137271.1, t
	AK026744.1	1, AK025414.1,	AK02/204.1, BC008483.1, AB062938.1, AN020030.1,
	ALI36843.1	, AKU25632.1, ALU80127.1, AL	1, ANOZOZZII, ANOZOZZII,

				AL080137.1, AL050138.1, AL137521.1, BC006195.1, AL122049.1, AB055374.1, AL049300. 1.
HKB1E57 156	876571	1 - 1128	15 - 1142	AL518848, BE795484, BE790580, BE793563, A1005330, AL530857, BE865465, BE740884, BG259765, BE559709, AW972157, BE793925, BF732476, A1523173, A1133648, BF132480.
	-			AA741065, BE266365, AW246779, AA483640, AI553793, AA889963, AW731821, AW376863,
				A1457636, AU159951, A1076501, BE865290, AW250974, BF683810, A1245539, A1160351, AA122216,
				N70566, A1123318, W04730, A1298575, A1094218, BF840014, A1298397, AA627412, AW474453,
				BF063304, AI304872, W80875, BE645309, AI829879, AA877594, AW514292, AA721451, AI032434,
				AA564388, AA723454, AW571641, AW591598, AW605095, AA404537, BF326544, H07869, F13805,
		-		A1055951, AA122217, AV693323, AA308813, A1474982, T08020, A1678622, AA284386, AW839757,
				AW189626, AL530858, BE393850, W80766, BE143803, AA706470, AA319710, AA480437,
				BE936534, BE166705, AW051083, AA121863, A1432644, A1927233, A1687607, A1924051, A1431307,
				A10233U2, A1431310, A1431236, A13396UU, BE697032, A139UU43, A1269791, BE663391, BU10763U, A1985417 A186786 A1687588 A1637677 A1404301 A1877315 A1500659 A1866465 A1815333
		_		AISO1411, AIGO0760, AIGO7560, AIG57071, AI474201, AIG72515, AI5000027, AIG00402, AIG15252, AISO1325, AI500402, AIG1525, AI500402, AIG1525, AIG1
				AIS00706, AI445237, AI491776, AWI51138, AI889189, AI521560, AI500662, AWI51974, AI567971,
				A1804505, A1815239, AW172723, A1284509, A1582912, A1538885, A1440263, A1889168, A1866573,
				A1633493, A1434256, A1866469, A1434242, A1805769, A1866691, A1888661, A1500714, A1284513,
				A1888118, A1285439, A1859991, A1436429, A1355779, A1623736, A1889147, A1581033, A1371228,
	_			AW194509, AI491710, AI440252, AI926593, AI440238, AI860003, AI610557, AI242736, AW058275,
				A1828574, A1887499, A1539781, A1539707, A1702065, A1885949, A1285419, AW089557, A1559957,
	_			AI521571, AI469775, AI866581, AI866503, AW151132, AI539260, AI567953, AI815150, AI446495,
		- 1-2		AI431321, AI867068, AI932620, AI890907, AW074057, AL042729, AI889191, AI952433, AI225248,
				BE885490, AI358271, AI798359, AI282249, AI698352, BF812963, AI371229, BG252929, AI539771,
				BF811804, AI561170, AL042595, AW151979, AI284516, AI432666, AI289101, AW858522, BF814072,
				BF811802, AL039508, AW151136, AI866458, BG029667, AI371251, AI493559, AI866510, BG249858,
				BE826157, BG113493, A1866461, A1923046, BG110517, A1687944, BG176609, AL047611, A1955221,
				BG257535, A1889157, AL039390, BF795712, A1559976, A1690946, A1567947, A1436438, BG253986,
		<u></u>		AI648567, AL042787, AL134524, A1433157, A1362495, A1371243, BF796402, A1288076, AL515375,
				AL042853, AI469764, AV736134, AI432653, AI431323, BE886728, AL042655, AV736402, BF815930,
		-		AK027449.1, BC001215.1, AF152097.1, AL355392.7, AL136763.1,
				AL136825.1, AL133607.1, AL133076.1, AL122101.1, AL049423.1,
				AL133655.1, AL136765.1, AL136781.1, AL110223.1, AB048910.1,
				BC008781.1, BC007294.1, AL133015.1, AL133608.1, AL136828.1,
				AL162008.1, AL117445.1, BC008983.1, AL157482.1, AL122049.1,
		<u>-</u>		AL133051.1,
				AK025860.1,
				AC004213.1, AC006039.2, AK000225.1, BC000649.1, BC004314.1, AB047941.1, AL049300.1,

					BC000253.1, BC004530.1, AL080139.1, AK026912.1, AL389947.1, AL354864.16, AB047953.1, AL162062.1, AL137485.1, AL37354.1, AL353092.6, BC000009.1, AK000486.1, AC008755, 6
HKFBC53	157	1352286	1 - 2224	15 - 2238	BF027339, BF689868, BE791172, BE273437, BE260092, BG031379, BF727402, BF339469, BF984194, A1760572, A1760520, BE294301, BE676312, AW297966, A1244284, A1422554, AA962223, A1971830, BF975689, BE252368, BE383741, AA644162, AW245081, A1598190, A1090193, AA495832, A1143992, A1361951, A1990481, A1990174, N50101, A1350501, AA994262, A1859137, AW003834, A1380542, A1086091, A1394639, AA976745, AA293019, BF027207, R90773, AA253139, AA495776, E23330, BF690095, N33565, AA417706, R88936, BF869114, A1351614, A1202144, N72164, BE408877, AA115762, AW237082, W00431, AW025153, BE159093, A1284384, AA610858, A1766469, A1685216, A1672360, BF718243, AA745682, AL119175, A1582214, AW274357, AW134904, BG033163, BE546341, AW268196, A1913519, AA082841, R36266, AW072885, AA114066, AA496881, AW474388, BF745906, AA133537, A1693690, A1000915, AA293473, AC005786.1, AC005787.1, AF218008. 1.
HKGDL36	158	877489	1 - 1038	15 - 1052	BF966686, BF969262, BE798423, BE33172, BG108317, BF438085, BF967072, BF724971, BF310167, BF437374, BF525713, BF725537, BE312863, BE526596, BF983368, BF966496, BE392518, BE695542, AI261620, AI628667, AI955247, AI796185, AW024651, BF724972, AI365220, AI767645, BE695542, AI261620, AI628667, AI955247, AI796185, AW024651, BF724972, AI365220, AI767645, BE551437, AW051507, AI199503, AI418919, BF724666, AI039610, AW162506, AI955309, BE673721, AW138191, AI969138, AW583447, AI373491, AI696987, AW583390, AI952012, AW341037, BF310234, AI758216, BF438130, AW013963, AI955147, BE669440, AI768473, D61105, BF592013, AI352910, AI96902, AI913491, AW027769, AW271649, AI672532, AI991536, AI421291, BF739771, AW103643, AA894790, BF197412, BF724667, BF197448, AW583609, AW000053, AW299323, AI702136, AA877175, AW583672, AA757536, D59877, AA706516, AW39332, AW590037, AW955700, AI602136, AA877175, AW583672, AA757536, D59877, AA706516, AW012965, AW163721, BE318723, BF346124, AI985164, AW000934, BF967708, AW001692, AI701771, D59848, D59725, A873392, AA364835, BE94180, BF81536, BF910849, BE963809, BF816069, BF816360, AV065029, BF921092, AV712606, AV681927, BE964621, AI866741, AW058713, BC108334, BE536377, BF929885, AI254754, BF7664621, AI866741, AW083913, BC108334, BE533677, BF929885, AI534754, AW053209, AI53466599, AI924035, AI445876, BE87596, AI122016, AI46605, AL513741, AA830821, BF814360, AW005029, BF921863, AB624031, AR86741, AW083804, AI539462, BE885333, BE38466, AI620093, AI537643, AI864827, BE9480697, AI683255, AI591142, AI591081, W81248, AV706465, AI645588, BB907440, AI884574, F53927, BE9965121, AI590057, AV7106465, AI445588, BB907440, AI884574, F53927, BE9965121, AI500039, AV7106465, AI445588, BB907440, AI884574, F53927, BE9965121, AI500039, AV7106465, AI445588, BB907440, AI884574, F53927, BE9965121, AI5500039, AV7106465, AI445588, BB907440, AI884574, F53927, BE9965121, AI500039, AV7106465, AI445588, BB907440, AI884574, F53927, BE9965121, AI500039, AV7106465, AI445588, BB907470, AI6724012, AI672714, AI5900571, AI570009, AV7106465,

	AW265004, AI623682, BF341610, AW079032, AI925736, AI252077, AI590787, AW025533,
	AI267185, BG105895, BE964600, AL513789, F20535, AL046377, BE905257, BE505253, BE5057773, AW946864, AL514167, AI627880, BE621140, AV710267, AI678302, AI926878, BE878028, AI6333300,
	BF817402, BF753053, BE875407, BF752999, AI689614, AI624668, BE966390, AI811192, AI866002,
	F28295, BG260275, BE963286, BF753056, BC002851.1, AF181562.1, AF196971.1, AJ012582.1,
	BC003104.1, BC007248.1, BC001470.1, AF230402.1, BC002948.1, AF352728.1, U77594.1,
-	BC004314.1, AK026865.1, AK025491.1,
	, AL137557.1, AL136752.1, AK000598.1, AL121656.2,
	BC002356.1, AJ010277.1, BC002397.1, BC004529.1, AL157464.1, BC000785.1, BC000725.1,
-	L080162.1, BC002777.1, AF022813.1, AK
	BC004370.1, AB055374.1, AL137556.1, AK024601.1, AK026164.1, AL512705.1, AK026613.1,
	BC001969.1, BC004310.1,
	AF112208.1, AL136767.1, BC003602.1, BC005890.1, AL137665.1,
	AF218034.1, AB049629.1, AF239683.1, AL136799.1, BC008196.1
	AL049347.1, AK026603.1, AL389978.1, AL049460.1, S77771.1, Al
	BC005678.1, BC001093.1,
	V16645.1. AB060893.1. Bo
	AF111847 1 AB060914.1 AL353935.1. AL136766.
	AL096720.1, AL359622.1, AL049314.1
	AL133568.1, AL136586.1, M92439.1, AL136790.1, Al
	BC007207.1, AL133081.1, BC004202.1, BC005931.1,
	AF090934.1, B
	BC000217.1, BC008488.1, AL162062.1, BC004131.1, AL136842.1,
	BC000348.1, AK024594.1, AF188698.1, AL122050.1, BC004530.
	BC006133.1, AF348209.1, AL353625.5, BC002911.1, X66975.1, AK
	, BC008070.1, AK024533.1, AB048888.1, AK000432.1, AL133645.1,
	, AF271781.1, AL117585.1,
	AB049758.1, AL080074.1, AL442082.1,
	AL049339.1, AF358829.1, AK026086.1, I
	AB055366.1, AB060929.1, AK025239.1,
	AL122118.1, AF321617.1, AC025226.4, A
	AK000652.1, AK000445.1, AL133062.1, BC002519.1,
	AL136828.1, AL137648.1, BC006196.1, BC002343.1,
	AL157483.1, AK027142.1,
	ALUSUNO.1, DOUGLINE.1, ECONOCION,

					AL162008.1, AK024538.1, BC005007.1, BC004265.1, AK027081.1, BC001293.1,
HKISB57	159	625956	1 - 1478	15 - 1492	BG253059, AI888563, AW083174, AI890983, BE677527, AI742994, AA581853, BE208188,
					AA420043, A1743379, A1433172, AA312110, AC132413, AC131244, AC22233, W72233, A1763313, AA029171, A1289783, AA147482, AW001837, BE744941, BF851250, W76470, A1148076, A1619715,
					W32695, A1973179, BF856405, AA086231, A1536682, A1244167, AW205328, AA112137, A1015550,
					A1159953, AA449234, AA449289, A1886081, K48602, AW9/4/49, K48/05, N5/904, W75012, A515733, A1095398, AA086322, AA554446, AA317019, BE019888, R07096, AA894669, AA112027,
					T96414, AA923651, T96497, AI581984, AI093238, AW084446, BE834394, T65129, AA100811,
					BF767404, AA652428, W32694, AW364698, BF371383, AW390788, AI903419, AI903380, AI903350,
					AA300051, AW886927, H55267, AA029067, AA588851, AA588463, BF931116, BE646329, AW514396 T65909 AW578218, AW800794, R07042, AA625855, AA663955, AA687595, AI581808.
					R76016, W22074, AA043407, AA436950, H39017, BF814527, AI824576, AI702073, AI698391,
					AW080090, AI633062, AI608936, BE786043, AI358213, AI306705, AW983832, BE963838,
-					BG179993, AW051258, AI677796, AW051088, BF856017, AI932794, AI366900, AI352497, AI889189,
					AW983829, AI270183, AW163834, AL514731, AI434468, AI812015, AI249877, AI679672,
					AW118518, BF812960, AI284131, AW029611, AI468872, AI699011, AI927755, BF792961, BE966388,
					A1886753, AW827289, A1564719, AV743962, BG108406, A156/846, AV/4132/, A15/3060, A1/83504, PG113218, A1667278, A167728, A1677
					BG112/18, A1620284, A1866/70, AW198073, BF032768, AW083778, AL314699, A1011738, A 1570807 A 1570807 A W004886
					A1452560, AW026882, AW151136, A1923370, A1627988, BF812938, AL118781, BF970652,
				····· 4 .4-	BE789764, AW104724, AI670009, AI863382, AI433157, BE543089, BF812961, AI452993, AI624548,
					A1659795, AW079572, A1860783, A1633125, BF812426, F27788, AW089179, A1673785, A1915291,
					AI354998, AW152182, AI537024, AI917252, BE967261, BF725599, AW080746, AL120853,
					AW129659, AW163554, AI537677, AI499890, AI612852, BF526020, AI174394, AW192461,
					AI613270, AW105620, AL119863, AI520809, AI923989, AL036673, AI571909, AI803778, AI653979,
					BG036846, AW192687, AV682249, AL514357, AW839006, AI2/4507, AI632408, AI288305,
					A1033001, B0100273, A1012913, AL113020, A V 002212, A1330000, A1433200, A1432030, BLO40071, A1500588 A1638217 BF047606 A1637748 AW338688 RG039879 AF064238 3 A1010306 2
					V13492.2. Z49989.1. AF115564.1. AF115570.1. AF115567.1. AF115569.1, AF115568.1,
			-		AL122098.1, AL137533.1, AB056420.1, BC006195.1, BC005858.1, AK024524.1, AL133067.1,
					AK025092.1, BC001045.1, AL137550.1, AL080159.1, AK026462.1, AK024538.1, AL512733.1,
		_			AL389939.1,
					X72889.1, AL137500.1, AL1372/1.1, BC004951.1, AB060916.1, AK026532.1, AF183393.1,

				AL137478.1,	1	AL583915.1,	AK025484.1,	AF057300.1,	AF057299.1,	AK000652.1,
				AF348209.1,		AK026480.1,	AF218014.1,	AF225424.1,	Z82022.1, AK	AK027213.1,
				AK027164.1,	AK027160.1,	AF056191.1,	BC003122.1,	AF111112.1,	AB048974.1,	
				AL050393.1,	AK026534.1,	AL122049.1,	AL136915.1,	AB055361.1,	AK025632.1,	
	_			BC006525.1,	AL110225.1,	AL133568.1,	BC004556.1,	AL136892.1,	BC008365.1,	BC005678.1,
				AL080124.1,	AK026408.1,	AL162002.1,	AL122110.1,	AK026533.1,	U39656.1, AI	L136893.1,
				AL050149.1,	AK000418.1,	AJ299431.1,	AB047904.1,	AL122093.1,	AL050138.1,	AL133560.1,
				AL137463.1,	AL136749.1,	BC006807.1,	AL133557.1,	AF262032.1,	AB049758.1,	AK000323.1,
				AF146568.1,	AF162270.1,	AL133113.1,	AK025465.1,	AL133072.1,		AK026583.1,
				AK026642.1,	AL133640.1,	AL359583.1,	AK026744.1,	AK025084.1,		AK000083.1,
				AL133016.1,	AK025708.1,	AL353940.1,	AL442082.1,	U80742.1, AK000718.1,	4000718.1 ,	AL110280.1,
				AK026865.1,	AL512750.1,	AL162083.1,	AF090934.1,	AB048919.1,	AL359620.1,	AL050172.1,
				AL359618.1,	BC004958.1,	BC003682.1,	AB046642.1,	AL110221.1,	BC006164.1,	BC003684.1,
				AL512765.1,				AL137476.1,	AL137476.1, AK000391.1,	BC008417.1,
				U58996.2, Al	B063084.1, AE	AB056809.1, AI	AF090900.1, AI	² 42525.1, Al	AF242525.1, AL353956.1, AK026551.1,	K026551.1,
				AL080148.1,				AL137557.1,	AK026528.1,	AK000432.1,
				BC006440.1,	AK026947.1,	AK027204.1,	AB047801.1,	AL117457.1,	AL050116.1,	AL136586.1,
				AL137480.1,		AF061573.2, 1	BC009341.1,	AJ012755.1, 7	AL512718.1, E	BC008070.1,
				AK027096.1,	BC008899.1,	AB056427.1,	AF217987.1,	•	BC006494.1,	AK026762.1,
				AK027182.1,	AL512689.1,	BC002733.1,	AK027116.1,	AL133075.1,	AL133093.1,	U78525.1,
				AL136787.1,	BC008387.1,	AF106862.1,	AL080060.1,	AL359941.1,	AK000445.1,	AB060826.1,
				BC005890.1,	AB048953.1,	AB050410.1,	AB050510.1,	AK026629.1,	AK026045.1,	AB050534.1,
	-			AF177336.1,	AK025414.1,	AL117460.1,	AL136768.1,	AF090903.1,		AK026927.1,
				AL117440.1,	AY033593.1,	AL133565.1,	AL390167.1,			AK024601.1,
				AB063008.1,	AB055374.1,	AK025958.1,				AK026452.1,
				AK025254.1,	AB060214.1,	ALI10222.1,	X53587.1, A	AK026959.1, A	L162008.1,	
				BC005151.1,		BC004370.1,	BC006103.1,	AY034001.1,		
-				BC003548.1,		AL122118.1,	AB062978.1,	AL136789.1,	AL049452.1,	AK025391.1,
_	\dashv			BC008284.1,	AK000647.1,	AL136786. 1.				
HKMLM11 160	0 514788	1 - 940	15 - 954	BG036576, A	BG036576, AW376266, AW024675, AW965560, AA946948, BE834077, AA306783, AV73852 [.]	124675, AW96:	5560, AA94694	8, BE834077,	AA306783, AV	738527,
				AV739697, B.	AV739697, BF241514, AV740463, AA758808, AA431001, AA910368, AA336054, AA335971,	0463, AA7588	08, AA431001,	AA910368, A	A336054, AA3	135971,
				AW237846, A	AW237846, AW827285, AI050666, AV755459, AI583054, AA764946, AA459982, AI811603	50666, AV7554	159, AI583054,	AA764946, A.	A459982, AI81	1603,
				AI683160, AV	A1683160, AV734888, AV721366, AA648361, BE397723, BF970114, A1336575, BF306639, F37462,	1366, AA64830	51, BE397723,	BF970114, AĽ	36575, BF306	639, F37462,
				AI872164, AV	AI872164, AV694812, AW301344, AA830333, AI633321, AA678887, BE876047, AV706721	1344, AA8303	33, AI633321,	AA678887, BE	876047, AV70	06721,
			,	AA563942, A	AA563942, AI245332, AA653346, BE740632, AI360195, BG177101, BG026443, AA437293,	3346, BE74063	2, AI360195, E	G177101, BG	026443, AA437	7293,
				AV698290, A	AV698290, AV706279, AI933756, AW102858, AW022121, AV656973, AW582932, AW238753	3756, AW1028	58, AW022121	, AV656973, A	W582932, AW	V238753,
				BG110384, A	BG110384, A1345143, A1224463, AA836317, AL047398, AL041154, A1814841, A1621106, A1436429	463, AA83631	7, AL047398, £	L041154, AI8	14841, AI6211	06, AI436429,

					AP001706.1, AL121754.18,
					AC003012.1, AL163279.2, AC007850.29, U95743.1, AC034199.5, AC007876.2, AL391139.19,
					AC006159.3, AC004126.1, A
					, AL132818.2, AL031056.1,
					AL050335.32, AC002368.1, AC073898.1, AL009047.1, AP001726.1, AC006327.3, AP000946.3,
					Z82189.1, AC008984.5, AC005583.1, AP000696.1, AC003969.1, AC008444.4, AP000040.1,
					AL022574.7,
-					AC006462.3, AC002080.1, A
					AL161716.14, AL121755.23, AC005227.2,
					AL356213.10, AC018840.3, AC006366.3,
					AL389925.10, AC005386.1, AC010279.4, AL132641.3, AC008755.6, AE000658.1, AC009491.3,
					AL096772.5, AP000313.1, AC010148.13, AC008162.3, Z96074.4, AC007221.2, AL135961.4,
					AL133173.19,
					AP003113.1, AC006042.2, A
					-:
HKMMDI	162	604751	1 - 929	15 - 943	R69692, A1254831, BE439823, AW473380, AW967329, A1582769, A1076062, AA079635, AU148170,
3					U95737.1, AC072061.8, AC009032.7, Z84486.1, AF003529.1, AC008687. 4.
HKMMW7	163	668188	1 - 1780	15 - 1794	AI524360, AA582463, AW970030, AW088049, BF845261, AV744082, BG166773, BF970654,
4				·	٠.
					AL158070.11, AL136231.12, AP000555.1, Z96074.4, AC006430.22, AP001695.1, AL354811.13,
					AL121834.20, AL109921.21, AC008551.5,
					AC068799.14, AC006036.3, AC005725.1, AC015982.9,
					AL132988.4, AP000692.1, AL590116.8, AL158144.15,
					AC005520.2, AL353135.32,
					AC004774.1, AC004634.1, AL121900.26, AC034198.6, AC006460.3,
					AC018828.3, AC067742.5, AC022383.3, AL161655.8, AL445686.14, AL031224.1, AP000128.1,
					AL021154.1,
					AL133387.8, AC006115.1, AC026439.3, AL034394. 2.
HKMND01	164	527402	1 - 873	15 - 887	BE049073, AI252114, AI792903, BE063133, AI734002, AI307426, AW301818, BE049088, AV740060,
					AV738722, AW105737, AW851028, AI200051, BE049095, AW406755, AW361583, AI054246,
					AV756693, AV758600, AI792864, AI733957, AA610491, AI334443, AI053816, AI252085, AL138242,
					A1358229, BF668217, AA501784, A1954260, AW966759, BE147093, AW303196, AW301350,
					AI254798, AW419262, BG014866, BF308728, AI431303, BG249643, F29989, BG010083, AV703137,
					AV701499, AV706025, AV759204, AW086257, BE147117, AV763540, BE139371, BF970654,

	AW950632, BF725504, AI246796, AI016000, AW074398, AW474160, AI216978, BF873504,
	A1349874, AA663306, AU122216, AW969988, AW905746, AV682003, BF761328, AV761745,
	AW833862, AV /33328, BG16//43, A1/34689, A1034329, BF4301/11, AW300123, A1601203,
	AWY/U364, AI89U348, AWY62/13, AI623/20, AA441/66, DF/733U3, AWU3743U, AWZ7034, AW13741, AW13741 A 1023730 AW13141 AW138434 AW13844 AW1384 AW
	A1903 / 20, BE042049, Bro083 / 0, AV 723009, RE130209, BE047139, Y. W. 221711, Y. Y. 22122, AV 701040072, BF676536, BF681427, AV 704740, AV 701613, AW 271904, AV 701844, BG167139,
	AA557879, F36373, AV760466, AV710606, AW023389, AI281807, AF074677, BF337291, AW472872,
	A1569202, BF827410, AV761810, BF887156, BF917533, AV762645, A1365988, BE540527, AV705518,
	AU147488, AW963497, BE139267, BE205860, AV710482, AL046409, T06828, AL048616, A1754013,
	BE349302, AV703266, BG231767, AW339687, AV725423, AA394271, AU146189, AU145473,
-	AI754955, BF908593, AI345695, AL118911, AW028429, AI635272, BG033926, AI285615, BE909262,
	BE744242, BE293802, AV729000, BF058000, BE304890, AL041690, BE293845, BF769461, AI753365,
	AV725974, F32705, F36273, AA555260, AV762395, AI281808, AI355206, AA128592, AW236342,
	AV763971, AA366035, AA501614, BG010931, BG152682, AW503666, AA932099, AA744001,
	AW576389, AA581903, AW970848, AI282336, AI151261, BF869171, AV740801, BF241967,
	A1370475, BG176793, AV763583, AA515435, BF916567, AW839174, AW979060, AV764329,
	AW064321, AC010727.6, AJ300188.1, AP000320.1, AL513128.11, AC002429.1, AL162374.8,
	AP000120.1, AP000167.1, AP000052.1, AC009502.4, AP000099.1, AP000036.1, AC010719.4,
ţ	AC012306.11, AC009247.12, AC010601.5, AP001719.1, AC000360.35, AC006288.1,
	AC004460.1, AC002369.1, AC021016.4, AL445683.11, AC005221.1, AP001718.1, AP001479.1,
	AC024164.6, Z86061.1, AC004873.3, AF045555.1, AC004087.1, Z93022.1, AC087589.2,
	M37551.1, AL160411.25, AL359986.15, D83989.1, AC020658.6, AL390023.8, AP000314.1,
	AL450320.4, AB020870.1, AC017033.5, AC083866.2, AC004797.1, AC020751.5, AC068314.5,
	AC025577.15,
	AL080243.21
	~
	AL096770.16, Z93015.9, AL023579.1, AL121981.17,
	~
	•
	AL162252.17, AC005081.3, AL450336.7, AP000925.5, AL158830.17, AC090948.1,
	AL139800.10, AL161731.20, AC020931.5, AL121926.24, AC005988.1, AL590709.5,
	AL096701.14, Z49258.1, AP001729.1, AL137017.9, U6/221.1, AC000094.3, AC011255.4,
	AL137796.6, AL035367.5, AP001233.4, AC007878.2, AL133454.6, AL133397.1, AL550776.4, 115552, AL135454.6, AL155577.1, AC005675.1
	U18393.1, ALU/3542.11, ALI30101.1, 202244.1, ALI304/20.11, ALI30101.1, ALI3010

AL132986.4, AP001961.2, AL161454.10, AC011904.3, AC005480.3, AP001716.1, AF031078.1, U95743.1, AC022150.5, AP001428.1, AP000153.1, AL049539.21, AP000012.2, AF030876.1, U18391.1, AC015933.8, AL049588.11, AC009316.3, AC007021.3, AL391001.12, Z83844.5, AL136172.16, AC018801.4, AC005840.2, AC009196.13, AC016587.7, AL109801.13, AL13996.17, AC022407.6, AC005000.2, AC019178.7, AL035450.1, AC005488.2, AL023755.5, AL389925.10, BC000726.1, AL356499.16, AC066612.7, AC004913.2, AC012512.7, AL06345.1, AC087863.9, AC006512.12, AP0002371.3, AC025771.5, AC024082.6, AL157791.4, AL035415.22, AL139020.5, AL121902.13, AL450104.14, U57005.1, AC024082.6, AL157791.4, AL122035.6, AC002365.1, X55925.1, AC004417.1, AL138721.16, AC003013.1, AC004987.2, AL365364.19, AL161742.7, AC005670.1, Z98744.1, AC022415.5, X54180.1, AL136131.15, AP000952.2, AL035658.7, AL035455.30, AC024060.5, AP0003021.1, AL035400.13, AL36589.1, AC011242.8, AL049870.3, AL137059.20, AB003151.1, AC0110242.8, AL277546.2, AC005696.1, AP001604.1, AF196779.1, AC010326.6, AP000112.1, AC010285.4, AJ277546.2, AC005696.1, AP001604.1, AF196779.1, AC010326.6, AP000884.1, AL034419.22, AP000263.1.	A1632044, BF871813, BF747135, AW630757, BF873312, BF770534, BF813448, A1608881, AA101562, BF700364, BF8713737, BF771630, AA513370, C75490, BF848642, AW999404, AA861308, AA890390	BE192261, AI087131, BF771033, AA3133701, C75490, BF048042, AW959404, AA301303, AA313343, BF771033, AA3193937, BE871109, AW338261, AI199264, AI193265, AA486100, AW190875, C75621, AW339937, BE871109, AW338261, AI799264, AI193265, AA149993, AI469580, AW936241, AI925871, AI002582, AI955238, AI333843, AA486163, AI241578, AA702259, T86963, AI263270, BE350662, AI093487, H57108, BE934125, BF747862, BF807059, BF813934, R01692, AA8373819, BF849699, BE927881, AW936086, AA714224, BF984148, BE927955, BF871808, AV725597, AI273968, BE386265, AV726550, AI350492, BF946044, AI633478, AW502975, BF998270, AL120483, AW903691, AI306524, AI312259, BF842579, AW405759, AC0058991, AL355593.21, AC006026.2, AP003352.2, AC004491.1, AP000133.1, AP000211.1, AC008992.3, AL163032.3, AC07848.1, AP000563.1, AL590762.1, AL031666.6, AC008498.3, AC0005471.2, AC007666.12, AC049761.11, AC008982.5, AC012211.5, AC007850.29, AL1306411., AC00806126.1, AC010271.6, AP001630.1, AC006071.1, AC000052.16, AL138830.17, AC010271.6, AP001630.1, AC0060121.1, AC000052.16, AL162505.20, AP001711.1, AC000052.16, AL109627.18, AL109628.5, AC005332.2, AL031668.23, AL132640.4, AC0053024.1, AC008992.6, AC003962.1, AC006337.4, AC005280.3, AL136137.15, AC006515.7, AL08992.6, AC001464.5, AL513008.14, AC0049752., AC008812.7, AC026061.8, AL049759.10, AC011464.5, AL513008.14, AC004975.2, AC008812.7, AC026061.8, AL049759.10, AC011464.5, AL513008.14, AC004975.2, AC008812.7, AC026061.8,
	15 - 1815	
	1-1801	
	815665	
	991	
	HLDBX13	

AC005399.19, AC025588.1, AL109811.39, AC008745.6, AC005755.1, AC007676.19, AL512843.4, AC009131.6, AC090942.1, AL118520.26, AC005808.1, AL356299.16, AC005516.1, AP000555.1, AL355480.22, AC006468.9, AC004883.2, AC008044.4, AL035587.5, AC002544.1, AL157838.24, AC020913.6, AL096791.12, AP001725.1, AC018663.3, AC011452.6, AL031003.1, AC020983.7, AC006139.1, AL035659.22, AC016554.7, AL139809.16, AL096701.14, AC004019.20, AC008115.3, AL356257.14, AC011495.6, AC003109.1, AP001695.1, AP000113.1, AP000045.1, AL117381.32, AL035086.12, AC0127124.4, AC018842.5, AC006449.19, AC011737.10, AC004257.1, AL121653.2,	AP001717.1, AP001748.1, AP001760.1, AC004821.3, AC005527.3, A AC011497.6, AL359400.4, AC007564.9, AL034429.1, U95742.1, AC0, AC000102.1, AC000075.2, AC009077.7, AL161669.5, AL161624.7, AC083884.6, AC004971.3, AE006639.1, AF254822.1, AC073542.4, A AP002849.2, AL391114.12, AC007963.7, AC007637.9, AF207907.1, AC011490.7, AC037475.9, AL031680.20, AC06211.1, AC022407.6,	AC006334.3, AL357137.7, AL159191.4, AL138720.19, AC006512.12, AP000049.1, AC004167.1, AC074270.25, AC020916.7, AL354932.26, AP001671.1, AC005520.2,		AC018633.2, AL050335.32, AC011453.4, AC011450. 4. AL529086, BE904120, BF337766, BF345489, AV706125, AI681123, BF002270, BF055322, BE856092, AL529086, BE904120, BF337766, BF345489, AV706125, AI681123, BF196165, A1741848, AI636347, AI973055, AI554720, AI871117, BE220195, AI745311, AW192924, AW340966, AA706712, AI091179, BF445900, BE645773, AI677802, AI889659, AI804323, AI688189, AW673266, AI298377, BE046787, AA535027, AW612722, AI830304, AW675294, AI139157, AW089901, AA410579, AW073842, AW316637, AA417232, AA416567, AI827376, AI372513, AA411560, AW001905, AI796719, AW673062, AI334363, AI085075, AI400032, AI452964, AA308319, AI888902, AI400560, T33187, AA877609, AI337305, AI77512, AA485507, AA017127, BG178589, R85136, AV705959, AL526358,	BG056798, H94860, BF476221, AW016699, BF594282, R18537, AA988884, A1925753, AA993373, AW953175, W05059, A1263531, AA282629, E59641, R01402, AA625328, AA126985, AA354334, H58095, BE251679, AW662030, A1559961, AW337874, AA282410, A1014243, A1671403, R41526, AA485352, R43109, Z39066, BF925559, F04091, R01401, W04796, AV751453, BE871534, AA128150, AW375092, BF237662, BE155754, T25085, F17839, AW371533, N74669, AW058382, AW371557,
ACC ACC ACC ACC ACC ACC ACC	A A L	AL AF	AC AC AC V4'	15 - 1262 AL BE BE BE BE AND	BG BG AA AAAV
				1 - 1248	
				636083	
				167	
				HLDON23	

					BF063353 A13602561 A1117482 1
HLDQC46	891	847397	1 - 618	15 - 632	AW274515, AA442374, AL522283, AI806931, AI928433, AI092561, AA628013, AI184518, AW262020, AW363180, AA729980, W92109, AL516443, AI436261, AA659720, AW340561, AI803297, AI802763, AA527556, AI186442, R77144, AW593087, AA953344, W91980, AI444603, R54966, AI799506, AI831001, F24469, AI934101, Z38258, AW451099, BE813043, AW956287, H00226, AI028279, AA649995, T35406, F35703, W23709, R71423, AA548429, AL530766, R77145, W35309, AL522284, N39838, AI940309, BF527253, H27628, BE896237, H44089, AF327923.1, AC006330. 5.
HLDQR62	691	753742	1 - 2558	15 - 2572	BE876197, AU133975, AW170131, AV723948, BG178057, AV652458, AW836234, AW608052, AA047046, BF104746, AA486037, BE395776, AW385580, AA488655, BE699041, AA932253, BG104619, BF671350, AA854943, AA418105, AA829456, AA243385, BE699051, BE936060, A1346694, AA418007, AA503398, AA053835, AW067836, AA817807, AA1090218, BF820483, AA287990, W37960, A1401102, A1279485, W37900, A1423510, AA610711, A1050735, BF820483, AA287990, W37960, A1401102, A1279485, W37900, A1423510, AA610711, A1050735, BF820483, AA133579, AV721259, H81907, BE908122, H11712, AA657490, H09562, R97956, BF810354, N68428, BE699047, AA701403, W30974, AA017371, AW385388, AA911160, BF928600, H10281, W32542, AA133579, AV721259, H81907, BE908122, H11712, AA657490, H09562, R97956, BF810354, AA133579, AA018681, BF80349, AA87145, F11358, AW838692, AA673600, AA133579, AA7744873, Z43397, AA677745, F11358, AW838680, Z42508, H08994, H11779, R18755, AW067888, H86384, R20010, R44826, T78746, BE546845, BF768152, AA67620, R61792, BF925722, AA298600, AA298600, AA572799, AA018662, BE793798, AA098606, F09175, AW054091, AA575408, C02381, H38137, H80857, AA190438, AA058662, BE735257, AA292608, H39230, BF087406, BF841077, BE699066, F09175, AW051915, AA552508, BE935974, AA910836, BF756516, AA50226, BE87667, BG011131, AA233315, AW169463, BE935974, AA910836, BF756516, AA50222, BE88890, BE699076, AA993673, AA6917601, AA52221, BF9332022, BE080981, AW385586, BE092405, BE047109, AW838675, BE074538, AB046801.1, AC026749.5, AC026437.5, AC010491.3, AK001799.1, AF274753.1.
нгроп79	170	740755	1 - 1474	15 - 1488	BG256275, BE867624, BE907396, BE855521, BF034422, BF530803, AW959247, BE782005, AI126689, AL121446, AA757065, AW630129, BF768037, BE746763, AA206154, AA460401, AI276320, BF998689, AA295243, BE242732, BG035901, AL040350, BE242810, T86168, BF983867, W05088, AA347337, BG252443, AI133502, AF064093. 1.
HLDRM43	171	846330	1 - 595	15 - 609	AA502331, AW444616, AA568450, AW592433, AA503839, AI017393, AW957011, T85589, T78178, T72043, T85588, AI699382, BF593574, AA299977, T86494, AW956056, AW605240, AA335186, AA551860.

2, AP001717.	AA359084, AC018797.4, AF224669.1, AF283321.1, AC007883.3, AC006038.2, AC034231.3, AC006345.4, AC008149.14, AL355392.7, AC006057.5, AC084864.2, AL354720.14, AC084865.2, AC006435. 7.	H46196, A1421986, H19572, H46195, BF947135, H19490, BF738481, BF994257, BF127477, AW139949, BF947011, AF321824. 1.	AL538046, BF975484, BG260893, BF062040, AW250850, AW954319, BG118275, Al633756, Al436560, BE646174, AA975057, AW302253, Al651397, AI825665, Al479926, Al635567, Al612806, AI640598, AI653427, Al248825, BF770160, Al333221, AA609320, Al916748, BF346659, AW001438, BF941021, AA397893, Al083783, AA399663, AA302889, AA484860, Al659648, BF222019, Al692578, R49550, AW016187, AA393712, Al673346, D80738, D81106, D81495, D81643, C15479, Al696498, C15522, R42643, Al761655, AA302888, D81794, D81487, D60344, AA302884, AA302883, BF813253, AA091824, BE743563, N49704, Al476597, D81533, N87760, BE396027, AA352126, AA281538, AA280240, AL133447. 1.	BF980403, BF726329, AI984197, AI192533, AI559494, AI378638, AA430026, AI061413, AW17210, AB190915, AA430235, N62729, AI689890, AI360764, AA705532, H90333, H30177, T99745, H78217, T86019, H26993, T91236, AV645894, AA330598, N75483, H42449, BE766728, AW135351, AA976652, AA383620, BE220880, AI630095, BF381551, BF767666, BE087130, H42847, W05293, AA911697, AI659925, BE766726, H82733, T99746, BF889067, AW955970, AW971740, AI432644, AI431328, AI659925, BE766726, H82733, T99746, BF889067, AW9653970, AW971740, AI432654, AI431255, AI431310, AI431312, AW081103, AI432677, AW968356, AI431323, AW972093, AW968729, AI431354, AI432661, BE672719, AI431307, AI431316, BE672732, AI431337, AI432650, AI432651, AI432647, AI431243, AI431239, AI431249, AI431257, AI431244, AI431247, AI431318, BE672742, BE672792, AI431331, AI431315, AI431246, AI432662, AI431247, AI431318, BE672640, AW129223, AL042931, BE672622, BE672627, AI492510, AL042729, AL042832, BE672626, AL043295, AL337075117, AF0648541, AL133082. 1.	BE962422, AW027068, BE617458, AW978331, AW992500, AW274634, AW 131041, N32373, A1917820, A1907429, A1610587, A1348386, R50855, T16683, AA807222, R42665, R45605, R15777, N47819, A1699177, Z39130, M85559, AB033057.1, AF275817. 1.	AL525142, AW274273, BE327124, AI885095, AI885299, AA085210, AW340136, AI985381, AI369742, AW086489, BE298417, AI476470, AI039658, AI034384, AI333584, BE298210, AA455921, AI287650, AW592624, AA456390, AI266556, AI672315, R14963, BF688522, AI310815, AW962407, AA902537, AW954994, AV707146, AW960308, AW952064, AW960237, AW965813, AW963378, AW963660, AV703158, AW955713, AV727916, AW955616, AW951707, AV705433, AW953066, AV708850, AW960276, AW963023, AW953059, AV709232, AW958280, AW966031, AW957853, AW953868,
15-612	15 - 704	15 - 613	15 - 1022	i	15 - 815	15 - 617
1 - 598	069 - 1	1 - 599	1 - 1008	1 - 1752	1 - 801	1 - 603
647430	684216	460467	778073	791828	626831	543017
172	173	174	175	176	171	178
HLDRP33	НГНАГ68	HLHFP03	HLIBD68	нысо90	HLMB076	HLTEJ06

нстнк66	6/1	699812	1-2272	15 - 2286	AW952011, AV658299, AI525316, AV661286, AW959983, AW953163, AW955152, AV704798, AW952011, AV658299, AV707329, AW949779, AV690209, AV707196, AV726026, AW952328, AV725709, AW952583, AW951551, AW949779, AV690209, AV707196, AV726026, AW952383, AV709786, AW967182, AW952579, AW965372, AV653846, AW959721, AV707171, AW964112, AW965730, AW967182, AW962324, AW952375, AV709555, AW960299, AV727272, AW955088, AW961124, AW960537, AW963088, AW961228, AW960201, AV707171, AW961228, AW960201, AV7071787, AV706925, AW956010, AV706407, AV702120, AW965739, AV652528, AW960201, AV7071787, AV706925, AW951549, AV658784, AV726203, AW959366, AW955161, AV709025, AV708438, AW956762, AW949351, AV708007, AV726142, AW956138, AW955111, AV726755, AW956010, AW963641, AV727377, AW95427, AV726619, AV726619, AV702755, AW956118, AW95116, AW95427, AV726619, AV725619, AW963641, AV727377, AW954238, AW950197, AV659294, AW963111, AV709587, AV7089859, AV654287, AW95116, AW954238, AW950197, AV659294, AW963111, AV709587, AV606068, AV64504, AW951768, AV705665, AV702851, AW952192, AW963354, AV690889, AV660608, AV645504, AW954225, AW952329, AV655280, AV708501, AV728997, AV728590, AV728590, AV728590, AV728590, AV708144, AW954225, AW952329, AV655280, AV708560, AV70860, AV708131, AW953466, AV653284, AV660608,
				`	AW118937, A1912990, A1651420, A1754531, A1285856, BF431306, A1760176, A1805972, BF511821, A1123209, AW001864, A1377932, A1141443, A1743946, H19020, BE857717, AW962968, A1221575, AA588506, BF475287, AA026012, A1249502, A1660528, A1949710, R68887, AV653095, AA026000, R77684, H19313, A1460280, AA829761, AA357748, BF511571, R77685, BE671786, AA084602, A1687732, AW889295, BE002919, A1812062, BF365444, C21025, AL136231.12, AF147395. 1.
HLTIP94 HLWAA17	181	1087335 629552	1 - 1226	15 - 1240	AA552985, AA314716, BE778519, BE894256, BE779790, AA228159, A1802546, AC005525. 1. AL522002, BF305304, AL521608, BE732838, BE899550, BF344719, BG115015, BG109203, BF982386, BE410162, BE735023, BE901175, BG117962, BE281306, BG165427, BF793440, BF901577, BE877447, BF316646, BF400987, BF982551, BF970528, BF262711, BE299415, BF340859,
					BE386152, BF569778, BE281612, BF305644, BG251248, BF673757, BF183244, BE547252, AL52166, BF537978, BG249255, BE280374, BE301894, AL532064, AW250139, AA580387, BE018945, BG170896, AW732476, BE779176, BE018944, AL532064, AW250139, AA580387, H20615, BE741195, BE736037, BE272171, A1752100, BE870251, BE742694, BE883834, Z42865, W21970, AA873793, AW579408, BF753347, AA204913, AA206511, AA158660, BF971112, H66924, R25678, AA233944, BE743048, BE743976, BF304498, BE546682, BG112068, BF317329, BE278514,
	_				BE246887, BE298316, BE410692, BE707861, BF125052, BE388318, BF970723, BF675911, BE868990,

					BF031826, AA380216, AJ271671.1, BC007886.1, BC002563.1, AJ243649.1, BC003152.1, AF151829.1, AF132942.1, AJ243650.1, AC004832.3, AC005585. 1.
HLWAA88	182	588485	1 - 1756	15 - 1770	AI075040, AI566035, AI346970, AW453036, AU136077, AW572319, BE677521, AI971962, AI354722, AI611131, AI285086, AI017423, AW612105, AA719963, AI493120, AI910743, AI346087, AA860835, BG055741, AA995966, AW235992, AI188298, BF740313, AI205497, BG055743, AI949884, BF851530, AA939291, AA883259, AI985431, AA070019, AA613006, BE075994, AK023527. 1.
HLWAD77	183	653513	1 - 1153	15 - 1167	BG250493, BE786038, BF968793, AI148564, AV714668, AI911259, AV717040, BF031366, BF970799, W60958, BE221213, AV701362, AI683823, AW268612, AV711084, AW275920, BE551456, BE551386, BF244446, BE550880, BG110482, BF669035, AA404358, AW956755, BE669452, BE504275, BE674209, AV763474, AA443743, BF381847, AI271616, AA936391, AI675766, AV703458, AI695003, AA403095, BF968311, A1311856, AI082141, BF036575, BF575757, BE905833, AA503819, N30670, BF027805, T86418, AI079408, AA393808, AV711478, BE872085, AA393892, AA877290, AI189388, AA910984, R21152, H96780, AW804422, AI014740, AA804216, AV714823, AI219049, H23300, AI566294, R99539, BF724670, N75557, R99538, AI299755, AA476793, AA974212, AA417638, AI374805, AW952564, AV725011, AI094470, AI133161, BF221760, W05584, AI089034, AA905867, T86508, AA677753, R99560, BF753822, AA335337, AI240536, AA313386, AW298229, R08382, BF475310, R08329, H97711, H96103, H80948, T99199, N24555, AA375092, T99198, H92437, BE260997, AA383378, BE536680, AI085108, BF920784, AF132289.1, AF242523.1, AK024574.1, AF151859.1, AC024148.1, AC024082.6, AC099263.6, AA419545.
HLWAEII	184	783071	1 - 1604	15 - 1618	A1344312, A1276017, A1476822, A1139478, A1160906, A1240398, AW001088, AA425919, AA011278, AA428788, A1354692, A1089176, AA622689, BF431807, A1968918, N68826, A1467807, BF436247, AW673768, AW135943, R24434, R16812, R31419, R31434, R24435, H83155, A1865939, R31418, AW673133, W67349, R31433, AA027080, R28030, BE542160, T81223, A1631986, AA677315, BF760063, A1872675, BF331923, BE926682, BE926741, AF329842.1, Z82188. 2.
HLWAO22	581	587270	1 - 1324	15 - 1338	AL515814, AL515776, AL534165, AL520605, BF342613, A1064806, BF528629, BE856301, A1140344, A1763061, BF063934, BF244655, BF683133, AW340290, BF344711, A1659614, AL515777, BF034915, A1554886, A1086027, BE929854, AW193974, AL515815, AL525649, AA410368, A1937139, AA918821, A1218197, BF313091, AL525747, AA829365, A1336469, AW473975, AA577435, AV645326, AW070946, H22929, AA722774, A1610462, T90764, AA404313, A1623603, R54057, AV723824, AA404713, AW168607, AA079100, AV752738, BF316436, AW402756, AA912779, BE742923, AL534166, AA609213, BE350786, AA406191, AA923714, AW750290, AA325220, AW952354, BE898647, BF092248, AA293154, A1218895, A1198020, A1672973, BG002684, AA649195, W81523, H08723, AW207732, AA927962, A1873660, AA774521, BF880685, AL520606, BF837510, AW794716, BE044401, BF767735, A1383372, A1204653, A1361791, Z39695, BE673415, BF797091, BF37142, BF541812, A1689520, AW297870, BF965605, AW590611, H08439, BE263819,

					BF086702, F02166, BE547512, BF115405, AA477404, F04433, T83213, BF036962, BF767508,
					BE795356, AA430434, AW797192, AA479566, K16340, BF678079, BF685049, BF847264, BF847234, BF804160 BF847373, BF904852, R41416, BF312226, Z45578, BF733974, AA971991, W81639
					A1902460, BF833057, BF804096, A1903581, BE798202, AA453110, Z42682, BF917644, A1564885,
					AA335484, AI811209, AW083638, BE260879, BF314999, BE274089, AI903535, AW376204,
-					A1755186, A1880283, BE540568, A1523835, BG165048, A1627893, AW008226, A1440284, A1568293,
					41559296, 41954721, 41446511, 41934011, 41364167, 41538564, 41744268, 41688858, 4V750565,
					A1339800, AW129204, A13401/9, A1364389, A1638044, A1690/84, A14993/0, A139043, BE906330, A 656600 A1836432 A164730 A1716817 A150061 A1873604 A147679 A174360 A1141406
					A1633125, A1620864, A1866040, ALS15021, A1885982, AW081383, A1824746, A1620056, A1269469,
					A1270448, A1274655, A1884318, A1287252, A1678446, A1651840, A1890183, A1701097, A1635634,
					A1763414, A1370623, A1476478, A1266652, A1696714, A1799968, A1628325, AW236186, A1653402,
					-
					AJ289856.1, AJ289847.1,
					AJ289853.1, AJ289850.1, A
					_
					AL512684.1, X99971.1, AL133084.1, AB055331.1, BC001336.1, AL389935.1, BC004373.1,
					AL133062.1, AK027209.1, AF115392.1, AL049959.1,
					BC000732.1, BC005070.1, AK026462.1, AK000418.1, Y14314.1, A
					AL050138.1, AF217973.1, AF131821.1, BC002849.1, BC006345.1,
					BC007641.1, AL157479.1, AK000414.1, AB060897.1, AL080154.1,
					BC005123.1, AK025658.1,
					L137682.1, AL138832.10, AP001601.1, A
					- 1
HLWBH18	981	1045194	1 - 799	15-813	BG000096, AC023490.5, AC018636.4, AC006435.7, U95742.1, AL121891.22, AL451142.7,
		•			AL035659.22, AC020716.3, AL136179.15, AL450339.5, AC007216.2, AL136418.4,
				:	AL139054.1, AC011533.6, AC000159. 6.
HLWBY76	187	609/6/	1 - 2067	15 - 2081	AA923172, A1139607, A1269739, A1802946, N30680, A1277957, A1277237, BE715040, BE838082,
					BF354274, AW797336, AW797335, BF987948, AW873630, AI806044, AK026806.1, AC003991.1,
					AK027807. 1.
HLYAC95	188	778075	1 - 298	15-312	AV764526.
HMADK33	681	561941	1 - 850	15 - 864	AL538273, AW139111, AA663592, AI582741, AL120259, H51572, AI122619, AI124509, BF366373,
					R86660, H50906, R86835, BF836623, BE884648, AF070673.1, AF030196.1, AL161976.1,
					BC00383/. 1.

HMADS41	061	596831	1 - 1253	15 - 1267	BE740695, BE739906, BE899124, BE742745, BF685920, BF971897, BF684948, BE336652, BE747520, BE925550, AI733012, AI492192, BE207602, AW275042, AA954656, AW139807, AI791409,
					AW136444, A1361524, BE207644, A1762361, A1762373, A1246377, BF684146, AA306161, BF062047, BF222947, AW003832, BG028044, AA865078, AA402599, N32269, BC007725.1, AF123757.1, AF123758.1, AF123759.1, AF123760.1, AF123761. 1.
HMAMI15	161	1352406	1 - 1244	15 - 1258	BE790239, A1114496, BE047613, A1609021, A1478544, A1949665, R96283, A1205799, W39248, A1670908, T70976, AA070919, A1243978, AW854183, A1796472, BF883407, AW975683, AA654405, A1125888, AA730911, AA545731, BE222003, AA730927, C21177, AA721678, A1478489, AL137139.9, AL139035, 27.
HMCFY 13	192	635301	1 - 869	15 - 883	BF026299, BE277091, AI343297, BF027218, BE390121, BE387283, AL514638, BE388858, AI364111, BE389119, AI668959, BE391988, AW206551, AA676232, BE870993, BF002101, BE277034, BE729557, BE276352, BF125430, BF896609, BE386944, AW207225, AA551687, BE718320, BF131318, AI990714, BE693868.
нмрав\$6	193	929095	1 - 1451	15 - 1465	AI073053, AW972336, AI199257, AA493693, N80663, AW879550, AL138455, AA633753, AA640410, AA640430, AW815064, BF820510, AA018283, AL037554, BG033220, BF822854, AV759329, BG033926, AL120343, BE062169, BF679557, AV757425, AI631355, AW129526, AV710289, BG033926, AL120343, BE062169, BF679557, AV757425, AI631355, AW129526, AV710289, BF868399, AW063373, BF437493, AW936354, AI094787, AW500029, BF915002, AA908411, AV760207, AV761925, AW975971, BF666395, BE88219, AV764035, AU137841, BF679274, AI805123, AP002088.2, AC0080145, AC0094704, AC0114504, AL133148.11, AC011475.6, AL158832.13, AC004634.1, AC005102.1, AL135749.3, AC01105.12, AC000088.2, AC001997.7, AL133214.12, AP000901.5, AC008891.7, AC001188.6, AL450483.1, AC007097.4, Z84480.1, AC0022188.6, AL450483.1, AC007097.4, Z84480.1, AC0022415.5, AC008747.5, AC000082.4, AC007097.4, Z84480.1, AC001105.12, AC009044.1, AC0074338.1, AC0077318.4, AL136219.17, AC004461.1, AC001107.1, AC005746.1, AC005762.5, AL359935.23, AC069080.12, AL38988.8, AC007035.3, AL136359.13, AC004253.1, AC025165.27, AL133433.3, AC0047321.2, AL353194.13, AC004466.1, AC004253.1, AC002765.5, AC006380.2, AL353997.3, AL133433.3, AC0040602.1, AC101102.2, AL15972.2, AL161779.32, AL033378.1, AC0069080.1, AL13992.24, AL13902.24, AL13304.10, AL121552.13, AL12152.13, AL157406.19, AC025418.23, AC006018.1, AC006048.11, AC121752.13, AL157406.19, AC025418.23, AC006018.1, AC006048.10, AL133759.20, AL13378.10, AC006011.1, AL121752.13, AL157406.19, AC025418.23, AC007012.1, AC006548.20, AL13346.00, AL1346.00, AL134
HMDAM2	194	514394	1 - 982	15 - 996	BF741516, BF740289, BF740290, BF741538, BF760315, BF911969, BF830586, BF759998, BE083615,

4					BF932902. BF763222. BE079695. AC004797.1. AB023141. 1.
HMEA148	195	1352290	1-399	15-413	AA297104, AA298556, AA216561, AW957476, AL532709, AU124631, AA173361, AA206770, R14826, AL513976, BF726195, BF901681, AA873180, W20303, AF109127.1, AF109126. 1.
нмеер 18	961	560775	1 - 1355	15 - 1369	BF967947, BF794640, BE744676, BE872383, BE261972, BF680443, BF967220, BE732377, AI417193, W95515, AW294641, BF306808, AI189166, BE856708, BE64954, AI949989, BF530795, AA628537, BE551422, BE747031, BE304795, BE735201, AI457755, BE870962, AI634510, BF131863, AI671536, BF242851, AI870629, AW514766, AI813311, AI862663, BE293244, AI768533, AI823596, AA129467, AI446582, AI435116, AI627345, AA972422, AI968606, AI088367, AI827354, BF439637, AI824877, BE220123, AV703921, AW236583, AI377591, AI040592, AA648774, AI095815, AW953613, D59730, D59523, AA029160, AW009152, AA054405, AI244209, AW023899, BE674038, BF059180, D59622, AA778356, AI470145, BF378975, AA970493, AI368877, D598301, AA129466, AI659586, AI344665, AI824866, AI803930, D59455, AA993837, D59633, R61441, AA704531, AW022576, AA484947, BF955158, D59447, AV725111, BE870487, AI082578, R35366, T14319, BF948389, D59584, H09679, R23394, T77005, D59540, F10041, F10282, D80153, D80213, F10633, D59650, AA333625, BF855208, D59530, D59539, R25274, AA301260, D59438, H23420, D80341, D59769, D80323, AA827217, D59825, D59794, D59473, AA319561, R3808, R44178, R20566, D59692, F16283, D80260, R61396, D59749, AV726311, AA095729, D59772, AI088314, BF967226, AI383053, D59813, H22900, R14241, D59752, R40536, T34343, BF510049, F13475, D59782, AA346675, D80245, AI418992, BF948033, AW310581, D80381, BG054921, AW291373, D59812, AI418992, BF948033, AW312355, AI434666, BF837006, AW81632271, BC008873.1, BC006150.1, AL512689. 1.
HMEFT54	197	520307	1 - 582	15 - 596	A1925461, A1187417, AA527170, W51933, AA534506, A1699870, AA430389, AW264729, AA284284, D20078, A1350867, AW131222, W48637, AA400891, A1458334, A1168826, AA400960, BF590627, AV719049, AV699669, A1557751, AW962245, AW975618, AA365173, Z21582, C14298, C14331, C15076, AV699550, AV724520, AW973541, AV718692, AW950117, D80064, AV719758, AV718489, AW949498, D59787, D59467, AA526218, AA701131, F13647, AW817409, AA434346, D80164, AV729929, AW964468, A1201668, D59889, D80195, AA507526, AV720791, AV718530, A1694178, D81030, BF382730, AV720203, AW960553, D50995, AV700889, BE148028, AU119190, R20046, BE01177, AW949645, D80196, BE748599, D51423, T41134, BF837744, AV718800, BF876179, D80212, C14227, BC002933.1, AK026989.1, AF254260.1, AL136917.1, BC008301.1, AC090939.1, AC095230.1, AF037338.1, AC004823.1, AC004922.2, AC006716.3, Z95116.1, AC025166.7, AL445184.11, AC009131.6, AC005332.1, AC002492.1, AC007021.3, AC012476.8, AP000688.1, Z98884.11, AC031985.10, AL355312.24, AL355312.26, AC004526.1, AC007387.3, AF283320.1,

					AC034193.4, AC018808.4,
					AC008009.4, AC008397.7,
		-			AL590002.7,
					, AL160269.14, AC006312.8,
					AC010326.6, AC006571.12, AL034379.8,
					, ALI61669.5, AC000025.2,
		-			ACUIDI83.6, ACU/3366.3, AL339402.3, ACU03015.2, ACU0527.1.3, ACU03823.1, ACU26464.6,
!					ACUUSSOS:1, ACUUCHOUS, ACUIU422:1, ACUU4032:3, ACUU473:1,
HMEGF92	861	520304	1 - 615	15 - 629	T65556, BF952979, F09666, AA995112, AA983746, AA983748, AP001972. 4.
HMSDL37	661	943396	1 - 2483	15 - 2497	BF358189, BF358186, BF358188, BF673854, AV762975, AA481760, AL042906, BE908602,
					AU154050, AU158859, AI310464, AA113159, AV718718, AW080062, AI952885, AL042905,
					BG029899, AA679794, BF813805, BE206133, AL048969, A1132963, AW401509, AV700988,
		-			AA113272, N49425, BF968610, AW975169, AA524604, AW157616, BE300645, AW008089,
		-			AV699423, AW976010, AV700654, BF679169, AI016704, N80210, AW151713, AU117926,
					AA427470, AW957502, AV760701, AI631119, N48230, BE895796, AW962035, AW979158,
					BF673743, AL534685, AA833875, AA833896, BF926318, BE061906, AA081138, AL044339,
	-	•			AW268329, AW960015, BG254652, AW600804, AU140392, BF820678, BF668559, AV764259,
					AA572968, BF736198, AV734543, BG222875, AW897556, BF892846, AC022001.3, AC018811.4,
		••			AL353810.9, AC005553.1, AL139396.17, AL020995.14,
					AL021918.1, AC022534.7, AL135903.12, AL161443.13, AC007912.6, AC018684.3,
					AL163248.2, AJ400877.1, AC006313.1, AC022401.3, AC025165.27,
		-			AL137782.9, AL139322.13, AL355520.8, AC003065.1, AC004813.2, ,
					, AC027670.4, AC021396.6, AC005033.1, AC007251.3, A
	-	•			
					AC073964.3, AC004650.1, AL157955.5, AL358372.11,
		-			
	_				
	_				
_					
		_			AL133417.10, AC090497.2, AC007097.4, AC005280.3, AL359400.4,
					_
					AC009404.5, AC006543.7, AC007510.6, AL160162.11, AL354942.10, AC005862.1,

				BE612783, AV714585, BG107890, BE781717, BG030517, AV718270, BE888408, BF665580.
				BE880927, AV710046, BF666320, BF030581, C75683, BG029271, BE880632, BE887874, AV733955,
				BE695911, BF668753, BF666696, BF978924, AV757896, BE568697, BE932552, W55909, AV651776,
				AV714563, BF700463, AI377408, BF669293, AI857934, BF669212, BF213025, BE545003, BF691021,
_			-	AW024331, AA725652, BF185721, AI829947, AA454213, BF680798, BF964977, BE904360,
				BF701393, BF241919, BE789978, BE932459, BF665354, AA314273, BF037589, AW351912,
				BF028073, Al309773, BE932553, BF701113, BE932539, BE816887, BF665260, BE932447, BF692251,
				BF184304, AV701697, AV707435, AW270018, BF697317, BF244581, BF029708, BF129991,
_				BF185277, AA861381, AA001402, BF131429, BF670186, AA305370, BF696039, BF211541,
-	- ==			BF690925, AA447415, BF214411, BE932475, BF572141, BE932540, BF724466, BF667996, AI857939,
-				BE644614, BF968128, AA629424, BF700100, BE958024, BE646415, A1857941, BE968671,
				AA306430, BF692658, BE779388, AA858363, BF667913, BF242902, BE932484, BF700414,
				AV655721, BF695497, AA454212, BE932439, BF132852, BF031185, BF028474, AI589640, BF245173,
				AA521350, AW752399, AA447414, BF244157, BF381984, BE568476, W55910, BF195161, BE504467,
				BF185628, BF213439, AA809077, BE960947, BF104162, BE816941, BF031301, AW298803,
	<u></u>			BG260202, AI475816, AV700780, AW630212, BE569124, BF668875, BF541632, BE865509,
			***	BF699689, BF665760, N93336, BE898217, BE568064, BF372428, BF674472, BF664872, AIS40152,
_				BF693954, BF571750, BF792635, AA703503, BF307415, BF242078, AA629906, BF184679,
				BF243347, AW778874, AA523671, AA181455, AA431132, AI560791, BE958209, AA315633, H18045,
				AV755841, BF030440, BF131135, BG249184, BF670667, AA186625, AA861405, AA663419,
				AW996056, BE567887, BE865807, AA531308, AI139080, AA843632, W95504, R80694, BF664562,
				BF977109, A1291233, A1745163, H98623, C75579, BF666247, AW971769, A1274327, BE565642,
				AI218737, N93386, BF240785, AA204997, AI291765, W39740, BF757214, AV714850, AI027269,
				W44792, AA192752, AA772002, BF215015, BG058583, AI807027, AA493379, BE168171, AI285081,
			_	AA918748, AA459602, AV682318, W95451, W80402, AI085784, BF106436, AV681563, BE168154,
				AW604348, W32254, AA311342, AI346231, AI086810, AI348232, BF437332, AI304545, W79010,
			<u></u>	AW058049, AA157979, AI565637, BF215257, AA205366, AI302529, AW085164, AA432149, H99232,
				BF690888, AI358223, BE168394, BE932473, W15312, BG165346, BE835844, AA744881, BE814385,
			_	BF131056, AF288991.1, BC005294.1, AF051894.1, AL121989.12, AF288992.1, AF267986.1,
				AL132640.4, AL049779.6, AF267983.1, Z62873.1, AF267982.1, Z62874.1, AF267984.1,
				AF267985.1, T54811, T55185, R24125, R27504, R64164, R64278, R76615, R77750, R78101, R80695,
				H00161, H00199, H01506, H01612, H03815, H11302, H11303, H18029, H18238, H18276, H21844,
				H21845, H22737, H24019, H40729, H40861, H41003, H39213, H43589, H43591, R93867, H50227,
				H50262, N25143, N26355, N93005, N93049, W20245, W21356, W21385, W25189, W25405, W44746,
				W44715, W93846, W93867, W95402, W95407, AA001470, N91043, AA026860, AA026861,
\dashv				AA057539, AA057538, AA088796, AA179997, AA192828.
HMSHM14 202	461897	1 - 742	15 - 756	AW817008, AW817118, AW951170, AL078634. 24.

HMSHS36 203	1127691	1 1 - 1388	15 - 1402	AV701925, BF793477, AV652861, AV706319, BF733347, AV731015, AA649067, BF217767, AU116940, BG032917, BF811794, BF982391, AU120741, A1133602, BF871285, BF673583, BE620216, A1132952, BE250577, BE797641, AV652798, BF874267, BE883545, BF951636, BF877837,
				AL133895, BE898175, AU120778, AA577789, AW893125, AW962273, AA720812, AA225638, BE736918, BE153395, AA583363, A1926740, AA601152, BE563291, AA180390, AW845697, AW023095, BC000679, AW962826, BF871283, BF732306, BF616582, AA456928, BF803637, AW023095, BR803637, AW023095, BR803637, BF871283, BF732306, BF616582, AA456928, BF803637
				BE385152, AA553442, AA604116, AA503299, BE728115, BF763241, AA584599, A1568660,
-				BF918672, AA808950, N62150, AI761174, AU147985, BF943073, AA418822, BE646483, AW845701, AA081957, AI084217, AI832080, BE379426, AA584606, BE615376, AA593381, AW593396,
		····		AA630813, N23657, AA487214, AA601086, AA309271, AA179694, BF755046, AA524729,
				A4031403, AV 730201, AA 703313, BE134350, A1032300, BF8639625, N23040, AA620140, AA 713730, A1940701, BF815608, AA584589, BE790104, AW087334, AA487598, AW939910, A1493725,
				AA418919, AA779025, BF338817, A1686420, BF001825, BF063736, AA663257, AW872342, BE030667, BE0306677, BE030677, BE0306677, BE030677, BE0306677, BE030677, BE
-				BF922002, BF919120, BF919123, A1002260, A1940706, AW 645004, AU 156101, A1600642, AU 146272, AA669412, BE676217, AA584914, A1564481, AA593077, H71269, AW088584, A1479770, BE167158,
-				T07383, AU140348, BF958620, T57745, T57474, T63786, BE141836, AL134317, AI671215,
-,				AA910874, AW439349, AA171526, AI968135, BF871286, AA774178, AA353087, AA281350,
				BE531051, A1858454, H63688, AA076475, AW993580, AW865469, AA280232, AU139668, BE507714 BC017085, A1748086, AW819076, BE718444, AW190086, AW738615, AA084108
•				H71280, AA258511, H92806, BF767788, BF763870, BF878613, BF905882, BF969711, BE783575,
	-			AL048837, H59185, AA632760, AA076364, AA281143, AA227286, AA587277, A1795961, AA481809,
				AA434462, BF812273, AW513636, AV653743, BE897813, AA581506, AI081365, AA180023,
				BE177666, BF869076, AA969742, AA188746, AW843678, BF878615, AA218640, AW088010,
-				AA334211, AV632938, BEU128/4, AA383368, BF829331, AI634394, AW803403, N/0043, AA487808, AA431655, AA486314, AA64413, A1114647, AD0035321, A11121696, 12, AB045358, I
				AL450382.6, AL121879.14, AC073311.7, AC004389.1, AL035397.4, AL355379.5, AC022416.5,
				AC079147.5, AL133226.16, AC006154.1, AL355796.11, AC018795.9, AC005521.1,
			-	
				_
_				
				AP001712.1,
_				AJ400877.1, AL109662.3, AC002086.1, AP001208.3, AC012323.7, A
	-			
				AC0049/9.1, AL035351.6, AL35923/.4, AC016/48.3, AC010289.1, AL163248.2, AF20/955.1,

					AL162390.9, AC018705.10, AL035427.17, AL139141.22, AC048346.13, AF235098.1, AL163206.2, AF198099.1, U82696.1, AF274856.2, AC078955.24, AC022073.13, AL008633.1,
					AL590675.3, AL121780.11, AL356115.9, Z95333.1, AC006477.3, AL500522.9, AL365222.24, AL031622.1, AL138743.5, AC007035.3, AL162580.20, AC007759.1, AC025265.21.
					, AC003098.1,
					AC090645.1, AC018833.3,
					, AP001669.1,
					AF196972.1, A
					AL162464.5,
					AL080316.8, AF117829.1, A
					, AL356804.4, AC006979.2, Z99570.1, AL355540.12, AC002479.1,
					AC011339.3, AC090497.2, AL139231.13, AL390043.7, 073403.1, AL339012.1, AL03323.1, AC005023.1, AL391358.14, AP001634.1, AC083870.2, AL356956.11, AL034410.8,
					AL022401.1, AP001429.2, L
					AF257497.3, AL161871.6,
					, AP000924.6, AP002788.3, AP002076.3,
					AC008973.5, AL157791.4, AC008860.6,
					, AL133249.1, AC016716.6,
	_				AC009480.4, AC008407.4, AC090043.1, AL160234.2, AL137226.3,
					AC063979.4, AL354913.11,
					AC006399.6, AL136110.17,
	_		-		AL022399.2, AC016689.3, A
					AL360272.23, AL356317.8,
			-		AC022740.4, AC025447.4,
TIMON COA	800	200540	1 1403	15 1417	ACU00400.1, ALTI1/329.10, ACU000/11.2, AL307073. 3. DE013376 AAA03606 1173560 AA570740 AV60470 AI633764 AW060743 A1343102 AA560304
HIMSINCO4	5 07	199340	1 - 1403	•	Br 645270, AR463000, H3530, AR370749, AV623476, AR623704, AW763743, AISTEIGS, AR3200204, AISTEIGS, AR829036, AISTEIGS, AR829036, BF804388, AISTEIGS, AISTEIGS, AR829036, AISTEIGS, AISTEIG
					AW194325, AW161016, AL138182, AV763057, AC010191.24, AC004590.1, AL121586.31,
			_		AF168787.1, AP000046.1, AP001714.1, AL445686.14, AF222856.1, AF222854.1, AF222855.1,
					AP000104.1, AL138849.12, AL109758.2, AP001721.1, AL121758.24, AC008994.3,
				_	AP000512.1, AP001717.1, AL513008.14, AC018663.3, Z93017.6, AF042484.1, AJ003147.1,
				4	Z94056.1, AL118525.17, AC008738.6, AC011472.7, AL139342.7, AC005015.2, AC005756.1,
					AL355392.7, AC020906.6, AL136300.22, AC018755.3, AL512883.5, AC013429.12,
					AC004867.5, AL365445.11, AC005231.2, AC073347.3, AL391259.15, AJ400877.1,
					AC006236.1, AP001726.1, AL354720.14, AC005874.3, AF134471.1, AL136295.3,
					AL096840.25, U63630.3, AC069285.8, AC005295.1, AC004166.12, AC008753.8, AP001718.1,

AL121845.20, AL136418.4, AL139054.1, AL049869.6, AC005049.2, AL049713.20, AC004150.8, AF002223.1, AC007938.1, AC010271.6, Z83844.5, AC079316.15, AL163281.2, AC157823.9, AC010530.7, AP000045.1, AP000113.1, AC007129.3, AC004228.2, AL158207.15, AL13163.2, AC011510.7, AC015801.25, AC010319.7, AC002544.1, U91326.1, AF307337.1, AC005971.5, AP000466.1, AC005378.2, AC005571.5, AC00666.1, AC0066.1, AC0066.1, AC006040.3, AC013355.7, AC005071.2, AL121771.17, AC006160.9, AC005940.3, AC01449.6, Z95113.2, AP001747.1, AC017033.5, AC00522.2, Z93241.11, AC011465.4, AF015416.1, AC005378.2, AC020552.4, AL139035.27, AC007225.2, AP002852.3, AC009086.5, AC01449.6, Z95113.2, AP001747.1, AL132825.35, AL365444.11, AL163280.2, AF139813.1, AL35589.8, AP001747.1, AC01461.4, AL049871.4, AC00591.1, AL35589.8, AP001711.1, AC069262.24, AL355385.15, AL136137.15, AC006121.1, AL031283.26, AC011484.4, AL355589.8, AP001754.1, AC004983.2, AL121897.32, AL158830.17, AL050331.11, AC004983.2, AL131272.14, AC084865.2, AF047825.1, AC004953.1, AC004051.1, AP001712.1, AL049569.13, AL354873.19, AL031311.1, AC051619.7, AF124523.1, AP001712.1, AL049569.13, AL354873.19, AC0068799.14, AC003684.1, AL138743.5, AC009570.13, AP001745.1, AL022322.1, AC004963.2, AE006467.1, AL161937.13, AP001745.1, AL022322.1, AC004963.2, AE006467.1, AL161937.13, AP002812.3, AL450104.14, AC004498.2, AL121827.3, AC004568.1.	BE613319, AV687447, AV725712, AV687625, BG166531, BE612728, BG114876, AV686519, AW952404, AV725638, A1061630, BE877777, BF055022, BF439548, BF692350, BF732575, BF967994, BG054984, AW372569, BE886270, AW160677, AV706186, BF690981, AA813278, BF206792, BE876393, BE645016, AV728247, BF195583, A1612729, BF446480, BF210620, AW167859, AW167859, AW167852, AA521082, BF445077, BF698977, BE348758, AW753532, AA161332, BF665995, BF195330, A1806813, A1887683, AA843967, AA525839, A1869290, AA447934, AW068627, BE881059, A1912708, AA843171, AW206294, BF673423, AA402367, AA910679, AA0779099, A1057601, BG168894, BE327200, AA781082, AA496466, AW022886, AW275342, AM79099, A1057601, BG168894, BE327200, AA781082, AA496466, AW022886, AW275342, AW003760, AA287895, AA774263, N22752, AA843277, BF001600, A1685261, AA283859, A1678620, AW403982, AA984140, AA056053, AA907413, A1361356, BF572327, AW157133, N94537, A1816334, B58802, N2749347, N92441, BE673987, W23456, AA410485, D81853, AA9335683, D58802, N27027, H99819, A1004733, N30220, AW516562, AA410485, D81853, AA64059
ACO ACO ACO ACO ACO ACO ACO ACO	15 - 1965 BE6 BF90 BF90 BF10 AW10 AW2 AW2 AW2 AW2 AW2 AW2 AW2 AW2
	1 - 1951 - 1
	872208
	0 202
	HMUAP70

A1446094, AA872758, AA725042, AW160789, AV684142, BF762393, AA861311, BE167341, N34534,
 AA399445, AA515285, R90917, AA399423, AA911982, AA995135, BF036554, AW513259,
AA577338, AA872812, T63367, AI423456, AA643728, AI027067, AA293329, AW162091, AA085090,
R56184, A1245725, BF436213, BG109166, H23642, A1973249, AV650608, AV686647, BE928331,
N68929, R64440, AA029562, H13310, W46630, AA114922, H41386, N57112, AA258388, AA744562,
AA993782, AI499779, AI571822, AA744564, N40152, AA029728, Z43644, AA837702, Z45519,
AV689458, AA620561, AI093848, AA602387, AA421573, AA922986, BE564509, C14582, R12614,
AA410303, AA782100, AW083148, N36220, R32391, AA055763, AI570545, AA939289, R90813,
 AA112870, AI207050, H16135, N89859, F06244, AW162345, W92571, AI027262, AI149386,
 AW023549, R63828, AA311835, AW517389, H38655, AI348632, AW015099, T54934, AI826301,
 BE464247, Al360861, W30811, Al028088, Al768693, Al307614, Al343572, R32390, Al744258,
 AW276195, AA055962, AA724357, R42373, AW206298, AI167826, N78834, BC004317.1,
AC004752.1, AK025312.1, AL583915.1, AL353956.1, AL122045.1, AK025209.1, AK026480.1,
AL389935.1, AK026542.1, AL136790.1, AF159615.1, AL122050.1, AF125948.1, AF217982.1,
AL049382.1, AF353396.1, AB063100.1, AL162002.1, AL080163.1, AJ299431.1, AF058921.1,
 C000450.1, A
 BC002454.1, BC000556.1, AL353940.1, AK000718.1, AL137429.1, AL136844.1, AL512689.1,
AF061573.2, AK027193.1, AL122123.1, AK000618.1, AF217966.1,
 AK025375.1, AB047904.1, AL133665.1, AL080159.1,
 AL117460.1, AL050116.1, AL389939.1, AK025465.1, AJ012755.1,
AL133557.1, AL049452.1, AL137533.1, AL133113.1, AF106862.
, BC006332.1, AK000418.1, AK026642.1, AL049314.1,
AK025378.1, BC009033.1, AB060826.1, AB052191.1,
AF090901.1, AL110222.1, AL389982.1, AL136799.1, S61953.1, AF
 AL137271.1, AB055352.1, AB050431.1, AL110158.1, AL096744.1,
 AF271350.1, AK026408.1, AL136850.1, BC007326.1, AK026583.1,
AB060839.1, BC007567.1, AF155827.1, AL136845.1, AL137294.1,
AF090934.1, BC003683.1, AF090943.1, BC006440.1,
BC008485.1, AF090903.1, BC005678.1, AF090896.1, D83032.1,
X53587.1, BC004530.1, AB060211.1, BC002523.1, BC007198.1, AL
AL136892.1, BC002733.1, AK027868.1, AK026532.1,
AL122110.1, AB048913.1, AB048919.1, BC004951.1, AL050172.1,
BC003682.1, AL133075.1, AK025524.1, AL133072.1, AK026462.1,
AK024992.1, AK025967.1, AK026855.1, AB047623.1, BC004899.1,
AB060863.1, AL117416.1, AL512733.1, AB060929.1, BC001964.1,
AB056809.1, AL137711.1, AB056372.1, AL162062.1, AK026627.1, BC002466.1, AF252872.1,

					AK026927.1, AL023657.1, AF274347.1, AL157431.1, BC004264.1,
					AF056191.1, AL137292.1, BC003687.1, AK027114.1, AK026504.1,
					ALU49938.1, ABU4/8/8.1, ARU26630.1, ALI36/92.1, ARU2/144.1, ALI3/538.1, ALS12/63.1,
					AN024394.1, BC002303.1, BC000309.1, AL137703.1, AB002942.1, RC007456.1 AF303636.1 AF048974.1 AL136540.1 AL1565006.1
	_				A1359618 1 BC004215 1 BC003122 1 AL136805 1 AF207829 1
					AL049460.1, AK000247.1, BC002839.1, AL137478.1, AK000323.1,
					AK026762.1, AK026784.1, AL133077.1, AB055303.1, AL359601.1,
					AF090886.1, AB060887.1, BC003548.1, AK027142.1, AL137256.1,
					AL133619.1, AL050393.1, AL137548.1, AK027136.1, AL122121.1,
					AL390167.1, AL359941.1, AL512750.1, BC008673.1, AK027096.1, AK026528.1, AF245044.1,
	_				AB063070.1, T54768, T63693, T91023, T84597, R13763, R18327, R20519, R25031, R43789, R53025,
					R20519, R43789, R55911, R81848, R81849, R90812, R90918, H53640, H53684, H86289, H97448,
					N25711, N43983, N59141, N75178, N76730, W31472, W31935, W35396, N89770, AA018416,
				-	AA019585, AA122341, AA565211, AA583521, AA613126, AA767024, AA807259, AA829478,
					AA831898, AA876196, AA906972, AA932624, AA953784, AA953789, AA975996, AI028021, N56132,
					C00677, R29165, AA092968, AA679878, AA782815, AA890689, AI042642, AI041151, AI093012,
					T24514, F02527, F04381, F04532, F08307, AI244846, AI276792, AI279043, AI298862, AI334644,
					A1348509, A1364763, A1202774, A1453449, A1400913, A1401566, A1417788, A1418178, A1498899,
				-	A1419614, A1582814, A1423417, A1127285, A1147786, A1148738, A1167754, A1187434, A1652739,
					A1219638.
HMVBS81	206	639203	1-515	15 - 529	AW080812, AW082817, AI951822, AW328562, BE138773, AI453744, AW246456, AW248692,
					A1953814, AA916922, AW166193, BE741575, A1189652, A1554578, BE207752, AW051430,
					A1143755, AW631158, A1378866, AA602780, AW166148, A1346750, AA402608, A1191618,
					AA643353, BE207747, AA703840, BF969135, AA503856, AI991172, AI150232, AI885695, BE312018,
					AA599791, BF940193, AI951334, AI192449, AI423588, AI089026, AI564055, AI160783, BE904552,
					BE673401, AA722619, A1333580, BE465600, A1147788, A1201929, N39330, A1806345, AA740539,
					A1359694, BF569026, BG111020, AW078736, W42999, AA915948, BG231541, A1453740, AA845228,
					AA128902, A1262427, BG111584, AW005011, A1191380, AA838219, N93880, AL529784, A1289245,
					AA975577, AA654241, BE270980, R17925, AA455946, AA858122, AL529713, AW070627,
					AW068993, AA480313, AW249124, AL530076, AL044257, AW381690, AW381728, A1073423,
					AW606063, AW381754, AW381773, W40373, H84216, AW381761, AW381723, AA032144,
					AW381716, AA639632, BE151932, AI284233, AW606042, AW606073, AL530075, AW381757,
					AW381711, BE151941, AW606072, H82810, AW328561, BE151934, AW606039, AI001133, D20808,
					F35123, AW606054, AW381758, F21453, BE909136, AI866123, T50401, AL526916, AA126629,
					AA282016, AW881457, AA308337, AA134834, AW364188, BG024191, AL529714, AI220753,
					AW601155, AI186566, H48575, BE908027, BE265069, AW469208, BF531105, AW182036, BE733058,

					AI202946, BE409400, AW250560, BE408657, AA774739, BE514152, AI902442, AA448447, BE792882, BE269512, AW951942, W45258, AW381677, AW885253, BF125578, AW885254, AW996198, H48844, AA402390, AI874330, AA032143, BF806199, BC001299.1, AF004876, 1.
HMWDC2 8	207	460487	1 - 1132	15 - 1146	
HMWFT65	208	562063	1 - 1332	15 - 1346	AW795416, AL121287, AL133445.4, Z85996.1, AL034548.25, Z98304.1, AC004953.1, AC068799.14, AC074121.16, AC004905.1, AL031431.8, AC003982.1, AC006487.8, AC005971.5, AL050335.32, AL009181.1, AC010271.6, AC006483. 3.
HMWGY6 5	209	1308287	1 - 1960	15 - 1974	AW963001, BF059395, AW466899, BF590276, AIS82610, AI281917, AI983184, BE501967, BF848401, BE219310, AI359514, AI582296, AI033082, AW594623, AW770514, AI088503, AI307166, AI818405, AW272259, AI143722, AW204164, AI590378, AI285806, AA004670, AI580084, AA904597, R51653, AW293660, AA968840, AA358991, AI278964, AW970496, AA836864, AA699611, BF003024, AA292694, T05806, R51562, A1935808, AW243480, AW243365, R14788, AV741332, F37583, AA365140, AI814209, BE842966, AA004251, AW103604, R40100, H46612, AI270512, AA092304, A1989617, R63257, AV734885, AL161751.2, AL450109. 3.
HNEEB45	210	519340 1036397	1 - 876 1 - 1029	15 - 890 15 - 1043	BF095683, BF767062, AL121059, BE082604, AB011104.1, AP003473.2, AP001573. 3. AW007722, F08319, C14331, AW978633, D80132, AV718681, AW949655, L81855.1, AC003677.1, AC048330.20, AC018769.2, AL513342. 7.
HNEEE24	212	. 553558	1 - 1065	15 - 1079	BE695767, H18634, R44271, AA022988, AA454219, AA454220, AA022950, AA429414, BF112103, AI183463, AW293235, AA584870, AI608821, AA564655, AI467968, H69890, Z95152.1, Z77249.1, AC004837.1, AL050335.32, AC009399.5, AF222686.1, AD000090.1, AC069539.4, AC005000.2, AP0000427.3, AF039905.1, AC027319.5, AC004996.1, AC010328.4, AP000043.1, AP000111.1, AP001716.1, AP000424.3, AP000292.1, AC073321.4, AL133330.14, AL138743.5, AL050338.12, AL45423.13, AC068715.5, AC009003.7, AL450026.10, AC008493.4, AL355334.26, AC002300. 1.
HNFFC43	213	753337	1 - 2089	15 - 2103	678076, BF527660, BE728354, 530935, BE314879, AL042802, AS30935, BE314879, AL042805, W027201, A1424792, AL344032, S383358, A1499074, A1344032, F509684, BE208853, A1342638, I1904, AW961340, AI289643, AW769937, AA493773, AA298993, AA377693, AW7696, BE273248, AL039675, BE273248, BF919453, BF919451

	AW080090, Al367680, BF812961, Al619820, Al633125, Al828682, Al818240, AW152182, BF811804,
	A1796113, BF968679, BF669151, A1800648, A1500714, A1702073, A1884318, A1590043, A1868680,
	BG122005, AA740450, A1866469, A1971615, A1345415, A1934259, A1570056, A1433157, AL046466,
	AI819545, AI499570, AI698391, AI440448, AI915291, AI434731, AI445829, AI889189, AI638644,
	A1370623, AW188525, AW008226, A1699823, T69241, A1635634, AW148363, A1818350, AW089844,
	AI686817, AI376425, AI609375, AW051088, AI744268, AV736995, BF970652, AI569637, AW163834,
	AI270295, BE393784, AI471282, AW075381, AL043355, AI872423, AI801460, AI620864, W74529,
	AI421252, BF812938, AW081256, AI581362, AL513817, AW193911, AI670009, AI871697, AI537261,
	A1950729, AV709679, A1651840, A1281757, A1619502, A1591387, AW168822, A1473536, AW196720,
	AI345612, AI620056, AW834282, AL046595, AI677796, AI582932, N21402, AI922266, AI500061,
	A1474646, A1345416, AW079409, AA641818, A1621341, A1702068, AW081383, A1633198, BF814761,
	AI619662, T49776, AI565172, AI696714, AV747571, AI524179, BF766531, AI366900, AI521560,
	BF925771, AI927233, AI536638, AI479292, AI564719, AW027898, AI419826, AI432969, AI432030,
	AI799183, AW238688, AI932966, AI354643, AW168788, AI401697, AI357940, AI890214, AW078712,
	A1250627, A1636507, A1357273, A1634345, A1579901, A1352497, AV711455, AW104724, ALS14079,
	A1783825, A1612852, A1956080, A1524654, AW104827, A1445025, A1815232, AW198090, A1684244,
	AL513761, AW078606, AW083374, AA830709, AW192652, AK001356.1, AF260728.1,
	AL137599.1, AK001651.1, BC008337.1, AB033000.1, AF351620.1, AF183393.1, AL389935.1,
	BC003573.1, AK026408.1, AL117587.1, BC008591.1, AL080159.1, BC006103.1, AK026462.1,
	AL137530.1, BC002466.1, AK026744.1, AK026593.1, BC003101.1, AL133075.1, AL137537.1,
	BC005825.1, AK000418.1, AL136850.1, AL023657.1, BC001199.1, AK026389.1, BC004945.1,
	L19437.2, BC004349.1, AL122104.1, AL050149.1, AL389982.1, BC006181.1, BC001964.1,
	AB047878.1, BC002631.1, AL050138.1, AB050410.1, AB050421.1, BC006345.1, AK000414.1,
	X82434.1, BC008364.1, AL080146.1, BC004925.1, AB060897.1,
	Z82022.1, Bo
	AL117416.1, BC008717.1, AF132730.1,
	AK025889.1,
	AL583915.1, BC001655.1,
	AF205073.1,
	AL133077.1, BC006487.1, AK027096.1, BC001785.1, AK027173.1, BC006410.1, S77771.1,
	AL133062.1, AL050143.1, A
	BC005678.1, AL080154.1,
-	
	AL442083.1, AL137574.1, AF285167.1, BC005002.1, AF169154.1, AF038847.1, AL136615.1,

AW973541, AW966030, AW964488, AW949641, AV720791, AW952852, AW966054, AW949645, AV720203, AW964756, AW966050, AV719188, D80043, D80227, AW949657, AW966062, AV719783, D59502, AW965028, AW966073, AW965177, AW959570, AV719468, AV718800, AW965185, AW965197, AW965196, AW973485, AW965177, AW959570, AV719468, AV718800, AW965197, AW965196, AW973485, AW965184, AV720104, AW965175, AW966400, AW962395, D80196, AV718844, AV720464, AV718770, AV720150, AW966380, AV700229, AV724520, AW959062, AW964477, AW956434, AV699550, AW949653, AW96633, D801026, D80261, D80261, D80611, D806122, AV72033, D80269, AW976523, AW996632, D80133, D50979, AV750778, D80522, AW966343, D80157, AV719945, AA305578, C15076, AV718530, AV719632, AV718487, D89653, AV719049, AV723097, AW966043, AW965176, AW973465, AW966136, D80157, AV719045, AW949633, AW978649, AW978642, AW966389, AW966329, D80157, AW949632, AW949638, AW978649, AW978642, AW966377, D80378, AW9750137, AW966023, AV720035, AW9660377, D80378, AW975033, AW177440, D51103, AV720035, AV702035, AW966379, AW178893, AL0223391, AL021937.1, AB028859.1, AF058696.1, AB002449.1, AF271371.1, X67155.2, D34614.1, AB038216.1, D88547.1, D50010. 1.	AW275971, AI369580, AW576034, AL3353692.14, AC004638.1, AC027319.5, AC007011.1, AL354932.26, AK000932.1, AC074121.16, AC019171.4, AL390374.16, AJ400877.1, AL109897.30, AC008403.6, AL121929.17, AC016025.12, AC002390.1, AL360227.17, AL049709.18, AL353777.18, AC004890.2, AC005098.2, AC005015.2, AL354794.16, AL590762.1, AC0020931.5, AP001695.1, AC005052.2, AL131754.18, AC073655.26, AC004166.12, AC005225.2, AC010328.4, AC005052.2, AL131353.6, AC004166.12, AC005225.2, AC010328.4, AC004876.2, AL133353.6, AC003962.1, AL131972.17, AC011472.7, AC011462.4, AC073316.6, AC079602.15, AC003962.1, AL21972.17, AC011472.7, AC011462.4, AC073316.6, AC079602.15, AL33453.3, AC011514.3, AC008072.3, AC009123.6, AC006130.1, AC005899.1, AC005800.1, AC016995.4, AL021368.1, AC005280.3, AC020629.6, AL445490.6, AP000067.1, AC016995.4, AL213347.14, AC010203.13, AC004893.1, AC004910.1, AC005041.1, AC016203.13, AC004891.1, AC016203.13, AC004910.1, AC005041.19, AC065282.6, AF111168.2, AC005089.2, AC004910.1, AC01643.6, AC06544.19, AC065491.1, AF001581.1, AC0102984.1, AL133246.2, AC006549.1, AL133246.2, AL336299.16, AC0050841.1, AC005051.2, AC006519.1, AC005051.1, AC005051.2, AC006519.1, AC005051.1, AC005051.1, AC005051.1, AC005051.1, AC005051.1, AC005051.1, AC005051.1, AC005051.1, AC005051.2, AC006519.1, AC005051.1, AC005051.1
	15 - 1042
	1 - 1028
	499076
	219
	HNGEP09

	-				AC018653.29, AL138499.4, AP000486.5, AC072061.8, AC005181.1, AL137818.3,
					AC005844.7, AL139396.17, AC025165.27, AP000080.1, AL334696.11, AC008651.7,
				•	AL354861.11, AL157915.3, AC010585.6, AC007256.5, AL513548.8, AC005779.1, AC007912.6,
				~	AC002302.1,
					AL139095.15,
					AL137782.9, AC016950.8, AL133328.13,
					AC025207.5, AL357150.7, AC008536.6, AC005291.1, AC0052507.5
					, AL354816.5, AL513342.7, AL390039.10, AC002990.1,
					AL022069.1, AL355343.18, AL160411.25, AC005036.1,
					AC002996.1, AL049835.3, 7
					AC020558.4, AL583856.6, AP002392.3, AL031643.1,
					AC005079.6, AC009953.4, AL121865.7,
					AC002395.1, AL391601.6, AC073125.5, AL161892.9, AL133377.5, AC019184.3, AC009137.6,
				-	Z84483.1, AC002381.1, AC017099.11, AL162426.20, AL136234.12, AC009955.4, Z99716.4,
					AL117337.25, AL138743.5, AC011005.7, AC007543.4, AC004847.3, AC008901.5,
					AC009961.11, AL135783.6, AF229163.1, Z84480.1, AL122057.4, AL035455.30, AC016644.7,
				•	AJ400879.1, AL590387.7, AL158828.14, AC089985.14, AC069548.4, AC016831.1,
					AC027129.5, AL022165.1, AL162503.12, AL022067.1, AC016705.4
					AP001727.1, AC008268.3, AL049646.19, AC006461.2,
	7				AL445483.13, AC007345.5, AL442167.1, AC007956.5, AC006544.19, AC008569. 6.
HNHFM14	ᆲ	664507	1 - 283	15 - 297	AC020552.4.
HNHF029	231 4	463568	1 - 685	15 - 699	N68677, BE063506, AA659190, AW063123, AW797598, AW337282, AW074332, BF844388,
					AA573067, BF844391, AA504679, AA578326, AW499708, BF678990, BF913236, AA749062,
		-			AA330576, AC060231.6, AC022027.5, AC023105.7, AL031005.1, AC007221.2, AP002852.3,
					AP000907.5, AC007541.9, AC020663.1, AC007263.4, AC027124.4, AC004217.1, AC008569.6,
					AL034379.8, AL022311.5, AF001551.1, AC011472.7, AC012512.7, AC009244.24, AL590763.1,
	<u>-</u>				AC018695.6, AL353804.22, AJ295844.1, Z79488.1, AC011114.5, AC011465.4, AC004159.1,
					AP000338.2, AL354735.14, AL031120.1, AP000216.1, AC073316.6, AL031597.7,

				AL138724.12, AL121759.25, AL049793.4, AC018868.4, AC007225.2, AC012085.4,
				AC007110.3, AC005335.1, AC007365.3, AC007298.17,
				AC004477.1, AL139105.17, AC002045.1,
				AC011500.7,
				AC011475.6, AC073542.4, AC006139.1,
				AC010422.7, AC011479.6, AC010878.4,
				AL160492.5, AF172277.1, AC010768.9, AC005516.1, AE006639.1,
				AF228703.1, AF095725.1, AC020983.7, A
			-	AC091529.1, AL139035.27, AC002126.1,
			_	AC007064.27, AC004231.1, AC005940.3, AC006213.1,
				AC005829.1, AC025457.5, AC002401.1, AL096791.12, AL162724.16, Z83838.2, AC006581.16,
				AL445263.6, AC011443.6, AC005323.1, AL441883.11, AC005031.1, AC004867.5,
	_			AL445465.10, AC090937.1, AL139317.5, AF126483.1, AL445483.13, AC011461.4,
				AL121591.3, AC006011.2, Z82215.1, AL109613. 11.
HNHNB29 232	2 895462	1 - 1880	15 - 1894	A1049955, AA904211, A1921765, AU146342, R98218, BF725178, BF337320, AA515728, AL524675,
				BF772474, BG057207, BE675681, BE063437, BF804385, AI962030, R74433, BF724699, AV656063,
				A1499954, A1653776, A1523074, A1362442, AU118374, AW023302, AW957372, BE150793,
				AV763026, AV763058, BE281645, AW410354, AL038842, AW963444, AW403829, AA503298,
				AI709307, AW023111, AA825827, AV756491, AU158454, BF877926, AA713705, BG236484,
				A1735609, AW082104, AW780190, AV760014, A1254779, AA558404, AV719392, AA502532,
				A1114704, AA833875, AA833896, AA832145, AW957600, AA644090, BE072475, AW575605,
				AV703785, AW503420, AW973992, AI802087, BE301610, AW302017, AV738383, AW237905,
				AI859438, BF760573, AW962611, AV733437, BF944736, AV647070, AW513789, BG110818,
				AA581247, AI687343, BF854308, AW970958, AW615560, AI755057, AU157093, AI821987,
				BG222875, AA714110, A1732869, AA811741, AW849714, AL079734, A1889995, AA452887,
				AW978041, AV740009, AV764259, AA084609, H63660, AI587349, AW965008, AW190484,
				BE677244, AW501542, AW236219, BF217723, AA056248, AW843204, AV695478, AA633875,
				AW978591, AW192373, AW957154, AA604831, AW303872, A1141130, BF977305, AA297776,
	_			A1160786, AU151428, AU150634, AW083934, AA613624, AW051819, A1961983, BE968477,
	· -			AW510513, AI417469, AC084881.19, Y10196.1, AL357515.26, AC005736.1, AL139396.17,
				AL356415.26, AC006241.1, AC006121.1, AL590763.1, AL022316.2, AL096677.21,
				AC016597.4, AF053356.1, AC002996.1, AL158040.13, AC012320.6, AC013434.8,
				AL109843.25, AC009194.8, AL356020.3, AC002425.1, AL133448.4, AC020916.7, AC005081.3,
				AL161731.20, AC078846.2, Z83819.1, AC011247.10, AL139317.5, AL022323.7, U95090.1,
				AC007225.2, AC083884.6, D86995.1, AC020913.6, AL356915.19, AL050349.27, AC023425.20,
				AC034242.5, AP001705.1, AC008946.6, Z95331.2, AP002008.5, Z98752.16, AC005920.1,

					AL157838.24, AL135839.15, Z93023.1, AC002045.1, AC005522.2, AC010419.5, AC016655.6, AC008616 6, AP001718 1, A1161669 5, A1013584.25, AP001752 1, AC00369 1, 1195739 1
		-			AC015982.9, AL121586.31, AC009087.4, AC026202.6, AC008733.7,
	•				AC005015.2, AL023575.1, AC007685.2, AC008397.7,
					AP001922.4, AC011442.5, AC006430.22, AC008766.4, AL132639.4,
	-				AC006334.3, AC002492.1, AL157372.18,
	_				Z99716.4, Z83844.5, AP00
	-				AC007404.4, AL022326.1, AC018523.9, AC008755.6, AC008622.5,
					AC000353.27, AP001728.1,
		-			AL049643.12, AL392106.4, AP001711.1, AC006028.3, AC008745.6,
					AC025280.4, AC010150.3, AB001523.1, A
			-		AL138920.11, AC010271.6, AC022116.5,
-	_			_	AL139353.3, AF139813.1, AC007462.2,
					AC022217.5, AC009165.6, AC004491.1,
		•			AL162584.9, AB000882.1, AL121652.2,
					AC022425.6, AL031843.2, AL163032.3,
	-				AL049757.14, AP001753.1, AC007249.5,
					, AC072052.6, AC027644.9, AC011508.4,
	_				, AC004840.3,
					AL118497.9, AL137078.20, AL022159.1, AC003025.1, AC005014.1,
					AC007242.3, AC084865.2, AL109759.4,
					AC006013.3, AC006205.7, AC084732.1, Z98044.13, AL137853.12,
					AL078461.38, AC008264.10, Z83826.12,
			-		, AD000671.1, AF312915.1, AF279660.2,
					~
					AL354928.9, AC002314.1,
	_				AC004477.1, AC008738.6, AC003085.1, AC004230.1, AJ295844.1, AC007114.7, AL109801.13,
		_			AC005057.2, AC020915.6,
-			-		AC007664.12, AC009220.10, U91326.1, AL031433.4, AP001727.1, AC004757.1, AL109798.19,
					AC008074.3, AC003962.1, AC005228.1, AL133551. 13.
HNHOD46	233 8	843488	1 - 1341	15 - 1355	AV700498, BG164166, AV700988, AV700545, AL037632, AV762783, BG260565, AV714931,
					AV760723, AF074667, BF792326, AF034176, BE796439, AW962035, AW976010, AA524604,
					AV760360, BE541237, AU118837, AV719941, BF678427, AL138265, AW188427, AV733710,
					AL048626, AU117926, BE909125, AV764490, AU119532, BE067011, AL534817, AV699709,
					AV686853, AV722030, BE393367, BE538259, AA708751, AI732911, BF346320, AW970915,
					AA526787, AW131249, AU147226, AV763174, AV760497, BF805173, BF968141, AV762900,

AV759711, AV759356, AV760364, BF307044, AV762902, BF679169, AV759686, AV762779,
AW963982, AL042906, AV759684, AV762001, AV759683, AL135377, AV734543, AW408643,
AU155227, AV759046, AA601355, BF913258, BE273856, AL044340, AA081138, AI952885,
AA584482, AV734401, AL042905, AV722075, AV737621, BF666736, AA211734, AW080062,
 AV762002, AV761309, AI791227, AW961160, AV763305, AI038990, AV759172, AW102955,
AA708108, BF381650, BF828714, AI685198, AI679294, BE066950, AV763952, AA831913, AI679871,
AU145521, AI204309, AW151713, AW069670, AA481760, BF892846, AW130036, AV763135,
AU140392, AA284247, AW102811, AA722372, AW008212, AU158859, AA640277, U51704,
 AU155168, BG258140, AW088689, AU155048, AA577824, BE387734, BE867712, AL119123,
 AW079809, AA601326, BF968610, AA515829, AC008440.8, AC011531.7, AC002302.1,
 AC027319.5, AC005484.2, AC005972.1, AC010469.7, AL109743.4, AC005077.5, AL035398.19,
AC020916.7, AC022211.5, AC002301.1, AC018808.4, AP001711.1, AC008745.6, AC000052.16,
 AC008720.6,
 AF045555.1, AC007374.6, AL096814.26, AC005081.3, AL445685.17, AJ400877.1,
AC008443.8, AL031447.4, AC006028.3,
AL121992.24, AC011465.4, AC008655.6, AC008616.6, AL135928.6, AL513550.9, AL031295.1,
AC011005.7,
AC007000.2, 1
AC002477.1, AC011443.6, AC018751.30, AC008622.5, AC023058.17, L78833.1, AC007956.5,
2072052.6, AL137067.7, AC
AC018506.4, AP000116.1, AL135927.14, AC007227.3, AL445248.7, AL590763.1, AC005914.1,
ALI58207.15, AC010320.9, AP000557.2, AL050318.13, AL139809.16
 AC004882.2, AC007731.14, AJ312686.1, A
, AC027130.5, AC087590.1, AL513008.14, AC005520.2, AC005088.2,
 AC008551.5, AL109976.23, AC011461.4, AL132639.4, ≠
t, AC006930.1, AC007318.4, AC005098.2, AC005399.19, AC005529.7
 AL031584.1, AL160471.5,
AC011890.4, AC005231.2, A
AC010328.4, AC073657.5, AC006120.1, AL117692.5,
AC022382.3, AL445435.11, AC005722.1,
 AL163636.6, AL049766.14, AL137792.11,
 , AC020983.7,
AL022312.7, AP003357.2,
 AC008760.6, AL450226.1, AL163249.2, A
4C091118.2,
AC008755.6, AF001549.1,
AF064861.1, AC011247.10, AL354808.24, AP001718.1, AL355480.22, AC005015.2,

					AL079335.29, AC002299.1, AL035086.12, AC005368.1, AL357515.26, AF168787.1,
					AC010458.5, AF196779.1, AC006285.11, AC010422.7, AC010463.6, AC004813.2, AC024561.4,
-					AC005280.3,
					AC004257.1, ALU35329.25, AL353092.14, 233025.1, AP001725.1, AL357300.11, AC022201.8, AL031681.16, AC025166.7, AC007999.12, AC005874.3, AF134471.1, AC016025.12
					AC004148.1,
					AC011442.5, 1
_					AL136300.22, AC006337.4, AL157838.24, AL158040.13, AC006970.6, AC007488.15,
					AC000026.3, AC008687.4, AC018720.5, Z84487.2, AL445222.9, AL132855.4, AC006480.3,
					AL031286.1, AC004906.3, AF196971.1, Z83843.1, AC003043. 1.
HNHOG73	234	835026	1 - 788	15 - 802	AA584096, BF853760, AL137798.8, AL049569.13, AL137802. 7.
HNTBI26	235	1310821	1 - 1368	15 - 1382	AL528533, AL520935, AL521290, AL515806, AL520965, BE293492, AL520936, AL515807,
					AW972854, AV753139, BG178370, BF968317, AL520966, BE780476, BE305183, AI678037,
					AW293248, AL521291, Al269883, BF978348, AA894746, Al493776, AA778869, Al424848,
					AAS2S497, BF307374, AA622403, BG109953, N21347, A1095265, BF792489, AL519236, AAS64674,
					BE249905, AI268502, AA995849, AA894745, AI249680, AW087844, AI300762, N72839, AI244187,
					A1089147, A1368934, A1740804, A1339842, AW516709, BF315359, A1335796, AW192649,
					AW801578, N28008, A1095231, BF977145, BF977663, BF765528, BE778762, BE875935, A1951011,
					BF669511, BG033337, AW393151, AL519237, AW819092, AW393138, BE868896, AV691113,
					BE875559, AV693124, BF976999, BF690855, A1127890, BE293585, AW984556, BF994881,
					AW090182, W76593, AA362394, AI906642, BE741647, T57136, AW753803, BF813621, AA533658,
					BF882501, AI638644, AI370623, AI698391, AA806720, T49776, AW008226, AI568293, AI332957,
					BE393784, AI590043, AI954721, AW128834, AI364167, AI419826, AW166870, AI884318, AI685005,
					A1473799, A1699823, A1440239, A1956080, A1393038, A1889189, A1621341, BG119543, AW166583,
					AW105296, AI580451, AI634345, BE966496, AI619820, AI570807, AW834282, AI499570, AI500113,
					AI620864, AI684369, AI633125, AW983832, AW103928, BF752997, BF727091, BF761618, AI254731,
					AW087934, AI802542, BE964556, AI927233, AI538564, AI270706, AW148882, AI915291,
					AW152182, N21402, AL046466, AA019328, BF811804, AI678446, AI473536, BF669151, AA102339,
					AW130362, AI653402, AI869765, AI270183, AI613038, BE965129, BG122005, AI950729, AI540821,
					A1700358, A1266652, A1701097, AW004606, AW198090, AW262552, A1934011, A1282669, A1349482,
					AI612913, AW084873, AI125015, BE963426, AI695857, AI636588, AI610446, AI572096, AI689157,
					AW075671, BF812960, BF996654, AI799183, AI687127, AI866419, AI824688, AI866040, AI824576,
					BE895003, AI683563, AW029489, AI540350, AI499890, BE963355, AI951950, BF724420, BG251076,
					AI421149, AI567513, AI866469, AI932966, AW129659, AI474146, AI298321, BE275487, AI816306,
					BE961919, AI539260, AW243451, AL080011, AA878142, AI567769, AV720998, AI524626, AI096481,
					A1470717, BF814527, AW102794, BE963310, A1478723, A1800341, AW089726, A1912434, A1648509,

A1499963, A1673363, AF086351.1, AL117587.1, AL080156.1, BC008591.1, AB056106.1, X78627.1, X99971.1, BC004945.1, AL080159.1, AL080199.1, BC003573.1, AL080148.1, AL080146.1, AK027095.1, AL136752.1, AC004942.1, AB047627.1, X68560.1, BC004416.1, AL133619.1, BC006181.1, AL133084.1, AF044323.1, BC004373.1, AK027052.1, AK026408.1, AL133653.1, AL13359.1, AL133089.2, AL162066.1, AK025350.1, AL130880.1, AB056420.1, BC006345.1, AB050431.1, BC002349.1, Y14314.1, AK026310.1, AL137682.1, AC006288.1, AF115392.1, AK026182.1, AL133062.1, AL162729.8, BC008708.1, AK026746.1, AL357195.1, AL050155.1, BC002491.1, AL37478.1, AK000484.1, AJ299431.1, L25851.2, AC016706.6, BC004349.1, AL137478.1.	15 - 791 AW169270, BF475369, AL524823, BE9039 BF033804, AA716162, AW183635, AI1882' BE903838, AI828817, AI308087, BE544869 AW615124, AA701470, BF447518, AW025 AW304333, AI239598, BE697836, BE74266 AW376334, AW376337, AW152527, AW19	1-2149 15-2163	85 1 - 2073 15 - 2087 AA447485, AA196688, M86015, A1750365, R13985, BF356780, N28763, AC005028. 1.	1 - 1925 15 - 1939
	236 545534	237 1160395	$\vdash \vdash$	240 422913
	HNTBL27	HNTCE26	HNTNI01	

					AV741009, BE835410, A1084517, N83238, AW362842, AA247541, R31089, T91125, AA493776, BE818350, BE818352, A1253986, R31247, AW303285, N95696, BE708493, AA678297, A1003856, BE818343, N95562, AW024721, AA862707, N95587, AA401399, AA399957, AW511080.
!					AL157879.7, AL021368.1, AL009030.15, AL049987.1, AL133255.13, AL390738. 4.
HODGE68	242	834907	1 - 837	15 - 851	AW812930, AI741403, AI193921, AA292663, AW812933, AV707090, BF892766, AA528261,
					AAS13570, BE152032, AW812788, AL139296.4, AL355886.4, AL512449.6, AL360179.8,
					AC005284.1, AC011246.6, D84394.1, AC034245.4, AC012361.10, AL133373.5, AC027287.20,
					ALU/8034.24, ACU12039.10, AB020803.1, ALI38004.10, ALI38/38.1, ACU34240.4, ALI31575.24, AC016045.8, ALI37819, 15.
HOEDB32	243	634994	1 - 1448	15 - 1462	BE728085, BF525463, AL043598, BE379024, BE729709, BE388931, BF058202, BE389160, BF219910,
		-			AA937045, BE888648, BF983683, BF058514, BE729777, BE386542, BE270287, BF220144,
					BF732488, BF205132, N37022, A1806995, BE302761, A1218926, A1040017, AV700992, BF204637,
					AW269653, AW664365, BF851636, AA558441, AI971923, BE389935, AI971822, AI984087,
					BF109553, BE149505, AI371806, BE466285, N63999, AI218921, BE896831, AW105333, AW264122,
					H97490, BF830445, AW410288, AW856197, AI041603, AW469216, N28797, BE379424, AW662759,
					A1218000, A1283819, AA789225, AA916425, W67366, A1354311, AW517796, A1343922, AA872912,
					BE207555, AW410287, AI751344, AI537028, AW379887, AI469495, N23215, AA305895, AV700226,
					A1399649, AW602751, A1857609, BF832669, BF738545, BF732356, AW960917, W67367, A1093054,
					AW132083, AA613324, AI220983, AW241183, AJ239424, AW876666, N32087, AI126987, AA722964,
					BF361409, AI312696, AI193728, H93764, W24695, H11009, AW876671, BF515670, AA166810,
					AI754948, AA166918, N93890, N93062, H92111, AI208255, AA994700, AA341436, AL043597,
					AI751345, T58592, R57961, BF929058, AI015141, AA375135, C01839, H14764, AW889983, D12283,
					BF755440, H06898, A1868297, AA594530, AA303707, AA535409, AA373071, AA885934, AA359174,
-					AI280938, D83887, AW889975, N88528, BE673462, AA341295, BF088497, AA090557, H06857,
					BF512261, BC000526.1, AL117619.1, AF132000.1, AC003687.1, AL049873.3, AL450324. 10.
НОЕМОЗЗ	244	1184465	1 - 2396	15 - 2410	AL528504, AU121718, A1820674, T94707, AJ224741.1, Y13341.1, AC079145.3, AJ001047. 1.
HOFMT75	245	911180	1-2117	15-2131	AL532142, BG260401, BF688316, BF796465, BE907259, BE878185, BF311180, BF182869, BF793219,
					BF528084, BG164901, BF025894, BF343463, BF027348, BE615276, BF339485, BG251657, BF340866,
					BE869513, BG168879, BF312304, BF344218, BG035574, BE909308, BF317451, BF346215,
					BF569244, BF569508, BF341893, BG164819, BG251015, BE876727, BE314260, AU119847,
					AW732268, AV691326, BF346288, BE907910, BE792057, BF314016, BE386414, BE787546,
					BF337708, BE384083, BF032872, BF308223, BF982476, BF313919, BF967499, BE272948, BE878890,
					BE272586, BE878055, BF853224, BE386215, BG035861, BF686718, BF569555, BE907675,
					AL036113, BE262510, BE261041, BG114738, BF315298, AU141949, BG171668, BE383392,
					BE906327, BF316184, BF846927, BE871813, BE780677, BE266551, BF316458, BE793972, BE870259,
					A1869324, BG171700, BG251535, BE302664, BE261412, BE905686, BF314291, BF528326, BE018644,
					BF846926, BF338012, BF344721, BE170034, BE797588, BF725914, BF313723, BE295702, BE539065,

BE789580, BF526208, BE547474, AA433879, BF312413, BE735885, BE260798, BF724105,
AW601604, BF724433, BE736776, BF314509, BE906884, AL526830, AW068684, BF312224,
BF807244, BE890682, AL045190, BF344403, AW239170, BG165173, BE382506, BF872251,
BE909949, AW630822, N20475, BF026564, BG178360, BE294687, BE867221, AW403966, BE392521,
BE167525, BF985419, AW179034, BF872266, BF743019, AW239410, AW375966, BE277237,
BE276165, BE276172, AW402407, BE543928, BE062186, BF378665, BF087437, BF880137,
BE567147, BE938659, BE617502, AW067770, BF868761, BE336783, BE312715, AA057554,
 BG004418, BF985426, AW841776, BF851414, BF872268, AA410697, BE908992, BF883702,
BE538481, AW884175, AI752785, BE542584, BG168264, BF883546, AW067904, AW068103,
BE697629, BE697634, BF764898, BF870917, AW797744, R88501, AA074710, BE697637, BE717209,
BF761588, H10878, BG164643, AI868439, AA603295, BF125971, AI751896, BF063288, BF846855,
BG116325, BE174856, BF880542, BF304390, BE875185, A1909381, AW889411, BE796125,
BF724712, R87863, BF817489, BG167275, BF380296, BF087740, BE006180, BF087690, BE075860,
BE905813, AA852669, R88022, BF087652, BF087788, R87854, BF815395, BF354394, BE932097,
 F05545, BE707522, AW372168, M11233.1, X05344.1, M63138.1, M63135.1, M63136.1,
 BC008983.1, AK024538.1, AK026534.1, BC008382.1, AB056768.1, AK026592.1, AF090900.1,
 AK026464.1, AK000432.1, BC004370.1,
AB063084.1, AL080127.1, AL136768.1,
 AK027116.1, AL050393.1, AL512718.1, Z82022.1, AL
AF271350.1, AL122121.1, BC005890.1, BC003687.1, BC006164.1,
AF177336.1, AL117585.1, AL050108.1, AL136799.1, AL050138.1,
AL512719.1, AK024524.1, AB056420.1, AF207829.1, AB063079.1,
AK026542.1, AK000137.1, AL049464.1, AL359618.1, AL050277.1,
, AK025524.1, AK026532.1, BC008488.1, AL442072.1,
AL049466.1,
AL049382.1, X69819.1, Bo
AL133072.1, AL136787.1, AF104032.1, X72889.1, AF003737.1, BC
 AL512684.1, AL080159.1, AL133640.1, AB060883.1, BC005678.1,
AK025092.1, BC001045.1, AL136915.1, AK025632.1, AL133016.1,
 AL157431.1, AF146568.1, AL133565.1, AB019565.1, AL136805.1,
AL512733.1, AB060825.1, AL359615.1, AL359620.1, AL136928.1,
 BC005168.1, AL080124.1,
BC008417.1, AK026597.1, AK025414.1,
AB060852.1, AL162062.1,
 AJ012755.1, AL137556.1, AF090934.1,
AL050024.1, BC002839.1, AL110196.1, AL512761.1, AB047615.1,
AL359596.1, AL050172.1, AB055366.1, AB060929.1, AL137538.1, AK027164.1, AK026630.1,

				AL136843.1, AB055303.1, AB060887.1, AK025312.1, BC003684.1, AK025772.1, AK025484.1,
				AB047801.1, AB062938.1, AL133557.1, AL133075.1,
				AL133077.1, AL133014.1, BC008365.1, AL133113.1, AL137527.1,
				BC006195.1, AB051158.1, AB055361.1, AK026855.1, AL389939.1,
				BC007021.1, AF125949.1, AB055315.1, BC007326.1, AK026533.1,
				AL049452.1, AK026504.1, AK026526.1, BC005151.1, AB048953.1, AL137550.1, AB063070.1,
4	\dashv			AB047904.1, AB056427.1, AL049314.1, AL117583. 1.
HOFNY91 2	246 847425	1 - 2392	15 - 2406	AL529530, BE896219, BE905006, BF701370, AV726968, BF697098, D56471, AA398982, D54791,
				AW952054, D54998, AA137223, D52957, AL529529, BF667411, AV722244, BE539516, AW603940,
				BG252620, R33682, D53702, AL537902, BG171582, AW752566, BE874188, R79409, BE891332,
				BE888598, BG180774, AA702285, D52438, AA306169, F00618, M78614, AW965817, BF515338,
				BF091420, AW847750, AA307191, AA446770, BE785930, AW157201, AW801965, BF031768,
				T31797, BF031629, AA658190, D52945, BE565940, AA157919, AA136378, AA150656, AW162647,
				AA282187, AI684319, BE540207, BF028795, H22397, AW847690, AW293605, AI457838, AA938423,
				T36093, BE878093, T30493, BG251689, BF341242, AW847685, BG169305, BF115649, BG166888,
		-		AV727838, BE739764, BF207904, BE738987, AV725549, AV726582, BE865924, BE866601,
				BE811512, BF028097, BF028440, AA155611, BF030153, AW070701, AA357234, D55509, BF028402,
_				BF208666, BG054885, BF947687, AW997229, BE699329, BG164817, AV727582, AW750879,
				BG258115, BF446900, BG151519, BF001920, AW300512, AA639868, AA256021, W23904,
				BE866188, A1925691, R56031, AW379828, H08997, A1904379, A1632020, AW029553, A1950933,
				BG104880, AA828915, AI904416, AI986473, BF131266, BF588526, BF433181, AI125136, BF476107,
-				AW770808, AA399621, AW801803, AI978599, AI700677, BE184726, BE184725, R35739, N52155,
{	7			AB024334.1, AK024230.1, AC006388. 3.
HOFOC73 2 [,]	247 931871	1 - 1477	15 - 1491	BF195687, AI762843, BF435173, AW167715, BE675436, AI829951, BF195590, AW517368,
				A1831464, BF110813, BF939079, AW573230, BE747230, A1760936, BF348602, AA418800, A1870845,
				A1420441, A1377190, BF196297, N32270, A1813507, A1313119, A1472198, A1340272, AA502942,
				A1363372, A1806717, A1479956, AA861188, A1073435, A1128897, A1799480, N35138, AA832426,
		-		AW753935, AA421515, AW362239, AA258517, AI907351, AA789084, BF924856, H42825, F35882,
			-	BF814541, AW409775, AW265004, AA830821, AW089179, AL133741, AA835966, BG029053,
				BE781369, A1696969, A1565172, AW089006, BE965169, BF527012, AA807088, BE048071, A1567637,
				AW088899, AI571868, BF725863, BF970263, AI244380, AL119791, BG058039, AW020419,
				BE964497, AW999906, BE785868, AI400725, AL046463, AI874166, AI922577, AI874151,
				AW081034, AI620093, AI282903, AI280661, AW193203, AA603709, AI570966, BG260144,
!				BE061389, AI537617, AI919345, BG027628, AW130863, BF915537, AW834355, BF815196,

A1648567, BE963918, BF915208, BE072233, A1952302, A1805638, A1366549, A1636719, A1539153,
BEY64/6/, AW085/86, BE538466, BFY04180, BE1/24YY, BEY65286, ALU36638, A185/700, AA568405, A1611743, A1689420, AW083804, A1696626, A1633477, AV757067, A1589993, A1365256, A
T99953, BG105895, AL038505, BF814449, AW022682, BE393551, AA464646, AI963062, BF817746,
A1886055, A1472536, A1677797, AW999599, AF009923.1, AL109840.24, AC010102.3,
AF136273.1, AF032906.1, AF136275.1, AL389978.1, E
AK000137.1, AB063079.1, AL359600.1, BC004265.1,
AB063074.1, AF188698.1, BC007355.1, AK000421.1,
BCUU8382.1, BCUU4908.1, AL539620.1, AKU2/868.1, BCUU/430.1, JU3U32.1, AFU3V680.1, A 113700.1, BCUU783844 A 113700.1 BCUU78844 A 113700.1 BCUU78844 BCUU450.1 BCUU78844 BCUU788
BC008488.1, AF125949.1, BC000556.1, BC008893.1, AL080060.1,
AL389935.1, AB019565.1, BC005007.1, AK025708.1,
 AL136692.1, AL050277.1, AL512719.1, AF067420.1, I
AL137521.1, U91329.1, AL137665.1, AL117432.1, AF271350.1, AL133104.1, AL110196.1,
 AK000445.1, AF218014.1, BC006164.1, AK026522.1, AK026626.1, AL133081.1, AK025958.1,
 U77594.1, U
 AB060211.1, BC008785.1,
BC006201.1, BC006412.1, S76508.1, AF081197.1, AF081195.1, BC
, AF348209.1, AL353625.5, AL117648.1, AL137429.1, AK026533.1,
, AL512761.1, AF305835.1, AB049758.1, AF217991.1, AL122121.1,
 AF091084.1, AF162270.1, AF159141.1, AK026642.1, AB060905.1
AK027081.1, M92439.1, AL390167.1, AL080086.1, AL080074.1, Bo
 AB063070.1, AK000432.1, BC003602.1, AB050510.1, BC007391.1,
AB060852.1, AF303581.1, AF178432.1, AL136586.1, AL389939.1, A
 AB047615.1, AB047897.1, BC008040.1, BC008280.1, AK025573.1,
BC007998.1, AL442072.1, AL137527.1, AL050393.1, AK000450.1,
AL136790.1, AC006451.5, AF012536.1, AL049460.1,
AL133645.1, AK025375.1, AK025541.1, AB063084.1, AK026452.1, U00686.1, AF040751.1,
$^{\circ}$
BC004533.1,
BC009403.1, AK000391.1, AB048964.1, AK025391.1, AK026528.1, AF245044.1, AK026597.1,

					AL1220501. BC008899.1. AK026855.1. BC001967.1. AK026164.1. AF225424.1. AB047941.1.
					X69819.1, AK026959.1, AL117583.1, AL136844.1, AL133098.1, AK027182.1, AL512746.1,
HOGAW62	248	168615	1 - 557	15-571	BF673679, BF340318, BF681126, AW630816, AW630056, BF684524, AI471808, D31084, BE932204, BE778532, Al365605.
нонсн55	249	827481	1 - 2485	15 - 2499	AW967050, BF793252, AA150407, A1889756, AW068908, A1539422, A1189000, AA149419, AA047109, AW304902, A1750990, A1123024, AA317245, A1752854, A1095919, A1984090, A1679980, A1954496, AA047265, BF749346, AW068311, AA136657, AA417383, AA446268, BE763257, AA136596, AA852682, BG222753, AA150286, AA417352, N52533, N52541, AA149305, A1129506, AA723730, BF987955, C01867, AA445992, BF928215, AF072752.1, AB008375.1, AL160153.11,
НООВ182	250	1352356	1 - 3516	15 - 3530	BE904978, BE383830, BE890564, BE729647, BE732309, BE789481, BE886173, BE733387, BE904978, BE383830, BE890564, BE729647, BE732309, BE280391, BE515074, AI459129, BE281548, BE386405, BG258301, BE383286, BF125887, BE777790, BE280391, BE515074, AI459129, BE281548, BE644930, AI660728, BE894488, AW749978, AW169336, AW370341, AA719364, AW452738, BG256682, BF439379, AI361918, AW188152, AI690424, AI810025, AA281766, BE890960, AI150426, AI58146, AA6340686, AI160979, AI741787, AA634292, AW264224, AA824631, BE207252, AW900280, AI689370, AA633695, BF125572, AA351589, AA769227, AI351341, AW0295513, R41719, AI875709, AA634567, AW269038, AA351643, AW674550, R36553, H23984, H22704, AI819095, AA984407, AA355743, AW408651, AA973659, AI538888, T58501, AW661810, AA649086, AI933293, AI673569, BG057154, AI364341, R32827, AA973736, AW273585, AI497846, BF755875, BF927524, AW026761, T99539, R27062, AA280121, H63038, R32930, AI57859, AI796641, BF927128, AI250269, D81030, AA693444, R27063, AV723591, R06448, AW375956, N56014, AA126901, AW802995, BF346206, AW410405, BF307973, BF755869, T58551, AA905213, BF346212, AI3052226.1, AJ3052227.1, AL136564.1, AL035681, 13.
HOSBY40	251	589431	1 - 1131	15 - 1145	BE465874, BE465890, AW418562, AW814995, AA721114, AC002543. 1.
HOSDJ25	252	854234	1 - 2200	15 - 2214	AL521533, BF966564, BG109192, BE621548, BG259805, BF666690, BF667661, BF185318, BF666019, BE621125, Al433432, AW963800, BE883279, BF028488, BF667980, BF196902, BF111775, BF667265, BF664922, BF966437, BF667218, AI277896, BF028500, Al401346, BF696865, BF698781, BG169528, BF696312, AW338135, A1280253, AA873621, A1435513, BE552077, BF699387, BF695949, BF697521, BE542555, AI277959, AA121788, A1961880, AW969937, BF478121, AW338124, AA528626, AW367010, R76478, AA101422, T62844, A1918990, BE167397, W72961, BF570557, A1077290, AA127501, R66340, A1926197, C00153, AA813575, R28517, A1580500, A1222072, A1033269, AA758476, W86851, AV661704, AV725920, AV728997, AV704234, AV726624, AV655280, AV729378, AV727787, AV709407, AV654908, AV660608, AV652001,

AV656903, AV707541, AV706854, AV702117, AV726738, AV728733, AV708834, AV687035, AV66903, AV707541, AV76884, AV656478, AV698545, AV709314, AV708381, AV660728, AV6911080, AV651955, AV703169, AV728518, AW952409, AV709560, AV729220, AV696866, AV7081080, AV651955, AV703169, AV728518, AW952409, AV709660, AV729220, AV69866, AV7081108, AV651955, AV703169, AV7082518, AW952409, AV7075103, AV705194, AV702516, AV693523, AV706103, AV727029, AV725826, AV725134, AV705280, AV702994, AV683272, AV697288, AV652156, AV728670, AV708723, AV702944, AV70510, AV699089, AV688111, AV728157, AV708109, AV692345, AV708723, AV706744, AV708438, AW951263, AV689111, AV728157, AV708109, AV690604, AV706744, AV708893, AV699089, AV689111, AV728157, AV708693, AW960720, AV706644, AV706721, AV701067, AV706044, AV708693, AV690684, AV706644, AV7066932, AV706721, AV701067, AV706044, AV708693, AV708893, AV689604, AV708604, AV708869, AV698604, AV708604, AV708869, AV69889, AV68906, AV708604, AV708869, AV7088980, AV686064, AV7088980, AV686064, AV708980, AV708980, AV708990, AV708990, AV7089429, AV761166, AV699088, AV689800, AV693005, AV709390, AW953065, AV6985688, AV689800, AV684075, AW951618, AV6889363, AV706185, AV684075, AW951618, AV688332, AV70168, AV648263, AV706184, AV725110, AV7053384, AV707024, AV725110, AV7053384, AV707024, AV725111, AV698583, BC005700.1, AL137163.1, Z83826.12, AF217994.1, Y08991. 1.	AL517202, AL517203, AW957146, BG116418, BF038478, A1563954, AU132232, AA932901, A1755091, A1831671, BE889854, AU127679, BE891799, A1582904, A1038368, BE246025, BG177748, BE906332, BE277910, BF982210, BE276343, A1633334, BE891988, A1954440, A1687563, BF984413, AW956931, A1565064, A1879207, AW778725, A1472032, A1924693, BF972236, BE889752, AV753606, BE536916, BE269039, BF196580, AA165526, A1248179, BF060729, BF3084455, BE539211, AV734590, AA165570, A1219806, A1803270, BF027703, A1433120, AA780394, AW593783, AA305509, BE887807, BF032636, AA314159, AA745958, BE677439, AU150180, A1525645, AL046195, AW388378, AA740296, BE858748, AA745958, BE677439, AU150180, AA593868, BE550016, N39180, A1249054, BE301992, A1147071, AA137129, AA9339319, AA593868, BE550016, N39180, A1249054, BE301992, A1147071, AA137129, AA9339319, AA593868, BE550016, N39180, A1249054, BE301992, A1147071, AA137129, AA9339319, AA593863, AW644510, BE018377, H12907, N39112, A1751806, A1538630, A1478724, A1364661, R54299, AA137058, AW571962, AW137978, AA236150, BF512413, T31959, AW273552, AA807100, AV695683, AW085260, T36296, AA236118, A1091951, H50337, AA493467, AW564539, AA30802, AM15022, BA30201951, A1091951, H50337, AA493467, AW564539, AA30802, AM15022, BA30802, AM15022, BA30802, AM15022, BA30802, AM15022, BA30802, AM15022, BA30802, AM15022, AM2505118, AM08526118, AM08526118, AM09561, AM085260, T36296, AA30802, AM15022, AM264539, AM50022, AM5002, AM50022, AM500
	15 - 2527
	1 - 2513
	614040
	253
	HOSFD58

A1672263, A1198257, BF055537, A1199035, AA677064, W69895, AA040154, BF196981, W73711, AA029867, W69841, BF222273, AW900121, AW022270, W69574, A1373227, A1200161, AA701858, AV690112, AW044223, W69662, A1052153, AA872860, H29417, H29324, N26312, A1283749, AA036704, A1383659, AA332627, N47677, A1424682, BE089934, AA329748, AW952484.	AUSAG40, AL079734, AI345695, AA410788, AA128592, AV760508, AA449997, AUI47162, AV765691, AW902315, AI801482, AW265385, AW002183, AW265393, AT733856, AAA221323, AW056117, AW27624, AV763026, AV763058, BE150796, BE05395, AV759204, AV760915, BER27410, BEL47833, BE662478, AW669294, AW06724, AA654786, BE062437, AA521399, AV764259, AV765971, AW270258, AV866332, AW302909, AW504485, AW974932, AV764259, AV765971, AW270258, AV866332, AW302909, AW504485, AW974932, AV764259, AV765971, AW270258, AV866332, AW302909, AW504485, AW665289, AI616468,
4444	15- 1139 15- 17- 17- 17- 17- 17- 17- 17- 17- 17- 17
	1-1125
	1042309
	258
	HPICB53

					AC004511.5, AC023490.5, AC004821.3, AC011472.7, AC018633.2, AC005531.1, AL133448.4, AC004103.1, AP000115.1, Z82182.2, AC012450.9, AP002810.3, AL161454.10, AC010458.5, AC009756.9, AL031596.7, AL136984.20, AC009309.4, AC026439.3, AL159970.16, AP003357.2, AL121826.11, AL035450.1, AJ009610.1, AC034353.3, AL050404.3, AC090942.1, M63796.1, AL356796.16, Z84469.1, AL033528.19, AC079175.24, AC004826.3, AC004921.1, AC026161.4, AC083871.2, U91323.1, AC000085.5, AC004824.3, AC022415.5, Z84486.1, AC066130.1, AL56679.16, AL15667.3, AC066130.1, AL56679.16, AL15667.1, AL
					AC006483.3, U47924.1, AL132772.14, AF196969.1, AL590762.1, AC018808.4, AP001060.1, AL138823.11, AC006483.3, U47924.1, AL132772.14, AF196969.1, AL590762.1, AC010150.3, AL136303.15, AL391595.14, AC073193.10, AC008946.6, AL031291.3, AC005387.1, AL136992.22, AL136172.16, AF312032.1, AC009087.4, AL535392.7, AC024028.10, AC005057.2,
					AC002231.2, AC002350.1, AC034198.6, AC022201.4, AC067122.21, U29895.1, AF053539.1, AC024166.3, AF336797.2, AC007637.9, AP000306.1, AL445532.8, AC025280.4, AC004662.1, AL021939. 1.
HPJBI33	259	682699	1 - 1663	15 - 1677	AI679782, BE796439, AV763892, BE387734, AW303196, AW301350, AW274349, AL046409, AI204304, AU148742, AL048142, F36273, BF475381, BE156019, AL041690, BE872393, N94311,
					BG236735, AA599480, AW630298, AW473163, A1734955, BF683672, A1281881, AW276827, A1341548, BF806176, AW467362, BF805094, BF940837, AV762050, BE350475, AA631507, AV657936, AW963497, BF965007, AV681599, BF042649, AV762139, AW080939, AW276435.
					AI291268, AI291124, AW339568, AU154961, AA426277, AI133164, AW088616, AI951863, AW873530, BF816072, AL038785, AW148792, AW338086, BE869857, AW408717, BE042475,
					A1580652, AA525190, AL044940, AV760466, AV713243, AW969694, A1537955, AC005527.3, AL050318.13. AC010279.4. AC000025.2. AF134726.1. AC008736.6. AC004983.2. AC004965.2.
					AL162458.10, AC009269.6, AC020552.4, U91321.1, AL136179.15, AC011455.6, AC020916.7,
					AC009244.24, AP001725.1,
					AL021391.2, AC007055.3, AC011464.5, AC010422.7, AC006430.22, AL390738.4, AL109805.14 AC006483.3, AL1033528.19 AP001716.1 AF053356.1 AP000112.1
					AL160271.19, AL157882.5, AL022323.7, AC018751.30, AL121900.26, AL356354.10,
					AL121897.32, AC006435.7, AL160471.5, AC027689.10, AC004878.2, AL121903.13, AL121890.34, AP000044.1, AP000513.1, AC004662.1, AC027319.5, AC011236.8, AC008738.6,
					AL136980.5, AC020904.6, AL132640.4, AC009516.19, AC018506.4, AJ400877.1, AC003003.1,
					AC016587.7, AC004847.3, AC012476.8, AP000555.1, AC020931.5, AC018719.4, AC003029.2, C93241.11 AC004797.1 AL031281.6 AP001741.1 AC016894.7 AL033529.25 AC068533.7.
					AC011479,6, AJ003147.1, AL163248.2, AC022148.5, AP001727.1, AL031602.14, AC008403.6,
					AL139021.6, AC005488.2, AC006329.5, AC079602.15, AC020754.4, AC005736.1, AC004841.2,
					AL022316.2, AC003684.1, U47924.1, AL031733.3, AL365225.12, AL356915.19, AC008622.5,

					AC008073.4, AL050349.27, AL353135.32, AC005231.2, AC004707.1, AC022083.6, AL121585.22, AC005015.2, AL137800.12, AC016025.12, AC010616.5, AP001726.1,
					AC027644.9, AC034198.6, AC005295.1, AC007956.5, AL139321.28, AC006050.1, AC069262.24, AC013434.8, AC004382.1, AC010553.6, AC006581.16, AC004638.1,
					AE006463.1, AC007739.2, AC007011.1, AL049537.48, AL049760.26, AC006211.1,
					AF109907.1, Z93015.9, AC011462.4, AC090710.16, AC005844.7, AC006312.8, AC002990.1,
					AC008474.7, AC011489.6, AC007272.3, AL136418.4, AL139054.1, AL136137.15,
					AC024028.10, AC004089.25, AL035659.22, AL354932.26, AC005529.7, AC007226.3,
					AC006452.4, AB050050.1, AC005837.1, AF111168.2, AL109797.18, AL135838.5, AL355392.7,
					AL021155.1, AC005512.1, AL009181.1, AC009137.6, AC004491.1, AC018720.5, AL445686.14,
					Z97054.1, AC007686.5, AC023344.4, AC011005.7, AC007597.3, AC005562.1, AL133367.4,
					AC010618.7, AP000347.1, AC002369.1, AC004953.1, AC010654.8, AC005081.3, AC008946.6,
					AC025540.7, AC011495.6, AP001748.1, AL049869.6, AC011461.4, Z86090.10, AC002470.17,
					ALI38724.12, AC009412.6, AC005840.2, AC008760.6, AJ009611.6, AC008985.6, AC011484.4,
					AC015982.9, AC002133.1, AL049709.18, AC011444.5, Z98200.8, AC010969.11, AL121652.2,
			_		AP002851.2, AC008372.6, AL022320.23, AL109965.34, AL096701.14, AL031584.1,
_				-	
					AC005778.1, AC022384.4, AC005037.2, AC020550.4, AL137140.12, AC004859. 2.
HPJBK12	260	1011467	1 - 2634	15 - 2648	AP001206.3, AP001329. 3.
HPMDK28	197	846357	1 - 1070	15 - 1084	BG112660, BG025264, AL528310, BG168817, BE744551, BE877617, Al356771, BG163540,
-					AA203523, BG031683, BF822950, AW592567, AA176981, AA904437, BF209639, BF312400,
			_		AU134583, BF194783, BF058517, BF445932, BF115227, BF732680, BF445936, AW303381,
					AW149649, AW027536, AW583459, AW475091, AA065227, BF869433, AW103970, AA703536,
					AA902103, AI735312, AI082224, BE262098, AW405660, AW009422, AA932869, BF940753,
					A1830877, A1830074, BG222176, A1742006, A1381584, AA133474, A1347025, BF869417, A1452483,
					AA993536, AW954279, BE737248, N66683, BE261151, A1369439, A1334008, A1005081, AL528309,
					BE166345, AA365303, BF222033, F32952, AI697441, AA488152, AI418548, BG248769, AI279351,
					AI888277, BF115544, AI200343, AA977299, AI612818, BE163359, AI830668, BE740423, AW574601,
					AA315546, BE397815, AA573402, BE004351, AA573411, AA633508, BF925742, AA741489, H82686,
					BF894571, AA065233, AA360707, AV728079, BG230581, N29979, BE561199, N98991, AW439071,
		<u></u>			AA744699, R73710, AW407745, AA877633, H99709, BF804312, AI381618, BF806994, BF806622,
					BF806680, BF807000, BF807012, AW407070, BF804328, BF807005, AU155517, AA933001,
					AA321772, W57549, BF806996, BE271504, H39645, H26855, BF807004, H82425, BF804308,

					BF975948, AI928746, R81659, R82397, BE791088, R73635, BE939764, AI688429, BE171442, BF378561, BE261882, BF818292, AA469038, AA913203, AA300974, BE171441, AA298641, AW999308, BF206994, BF807016, H26756, BF093709, AW884799, BF737549, AW797205, H11203, AA305598, R81461, BF773046, BF804289, AI738864, BE814697, H49134, H40077, AW889970, AI669504, BE561022, BE394911, AA911419, H40072, BE706979, R82344, H40077, AW889970, AA664931, AI300423, AA380950, AI301586, BE902194, BE707909, AI983746, AA533457, AI68033, AX803830, AA737402, AI926327, AI263788, R52293, F26866, AA827751, BF868527, AI168033, AA463767, AU130766, BE673288, BF109947, AA364441, BE464383, AI693626, AA133473, AA463767, AU130766, BE673288, BF109947, AA364441, BE644139, BE080941, BF059063, BE671687, AA463767, AI051392, BE348682, AI279199, BF437797, BF064139, BE080941, BF059063, BE671687, AA732692, AI261971, AA976709, BF091789, AW002951, BE163143, AI697488, T25507, AA341138, N86893, AI951605, BF058146, BE270120, BC008070.1, AK001809.1, AF277178.1, AK023110. 1.
HPMFP40	262	638165	1 - 1203	15 - 1217	U48436.1, AC005731. 2.
HPRAL78	263	1352342	1 - 2058	15 - 2072	BF342508, BE745079, BF316647, AW954022, BF219864, BF220093, BF182978, BG108443, BE879671, Al684112, BE840525, AW957217, BE840530, AI148569, AI128199, AL041807, BF027688, AA401860, BF915566, BF914452, AA938143, AA588312, AI991034, AI672251, AI862148, AI33529, AI798586, AI095534, BF826436, AA976203, AA424398, AI475525, AL039685, T52017, AI055912, AI798586, AI095534, BF826436, AA976203, AA424398, AI475525, AW268634, AI300146, AA340540, AA411182, C04045, AI926947, AW088744, AA757547, AI798454, AW473352, AV691484, AI076726, AV647523, AW475065, AA364829, AW028194, AW249610, W22554, H66782, AA081290, N95459, W25198, R60726, AI311111, AI351724, AW614976, AA506965, AI142999, BF091172, AA604134, R60727, AA578520, AW129067, AA612772, AW60121, AA081115, AA081697, AA411256, BF679941, R60727, AA578520, AW129067, AA612772, AI824391, AA470674, H66783, AW953852, AW006565, AA315553, AA702770, AW246146, AA370468, AA832305, AW082570, AI568825, BF929006, AA251006, AA043375, AA508725, AW068182, AA766464, BF769780, AW316684, BE260322, BE819573, AA082047, AA370467, BF929011, BG056952, AW241232, BF751574, AI686507, AC022007.3, AC018809. 4.
HPRBC80	264	829136	1 - 2529	15 - 2543	BF508706, BG251902, BG118348, AL522364, AI690187, AW959485, AV705315, BF672789, AL520227, BG176557, AL528876, AV713609, BE439925, BF130665, AW963928, BF994344, AL536566, AA446397, AA180531, BG026529, AA180520, BF672895, BF029282, BF670440, BF799935, BF510400, AA179618, AL513906, BE246173, AA625572, BE244085, BF671786, AI681635, BE004447, AA431963, AV701964, BE566300, AV653358, BE004444, BF790083, Z30124, AA164383, C17250, AA379401, N24451, AA363823, BE004648, AA180509, AV713647, T35331, AW961450, BF800059, AV686722, BF575322, AW020971, BF229438, AW361378, AA465249, AA313690, BF979498, BE694196, AW999825, T35345, AA625571, BE925937, T30431, AA135096,

BE172414, BF980120, N54675, AW897938, BF210564, AW665936, AA769851, Z20951, AW242738, Z19798, C16481, AW197150, A1567621, BE222028, BE622950, AW883664, AA885770, A1039327, AA628005, N50019, A1650889, AJ271835.1, AF136972.1, AC013717.8, AJ271832.1, AF294792.1, AJ005801. 1.	AA968657, AA493222, AW964196, AW945159, AW950095, AW963925, AW994382, AW964211, AW964281, AW964282, AW964281, AW964282, AW964885, AW964885, AW964282, AW9648882, AW964282, AW964282, AW9643882, AW9643883, AW964444, AW9643818, AW9643882, AW964388, AW964444, AW9643818, AW964388, AW964444, AW964388, AW964444, AW964388, AW964444, AW964388, AW964444, AW964388, AW964444, AW964388, AW964444, AW964488, AW964444, AW964444, AW964488, AW964444, AW9644	AW993896, AA493291, AA526359, AW972615, AI720194, AA358397, AW204400, AA508549.	BG111918, A1823987, A1807761, AW165961, A1418806, A1738753, C05983, BG152897, A1439259,
	15 - 559	15 - 1676	15 - 1747
	1 - 545	1 - 1662	1 - 1733
	635033	585702	658717
	265	266	267
	HPTTG19	HPZAB47	HRAAB15

					BF327504, AA923586, AI424510, BE003132, BF894183,
HRABA80	268	882176	1 - 1237	15 - 1251	AU147250, F24079, AI791459, AI732503, AA523577, AI791342, AU121439, BF309840, BF308519, AI659402, AA719317, AA602233, AI752815, AW967109, AV694013, AA470486, AI218622, AA644545, AK022184.1, AC005777.1, AL031431.8, AC007406.1, AC032011.14, AC004143.1, AC006131.1, AC074121.16, AC005760.1, AC005529.7, AL354766.17, AC025166.7, AC012476.8, AC005544.1, AL035079.14, AL356299.16, AL031297.4, AC005778.1, AC011666. 28.
HRACD15	569	871221	1 - 1525	15 - 1539	AL519765, AL519766, BE910445, BF684654, BE270497, BE513843, BF97395, BE396890, BF973472, BE515166, BF686665, BE744708, BG257119, BE880162, BE797305, AW248552, BF591606, BE56417326, BE970108, BE27727, BE27727, BE2770509, BU277326, BF0920627, BE77971, BE2770509, AU133849, AW248687, AU120611, BE77326, BF0920627, BE77971, BE2770509, AU133849, AW248687, AU261853, AW248687, AU1620619, BE770509, BF0727052, BE38166, A1565688, BE513870, AU13107, A1524253, BE391940, AW245114, AU145208, BE312276, BE796133, BE561087, A1953094, BE390017, AA283855, BE265439, BE26646, AW083553, AW131075, A1768778, AA401964, BE390017, AA283855, BE265439, BE26646, AW083553, AW131075, A1768778, AA401964, BE390015, A1752666, BF26619, AA831894, W60024, AA462623, A1664882, A16254074, AA62623, AA6830894, W60024, AA462623, A1664882, A1635409, BE503489, A1626582, A1832018, N29665, AA622755, A1439625, AW13362, BE503489, A1626589, BE51092, AA622755, A1439625, A1193362, AR4039788, AN162745, BE728607, AW021987, AR403849, AW06024, AW087437, A1662034, AR503404, A163638, AU118709, AW154085, AW86699, AW154085, AW86699, AW154085, AW86699, AW154085, AW1540849, AW867437, AR6287820, AW15409, AW15409, AW57437, A1626034, A1425870, AW02140, A1309558, AU118709, W96176, AW062187, AW062187, AW062187, AW246086, AN24698, AN144163, AW062187, AW246086, AN246115, D29066, AA65647, R87509, BF056111, AA643222, AA62204, AA072469, AA56647, R87509, BF056111, AA643222, AA62204, AN14088, AN144184, AA62204, A153112, AN144183, AN144183, AN144184, AN18754, AW15784, AW05631, A144088, AW246566, AW1789, BE2102252, AA62869982, A12039474, A153115, A15788, AN13379, BF28156, BG031018, BE513491, BE513601, AW149113, AW19363, A1202252, AA628809, BE869982, A1203978, A157909, AA077110, AW152907, A144187, AA913797, BF21816, AA941187, AA932001, BF817875, BE104043, AN195409, AA77861, BE513491, BF817875, BE104043, AN195403, AA195644, BF913472, HR91388, AA996484, AN06864, AA62804, BF934477, W080774, BF21807, AA77824, BA778244, AA077601, AW08244, BF7944, BF794477, W080774, BF23807, A142843, BF7944, BA7
					AW298462, AA496322, T50535, BC008084.1, AK001129.1, AK021688.1, BC007488.1,

270 877666 1-2 271 567004 1-7 272 910133 1-2	AL117583.1, AC006014.2, AB014518.1, AC005488.2, Y16704.1, N54250, N81046, AA036807, AA135546, AA236044, AA262692, AA938381, AA204918, AA402082, AA455506, AA455507, AI217271.	15 - 2077 BE906771, BE218907, AI912661, BE670671, BG166321, AW167740, AI698131, AI796048, BF476110, AW952474, AW474992, AW149683, AI814137, BF436724, AA452391, AI635719, AI422285, AI675301, AW301634, AI800309, AI023300, AI269915, AA054467, BF062213, AI220479, AA991181, AI159765, W88683, AI623293, AI205308, AA043330, AA461136, BE669608, AI032982, AA60833, AI361429, AA877688, BF681677, AW868366, AI683625, AI094869, AI268543, AI040482, AA460833, AI042583, AI800329, H40189, AA041196, AI420048, AA127006, AI023081, AA045134, T96696, M79132, W23483, BF000996, AI161385, BF476853, AI521085, AI984382, AA492294, AA016124, N95081, R13864, AI146307, W28330, AI022619, T19296, AA410735, BF573582, BF056915, T30952, AI071069, AA044035, R05716, AA2167801, AA0460135, AV693019, AA216384, R18560, AA041433, AW244035, R05716, AA88767, BF222351, H40140, AW589719, AV686312, BF207973, AA226035, AA228673, AI817777, AI420271, AV747189, AI248289, R05717, T30818, BF847400, Z38161, AA879250, D57208, R37006, AA319785, AI699205, T96591, AW945698, AA225132, AA333327, AA045610, D57177, AA226695, AA045355, BE905736, BE670421, AW469919, BF000980, AW771589, BF871391, F19153, AW152062, AW964837, R41427, BE242459, BF485505, AW373047, AW069103, W88670, AA761464, BF844537, AF107834.1, AF119386.1, AP003117.2, AP003117.1, AP	15 - 805	- 2094 15 - 2108 BE271199, AW575245, BF794609, BF79700, BE559773, BE384088, BE513826, BE270971, BF572042, BE560978, BF690655, BE674800, BE275832, BF303959, AW205367, AW402801, BF203242, AW402242, AW402928, BF305905, BE466652, BE892536, AW403946, N24246, AW968460, AI654541, N28316, BF72179, N29315, N38941, AW383418, AA458944, AI276242, BE729612, AA215300, N33010, AW383426, AW383396, N20230, BF692515, AI439520, N29316, AA459158, N25452, W03476, AW383428, AW402824, N30453, N28949, N21241, AI760983, N20533, AI434284, BG025865, N72999, N20563, BF896859, AW403434, N67502, AI470743, N73074, AA837208, AW407871, H84381, AW404443, N26470, W02963, AI864746, N46511, W02298, H98912,
		66 1 - 2063	04 1 - 79	-
				
HRACJ35 2				<u> </u>

				BE006108, AA311800, AW962850, AW516636, BF881635.
274	1181699	1 - 1132	15 - 1146	T66247, BE081925, R34513, F12057, AA852760, AA125904, BF996914, BF107281, BF743278, BF742834, AB040901. 1.
275	827306	1 - 1984	15 - 1998	A128560, AL0192053, C1730, AW19912, AL992286, AU15470, AW1571101, AW102963, C1730, AW19912, AW192050, AW1921101, AW1025047, AW27297, AW272276, A1862212, A1246569, W58428, AU146383, A1610350, AL035047, A186945, A1818151, AA811111, A1453790, AA130476, F16040, A1685116, A1610326, A159942, A1868945, A1809945, A1809946, A4864188, H96719, AA961590, A1082454, AA902028, BF112065, AA129986, A1439415, A180994, AA864188, H96719, AA95201, AA657353, AA550798, A102382, AM52021, A18093, A313708, A313808, A313808
	275		827306 1 1 827306 1	827306 1 - 1984 1

					AL450305.7, AL356005.9, AL163248.2, AC090527.3, AF001549.1, AC008014.5, AP001922.4, AC005213.1, AC025471.5, AC006287.1, AL121595.5, AC012491.7, AF241726.1, AC069543.4.
					AF196972.1, AC005562.1, AC022274.5, AP002436.3, AC002456.1,
					AC019100.4, AC004993.1, AC004848.1, AC002541.1,
					AC005146.1,
					39090.11, AP001700.1, AL356269.10, AL136307.12, AL390731.9,
					, AC034240.4, AL354937.12, AC005939.1,
					AC006961.16
					AF130343.1, AL009172.1,
					AC005988.1, AL132985.4, A
					AL133353.6, AL049767.12,
					AC000115.1, AL589693.3, AC002458.1, AC025887.4, AC005406.2, AC005606.2, AC0056
					AL135978.4, AL391221.15, AE000661.1, AC022404.7, AL031643.1,
					AL138758.7, ,
				·	AL022308.1, AL049831.2, AL158193.13,
					AC084373.24,
					AL136419.2, AC025265.21, AL137145.13,
					AC006994.4, AC005593.1, AC006840.17,
					AC006016.2, AC068726.5, AL359502.14,
					AC024084.4, AL157698.8, AC021079.4, A
					AC011288.4, AC068812.13, AC022267.8, AL132800.4, AC021850.8, AF235093. 1.
HSATR82	276	531973	1 - 763	15 - 777	BG056575, N22501, AW884147, BF903801, H59173, AW963463, BF997339, AW958318, AA374525,
					AW502694, BF816190, AA364420, AA378207, AA810158, AC007130.2, AL122035.6,
					AL353692.14, AF124523.1, AL391122.9, AL035404.20, Z93241.11, AC007917.15, AL353680.8,
					AC005881.3, AC005740.1, AP002851.2, AL133477.16, AC004805.1, AC008891.7,
					•
					•
					•
					AC004883.2, AL392166.19, AL050318.13, AP003357.2, AC009331.5, AC011455.6,
					AC005519.3, AC069025.4, AC008088. 8.
HSAVH65	277	545459	1 - 586	15 - 600	BF793712, AW080832, A1693734, BE869501, A1564525, BF037343, AW475057, AA523950,
				! ! !	AV719716, AW024144, BF827012, AI185475, AI197788, AV660309, AI708671.
HSAWD74	278	460527	1 - 956	15 - 970	BG056446, N32720, AW152171, AA339555, AA076697, AA525291, AA380007, BE734992,
					AA017031, AA319882, BE047929, AA515728, AI282253, AA683069, AW275432, AW274078,
					AA533025, A1675615, AL040054, AA644090, A1345123, N42169, AW023111, AV756491, A1962030,

AV758870, AW021774, AA602906, BG222564, BG222326, AV762454, AL048060, AA225406,
 A1879951, AA078830, AW514006, BE063437, BF725844, A1591299, A1590522, H68343, AA825827,
 AA559166, AW272294, BF213224, BE049095, AI344810, AA714011, AW502237, H63660, H24331,
AA171400, AL449689, A1753113, F18888, AA282951, AV761486, AW193493, AA669238, AI557644,
 A1049868, AW631267, AA525331, AW117740, AA507623, AA862183, BE968744, BE677164,
 AW571963, A1433952, BF991881, AA701080, BF970107, BF212465, AA832175, AA470933,
AW157128, AI343144, AW974751, AW338376, AW410409, AW844636, AW664505, AA827383,
 AV760014, A1745116, A1003611, AV683406, AW021154, AW501278, BE968477, BF991882,
 A1189682, AU124213, A1336637, AW572140, AA610644, AW963463, AA708322, AA489390,
A1887235, AC004084.1, AC004951.5, AP000252.1, AP001711.1, AC006160.9, AP000031.1,
AP001753.1, AC026794.4, AL139022.4, AC009179.17, AL033383.26, AC090498.2,
AC011472.7, AL162578.13, AL590762.1, AL117380.28, AF045555.1, AE006467.1,
AC006088.1, AL096701.14, AL137881.12, AC011491.5, AC018828.3, AC005081.3,
 AL110115.38, AB001523.1, AL023586.1, AL022237.1,
 AL133367.4,
 AP001718.1, A
AL354720.14, AC004129.1, AL035461.11, AL161727.15, AF217413.1, AC007371.16,
AC004263.1, AC006441.13,
 , AC004777.1,
AC018663.3, AC011479.6, AL139193.4, AC005692.1, AC009220.10,
AC005049.2, AC004913.2,
 AC006345.4, AC006241.1, AL356805.5, AC004089.25,
AC004910.1, /
 , AC002554.1,
AC003029.2, AC005291.1, AC006430.22,
AC004647.1, AC002429.1, AJ277546.2,
, AL137140.12
 AC004883.2, AL135924.11, M12901.1, AL109984.14,
AC005736.1,
AL445195.4,
AL021579.1, AL354935.23, Z81364.1, AL109925.11, AL139339.22, AC004876.2, AC020983.7,
AF195658.1, AL022727.1, AC005598.6, Z93930.10, AC011480.3, AF312915.1, AC005220.1,
AC074121.16, AL139123.14, AC010679.6, AC027124.4, AL157838.24, AC010205.5,

				AL049547.10, AJ300188.1, AL357972.18, AC002350.1, AL356095.11, AL162505.20, AL118502.38, AL022331.1, AC021016.4, AC008753.8, AC011890.4, AC005409.1, AC005516.1, Z97987.1, AC010458.5, AF053356.1, AC006111.3, AC007537.3, AC002133.1, AL390026.1, AC007319.1 AL37142.20, AP000555.1, AC005180.2, AL135838.5, AC024028.10.
				AL034429.1, AC007055.3, AC007298.17, AE006639.1, AL078633.32, AC066597.4, AC007766.1, AC010605.4, AC025280.4, AC005363.1, Z68870.1, AL162503.12, AP000501.1,
				AC006208.3, AC005038.5
				AC025166 7
HSAWZ41 279	9 580872	2 1-1374	15-1388	AI547110, AI344906, AI318548, AV683406, AA425283, AW162314, AW409621, AI174703,
	<u>.</u>			AF126947, AA493546, BE139230, AV758849, BE677164, BG003974, AI065031, AA280886,
				AV763460, AA584360, AI251024, AW504667, AA533660, AW021674, AA493245, AW162332,
				AA577706, AW963552, AI890283, AU120423, AW474825, AW514844, AW023975, A1003068,
				A1281622, A1275989, AA601376, A1753131, AW151848, A1754926, AW662484, AA533066,
				AV762541, A1114543, AW265468, BE244308, A1572680, AW085811, BE747923, AV760048,
				AA636077, BF882223, AV764119, AA515727, AW875184, AI797998, BF970107, AW962971,
				AI/32699, AII/4827, BEU49409, BEU42524, AA828840, BGU39139, AI921/44, BF/24410, AAU84439, A A748071 AI446618 A W963489 BF943991 AI813930 AA807704 AI826857 AI732730
				AA702637, AW439224, AI755227, AA640305, AA658443, AA804177, AI431442, H62123, AA676462,
				BE080768, A1114755, AA535558, AW501278, AL121039, AW631267, A1702049, AW262946,
				AV712092, AW403177, AW979200, N99245, BF944618, BF445745, AA601712, AW162762,
				AW409626, AI064968, AV732057, AW855527, BF876005, AW157128, AW148964, AA663579, AW1947344 AA665043 A1850358 A1571804 AA607533 AA646005 AA554780 AW085636
	<u> </u>			AW64/344, AA060042, A1637306, A1371674, AA307023, AA040700, AA334263, AW660263, AW671247, AW151247, AW148821, A1821901, A1570067, BE882869, AA600127, AW103990, AA632355,
				A1640717, AL039436, A1828721, BF949151, AA157876, AW084152, AW960129, AA618531,
				AI744890, AI252005, AI038029, AI254463, BE967607, AA809125, AW771679, AW975150,
				AA419230, AA167656, AL046620, AI733523, AV706458, AW166996, AW022796, AV683668,
				AC015541.21, AC026162.5, AC018816.5, AC004953.1, L44140.1, AC008891.7, AC009131.6,
				AP001711.1, AL139100.9, AC007376.9,
			×	AC010319.7, AC006468.9, AC005236.4,
				AC005527.3, AL049869.6, AC011531.7, AC008649.6, AL022336.1,
	_			AC020916.7, AC009996.7, AL096840.25, AC004167.1, U80017.1, AC002991.1, AC006538.1,

					AL160166.10, AF288742.1, AL449305.4, AC010422.7, AC005000.2, AC006345.4,
					AL121712.27, U73169.1, AC005057.2, AC013449.8, AL121601.13, AL161624.7, AL355480.22,
					AC005212.1, AC009032.7, AC016894.7, AC006162.1, AC020983.7, AC006460.3, A1009616.3,
					AL031847.17, AC008843.5, AF271269.1, AP000872.5, AC044797.5, AC007957.36,
					AC002310.1, AL391827.18, AC020896.5, AC063979.4, L78833.1, AL139286.13, AF196779.1,
					ALS90762.1, Z97054.1, AC004895.2, AC089987.26, AL022323.7, AC002126.1, AF038458.1,
					_
					AP000563.1, AL050328.24, AC009314.4, AL135927.14, AC007227.3, AL021453.1,
					AL031427.15, AL353804.22, AL445528.16, AC010145.9, AC005529.7, AL139415.10,
	_				298050.1, AL136126.34, AD0000092.1, AL0/9342.1/, AC004814.2, Z82198.2, AC004821.3,
					AC0054847, AC000353.77, AC005840.21,
					AC007941.1, AC003464.2, AC000353.21, AC005640.2, AC073525.3, AC003521.3, AC004150.8, AL1096814.26, AC022137.5, AC090949.1, AL161747.5, AC008812.7, AP000466.1, AC004150.8,
				 _	AP000132.1, AC021016.4, AC000360.35, AP000213.1,
					, AP000135.1, AP001870.2, AL359513.12, AL135844.9, AC006057.5,
	_				AL020997.1, AC007404.4, AL117334.29, AC026776.4, 1
					AJ003147.1, AL035659.22, AL161937.13, AL137800.12,
					⋖.
	_				, Z93930.10, AC018633.2, AL138756.23,
	_				
					AL313330.9, AC013410.4, AL333332.7, AF000030.1, AL10179.19, AC010230.3, AC001037.3, AC0004643.1 A1006700 14
HCAYA83	280	545051	1 635	15.640	- 1 (1
COVVVCII	707	- 000+0		,	DEE15370, DEE15001, ARS15101, D1511055, ARG40152, AV107081, DE611010, ME21225, D105127, AV100815, D105127, D105127, D106127, D1
					AA336782, BG258938, BE142105, BF896038, BG031184, BE168021, BE890609, AV752295, W25439,
					R18412, BE903633, BC008739.1, AF164793. 1.
HSAYB43	281	604143	1 - 1685	15 - 1699	F17610, BF109566, AC026185.3, AC067941.7, AC002527.1, AC007263.4, AC006581.16, A1 445337.16, AC005201.1, A1.139415.10, AB045358.1, AP001711.1, AC013751.6
					ALTTOLIN, ACCOURTED TO THE TOTAL TOT

					AC004104.1, AL109628.5, AL121986.12, AC005086.2, AC011890.4, AL512378.7, AP002532.1, AP001712.1, Y10196.1, AC005883.14, AC026672.44, AP000036. 1.
HSDEK49	282	1352253	1 - 1768	15 - 1782	AL513706, AL513705, AV700980, BF343961, AV710516, AV716397, AV715849, BF351156, AV717025, AW071975, AI922669, AI129815, BF106386, AA702864, W32947, AV690218, AV685715, AV693576, AV686846, AV695322, AV697709, BF924861, AI168499, AI343825, AA627735, AI554367, AI335089, AV697729, AI290781, AA875852, AA442570, AV686969, AV698914, AA486920, AI357884, AI088635, W79882, R39812, AV683817, BF932594, W17367, N78991, AA972857, R62969, R59135, AW961380, R56601, BE857524, R66262, W74268, AA436814, AA813538, H05057, AA133776, Z43556, R14044, R81029, T48889, AA228697, R5602, AA142932, R63023, Z39624, F02373, AA993978, R66723, R67603, R59136, R80928, AA133775, AW874480, T48888, AA228698, AA368546, BF525711, AA115592, AA328299, AA486747, BG001652, AJ132502.1, AL034397. 1.
HSDFJ26	283	834619	1611 - 1	15 - 1205	A1770009, BE467511, AW593206, AA434584, A1767843, AA780308, AA563708, AA317400, AA433906, AB021123.1, AC005598.6, AF361936. 1.
HSDJJ82	284	460602	1 - 448	15 - 462	AW594636, AA610164, AL050309.4, AC011445. 6.
HSDSB09	285	1301498	1 - 795	15 - 809	BF432333, A1861851, A1240993, A1795956, A1074484, A1640759, AW006868, AW241621, BF592070, AW271387, AW614840, AW450466, AW243423, A1244694, A1640517, BF431431, BF431530, A1439169, A1613108, A1915938, A1984796, A1245393, AW300335, AA931466, AW235983, AC005722. 1.
HSDSE75	286	545057	1 - 1137	15 - 1151	AW378251, BF349814, AA687791, BF739001, AW378183, AA661723, H61383, T88677, H62404, AA443169, AW339864, AA458622, AA252063, AI129690, AW960791, AB006755.1, AB006756.1, AB006757. 1.
HSDZR <i>S7</i>	287	651375	1 - 294	15 - 308	BE255995, AW473473, AW206723, BE312252, AI571368, AI810895, AI479711, AI656582, BE676619, AI492370, AI929750, AI762058, AW271956, BF591321, BF434884, AI500262, AW612319, AW085870, AI627969, AW168428, BE796769, AI767097, AI205848, AA632229, AI565786, BG033526, AV729047, AA876257, BE563237, BE905450, AA478285, BE257238, BE878838, BF664024, AA641693, AA478343, BC002907.1, AK000519.1, AC008755. 6.
HSIDJ81	288	589447	1 - 1289	15 - 1303	H27567, H27494, H71543, A1754653, BF857849, AW023111, A1521525, AW572721, AW963450, A1254770, A1926102, AV701462, AW020150, A1871973, AW500534, AW275432, AA218851, AA595661, BF854170, BF853574, BF853009, AW151247, AA536040, AW274078, AW958962, A1791659, AA669238, A1223626, A1249853, AW302048, BF725844, A1284543, BE139139, AW855625, AL042621, AW575000, A1801505, N68677, A1250552, AV758870, AW272294, H86725, AW851405, A1625604, A1251034, AA525807, AW075979, A1697235, A1090377, AA570255, AA702637, AV760014, AA729387, AA831426, A1697239, A1697242, AW504224, A1879951, AW502949, H77492, AW514065, A124583, AV759203, BF527070, AA491767, AA229496, AL158830.17, AC005412.6, AL355855.23, AL132718.5, AL391868.15, AF285442.1, U91321.1, AP0005051, AF129756.1, Y14768.1, AB000882.1, AL353804.22, AC005013.1, AC004448.2,

					AC009309.4,
					AC005274.1,
					AC020552.4, AC008126.9, AC090509.1, AL096701.14, AC090951.1, AC066597.4, AC068319.4,
					AC006581.16, AC005332.1, AL117334.29, AC005200.1, AC024163.2, AC005632.2,
					AL031447.4, AL163279.2, AL355074.5, AL121586.31, AL021546.1, AJ295844.1, AC005484.2,
					AC013717.8, AL445196.7, AC007255.4, AC008760.6, AL136219.17, AL160274.9, AL031277.1,
				_	AL031658.11
				•	AC005921.3, AL121808.4, AC004699.1, AC009412.6, A
					AB053170.1, AL109965.34, AC009488.5, AF312915.1, AL132713.11, AL133173.19,
					AC022516.4, AC009314.4, AC007376.9,
					AL449305.4, AC020913.6, AC010326.6, AL391259.15, AL512885.4,
					AL031726.22, AC005180.2,
					AL109963.4, AC012085.4,
					AL139039.17, AL121973.2, AL022326.1, AC073101.7, AL359986.15, AC006449.19,
					AL358237.13
				***	AP002436.3, AL445143.2, /
					AC008641.6,
					, AC004840.3, Y10196.1, A
					_
					AC090518.2,
					AL356299.16, AC091493.1, AL136179.15, AC005257.1, AL096791.12, AL139113.21,
					AP000135.1, AL357518.15, AL021808.1, AL133453.3, Z93017.6, AL365444.11, AL390838.26,
					AL445669.9, AC008812.7, AL513008.14, AC007537.3, AC004447.1, AC003029.2, AC026776.4,
					Z97054.1, AC005399.19, AC010412.7, AL133466.22, AL136164.8, AC005527.3, AP000031.1,
					AC010616.5, AC074295.7, AC090532.1, AC004846.2, AC018808.4, AP001724.1, AC005529.7,
					AC004551.1, AL353777.18, AC004686.1, AC008044.4, AC018663.3, AC004873.3, AP001412.2,
					AF064858.2, AC008279.3, Z94801.1, ACC
					AL590762.1, AC079177.21, AC003101.1, AC004644.1, AC006101.3,
					AL049576.19, AC008784.6,
				-	AC009319.19, AC007541.9, AL136295.3, AC013449.8,
					AC007991.7, AF168787.1,
					AC027130.5, AP000152.1, AL138958.18, AC020633.3
					AC018500.3, AC006077.1, AL109956.19, AL139317.5, AC004851.2, AF243527. 1.
HSKDA27	289	1352409	1 - 4398	15 - 4412	BF338364, BG253437, BG122685, BF037455, AW303375, AW173315, BF037378, BG120262, BG117983, BF915045, BF057308, BG252401, BG034853, BF793365, AW379378, BF826037,
					AA570507, BF915582, BG122734, W07328, AA600736, AI971935, BE697573, BE313814, AI090486,

				AI751258, BE839359, BF447303, AW631492, AA625303, BF513067, AI609700, AI768270, AI751257,
				BE939504, AA417652, AI751036, BE378218, AI652363, AI971415, AA599207, AI371013, AA024968,
	-			A1147536, W55850, AA063585, AW794702, AA446024, BE889110, A1828437, A1862133, AA421744,
				ALZ/2040, AI148253, AA419009, AW003418, AA034323, BF883408, BF3/82/1, AA416/07, AA258414 AW305114 A1083516, AI752526, AW024492, AI698032, AW957682, AI092202
		-		AI191710, C05155, AA419525, AI218226, AI754332, AW794499, AA410929, AI936116, AI079893,
				BE272411, AA593295, AA455497, A1039656, BG035195, AA747741, AA774270, AA364833,
				A1350380, BF940413, T59268, BF197746, A1084698, AW800540, AA834031, A1673545, AW795817,
	-			AA978105, AA622501, AA032249, AA912802, AI432010, N66832, AI751035, AI754989, AI082183,
				BE178218, AI751086, N75819, N67061, AA971661, AA873147, AA478719, AA036654, T59227,
	-			AI538117, AA662437, BE765721, T66232, AI751085, AW674273, AA024662, BF197986, AI564218,
				AA319726, AA657729, N64555, AA852211, C03119, AI221431, AA455496, AA033678, C04206,
				AIS20867, AA258397, AW867914, AW867908, AA382381, N24008, AA456579, AA936765,
				AI433202, AA446297, AW338252, BF940540, AI075349, D31528, BE839377, AI537292, AA382234,
				AI446798, BE839418, AA459088, BF724219, BE839363, BE773013, AI064722, AW375493,
				AW375513, AW375482, AW375483, AW375502, AW370152, AW134700, BF352435, AW375514,
				F12285, BE772982, AW797394, BE839409, BE710069, AA299257, A1061637, BE773049, AW375497,
			-	H63649, AW805832, H29954, AI587210, AW836298, BE773047, H75893, BF985423, BF089372,
	-			AA610296, T73259, D30912, BE839372, BE934501, AW937287, AL531501, AI270416, AW376140,
				AW838930, AI886158, AA375571, AL134647, H94943, BG006581, AW964941, AA336003,
				AA410897, R94988, W47433, R64321, D31541, W39467, AV693669, T82080, W04350, AA384793,
			<u>.</u>	AW572523, BE693478, AW375499, BF569459, AA428478, BF001215, H43934, AA382233, Z20767,
			-	AA382380, BE157468, W16893, BE066790, AW384231, BE157596, H80974, R96403, BE814079,
			***	AA345211, BG153436, AV654605, BE157507, AW292030, H62182, AW384236, AI382511, BF674009,
				AA335755, H25902, W65400, BG169442, AV710284, T64640, AA994712, BF944442, BF725435,
\dashv	1		l	M13203.1, X54486.1, X07432.1, AB062098.1, X07431.1, AB062097.1, AB062096. 1.
HSKGN81 290	676075	1 - 1893	15 - 1907	BG110811, BE745101, BE743722, BE545826, BE745120, BF681303, AW978606, AV702796,
				BE047756, BF848815, AW961578, AA446896, AI422823, BF848816, AI911304, AI038608,
				AA312710, A1143843, A1150244, BF829479, A1193547, AA705005, A1268239, A1140112, T65948,
				BES47522, AA393113, AI366477, AI085862, AI074853, AI277116, AI983894, AA394060, AA643650,
				AA100891, BF819277, AA922511, AV762171, AA478086, AI689302, AI275103, AI359079,
				AA532473, AV729423, BE349933, AI287604, AA477628, AV704180, BF847512, AI921910,
				AW105712, AW370596, AI624549, AW149890, AA505962, AA321215, AI357856, AA292337,
-				BE292730, T34097, AW439882, AA447016, AI914726, R42595, AI858704, AI446219, AI275944,
				Z43230, BE707350, AW194214, AA135290, AW378090, BE241555, BE243232, AA010669,
				AW953547, AA632244, AW662488, BG057144, AW068278, R12726, BE151809, AW674205, T74373,

				N78860, BE242323, T31535, A1689506, R27706, F09665, R17501, AA435604, AW572245, BE548954, A1023355, BE545268, Z41318, AA383547, AA54729, AA570630, AA031630, AW173762.
				AW840945, AA381001, AA234325, T35951, Z45645, BE242712, T35949, A1866536, AA381111,
				AA693741, D82426, U83555, BE243322, F12018, AW793087, D82527, T64523, AW130852,
				AW262657, AA090647, AA359844, T19865, AA082483, U52870, R39778, W17267, AW603488, AA858156, AW068025, AW801618, BE242609, R05679, BE672790.
HSLCQ82 291	1352226	1 - 1462	15 - 1476	BF116042, AA454571, AW192766, A1278160, H24834, A1091291, AA456465, A1242593, AA098966, A1379014 H74785, AA971986, BF745395
HSNAD72 292	467397	1 - 847	15 - 861	AW971203, AW861646, AI610321, AI880774, AA829195, AI880765, AA551170, AI969833,
				AA133550, T61620, AV758870, AA557945, AW873417, AI635819, C06160, AV761107, BE268727,
				AA743968, AA845333, BF574331, BG222875, BF946125, BF882222, BE068993, BF946124,
				AA493841, AW169469, AI251576, AI821901, BE044000, AI701898, H86399, H47461, AI338426,
				AI926093, AC009086.5, AC003007.1, AF001549.1, AC004638.1, AC018868.4, AC008747.5,
				AC090527.3, AL050318.13, AC078846.2, AC006254.10, AL035462.21, AL355476.12,
				AC026431.3, AC087091.1, AC005245.1, AL031311.1, AL136981.22, AL391241.21,
				AC010422.7, AC010267.6, AC011609.9, AC006538.1, AC006483.3, AL353807.18, AL049776.3,
				Z98200.8, AC067722.21, AC010913.9, AC008622.5, AC018828.3, AL080317.11, AC005484.2,
				AC022383.3, Z97989.1, AL117258.4, AC004531.1, AL121594.6, AL161656.20, AL122020.5,
				AL157372.18, AC067742.5, AL021453.1, AL390074.17, U47924.1, AC005077.5, AC002404.1,
				AC008482.5, AL035404.20, AL136124.10, AC005519.3, AL359983.7, AC005932.1, Z74739.1,
				ч,
		-		, Z83844.5, A
				AC007193.1, AC008812.7, AC025588.1, AL445212.9, AL121890.34, AC011497.6, AC008752.6,
				AC007216.2,
				, AC006251.3,
				AC005041.2, AL050302.2,
				AC005257.1, AL137918.4, AC007163.3, AP000555.1, A
		_		AL049868.20
			_	AC007686.5,
				AC009238.4, AL353804.22, U91323.1, AL160236.4, AL450224.1, AL159997.14, AP001724.1,
				AC006452.4, AL158830.17, AC004812.1, AC007751.3, AC004675.1, AL080243.21,
				AJ246003.1, AL354932.26, AC009488.5, AL391987.15, AP000213.1, AL354935.23,
				AL158813.16, AP000744.4, AC002543.1, AC010271.6, AL138878.10, AP000558.1,

HSNMC45 HSQFP66 HSRFZ57 HSSFT08 HSSGD52	293 294 295 296 297	1352201 460537 892171 589978 1352343	1 - 573 1 - 463 1 - 1916 1 - 777 1 - 2411	15 - 587 15 - 477 15 - 1930 15 - 791 15 - 2425	AC009144.5, AL020997.1, AC004913.2, AC008392.6, AL133246.2, AL161436.12, AC073073.2, AC012306.11, AC020914.7, AC090942.1, U52112.1, AL110115.38, AC004491.1, Z960744, AP000135.1, AC005410.2, AC0966.3, AF165926.2, AL12186.22, AL109628.5, AL109743.4, AC008760.6, AL078477.5, AC004521.5, AC006077.1, AC008760.6, AL078477.5, AC004521.5, AC006067.1, AC008674.6, AC00867.4, AC00820.1, AC004234.1, AC012476.8, AL513042.1, AL136051.6, AC001818.1, AC00867.4, AC00652.1, AC004234.1, AC012476.8, AL513042.7, L44140.1, AL136305.14, AC010805.4, AL022323.7, AC004234.1, AC013436.5, AL138752.5, AL13712.4, AL135092.14, AC018758.2, AC01310.7, AC004234.1, AC013436.5, AL138752.5, AL13712.4, AL136092.0, AL133255.13, AL137872.5, AL13712.4, AL136092.10, AC004592.1, AC007597.3, AL353602.10, AL136039.4, AC008521.5, AL390738.4, AC006159.3, AF125348.1, AC084730. AL13785.4, AR69740.8, AR69740.2, AR8741.8, AR69740.2, AR69740
					R69447, AA303616, BE301258, W78796, W52012, BF956541, T07614, AW439006, T75428, BF917390, BE179163, A1086470, BF821360, BE938534, AA577454, BE301248, A1869470, AU076647, BF001674, A1086839, W94113, U94831.1, AL136295. 3.
HSSGG82	298	618535	1 - 1529	15 - 1543	AW964177, BF663662, AW603820, AI884560, AA398834, AA054137, BE503763, AW613529, BF509801, AA378851, H86275, H84069, BF346487, BF754228, AA327575, AA421165, BF686426, AI825151, BF476556, AI700323, AI591094, AW206900, AI948671, AI695979, AI632290, AW204774, AW134977.

		6 %	50,		3,		9,
~ · ++	AW839808, AA077633, BF919965, AC008171.3, AF041056.1, AC004089.25, AC005081.3, AC005015.2, AB006629. 2.	BF313680, BE742185, BE383304, BE741869, BF526599, BE619099, AI341487, AI971709, AI623222, AW593800, AW959076, AI983635, AI952164, AW275114, AI800442, AA977038, AW513859, AW273202, AW337946, AW273147, AI801910, BE463718, AA250733, AW072844, AI453134, AI818468, AI086791, BF329916, AW166266, AW300481, AI561259, AW103087, BE048584, AE907359, AW470887, BF063936, AI207341, AW235230, AA448721, AW206033, AW175624, AW193322, AW193240, AI128968, AW26492, AA410939, AI682412, AA455784, BF525380, AM195959, AI825128, AA327876, AI168173, BF376618, N79049, AA349394, AI470892, BF194812, D79030, AA902669, AI569983, AI672486, AA769789, N91773, BF944570, C02034, AI955870, AC005222. 1.	AW195720, AI765273, AI817356, AI928166, AI283845, BE503396, AW081502, BE349083, BF059350, AA419437, AA758800, AW206944, AA933673, AW104261, AI627565, AI264565, AW469909, AA845240, AA332515, AL021453. 1.	AA437009, A1806582, A1040972, AA442839, AA759268, A1214390, A1799076, AA918443, AW195596, AA910234.		AW072387, R83559, A1924465, A1364031, AW513660, BF361111, AA705541, AL162032. 1. BF059486, AW293425, A1190540, A1201137, A1026778, A1016787, AA604883, AW172655, AA393061, AA709172, AC002456. 1.	AI651078, AW193716, AA833735, AI656090, AA939044, AI005061, BE550563, AA972135, AW173087, BE551605, AI807541, AW235353, AA769984, AI631437, BF755659, BF755660, AA910026, AI954833, AA442458, AW236934, BF478195, AW291899, AA807414, AW003815, AA436650, AI001919, W26260, AW070283, AW302924, AI344928, AI344933, BF968779, AI335449,
	¥ Y			A		+	4 4 4 4
15 - 1021	15 - 727	15 - 2801	15 - 1341	15 - 839	15 - 1022	15 - 1028 15 - 450	15 - 531
1 - 1007	1 - 713	1 - 2787	1 - 1327	1 - 825	8001 - 1	1 - 1014	1-517
413246	898965	847358	1018291	1352365	206980	543396 381995	834058
299	300	301	302	303	304	305	307
HSUBW09	HSVBU91	HSYAV50	HTAEE28	HTECC05	нтеев42	HTEFU65 HTEGA76	HTELM16

					AL031650.22, AL121751. 12.
HTELP17	308	836072	1 - 794	15 - 808	AW976593, AW275003, BF103848, AA744857, AI458735, AW013800, AA453589, AI684921,
					A1184517, A1376535, AA621297, A1970221, AW015543, AA969112, AA992291, AA442130, W01308,
					H72782, AL519628, AA129060, AA460996, AA721433, BF665557, BE170715, AA460649, BG035897,
					H72781, A1382100, BF541499, AW800324, A1806305, BF885871, A1868710, A1241242, BE386136,
					AV723953, R75918, N75771, A1865320, A1355277, A1500061, AW088944, A1491842, BE544111,
					A1866469, AW007955, A1800464, A1335426, A1348777, BE891834, BG179438, AW409772,
					AL037582, AL037602, AV738017, AV712838, AV713988, AI536563, H42557, AV713143, AV755673,
					AV702147, AI174799, BE881061, BF814357, BF797305, AV721644, AI345010, AW021717,
		_			BG029829, BF793891, BF909758, AI538817, AW827289, AL037454, AW025279, AA766104,
					AV717730, AI817523, AL046942, BG001293, BF969354, AI554818, BE887537, AI583032, AI473536,
					BE789373, AI582932, AI590043, AV714010, AV717397, BG121959, AV706915, AV706624,
			-		AW027374, AA744531, AV703585, BF924856, A1819545, BE883591, AW196078, A1811631,
	•				AL036705, Al929108, BF997967, Al345745, BF921291, BE964497, Al279925, Al873638, BG029053,
_					A1923989, A1288152, A1305745, A1539800, BF816685, A1567582, AL040694, BF751288, BG166654,
					AL039276, AW090102, AI440238, AW161202, AI309306, AI401697, AI679959, AI345131, AL118781,
					AW078818, A1628325, A1697324, A1471429, T69241, A1470293, A1687568, BG033723, BF826429,
		_			AW965840, AA603709, AI371786, AI376748, AL043355, AI499986, BG032919, AI866770, BF924855,
					AW827211, AW059713, BG107590, AI125884, AI866465, BF092710, BE612681, AV750565,
					A1452707, A1446721, A1912438, A1288335, A1371243, AW020425, A1568138, AV682249, AV763927,
			_		A1972112, BG164558, BF811802, AW020397, AV713908, AW160905, AV681643, AW150826,
					A1864102, BG031447, AW193467, BG171892, AW162189, A1345415, AA514684, BE927769,
					AW059765, AL039274, AV648334, BF792047, BF970768, AI866780, AI570140, AI648663, AI363957,
					BF341210, BF792781, BG253033, AI890887, AL045626, BE957870, AI560679, AI434969, AL110306,
					AI561228, AA652505, AW172723, AI802244, AW022494, BE536058, AV705066, BF904265,
					AW410430, BF752997, AW183130, N81164, AI954293, AL120254, AW163464, BG112644,
					AW021662, AI571000, BG165979, AI927256, AI250852, AV682289, BF812963, AI336575, AL040241,
					AV682300, AI799364, AI445620, AL040449, AI656270, BF337602, BE965724, BF814412, BG260037,
					AA806719, AW264895, BE964614, BF904180, BF032768, AW151132, BE965432, AI474646,
					AW089664, AI653769, AW089275, AW020095, AI434656, Z99428, AW834325, AI923833, AI285419,
			_		BG122101, AC000077.2, AK026885.1, BC008365.1, AK024570.1, AB063093.1, Y14040.1,
	_				X82434.1, AL136748.1, AF078844.1, AF073483.1, AF285836.1, AL050092.1, AK025958.1,
			_		AK025435.1,
-					BC003410.1, BC007534.1,
		_			AB062978.1, AK025407.1,
					AK026556.1,
					AL137283.1, AB060826.1, AF262032.1, AL133049.1, AK026608.1, BC001328.1, AK027164.1,

					AL122050.1, AK026522.1, AL137533.1, AL136864.1, S76508.1, AK
					BCUU8/83.1, BCUU2/30.1, BCUU2/89U.1, AKUZ4944.1, AL133603.1, AKUZ3U99.1, AF133827.1, BCUU8/85.1 BCUU2/30.1 BCUU3873.1 AL167008.1 BCUU1785.1 AKUZ5U69.1 BCUU6164.1
					AK025209.1, AK026762.1, AE102006.1, BC001/83.1, AR025300.1, AK02509.1, AK026762.1, BC001964.1, AL122100.1, AB056372.1,
					AK026534.1, AL133081.1, BC000316.1, AK026630.1, AK025410.1,
					BC005070.1, AL137479.1, BC006807.1, AL162002.1, AL080074.1,
					AB055303.1, AB060887.1, AL136766.1, AK026464.1, BC006408.
					, AL117460.1, AL117649.1, AK026649.1, AF044323.1,
					AL133067.1, BC003683.1, BC008649.1, AK026528.1, 1
					, AK027173.1, AK026797.1, AK027146
					1, U88966.1, BC002777.1, AK026462.1, BC002688.1, `
					IK026642.1, AK025084.1, AK000083.1, AB052191.1, AB055368.1,
	-				AK027111.1, S61953.1, AF090934.1, BC
					BC004530.1, AF110640.1, AF159615.1, AF106697.1, AB063079.1,
					AL157482.1, AL050393.1, AL136540.1,
					BC008723.1, AL136789.1, AL133062.1, U72621.3, BC004960.1, AB
					AK024747.1, BC002409.1, AK025375.1, AF232009.1,
					AK025491.1, AL080162.1, BC003548.1, BC002473.1, AK000647.1,
					AK026506.1, AL162004.1, AK024546.1, BC007499.1,
					AL512718.1, AB060897.1, AK027161.1, AF202636.1, BC000090.1,
					, AF151685.1, AL136754.1, BC003684.1, AF260566.1, AK000391.1,
					BC005997.1, AL136784.1, AL133560.1, AK026408.1, BC007053.1,
					BC006091.1, AL357195.1, AF218014.1, AK025857.1, AB060879.1,
					BC007680.1, AL137558.1, AL583915.1, AL117432.1, AL389982.1,
					AB051158.1, AL389939.1, BC003614.1, AJ299431.1, AK027082.1, 1
					AK026947.1, AB048954.1, AB048975.1, AL110221.1, AL096744.1,
	-				AK026542.1, BC007326.1, AB050407.1, AL136850.1, AB060893.1,
		-			, AF061836.1, AL117583.1, AL137648.1, AL512733.1,
					, AF274347
HTELS08	309	847090	1 - 1884	15 - 1898	AW664990, AA608835, BE972717, AA383680, AW572898, AI028204, AI554902, AI138881.
HTEPG70	310	834931	1 - 799	15-813	
					AW072458, AA678521, AA442457, AC005789.1, AC005625. 1.
HTGEP89	311	410582	1 - 689	15 - 703	AV762334, AI300541, BG109719, AW663660, AA988368, AA927889, AA417006, AI206569,
					AA417219, AI005145, AI810124, AA723941, AA620800, AA917882, AA912169, BE927871,
				- 1	AA/3230/.
HTHBG43	312	116616	1 - 834	15 - 848	AA830144, AW196413, AW662711, AA346392, F01235, Z28908, AA704393, AV754716, AA602906, A1661313 BF804385 AA284247 A1609972, AW265614, AA491955, AW872574, AA715814

AW855528, AA552586, AW188742, AA622801, AA720774, AA502532, AA169245, AW238253,
 AI611533, BF870792, AI612070, AI301475, BF920612, AA528503, BE906142, AA558404, AA530958,
 AC020906.6, AC003043.1, A
AC074338.1, AL355792.8,
AL049637.43, AC005736.1, AP000116.1,
 AP001712.1, AC016968.24, AC008736.6, AC073345.10,
AC007687.16, AL035555.10, AL031678.2, AC010205.5,
AC002565.1, AL162587.20, AL031228.1, AL109935.39,
 AP001331.1, AL031728.12, AC010150.3, AL157372.18,
AC004821.3, AC005500.2, AL138759.20, AC009077.7, A
AL034405.16, AC018755.3, AC004611.1, AC021849.5,
AC002300.1, AC007917.15, AL390209.1,
AL121928.13, AC006057.5, AC002432.1, AC009756.9, AC005098.2,
, AC010311.8,
AL359494.17, AL008726.3, AL354766.17,
, AC073326.6, AP001748.1, AL118501.22,
, AC008946.6, AC009570.13,
AL049869.6, AC005215.1, AJ009613.4, AC009408.3,
, AC003104.1, U80017.1, AL117382.28, AL132716.6,
AL031447.4, AC011445.6, AP001726.1, AL163279.2, AP001715.1, A
 AC005288.1, AL137853.12, AC022383.3, AC010618.7,
AF067844.1, AC004032.7, AL034423.21, /
•
AL390294.19, AC004253.1, AL132777.4, AC009086.5, AC011890.4,
 AC007993.15,
AL512666.6, 4
 AC011811.42, AC004089.25,
AC005031.1, AL031681.16, AL160163.24, AC009144.5, AL132640.4, AC016995.4,
AP001725.1, AC005089.2, AC011444.5, A
AL121891.22, AL358972.13, AF207550.1, AL133445.4,
AL035659.22, AC011467.7, AL162417.22,
AC007991.7, AL096701.14, AC083884.6, AL121992.24, AL121594.
AC010458.5, AP002078.3, AC006966.3,
AL031846.2, AP000257.1, AP002982.2, AC005081.3, AC005363.1,
, AC007684.3, AL035587.5,
AF190464.1, AC002301.1, AL133294.10, AC004778. 1.

15-1061 AI801504, AA385855, AA812703, AA349881, AI254831, AW293292, AI963714, BF674168, AW967329, BE241437, T08386, AI521458, BF855114, AL357075.17, AL031668.23, AL358976.11, AP000067.1, AC004089.25, AL357519.19, AC005015.2, AL034417.14, AC004491.1, AC004962.1, AL133353.6, AC004634.1, AL080243.21, AC004841.2, AL035685.21, AP0000115.1, AC008957.7, AL035684.25, AP001717.1, AC015982.9, AC020916.7, AL139230.25, AL096773.6, AL137073.13, Z85996.1, AC010386.5, AC005098.2, AC003010.1, AC004166.12, AC005488.2, AC012170.6, AC005972.1, AC008569.6, AL049198.2, AC004166.1, AL157823.9, AL357507.9, AL3876.4, AC035077.1, AC011479.6, AC079171.21, AC004156.1, AL157823.9, AL35766.4, AC020904.6, AL035073.7, U91323.1, AC005103.3, AL078633.32, AF0047825. 1.	15 - 818 BF876683, A1755202, A1066646, AW613805, AA084609, AW769151, BE169870, AA601674, A150110, BF22568, AW265614, BF828830, A1613389, AL042667, AL042670, AW130427, BF586194, AW471092, AV766019, AW576485, A1281818, AA222596, NG4587, AU157209, BF941382, A13040151, A18539834, AW328202, AV756437, BF72284, BE336138, AW974363, T05118, AA524616, A1732682, AW268329, A1192440, AA669741, AW166920, D58782, A1653493, AW238341, A80030881, AC0088692, AC008442, AC0053092, AC005740.1, AB0208681, AC0088696, AC008716.2, AC0084976, AC0050882, AC0053092, AC005444.2, AC0050082, AC005868.0, AC0088696, AU1365279, AC0053273, AC0050002, AC0055297, AL133996.17, AC0109139, Z85987.13, AL5957579, AC0055723. AL2008763.1, AP001694.1, AC0048673, AL333123, AL595809.3, AC0085078, AL206763.1, AL5067621, AC0109139, AC008833.7, AL5067621, AC008509.2, AC008892.3, AC008892.3, AC008893.1, AC009882.1, AC0070521, AC008833.7, AL160163.24, AC011911, AC0052291, AL357515.26, AC010412.7, AL158141.14, AC005712, AC0019011, AC0052291, AL357515.26, AC010412.7, AL161670.4, AF169922.1, AC007051.4, AC005201.2, AC009882.3, AC002388.4, AC005902.1, AL357515.26, AC0040885.2, AC0050001.2, AC0060142, AC005012.1, AL353135.32, AL160231.4, AC005922.1, AC005921.1, AL3501283.24, AC005380.1, AL458811.10, AC005201.3, AL45883.1, AL56265.11, AL353135.32, AL160231.4, AC005932.1, AC0040885.2, AC0040861.5, AL161725.13, AC002390.1, AL450265.11, AL353135.32, AL160231.4, AC005422.1, AL161738.2,28, AL0213971.1, AC014975.1, AL17382.28, AL0213971.1, AC014985.2, AL035089.1, AL51241.9, AL121936.17, AC005302.2, AL035089.3, AL035089.3, AL035089.3, AL035089.3, AC006032.2, AL035089.3, AC006032.2, AL035089.3, AL035089.3, AL035089.3, AL035089.3, AL035089.3, AL035089.3, AL035089.3, AL033982.2, AL033982.3, AC006032.2, AL352084.4, AP000046.1, AC006378.1, AC0060381.1, AC0060881.3, AC0060883.2, AC0060893.2, AL033982.3, AC006083.2, AL033988.3, AC006083.1, AL352084.4, AP000046.1, AC0060142.4, AC006081.1, AC006081.1, AC006081.1, AC006081.1, AC006081.1, AC006081.1, AC006081.1, AC006081.1, AC006081.1,
1 - 1047	1 - 804
772559	634852
313	314
HTHDS25	HTLEP53

					AC007279.4, Z83840.7, AP001694.1, AL096764.11, AL031602.14, AC008895.7, AL391280.15, AC007073.2, AC005225.2, AL109614.28, AC008403.6, AL354808.24, AL133548.6, AL162430.15, AC008569.6, AL450104.14, AC007005.3, AL355392.7, AL133548.6,
					AL121997.7, AL034380.26, AL117352.12, AC009267.15, U91321.1, AL391827.18, AC022383.3, AC025438.5, AC091118.2, AC074013.5, AC002299.1, AL354797.16, U91326.1,
		_			AL034420.16, AC012384.16, AC022212.4, AL096840.25, AC005200.1, AC011489.6, AC008009.4, AL139317. 5.
HTOAK16	318	560744	1 - 1452	15 - 1466	AU145310, AW274654, BF838423, AW139789, AW205436, AA017033, AU118838, T87405, A1143925, A1174470, T87300, AA019253, AK021714, 1
HTOGR42	319	838160	1 - 1416	15 - 1430	AA573067, H30513, A1266619, R20206, AW084004, A1064724, AW851828, BF031134, AA773890,
					AA507343, AL031295.1, AL355343.18, AC005031.1, AL354932.26, AC044797.5, AL356019.5,
		·			AC011994.10, AL034420.16, U80460.1, AL031281.6, AC022392.4, AC073657.5, Z99716.4,
					AF196779.1, AC009144.5, L44140.1, AC008440.8, AL049776.3, AL031847.17, AC010378.6,
			-		AL139054.1, AC004797.1, AL353777.18, AL117382.28, AC005231.2,
				-	₹,
			_		AC005288.1, AC006538.1, D86995.1, AP000098.1, AC003007.1, AC009412.6, AL357497.17,
					Z83844.5, AL356575.8, AL031680.20, AL354735.14, AC007216.2, AL445071.14, AL136123.19,
					AC008149.14, AC010279.4, AC008018.20, AC011487.5, AC003041.1, AL159997.14,
					AL132713.11, AL365505.15, AC005632.2, U62317. 2.
HTOHT18	320	628300	1 - 1485	15 - 1499	AC004928.2.
HTOJK60	322	545067	1 - 890	15 - 904	AL079734, AI613389, AA129746, AI267356, AW970571, BE048991, AI267450, BF902572, AI133083,
					AI085242, H07953, AI253376, BG029528, AL038606, BF876179, AI207728, BF868994, AI049709,
					AA832016, BG222875, AA720774, AW089016, AW995665, BE084668, AA565911, BF821897,
					BG015615, BF529925, BE256101, A1357823, N30205, A1249447, A1537800, AA632839, A1440117,
					T74524, BE244243, AA501867, BE000614, BE154781, AA502207, AA084609, AA599080, AI679759,
					AV760019, AA191659, AA515351, BF678165, AW069412, AI284092, AW265359, AI056177,
					BE387304, AV757069, BF131490, BE049021, AW970987, AW276678, AW303098, AA584756,
					AW021627, AI628859, BE893315, AI251034, AA912287, BE501593, BE139139, AU117926,
					AC084864.2, AC078846.2, AC004815.2, U51560.1, AJ400877.1, AL445490.6, AC024082.6,
					AC007078.3, Z80896.2, AC012170.6, AJ009612.5, AC005940.3, AL357497.17, AC022415.5,
					AC008736.6, AL023879.1, AC004520.1, AL009031.1, AP003352.2, Z95116.1, AL356095.11,